<?xml version="1.0" encoding="UTF-8" ?><xml><records><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>19</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">19</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Baird, J. K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Eijkman-Oxford Clinical Research Unit, Eijkman Institute for Molecular Biology, Jakarta, Indonesia kbaird@eocru.org.&#xD;Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.</style></auth-address><titles><title><style face="normal" font="default" size="100%">8-Aminoquinoline Therapy for Latent Malaria</style></title><secondary-title><style face="normal" font="default" size="100%">Clin Microbiol Rev</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Clin Microbiol Rev</style></full-title></periodical><volume><style face="normal" font="default" size="100%">32</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2019/08/02</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Aminoquinolines/*therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Antimalarials/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Malaria/*drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">*8-aminoquinolines</style></keyword><keyword><style face="normal" font="default" size="100%">*cyp2d6</style></keyword><keyword><style face="normal" font="default" size="100%">*G6PD deficiency</style></keyword><keyword><style face="normal" font="default" size="100%">*Plasmodium vivax</style></keyword><keyword><style face="normal" font="default" size="100%">*hemolytic toxicity</style></keyword><keyword><style face="normal" font="default" size="100%">*latency</style></keyword><keyword><style face="normal" font="default" size="100%">*plasmochin</style></keyword><keyword><style face="normal" font="default" size="100%">*primaquine</style></keyword><keyword><style face="normal" font="default" size="100%">*tafenoquine</style></keyword><keyword><style face="normal" font="default" size="100%">*therapy</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2019</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep 18</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0893-8512 (Print)&#xD;0893-8512</style></isbn><accession-num><style face="normal" font="default" size="100%">31366609</style></accession-num><abstract><style face="normal" font="default" size="100%">The technical genesis and practice of 8-aminoquinoline therapy of latent malaria offer singular scientific, clinical, and public health insights. The 8-aminoquinolines brought revolutionary scientific discoveries, dogmatic practices, benign neglect, and, finally, enduring promise against endemic malaria. The clinical use of plasmochin-the first rationally synthesized blood schizontocide and the first gametocytocide, tissue schizontocide, and hypnozoitocide of any kind-commenced in 1926. Plasmochin became known to sometimes provoke fatal hemolytic crises. World War II delivered a newer 8-aminoquinoline, primaquine, and the discovery of glucose-6-phosphate dehydrogenase (G6PD) deficiency as the basis of its hemolytic toxicity came in 1956. Primaquine nonetheless became the sole therapeutic option against latent malaria. After 40 years of fitful development, in 2018 the U.S. Food and Drug Administration registered the 8-aminoquinoline called tafenoquine for the prevention of all malarias and the treatment of those that relapse. Tafenoquine also cannot be used in G6PD-unknown or -deficient patients. The hemolytic toxicity of the 8-aminoquinolines impedes their great potential, but this problem has not been a research priority. This review explores the complex technical dimensions of the history of 8-aminoquinolines. The therapeutic principles thus examined may be leveraged in improved practice and in understanding the bright prospect of discovery of newer drugs that cannot harm G6PD-deficient patients.</style></abstract><notes><style face="normal" font="default" size="100%">1098-6618&#xD;Baird, J Kevin&#xD;WT_/Wellcome Trust/United Kingdom&#xD;106680/Z/14/Z/WT_/Wellcome Trust/United Kingdom&#xD;Journal Article&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Review&#xD;Clin Microbiol Rev. 2019 Jul 31;32(4):e00011-19. doi: 10.1128/CMR.00011-19. Print 2019 Sep 18.</style></notes><urls></urls><custom2><style face="normal" font="default" size="100%">PMC6750137</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1128/cmr.00011-19</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>62</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">62</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Tekwani, B. L.</style></author><author><style face="normal" font="default" size="100%">Walker, L. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">National Center for Natural Products Research and Department of Pharmacology, University of Mississippi, University, Mississippi 38677, USA. btekwani@olemiss.edu</style></auth-address><titles><title><style face="normal" font="default" size="100%">8-Aminoquinolines: future role as antiprotozoal drugs</style></title><secondary-title><style face="normal" font="default" size="100%">Curr Opin Infect Dis</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Curr Opin Infect Dis</style></full-title></periodical><pages><style face="normal" font="default" size="100%">623-31</style></pages><volume><style face="normal" font="default" size="100%">19</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2006/11/01</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Aminoquinolines/adverse effects/chemistry/pharmacology/*therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Antiprotozoal Agents/adverse effects/pharmacology/*therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Leishmania/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Protozoan Infections/*drug therapy/parasitology</style></keyword><keyword><style face="normal" font="default" size="100%">Trypanosoma/drug effects</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2006</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0951-7375 (Print)&#xD;0951-7375</style></isbn><accession-num><style face="normal" font="default" size="100%">17075340</style></accession-num><abstract><style face="normal" font="default" size="100%">PURPOSE OF REVIEW: This review focuses on recent developments on evaluation of 8-aminoquinoline analogs with broader efficacy and reduced toxicity, which would provide better drugs for treatment of protozoal infections. RECENT FINDINGS: The earlier efforts towards development of 8-aminoquinoline analogs have been directed to extensive derivatization programs. This has led to discovery of tafenoquine for prophylaxis against malaria infections and sitamaquine with utility for treatment of visceral leishmaniasis. Bulaquine, a primaquine pro-drug, has shown reduced methemoglobin toxicity and better malaria-transmission-blocking activity than primaquine. Stereoselective pharmacologic and toxicologic characteristics of chiral 8-aminoquinolines provided the lead for enantiomeric separation of an 8-aminoquinoline analog NPC1161B, with greatly reduced toxicity and potent antimalarial action against blood as well as tissue stages of the parasite. NPC1161B has also shown promising use as an antileishmanial agent. Better understanding of the mechanisms of toxicity and efficacy may help in development of 8-aminoquinoline analogs with superior therapeutic actions, reduced toxicity and broader utility. SUMMARY: Extensive derivatization approaches followed by better understanding of structure-activity relationships and biotransformation mechanisms of toxicity have provided 8-aminoquinoline analogs with better pharmacologic and reduced toxicologic profiles. The novel 8-aminoquinoline analogs may have broader utility in public health as future antiprotozoals.</style></abstract><notes><style face="normal" font="default" size="100%">Tekwani, Babu L&#xD;Walker, Larry A&#xD;1 U01 CI000211-02/CI/NCPDCID CDC HHS/United States&#xD;U50/CCU423310-03/PHS HHS/United States&#xD;Journal Article&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Research Support, U.S. Gov&apos;t, P.H.S.&#xD;Review&#xD;United States&#xD;Curr Opin Infect Dis. 2006 Dec;19(6):623-31. doi: 10.1097/QCO.0b013e328010b848.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1097/QCO.0b013e328010b848</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>117</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">117</key></foreign-keys><ref-type name="Generic">13</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Waters, N. C.</style></author><author><style face="normal" font="default" size="100%">Edstein, M. D.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">N. C. Waters, Australian Army Malaria Institute, Gallipoli Barracks, Weary Dunlop Drive, Enoggera, QLD 4051, Australia</style></auth-address><titles><title><style face="normal" font="default" size="100%">8-aminoquinolines: Primaquine and tafenoquine</style></title><alt-title><style face="normal" font="default" size="100%">Milestones Drug Ther.</style></alt-title></titles><pages><style face="normal" font="default" size="100%">69-94</style></pages><volume><style face="normal" font="default" size="100%">41</style></volume><number><style face="normal" font="default" size="100%">(Waters N.C., norman.waters@us.army.mil; Edstein M.D.) Australian Army Malaria Institute, Gallipoli Barracks, Weary Dunlop Drive, Enoggera, QLD 4051, Australia</style></number><keywords><keyword><style face="normal" font="default" size="100%">8 aminoquinoline derivative</style></keyword><keyword><style face="normal" font="default" size="100%">artemisinin</style></keyword><keyword><style face="normal" font="default" size="100%">artesunate</style></keyword><keyword><style face="normal" font="default" size="100%">atovaquone</style></keyword><keyword><style face="normal" font="default" size="100%">chloroquine</style></keyword><keyword><style face="normal" font="default" size="100%">mefloquine</style></keyword><keyword><style face="normal" font="default" size="100%">methylene blue</style></keyword><keyword><style face="normal" font="default" size="100%">placebo</style></keyword><keyword><style face="normal" font="default" size="100%">primaquine</style></keyword><keyword><style face="normal" font="default" size="100%">quinine</style></keyword><keyword><style face="normal" font="default" size="100%">tafenoquine</style></keyword><keyword><style face="normal" font="default" size="100%">abdominal pain</style></keyword><keyword><style face="normal" font="default" size="100%">antimalarial activity</style></keyword><keyword><style face="normal" font="default" size="100%">antimalarial drug resistance</style></keyword><keyword><style face="normal" font="default" size="100%">article</style></keyword><keyword><style face="normal" font="default" size="100%">chemoprophylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">clinical effectiveness</style></keyword><keyword><style face="normal" font="default" size="100%">combination chemotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">cyanosis</style></keyword><keyword><style face="normal" font="default" size="100%">diarrhea</style></keyword><keyword><style face="normal" font="default" size="100%">dizziness</style></keyword><keyword><style face="normal" font="default" size="100%">dose response</style></keyword><keyword><style face="normal" font="default" size="100%">drug absorption</style></keyword><keyword><style face="normal" font="default" size="100%">drug bioavailability</style></keyword><keyword><style face="normal" font="default" size="100%">drug clearance</style></keyword><keyword><style face="normal" font="default" size="100%">drug delivery system</style></keyword><keyword><style face="normal" font="default" size="100%">drug distribution</style></keyword><keyword><style face="normal" font="default" size="100%">drug dose comparison</style></keyword><keyword><style face="normal" font="default" size="100%">drug effect</style></keyword><keyword><style face="normal" font="default" size="100%">drug efficacy</style></keyword><keyword><style face="normal" font="default" size="100%">drug elimination</style></keyword><keyword><style face="normal" font="default" size="100%">drug excretion</style></keyword><keyword><style face="normal" font="default" size="100%">drug half life</style></keyword><keyword><style face="normal" font="default" size="100%">drug indication</style></keyword><keyword><style face="normal" font="default" size="100%">drug mechanism</style></keyword><keyword><style face="normal" font="default" size="100%">drug metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">drug potentiation</style></keyword><keyword><style face="normal" font="default" size="100%">drug safety</style></keyword><keyword><style face="normal" font="default" size="100%">drug stability</style></keyword><keyword><style face="normal" font="default" size="100%">drug structure</style></keyword><keyword><style face="normal" font="default" size="100%">drug tolerability</style></keyword><keyword><style face="normal" font="default" size="100%">lack of drug effect</style></keyword><keyword><style face="normal" font="default" size="100%">drug urine level</style></keyword><keyword><style face="normal" font="default" size="100%">drug withdrawal</style></keyword><keyword><style face="normal" font="default" size="100%">electrocardiogram</style></keyword><keyword><style face="normal" font="default" size="100%">flatulence</style></keyword><keyword><style face="normal" font="default" size="100%">gastrointestinal symptom</style></keyword><keyword><style face="normal" font="default" size="100%">glucose 6 phosphate dehydrogenase deficiency</style></keyword><keyword><style face="normal" font="default" size="100%">headache</style></keyword><keyword><style face="normal" font="default" size="100%">heartburn</style></keyword><keyword><style face="normal" font="default" size="100%">hemolytic anemia</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">IC50</style></keyword><keyword><style face="normal" font="default" size="100%">infection prevention</style></keyword><keyword><style face="normal" font="default" size="100%">keratopathy</style></keyword><keyword><style face="normal" font="default" size="100%">LD50</style></keyword><keyword><style face="normal" font="default" size="100%">leukocyte count</style></keyword><keyword><style face="normal" font="default" size="100%">loading drug dose</style></keyword><keyword><style face="normal" font="default" size="100%">malaria</style></keyword><keyword><style face="normal" font="default" size="100%">malaria control</style></keyword><keyword><style face="normal" font="default" size="100%">malaria falciparum</style></keyword><keyword><style face="normal" font="default" size="100%">methemoglobinemia</style></keyword><keyword><style face="normal" font="default" size="100%">muscle cramp</style></keyword><keyword><style face="normal" font="default" size="100%">nausea</style></keyword><keyword><style face="normal" font="default" size="100%">nonhuman</style></keyword><keyword><style face="normal" font="default" size="100%">parasite transmission</style></keyword><keyword><style face="normal" font="default" size="100%">parasitemia</style></keyword><keyword><style face="normal" font="default" size="100%">patient compliance</style></keyword><keyword><style face="normal" font="default" size="100%">Plasmodium ovale malaria</style></keyword><keyword><style face="normal" font="default" size="100%">Plasmodium vivax malaria</style></keyword><keyword><style face="normal" font="default" size="100%">priority journal</style></keyword><keyword><style face="normal" font="default" size="100%">side effect</style></keyword><keyword><style face="normal" font="default" size="100%">single drug dose</style></keyword><keyword><style face="normal" font="default" size="100%">thrombocytopenia</style></keyword><keyword><style face="normal" font="default" size="100%">time to maximum plasma concentration</style></keyword><keyword><style face="normal" font="default" size="100%">treatment duration</style></keyword><keyword><style face="normal" font="default" size="100%">treatment planning</style></keyword><keyword><style face="normal" font="default" size="100%">vomiting</style></keyword><keyword><style face="normal" font="default" size="100%">sb 252263</style></keyword><keyword><style face="normal" font="default" size="100%">wr 238605</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><isbn><style face="normal" font="default" size="100%">9783034604796</style></isbn><abstract><style face="normal" font="default" size="100%">8-Aminoquinolines are an important class of antimalarial drugs because they are effective against the liver stages of Plasmodium infections and thus are administered for radical cure and presumptive antirelapse therapy against relapsing malaria. In this chapter, we discuss pnozoite), which re-emerges much later to cause clinical disease. Tafenoquine, a primaquine analog, is currently under advanced clinical development. Tafenoquine has a much longer elimination half-life compared with primaquine (14 days versus 6 h) and is highly effective both in treating relapses of P. vivax malaria and as a causal prophylactic agent against P. falciparum and P. vivax malaria. A major drawback to the 8-aminoquinolines is their toxicity in glucose-6-phosphate dehydrogenase (G6PD)-deficient individuals. We discuss clinical uses, pharmacokinetics and metabolism, safety and tolerability, mechanisms of action and drug resistance for both these drugs. © Springer Basel AG 2012.</style></abstract><notes><style face="normal" font="default" size="100%">L365765466&#xD;2012-10-10&#xD;2012-10-23</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L365765466&amp;from=export</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1007/978-3-0346-0480-2_4</style></url></related-urls></urls><custom1><style face="normal" font="default" size="100%">sb 252263&#xD;wr 238605</style></custom1><custom2><style face="normal" font="default" size="100%">Glaxo SmithKline</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1007/978-3-0346-0480-2_4</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>112</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">112</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ghosh, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">S. Ghosh, Thomson Reuters, Barcelona, Spain</style></auth-address><titles><title><style face="normal" font="default" size="100%">62&lt;sup&gt;ND&lt;/sup&gt; Annual meeting of the american society of tropical medicine and hygiene (ASTMH) Washington, D.C., USA - November 13-17, 2013</style></title><secondary-title><style face="normal" font="default" size="100%">Drugs of the Future</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Drugs of the Future</style></full-title></periodical><pages><style face="normal" font="default" size="100%">85-90</style></pages><volume><style face="normal" font="default" size="100%">39</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">NCT01441167</style></keyword><keyword><style face="normal" font="default" size="100%">antimalarial agent</style></keyword><keyword><style face="normal" font="default" size="100%">artefenomel mesylate</style></keyword><keyword><style face="normal" font="default" size="100%">artemether plus benflumetol</style></keyword><keyword><style face="normal" font="default" size="100%">chloroquine</style></keyword><keyword><style face="normal" font="default" size="100%">chloroquine plus primaquine</style></keyword><keyword><style face="normal" font="default" size="100%">dengue vaccine</style></keyword><keyword><style face="normal" font="default" size="100%">elq 121</style></keyword><keyword><style face="normal" font="default" size="100%">elq 300</style></keyword><keyword><style face="normal" font="default" size="100%">elq 400</style></keyword><keyword><style face="normal" font="default" size="100%">hemoglobin</style></keyword><keyword><style face="normal" font="default" size="100%">immunological adjuvant</style></keyword><keyword><style face="normal" font="default" size="100%">iscomatrix</style></keyword><keyword><style face="normal" font="default" size="100%">jpc 2997</style></keyword><keyword><style face="normal" font="default" size="100%">cipargamin</style></keyword><keyword><style face="normal" font="default" size="100%">Leishmania vaccine</style></keyword><keyword><style face="normal" font="default" size="100%">oz 439</style></keyword><keyword><style face="normal" font="default" size="100%">quinolone derivative</style></keyword><keyword><style face="normal" font="default" size="100%">recombinant vaccine</style></keyword><keyword><style face="normal" font="default" size="100%">sporozoite vaccine</style></keyword><keyword><style face="normal" font="default" size="100%">tafenoquine</style></keyword><keyword><style face="normal" font="default" size="100%">tetravax dv</style></keyword><keyword><style face="normal" font="default" size="100%">tv 003</style></keyword><keyword><style face="normal" font="default" size="100%">unclassified drug</style></keyword><keyword><style face="normal" font="default" size="100%">v 180</style></keyword><keyword><style face="normal" font="default" size="100%">vrc 132</style></keyword><keyword><style face="normal" font="default" size="100%">acquired immune deficiency syndrome</style></keyword><keyword><style face="normal" font="default" size="100%">antimalarial activity</style></keyword><keyword><style face="normal" font="default" size="100%">career mobility</style></keyword><keyword><style face="normal" font="default" size="100%">conference paper</style></keyword><keyword><style face="normal" font="default" size="100%">drug dose escalation</style></keyword><keyword><style face="normal" font="default" size="100%">drug efficacy</style></keyword><keyword><style face="normal" font="default" size="100%">drug megadose</style></keyword><keyword><style face="normal" font="default" size="100%">drug safety</style></keyword><keyword><style face="normal" font="default" size="100%">drug tolerability</style></keyword><keyword><style face="normal" font="default" size="100%">headache</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">immune response</style></keyword><keyword><style face="normal" font="default" size="100%">immunogenicity</style></keyword><keyword><style face="normal" font="default" size="100%">leishmaniasis</style></keyword><keyword><style face="normal" font="default" size="100%">low drug dose</style></keyword><keyword><style face="normal" font="default" size="100%">malaria</style></keyword><keyword><style face="normal" font="default" size="100%">malaria falciparum</style></keyword><keyword><style face="normal" font="default" size="100%">medical education</style></keyword><keyword><style face="normal" font="default" size="100%">medical profession</style></keyword><keyword><style face="normal" font="default" size="100%">medical society</style></keyword><keyword><style face="normal" font="default" size="100%">nonhuman</style></keyword><keyword><style face="normal" font="default" size="100%">parasite clearance</style></keyword><keyword><style face="normal" font="default" size="100%">parasitemia</style></keyword><keyword><style face="normal" font="default" size="100%">phase 1 clinical trial (topic)</style></keyword><keyword><style face="normal" font="default" size="100%">phase 2 clinical trial (topic)</style></keyword><keyword><style face="normal" font="default" size="100%">phase 3 clinical trial (topic)</style></keyword><keyword><style face="normal" font="default" size="100%">Plasmodium falciparum</style></keyword><keyword><style face="normal" font="default" size="100%">Plasmodium vivax</style></keyword><keyword><style face="normal" font="default" size="100%">Plasmodium vivax malaria</style></keyword><keyword><style face="normal" font="default" size="100%">Plasmodium yoelii infection</style></keyword><keyword><style face="normal" font="default" size="100%">randomized controlled trial (topic)</style></keyword><keyword><style face="normal" font="default" size="100%">rash</style></keyword><keyword><style face="normal" font="default" size="100%">single drug dose</style></keyword><keyword><style face="normal" font="default" size="100%">tropical medicine</style></keyword><keyword><style face="normal" font="default" size="100%">United States</style></keyword><keyword><style face="normal" font="default" size="100%">unspecified side effect</style></keyword><keyword><style face="normal" font="default" size="100%">upper respiratory tract infection</style></keyword><keyword><style face="normal" font="default" size="100%">vaccination</style></keyword><keyword><style face="normal" font="default" size="100%">visceral leishmaniasis</style></keyword><keyword><style face="normal" font="default" size="100%">kae 609</style></keyword><keyword><style face="normal" font="default" size="100%">nitd 609</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><isbn><style face="normal" font="default" size="100%">0377-8282</style></isbn><abstract><style face="normal" font="default" size="100%">The American Society of Tropical Medicine and Hygiene (ASTMH), founded in 1903, is a worldwide organization of scientists, clinicians and program professionals whose mission is to promote global health. Specific ASTMH goals include the health improvement of people worldwide, advancing research in tropical diseases, fostering international scientific collaborations, supporting career development in tropical medicine, educating medical professionals, policy makers and the public about tropical medicine, promoting science-based policy regarding tropical medicine, and finally, to recognize exceptional achievement in tropical medicine and global health. Peter Piot (London School of Hygiene and Tropical Medicine), who led the original Ebola virus discovery team in 1976 and conducted extensive studies on life-threatening diseases such as AIDS, presented the keynote address to kick off the 62&lt;sup&gt;nd&lt;/sup&gt; Annual Meeting in Washington, D.C. Professor Piot stated that science without politics will not have an impact and science without evidence can be extremely dangerous, calling upon investigators to ignore the challenges and continue with the efforts to fight neglected infectious diseases and improve global human health. The following report covers highlights from the meeting. Copyright © 2014 Prous Science, S.A.U. or its licensors. All rights reserved.</style></abstract><notes><style face="normal" font="default" size="100%">L372294201&#xD;2014-02-14&#xD;2014-02-21</style></notes><work-type><style face="normal" font="default" size="100%">Conference Paper</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L372294201&amp;from=export</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1358/dof.2014.039.01.2094802</style></url></related-urls></urls><custom1><style face="normal" font="default" size="100%">elq 121&#xD;elq 300&#xD;elq 400&#xD;iscomatrix&#xD;jpc 2997(Jacobus)&#xD;kae 609(Novartis)&#xD;nitd 609(Novartis)&#xD;oz 439&#xD;tetravax dv&#xD;tv 003&#xD;v 180&#xD;vrc 132</style></custom1><custom2><style face="normal" font="default" size="100%">Glaxo SmithKline&#xD;Jacobus&#xD;Novartis</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1358/dof.2014.039.01.2094802</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>41</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">41</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bhagavathula, A. S.</style></author><author><style face="normal" font="default" size="100%">Elnour, A. A.</style></author><author><style face="normal" font="default" size="100%">Shehab, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Clinical Pharmacy, University of Gondar-College of Medicine and Health Sciences, School of Pharmacy, Gondar, Ethiopia. akshaypharmd@gmail.com.&#xD;Pharmacy College, Fatima College of Health Sciences, Al Ain, Abu Dhabi, United Arab Emirates.&#xD;Department of Internal medicine, College of Medicine and Health Sciences, UAE University, Al Ain, Abu Dhabi, United Arab Emirates.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Alternatives to currently used antimalarial drugs: in search of a magic bullet</style></title><secondary-title><style face="normal" font="default" size="100%">Infect Dis Poverty</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Infect Dis Poverty</style></full-title></periodical><pages><style face="normal" font="default" size="100%">103</style></pages><volume><style face="normal" font="default" size="100%">5</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2016/11/05</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Antimalarials/adverse effects/*therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Clinical Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Malaria/*drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Artemisinin derivatives</style></keyword><keyword><style face="normal" font="default" size="100%">Chemotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">Drug development</style></keyword><keyword><style face="normal" font="default" size="100%">Fosmidomycin</style></keyword><keyword><style face="normal" font="default" size="100%">Malaria</style></keyword><keyword><style face="normal" font="default" size="100%">Medicine for malaria venture</style></keyword><keyword><style face="normal" font="default" size="100%">Novel antimalarial drugs</style></keyword><keyword><style face="normal" font="default" size="100%">Tafenoquine</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2016</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov 4</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">2049-9957</style></isbn><accession-num><style face="normal" font="default" size="100%">27809883</style></accession-num><abstract><style face="normal" font="default" size="100%">Malaria is a major cause of morbidity and mortality in many African countries and parts of Asia and South America. Novel approaches to combating the disease have emerged in recent years and several drug candidates are now being tested clinically. However, it is long before these novel drugs can hit the market, especially due to a scarcity of safety and efficacy data.To reduce the malaria burden, the Medicines for Malaria Venture (MMV) was established in 1999 to develop novel medicines through industry and academic partners&apos; collaboration. However, no reviews were focused following various preclinical and clinical studies published since the MMV initiation (2000) to till date.We identify promising approaches in the global portfolio of antimalarial medicines, and highlight challenges and patient specific concerns of these novel molecules. We discuss different clinical studies focusing on the evaluation of novel drugs against malaria in different human trials over the past five years.The drugs KAE609 and DDD107498 are still being evaluated in Phase I trials and preclinical developmental studies. Both the safety and efficacy of novel compounds such as KAF156 and DSM265 need to be assessed further, especially for use in pregnant women. Synthetic non-artemisinin ozonides such as OZ277 raised concerns in terms of its insufficient efficacy against high parasitic loads. Aminoquinoline-based scaffolds such as ferroquine are promising but should be combined with good partner drugs for enhanced efficacy. AQ-13 induced electrocardiac events, which led to prolonged QTc intervals. Tafenoquine, the only new anti-relapse scaffold for patients with a glucose-6-phosphate dehydrogenase deficiency, has raised significant concerns due to its hemolytic activity. Other compounds, including methylene blue (potential transmission blocker) and fosmidomycin (DXP reductoisomerase inhibitor), are available but cannot be used in children.At this stage, we are unable to identify a single magic bullet against malaria. Future studies should focus on effective single-dose molecules that can act against all stages of malaria in order to prevent transmission. Newer medicines have also raised concerns in terms of efficacy and safety. Overall, more evidence is needed to effectively reduce the current malaria burden. Treatment strategies that target the blood stage with transmission-blocking properties are needed to prevent future drug resistance.</style></abstract><notes><style face="normal" font="default" size="100%">2049-9957&#xD;Bhagavathula, Akshaya Srikanth&#xD;Elnour, Asim Ahmed&#xD;Shehab, Abdulla&#xD;Journal Article&#xD;Review&#xD;Infect Dis Poverty. 2016 Nov 4;5(1):103. doi: 10.1186/s40249-016-0196-8.</style></notes><urls></urls><custom2><style face="normal" font="default" size="100%">PMC5095999</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1186/s40249-016-0196-8</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>55</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">55</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Shiraki, H.</style></author><author><style face="normal" font="default" size="100%">Kozar, M. P.</style></author><author><style face="normal" font="default" size="100%">Melendez, V.</style></author><author><style face="normal" font="default" size="100%">Hudson, T. H.</style></author><author><style face="normal" font="default" size="100%">Ohrt, C.</style></author><author><style face="normal" font="default" size="100%">Magill, A. J.</style></author><author><style face="normal" font="default" size="100%">Lin, A. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Experimental Therapeutics, Walter Reed Army Institute of Research, Silver Spring, Maryland 20910, United States.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Antimalarial activity of novel 5-aryl-8-aminoquinoline derivatives</style></title><secondary-title><style face="normal" font="default" size="100%">J Med Chem</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Med Chem</style></full-title></periodical><pages><style face="normal" font="default" size="100%">131-42</style></pages><volume><style face="normal" font="default" size="100%">54</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2010/12/15</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Aminoquinolines/*chemical synthesis/pharmacology/toxicity</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Antimalarials/*chemical synthesis/pharmacology/toxicity</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Line</style></keyword><keyword><style face="normal" font="default" size="100%">Chloroquine/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Resistance</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">In Vitro Techniques</style></keyword><keyword><style face="normal" font="default" size="100%">Malaria/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Microsomes, Liver/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Plasmodium berghei</style></keyword><keyword><style face="normal" font="default" size="100%">Plasmodium falciparum/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Structure-Activity Relationship</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2011</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan 13</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0022-2623</style></isbn><accession-num><style face="normal" font="default" size="100%">21141892</style></accession-num><abstract><style face="normal" font="default" size="100%">In an attempt to separate the antimalarial activity of tafenoquine (3) from its hemolytic side effects in glucose-6-phosphate dehydrogenase (G6PD) deficiency patients, a series of 5-aryl-8-aminoquinoline derivatives was prepared and assessed for antimalarial activities. The new compounds were found metabolically stable in human and mouse microsomal preparations, with t(1/2) &gt; 60 min, and were equal to or more potent than primaquine (2) and 3 against Plasmodium falciparum cell growth. The new agents were more active against the chloroquine (CQ) resistant clone than to the CQ-sensitive clone. Analogues with electron donating groups showed better activity than those with electron withdrawing substituents. Compounds 4bc, 4bd, and 4be showed comparable therapeutic index (TI) to that of 2 and 3, with TI ranging from 5 to 8 based on IC(50) data. The new compounds showed no significant causal prophylactic activity in mice infected with Plasmodium berghei sporozoites, but are substantially less toxic than 2 and 3 in mouse tests.</style></abstract><notes><style face="normal" font="default" size="100%">1520-4804&#xD;Shiraki, Hiroaki&#xD;Kozar, Michael P&#xD;Melendez, Victor&#xD;Hudson, Thomas H&#xD;Ohrt, Colin&#xD;Magill, Alan J&#xD;Lin, Ai J&#xD;Journal Article&#xD;Research Support, U.S. Gov&apos;t, Non-P.H.S.&#xD;United States&#xD;J Med Chem. 2011 Jan 13;54(1):131-42. doi: 10.1021/jm100911f. Epub 2010 Dec 8.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1021/jm100911f</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>99</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">99</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Baird, J. K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">J.K. Baird, Eijkman Oxford Clinical Research Unit, Jalan Diponegoro No.69, Jakarta, Indonesia</style></auth-address><titles><title><style face="normal" font="default" size="100%">Asia-Pacific malaria is singular, pervasive, diverse and invisible</style></title><secondary-title><style face="normal" font="default" size="100%">International Journal for Parasitology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">International Journal for Parasitology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">371-377</style></pages><volume><style face="normal" font="default" size="100%">47</style></volume><number><style face="normal" font="default" size="100%">7</style></number><keywords><keyword><style face="normal" font="default" size="100%">artemisinin</style></keyword><keyword><style face="normal" font="default" size="100%">insecticide</style></keyword><keyword><style face="normal" font="default" size="100%">malaria vaccine</style></keyword><keyword><style face="normal" font="default" size="100%">tafenoquine</style></keyword><keyword><style face="normal" font="default" size="100%">article</style></keyword><keyword><style face="normal" font="default" size="100%">Asia</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">indoor residual spraying</style></keyword><keyword><style face="normal" font="default" size="100%">insecticide treated net</style></keyword><keyword><style face="normal" font="default" size="100%">malaria</style></keyword><keyword><style face="normal" font="default" size="100%">malaria rapid test</style></keyword><keyword><style face="normal" font="default" size="100%">migrant</style></keyword><keyword><style face="normal" font="default" size="100%">nonhuman</style></keyword><keyword><style face="normal" font="default" size="100%">Pacific islands</style></keyword><keyword><style face="normal" font="default" size="100%">parasite clearance</style></keyword><keyword><style face="normal" font="default" size="100%">parasite load</style></keyword><keyword><style face="normal" font="default" size="100%">parasite transmission</style></keyword><keyword><style face="normal" font="default" size="100%">parasite vector</style></keyword><keyword><style face="normal" font="default" size="100%">phase 2 clinical trial (topic)</style></keyword><keyword><style face="normal" font="default" size="100%">phase 3 clinical trial (topic)</style></keyword><keyword><style face="normal" font="default" size="100%">Plasmodium falciparum</style></keyword><keyword><style face="normal" font="default" size="100%">Plasmodium vivax</style></keyword><keyword><style face="normal" font="default" size="100%">randomized controlled trial (topic)</style></keyword><keyword><style face="normal" font="default" size="100%">vaccination</style></keyword><keyword><style face="normal" font="default" size="100%">World Health Organization</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2017</style></year></dates><isbn><style face="normal" font="default" size="100%">1879-0135&#xD;0020-7519</style></isbn><abstract><style face="normal" font="default" size="100%">Malaria in the Asia-Pacific region has been targeted for elimination by the year 2030. This article asks the question, “by what means?” in the context of proven technical strategies and tools against key challenges imposed by the distinct character of the Asia-Pacific malaria problem. The misperception of malaria in the Asia-Pacific region as a less serious but otherwise essentially similar problem to African malaria lulls us into rote application of the same tools and strategies. Those now mitigating the harm done by malaria in Africa will not suffice to eliminate malaria in the Asia-Pacific region – these tasks and the problems are fundamentally distinct. This article describes the singular characteristics of Asia-Pacific malaria and the bearing of those upon the technical strategy of malaria elimination. Most of the tools needed for that endeavour do not yet exist and spirited calls for elimination within the next 14 years may discourage the patience and investments needed to conceive, optimise and validate them.</style></abstract><notes><style face="normal" font="default" size="100%">L613873024&#xD;2016-12-30&#xD;2017-06-22</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L613873024&amp;from=export</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1016/j.ijpara.2016.06.006</style></url></related-urls></urls><custom5><style face="normal" font="default" size="100%">27836630</style></custom5><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.ijpara.2016.06.006</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase&#xD;Medline</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>128</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">128</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Patel, S. N.</style></author><author><style face="normal" font="default" size="100%">Kain, K. C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">K.C. Kain, McLaughlin-Rotman Center for Global Health, University of Toronto, Toronto General Hospital, 200 Elizabeth Street, Toronto, Ont. M5G 2C4, Canada</style></auth-address><titles><title><style face="normal" font="default" size="100%">Atovaquone/proguanil for the prophylaxis and treatment of malaria</style></title><secondary-title><style face="normal" font="default" size="100%">Expert Review of Anti-Infective Therapy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Expert Review of Anti-Infective Therapy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">849-861</style></pages><volume><style face="normal" font="default" size="100%">3</style></volume><number><style face="normal" font="default" size="100%">6</style></number><keywords><keyword><style face="normal" font="default" size="100%">amodiaquine</style></keyword><keyword><style face="normal" font="default" size="100%">antimalarial agent</style></keyword><keyword><style face="normal" font="default" size="100%">artemether plus benflumetol</style></keyword><keyword><style face="normal" font="default" size="100%">artemisinin</style></keyword><keyword><style face="normal" font="default" size="100%">artesunate</style></keyword><keyword><style face="normal" font="default" size="100%">atovaquone</style></keyword><keyword><style face="normal" font="default" size="100%">atovaquone plus proguanil</style></keyword><keyword><style face="normal" font="default" size="100%">azithromycin</style></keyword><keyword><style face="normal" font="default" size="100%">chloroquine</style></keyword><keyword><style face="normal" font="default" size="100%">cycloguanil</style></keyword><keyword><style face="normal" font="default" size="100%">doxycycline</style></keyword><keyword><style face="normal" font="default" size="100%">pyrimethamine plus sulfadoxine</style></keyword><keyword><style face="normal" font="default" size="100%">halofantrine</style></keyword><keyword><style face="normal" font="default" size="100%">mefloquine</style></keyword><keyword><style face="normal" font="default" size="100%">metoclopramide</style></keyword><keyword><style face="normal" font="default" size="100%">placebo</style></keyword><keyword><style face="normal" font="default" size="100%">primaquine</style></keyword><keyword><style face="normal" font="default" size="100%">proguanil</style></keyword><keyword><style face="normal" font="default" size="100%">quinine</style></keyword><keyword><style face="normal" font="default" size="100%">rifabutin</style></keyword><keyword><style face="normal" font="default" size="100%">rifampicin</style></keyword><keyword><style face="normal" font="default" size="100%">tafenoquine</style></keyword><keyword><style face="normal" font="default" size="100%">tetracycline</style></keyword><keyword><style face="normal" font="default" size="100%">zidovudine</style></keyword><keyword><style face="normal" font="default" size="100%">abdominal pain</style></keyword><keyword><style face="normal" font="default" size="100%">abnormally high substrate concentration in blood</style></keyword><keyword><style face="normal" font="default" size="100%">clinical trial</style></keyword><keyword><style face="normal" font="default" size="100%">congenital malformation</style></keyword><keyword><style face="normal" font="default" size="100%">coughing</style></keyword><keyword><style face="normal" font="default" size="100%">diarrhea</style></keyword><keyword><style face="normal" font="default" size="100%">digestive system function disorder</style></keyword><keyword><style face="normal" font="default" size="100%">dizziness</style></keyword><keyword><style face="normal" font="default" size="100%">drug blood level</style></keyword><keyword><style face="normal" font="default" size="100%">drug dose regimen</style></keyword><keyword><style face="normal" font="default" size="100%">drug eruption</style></keyword><keyword><style face="normal" font="default" size="100%">drug metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">drug potentiation</style></keyword><keyword><style face="normal" font="default" size="100%">drug structure</style></keyword><keyword><style face="normal" font="default" size="100%">drug withdrawal</style></keyword><keyword><style face="normal" font="default" size="100%">endemic disease</style></keyword><keyword><style face="normal" font="default" size="100%">headache</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">in vitro study</style></keyword><keyword><style face="normal" font="default" size="100%">in vivo study</style></keyword><keyword><style face="normal" font="default" size="100%">infection risk</style></keyword><keyword><style face="normal" font="default" size="100%">malaria</style></keyword><keyword><style face="normal" font="default" size="100%">mental disease</style></keyword><keyword><style face="normal" font="default" size="100%">parasitemia</style></keyword><keyword><style face="normal" font="default" size="100%">pharmacodynamics</style></keyword><keyword><style face="normal" font="default" size="100%">Plasmodium falciparum</style></keyword><keyword><style face="normal" font="default" size="100%">Plasmodium vivax</style></keyword><keyword><style face="normal" font="default" size="100%">postmarketing surveillance</style></keyword><keyword><style face="normal" font="default" size="100%">review</style></keyword><keyword><style face="normal" font="default" size="100%">side effect</style></keyword><keyword><style face="normal" font="default" size="100%">Stevens Johnson syndrome</style></keyword><keyword><style face="normal" font="default" size="100%">stomach pain</style></keyword><keyword><style face="normal" font="default" size="100%">travel</style></keyword><keyword><style face="normal" font="default" size="100%">treatment failure</style></keyword><keyword><style face="normal" font="default" size="100%">vomiting</style></keyword><keyword><style face="normal" font="default" size="100%">malarone</style></keyword><keyword><style face="normal" font="default" size="100%">wr 238605</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2005</style></year></dates><isbn><style face="normal" font="default" size="100%">1478-7210&#xD;1744-8336</style></isbn><abstract><style face="normal" font="default" size="100%">Increases in international travel and escalating drug resistance have resulted in a growing number of travelers at risk of contracting malaria. Drug resistance and intolerance to standard agents such as chloroquine, sulfadoxine/pyrimethamine and mefloquine has highlighted the need for new antimalarials. The recently licensed fixed combination of atovaquone and proguanil hydrochloride (Malarone™) is a promising new agent to prevent and treat Plasmodium falciparum malaria. Randomized controlled trials have shown that atovaquone/proguanil is well tolerated and efficacious for the prevention and treatment of drug-resistant P. falciparum malaria. Atovaquone/proguanil is active against the liver stage of P. falciparum malaria parasites and when used as a prophylactic agent it can be discontinued shortly after leaving malaria-endemic areas, offering a clear advantage for drug adherence. © 2005 Future Drugs Ltd.</style></abstract><notes><style face="normal" font="default" size="100%">L41782586&#xD;2005-12-30</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L41782586&amp;from=export</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1586/14787210.3.6.849</style></url></related-urls></urls><custom1><style face="normal" font="default" size="100%">malarone(Glaxo SmithKline)&#xD;wr 238605(Walter Reed,United States)</style></custom1><custom2><style face="normal" font="default" size="100%">Glaxo SmithKline&#xD;Walter Reed(United States)</style></custom2><custom5><style face="normal" font="default" size="100%">16307498</style></custom5><electronic-resource-num><style face="normal" font="default" size="100%">10.1586/14787210.3.6.849</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase&#xD;Medline</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>159</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">159</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">McCarthy, J. S.</style></author><author><style face="normal" font="default" size="100%">Smith, B.</style></author><author><style face="normal" font="default" size="100%">Reid, M.</style></author><author><style face="normal" font="default" size="100%">Berman, J.</style></author><author><style face="normal" font="default" size="100%">Marquart, L.</style></author><author><style face="normal" font="default" size="100%">Dobbin, C.</style></author><author><style face="normal" font="default" size="100%">West, L.</style></author><author><style face="normal" font="default" size="100%">Read, L. T.</style></author><author><style face="normal" font="default" size="100%">Dow, G.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Blood schizonticidal activity and safety of tafenoquine when administered as chemoprophylaxis to healthy, non-immune participants followed by blood stage Plasmodium falciparum challenge: a randomized, double-blinded, placebo-controlled Phase 1b study</style></title><secondary-title><style face="normal" font="default" size="100%">Clinical infectious diseases</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Clinical Infectious Diseases</style></full-title></periodical><dates><year><style face="normal" font="default" size="100%">2018</style></year></dates><accession-num><style face="normal" font="default" size="100%">CN-01954105</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: Tafenoquine was recently approved as a chemoprophylaxis for malaria (all species). Its activity against liver and blood stages has been separately characterized in animals but not in humans. Methods: In this randomized, double‐blinded, placebo‐controlled study, 16 malaria naive, G6PD‐normal participants aged 20‐42 years received tafenoquine chemoprophylaxis prior to challenge with blood stage P. falciparum. Participants were randomly assigned to either tafenoquine (n=12) or placebo (n=4) and took blinded study medication (single 200 mg dose) on days 1, 2, 3 and 10, followed by intravenous inoculation with ~2,800 P.falciparum parasitized erythrocytes on day 13. The primary endpoint was the number of participants requiring rescue treatment with artemether/lumefantrine due to the onset of parasitemia as determined by qPCR. Results: None of the 12 participants who received tafenoquine developed parasitemia while all placebo participants developed parasitemia (p=0.0005). Two cases of mild hemoglobin decrease and a single case of mild hyperbilirubinemia occurred in the tafenoquine group. Conclusions: Tafenoquine chemoprophylaxis is safe and effective in preventing malaria in healthy non‐immune participants challenged with blood stage P. falciparum.</style></abstract><caption><style face="normal" font="default" size="100%">Duplicate</style></caption><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01954105/full</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1093/cid/ciy939</style></electronic-resource-num></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>30</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">30</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">McCarthy, J. S.</style></author><author><style face="normal" font="default" size="100%">Smith, B.</style></author><author><style face="normal" font="default" size="100%">Reid, M.</style></author><author><style face="normal" font="default" size="100%">Berman, J.</style></author><author><style face="normal" font="default" size="100%">Marquart, L.</style></author><author><style face="normal" font="default" size="100%">Dobbin, C.</style></author><author><style face="normal" font="default" size="100%">West, L.</style></author><author><style face="normal" font="default" size="100%">Read, L. T.</style></author><author><style face="normal" font="default" size="100%">Dow, G. S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">QIMR Berghofer Medical Research Institute, Brisbane, Queensland.&#xD;60P Australia Pty Ltd, Sydney, New South Wales.&#xD;Graythan Regulatory Services Pty Ltd, Brisbane, Queensland, Australia.&#xD;Clinical Network Services Pty Ltd, Brisbane, Queensland, Australia.&#xD;Fast-Track Drugs and Biologicals LLC, North Potomac.&#xD;US Army Medical Materiel Development Activity, Fort Detrick, Maryland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Blood Schizonticidal Activity and Safety of Tafenoquine When Administered as Chemoprophylaxis to Healthy, Nonimmune Participants Followed by Blood Stage Plasmodium falciparum Challenge: A Randomized, Double-blind, Placebo-controlled Phase 1b Study</style></title><secondary-title><style face="normal" font="default" size="100%">Clin Infect Dis</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Clin Infect Dis</style></full-title></periodical><pages><style face="normal" font="default" size="100%">480-486</style></pages><volume><style face="normal" font="default" size="100%">69</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2018/11/06</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Aminoquinolines/*administration &amp; dosage</style></keyword><keyword><style face="normal" font="default" size="100%">Antimalarials/*administration &amp; dosage</style></keyword><keyword><style face="normal" font="default" size="100%">Chemoprevention/methods</style></keyword><keyword><style face="normal" font="default" size="100%">Double-Blind Method</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Healthy Volunteers</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Malaria, Falciparum/*prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Parasitemia/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Placebos</style></keyword><keyword><style face="normal" font="default" size="100%">Plasmodium falciparum/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Schizonts/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Young Adult</style></keyword><keyword><style face="normal" font="default" size="100%">*blood schizonticide</style></keyword><keyword><style face="normal" font="default" size="100%">*challenge</style></keyword><keyword><style face="normal" font="default" size="100%">*human</style></keyword><keyword><style face="normal" font="default" size="100%">*tafenoquine</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2019</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul 18</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1058-4838</style></isbn><accession-num><style face="normal" font="default" size="100%">30388194</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Tafenoquine was recently approved for chemoprophylaxis of malaria. Its specific activity against liver and blood stages of Plasmodium species has been separately characterized in animals but not in humans. METHODS: In this randomized, double-blind, placebo-controlled study, 16 malaria-naive, glucose-6-phosphate dehydrogenase-normal participants aged 20-42 years received tafenoquine chemoprophylaxis prior to challenge with blood stage Plasmodium falciparum. Participants were randomly assigned to either tafenoquine (n = 12) or placebo (n = 4) and took blinded study medication (single 200-mg dose) on days 1, 2, 3, and 10, followed by intravenous inoculation with approximately 2800 P. falciparum parasitized erythrocytes on day 13. The primary endpoint was the number of participants requiring rescue treatment with artemether/lumefantrine due to the onset of parasitemia as determined by quantitative polymerase chain reaction. RESULTS: None of the 12 participants who received tafenoquine developed parasitemia, whereas all placebo participants developed parasitemia (P = .0005). Two cases of mild hemoglobin decrease and a single case of mild hyperbilirubinemia occurred in the tafenoquine group. CONCLUSIONS: Tafenoquine chemoprophylaxis is safe and effective in preventing malaria in healthy nonimmune participants challenged with blood stage P. falciparum. CLINICAL TRIALS REGISTRATION: Australian and New Zealand Clinical Trials Registry (ANZCTR): ACTRN12617000102370.</style></abstract><caption><style face="normal" font="default" size="100%">Duplicate</style></caption><notes><style face="normal" font="default" size="100%">1537-6591&#xD;McCarthy, James S&#xD;Smith, Bryan&#xD;Reid, Mark&#xD;Berman, Jonathan&#xD;Marquart, Louise&#xD;Dobbin, Caroline&#xD;West, Leanne&#xD;Read, Lisa T&#xD;Dow, Geoff S&#xD;Clinical Trial, Phase I&#xD;Journal Article&#xD;Randomized Controlled Trial&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Research Support, U.S. Gov&apos;t, Non-P.H.S.&#xD;United States&#xD;Clin Infect Dis. 2019 Jul 18;69(3):480-486. doi: 10.1093/cid/ciy939.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1093/cid/ciy939</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>91</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">91</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">McCarthy, J. S.</style></author><author><style face="normal" font="default" size="100%">Smith, B.</style></author><author><style face="normal" font="default" size="100%">Reid, M.</style></author><author><style face="normal" font="default" size="100%">Berman, J.</style></author><author><style face="normal" font="default" size="100%">Marquart, L.</style></author><author><style face="normal" font="default" size="100%">Dobbin, C.</style></author><author><style face="normal" font="default" size="100%">West, L.</style></author><author><style face="normal" font="default" size="100%">Read, L. T.</style></author><author><style face="normal" font="default" size="100%">Dow, G. S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">G.S. Dow, 60P Australia Pty Ltd, Brookvale, NSW, Australia</style></auth-address><titles><title><style face="normal" font="default" size="100%">Blood Schizonticidal Activity and Safety of Tafenoquine When Administered as Chemoprophylaxis to Healthy, Nonimmune Participants Followed by Blood Stage Plasmodium falciparum Challenge: A Randomized, Double-blind, Placebo-controlled Phase 1b Study</style></title><secondary-title><style face="normal" font="default" size="100%">Clinical Infectious Diseases</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Clinical Infectious Diseases</style></full-title></periodical><pages><style face="normal" font="default" size="100%">480-486</style></pages><volume><style face="normal" font="default" size="100%">69</style></volume><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">ACTRN12617000102370</style></keyword><keyword><style face="normal" font="default" size="100%">artemether plus benflumetol</style></keyword><keyword><style face="normal" font="default" size="100%">hemoglobin</style></keyword><keyword><style face="normal" font="default" size="100%">tafenoquine</style></keyword><keyword><style face="normal" font="default" size="100%">abdominal discomfort</style></keyword><keyword><style face="normal" font="default" size="100%">abdominal pain</style></keyword><keyword><style face="normal" font="default" size="100%">adult</style></keyword><keyword><style face="normal" font="default" size="100%">article</style></keyword><keyword><style face="normal" font="default" size="100%">chemoprophylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">controlled study</style></keyword><keyword><style face="normal" font="default" size="100%">dehydration</style></keyword><keyword><style face="normal" font="default" size="100%">double blind procedure</style></keyword><keyword><style face="normal" font="default" size="100%">drug safety</style></keyword><keyword><style face="normal" font="default" size="100%">erythrocyte</style></keyword><keyword><style face="normal" font="default" size="100%">female</style></keyword><keyword><style face="normal" font="default" size="100%">headache</style></keyword><keyword><style face="normal" font="default" size="100%">hemoglobin blood level</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">human experiment</style></keyword><keyword><style face="normal" font="default" size="100%">hyperbilirubinemia</style></keyword><keyword><style face="normal" font="default" size="100%">limb pain</style></keyword><keyword><style face="normal" font="default" size="100%">loading drug dose</style></keyword><keyword><style face="normal" font="default" size="100%">malaria falciparum</style></keyword><keyword><style face="normal" font="default" size="100%">male</style></keyword><keyword><style face="normal" font="default" size="100%">muscle tightness</style></keyword><keyword><style face="normal" font="default" size="100%">myalgia</style></keyword><keyword><style face="normal" font="default" size="100%">nausea</style></keyword><keyword><style face="normal" font="default" size="100%">normal human</style></keyword><keyword><style face="normal" font="default" size="100%">oropharynx pain</style></keyword><keyword><style face="normal" font="default" size="100%">parasitemia</style></keyword><keyword><style face="normal" font="default" size="100%">Plasmodium falciparum</style></keyword><keyword><style face="normal" font="default" size="100%">priority journal</style></keyword><keyword><style face="normal" font="default" size="100%">pyelonephritis</style></keyword><keyword><style face="normal" font="default" size="100%">randomized controlled trial</style></keyword><keyword><style face="normal" font="default" size="100%">real time polymerase chain reaction</style></keyword><keyword><style face="normal" font="default" size="100%">side effect</style></keyword><keyword><style face="normal" font="default" size="100%">single drug dose</style></keyword><keyword><style face="normal" font="default" size="100%">upper respiratory tract infection</style></keyword><keyword><style face="normal" font="default" size="100%">vomiting</style></keyword><keyword><style face="normal" font="default" size="100%">xerostomia</style></keyword><keyword><style face="normal" font="default" size="100%">young adult</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2019</style></year></dates><isbn><style face="normal" font="default" size="100%">1537-6591&#xD;1058-4838</style></isbn><abstract><style face="normal" font="default" size="100%">Background: Tafenoquine was recently approved for chemoprophylaxis of malaria. Its specific activity against liver and blood stages of Plasmodium species has been separately characterized in animals but not in humans. Methods: In this randomized, double-blind, placebo-controlled study, 16 malaria-naive, glucose-6-phosphate dehydrogenase-normal participants aged 20-42 years received tafenoquine chemoprophylaxis prior to challenge with blood stage Plasmodium falciparum. Participants were randomly assigned to either tafenoquine (n = 12) or placebo (n = 4) and took blinded study medication (single 200-mg dose) on days 1, 2, 3, and 10, followed by intravenous inoculation with approximately 2800 P. falciparum parasitized erythrocytes on day 13. The primary endpoint was the number of participants requiring rescue treatment with artemether/lumefantrine due to the onset of parasitemia as determined by quantitative polymerase chain reaction. Results: None of the 12 participants who received tafenoquine developed parasitemia, whereas all placebo participants developed parasitemia (P =. 0005). Two cases of mild hemoglobin decrease and a single case of mild hyperbilirubinemia occurred in the tafenoquine group. Conclusions: Tafenoquine chemoprophylaxis is safe and effective in preventing malaria in healthy nonimmune participants challenged with blood stage P. falciparum. Clinical Trials Registration: Australian and New Zealand Clinical Trials Registry (ANZCTR): ACTRN12617000102370.</style></abstract><caption><style face="normal" font="default" size="100%">Duplicate</style></caption><notes><style face="normal" font="default" size="100%">L629408226&#xD;2019-10-01&#xD;2019-10-03</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L629408226&amp;from=export</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1093/cid/ciy939</style></url></related-urls></urls><custom5><style face="normal" font="default" size="100%">30388194</style></custom5><electronic-resource-num><style face="normal" font="default" size="100%">10.1093/cid/ciy939</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase&#xD;Medline</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>153</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">153</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">McCarthy, J. S.</style></author><author><style face="normal" font="default" size="100%">Smith, B.</style></author><author><style face="normal" font="default" size="100%">Reid, M.</style></author><author><style face="normal" font="default" size="100%">Berman, J.</style></author><author><style face="normal" font="default" size="100%">Marquart, L.</style></author><author><style face="normal" font="default" size="100%">Dobbin, C.</style></author><author><style face="normal" font="default" size="100%">West, L.</style></author><author><style face="normal" font="default" size="100%">Read, L. T.</style></author><author><style face="normal" font="default" size="100%">Dow, G. S.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Blood Schizonticidal Activity and Safety of Tafenoquine When Administered as Chemoprophylaxis to Healthy, Nonimmune Participants Followed by Blood Stage Plasmodium falciparum Challenge: a Randomized, Double-blind, Placebo-controlled Phase 1b Study</style></title><secondary-title><style face="normal" font="default" size="100%">Clinical infectious diseases</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Clinical Infectious Diseases</style></full-title></periodical><pages><style face="normal" font="default" size="100%">480‐486</style></pages><volume><style face="normal" font="default" size="100%">69</style></volume><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Aminoquinolines [*administration &amp; dosage]</style></keyword><keyword><style face="normal" font="default" size="100%">Antimalarials [*administration &amp; dosage]</style></keyword><keyword><style face="normal" font="default" size="100%">Chemoprevention [methods]</style></keyword><keyword><style face="normal" font="default" size="100%">Double‐Blind Method</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Healthy Volunteers</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Malaria, Falciparum [*prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Parasitemia [prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Placebos</style></keyword><keyword><style face="normal" font="default" size="100%">Plasmodium falciparum [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Schizonts [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Young Adult</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2019</style></year></dates><accession-num><style face="normal" font="default" size="100%">CN-02145222</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Tafenoquine was recently approved for chemoprophylaxis of malaria. Its specific activity against liver and blood stages of Plasmodium species has been separately characterized in animals but not in humans. METHODS: In this randomized, double‐blind, placebo‐controlled study, 16 malaria‐naive, glucose‐6‐phosphate dehydrogenase‐normal participants aged 20‐42 years received tafenoquine chemoprophylaxis prior to challenge with blood stage Plasmodium falciparum. Participants were randomly assigned to either tafenoquine (n = 12) or placebo (n = 4) and took blinded study medication (single 200‐mg dose) on days 1, 2, 3, and 10, followed by intravenous inoculation with approximately 2800 P. falciparum parasitized erythrocytes on day 13. The primary endpoint was the number of participants requiring rescue treatment with artemether/lumefantrine due to the onset of parasitemia as determined by quantitative polymerase chain reaction. RESULTS: None of the 12 participants who received tafenoquine developed parasitemia, whereas all placebo participants developed parasitemia (P = .0005). Two cases of mild hemoglobin decrease and a single case of mild hyperbilirubinemia occurred in the tafenoquine group. CONCLUSIONS: Tafenoquine chemoprophylaxis is safe and effective in preventing malaria in healthy nonimmune participants challenged with blood stage P. falciparum. CLINICAL TRIALS REGISTRATION: Australian and New Zealand Clinical Trials Registry (ANZCTR): ACTRN12617000102370.</style></abstract><caption><style face="normal" font="default" size="100%">Duplicate</style></caption><work-type><style face="normal" font="default" size="100%">Clinical Trial, Phase I; Journal Article; Randomized Controlled Trial; Research Support, Non‐U.S. Gov&apos;t; Research Support, U.S. Gov&apos;t, Non‐P.H.S.</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02145222/full</style></url></related-urls></urls><custom3><style face="normal" font="default" size="100%">PUBMED 30388194</style></custom3><electronic-resource-num><style face="normal" font="default" size="100%">10.1093/cid/ciy939</style></electronic-resource-num></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>160</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">160</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">McCarthy, J. S.</style></author><author><style face="normal" font="default" size="100%">Smith, B.</style></author><author><style face="normal" font="default" size="100%">Reid, M.</style></author><author><style face="normal" font="default" size="100%">Berman, J.</style></author><author><style face="normal" font="default" size="100%">Marquart, L.</style></author><author><style face="normal" font="default" size="100%">Dobbin, C.</style></author><author><style face="normal" font="default" size="100%">West, L.</style></author><author><style face="normal" font="default" size="100%">Read, L. T.</style></author><author><style face="normal" font="default" size="100%">Dow, G. S.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Blood Schizonticidal Activity and Safety of Tafenoquine When Administered as Chemoprophylaxis to Healthy, Nonimmune Participants Followed by Blood Stage Plasmodium falciparum Challenge: a Randomized, Double-blind, Placebo-controlled Phase 1b Study</style></title><secondary-title><style face="normal" font="default" size="100%">Clinical infectious diseases</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Clinical Infectious Diseases</style></full-title></periodical><pages><style face="normal" font="default" size="100%">480‐486</style></pages><volume><style face="normal" font="default" size="100%">69</style></volume><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">*Plasmodium falciparum</style></keyword><keyword><style face="normal" font="default" size="100%">*chemoprophylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">*malaria falciparum /drug therapy /prevention</style></keyword><keyword><style face="normal" font="default" size="100%">Abdominal discomfort /side effect</style></keyword><keyword><style face="normal" font="default" size="100%">Abdominal pain /side effect</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Article</style></keyword><keyword><style face="normal" font="default" size="100%">Controlled study</style></keyword><keyword><style face="normal" font="default" size="100%">Dehydration /side effect</style></keyword><keyword><style face="normal" font="default" size="100%">Double blind procedure</style></keyword><keyword><style face="normal" font="default" size="100%">Drug safety</style></keyword><keyword><style face="normal" font="default" size="100%">Erythrocyte</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Headache /side effect</style></keyword><keyword><style face="normal" font="default" size="100%">Hemoglobin blood level</style></keyword><keyword><style face="normal" font="default" size="100%">Human</style></keyword><keyword><style face="normal" font="default" size="100%">Human experiment</style></keyword><keyword><style face="normal" font="default" size="100%">Hyperbilirubinemia /side effect</style></keyword><keyword><style face="normal" font="default" size="100%">Limb pain /side effect</style></keyword><keyword><style face="normal" font="default" size="100%">Loading drug dose</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Muscle tightness /side effect</style></keyword><keyword><style face="normal" font="default" size="100%">Myalgia /side effect</style></keyword><keyword><style face="normal" font="default" size="100%">Nausea /side effect</style></keyword><keyword><style face="normal" font="default" size="100%">Normal human</style></keyword><keyword><style face="normal" font="default" size="100%">Oropharynx pain /side effect</style></keyword><keyword><style face="normal" font="default" size="100%">Parasitemia</style></keyword><keyword><style face="normal" font="default" size="100%">Priority journal</style></keyword><keyword><style face="normal" font="default" size="100%">Pyelonephritis /side effect</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized controlled trial</style></keyword><keyword><style face="normal" font="default" size="100%">Real time polymerase chain reaction</style></keyword><keyword><style face="normal" font="default" size="100%">Side effect /side effect</style></keyword><keyword><style face="normal" font="default" size="100%">Single drug dose</style></keyword><keyword><style face="normal" font="default" size="100%">Upper respiratory tract infection /side effect</style></keyword><keyword><style face="normal" font="default" size="100%">Vomiting /side effect</style></keyword><keyword><style face="normal" font="default" size="100%">Xerostomia /side effect</style></keyword><keyword><style face="normal" font="default" size="100%">Young adult</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2019</style></year></dates><accession-num><style face="normal" font="default" size="100%">CN-01997878</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: Tafenoquine was recently approved for chemoprophylaxis of malaria. Its specific activity against liver and blood stages of Plasmodium species has been separately characterized in animals but not in humans. Methods: In this randomized, double‐blind, placebo‐controlled study, 16 malaria‐naive, glucose‐6‐phosphate dehydrogenase‐normal participants aged 20‐42 years received tafenoquine chemoprophylaxis prior to challenge with blood stage Plasmodium falciparum. Participants were randomly assigned to either tafenoquine (n = 12) or placebo (n = 4) and took blinded study medication (single 200‐mg dose) on days 1, 2, 3, and 10, followed by intravenous inoculation with approximately 2800 P. falciparum parasitized erythrocytes on day 13. The primary endpoint was the number of participants requiring rescue treatment with artemether/lumefantrine due to the onset of parasitemia as determined by quantitative polymerase chain reaction. Results: None of the 12 participants who received tafenoquine developed parasitemia, whereas all placebo participants developed parasitemia (P =. 0005). Two cases of mild hemoglobin decrease and a single case of mild hyperbilirubinemia occurred in the tafenoquine group. Conclusions: Tafenoquine chemoprophylaxis is safe and effective in preventing malaria in healthy nonimmune participants challenged with blood stage P. falciparum. Clinical Trials Registration: Australian and New Zealand Clinical Trials Registry (ANZCTR): ACTRN12617000102370.</style></abstract><caption><style face="normal" font="default" size="100%">Duplicate</style></caption><work-type><style face="normal" font="default" size="100%">Journal: Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01997878/full</style></url></related-urls></urls><custom3><style face="normal" font="default" size="100%">EMBASE 629408226</style></custom3><electronic-resource-num><style face="normal" font="default" size="100%">10.1093/cid/ciy939</style></electronic-resource-num></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>39</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">39</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Thriemer, K.</style></author><author><style face="normal" font="default" size="100%">Ley, B.</style></author><author><style face="normal" font="default" size="100%">Bobogare, A.</style></author><author><style face="normal" font="default" size="100%">Dysoley, L.</style></author><author><style face="normal" font="default" size="100%">Alam, M. S.</style></author><author><style face="normal" font="default" size="100%">Pasaribu, A. P.</style></author><author><style face="normal" font="default" size="100%">Sattabongkot, J.</style></author><author><style face="normal" font="default" size="100%">Jambert, E.</style></author><author><style face="normal" font="default" size="100%">Domingo, G. J.</style></author><author><style face="normal" font="default" size="100%">Commons, R.</style></author><author><style face="normal" font="default" size="100%">Auburn, S.</style></author><author><style face="normal" font="default" size="100%">Marfurt, J.</style></author><author><style face="normal" font="default" size="100%">Devine, A.</style></author><author><style face="normal" font="default" size="100%">Aktaruzzaman, M. M.</style></author><author><style face="normal" font="default" size="100%">Sohel, N.</style></author><author><style face="normal" font="default" size="100%">Namgay, R.</style></author><author><style face="normal" font="default" size="100%">Drukpa, T.</style></author><author><style face="normal" font="default" size="100%">Sharma, S. N.</style></author><author><style face="normal" font="default" size="100%">Sarawati, E.</style></author><author><style face="normal" font="default" size="100%">Samad, I.</style></author><author><style face="normal" font="default" size="100%">Theodora, M.</style></author><author><style face="normal" font="default" size="100%">Nambanya, S.</style></author><author><style face="normal" font="default" size="100%">Ounekham, S.</style></author><author><style face="normal" font="default" size="100%">Mudin, R. N.</style></author><author><style face="normal" font="default" size="100%">Da Thakur, G.</style></author><author><style face="normal" font="default" size="100%">Makita, L. S.</style></author><author><style face="normal" font="default" size="100%">Deray, R.</style></author><author><style face="normal" font="default" size="100%">Lee, S. E.</style></author><author><style face="normal" font="default" size="100%">Boaz, L.</style></author><author><style face="normal" font="default" size="100%">Danansuriya, M. N.</style></author><author><style face="normal" font="default" size="100%">Mudiyanselage, S. D.</style></author><author><style face="normal" font="default" size="100%">Chinanonwait, N.</style></author><author><style face="normal" font="default" size="100%">Kitchakarn, S.</style></author><author><style face="normal" font="default" size="100%">Nausien, J.</style></author><author><style face="normal" font="default" size="100%">Naket, E.</style></author><author><style face="normal" font="default" size="100%">Duc, T. N.</style></author><author><style face="normal" font="default" size="100%">Do Manh, H.</style></author><author><style face="normal" font="default" size="100%">Hong, Y. S.</style></author><author><style face="normal" font="default" size="100%">Cheng, Q.</style></author><author><style face="normal" font="default" size="100%">Richards, J. S.</style></author><author><style face="normal" font="default" size="100%">Kusriastuti, R.</style></author><author><style face="normal" font="default" size="100%">Satyagraha, A.</style></author><author><style face="normal" font="default" size="100%">Noviyanti, R.</style></author><author><style face="normal" font="default" size="100%">Ding, X. C.</style></author><author><style face="normal" font="default" size="100%">Khan, W. A.</style></author><author><style face="normal" font="default" size="100%">Swe Phru, C.</style></author><author><style face="normal" font="default" size="100%">Guoding, Z.</style></author><author><style face="normal" font="default" size="100%">Qi, G.</style></author><author><style face="normal" font="default" size="100%">Kaneko, A.</style></author><author><style face="normal" font="default" size="100%">Miotto, O.</style></author><author><style face="normal" font="default" size="100%">Nguitragool, W.</style></author><author><style face="normal" font="default" size="100%">Roobsoong, W.</style></author><author><style face="normal" font="default" size="100%">Battle, K.</style></author><author><style face="normal" font="default" size="100%">Howes, R. E.</style></author><author><style face="normal" font="default" size="100%">Roca-Feltrer, A.</style></author><author><style face="normal" font="default" size="100%">Duparc, S.</style></author><author><style face="normal" font="default" size="100%">Bhowmick, I. P.</style></author><author><style face="normal" font="default" size="100%">Kenangalem, E.</style></author><author><style face="normal" font="default" size="100%">Bibit, J. A.</style></author><author><style face="normal" font="default" size="100%">Barry, A.</style></author><author><style face="normal" font="default" size="100%">Sintasath, D.</style></author><author><style face="normal" font="default" size="100%">Abeyasinghe, R.</style></author><author><style face="normal" font="default" size="100%">Sibley, C. H.</style></author><author><style face="normal" font="default" size="100%">McCarthy, J.</style></author><author><style face="normal" font="default" size="100%">von Seidlein, L.</style></author><author><style face="normal" font="default" size="100%">Baird, J. K.</style></author><author><style face="normal" font="default" size="100%">Price, R. N.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Global and Tropical Health Division, Menzies School of Health Research and Charles Darwin University, Darwin, Australia. kamala.ley-thriemer@menzies.edu.au.&#xD;Global and Tropical Health Division, Menzies School of Health Research and Charles Darwin University, Darwin, Australia.&#xD;National Vector Borne Disease Control Programme, Honiara, Solomon Islands.&#xD;National Center for Parasitology, Entomology and Malaria Control, Phnom Penh, Cambodia.&#xD;School of Public Health, National Institute of Public Health, Phnom Penh, Cambodia.&#xD;International Centre for Diarrheal Diseases and Research, Dhaka, Bangladesh.&#xD;Department of Pediatrics, Medical Faculty, University of Sumatera Utara, Medan, Indonesia.&#xD;Mahidol Vivax Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangok, Thailand.&#xD;Medicines for Malaria Venture (MMV), Geneva, Switzerland.&#xD;Diagnostics Program, PATH, Seattle, USA.&#xD;Mahidol Oxford Tropical Medicine Research Unit (MORU), Bangok, Thailand.&#xD;Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK.&#xD;Ministry of Health and Family Welfare, Malaria and Parasitic Disease Control, Director General of Health Services, Mohakhali, Dhaka, Bangladesh.&#xD;Vector-borne Disease Control Programme (VDCP), Department of Public Health, Ministry of Health in Bhutan, Thimphu, Bhutan.&#xD;National Vector Borne Disease Control Programme Directorate General of Health Services Ministry of Health &amp; Family Welfare, New Delhi, India.&#xD;National Malaria Control Program, Jakarta, Indonesia.&#xD;National Center for Entomology Parasitology and Malaria Control, Vientiane, Laos.&#xD;Vector-borne Diseases Control Programme, Ministry of Health Malaysia, Kuala Lumpur, Malaysia.&#xD;Malaria Control Programme, Epidemiology and Disease Control Division, Department of Health Services, Ministry of Health and Population, Kathmandu, Nepal.&#xD;National Malaria Control Programme, Goroka, Papua New Guinea.&#xD;Malaria Control Programme, Department of Health, Manila, Philippines.&#xD;Division of Malaria &amp; Parasitic Diseases, Korea Centers for Disease Control and Prevention, Seoul, South Korea.&#xD;Antimalaria Campaign, Ministry of Health, Colombo, Sri Lanka.&#xD;Bureau of Vector-Borne Disease, Department of Disease Control, Ministry of Public Health, Bangkok, Thailand.&#xD;National Malaria Control Programme, Port Vila, Vanuatu.&#xD;National Institute of Malaria, Parasitology, and Entomology (NIMPE), Tam Kỳ, Vietnam.&#xD;Access Bio Inc, Monmouth, USA.&#xD;Australian Army Malaria Institute, Enoggera, QLD, Australia.&#xD;Centre for Biomedical Research, Burnet Institute, Melbourne, Australia.&#xD;Vector Borne Disease Control, Ministry of Health, Jakarta, Indonesia.&#xD;Indonesian Parasitic Association, Jakarta, Indonesia.&#xD;Eijkman Institute of Molecular Biology, Jakarta, Indonesia.&#xD;FIND, Geneva, Switzerland.&#xD;Jiangsu Institute of Parasitic Diseases, Wuxi, China.&#xD;Karolinska Institutet, Stockholm, Sweden.&#xD;Osaka City University, Osaka, Japan.&#xD;Centre for Genomics and Global Health, Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK.&#xD;Wellcome Trust Sanger Institute, Hinxton, UK.&#xD;Department of Molecular Tropical Medicine, Faculty of Tropical Medicine, Mahidol University, Salaya, Thailand.&#xD;Malaria Atlas Project, Nuffield Department of Medicine, Oxford Big Data Institute, University of Oxford, Oxford, UK.&#xD;Malaria Consortium, London, UK.&#xD;Model Rural Health Research Unit (MRHRU), Tripura State, ICMR, Agartala, India.&#xD;Yayasan Pengembangan Kesehatan dan Masyarakat Papua Timika, Timika, Indonesia.&#xD;The Research Institute for Tropical Medicine, Manila, Philippines.&#xD;The Walter + Eliza Hall Institute of Medical Research, Melbourne, Australia.&#xD;Department of Medical Biology, University of Melbourne, Parkville, VIC, Australia.&#xD;President&apos;s Malaria Initiative, United States Agency for International Development, Bangkok, Thailand.&#xD;World Health Organization Western Pacific Region, Manila, Philippines.&#xD;WWARN, Oxford, UK.&#xD;University of Washington, Seattle, WA, USA.&#xD;QIMR Berghofer Medical Research Institute, Brisbane, Australia.&#xD;Eijkman-Oxford Clinical Research Unit, Jakarta, Indonesia.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Challenges for achieving safe and effective radical cure of Plasmodium vivax: a round table discussion of the APMEN Vivax Working Group</style></title><secondary-title><style face="normal" font="default" size="100%">Malar J</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Malar J</style></full-title></periodical><pages><style face="normal" font="default" size="100%">141</style></pages><volume><style face="normal" font="default" size="100%">16</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2017/04/07</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Antimalarials/*administration &amp; dosage/*adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Asia</style></keyword><keyword><style face="normal" font="default" size="100%">Diagnostic Tests, Routine/statistics &amp; numerical data</style></keyword><keyword><style face="normal" font="default" size="100%">Drug-Related Side Effects and Adverse Reactions/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Glucosephosphate Dehydrogenase Deficiency/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Malaria, Vivax/*drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Pacific Islands</style></keyword><keyword><style face="normal" font="default" size="100%">*apmen</style></keyword><keyword><style face="normal" font="default" size="100%">*P. vivax</style></keyword><keyword><style face="normal" font="default" size="100%">*Primaquine</style></keyword><keyword><style face="normal" font="default" size="100%">*Radical cure</style></keyword><keyword><style face="normal" font="default" size="100%">*Tafenoquine</style></keyword><keyword><style face="normal" font="default" size="100%">*Vivax malaria</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2017</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr 5</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1475-2875</style></isbn><accession-num><style face="normal" font="default" size="100%">28381261</style></accession-num><abstract><style face="normal" font="default" size="100%">The delivery of safe and effective radical cure for Plasmodium vivax is one of the greatest challenges for achieving malaria elimination from the Asia-Pacific by 2030. During the annual meeting of the Asia Pacific Malaria Elimination Network Vivax Working Group in October 2016, a round table discussion was held to discuss the programmatic issues hindering the widespread use of primaquine (PQ) radical cure. Participants included 73 representatives from 16 partner countries and 33 institutional partners and other research institutes. In this meeting report, the key discussion points are presented and grouped into five themes: (i) current barriers for glucose-6-phosphate deficiency (G6PD) testing prior to PQ radical cure, (ii) necessary properties of G6PD tests for wide scale deployment, (iii) the promotion of G6PD testing, (iv) improving adherence to PQ regimens and (v) the challenges for future tafenoquine (TQ) roll out. Robust point of care (PoC) G6PD tests are needed, which are suitable and cost-effective for clinical settings with limited infrastructure. An affordable and competitive test price is needed, accompanied by sustainable funding for the product with appropriate training of healthcare staff, and robust quality control and assurance processes. In the absence of quantitative PoC G6PD tests, G6PD status can be gauged with qualitative diagnostics, however none of the available tests is currently sensitive enough to guide TQ treatment. TQ introduction will require overcoming additional challenges including the management of severely and intermediately G6PD deficient individuals. Robust strategies are needed to ensure that effective treatment practices can be deployed widely, and these should ensure that the caveats are outweighed by  the benefits of radical cure for both the patients and the community. Widespread access to quality controlled G6PD testing will be critical.</style></abstract><notes><style face="normal" font="default" size="100%">1475-2875&#xD;Thriemer, Kamala&#xD;Orcid: 0000-0003-2000-2874&#xD;Ley, Benedikt&#xD;Bobogare, Albino&#xD;Dysoley, Lek&#xD;Alam, Mohammad Shafiul&#xD;Pasaribu, Ayodhia P&#xD;Sattabongkot, Jetsumon&#xD;Jambert, Elodie&#xD;Domingo, Gonzalo J&#xD;Commons, Robert&#xD;Auburn, Sarah&#xD;Marfurt, Jutta&#xD;Devine, Angela&#xD;Aktaruzzaman, Mohammad M&#xD;Sohel, Nayeem&#xD;Namgay, Rinzin&#xD;Drukpa, Tobgyel&#xD;Sharma, Surender Nath&#xD;Sarawati, Elvieda&#xD;Samad, Iriani&#xD;Theodora, Minerva&#xD;Nambanya, Simone&#xD;Ounekham, Sonesay&#xD;Mudin, Rose Nanti Binti&#xD;Da Thakur, Garib&#xD;Makita, Leo Sora&#xD;Deray, Raffy&#xD;Lee, Sang-Eun&#xD;Boaz, Leonard&#xD;Danansuriya, Manjula N&#xD;Mudiyanselage, Santha D&#xD;Chinanonwait, Nipon&#xD;Kitchakarn, Suravadee&#xD;Nausien, Johnny&#xD;Naket, Esau&#xD;Duc, Thang Ngo&#xD;Do Manh, Ha&#xD;Hong, Young S&#xD;Cheng, Qin&#xD;Richards, Jack S&#xD;Kusriastuti, Rita&#xD;Satyagraha, Ari&#xD;Noviyanti, Rintis&#xD;Ding, Xavier C&#xD;Khan, Wasif Ali&#xD;Swe Phru, Ching&#xD;Guoding, Zhu&#xD;Qi, Gao&#xD;Kaneko, Akira&#xD;Miotto, Olivo&#xD;Nguitragool, Wang&#xD;Roobsoong, Wanlapa&#xD;Battle, Katherine&#xD;Howes, Rosalind E&#xD;Roca-Feltrer, Arantxa&#xD;Duparc, Stephan&#xD;Bhowmick, Ipsita Pal&#xD;Kenangalem, Enny&#xD;Bibit, Jo-Anne&#xD;Barry, Alyssa&#xD;Sintasath, David&#xD;Abeyasinghe, Rabindra&#xD;Sibley, Carol H&#xD;McCarthy, James&#xD;von Seidlein, Lorenz&#xD;Baird, J Kevin&#xD;Price, Ric N&#xD;001/World Health Organization/International&#xD;Journal Article&#xD;Review&#xD;Malar J. 2017 Apr 5;16(1):141. doi: 10.1186/s12936-017-1784-1.</style></notes><urls></urls><custom2><style face="normal" font="default" size="100%">PMC5382417</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1186/s12936-017-1784-1</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>121</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">121</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">McBride, W. J. H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">W. J. H. McBride, School of Medicine and Dentistry, James Cook University, Cairns Base Hospital campus, Esplanade, Cairns, QLD 4870, Australia</style></auth-address><titles><title><style face="normal" font="default" size="100%">Chemoprophylaxis of tropical infectious diseases</style></title><secondary-title><style face="normal" font="default" size="100%">Pharmaceuticals</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Pharmaceuticals</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1561-1575</style></pages><volume><style face="normal" font="default" size="100%">3</style></volume><number><style face="normal" font="default" size="100%">5</style></number><keywords><keyword><style face="normal" font="default" size="100%">amoxicillin plus clavulanic acid</style></keyword><keyword><style face="normal" font="default" size="100%">antibiotic agent</style></keyword><keyword><style face="normal" font="default" size="100%">artemether</style></keyword><keyword><style face="normal" font="default" size="100%">atovaquone</style></keyword><keyword><style face="normal" font="default" size="100%">atovaquone plus proguanil</style></keyword><keyword><style face="normal" font="default" size="100%">azithromycin</style></keyword><keyword><style face="normal" font="default" size="100%">cefotaxime</style></keyword><keyword><style face="normal" font="default" size="100%">chloroquine</style></keyword><keyword><style face="normal" font="default" size="100%">chloroquine plus proguanil</style></keyword><keyword><style face="normal" font="default" size="100%">ciprofloxacin</style></keyword><keyword><style face="normal" font="default" size="100%">cotrimoxazole</style></keyword><keyword><style face="normal" font="default" size="100%">doxycycline</style></keyword><keyword><style face="normal" font="default" size="100%">hydroxychloroquine</style></keyword><keyword><style face="normal" font="default" size="100%">mefloquine</style></keyword><keyword><style face="normal" font="default" size="100%">norfloxacin</style></keyword><keyword><style face="normal" font="default" size="100%">penicillin G</style></keyword><keyword><style face="normal" font="default" size="100%">placebo</style></keyword><keyword><style face="normal" font="default" size="100%">primaquine</style></keyword><keyword><style face="normal" font="default" size="100%">proguanil</style></keyword><keyword><style face="normal" font="default" size="100%">quinoline derived antiinfective agent</style></keyword><keyword><style face="normal" font="default" size="100%">ribavirin</style></keyword><keyword><style face="normal" font="default" size="100%">rifampicin</style></keyword><keyword><style face="normal" font="default" size="100%">rifaximin</style></keyword><keyword><style face="normal" font="default" size="100%">tafenoquine</style></keyword><keyword><style face="normal" font="default" size="100%">tenofovir</style></keyword><keyword><style face="normal" font="default" size="100%">tenofovir disoproxil</style></keyword><keyword><style face="normal" font="default" size="100%">valaciclovir</style></keyword><keyword><style face="normal" font="default" size="100%">anthrax</style></keyword><keyword><style face="normal" font="default" size="100%">brucellosis</style></keyword><keyword><style face="normal" font="default" size="100%">chemoprophylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">clinical trial</style></keyword><keyword><style face="normal" font="default" size="100%">drug bioavailability</style></keyword><keyword><style face="normal" font="default" size="100%">drug half life</style></keyword><keyword><style face="normal" font="default" size="100%">enamel hypoplasia</style></keyword><keyword><style face="normal" font="default" size="100%">eye toxicity</style></keyword><keyword><style face="normal" font="default" size="100%">gastrointestinal symptom</style></keyword><keyword><style face="normal" font="default" size="100%">herpes simplex</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">Human immunodeficiency virus infection</style></keyword><keyword><style face="normal" font="default" size="100%">keratopathy</style></keyword><keyword><style face="normal" font="default" size="100%">leprosy</style></keyword><keyword><style face="normal" font="default" size="100%">leptospirosis</style></keyword><keyword><style face="normal" font="default" size="100%">malaria</style></keyword><keyword><style face="normal" font="default" size="100%">melioidosis</style></keyword><keyword><style face="normal" font="default" size="100%">nausea</style></keyword><keyword><style face="normal" font="default" size="100%">neurotoxicity</style></keyword><keyword><style face="normal" font="default" size="100%">nonhuman</style></keyword><keyword><style face="normal" font="default" size="100%">patient compliance</style></keyword><keyword><style face="normal" font="default" size="100%">plague</style></keyword><keyword><style face="normal" font="default" size="100%">Plasmodium malariae</style></keyword><keyword><style face="normal" font="default" size="100%">review</style></keyword><keyword><style face="normal" font="default" size="100%">schistosomiasis</style></keyword><keyword><style face="normal" font="default" size="100%">scrub typhus</style></keyword><keyword><style face="normal" font="default" size="100%">single drug dose</style></keyword><keyword><style face="normal" font="default" size="100%">skin toxicity</style></keyword><keyword><style face="normal" font="default" size="100%">Stevens Johnson syndrome</style></keyword><keyword><style face="normal" font="default" size="100%">tooth discoloration</style></keyword><keyword><style face="normal" font="default" size="100%">traveller diarrhea</style></keyword><keyword><style face="normal" font="default" size="100%">virus infection</style></keyword><keyword><style face="normal" font="default" size="100%">vomiting</style></keyword><keyword><style face="normal" font="default" size="100%">malarone</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2010</style></year></dates><isbn><style face="normal" font="default" size="100%">1424-8247</style></isbn><abstract><style face="normal" font="default" size="100%">Travelers to tropical countries are at risk for a variety of infectious diseases. In some cases effective vaccinations are available, but for other infections chemoprophylaxis can be offered. Malaria prevention has become increasingly complex as Plasmodium species become resistant to available drugs. In certain high risk settings, antibiotics can be used to prevent leptospirosis, scrub typhus and other infections. Post-exposure prophylaxis is appropriate for selected virulent infections. In this article the evidence for chemoprophylaxis will be reviewed. © 2010 by the authors.</style></abstract><notes><style face="normal" font="default" size="100%">L359242012&#xD;2010-08-03&#xD;2010-08-10</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L359242012&amp;from=export</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.3390/ph3051561</style></url></related-urls></urls><custom1><style face="normal" font="default" size="100%">malarone</style></custom1><electronic-resource-num><style face="normal" font="default" size="100%">10.3390/ph3051561</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>124</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">124</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Dow, G. S.</style></author><author><style face="normal" font="default" size="100%">Magill, A. J.</style></author><author><style face="normal" font="default" size="100%">Ohrt, C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">G.S. Dow, Division of Experimental Therapeutics, Walter Reed Army Institute of Research, 503 Robert Grant Ave, Silver Spring, MD 20910, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Clinical development of new prophylactic antimalarial drugs after the 5th Amendment to the Declaration of Helsinki</style></title><secondary-title><style face="normal" font="default" size="100%">Therapeutics and Clinical Risk Management</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Therapeutics and Clinical Risk Management</style></full-title></periodical><pages><style face="normal" font="default" size="100%">803-819</style></pages><volume><style face="normal" font="default" size="100%">4</style></volume><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">artemether plus benflumetol</style></keyword><keyword><style face="normal" font="default" size="100%">atovaquone</style></keyword><keyword><style face="normal" font="default" size="100%">atovaquone plus proguanil</style></keyword><keyword><style face="normal" font="default" size="100%">azithromycin</style></keyword><keyword><style face="normal" font="default" size="100%">chloroquine</style></keyword><keyword><style face="normal" font="default" size="100%">chloroquine plus proguanil</style></keyword><keyword><style face="normal" font="default" size="100%">dihydroartemisinin</style></keyword><keyword><style face="normal" font="default" size="100%">doxycycline</style></keyword><keyword><style face="normal" font="default" size="100%">pyrimethamine plus sulfadoxine</style></keyword><keyword><style face="normal" font="default" size="100%">mefloquine</style></keyword><keyword><style face="normal" font="default" size="100%">piperaquine</style></keyword><keyword><style face="normal" font="default" size="100%">placebo</style></keyword><keyword><style face="normal" font="default" size="100%">primaquine</style></keyword><keyword><style face="normal" font="default" size="100%">tafenoquine</style></keyword><keyword><style face="normal" font="default" size="100%">central nervous system disease</style></keyword><keyword><style face="normal" font="default" size="100%">clinical trial</style></keyword><keyword><style face="normal" font="default" size="100%">cost benefit analysis</style></keyword><keyword><style face="normal" font="default" size="100%">drug approval</style></keyword><keyword><style face="normal" font="default" size="100%">drug contraindication</style></keyword><keyword><style face="normal" font="default" size="100%">drug efficacy</style></keyword><keyword><style face="normal" font="default" size="100%">drug fatality</style></keyword><keyword><style face="normal" font="default" size="100%">drug formulation</style></keyword><keyword><style face="normal" font="default" size="100%">drug mechanism</style></keyword><keyword><style face="normal" font="default" size="100%">drug safety</style></keyword><keyword><style face="normal" font="default" size="100%">drug tolerability</style></keyword><keyword><style face="normal" font="default" size="100%">lack of drug effect</style></keyword><keyword><style face="normal" font="default" size="100%">esophagitis</style></keyword><keyword><style face="normal" font="default" size="100%">food drug interaction</style></keyword><keyword><style face="normal" font="default" size="100%">gastrointestinal symptom</style></keyword><keyword><style face="normal" font="default" size="100%">health care policy</style></keyword><keyword><style face="normal" font="default" size="100%">high risk population</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">malaria</style></keyword><keyword><style face="normal" font="default" size="100%">malaria falciparum</style></keyword><keyword><style face="normal" font="default" size="100%">medical ethics</style></keyword><keyword><style face="normal" font="default" size="100%">mortality</style></keyword><keyword><style face="normal" font="default" size="100%">nonhuman</style></keyword><keyword><style face="normal" font="default" size="100%">patent</style></keyword><keyword><style face="normal" font="default" size="100%">patient compliance</style></keyword><keyword><style face="normal" font="default" size="100%">Plasmodium ovale</style></keyword><keyword><style face="normal" font="default" size="100%">Plasmodium vivax</style></keyword><keyword><style face="normal" font="default" size="100%">review</style></keyword><keyword><style face="normal" font="default" size="100%">risk benefit analysis</style></keyword><keyword><style face="normal" font="default" size="100%">risk reduction</style></keyword><keyword><style face="normal" font="default" size="100%">coartem</style></keyword><keyword><style face="normal" font="default" size="100%">malarone</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2008</style></year></dates><isbn><style face="normal" font="default" size="100%">1176-6336</style></isbn><abstract><style face="normal" font="default" size="100%">Malaria is of continuing concern in nonimmune traveling populations. Traditionally, antimalarial drugs have been developed as agents for dual indications (treatment and prophylaxis). However, since 2000, when the 5th Amendment to the Declaration of Helsinki (DH2000) was adopted, development of new malaria prophylaxis drugs in this manner has ceased. As a consequence, there may not be any new drugs licensed for this indication in the foreseeable future. Major pharmaceutical companies have interpreted DH2000 to mean that the traditional development paradigm may be considered unethical because of doubt over the likelihood of benefit to endemic populations participating in clinical studies, the use of placebo, and the sustainability of post-trial access to study medications. In this article, we explore the basis of these concerns and suggest that the traditional development paradigm remains ethical under certain circumstances. We also consider alternative approaches that may be more attractive to sponsors as they either do not use placebo, or utilize populations in endemic countries who may unambiguously benefit. These approaches represent the way forward in the future, but are at present unproven in clinical practice, and face numerous regulatory, logistical and technical challenges. Consequently, in the short term, we argue that the traditional clinical development paradigm remains the most feasible approach and is ethical and consistent with the spirit of DH2000 under the appropriate circumstances. © 2008 Dove Medical Press Limited. All rights reserved.</style></abstract><notes><style face="normal" font="default" size="100%">L352436897&#xD;2008-10-09</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L352436897&amp;from=export</style></url></related-urls></urls><custom1><style face="normal" font="default" size="100%">coartem(Novartis)&#xD;malarone</style></custom1><custom2><style face="normal" font="default" size="100%">Glaxo SmithKline&#xD;Novartis</style></custom2><remote-database-name><style face="normal" font="default" size="100%">Embase</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>26</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">26</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hounkpatin, A. B.</style></author><author><style face="normal" font="default" size="100%">Kreidenweiss, A.</style></author><author><style face="normal" font="default" size="100%">Held, J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Institute of Tropical Medicine, Eberhard Karls University Tübingen, Tübingen, Germany, janaheld@hotmail.de.&#xD;German Centre for Infection Research, Partner Site Tübingen, Tübingen, Germany, janaheld@hotmail.de.&#xD;Centre de Recherches Médicales de Lambaréné (CERMEL), Lambaréné, Gabon, janaheld@hotmail.de.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Clinical utility of tafenoquine in the prevention of relapse of Plasmodium vivax malaria: a review on the mode of action and emerging trial data</style></title><secondary-title><style face="normal" font="default" size="100%">Infect Drug Resist</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Infect Drug Resist</style></full-title></periodical><pages><style face="normal" font="default" size="100%">553-570</style></pages><volume><style face="normal" font="default" size="100%">12</style></volume><edition><style face="normal" font="default" size="100%">2019/03/19</style></edition><keywords><keyword><style face="normal" font="default" size="100%">8-aminoquinoline</style></keyword><keyword><style face="normal" font="default" size="100%">Wr238605</style></keyword><keyword><style face="normal" font="default" size="100%">hypnozoite</style></keyword><keyword><style face="normal" font="default" size="100%">radical cure</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2019</style></year></dates><isbn><style face="normal" font="default" size="100%">1178-6973 (Print)&#xD;1178-6973</style></isbn><accession-num><style face="normal" font="default" size="100%">30881061</style></accession-num><abstract><style face="normal" font="default" size="100%">Tafenoquine is an 8-aminoquinoline with activity against all human life cycle stages of Plasmodium vivax, including dormant liver stages - so called hypnozoites. Its long half-life of ~15 days is allowing for a single exposure regimen. It has been under development since 1980 and received approval by the US Food and Drug Administration in summer 2018 as an anti-relapse drug for P. vivax malaria in patients aged 16 years and older and for prophylaxis of malaria caused by any Plasmodium species in adults. Prior to tafenoquine administration, glucose-6-phosphate dehydrogenase (G6PD) deficiency needs to be excluded by testing. Individuals with a deficient G6PD activity are at risk of tafenoquine-induced hemolysis - as is the case for primaquine, the mainstay drug for P. vivax radical cure. A wealth of clinical studies have been conducted and are still ongoing to assess the safety, tolerability, and efficacy of tafenoquine. This review focuses on data emerging from the latest clinical trials on P. vivax radical cure with tafenoquine, the key studies for regulatory approval of tafenoquine, and elucidates the latest hypothesis on the mode of action.</style></abstract><notes><style face="normal" font="default" size="100%">1178-6973&#xD;Hounkpatin, Aurore B&#xD;Kreidenweiss, Andrea&#xD;Held, Jana&#xD;Journal Article&#xD;Review&#xD;Infect Drug Resist. 2019 Mar 6;12:553-570. doi: 10.2147/IDR.S151031. eCollection 2019.</style></notes><urls></urls><custom2><style face="normal" font="default" size="100%">PMC6411314</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.2147/idr.S151031</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>135</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">135</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Nasveld, P.</style></author><author><style face="normal" font="default" size="100%">Kitchener, S.</style></author><author><style face="normal" font="default" size="100%">Edstein, M.</style></author><author><style face="normal" font="default" size="100%">Rieckmann, K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">P. Nasveld, Australian Defence Force, Combined Health Element, Loloho, North Solomons Province, Papua New Guinea</style></auth-address><titles><title><style face="normal" font="default" size="100%">Comparison of tafenoquine (WR238605) and primaquine in the post-exposure (terminal) prophylaxis of vivax malaria in Australian Defence Force personnel</style></title><secondary-title><style face="normal" font="default" size="100%">Transactions of the Royal Society of Tropical Medicine and Hygiene</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Transactions of the Royal Society of Tropical Medicine and Hygiene</style></full-title></periodical><pages><style face="normal" font="default" size="100%">683-684</style></pages><volume><style face="normal" font="default" size="100%">96</style></volume><number><style face="normal" font="default" size="100%">6</style></number><keywords><keyword><style face="normal" font="default" size="100%">primaquine</style></keyword><keyword><style face="normal" font="default" size="100%">tafenoquine</style></keyword><keyword><style face="normal" font="default" size="100%">abdominal cramp</style></keyword><keyword><style face="normal" font="default" size="100%">article</style></keyword><keyword><style face="normal" font="default" size="100%">Australia</style></keyword><keyword><style face="normal" font="default" size="100%">clinical trial</style></keyword><keyword><style face="normal" font="default" size="100%">controlled clinical trial</style></keyword><keyword><style face="normal" font="default" size="100%">controlled study</style></keyword><keyword><style face="normal" font="default" size="100%">diarrhea</style></keyword><keyword><style face="normal" font="default" size="100%">drug absorption</style></keyword><keyword><style face="normal" font="default" size="100%">drug blood level</style></keyword><keyword><style face="normal" font="default" size="100%">drug efficacy</style></keyword><keyword><style face="normal" font="default" size="100%">drug elimination</style></keyword><keyword><style face="normal" font="default" size="100%">drug half life</style></keyword><keyword><style face="normal" font="default" size="100%">drug safety</style></keyword><keyword><style face="normal" font="default" size="100%">drug tolerability</style></keyword><keyword><style face="normal" font="default" size="100%">exposure</style></keyword><keyword><style face="normal" font="default" size="100%">female</style></keyword><keyword><style face="normal" font="default" size="100%">headache</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">human experiment</style></keyword><keyword><style face="normal" font="default" size="100%">lethargy</style></keyword><keyword><style face="normal" font="default" size="100%">malaria</style></keyword><keyword><style face="normal" font="default" size="100%">malaria control</style></keyword><keyword><style face="normal" font="default" size="100%">male</style></keyword><keyword><style face="normal" font="default" size="100%">nausea and vomiting</style></keyword><keyword><style face="normal" font="default" size="100%">normal human</style></keyword><keyword><style face="normal" font="default" size="100%">Papua New Guinea</style></keyword><keyword><style face="normal" font="default" size="100%">patient attitude</style></keyword><keyword><style face="normal" font="default" size="100%">Plasmodium vivax</style></keyword><keyword><style face="normal" font="default" size="100%">prophylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">randomized controlled trial</style></keyword><keyword><style face="normal" font="default" size="100%">military personnel</style></keyword><keyword><style face="normal" font="default" size="100%">treatment outcome</style></keyword><keyword><style face="normal" font="default" size="100%">volunteer</style></keyword><keyword><style face="normal" font="default" size="100%">wr 238605</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2002</style></year></dates><isbn><style face="normal" font="default" size="100%">0035-9203</style></isbn><abstract><style face="normal" font="default" size="100%">On return from duty in North Solomons Province (including Bougainville Island), Papua New Guinea, 586 Australian Defence Force personnel received either primaquine (14-d) or tafenoquine (3-d) post-exposure malaria prophylaxis. Within 12 months, 6 of the 214 volunteers receiving primaquine and 7 of 378 receiving tafenoquine had developed vivax malaria. Overall, volunteers preferred the shorter course of tafenoquine.</style></abstract><caption><style face="normal" font="default" size="100%">Duplicate</style></caption><notes><style face="normal" font="default" size="100%">L36231497&#xD;2003-03-05</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L36231497&amp;from=export</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1016/S0035-9203(02)90351-2</style></url></related-urls></urls><custom1><style face="normal" font="default" size="100%">wr 238605(Glaxo SmithKline)</style></custom1><custom2><style face="normal" font="default" size="100%">Glaxo SmithKline</style></custom2><custom5><style face="normal" font="default" size="100%">12625150</style></custom5><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/S0035-9203(02)90351-2</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase&#xD;Medline</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>172</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">172</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Nasveld, P.</style></author><author><style face="normal" font="default" size="100%">Kitchener, S.</style></author><author><style face="normal" font="default" size="100%">Edstein, M.</style></author><author><style face="normal" font="default" size="100%">Rieckmann, K.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Comparison of tafenoquine (WR238605) and primaquine in the post-exposure (terminal) prophylaxis of vivax malaria in Australian Defence Force personnel</style></title><secondary-title><style face="normal" font="default" size="100%">Transactions of the royal society of tropical medicine and hygiene</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Transactions of the Royal Society of Tropical Medicine and Hygiene</style></full-title></periodical><pages><style face="normal" font="default" size="100%">683‐684</style></pages><volume><style face="normal" font="default" size="100%">96</style></volume><number><style face="normal" font="default" size="100%">6</style></number><dates><year><style face="normal" font="default" size="100%">2002</style></year></dates><accession-num><style face="normal" font="default" size="100%">CN-00677540</style></accession-num><abstract><style face="normal" font="default" size="100%">On return from duty in North Solomons Province (including Bougainville Island), Papua New Guinea, 586 Australian Defence Force personnel received either primaquine (14‐d) or tafenoquine (3‐d) post‐exposure malaria prophylaxis. Within 12 months, 6 of the 214 volunteers receiving primaquine and 7 of 378 receiving tafenoquine had developed vivax malaria. Overall, volunteers preferred the shorter course of tafenoquine.</style></abstract><caption><style face="normal" font="default" size="100%">Duplicate</style></caption><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.cochranelibrary.com/central/doi/10.1002/central/CN-00677540/full</style></url></related-urls></urls></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>173</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">173</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Nasveld, P.</style></author><author><style face="normal" font="default" size="100%">Kitchener, S.</style></author><author><style face="normal" font="default" size="100%">Edstein, M.</style></author><author><style face="normal" font="default" size="100%">Rieckmann, K.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Comparison of tafenoquine (WR238605) and primaquine in the post-exposure (terminal) prophylaxis of vivax malaria in Australian Defence Force personnel</style></title><secondary-title><style face="normal" font="default" size="100%">Transactions of the royal society of tropical medicine and hygiene</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Transactions of the Royal Society of Tropical Medicine and Hygiene</style></full-title></periodical><pages><style face="normal" font="default" size="100%">683‐684</style></pages><volume><style face="normal" font="default" size="100%">96</style></volume><number><style face="normal" font="default" size="100%">6</style></number><keywords><keyword><style face="normal" font="default" size="100%">*Plasmodium vivax</style></keyword><keyword><style face="normal" font="default" size="100%">*malaria /drug therapy /etiology /prevention</style></keyword><keyword><style face="normal" font="default" size="100%">Abdominal cramp /side effect</style></keyword><keyword><style face="normal" font="default" size="100%">Article</style></keyword><keyword><style face="normal" font="default" size="100%">Australia</style></keyword><keyword><style face="normal" font="default" size="100%">Clinical trial</style></keyword><keyword><style face="normal" font="default" size="100%">Controlled clinical trial</style></keyword><keyword><style face="normal" font="default" size="100%">Controlled study</style></keyword><keyword><style face="normal" font="default" size="100%">Diarrhea /side effect</style></keyword><keyword><style face="normal" font="default" size="100%">Drug absorption</style></keyword><keyword><style face="normal" font="default" size="100%">Drug blood level</style></keyword><keyword><style face="normal" font="default" size="100%">Drug efficacy</style></keyword><keyword><style face="normal" font="default" size="100%">Drug elimination</style></keyword><keyword><style face="normal" font="default" size="100%">Drug half life</style></keyword><keyword><style face="normal" font="default" size="100%">Drug safety</style></keyword><keyword><style face="normal" font="default" size="100%">Drug tolerability</style></keyword><keyword><style face="normal" font="default" size="100%">Exposure</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Headache /side effect</style></keyword><keyword><style face="normal" font="default" size="100%">Human</style></keyword><keyword><style face="normal" font="default" size="100%">Human experiment</style></keyword><keyword><style face="normal" font="default" size="100%">Lethargy /side effect</style></keyword><keyword><style face="normal" font="default" size="100%">Malaria control</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Nausea and vomiting /side effect</style></keyword><keyword><style face="normal" font="default" size="100%">Normal human</style></keyword><keyword><style face="normal" font="default" size="100%">Papua New Guinea</style></keyword><keyword><style face="normal" font="default" size="100%">Patient attitude</style></keyword><keyword><style face="normal" font="default" size="100%">Prophylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized controlled trial</style></keyword><keyword><style face="normal" font="default" size="100%">Soldier</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Volunteer</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2002</style></year></dates><accession-num><style face="normal" font="default" size="100%">CN-01781439</style></accession-num><abstract><style face="normal" font="default" size="100%">On return from duty in North Solomons Province (including Bougainville Island), Papua New Guinea, 586 Australian Defence Force personnel received either primaquine (14‐d) or tafenoquine (3‐d) post‐exposure malaria prophylaxis. Within 12 months, 6 of the 214 volunteers receiving primaquine and 7 of 378 receiving tafenoquine had developed vivax malaria. Overall, volunteers preferred the shorter course of tafenoquine.</style></abstract><caption><style face="normal" font="default" size="100%">Duplicate</style></caption><work-type><style face="normal" font="default" size="100%">Journal: Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01781439/full</style></url></related-urls></urls><custom3><style face="normal" font="default" size="100%">PUBMED 12625150,EMBASE 36231497</style></custom3><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/S0035-9203(02)90351-2</style></electronic-resource-num></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>98</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">98</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">McCarthy, J. S.</style></author><author><style face="normal" font="default" size="100%">Smith, B. L.</style></author><author><style face="normal" font="default" size="100%">Read, L. T.</style></author><author><style face="normal" font="default" size="100%">Dow, G.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">J.S. McCarthy, QIMR Berghofer Medical Research Institute, Herston, Australia</style></auth-address><titles><title><style face="normal" font="default" size="100%">Confirmation of the blood stage schizonticidal activity of tafenoquine in a randomized, doubleblinded, placebo-controlled plasmodium falciparum induced blood stage malaria challenge study</style></title><secondary-title><style face="normal" font="default" size="100%">American Journal of Tropical Medicine and Hygiene</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">American Journal of Tropical Medicine and Hygiene</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3</style></pages><volume><style face="normal" font="default" size="100%">97</style></volume><number><style face="normal" font="default" size="100%">5</style></number><keywords><keyword><style face="normal" font="default" size="100%">benflumetol</style></keyword><keyword><style face="normal" font="default" size="100%">endogenous compound</style></keyword><keyword><style face="normal" font="default" size="100%">glucose 6 phosphate dehydrogenase</style></keyword><keyword><style face="normal" font="default" size="100%">placebo</style></keyword><keyword><style face="normal" font="default" size="100%">tafenoquine</style></keyword><keyword><style face="normal" font="default" size="100%">adult</style></keyword><keyword><style face="normal" font="default" size="100%">adverse event</style></keyword><keyword><style face="normal" font="default" size="100%">blood</style></keyword><keyword><style face="normal" font="default" size="100%">clinical article</style></keyword><keyword><style face="normal" font="default" size="100%">cohort analysis</style></keyword><keyword><style face="normal" font="default" size="100%">conference abstract</style></keyword><keyword><style face="normal" font="default" size="100%">controlled study</style></keyword><keyword><style face="normal" font="default" size="100%">double blind procedure</style></keyword><keyword><style face="normal" font="default" size="100%">drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">female</style></keyword><keyword><style face="normal" font="default" size="100%">gene expression</style></keyword><keyword><style face="normal" font="default" size="100%">genotype</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">inoculation</style></keyword><keyword><style face="normal" font="default" size="100%">liver</style></keyword><keyword><style face="normal" font="default" size="100%">malaria</style></keyword><keyword><style face="normal" font="default" size="100%">male</style></keyword><keyword><style face="normal" font="default" size="100%">nonhuman</style></keyword><keyword><style face="normal" font="default" size="100%">parasite</style></keyword><keyword><style face="normal" font="default" size="100%">parasitemia</style></keyword><keyword><style face="normal" font="default" size="100%">Plasmodium falciparum</style></keyword><keyword><style face="normal" font="default" size="100%">polymerase chain reaction</style></keyword><keyword><style face="normal" font="default" size="100%">prevention</style></keyword><keyword><style face="normal" font="default" size="100%">randomized controlled trial</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2017</style></year></dates><isbn><style face="normal" font="default" size="100%">0002-9637</style></isbn><abstract><style face="normal" font="default" size="100%">Tafenoquine (TQ), a primaquine analog, with a half-life of ∼14 days, has appealing properties as a drug for malaria chemoprophylaxis. Previous studies have suggested that TQ is effective against both liver and asexual blood stages of Plasmodium falciparum. However, it was difficult to determine the contribution of the blood stage activity to its overall prophylactic effect. To investigate its blood stage schizonticidal activity distinct from liver stage activity, a randomized, double-blinded, placebocontrolled blood stage challenge study with P. falciparum was undertaken in 16 healthy, malaria-naive adults. The study was conducted in 2 cohorts of 8 (6 active/2 placebo), with subjects in each cohort receiving 200 mg of TQ or placebo on days 1, 2, 3 and 10, followed by an IV inoculation with 2,800 P. falciparum blood stage parasites on day 13. The primary endpoint was the number of participants requiring rescue treatment with artementher/lumefantrine due to PCR-determined parasitemia &gt;5,000/mL before end of study (Day 32). Secondary endpoints include adverse effects, and TQ concentration if drug failure occurred. All 12 subjects in the TQ arm remained PCR-negative, while all 4 subjects allocated to placebo reached target parasitemia in the expected timeframe. Two subjects had a mild asymptomatic drop in Hb: A female subject allocated to the TQ arm had a 28g/L (20.3% from baseline of 138g/L) drop despite normal G6PD levels. G6pd Genotyping is underway; a male subject, also allocated to TQ had a transient 20g/L (13.7% from baseline of 146g/L)drop in Hb. In conclusion, the findings of this study support the hypothesis that TQ has sufficient blood stage schizontocidal activity to prevent clinical malaria if there is a small subpopulation of liver stage P. falciparum parasites that escape its causal prophylactic effect of TQ.</style></abstract><caption><style face="normal" font="default" size="100%">Duplicate</style></caption><notes><style face="normal" font="default" size="100%">L620729740&#xD;2018-02-21</style></notes><work-type><style face="normal" font="default" size="100%">Conference Abstract</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L620729740&amp;from=export</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Embase</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>154</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">154</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">McCarthy, J. S.</style></author><author><style face="normal" font="default" size="100%">Smith, B. L.</style></author><author><style face="normal" font="default" size="100%">Read, L. T.</style></author><author><style face="normal" font="default" size="100%">Dow, G.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Confirmation of the blood stage schizonticidal activity of tafenoquine in a randomized, doubleblinded, placebo-controlled plasmodium falciparum induced blood stage malaria challenge study</style></title><secondary-title><style face="normal" font="default" size="100%">American journal of tropical medicine and hygiene</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">American Journal of Tropical Medicine and Hygiene</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3‐</style></pages><volume><style face="normal" font="default" size="100%">97</style></volume><number><style face="normal" font="default" size="100%">5</style></number><keywords><keyword><style face="normal" font="default" size="100%">*Plasmodium falciparum</style></keyword><keyword><style face="normal" font="default" size="100%">*blood</style></keyword><keyword><style face="normal" font="default" size="100%">*malaria</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Adverse event</style></keyword><keyword><style face="normal" font="default" size="100%">Clinical article</style></keyword><keyword><style face="normal" font="default" size="100%">Cohort analysis</style></keyword><keyword><style face="normal" font="default" size="100%">Conference abstract</style></keyword><keyword><style face="normal" font="default" size="100%">Controlled study</style></keyword><keyword><style face="normal" font="default" size="100%">Double blind procedure</style></keyword><keyword><style face="normal" font="default" size="100%">Drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Gene expression</style></keyword><keyword><style face="normal" font="default" size="100%">Genotype</style></keyword><keyword><style face="normal" font="default" size="100%">Human</style></keyword><keyword><style face="normal" font="default" size="100%">Inoculation</style></keyword><keyword><style face="normal" font="default" size="100%">Liver</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Nonhuman</style></keyword><keyword><style face="normal" font="default" size="100%">Parasite</style></keyword><keyword><style face="normal" font="default" size="100%">Parasitemia</style></keyword><keyword><style face="normal" font="default" size="100%">Polymerase chain reaction</style></keyword><keyword><style face="normal" font="default" size="100%">Prevention</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized controlled trial</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2017</style></year></dates><accession-num><style face="normal" font="default" size="100%">CN-01462140</style></accession-num><abstract><style face="normal" font="default" size="100%">Tafenoquine (TQ), a primaquine analog, with a half‐life of ∼14 days, has appealing properties as a drug for malaria chemoprophylaxis. Previous studies have suggested that TQ is effective against both liver and asexual blood stages of Plasmodium falciparum. However, it was difficult to determine the contribution of the blood stage activity to its overall prophylactic effect. To investigate its blood stage schizonticidal activity distinct from liver stage activity, a randomized, double‐blinded, placebocontrolled blood stage challenge study with P. falciparum was undertaken in 16 healthy, malaria‐naive adults. The study was conducted in 2 cohorts of 8 (6 active/2 placebo), with subjects in each cohort receiving 200 mg of TQ or placebo on days 1, 2, 3 and 10, followed by an IV inoculation with 2,800 P. falciparum blood stage parasites on day 13. The primary endpoint was the number of participants requiring rescue treatment with artementher/lumefantrine due to PCR‐determined parasitemia &gt;5,000/mL before end of study (Day 32). Secondary endpoints include adverse effects, and TQ concentration if drug failure occurred. All 12 subjects in the TQ arm remained PCR‐negative, while all 4 subjects allocated to placebo reached target parasitemia in the expected timeframe. Two subjects had a mild asymptomatic drop in Hb: A female subject allocated to the TQ arm had a 28g/L (20.3% from baseline of 138g/L) drop despite normal G6PD levels. G6pd Genotyping is underway; a male subject, also allocated to TQ had a transient 20g/L (13.7% from baseline of 146g/L)drop in Hb. In conclusion, the findings of this study support the hypothesis that TQ has sufficient blood stage schizontocidal activity to prevent clinical malaria if there is a small subpopulation of liver stage P. falciparum parasites that escape its causal prophylactic effect of TQ.</style></abstract><caption><style face="normal" font="default" size="100%">Duplicate</style></caption><work-type><style face="normal" font="default" size="100%">Journal: Conference Abstract</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01462140/full</style></url></related-urls></urls><custom3><style face="normal" font="default" size="100%">EMBASE 620729740</style></custom3></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>75</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">75</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Milhous, W. K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Experimental Therapeutics Division, Walter Reed Army Institute of Research, Silver Spring, MD 20910, USA. wilbur.milhous@na.amedd.army.mil</style></auth-address><titles><title><style face="normal" font="default" size="100%">Development of new drugs for chemoprophylaxis of malaria</style></title><secondary-title><style face="normal" font="default" size="100%">Med Trop (Mars)</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Med Trop (Mars)</style></full-title></periodical><pages><style face="normal" font="default" size="100%">48-50</style></pages><volume><style face="normal" font="default" size="100%">61</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2001/10/05</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Antimalarials/*therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Approval</style></keyword><keyword><style face="normal" font="default" size="100%">*Drug Design</style></keyword><keyword><style face="normal" font="default" size="100%">Drugs, Investigational</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Malaria/drug therapy/*prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Military Personnel</style></keyword><keyword><style face="normal" font="default" size="100%">*Technology, Pharmaceutical</style></keyword><keyword><style face="normal" font="default" size="100%">United States</style></keyword><keyword><style face="normal" font="default" size="100%">United States Food and Drug Administration</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2001</style></year></dates><isbn><style face="normal" font="default" size="100%">0025-682X (Print)&#xD;0025-682x</style></isbn><accession-num><style face="normal" font="default" size="100%">11584654</style></accession-num><abstract><style face="normal" font="default" size="100%">When U.S. troops first encountered drug resistant malaria during the Vietnam war, the United States Army responded by establishing a malaria drug research program. In 1988, the Walter Reed Army Institute of Research developed mefloquine (WR 149240) and halofantrine (WR 171669). Actually, in association with SmithKline Beecham, the WRAIR is developing tafenoquine (WR 238605), an analog of primaquine, which is expected to be effective in both preventing and treating malaria in deployed military personnel. Final phase III studies leading to U.S. Food and Drug Administration approval are planned for 2000. Applied research is also carried out with the association atovaquone-proguanil (Malarone) or with azithromycin, but also with primaquine, the associations paludrine-dapsone or lapudrine-dapsone, analogs of floxacrine (WR 243251), and a guanylhydrazone (WR 182393). The future scientific directions must focus on basic and applied research for a better understanding of the modes of action and mechanisms of resistance to standard and developmental drugs. Using new techniques, the design and synthesis of new drugs would hopefully result in the development of drugs that circumvent the malaria parasites elusive mechanisms of drug resistance.</style></abstract><notes><style face="normal" font="default" size="100%">Milhous, W K&#xD;Journal Article&#xD;Review&#xD;France&#xD;Med Trop (Mars). 2001;61(1):48-50.</style></notes><urls></urls><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>83</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">83</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Trigg, P. I.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Malaria Unit, World Health Organization, Geneva, Switzerland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Drug use and design in the nineties</style></title><secondary-title><style face="normal" font="default" size="100%">Acta Leiden</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Acta Leiden</style></full-title></periodical><pages><style face="normal" font="default" size="100%">147-56</style></pages><volume><style face="normal" font="default" size="100%">60</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">1991/01/01</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Aminoquinolines/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Amodiaquine/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Antimalarials/*therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">*Artemisinins</style></keyword><keyword><style face="normal" font="default" size="100%">Calcium Channel Blockers/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Chloroquine/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Malaria/*drug therapy/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Mefloquine/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Naphthoquinones/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Phenanthrenes/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Primaquine/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Quinine/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Sesquiterpenes/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Sulfadoxine/therapeutic use</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">1991</style></year></dates><isbn><style face="normal" font="default" size="100%">0065-1362 (Print)&#xD;0065-1362</style></isbn><accession-num><style face="normal" font="default" size="100%">1820704</style></accession-num><notes><style face="normal" font="default" size="100%">Trigg, P I&#xD;Journal Article&#xD;Netherlands&#xD;Acta Leiden. 1991;60(1):147-56.</style></notes><urls></urls><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>34</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">34</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ashley, E. A.</style></author><author><style face="normal" font="default" size="100%">Phyo, A. P.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Myanmar Oxford Clinical Research Unit, Yangon, Myanmar. liz@tropmedres.ac.&#xD;Nuffield Department of Medicine, Centre for Tropical Medicine and Global Health, University of Oxford, Oxford, UK. liz@tropmedres.ac.&#xD;Myanmar Oxford Clinical Research Unit, Yangon, Myanmar.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Drugs in Development for Malaria</style></title><secondary-title><style face="normal" font="default" size="100%">Drugs</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Drugs</style></full-title></periodical><pages><style face="normal" font="default" size="100%">861-879</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2018/05/29</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Aminoquinolines/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Antimalarials/administration &amp; dosage/adverse effects/*chemistry/*therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Artemisinins/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Discovery</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Resistance, Multiple</style></keyword><keyword><style face="normal" font="default" size="100%">Ferrous Compounds/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Imidazoles/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Lumefantrine/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Malaria/*drug therapy/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Metallocenes</style></keyword><keyword><style face="normal" font="default" size="100%">Piperazines/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Signal Transduction</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2018</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0012-6667 (Print)&#xD;0012-6667</style></isbn><accession-num><style face="normal" font="default" size="100%">29802605</style></accession-num><abstract><style face="normal" font="default" size="100%">The last two decades have seen a surge in antimalarial drug development with product development partnerships taking a leading role. Resistance of Plasmodium falciparum to the artemisinin derivatives, piperaquine and mefloquine in Southeast Asia means new antimalarials are needed with some urgency. There are at least 13 agents in clinical development. Most of these are blood schizonticides for the treatment of uncomplicated falciparum malaria, under evaluation either singly or as part of two-drug combinations. Leading candidates progressing through the pipeline are artefenomel-ferroquine and lumefantrine-KAF156, both in Phase 2b. Treatment of severe malaria continues to rely on two parenteral drugs with ancient forebears: artesunate and quinine, with sevuparin being evaluated as an adjuvant therapy. Tafenoquine is under review by stringent regulatory authorities for approval as a single-dose treatment for Plasmodium vivax relapse prevention. This represents an advance over standard 14-day primaquine regimens; however, the risk of acute haemolytic anaemia in patients with glucose-6-phosphate dehydrogenase deficiency remains. For disease prevention, several of the newer agents show potential but are unlikely to be recommended for use in the main target groups of pregnant women and young children for some years. Latest predictions are that the malaria burden will continue to be high in the coming decades. This fact, coupled with the repeated loss of antimalarials to resistance, indicates that new antimalarials will be needed for years to come. Failure of the artemisinin-based combinations in Southeast Asia has stimulated a reappraisal of current approaches to combination therapy for malaria with incorporation of three or more drugs in a single treatment under consideration.</style></abstract><notes><style face="normal" font="default" size="100%">1179-1950&#xD;Ashley, Elizabeth A&#xD;Orcid: 0000-0002-7620-4822&#xD;Phyo, Aung Pyae&#xD;Wellcome Trust/United Kingdom&#xD;Journal Article&#xD;Review&#xD;Drugs. 2018 Jun;78(9):861-879. doi: 10.1007/s40265-018-0911-9.</style></notes><urls></urls><custom2><style face="normal" font="default" size="100%">PMC6013505 Venture and KAF156 and cipargamin sponsored by Novartis. EAA was a co-investigator on studies of DHA–piperaquine funded by Medicines for Malaria Venture and of artesunate–mefloquine funded by Drugs for Neglected Disease Initiative.</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1007/s40265-018-0911-9</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>29</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">29</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Fukuda, M. M.</style></author><author><style face="normal" font="default" size="100%">Wojnarski, M.</style></author><author><style face="normal" font="default" size="100%">Martin, N.</style></author><author><style face="normal" font="default" size="100%">Zottig, V.</style></author><author><style face="normal" font="default" size="100%">Waters, N. C.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Editorial: Malaria in the Korean peninsula: Risk factors, latent infections, and the possible role of tafenoquine, a new antimalarial weapon</style></title><secondary-title><style face="normal" font="default" size="100%">Msmr</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Msmr</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2-3</style></pages><volume><style face="normal" font="default" size="100%">25</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2018/11/27</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Aminoquinolines/*therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Antimalarials/*therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Malaria/*drug therapy/*prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Military Personnel</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2018</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">2152-8217</style></isbn><accession-num><style face="normal" font="default" size="100%">30475635</style></accession-num><notes><style face="normal" font="default" size="100%">2152-8217&#xD;Fukuda, Mark M&#xD;Wojnarski, Mariusz&#xD;Martin, Nicholas&#xD;Zottig, Victor&#xD;Waters, Norman C&#xD;Journal Article&#xD;United States&#xD;MSMR. 2018 Nov;25(11):2-3.</style></notes><urls></urls><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>181</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">181</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Nct,</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Efficacy and Safety Study of Tafenoquine (TQ) Co-administered With Dihydroartemisinin-piperaquine (DHA-PQP) for the Radical Cure of Plasmodium Vivax (P. Vivax) Malaria</style></title><secondary-title><style face="normal" font="default" size="100%">https://clinicaltrials.gov/show/NCT02802501</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">https://clinicaltrials.gov/show/NCT02802501</style></full-title></periodical><keywords><keyword><style face="normal" font="default" size="100%">Artemisinins</style></keyword><keyword><style face="normal" font="default" size="100%">Dihydroartemisinin</style></keyword><keyword><style face="normal" font="default" size="100%">Malaria</style></keyword><keyword><style face="normal" font="default" size="100%">Malaria, Vivax</style></keyword><keyword><style face="normal" font="default" size="100%">Piperaquine</style></keyword><keyword><style face="normal" font="default" size="100%">Primaquine</style></keyword><keyword><style face="normal" font="default" size="100%">Tafenoquine</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2016</style></year></dates><accession-num><style face="normal" font="default" size="100%">CN-01578224</style></accession-num><abstract><style face="normal" font="default" size="100%">Tafenoquine (TQ) is an 8‐aminoquinoline anti‐malarial drug which is in development as a single‐dose treatment for the radical cure of P.vivax malaria when given with standard doses of chloroquine. Currently, the only available drug for radical cure is primaquine (PQ) which requires administration over 14 days, resulting in poor compliance. In Indonesia, chloroquine has been replaced by artemisinin‐based combination therapy (i.e. ACTs) due to widespread chloroquine resistance. This study will evaluate the efficacy and safety of a single dose of tafenoquine when co‐administered with an ACT (i.e. DHA‐PQP). This single‐center, double‐blind, double‐dummy, randomized study will test the superiority of DHA‐PQP plus TQ against DHA‐PQP alone in the prevention of P. vivax malaria relapse at 6 months. The study will be conducted in male Indonesian soldiers diagnosed with P.vivax malaria on return from deployment to a malarious region of Indonesia. A PQ plus DHA‐PQP comparator arm is included to provide an informal comparison against the standard 14 day treatment for P.vivax malaria in Indonesia. Subjects who are glucose‐6‐phosphate dehydrogenase deficient (G6PD deficient) will be excluded due to the risk of acute hemolysis following dosing with 8‐aminoquinolines drugs. Subjects who have a recurrence of P.vivax malaria during the study will be treated with an ACT plus PQ (0.5mg/kg for 14 days), in line with local treatment guidelines. At the end of the 6 month follow up period, any subject who has not relapsed will be given open label PQ (0.5mg/kg daily for 14 days) to minimize the likelihood of relapse after the study. Approximately 200 subjects will be screened to achieve 150 randomized subjects. The total duration of study for each subject will be 180‐195 days. This study is being carried out to support registration of TQ in Indonesia and other countries where ACTs are first line therapy.</style></abstract><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01578224/full</style></url></related-urls></urls></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>58</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">58</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Elmes, N. J.</style></author><author><style face="normal" font="default" size="100%">Nasveld, P. E.</style></author><author><style face="normal" font="default" size="100%">Kitchener, S. J.</style></author><author><style face="normal" font="default" size="100%">Kocisko, D. A.</style></author><author><style face="normal" font="default" size="100%">Edstein, M. D.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Australian Army Malaria Institute, Enoggera, Brisbane, QLD 4051, Australia. nathan.elmes@defence.gov.au</style></auth-address><titles><title><style face="normal" font="default" size="100%">The efficacy and tolerability of three different regimens of tafenoquine versus primaquine for post-exposure prophylaxis of Plasmodium vivax malaria in the Southwest Pacific</style></title><secondary-title><style face="normal" font="default" size="100%">Trans R Soc Trop Med Hyg</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Trans R Soc Trop Med Hyg</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1095-101</style></pages><volume><style face="normal" font="default" size="100%">102</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2008/06/11</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Aminoquinolines/*administration &amp; dosage/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Antimalarials/*administration &amp; dosage/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Australia</style></keyword><keyword><style face="normal" font="default" size="100%">Dose-Response Relationship, Drug</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Malaria, Vivax/*drug therapy/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Military Personnel</style></keyword><keyword><style face="normal" font="default" size="100%">Plasmodium vivax/*drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Primaquine/*administration &amp; dosage/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Statistics as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Young Adult</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2008</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0035-9203</style></isbn><accession-num><style face="normal" font="default" size="100%">18541280</style></accession-num><abstract><style face="normal" font="default" size="100%">Tafenoquine is being developed for radical cure and post-exposure prophylaxis of Plasmodium vivax malaria. In an open-label study, 1512 Australian Defence Force personnel received one of three tafenoquine 3 d regimens [400 mg once daily (od), 200 mg twice daily (bid), 200 mg od] or daily primaquine (22.5 mg) plus doxycycline (100 mg) over 14 d in Bougainville and in Timor-Leste for post-exposure prophylaxis. The relapse rate of subjects treated in Bougainville with tafenoquine (n=173) was 1.2% (200 mg bid x 3 d) and 2.3% (400 mg od x 3 d), while primaquine plus doxycycline (n=175) was 3.4%. For subjects treated in Timor-Leste with tafenoquine (n=636), the relapse rate was 4.9% (200 mg od x 3 d), 5.3% (200 mg bid x 3 d) and 11.0% (400 mg od x 3d), while primaquine plus doxycycline (n=289) was 10.0%. The most frequent adverse events reported across all groups were nausea, abdominal distress and diarrhoea. There was a dose-dependent reduction in adverse events with a reduced dose of tafenoquine, with the lowest dose (total 600 mg over 3 d) producing rates of adverse events equivalent to that of primaquine plus doxycycline. The much shorter dosing regimen of tafenoquine should increase compliance, which is often suboptimal with primaquine after leaving an endemic area. [Australian New Zealand Clinical Trials Registry Number 12607000588493].</style></abstract><caption><style face="normal" font="default" size="100%">Duplicate</style></caption><notes><style face="normal" font="default" size="100%">1878-3503&#xD;Elmes, N J&#xD;Nasveld, P E&#xD;Kitchener, S J&#xD;Kocisko, D A&#xD;Edstein, M D&#xD;Journal Article&#xD;Randomized Controlled Trial&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;England&#xD;Trans R Soc Trop Med Hyg. 2008 Nov;102(11):1095-101. doi: 10.1016/j.trstmh.2008.04.024. Epub 2008 Jun 9.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.trstmh.2008.04.024</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>123</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">123</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Elmes, N. J.</style></author><author><style face="normal" font="default" size="100%">Nasveld, P. E.</style></author><author><style face="normal" font="default" size="100%">Kitchener, S. J.</style></author><author><style face="normal" font="default" size="100%">Kocisko, D. A.</style></author><author><style face="normal" font="default" size="100%">Edstein, M. D.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">N.J. Elmes, Australian Army Malaria Institute, Enoggera, Brisbane, QLD 4051, Australia</style></auth-address><titles><title><style face="normal" font="default" size="100%">The efficacy and tolerability of three different regimens of tafenoquine versus primaquine for post-exposure prophylaxis of Plasmodium vivax malaria in the Southwest Pacific</style></title><secondary-title><style face="normal" font="default" size="100%">Transactions of the Royal Society of Tropical Medicine and Hygiene</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Transactions of the Royal Society of Tropical Medicine and Hygiene</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1095-1101</style></pages><volume><style face="normal" font="default" size="100%">102</style></volume><number><style face="normal" font="default" size="100%">11</style></number><keywords><keyword><style face="normal" font="default" size="100%">doxycycline</style></keyword><keyword><style face="normal" font="default" size="100%">primaquine</style></keyword><keyword><style face="normal" font="default" size="100%">tafenoquine</style></keyword><keyword><style face="normal" font="default" size="100%">abdominal discomfort</style></keyword><keyword><style face="normal" font="default" size="100%">adult</style></keyword><keyword><style face="normal" font="default" size="100%">article</style></keyword><keyword><style face="normal" font="default" size="100%">Australia</style></keyword><keyword><style face="normal" font="default" size="100%">chemoprophylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">civil defense</style></keyword><keyword><style face="normal" font="default" size="100%">clinical trial</style></keyword><keyword><style face="normal" font="default" size="100%">controlled clinical trial</style></keyword><keyword><style face="normal" font="default" size="100%">controlled study</style></keyword><keyword><style face="normal" font="default" size="100%">diarrhea</style></keyword><keyword><style face="normal" font="default" size="100%">dosage schedule comparison</style></keyword><keyword><style face="normal" font="default" size="100%">dose response</style></keyword><keyword><style face="normal" font="default" size="100%">drug blood level</style></keyword><keyword><style face="normal" font="default" size="100%">drug dose reduction</style></keyword><keyword><style face="normal" font="default" size="100%">drug dose regimen</style></keyword><keyword><style face="normal" font="default" size="100%">drug efficacy</style></keyword><keyword><style face="normal" font="default" size="100%">drug induced headache</style></keyword><keyword><style face="normal" font="default" size="100%">drug megadose</style></keyword><keyword><style face="normal" font="default" size="100%">drug safety</style></keyword><keyword><style face="normal" font="default" size="100%">drug tolerability</style></keyword><keyword><style face="normal" font="default" size="100%">female</style></keyword><keyword><style face="normal" font="default" size="100%">flatulence</style></keyword><keyword><style face="normal" font="default" size="100%">gastrointestinal disease</style></keyword><keyword><style face="normal" font="default" size="100%">gastrointestinal reflux</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">lethargy</style></keyword><keyword><style face="normal" font="default" size="100%">major clinical study</style></keyword><keyword><style face="normal" font="default" size="100%">malaria</style></keyword><keyword><style face="normal" font="default" size="100%">malaria control</style></keyword><keyword><style face="normal" font="default" size="100%">male</style></keyword><keyword><style face="normal" font="default" size="100%">nausea</style></keyword><keyword><style face="normal" font="default" size="100%">open study</style></keyword><keyword><style face="normal" font="default" size="100%">patient compliance</style></keyword><keyword><style face="normal" font="default" size="100%">Plasmodium vivax</style></keyword><keyword><style face="normal" font="default" size="100%">randomized controlled trial</style></keyword><keyword><style face="normal" font="default" size="100%">recurrence risk</style></keyword><keyword><style face="normal" font="default" size="100%">military personnel</style></keyword><keyword><style face="normal" font="default" size="100%">Timor-Leste</style></keyword><keyword><style face="normal" font="default" size="100%">vomiting</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2008</style></year></dates><isbn><style face="normal" font="default" size="100%">0035-9203</style></isbn><abstract><style face="normal" font="default" size="100%">Tafenoquine is being developed for radical cure and post-exposure prophylaxis of Plasmodium vivax malaria. In an open-label study, 1512 Australian Defence Force personnel received one of three tafenoquine 3 d regimens [400 mg once daily (od), 200 mg twice daily (bid), 200 mg od] or daily primaquine (22.5 mg) plus doxycycline (100 mg) over 14 d in Bougainville and in Timor-Leste for post-exposure prophylaxis. The relapse rate of subjects treated in Bougainville with tafenoquine (n = 173) was 1.2% (200 mg bid × 3 d) and 2.3% (400 mg od × 3 d), while primaquine plus doxycycline (n = 175) was 3.4%. For subjects treated in Timor-Leste with tafenoquine (n = 636), the relapse rate was 4.9% (200 mg od × 3 d), 5.3% (200 mg bid × 3 d) and 11.0% (400 mg od × 3d), while primaquine plus doxycycline (n = 289) was 10.0%. The most frequent adverse events reported across all groups were nausea, abdominal distress and diarrhoea. There was a dose-dependent reduction in adverse events with a reduced dose of tafenoquine, with the lowest dose (total 600 mg over 3 d) producing rates of adverse events equivalent to that of primaquine plus doxycycline. The much shorter dosing regimen of tafenoquine should increase compliance, which is often suboptimal with primaquine after leaving an endemic area. [Australian New Zealand Clinical Trials Registry Number 12607000588493]. © 2008 Royal Society of Tropical Medicine and Hygiene.</style></abstract><caption><style face="normal" font="default" size="100%">Duplicate</style></caption><notes><style face="normal" font="default" size="100%">L50170959&#xD;2008-10-30</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L50170959&amp;from=export</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1016/j.trstmh.2008.04.024</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">Boucher and Muir(Australia)&#xD;Glaxo SmithKline</style></custom2><custom5><style face="normal" font="default" size="100%">18541280</style></custom5><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.trstmh.2008.04.024</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase&#xD;Medline</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>175</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">175</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Elmes, N. J.</style></author><author><style face="normal" font="default" size="100%">Nasveld, P. E.</style></author><author><style face="normal" font="default" size="100%">Kitchener, S. J.</style></author><author><style face="normal" font="default" size="100%">Kocisko, D. A.</style></author><author><style face="normal" font="default" size="100%">Edstein, M. D.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">The efficacy and tolerability of three different regimens of tafenoquine versus primaquine for post-exposure prophylaxis of Plasmodium vivax malaria in the Southwest Pacific</style></title><secondary-title><style face="normal" font="default" size="100%">Transactions of the royal society of tropical medicine and hygiene</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Transactions of the Royal Society of Tropical Medicine and Hygiene</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1095‐1101</style></pages><volume><style face="normal" font="default" size="100%">102</style></volume><number><style face="normal" font="default" size="100%">11</style></number><keywords><keyword><style face="normal" font="default" size="100%">*Plasmodium vivax</style></keyword><keyword><style face="normal" font="default" size="100%">*malaria/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">*malaria/pc [Prevention]</style></keyword><keyword><style face="normal" font="default" size="100%">*primaquine/ae [Adverse Drug Reaction]</style></keyword><keyword><style face="normal" font="default" size="100%">*primaquine/cb [Drug Combination]</style></keyword><keyword><style face="normal" font="default" size="100%">*primaquine/cm [Drug Comparison]</style></keyword><keyword><style face="normal" font="default" size="100%">*primaquine/ct [Clinical Trial]</style></keyword><keyword><style face="normal" font="default" size="100%">*primaquine/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">*tafenoquine/ae [Adverse Drug Reaction]</style></keyword><keyword><style face="normal" font="default" size="100%">*tafenoquine/cm [Drug Comparison]</style></keyword><keyword><style face="normal" font="default" size="100%">*tafenoquine/cr [Drug Concentration]</style></keyword><keyword><style face="normal" font="default" size="100%">*tafenoquine/ct [Clinical Trial]</style></keyword><keyword><style face="normal" font="default" size="100%">*tafenoquine/do [Drug Dose]</style></keyword><keyword><style face="normal" font="default" size="100%">*tafenoquine/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Abdominal discomfort/si [Side Effect]</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Aminoquinolines [*administration &amp; dosage, adverse effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Antimalarials [*administration &amp; dosage, adverse effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Article</style></keyword><keyword><style face="normal" font="default" size="100%">Australia</style></keyword><keyword><style face="normal" font="default" size="100%">Chemoprophylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">Civil defense</style></keyword><keyword><style face="normal" font="default" size="100%">Clinical trial</style></keyword><keyword><style face="normal" font="default" size="100%">Controlled clinical trial</style></keyword><keyword><style face="normal" font="default" size="100%">Controlled study</style></keyword><keyword><style face="normal" font="default" size="100%">Diarrhea/si [Side Effect]</style></keyword><keyword><style face="normal" font="default" size="100%">Dosage schedule comparison</style></keyword><keyword><style face="normal" font="default" size="100%">Dose response</style></keyword><keyword><style face="normal" font="default" size="100%">Dose‐Response Relationship, Drug</style></keyword><keyword><style face="normal" font="default" size="100%">Doxycycline/ae [Adverse Drug Reaction]</style></keyword><keyword><style face="normal" font="default" size="100%">Doxycycline/cb [Drug Combination]</style></keyword><keyword><style face="normal" font="default" size="100%">Doxycycline/cm [Drug Comparison]</style></keyword><keyword><style face="normal" font="default" size="100%">Doxycycline/ct [Clinical Trial]</style></keyword><keyword><style face="normal" font="default" size="100%">Doxycycline/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Drug blood level</style></keyword><keyword><style face="normal" font="default" size="100%">Drug dose reduction</style></keyword><keyword><style face="normal" font="default" size="100%">Drug dose regimen</style></keyword><keyword><style face="normal" font="default" size="100%">Drug efficacy</style></keyword><keyword><style face="normal" font="default" size="100%">Drug induced headache/si [Side Effect]</style></keyword><keyword><style face="normal" font="default" size="100%">Drug megadose</style></keyword><keyword><style face="normal" font="default" size="100%">Drug safety</style></keyword><keyword><style face="normal" font="default" size="100%">Drug tolerability</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Flatulence/si [Side Effect]</style></keyword><keyword><style face="normal" font="default" size="100%">Gastrointestinal disease/si [Side Effect]</style></keyword><keyword><style face="normal" font="default" size="100%">Gastrointestinal reflux/si [Side Effect]</style></keyword><keyword><style face="normal" font="default" size="100%">Human</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Lethargy/si [Side Effect]</style></keyword><keyword><style face="normal" font="default" size="100%">Major clinical study</style></keyword><keyword><style face="normal" font="default" size="100%">Malaria control</style></keyword><keyword><style face="normal" font="default" size="100%">Malaria, Vivax [*drug therapy, prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Military Personnel</style></keyword><keyword><style face="normal" font="default" size="100%">Nausea/si [Side Effect]</style></keyword><keyword><style face="normal" font="default" size="100%">Open study</style></keyword><keyword><style face="normal" font="default" size="100%">Patient compliance</style></keyword><keyword><style face="normal" font="default" size="100%">Plasmodium vivax [*drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Primaquine [*administration &amp; dosage, adverse effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized controlled trial</style></keyword><keyword><style face="normal" font="default" size="100%">Recurrence risk</style></keyword><keyword><style face="normal" font="default" size="100%">Soldier</style></keyword><keyword><style face="normal" font="default" size="100%">Statistics as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Timor‐Leste</style></keyword><keyword><style face="normal" font="default" size="100%">Vomiting/si [Side Effect]</style></keyword><keyword><style face="normal" font="default" size="100%">Young Adult</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2008</style></year></dates><accession-num><style face="normal" font="default" size="100%">CN-00669183</style></accession-num><abstract><style face="normal" font="default" size="100%">Tafenoquine is being developed for radical cure and post‐exposure prophylaxis of Plasmodium vivax malaria. In an open‐label study, 1512 Australian Defence Force personnel received one of three tafenoquine 3 d regimens [400 mg once daily (od), 200 mg twice daily (bid), 200 mg od] or daily primaquine (22.5 mg) plus doxycycline (100 mg) over 14 d in Bougainville and in Timor‐Leste for post‐exposure prophylaxis. The relapse rate of subjects treated in Bougainville with tafenoquine (n=173) was 1.2% (200 mg bid x 3 d) and 2.3% (400 mg od x 3 d), while primaquine plus doxycycline (n=175) was 3.4%. For subjects treated in Timor‐Leste with tafenoquine (n=636), the relapse rate was 4.9% (200 mg od x 3 d), 5.3% (200 mg bid x 3 d) and 11.0% (400 mg od x 3d), while primaquine plus doxycycline (n=289) was 10.0%. The most frequent adverse events reported across all groups were nausea, abdominal distress and diarrhoea. There was a dose‐dependent reduction in adverse events with a reduced dose of tafenoquine, with the lowest dose (total 600 mg over 3 d) producing rates of adverse events equivalent to that of primaquine plus doxycycline. The much shorter dosing regimen of tafenoquine should increase compliance, which is often suboptimal with primaquine after leaving an endemic area. [Australian New Zealand Clinical Trials Registry Number 12607000588493].</style></abstract><caption><style face="normal" font="default" size="100%">Duplicate</style></caption><work-type><style face="normal" font="default" size="100%">Journal Article; Randomized Controlled Trial; Research Support, Non‐U.S. Gov&apos;t</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.cochranelibrary.com/central/doi/10.1002/central/CN-00669183/full</style></url></related-urls></urls><custom3><style face="normal" font="default" size="100%">PUBMED 18541280,EMBASE 50170959</style></custom3><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.trstmh.2008.04.024</style></electronic-resource-num></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>67</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">67</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Rajgor, D. D.</style></author><author><style face="normal" font="default" size="100%">Gogtay, N. J.</style></author><author><style face="normal" font="default" size="100%">Kadam, V. S.</style></author><author><style face="normal" font="default" size="100%">Kamtekar, K. D.</style></author><author><style face="normal" font="default" size="100%">Dalvi, S. S.</style></author><author><style face="normal" font="default" size="100%">Chogle, A. R.</style></author><author><style face="normal" font="default" size="100%">Aigal, U.</style></author><author><style face="normal" font="default" size="100%">Bichile, L. S.</style></author><author><style face="normal" font="default" size="100%">Kain, K. C.</style></author><author><style face="normal" font="default" size="100%">Kshirsagar, N. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Clinical Pharmacology, Seth GS Medical College &amp; KEM Hospital, Parel, Mumbai 400 012, India.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Efficacy of a 14-day primaquine regimen in preventing relapses in patients with Plasmodium vivax malaria in Mumbai, India</style></title><secondary-title><style face="normal" font="default" size="100%">Trans R Soc Trop Med Hyg</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Trans R Soc Trop Med Hyg</style></full-title></periodical><pages><style face="normal" font="default" size="100%">438-40</style></pages><volume><style face="normal" font="default" size="100%">97</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2004/07/21</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Aged, 80 and over</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Antimalarials/*therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Resistance</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Follow-Up Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Malaria, Vivax/*prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Parasitemia/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Plasmodium vivax/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Polymerase Chain Reaction/methods</style></keyword><keyword><style face="normal" font="default" size="100%">Polymorphism, Single-Stranded Conformational</style></keyword><keyword><style face="normal" font="default" size="100%">Primaquine/*therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Recurrence</style></keyword><keyword><style face="normal" font="default" size="100%">Single-Blind Method</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2003</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul-Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0035-9203 (Print)&#xD;0035-9203</style></isbn><accession-num><style face="normal" font="default" size="100%">15259476</style></accession-num><abstract><style face="normal" font="default" size="100%">We studied the antirelapse efficacy of a supervised 14-d 15 mg/d regimen of primaquine therapy (n = 131) compared with no antirelapse therapy (n = 142) in 273 patients with confirmed Plasmodium vivax malaria in Mumbai, India, between July 1998 and April 2000. There were 6/131 (4.6%) recurrences in patients given primaquine compared with 13/142 (9.2%) in those not given antirelapse therapy. In the 14-d primaquine group, polymerase chain reaction-single strand conformational polymorphism (PCR-SSCP) genotyping analysis of pre- and post-treatment blood samples was done for the 6 patients who had a recurrence of parasitaemia and the results gave a true relapse rate of 2.29% (3/131), 2 samples were classified as reinfections and 1 sample did not amplify. Our results indicate probable resistance to the 14-d regimen of primaquine for the first time in India and illustrate the need to (i) monitor patients given this regimen and (ii) carry out comparative studies between primaquine and new drugs such as tafenoquine and bulaquine for preventing relapses.</style></abstract><notes><style face="normal" font="default" size="100%">Rajgor, D D&#xD;Gogtay, N J&#xD;Kadam, V S&#xD;Kamtekar, K D&#xD;Dalvi, S S&#xD;Chogle, A R&#xD;Aigal, U&#xD;Bichile, L S&#xD;Kain, K C&#xD;Kshirsagar, N A&#xD;Clinical Trial&#xD;Journal Article&#xD;Randomized Controlled Trial&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;England&#xD;Trans R Soc Trop Med Hyg. 2003 Jul-Aug;97(4):438-40. doi: 10.1016/s0035-9203(03)90082-4.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/s0035-9203(03)90082-4</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>161</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">161</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Walsh, D. S.</style></author><author><style face="normal" font="default" size="100%">Eamsila, C.</style></author><author><style face="normal" font="default" size="100%">Sasiprapha, T.</style></author><author><style face="normal" font="default" size="100%">Sangkharomya, S.</style></author><author><style face="normal" font="default" size="100%">Khaewsathien, P.</style></author><author><style face="normal" font="default" size="100%">Supakalin, P.</style></author><author><style face="normal" font="default" size="100%">Tang, D. B.</style></author><author><style face="normal" font="default" size="100%">Jarasrumgsichol, P.</style></author><author><style face="normal" font="default" size="100%">Cherdchu, C.</style></author><author><style face="normal" font="default" size="100%">Edstein, M. D.</style></author><author><style face="normal" font="default" size="100%">et al.,</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Efficacy of monthly tafenoquine for prophylaxis of Plasmodium vivax and multidrug-resistant P. falciparum malaria</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of infectious diseases</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Infectious Diseases</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1456‐1463</style></pages><volume><style face="normal" font="default" size="100%">190</style></volume><number><style face="normal" font="default" size="100%">8</style></number><keywords><keyword><style face="normal" font="default" size="100%">Administration, Oral</style></keyword><keyword><style face="normal" font="default" size="100%">Aminoquinolines [*therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Antimalarials [*therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Double‐Blind Method</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Administration Schedule</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Resistance, Multiple</style></keyword><keyword><style face="normal" font="default" size="100%">Follow‐Up Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Malaria, Falciparum [*prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Malaria, Vivax [*prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Military Personnel</style></keyword><keyword><style face="normal" font="default" size="100%">Plasmodium falciparum [*drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Thailand</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2004</style></year></dates><accession-num><style face="normal" font="default" size="100%">CN-00491559</style></accession-num><abstract><style face="normal" font="default" size="100%">We assessed monthly doses of tafenoquine for preventing Plasmodium vivax and multidrug‐resistant P. falciparum malaria. In a randomized, double‐blind, placebo‐controlled study, 205 Thai soldiers received either a loading dose of tafenoquine 400 mg (base) daily for 3 days, followed by single monthly 400‐mg doses (n = 104), or placebo (n = 101), for up to 5 consecutive months. In volunteers completing follow‐up (96 tafenoquine and 91 placebo recipients), there were 22 P. vivax, 8 P. falciparum, and 1 mixed infection. All infections except 1 P. vivax occurred in placebo recipients, giving tafenoquine a protective efficacy of 97% for all malaria (95% confidence interval [CI], 82%‐99%), 96% for P. vivax malaria (95% CI, 76%‐99%), and 100% for P. falciparum malaria (95% CI, 60%‐100%). Monthly tafenoquine was safe, well tolerated, and highly effective in preventing P. vivax and multidrug‐resistant P. falciparum malaria in Thai soldiers during 6 months of prophylaxis.</style></abstract><caption><style face="normal" font="default" size="100%">Duplicate</style></caption><work-type><style face="normal" font="default" size="100%">Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non‐U.S. Gov&apos;t; Research Support, U.S. Gov&apos;t, Non‐P.H.S.</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.cochranelibrary.com/central/doi/10.1002/central/CN-00491559/full</style></url></related-urls></urls><custom3><style face="normal" font="default" size="100%">PUBMED 15378438</style></custom3><electronic-resource-num><style face="normal" font="default" size="100%">10.1086/424468</style></electronic-resource-num></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>129</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">129</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Walsh, D. S.</style></author><author><style face="normal" font="default" size="100%">Eamsila, C.</style></author><author><style face="normal" font="default" size="100%">Sasiprapha, T.</style></author><author><style face="normal" font="default" size="100%">Sangkharomya, S.</style></author><author><style face="normal" font="default" size="100%">Khaewsathien, P.</style></author><author><style face="normal" font="default" size="100%">Supakalin, P.</style></author><author><style face="normal" font="default" size="100%">Tang, D. B.</style></author><author><style face="normal" font="default" size="100%">Jarasrumgsichol, P.</style></author><author><style face="normal" font="default" size="100%">Cherdchu, C.</style></author><author><style face="normal" font="default" size="100%">Edstein, M. D.</style></author><author><style face="normal" font="default" size="100%">Rieckmanm, K. H.</style></author><author><style face="normal" font="default" size="100%">Brewer, T. G.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">D.S. Walsh, Dermatology Service, Eisenhower Army Medical Center, Ft. Gordon, GA 30905, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Efficacy of monthly tafenoquine for prophylaxis of Plasmodium vivax and multidrug-resistant P. falciparum malaria</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Infectious Diseases</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Infectious Diseases</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1456-1463</style></pages><volume><style face="normal" font="default" size="100%">190</style></volume><number><style face="normal" font="default" size="100%">8</style></number><keywords><keyword><style face="normal" font="default" size="100%">alanine aminotransferase</style></keyword><keyword><style face="normal" font="default" size="100%">aminotransferase</style></keyword><keyword><style face="normal" font="default" size="100%">artesunate</style></keyword><keyword><style face="normal" font="default" size="100%">aspartate aminotransferase</style></keyword><keyword><style face="normal" font="default" size="100%">doxycycline</style></keyword><keyword><style face="normal" font="default" size="100%">glucose 6 phosphate dehydrogenase</style></keyword><keyword><style face="normal" font="default" size="100%">liver enzyme</style></keyword><keyword><style face="normal" font="default" size="100%">mefloquine</style></keyword><keyword><style face="normal" font="default" size="100%">methemoglobin</style></keyword><keyword><style face="normal" font="default" size="100%">tafenoquine</style></keyword><keyword><style face="normal" font="default" size="100%">article</style></keyword><keyword><style face="normal" font="default" size="100%">blood smear</style></keyword><keyword><style face="normal" font="default" size="100%">chill</style></keyword><keyword><style face="normal" font="default" size="100%">clinical trial</style></keyword><keyword><style face="normal" font="default" size="100%">controlled clinical trial</style></keyword><keyword><style face="normal" font="default" size="100%">controlled study</style></keyword><keyword><style face="normal" font="default" size="100%">digestive system function disorder</style></keyword><keyword><style face="normal" font="default" size="100%">double blind procedure</style></keyword><keyword><style face="normal" font="default" size="100%">drowsiness</style></keyword><keyword><style face="normal" font="default" size="100%">drug efficacy</style></keyword><keyword><style face="normal" font="default" size="100%">drug safety</style></keyword><keyword><style face="normal" font="default" size="100%">drug tolerance</style></keyword><keyword><style face="normal" font="default" size="100%">fever</style></keyword><keyword><style face="normal" font="default" size="100%">follow up</style></keyword><keyword><style face="normal" font="default" size="100%">headache</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">major clinical study</style></keyword><keyword><style face="normal" font="default" size="100%">malaria</style></keyword><keyword><style face="normal" font="default" size="100%">nausea</style></keyword><keyword><style face="normal" font="default" size="100%">Plasmodium falciparum</style></keyword><keyword><style face="normal" font="default" size="100%">Plasmodium vivax</style></keyword><keyword><style face="normal" font="default" size="100%">priority journal</style></keyword><keyword><style face="normal" font="default" size="100%">randomized controlled trial</style></keyword><keyword><style face="normal" font="default" size="100%">rash</style></keyword><keyword><style face="normal" font="default" size="100%">vertigo</style></keyword><keyword><style face="normal" font="default" size="100%">vomiting</style></keyword><keyword><style face="normal" font="default" size="100%">sb 252263</style></keyword><keyword><style face="normal" font="default" size="100%">wr 238605</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2004</style></year></dates><isbn><style face="normal" font="default" size="100%">0022-1899</style></isbn><abstract><style face="normal" font="default" size="100%">We assessed monthly doses of tafenoquine for preventing Plasmodium vivax and multidrug-resistant P. falciparum malaria. In a randomized, double-blind, placebo-controlled study, 205 Thai soldiers received either a loading dose of tafenoquine 400 mg (base) daily for 3 days, followed by single monthly 400-mg doses (n = 104), or placebo (n = 101), for up to 5 consecutive months. In volunteers completing follow-up (96 tafenoquine and 91 placebo recipients), there were 22 P. vivax, 8 P. falciparum, and 1 mixed infection. All infections except 1 P. vivax occurred in placebo recipients, giving tafenoquine a protective efficacy of 97% for all malaria (95% confidence interval [CI], 82%-99%), 96% for P. vivax malaria (95% CI, 76%-99%), and 100% for P. falciparum malaria (95% CI, 60%-100%). Monthly tafenoquine was safe, well tolerated, and highly effective in preventing P. vivax and multidrug-resistant P. falciparum malaria in Thai soldiers during 6 months of prophylaxis.</style></abstract><caption><style face="normal" font="default" size="100%">Duplicate</style></caption><notes><style face="normal" font="default" size="100%">L39332185&#xD;2004-11-01</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L39332185&amp;from=export</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1086/424468</style></url></related-urls></urls><custom1><style face="normal" font="default" size="100%">sb 252263&#xD;wr 238605(Glaxo SmithKline)</style></custom1><custom2><style face="normal" font="default" size="100%">Atlantic&#xD;Glaxo SmithKline&#xD;Rugby</style></custom2><custom5><style face="normal" font="default" size="100%">15378438</style></custom5><electronic-resource-num><style face="normal" font="default" size="100%">10.1086/424468</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase&#xD;Medline</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>66</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">66</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Walsh, D. S.</style></author><author><style face="normal" font="default" size="100%">Eamsila, C.</style></author><author><style face="normal" font="default" size="100%">Sasiprapha, T.</style></author><author><style face="normal" font="default" size="100%">Sangkharomya, S.</style></author><author><style face="normal" font="default" size="100%">Khaewsathien, P.</style></author><author><style face="normal" font="default" size="100%">Supakalin, P.</style></author><author><style face="normal" font="default" size="100%">Tang, D. B.</style></author><author><style face="normal" font="default" size="100%">Jarasrumgsichol, P.</style></author><author><style face="normal" font="default" size="100%">Cherdchu, C.</style></author><author><style face="normal" font="default" size="100%">Edstein, M. D.</style></author><author><style face="normal" font="default" size="100%">Rieckmann, K. H.</style></author><author><style face="normal" font="default" size="100%">Brewer, T. G.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Immunology and Medicine, United States Army Medical Component, Bangkok, Thailand. douglas.walsh@se.amedd.army.mil.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Efficacy of monthly tafenoquine for prophylaxis of Plasmodium vivax and multidrug-resistant P. falciparum malaria</style></title><secondary-title><style face="normal" font="default" size="100%">J Infect Dis</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Infect Dis</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1456-63</style></pages><volume><style face="normal" font="default" size="100%">190</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2004/09/21</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Administration, Oral</style></keyword><keyword><style face="normal" font="default" size="100%">Aminoquinolines/*therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Antimalarials/*therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Double-Blind Method</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Administration Schedule</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Resistance, Multiple</style></keyword><keyword><style face="normal" font="default" size="100%">Follow-Up Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Malaria, Falciparum/*prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Malaria, Vivax/*prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Military Personnel</style></keyword><keyword><style face="normal" font="default" size="100%">Plasmodium falciparum/*drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Thailand</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2004</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct 15</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0022-1899 (Print)&#xD;0022-1899</style></isbn><accession-num><style face="normal" font="default" size="100%">15378438</style></accession-num><abstract><style face="normal" font="default" size="100%">We assessed monthly doses of tafenoquine for preventing Plasmodium vivax and multidrug-resistant P. falciparum malaria. In a randomized, double-blind, placebo-controlled study, 205 Thai soldiers received either a loading dose of tafenoquine 400 mg (base) daily for 3 days, followed by single monthly 400-mg doses (n = 104), or placebo (n = 101), for up to 5 consecutive months. In volunteers completing follow-up (96 tafenoquine and 91 placebo recipients), there were 22 P. vivax, 8 P. falciparum, and 1 mixed infection. All infections except 1 P. vivax occurred in placebo recipients, giving tafenoquine a protective efficacy of 97% for all malaria (95% confidence interval [CI], 82%-99%), 96% for P. vivax malaria (95% CI, 76%-99%), and 100% for P. falciparum malaria (95% CI, 60%-100%). Monthly tafenoquine was safe, well tolerated, and highly effective in preventing P. vivax and multidrug-resistant P. falciparum malaria in Thai soldiers during 6 months of prophylaxis.</style></abstract><caption><style face="normal" font="default" size="100%">Duplicate</style></caption><notes><style face="normal" font="default" size="100%">Walsh, Douglas S&#xD;Eamsila, Chirapa&#xD;Sasiprapha, Theerayuth&#xD;Sangkharomya, Suebpong&#xD;Khaewsathien, Pradith&#xD;Supakalin, Panpaka&#xD;Tang, Douglas B&#xD;Jarasrumgsichol, Phongsak&#xD;Cherdchu, Chainarong&#xD;Edstein, Michael D&#xD;Rieckmann, Karl H&#xD;Brewer, Thomas G&#xD;Clinical Trial&#xD;Comparative Study&#xD;Journal Article&#xD;Randomized Controlled Trial&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Research Support, U.S. Gov&apos;t, Non-P.H.S.&#xD;United States&#xD;J Infect Dis. 2004 Oct 15;190(8):1456-63. doi: 10.1086/424468. Epub 2004 Sep 20.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1086/424468</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>166</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">166</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Beck, H. P.</style></author><author><style face="normal" font="default" size="100%">Wampfler, R.</style></author><author><style face="normal" font="default" size="100%">Carter, N.</style></author><author><style face="normal" font="default" size="100%">Koh, G.</style></author><author><style face="normal" font="default" size="100%">Osorio, L.</style></author><author><style face="normal" font="default" size="100%">Rueangweerayut, R.</style></author><author><style face="normal" font="default" size="100%">Krudsood, S.</style></author><author><style face="normal" font="default" size="100%">Lacerda, M. V.</style></author><author><style face="normal" font="default" size="100%">Llanos-Cuentas, A.</style></author><author><style face="normal" font="default" size="100%">Duparc, S.</style></author><author><style face="normal" font="default" size="100%">et al.,</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Estimation of the Antirelapse Efficacy of Tafenoquine, Using Plasmodium vivax Genotyping</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of infectious diseases</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Infectious Diseases</style></full-title></periodical><pages><style face="normal" font="default" size="100%">794‐799</style></pages><volume><style face="normal" font="default" size="100%">213</style></volume><number><style face="normal" font="default" size="100%">5</style></number><keywords><keyword><style face="normal" font="default" size="100%">Aminoquinolines [administration &amp; dosage, *therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Antimalarials [administration &amp; dosage, *therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Chloroquine [administration &amp; dosage, therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Dose‐Response Relationship, Drug</style></keyword><keyword><style face="normal" font="default" size="100%">Double‐Blind Method</style></keyword><keyword><style face="normal" font="default" size="100%">Genotype</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Malaria, Vivax [*drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Plasmodium vivax [*genetics]</style></keyword><keyword><style face="normal" font="default" size="100%">Primaquine [administration &amp; dosage, therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Secondary Prevention</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2016</style></year></dates><accession-num><style face="normal" font="default" size="100%">CN-01704877</style></accession-num><abstract><style face="normal" font="default" size="100%">Prevention of relapse of Plasmodium vivax infection is a key treatment goal in malaria. Use of P. vivax genotyping in a multicenter, double‐blind, randomized, placebo‐controlled phase 2b study in Peru, India, Thailand, and Brazil allowed determination of genetically heterologous or homologous P. vivax infection recurrence following receipt of chloroquine plus one of 4 doses of tafenoquine (50, 100, 300, or 600 mg) or chloroquine plus primaquine, compared with receipt of chloroquine alone. The antihypnozoite efficacy of tafenoquine was evident as a reduction in homologous recurrences of P. vivax infection as drug doses were increased. No clear dose‐response pattern was evident for heterologous recurrences of P. vivax infection. Rates of homologous recurrence of P. vivax infection appear to be clinically useful for comparing drug efficacy for the prevention of P. vivax infection relapse. CLINICAL TRIALS REGISTRATION: NCT01376167.</style></abstract><caption><style face="normal" font="default" size="100%">Duplicate</style></caption><work-type><style face="normal" font="default" size="100%">Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non‐U.S. Gov&apos;t</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01704877/full</style></url></related-urls></urls><custom3><style face="normal" font="default" size="100%">PUBMED 26500351</style></custom3><electronic-resource-num><style face="normal" font="default" size="100%">10.1093/infdis/jiv508</style></electronic-resource-num></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>167</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">167</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Beck, H. P.</style></author><author><style face="normal" font="default" size="100%">Wampfler, R.</style></author><author><style face="normal" font="default" size="100%">Carter, N.</style></author><author><style face="normal" font="default" size="100%">Koh, G.</style></author><author><style face="normal" font="default" size="100%">Osorio, L.</style></author><author><style face="normal" font="default" size="100%">Rueangweerayut, R.</style></author><author><style face="normal" font="default" size="100%">Krudsood, S.</style></author><author><style face="normal" font="default" size="100%">Lacerda, M. V.</style></author><author><style face="normal" font="default" size="100%">Llanos-Cuentas, A.</style></author><author><style face="normal" font="default" size="100%">Duparc, S.</style></author><author><style face="normal" font="default" size="100%">et al.,</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Estimation of the antirelapse efficacy of tafenoquine, using plasmodium vivax genotyping</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of infectious diseases</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Infectious Diseases</style></full-title></periodical><pages><style face="normal" font="default" size="100%">794‐799</style></pages><volume><style face="normal" font="default" size="100%">212</style></volume><number><style face="normal" font="default" size="100%">11</style></number><keywords><keyword><style face="normal" font="default" size="100%">*Plasmodium vivax</style></keyword><keyword><style face="normal" font="default" size="100%">Aminoquinolines [administration &amp; dosage, *therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Antimalarials [administration &amp; dosage, *therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Brazil</style></keyword><keyword><style face="normal" font="default" size="100%">Chloroquine [administration &amp; dosage, therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Clinical trial</style></keyword><keyword><style face="normal" font="default" size="100%">Controlled clinical trial</style></keyword><keyword><style face="normal" font="default" size="100%">Controlled study</style></keyword><keyword><style face="normal" font="default" size="100%">Dose response</style></keyword><keyword><style face="normal" font="default" size="100%">Dose‐Response Relationship, Drug</style></keyword><keyword><style face="normal" font="default" size="100%">Double blind procedure</style></keyword><keyword><style face="normal" font="default" size="100%">Double‐Blind Method</style></keyword><keyword><style face="normal" font="default" size="100%">Drug efficacy</style></keyword><keyword><style face="normal" font="default" size="100%">Genotype</style></keyword><keyword><style face="normal" font="default" size="100%">Human</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">India</style></keyword><keyword><style face="normal" font="default" size="100%">Malaria, Vivax [*drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Multicenter study</style></keyword><keyword><style face="normal" font="default" size="100%">Peru</style></keyword><keyword><style face="normal" font="default" size="100%">Plasmodium vivax [*genetics]</style></keyword><keyword><style face="normal" font="default" size="100%">Plasmodium vivax malaria</style></keyword><keyword><style face="normal" font="default" size="100%">Prevention</style></keyword><keyword><style face="normal" font="default" size="100%">Primaquine [administration &amp; dosage, therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized controlled trial</style></keyword><keyword><style face="normal" font="default" size="100%">Relapse</style></keyword><keyword><style face="normal" font="default" size="100%">Secondary Prevention</style></keyword><keyword><style face="normal" font="default" size="100%">Thailand</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2016</style></year></dates><accession-num><style face="normal" font="default" size="100%">CN-01142480</style></accession-num><abstract><style face="normal" font="default" size="100%">Prevention of relapse of Plasmodium vivax infection is a key treatment goal in malaria. Use of P. vivax genotyping in a multicenter, double‐blind, randomized, placebo‐controlled phase 2b study in Peru, India, Thailand, and Brazil allowed determination of genetically heterologous or homologous P. vivax infection recurrence following receipt of chloroquine plus one of 4 doses of tafenoquine (50, 100, 300, or 600 mg) or chloroquine plus primaquine, compared with receipt of chloroquine alone. The antihypnozoite efficacy of tafenoquine was evident as a reduction in homologous recurrences of P. vivax infection as drug doses were increased. No clear dose‐response pattern was evident for heterologous recurrences of P. vivax infection. Rates of homologous recurrence of P. vivax infection appear to be clinically useful for comparing drug efficacy for the prevention of P. vivax infection relapse.</style></abstract><caption><style face="normal" font="default" size="100%">Duplicate</style></caption><work-type><style face="normal" font="default" size="100%">Journal: Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01142480/full</style></url></related-urls></urls><custom3><style face="normal" font="default" size="100%">EMBASE 608457685</style></custom3><electronic-resource-num><style face="normal" font="default" size="100%">10.1093/infdis/jiv508</style></electronic-resource-num></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>48</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">48</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Beck, H. P.</style></author><author><style face="normal" font="default" size="100%">Wampfler, R.</style></author><author><style face="normal" font="default" size="100%">Carter, N.</style></author><author><style face="normal" font="default" size="100%">Koh, G.</style></author><author><style face="normal" font="default" size="100%">Osorio, L.</style></author><author><style face="normal" font="default" size="100%">Rueangweerayut, R.</style></author><author><style face="normal" font="default" size="100%">Krudsood, S.</style></author><author><style face="normal" font="default" size="100%">Lacerda, M. V.</style></author><author><style face="normal" font="default" size="100%">Llanos-Cuentas, A.</style></author><author><style face="normal" font="default" size="100%">Duparc, S.</style></author><author><style face="normal" font="default" size="100%">Rubio, J. P.</style></author><author><style face="normal" font="default" size="100%">Green, J. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Medical Parasitology and Infection Biology, Swiss Tropical and Public Health Institute University of Basel.&#xD;GlaxoSmithKline Research and Development, Middlesex, United Kingdom.&#xD;School of Public Health, Universidad del Valle, Cali, Colombia.&#xD;Mae-Sot General Hospital, Tak Province.&#xD;Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.&#xD;Fundação de Medicina Tropical Doutor Heitor Vieira Amazonas Dourado, Manaus, Brazil.&#xD;Instituto de Medicina Tropical Alexander von Humboldt School of Public Health, Universidad Peruana Cayetano Heredia, Lima, Peru.&#xD;Medicines for Malaria Venture, Geneva, Switzerland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Estimation of the Antirelapse Efficacy of Tafenoquine, Using Plasmodium vivax Genotyping</style></title><secondary-title><style face="normal" font="default" size="100%">J Infect Dis</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Infect Dis</style></full-title></periodical><pages><style face="normal" font="default" size="100%">794-9</style></pages><volume><style face="normal" font="default" size="100%">213</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2015/10/27</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Aminoquinolines/administration &amp; dosage/*therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Antimalarials/administration &amp; dosage/*therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Chloroquine/administration &amp; dosage/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Dose-Response Relationship, Drug</style></keyword><keyword><style face="normal" font="default" size="100%">Double-Blind Method</style></keyword><keyword><style face="normal" font="default" size="100%">Genotype</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Malaria, Vivax/*drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Plasmodium vivax/*genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Primaquine/administration &amp; dosage/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">*Secondary Prevention</style></keyword><keyword><style face="normal" font="default" size="100%">Plasmodium vivax</style></keyword><keyword><style face="normal" font="default" size="100%">antihypnozoite</style></keyword><keyword><style face="normal" font="default" size="100%">efficacy</style></keyword><keyword><style face="normal" font="default" size="100%">genotyping</style></keyword><keyword><style face="normal" font="default" size="100%">tafenoquine</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2016</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar 1</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0022-1899 (Print)&#xD;0022-1899</style></isbn><accession-num><style face="normal" font="default" size="100%">26500351</style></accession-num><abstract><style face="normal" font="default" size="100%">Prevention of relapse of Plasmodium vivax infection is a key treatment goal in malaria. Use of P. vivax genotyping in a multicenter, double-blind, randomized, placebo-controlled phase 2b study in Peru, India, Thailand, and Brazil allowed determination of genetically heterologous or homologous P. vivax infection recurrence following receipt of chloroquine plus one of 4 doses of tafenoquine (50, 100, 300, or 600 mg) or chloroquine plus primaquine, compared with receipt of chloroquine alone. The antihypnozoite efficacy of tafenoquine was evident as a reduction in homologous recurrences of P. vivax infection as drug doses were increased. No clear dose-response pattern was evident for heterologous recurrences of P. vivax infection. Rates of homologous recurrence of P. vivax infection appear to be clinically useful for comparing drug efficacy for the prevention of P. vivax infection relapse. CLINICAL TRIALS REGISTRATION: NCT01376167.</style></abstract><caption><style face="normal" font="default" size="100%">Duplicate</style></caption><notes><style face="normal" font="default" size="100%">1537-6613&#xD;Beck, Hans-Peter&#xD;Wampfler, Rahel&#xD;Carter, Nick&#xD;Koh, Gavin&#xD;Osorio, Lyda&#xD;Rueangweerayut, Ronnatrai&#xD;Krudsood, Srivcha&#xD;Lacerda, Marcus V&#xD;Llanos-Cuentas, Alejandro&#xD;Duparc, Stephan&#xD;Rubio, Justin P&#xD;Green, Justin A&#xD;Journal Article&#xD;Multicenter Study&#xD;Randomized Controlled Trial&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;J Infect Dis. 2016 Mar 1;213(5):794-9. doi: 10.1093/infdis/jiv508. Epub 2015 Oct 23.</style></notes><urls></urls><custom2><style face="normal" font="default" size="100%">PMC4747625</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1093/infdis/jiv508</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>106</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">106</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Beck, H. P.</style></author><author><style face="normal" font="default" size="100%">Wampfler, R.</style></author><author><style face="normal" font="default" size="100%">Carter, N.</style></author><author><style face="normal" font="default" size="100%">Koh, G.</style></author><author><style face="normal" font="default" size="100%">Osorio, L.</style></author><author><style face="normal" font="default" size="100%">Rueangweerayut, R.</style></author><author><style face="normal" font="default" size="100%">Krudsood, S.</style></author><author><style face="normal" font="default" size="100%">Lacerda, M. V.</style></author><author><style face="normal" font="default" size="100%">Llanos-Cuentas, A.</style></author><author><style face="normal" font="default" size="100%">Duparc, S.</style></author><author><style face="normal" font="default" size="100%">Rubio, J. P.</style></author><author><style face="normal" font="default" size="100%">Green, J. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">H.-P. Beck, Department of Medical Parasitology and Infection Biology, Swiss Tropical and Public Health Institute, Socinstrasse 57, Basel, Switzerland</style></auth-address><titles><title><style face="normal" font="default" size="100%">Estimation of the Antirelapse Efficacy of Tafenoquine, Using Plasmodium vivax Genotyping</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Infectious Diseases</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Infectious Diseases</style></full-title></periodical><pages><style face="normal" font="default" size="100%">794-799</style></pages><volume><style face="normal" font="default" size="100%">213</style></volume><number><style face="normal" font="default" size="100%">5</style></number><keywords><keyword><style face="normal" font="default" size="100%">NCT01376167</style></keyword><keyword><style face="normal" font="default" size="100%">apical membrane antigen 1</style></keyword><keyword><style face="normal" font="default" size="100%">chloroquine</style></keyword><keyword><style face="normal" font="default" size="100%">circumsporozoite protein</style></keyword><keyword><style face="normal" font="default" size="100%">genomic DNA</style></keyword><keyword><style face="normal" font="default" size="100%">placebo</style></keyword><keyword><style face="normal" font="default" size="100%">primaquine</style></keyword><keyword><style face="normal" font="default" size="100%">tafenoquine</style></keyword><keyword><style face="normal" font="default" size="100%">adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">article</style></keyword><keyword><style face="normal" font="default" size="100%">Brazil</style></keyword><keyword><style face="normal" font="default" size="100%">controlled study</style></keyword><keyword><style face="normal" font="default" size="100%">drug dose increase</style></keyword><keyword><style face="normal" font="default" size="100%">drug efficacy</style></keyword><keyword><style face="normal" font="default" size="100%">drug megadose</style></keyword><keyword><style face="normal" font="default" size="100%">lack of drug effect</style></keyword><keyword><style face="normal" font="default" size="100%">female</style></keyword><keyword><style face="normal" font="default" size="100%">gene amplification</style></keyword><keyword><style face="normal" font="default" size="100%">genotype</style></keyword><keyword><style face="normal" font="default" size="100%">Giemsa stain</style></keyword><keyword><style face="normal" font="default" size="100%">haplotype</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">India</style></keyword><keyword><style face="normal" font="default" size="100%">low drug dose</style></keyword><keyword><style face="normal" font="default" size="100%">major clinical study</style></keyword><keyword><style face="normal" font="default" size="100%">male</style></keyword><keyword><style face="normal" font="default" size="100%">merozoite</style></keyword><keyword><style face="normal" font="default" size="100%">monotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">multicenter study (topic)</style></keyword><keyword><style face="normal" font="default" size="100%">multicenter study</style></keyword><keyword><style face="normal" font="default" size="100%">parasite clearance</style></keyword><keyword><style face="normal" font="default" size="100%">Peru</style></keyword><keyword><style face="normal" font="default" size="100%">phase 2 clinical trial</style></keyword><keyword><style face="normal" font="default" size="100%">Plasmodium vivax</style></keyword><keyword><style face="normal" font="default" size="100%">Plasmodium vivax malaria</style></keyword><keyword><style face="normal" font="default" size="100%">polymerase chain reaction</style></keyword><keyword><style face="normal" font="default" size="100%">priority journal</style></keyword><keyword><style face="normal" font="default" size="100%">randomized controlled trial</style></keyword><keyword><style face="normal" font="default" size="100%">recurrent infection</style></keyword><keyword><style face="normal" font="default" size="100%">single drug dose</style></keyword><keyword><style face="normal" font="default" size="100%">Thailand</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2016</style></year></dates><isbn><style face="normal" font="default" size="100%">1537-6613&#xD;0022-1899</style></isbn><abstract><style face="normal" font="default" size="100%">Prevention of relapse of Plasmodium vivax infection is a key treatment goal in malaria. Use of P. vivax genotyping in a multicenter, double-blind, randomized, placebo-controlled phase 2b study in Peru, India, Thailand, and Brazil allowed determination of genetically heterologous or homologous P. vivax infection recurrence following receipt of chloroquine plus one of 4 doses of tafenoquine (50, 100, 300, or 600 mg) or chloroquine plus primaquine, compared with receipt of chloroquine alone. The antihypnozoite efficacy of tafenoquine was evident as a reduction in homologous recurrences of P. vivax infection as drug doses were increased. No clear dose-response pattern was evident for heterologous recurrences of P. vivax infection. Rates of homologous recurrence of P. vivax infection appear to be clinically useful for comparing drug efficacy for the prevention of P. vivax infection relapse. Clinical Trials Registration. NCT01376167.</style></abstract><caption><style face="normal" font="default" size="100%">Duplicate</style></caption><notes><style face="normal" font="default" size="100%">L608980428&#xD;2016-03-21&#xD;2016-03-25</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L608980428&amp;from=export</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1093/infdis/jiv508</style></url></related-urls></urls><custom5><style face="normal" font="default" size="100%">26500351</style></custom5><electronic-resource-num><style face="normal" font="default" size="100%">10.1093/infdis/jiv508</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase&#xD;Medline</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>107</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">107</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Beck, H. P.</style></author><author><style face="normal" font="default" size="100%">Wampfler, R.</style></author><author><style face="normal" font="default" size="100%">Carter, N.</style></author><author><style face="normal" font="default" size="100%">Koh, G.</style></author><author><style face="normal" font="default" size="100%">Osorio, L.</style></author><author><style face="normal" font="default" size="100%">Rueangweerayut, R.</style></author><author><style face="normal" font="default" size="100%">Krudsood, S.</style></author><author><style face="normal" font="default" size="100%">Lacerda, M. V.</style></author><author><style face="normal" font="default" size="100%">Llanos-Cuentas, A.</style></author><author><style face="normal" font="default" size="100%">Duparc, S.</style></author><author><style face="normal" font="default" size="100%">Rubio, J. P.</style></author><author><style face="normal" font="default" size="100%">Green, J. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">H.-P. Beck, Department of Medical Parasitology and Infection Biology, Swiss Tropical and Public Health Institute, Socinstrasse 57, Basel, Switzerland</style></auth-address><titles><title><style face="normal" font="default" size="100%">Estimation of the antirelapse efficacy of tafenoquine, using plasmodium vivax genotyping</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Infectious Diseases</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Infectious Diseases</style></full-title></periodical><pages><style face="normal" font="default" size="100%">794-799</style></pages><volume><style face="normal" font="default" size="100%">212</style></volume><number><style face="normal" font="default" size="100%">11</style></number><keywords><keyword><style face="normal" font="default" size="100%">Brazil</style></keyword><keyword><style face="normal" font="default" size="100%">clinical trial</style></keyword><keyword><style face="normal" font="default" size="100%">controlled clinical trial</style></keyword><keyword><style face="normal" font="default" size="100%">controlled study</style></keyword><keyword><style face="normal" font="default" size="100%">dose response</style></keyword><keyword><style face="normal" font="default" size="100%">double blind procedure</style></keyword><keyword><style face="normal" font="default" size="100%">drug efficacy</style></keyword><keyword><style face="normal" font="default" size="100%">genotype</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">India</style></keyword><keyword><style face="normal" font="default" size="100%">multicenter study</style></keyword><keyword><style face="normal" font="default" size="100%">Peru</style></keyword><keyword><style face="normal" font="default" size="100%">Plasmodium vivax</style></keyword><keyword><style face="normal" font="default" size="100%">Plasmodium vivax malaria</style></keyword><keyword><style face="normal" font="default" size="100%">prevention</style></keyword><keyword><style face="normal" font="default" size="100%">randomized controlled trial</style></keyword><keyword><style face="normal" font="default" size="100%">relapse</style></keyword><keyword><style face="normal" font="default" size="100%">Thailand</style></keyword><keyword><style face="normal" font="default" size="100%">chloroquine</style></keyword><keyword><style face="normal" font="default" size="100%">chloroquine plus primaquine</style></keyword><keyword><style face="normal" font="default" size="100%">placebo</style></keyword><keyword><style face="normal" font="default" size="100%">tafenoquine</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2016</style></year></dates><isbn><style face="normal" font="default" size="100%">1537-6613&#xD;0022-1899</style></isbn><abstract><style face="normal" font="default" size="100%">Prevention of relapse of Plasmodium vivax infection is a key treatment goal in malaria. Use of P. vivax genotyping in a multicenter, double-blind, randomized, placebo-controlled phase 2b study in Peru, India, Thailand, and Brazil allowed determination of genetically heterologous or homologous P. vivax infection recurrence following receipt of chloroquine plus one of 4 doses of tafenoquine (50, 100, 300, or 600 mg) or chloroquine plus primaquine, compared with receipt of chloroquine alone. The antihypnozoite efficacy of tafenoquine was evident as a reduction in homologous recurrences of P. vivax infection as drug doses were increased. No clear dose-response pattern was evident for heterologous recurrences of P. vivax infection. Rates of homologous recurrence of P. vivax infection appear to be clinically useful for comparing drug efficacy for the prevention of P. vivax infection relapse.</style></abstract><caption><style face="normal" font="default" size="100%">Duplicate</style></caption><notes><style face="normal" font="default" size="100%">L608457685&#xD;2016-02-23</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L608457685&amp;from=export</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1093/infdis/jiv508</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1093/infdis/jiv508</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>12</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">12</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Calvaresi, E. C.</style></author><author><style face="normal" font="default" size="100%">Genzen, J. R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pathology, University of Utah, Salt Lake City.&#xD;ARUP Laboratories, Salt Lake City, UT.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Evaluating Percentage-Based Reporting of Glucose-6-Phosphate Dehydrogenase (G6PD) Enzymatic Activity</style></title><secondary-title><style face="normal" font="default" size="100%">Am J Clin Pathol</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Am J Clin Pathol</style></full-title></periodical><pages><style face="normal" font="default" size="100%">248-254</style></pages><volume><style face="normal" font="default" size="100%">154</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2020/05/15</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Aminoquinolines/*therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Antimalarials/*therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Child, Preschool</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Glucosephosphate Dehydrogenase/*metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Hematologic Tests</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Infant</style></keyword><keyword><style face="normal" font="default" size="100%">Malaria/*drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Reference Values</style></keyword><keyword><style face="normal" font="default" size="100%">Retrospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Young Adult</style></keyword><keyword><style face="normal" font="default" size="100%">* Plasmodium vivax</style></keyword><keyword><style face="normal" font="default" size="100%">* Malaria</style></keyword><keyword><style face="normal" font="default" size="100%">*Glucose-6-phosphate dehydrogenase</style></keyword><keyword><style face="normal" font="default" size="100%">*Hematology</style></keyword><keyword><style face="normal" font="default" size="100%">*Primaquine</style></keyword><keyword><style face="normal" font="default" size="100%">*Tafenoquine</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2020</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul 7</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0002-9173</style></isbn><accession-num><style face="normal" font="default" size="100%">32405645</style></accession-num><abstract><style face="normal" font="default" size="100%">OBJECTIVES: The World Health Organization recommends measurement of glucose-6-phosphate dehydrogenase (G6PD) activity before initiation of 8-aminoquinoline therapy. A new drug for malaria prophylaxis and treatment (tafenoquine) is contraindicated in patients with G6PD deficiency or unknown G6PD status given its prolonged half-life. Assessments of percentage of normal G6PD activity using laboratory-specific result distributions are not widely available, making tafenoquine-eligibility decisions potentially challenging. METHODS: Using an institutional review board-exempt protocol, a data set of quantitative G6PD results was retrieved from a national reference laboratory. G6PD testing was previously performed at 37 °C using an automated enzymatic assay configured on a Roche cobas c501 chemistry analyzer. RESULTS: Overall, 52,216 results from patients 18 years and older and 6,397 results from patients younger than 18 years were obtained. A modified adjusted male median of 12.7 U/g Hb was derived for adult males in this assay configuration. Result distributions showed higher G6PD activity in neonates. CONCLUSIONS: Retrospective data analysis can be used to determine laboratory-specific normal G6PD activity values in clinical populations and thus can assist in clinical-eligibility considerations for 8-aminoquinoline treatment.</style></abstract><notes><style face="normal" font="default" size="100%">1943-7722&#xD;Calvaresi, Emilia C&#xD;Genzen, Jonathan R&#xD;Journal Article&#xD;England&#xD;Am J Clin Pathol. 2020 Jul 7;154(2):248-254. doi: 10.1093/ajcp/aqaa040.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1093/ajcp/aqaa040</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>81</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">81</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Brueckner, R. P.</style></author><author><style face="normal" font="default" size="100%">Lasseter, K. C.</style></author><author><style face="normal" font="default" size="100%">Lin, E. T.</style></author><author><style face="normal" font="default" size="100%">Schuster, B. G.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Experimental Therapeutics, Walter Reed Army Institute of Research, Washington, District of Columbia 20307-5100, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">First-time-in-humans safety and pharmacokinetics of WR 238605, a new antimalarial</style></title><secondary-title><style face="normal" font="default" size="100%">Am J Trop Med Hyg</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Am J Trop Med Hyg</style></full-title></periodical><pages><style face="normal" font="default" size="100%">645-9</style></pages><volume><style face="normal" font="default" size="100%">58</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">1998/05/23</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Aminoquinolines/administration &amp; dosage/adverse</style></keyword><keyword><style face="normal" font="default" size="100%">effects/blood/chemistry/*pharmacokinetics</style></keyword><keyword><style face="normal" font="default" size="100%">Antimalarials/administration &amp; dosage/adverse</style></keyword><keyword><style face="normal" font="default" size="100%">effects/blood/chemistry/*pharmacokinetics</style></keyword><keyword><style face="normal" font="default" size="100%">Dose-Response Relationship, Drug</style></keyword><keyword><style face="normal" font="default" size="100%">Double-Blind Method</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">1998</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0002-9637 (Print)&#xD;0002-9637</style></isbn><accession-num><style face="normal" font="default" size="100%">9598455</style></accession-num><abstract><style face="normal" font="default" size="100%">WR 238605 is an 8-aminoquinoline drug currently under development for prophylaxis and treatment of malaria. Preclinical studies have demonstrated that it has greater efficacy and less toxicity compared with primaquine. In this first-time-in-human randomized, double-blind, placebo-controlled study designed to evaluate the safety, tolerance and pharmacokinetics, WR 238605 was administered to 48 men in single oral doses ranging from four to 600 mg (base). It was well tolerated, with gastrointestinal disturbances as possible side effects. Linear kinetics were demonstrated at these doses. WR 238605 has a long absorption phase and is slowly metabolized, with a tmax of 12 hr and an elimination half-life of 14 days. These safety, efficacy and pharmacokinetic properties make this drug an excellent candidate for further testing as a prophylactic, radical curative, and terminal eradication drug.</style></abstract><caption><style face="normal" font="default" size="100%">Duplicate</style></caption><notes><style face="normal" font="default" size="100%">Brueckner, R P&#xD;Lasseter, K C&#xD;Lin, E T&#xD;Schuster, B G&#xD;Clinical Trial&#xD;Journal Article&#xD;Randomized Controlled Trial&#xD;Research Support, U.S. Gov&apos;t, Non-P.H.S.&#xD;United States&#xD;Am J Trop Med Hyg. 1998 May;58(5):645-9. doi: 10.4269/ajtmh.1998.58.645.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.4269/ajtmh.1998.58.645</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>143</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">143</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Brueckner, R. P.</style></author><author><style face="normal" font="default" size="100%">Lasseter, K. C.</style></author><author><style face="normal" font="default" size="100%">Lin, E. T.</style></author><author><style face="normal" font="default" size="100%">Schuster, B. G.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">R.P. Brueckner, Div. of Experimental Therapeutics, Walter Reed Army Inst. of Research, Washington, DC, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">First-time-in-humans safety and pharmacokinetics of WR 238605, a new antimalarial</style></title><secondary-title><style face="normal" font="default" size="100%">American Journal of Tropical Medicine and Hygiene</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">American Journal of Tropical Medicine and Hygiene</style></full-title></periodical><pages><style face="normal" font="default" size="100%">645-649</style></pages><volume><style face="normal" font="default" size="100%">58</style></volume><number><style face="normal" font="default" size="100%">5</style></number><keywords><keyword><style face="normal" font="default" size="100%">antimalarial agent</style></keyword><keyword><style face="normal" font="default" size="100%">primaquine</style></keyword><keyword><style face="normal" font="default" size="100%">tafenoquine</style></keyword><keyword><style face="normal" font="default" size="100%">adult</style></keyword><keyword><style face="normal" font="default" size="100%">antimicrobial therapy</style></keyword><keyword><style face="normal" font="default" size="100%">article</style></keyword><keyword><style face="normal" font="default" size="100%">clinical trial</style></keyword><keyword><style face="normal" font="default" size="100%">controlled clinical trial</style></keyword><keyword><style face="normal" font="default" size="100%">controlled study</style></keyword><keyword><style face="normal" font="default" size="100%">demography</style></keyword><keyword><style face="normal" font="default" size="100%">double blind procedure</style></keyword><keyword><style face="normal" font="default" size="100%">drug absorption</style></keyword><keyword><style face="normal" font="default" size="100%">drug efficacy</style></keyword><keyword><style face="normal" font="default" size="100%">drug half life</style></keyword><keyword><style face="normal" font="default" size="100%">drug metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">drug safety</style></keyword><keyword><style face="normal" font="default" size="100%">drug tolerance</style></keyword><keyword><style face="normal" font="default" size="100%">gastrointestinal symptom</style></keyword><keyword><style face="normal" font="default" size="100%">headache</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">major clinical study</style></keyword><keyword><style face="normal" font="default" size="100%">malaria</style></keyword><keyword><style face="normal" font="default" size="100%">male</style></keyword><keyword><style face="normal" font="default" size="100%">oral drug administration</style></keyword><keyword><style face="normal" font="default" size="100%">randomized controlled trial</style></keyword><keyword><style face="normal" font="default" size="100%">vertigo</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">1998</style></year></dates><isbn><style face="normal" font="default" size="100%">0002-9637</style></isbn><abstract><style face="normal" font="default" size="100%">WR 238605 is an 8-aminoquinoline drug currently under development for prophylaxis and treatment of malaria. Preclinical studies have demonstrated that it has greater efficacy and less toxicity compared with primaquine. In this first-time-in-human randomized, double-blind, placebo-controlled study designed to evaluate the safety, tolerance and pharmacokinetics, WR 238605 was administered to 48 men in single oral doses ranging from four to 600 mg (base). It was well tolerated, with gastrointestinal disturbances as possible side effects. Linear kinetics were demonstrated at these doses. WR 238605 has a long absorption phase and is slowly metabolized, with a t(max) of 12 hr and an elimination half-life of 14 days. These safety, efficacy and pharmacokinetic properties make this drug an excellent candidate for further testing as a prophylactic, radical curative, and terminal eradication drug.</style></abstract><caption><style face="normal" font="default" size="100%">Duplicate</style></caption><notes><style face="normal" font="default" size="100%">L28237265&#xD;1998-06-16</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L28237265&amp;from=export</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.4269/ajtmh.1998.58.645</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">Ash Stevens(United States)</style></custom2><custom5><style face="normal" font="default" size="100%">9598455</style></custom5><electronic-resource-num><style face="normal" font="default" size="100%">10.4269/ajtmh.1998.58.645</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase&#xD;Medline</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>147</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">147</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Brueckner, R. P.</style></author><author><style face="normal" font="default" size="100%">Lasseter, K. C.</style></author><author><style face="normal" font="default" size="100%">Lin, E. T.</style></author><author><style face="normal" font="default" size="100%">Schuster, B. G.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">First-time-in-humans safety and pharmacokinetics of WR 238605, a new antimalarial</style></title><secondary-title><style face="normal" font="default" size="100%">American journal of tropical medicine and hygiene</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">American Journal of Tropical Medicine and Hygiene</style></full-title></periodical><pages><style face="normal" font="default" size="100%">645‐649</style></pages><volume><style face="normal" font="default" size="100%">58</style></volume><number><style face="normal" font="default" size="100%">5</style></number><keywords><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Aminoquinolines [administration &amp; dosage, adverse effects, blood, chemistry, *pharmacokinetics]</style></keyword><keyword><style face="normal" font="default" size="100%">Antimalarials [administration &amp; dosage, adverse effects, blood, chemistry, *pharmacokinetics]</style></keyword><keyword><style face="normal" font="default" size="100%">Dose‐Response Relationship, Drug</style></keyword><keyword><style face="normal" font="default" size="100%">Double‐Blind Method</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">1998</style></year></dates><accession-num><style face="normal" font="default" size="100%">CN-00688374</style></accession-num><abstract><style face="normal" font="default" size="100%">WR 238605 is an 8‐aminoquinoline drug currently under development for prophylaxis and treatment of malaria. Preclinical studies have demonstrated that it has greater efficacy and less toxicity compared with primaquine. In this first‐time‐in‐human randomized, double‐blind, placebo‐controlled study designed to evaluate the safety, tolerance and pharmacokinetics, WR 238605 was administered to 48 men in single oral doses ranging from four to 600 mg (base). It was well tolerated, with gastrointestinal disturbances as possible side effects. Linear kinetics were demonstrated at these doses. WR 238605 has a long absorption phase and is slowly metabolized, with a tmax of 12 hr and an elimination half‐life of 14 days. These safety, efficacy and pharmacokinetic properties make this drug an excellent candidate for further testing as a prophylactic, radical curative, and terminal eradication drug.</style></abstract><caption><style face="normal" font="default" size="100%">Duplicate</style></caption><work-type><style face="normal" font="default" size="100%">Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, U.S. Gov&apos;t, Non‐P.H.S.</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.cochranelibrary.com/central/doi/10.1002/central/CN-00688374/full</style></url></related-urls></urls><custom3><style face="normal" font="default" size="100%">PUBMED 9598455</style></custom3><electronic-resource-num><style face="normal" font="default" size="100%">10.4269/ajtmh.1998.58.645</style></electronic-resource-num></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>165</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">165</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Nct,</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">G6PD (Glucose-6-phosphate Dehydrogenase) Study to Evaluate Hemolysis Potential of TFQ (Tafenoquine)</style></title><secondary-title><style face="normal" font="default" size="100%">https://clinicaltrials.gov/show/NCT01205178</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">https://clinicaltrials.gov/show/NCT01205178</style></full-title></periodical><keywords><keyword><style face="normal" font="default" size="100%">Chloroquine</style></keyword><keyword><style face="normal" font="default" size="100%">Chloroquine diphosphate</style></keyword><keyword><style face="normal" font="default" size="100%">Glucosephosphate Dehydrogenase Deficiency</style></keyword><keyword><style face="normal" font="default" size="100%">Malaria</style></keyword><keyword><style face="normal" font="default" size="100%">Primaquine</style></keyword><keyword><style face="normal" font="default" size="100%">Tafenoquine</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2010</style></year></dates><accession-num><style face="normal" font="default" size="100%">CN-01583412</style></accession-num><abstract><style face="normal" font="default" size="100%">SB‐252263 (Tafenoquine, TQ) is an 8‐aminoquinoline (8‐AQ) antimalarial drug being developed by GlaxoSmithKline (GSK), the U.S. Army Medical Research and Materiel Command (USAMRMC) and Medicines for Malaria Venture (MMV). TQ is currently being developed for the radical cure of acute P. vivax malaria in combination with standard doses of CQ, which is 1500 mg over 3 days. The current gold standard for radical cure of P. vivax malaria in many areas of the world is chloroquine (CQ) for clearance of the acute parasitemia immediately followed by primaquine (PQ) to clear the liver stages of the parasite and prevent disease relapse. The 8‐AQ class of drugs, including PQ, is hemolytic in subjects with glucose‐6‐phosphate dehydrogenase (G6PD) deficiency. The current study will identify a dose of TQ within the target efficacious dose range that has a hemolytic effect similar to or less than PQ 15 mg OD x 14 days (i.e. ≤ 25‐30% hemoglobin decline in WHO class III G6PD‐deficient subjects).</style></abstract><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01583412/full</style></url></related-urls></urls></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>63</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">63</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Edstein, M. D.</style></author><author><style face="normal" font="default" size="100%">Nasveld, P. E.</style></author><author><style face="normal" font="default" size="100%">Kocisko, D. A.</style></author><author><style face="normal" font="default" size="100%">Kitchener, S. J.</style></author><author><style face="normal" font="default" size="100%">Gatton, M. L.</style></author><author><style face="normal" font="default" size="100%">Rieckmann, K. H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Australian Army Malaria Institute, Enoggera, Brisbane, Queensland 4051, Australia. mike.edstein@defence.gov.au</style></auth-address><titles><title><style face="normal" font="default" size="100%">Gender differences in gastrointestinal disturbances and plasma concentrations of tafenoquine in healthy volunteers after tafenoquine administration for post-exposure vivax malaria prophylaxis</style></title><secondary-title><style face="normal" font="default" size="100%">Trans R Soc Trop Med Hyg</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Trans R Soc Trop Med Hyg</style></full-title></periodical><pages><style face="normal" font="default" size="100%">226-30</style></pages><volume><style face="normal" font="default" size="100%">101</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2006/07/04</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Aminoquinolines/*adverse effects/blood/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Antimalarials/*adverse effects/blood/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Administration Schedule</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Monitoring/methods</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Gastrointestinal Diseases/blood/*chemically induced</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Malaria, Vivax/*prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Nausea/blood/chemically induced</style></keyword><keyword><style face="normal" font="default" size="100%">Sex Characteristics</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2007</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0035-9203 (Print)&#xD;0035-9203</style></isbn><accession-num><style face="normal" font="default" size="100%">16814823</style></accession-num><abstract><style face="normal" font="default" size="100%">In an open-label sequential cohort study, we compared gastrointestinal (GI) disturbances and plasma tafenoquine concentrations after administration of single-dose (400mg daily x 3 days; n=76 males, 11 females) and split-dose (200 mg twice daily x 3 days; n=73 males, 13 females) tafenoquine regimens in healthy Australian Defence Force volunteers for post-exposure malaria prophylaxis. The female and male volunteers had comparable demographic characteristics (age, weight, height) in the single- and split-dose treatment groups. GI disturbances were generally mild and self-limiting for both groups. The frequency of nausea and abdominal distress was over two-fold higher in females than in males for both treatment groups. Reporting of GI disturbances in the single-dose group differed significantly between males and females, but this gender difference was not seen for the split-dose group. In those volunteers who experienced GI disturbances, the mean plasma tafenoquine concentrations 12 h after the last dose of tafenoquine were approximately 1.3-fold higher in females than in males (means+/-SD: 737+/-118 ng/ml vs. 581+/-113 ng/ml). These preliminary findings suggest that further studies are required in a larger number of females to determine whether there is a need to reduce the dose of tafenoquine to minimise GI disturbances in females.</style></abstract><caption><style face="normal" font="default" size="100%">Duplicate</style></caption><notes><style face="normal" font="default" size="100%">Edstein, M D&#xD;Nasveld, P E&#xD;Kocisko, D A&#xD;Kitchener, S J&#xD;Gatton, M L&#xD;Rieckmann, K H&#xD;Controlled Clinical Trial&#xD;Journal Article&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;England&#xD;Trans R Soc Trop Med Hyg. 2007 Mar;101(3):226-30. doi: 10.1016/j.trstmh.2006.04.003. Epub 2006 Jun 30.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.trstmh.2006.04.003</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>164</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">164</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Edstein, M. D.</style></author><author><style face="normal" font="default" size="100%">Nasveld, P. E.</style></author><author><style face="normal" font="default" size="100%">Kocisko, D. A.</style></author><author><style face="normal" font="default" size="100%">Kitchener, S. J.</style></author><author><style face="normal" font="default" size="100%">Gatton, M. L.</style></author><author><style face="normal" font="default" size="100%">Rieckmann, K. H.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Gender differences in gastrointestinal disturbances and plasma concentrations of tafenoquine in healthy volunteers after tafenoquine administration for post-exposure vivax malaria prophylaxis</style></title><secondary-title><style face="normal" font="default" size="100%">Transactions of the royal society of tropical medicine and hygiene</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Transactions of the Royal Society of Tropical Medicine and Hygiene</style></full-title></periodical><pages><style face="normal" font="default" size="100%">226‐230</style></pages><volume><style face="normal" font="default" size="100%">101</style></volume><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Aminoquinolines [*adverse effects, blood, therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Antimalarials [*adverse effects, blood, therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Administration Schedule</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Monitoring [methods]</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Gastrointestinal Diseases [blood, *chemically induced]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Malaria, Vivax [*prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Nausea [blood, chemically induced]</style></keyword><keyword><style face="normal" font="default" size="100%">Sex Characteristics</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2007</style></year></dates><accession-num><style face="normal" font="default" size="100%">CN-00608773</style></accession-num><abstract><style face="normal" font="default" size="100%">In an open‐label sequential cohort study, we compared gastrointestinal (GI) disturbances and plasma tafenoquine concentrations after administration of single‐dose (400mg daily x 3 days; n=76 males, 11 females) and split‐dose (200 mg twice daily x 3 days; n=73 males, 13 females) tafenoquine regimens in healthy Australian Defence Force volunteers for post‐exposure malaria prophylaxis. The female and male volunteers had comparable demographic characteristics (age, weight, height) in the single‐ and split‐dose treatment groups. GI disturbances were generally mild and self‐limiting for both groups. The frequency of nausea and abdominal distress was over two‐fold higher in females than in males for both treatment groups. Reporting of GI disturbances in the single‐dose group differed significantly between males and females, but this gender difference was not seen for the split‐dose group. In those volunteers who experienced GI disturbances, the mean plasma tafenoquine concentrations 12 h after the last dose of tafenoquine were approximately 1.3‐fold higher in females than in males (means+/‐SD: 737+/‐118 ng/ml vs. 581+/‐113 ng/ml). These preliminary findings suggest that further studies are required in a larger number of females to determine whether there is a need to reduce the dose of tafenoquine to minimise GI disturbances in females.</style></abstract><caption><style face="normal" font="default" size="100%">Duplicate</style></caption><work-type><style face="normal" font="default" size="100%">Controlled Clinical Trial; Journal Article; Research Support, Non‐U.S. Gov&apos;t</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.cochranelibrary.com/central/doi/10.1002/central/CN-00608773/full</style></url></related-urls></urls><custom3><style face="normal" font="default" size="100%">PUBMED 16814823</style></custom3><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.trstmh.2006.04.003</style></electronic-resource-num></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>109</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">109</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Price, R. N.</style></author><author><style face="normal" font="default" size="100%">von Seidlein, L.</style></author><author><style face="normal" font="default" size="100%">Valecha, N.</style></author><author><style face="normal" font="default" size="100%">Nosten, F.</style></author><author><style face="normal" font="default" size="100%">Baird, J. K.</style></author><author><style face="normal" font="default" size="100%">White, N. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">R.N. Price, Menzies School of Health Research, Casuarina, Darwin, NT, Australia</style></auth-address><titles><title><style face="normal" font="default" size="100%">Global extent of chloroquine-resistant Plasmodium vivax: A systematic review and meta-analysis</style></title><secondary-title><style face="normal" font="default" size="100%">The Lancet Infectious Diseases</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">The Lancet Infectious Diseases</style></full-title></periodical><pages><style face="normal" font="default" size="100%">982-991</style></pages><volume><style face="normal" font="default" size="100%">14</style></volume><number><style face="normal" font="default" size="100%">10</style></number><keywords><keyword><style face="normal" font="default" size="100%">artemether</style></keyword><keyword><style face="normal" font="default" size="100%">benflumetol</style></keyword><keyword><style face="normal" font="default" size="100%">chloroquine</style></keyword><keyword><style face="normal" font="default" size="100%">chloroquine plus primaquine</style></keyword><keyword><style face="normal" font="default" size="100%">dihydroartemisinin plus piperaquine</style></keyword><keyword><style face="normal" font="default" size="100%">doxycycline</style></keyword><keyword><style face="normal" font="default" size="100%">halofantrine</style></keyword><keyword><style face="normal" font="default" size="100%">mefloquine</style></keyword><keyword><style face="normal" font="default" size="100%">pyrimethamine</style></keyword><keyword><style face="normal" font="default" size="100%">pyrimethamine plus sulfadoxine</style></keyword><keyword><style face="normal" font="default" size="100%">sulfadoxine</style></keyword><keyword><style face="normal" font="default" size="100%">tafenoquine</style></keyword><keyword><style face="normal" font="default" size="100%">antimalarial drug resistance</style></keyword><keyword><style face="normal" font="default" size="100%">antimicrobial therapy</style></keyword><keyword><style face="normal" font="default" size="100%">article</style></keyword><keyword><style face="normal" font="default" size="100%">continuous infusion</style></keyword><keyword><style face="normal" font="default" size="100%">drug absorption</style></keyword><keyword><style face="normal" font="default" size="100%">drug blood level</style></keyword><keyword><style face="normal" font="default" size="100%">drug dose regimen</style></keyword><keyword><style face="normal" font="default" size="100%">drug efficacy</style></keyword><keyword><style face="normal" font="default" size="100%">drug megadose</style></keyword><keyword><style face="normal" font="default" size="100%">drug quality</style></keyword><keyword><style face="normal" font="default" size="100%">lack of drug effect</style></keyword><keyword><style face="normal" font="default" size="100%">endemic disease</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">infection prevention</style></keyword><keyword><style face="normal" font="default" size="100%">low drug dose</style></keyword><keyword><style face="normal" font="default" size="100%">meta analysis</style></keyword><keyword><style face="normal" font="default" size="100%">microscopy</style></keyword><keyword><style face="normal" font="default" size="100%">monotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">multicenter study (topic)</style></keyword><keyword><style face="normal" font="default" size="100%">nonhuman</style></keyword><keyword><style face="normal" font="default" size="100%">parasite clearance</style></keyword><keyword><style face="normal" font="default" size="100%">parasitemia</style></keyword><keyword><style face="normal" font="default" size="100%">patient assessment</style></keyword><keyword><style face="normal" font="default" size="100%">Plasmodium vivax</style></keyword><keyword><style face="normal" font="default" size="100%">Plasmodium vivax malaria</style></keyword><keyword><style face="normal" font="default" size="100%">randomized controlled trial (topic)</style></keyword><keyword><style face="normal" font="default" size="100%">recurrence risk</style></keyword><keyword><style face="normal" font="default" size="100%">single drug dose</style></keyword><keyword><style face="normal" font="default" size="100%">systematic review</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><isbn><style face="normal" font="default" size="100%">1474-4457&#xD;1473-3099</style></isbn><abstract><style face="normal" font="default" size="100%">Background: Chloroquine is the first-line treatment for Plasmodium vivax malaria in most endemic countries, but resistance is increasing. Monitoring of antimalarial efficacy is essential, but in P vivax infections the assessment of treatment efficacy is confounded by relapse from the dormant liver stages. We systematically reviewed P vivax malaria treatment efficacy studies to establish the global extent of chloroquine resistance. Methods: We searched Medline, Web of Science, Embase, and the Cochrane Database of Systematic Reviews to identify studies published in English between Jan 1, 1960, and April 30, 2014, which investigated antimalarial treatment efficacy in P vivax malaria. We excluded studies that did not include supervised schizonticidal treatment without primaquine. We determined rates of chloroquine resistance according to P vivax malaria recurrence rates by day 28 whole-blood chloroquine concentrations at the time of recurrence and study enrolment criteria. Findings: We identified 129 eligible clinical trials involving 21 694 patients at 179 study sites and 26 case reports describing 54 patients. Chloroquine resistance was present in 58 (53%) of 113 assessable study sites, spread across most countries that are endemic for P vivax. Clearance of parasitaemia assessed by microscopy in 95% of patients by day 2, or all patients by day 3, was 100% predictive of chloroquine sensitivity. Interpretation: Heterogeneity of study design and analysis has confounded global surveillance of chloroquine-resistant P vivax, which is now present across most countries endemic for P vivax. Improved methods for monitoring of drug resistance are needed to inform antimalarial policy in these regions. Funding: Wellcome Trust (UK).</style></abstract><notes><style face="normal" font="default" size="100%">L600246542&#xD;2014-11-03&#xD;2014-11-06</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L600246542&amp;from=export</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1016/S1473-3099(14)70855-2</style></url></related-urls></urls><custom5><style face="normal" font="default" size="100%">25213732</style></custom5><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/S1473-3099(14)70855-2</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase&#xD;Medline</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>87</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">87</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Haston, J. C.</style></author><author><style face="normal" font="default" size="100%">Hwang, J.</style></author><author><style face="normal" font="default" size="100%">Tan, K. R.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Guidance for Using Tafenoquine for Prevention and Antirelapse Therapy for Malaria - United States, 2019</style></title><secondary-title><style face="normal" font="default" size="100%">MMWR. Morbidity and mortality weekly report</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">MMWR. Morbidity and mortality weekly report</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1062-1068</style></pages><volume><style face="normal" font="default" size="100%">68</style></volume><number><style face="normal" font="default" size="100%">46</style></number><keywords><keyword><style face="normal" font="default" size="100%">aminoquinoline derivative</style></keyword><keyword><style face="normal" font="default" size="100%">antimalarial agent</style></keyword><keyword><style face="normal" font="default" size="100%">tafenoquine</style></keyword><keyword><style face="normal" font="default" size="100%">emporiatrics</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">malaria</style></keyword><keyword><style face="normal" font="default" size="100%">practice guideline</style></keyword><keyword><style face="normal" font="default" size="100%">public health service</style></keyword><keyword><style face="normal" font="default" size="100%">randomized controlled trial (topic)</style></keyword><keyword><style face="normal" font="default" size="100%">secondary prevention</style></keyword><keyword><style face="normal" font="default" size="100%">United States</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2019</style></year></dates><isbn><style face="normal" font="default" size="100%">1545-861X</style></isbn><abstract><style face="normal" font="default" size="100%">An estimated 219 million cases of malaria occurred worldwide in 2017, causing approximately 435,000 deaths (1). Malaria is caused by intraerythrocytic protozoa of the genus Plasmodium transmitted to humans through the bite of an infective Anopheles mosquito. Five Plasmodium species that regularly cause illness in humans are P. falciparum, P. vivax, P. ovale, P. malariae, and P. knowlesi (2). The parasite first develops in the liver before infecting red blood cells. Travelers to areas with endemic malaria can prevent malaria by taking chemoprophylaxis. However, most antimalarials do not kill the liver stages of the parasite, including hypnozoites that cause relapses of disease caused by P. vivax or P. ovale. Therefore, patients with these relapsing species must be treated with two medications: one for the acute infection, and another to treat the hypnozoites (antirelapse therapy). Until recently, primaquine was the only drug available worldwide to kill hypnozoites. Tafenoquine, a long-acting 8-aminoquinoline drug related to primaquine, was approved by the Food and Drug Administration (FDA) on July 20, 2018, for antirelapse therapy (Krintafel) and August 8, 2018, for chemoprophylaxis (Arakoda) (3,4). This report reviews evidence for the efficacy and safety of tafenoquine and provides CDC guidance for clinicians who prescribe chemoprophylaxis for travelers to areas with endemic malaria and treat malaria.</style></abstract><notes><style face="normal" font="default" size="100%">L629943064&#xD;2019-11-28</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L629943064&amp;from=export</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.15585/mmwr.mm6846a4</style></url></related-urls></urls><custom5><style face="normal" font="default" size="100%">31751320</style></custom5><electronic-resource-num><style face="normal" font="default" size="100%">10.15585/mmwr.mm6846a4</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Medline</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>40</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">40</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Chu, C. S.</style></author><author><style face="normal" font="default" size="100%">Bancone, G.</style></author><author><style face="normal" font="default" size="100%">Moore, K. A.</style></author><author><style face="normal" font="default" size="100%">Win, H. H.</style></author><author><style face="normal" font="default" size="100%">Thitipanawan, N.</style></author><author><style face="normal" font="default" size="100%">Po, C.</style></author><author><style face="normal" font="default" size="100%">Chowwiwat, N.</style></author><author><style face="normal" font="default" size="100%">Raksapraidee, R.</style></author><author><style face="normal" font="default" size="100%">Wilairisak, P.</style></author><author><style face="normal" font="default" size="100%">Phyo, A. P.</style></author><author><style face="normal" font="default" size="100%">Keereecharoen, L.</style></author><author><style face="normal" font="default" size="100%">Proux, S.</style></author><author><style face="normal" font="default" size="100%">Charunwatthana, P.</style></author><author><style face="normal" font="default" size="100%">Nosten, F.</style></author><author><style face="normal" font="default" size="100%">White, N. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Shoklo Malaria Research Unit, Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Mae Sot, Thailand.&#xD;Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.&#xD;Macfarlane Burnet Institute for Medical Research and Public Health, Melbourne, Victoria, Australia.&#xD;Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, Victoria, Australia.&#xD;Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.&#xD;Department of Clinical Tropical Medicine, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Haemolysis in G6PD Heterozygous Females Treated with Primaquine for Plasmodium vivax Malaria: A Nested Cohort in a Trial of Radical Curative Regimens</style></title><secondary-title><style face="normal" font="default" size="100%">PLoS Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">PLoS Med</style></full-title></periodical><pages><style face="normal" font="default" size="100%">e1002224</style></pages><volume><style face="normal" font="default" size="100%">14</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2017/02/09</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Antimalarials/adverse effects/*pharmacology/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Child, Preschool</style></keyword><keyword><style face="normal" font="default" size="100%">Cohort Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Dose-Response Relationship, Drug</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">*Genotype</style></keyword><keyword><style face="normal" font="default" size="100%">Glucosephosphate Dehydrogenase/*genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Hematocrit</style></keyword><keyword><style face="normal" font="default" size="100%">Hemolysis/*drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Malaria, Vivax/parasitology/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Myanmar</style></keyword><keyword><style face="normal" font="default" size="100%">Phenotype</style></keyword><keyword><style face="normal" font="default" size="100%">Plasmodium vivax/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Primaquine/adverse effects/*pharmacology/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Thailand</style></keyword><keyword><style face="normal" font="default" size="100%">Young Adult</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2017</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1549-1277 (Print)&#xD;1549-1277</style></isbn><accession-num><style face="normal" font="default" size="100%">28170391</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Radical cure of Plasmodium vivax malaria with 8-aminoquinolines (primaquine or tafenoquine) is complicated by haemolysis in individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency. G6PD heterozygous females, because of individual variation in the pattern of X-chromosome inactivation (Lyonisation) in erythroid cells, may have low G6PD activity in the majority of their erythrocytes, yet are usually reported as G6PD &quot;normal&quot; by current phenotypic screening tests. Their haemolytic risk when treated with 8-aminoquinolines has not been well characterized. METHODS AND FINDINGS: In a cohort study nested within a randomised clinical trial that compared different treatment regimens for P. vivax malaria, patients with a normal standard NADPH fluorescent spot test result (≳30%-40% of normal G6PD activity) were randomised to receive 3 d of chloroquine or dihydroartemisinin-piperaquine in combination with primaquine, either the standard high dose of 0.5 mg base/kg/day for 14 d or a higher dose of 1 mg base/kg/d for 7 d. Patterns of haemolysis were compared between G6PD wild-type and G6PD heterozygous female participants. Between 21 February 2012 and 04 July 2014, 241 female participants were enrolled, of whom 34 were heterozygous for the G6PD Mahidol variant. Haemolysis was substantially greater and a larger proportion of participants reached the threshold of clinically significant haemolysis (fractional haematocrit reduction &gt;25%) in G6PD heterozygotes taking the higher (7 d) primaquine dose (9/17 [53%]) compared with G6PD heterozygotes taking the standard high (14 d) dose (2/16 [13%]; p = 0.022). In heterozygotes, the mean fractional haematocrit reductions were correspondingly greater with the higher primaquine dose (7-d regimen): -20.4% (95% CI -26.0% to -14.8%) (nadir on day 5) compared with the standard high (14 d) dose: -13.1% (95% CI -17.6% to -8.6%) (nadir day 6). Two heterozygotes taking the higher (7 d) primaquine dose required blood transfusion. In wild-type participants, mean haematocrit reductions were clinically insignificant and similar with both doses: -5.8 (95% CI -7.2% to -4.4%) (nadir day 3) compared with -5.5% (95% CI -7.4% to -3.7%) (nadir day 4), respectively. Limitations to this nested cohort study are that the primary objective of the trial was designed to measure efficacy and not haemolysis in relation to G6PD genotype and that the heterozygote groups were small. CONCLUSION: Higher daily doses of primaquine have the potential to cause clinically significant haemolysis in G6PD heterozygous females who are reported as phenotypically normal with current point of care tests. TRIAL REGISTRATION: ClinicalTrials.gov NCT01640574.</style></abstract><notes><style face="normal" font="default" size="100%">1549-1676&#xD;Chu, Cindy S&#xD;Orcid: 0000-0001-9465-8214&#xD;Bancone, Germana&#xD;Orcid: 0000-0003-4550-0431&#xD;Moore, Kerryn A&#xD;Orcid: 0000-0002-8333-8271&#xD;Win, Htun Htun&#xD;Thitipanawan, Niramon&#xD;Po, Christina&#xD;Chowwiwat, Nongnud&#xD;Raksapraidee, Rattanaporn&#xD;Wilairisak, Pornpimon&#xD;Phyo, Aung Pyae&#xD;Orcid: 0000-0002-0383-9624&#xD;Keereecharoen, Lily&#xD;Proux, Stéphane&#xD;Charunwatthana, Prakaykaew&#xD;Orcid: 0000-0001-5968-2032&#xD;Nosten, François&#xD;Orcid: 0000-0002-7951-0745&#xD;White, Nicholas J&#xD;Orcid: 0000-0002-1897-1978&#xD;Journal Article&#xD;Randomized Controlled Trial&#xD;PLoS Med. 2017 Feb 7;14(2):e1002224. doi: 10.1371/journal.pmed.1002224. eCollection 2017 Feb.</style></notes><urls></urls><custom2><style face="normal" font="default" size="100%">PMC5295665</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1371/journal.pmed.1002224</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>118</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">118</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Wieten, R. W.</style></author><author><style face="normal" font="default" size="100%">van Vugt, M.</style></author><author><style face="normal" font="default" size="100%">van Leth, F.</style></author><author><style face="normal" font="default" size="100%">Grobusch, M. P.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">R. W. Wieten, Tropencentrum Academisch Medisch Centrum, PO 226660, 1100DD Amsterdam, Netherlands</style></auth-address><titles><title><style face="normal" font="default" size="100%">Highlights of a symposium, malaria: Where are we today, where are we going?</style></title><secondary-title><style face="normal" font="default" size="100%">Open Infectious Diseases Journal</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Open Infectious Diseases Journal</style></full-title></periodical><pages><style face="normal" font="default" size="100%">99-106</style></pages><volume><style face="normal" font="default" size="100%">5</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">8 aminoquinoline derivative</style></keyword><keyword><style face="normal" font="default" size="100%">amodiaquine</style></keyword><keyword><style face="normal" font="default" size="100%">amodiaquine plus artesunate</style></keyword><keyword><style face="normal" font="default" size="100%">artemether plus benflumetol</style></keyword><keyword><style face="normal" font="default" size="100%">artemisinin derivative</style></keyword><keyword><style face="normal" font="default" size="100%">artesunate</style></keyword><keyword><style face="normal" font="default" size="100%">chloroquine</style></keyword><keyword><style face="normal" font="default" size="100%">clindamycin</style></keyword><keyword><style face="normal" font="default" size="100%">dihydroartemisinin</style></keyword><keyword><style face="normal" font="default" size="100%">dihydroartemisinin plus piperaquine</style></keyword><keyword><style face="normal" font="default" size="100%">fosmidomycin</style></keyword><keyword><style face="normal" font="default" size="100%">malaria vaccine</style></keyword><keyword><style face="normal" font="default" size="100%">pamaquine</style></keyword><keyword><style face="normal" font="default" size="100%">placebo</style></keyword><keyword><style face="normal" font="default" size="100%">primaquine</style></keyword><keyword><style face="normal" font="default" size="100%">proguanil</style></keyword><keyword><style face="normal" font="default" size="100%">pyrimethamine plus sulfadoxine</style></keyword><keyword><style face="normal" font="default" size="100%">quinine</style></keyword><keyword><style face="normal" font="default" size="100%">tafenoquine</style></keyword><keyword><style face="normal" font="default" size="100%">antimalarial activity</style></keyword><keyword><style face="normal" font="default" size="100%">article</style></keyword><keyword><style face="normal" font="default" size="100%">chemoprophylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">disease surveillance</style></keyword><keyword><style face="normal" font="default" size="100%">drug cost</style></keyword><keyword><style face="normal" font="default" size="100%">drug efficacy</style></keyword><keyword><style face="normal" font="default" size="100%">drug metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">drug safety</style></keyword><keyword><style face="normal" font="default" size="100%">drug tolerability</style></keyword><keyword><style face="normal" font="default" size="100%">dysphoria</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">hypoglycemia</style></keyword><keyword><style face="normal" font="default" size="100%">international cooperation</style></keyword><keyword><style face="normal" font="default" size="100%">malaria</style></keyword><keyword><style face="normal" font="default" size="100%">malaria control</style></keyword><keyword><style face="normal" font="default" size="100%">malaria falciparum</style></keyword><keyword><style face="normal" font="default" size="100%">medical research</style></keyword><keyword><style face="normal" font="default" size="100%">monotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">nausea</style></keyword><keyword><style face="normal" font="default" size="100%">Netherlands</style></keyword><keyword><style face="normal" font="default" size="100%">nonhuman</style></keyword><keyword><style face="normal" font="default" size="100%">patient compliance</style></keyword><keyword><style face="normal" font="default" size="100%">Plasmodium vivax</style></keyword><keyword><style face="normal" font="default" size="100%">Plasmodium vivax malaria</style></keyword><keyword><style face="normal" font="default" size="100%">priority journal</style></keyword><keyword><style face="normal" font="default" size="100%">sepsis</style></keyword><keyword><style face="normal" font="default" size="100%">single drug dose</style></keyword><keyword><style face="normal" font="default" size="100%">tinnitus</style></keyword><keyword><style face="normal" font="default" size="100%">vaccination</style></keyword><keyword><style face="normal" font="default" size="100%">vector control</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2011</style></year></dates><isbn><style face="normal" font="default" size="100%">1874-2793</style></isbn><abstract><style face="normal" font="default" size="100%">Malaria continues to pose a major public health threat in endemic areas. However, times are changing, and many investments have been made in recent years into funding of malaria research, the development of more and improved control tools, and applying those to the field. Consequently, there is a renewed interest in going as far as considering the prospects of malaria elimination on a global scale. This goal cannot be reached without optimising and combining biotechnical, economical and social anthropological aspects. A symposium held on 25 January 2011 in Amsterdam, the Netherlands, organised by the Amsterdam Institute for Global Health and Development, the Center for Infection and Immunity Amsterdam and the Academic Medical Center of the University of Amsterdam, focused on malaria and the malERA eradication program, summarizing the state of the art in malaria control and beyond, and offering insight into the various possible ways forward. This manuscript summarizes the information presented and the ensuing discussions. Antimalarial drugs, eradication, malaria, symposium, vaccines, vector control. © Wieten et al.</style></abstract><notes><style face="normal" font="default" size="100%">L362699154&#xD;2011-10-13&#xD;2011-10-21</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L362699154&amp;from=export</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.2174/1874279301105010099</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.2174/1874279301105010099</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>36</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">36</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Watson, J.</style></author><author><style face="normal" font="default" size="100%">Taylor, W. R. J.</style></author><author><style face="normal" font="default" size="100%">Bancone, G.</style></author><author><style face="normal" font="default" size="100%">Chu, C. S.</style></author><author><style face="normal" font="default" size="100%">Jittamala, P.</style></author><author><style face="normal" font="default" size="100%">White, N. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Mahidol Oxford Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.&#xD;Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, Oxford University, Oxford, United kingdom.&#xD;Shoklo Malaria Research Unit, Faculty of Tropical Medicine, Mahidol University, Mae Sot, Thailand.&#xD;Department of Clinical Tropical Medicine, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Implications of current therapeutic restrictions for primaquine and tafenoquine in the radical cure of vivax malaria</style></title><secondary-title><style face="normal" font="default" size="100%">PLoS Negl Trop Dis</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">PLoS Negl Trop Dis</style></full-title></periodical><pages><style face="normal" font="default" size="100%">e0006440</style></pages><volume><style face="normal" font="default" size="100%">12</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2018/04/21</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Aminoquinolines/*therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Antimalarials/*therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Glucosephosphate Dehydrogenase Deficiency/*genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Heterozygote</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Lactation</style></keyword><keyword><style face="normal" font="default" size="100%">Malaria, Vivax/*drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Plasmodium vivax/*drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Pregnancy</style></keyword><keyword><style face="normal" font="default" size="100%">Primaquine/*therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Young Adult</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2018</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1935-2727 (Print)&#xD;1935-2727</style></isbn><accession-num><style face="normal" font="default" size="100%">29677199</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: The 8-aminoquinoline antimalarials, the only drugs which prevent relapse of vivax and ovale malaria (radical cure), cause dose-dependent oxidant haemolysis in individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency. Patients with &lt;30% and &lt;70% of normal G6PD activity are not given standard regimens of primaquine and tafenoquine, respectively. Both drugs are currently considered contraindicated in pregnant and lactating women. METHODS: Quantitative G6PD enzyme activity data from 5198 individuals were used to estimate the proportions of heterozygous females who would be ineligible for treatment at the 30% and 70% activity thresholds, and the relationship with the severity of the deficiency. This was used to construct a simple model relating allele frequency in males to the potential population coverage of tafenoquine and primaquine under current prescribing restrictions. FINDINGS: Independent of G6PD deficiency, the current pregnancy and lactation restrictions will exclude ~13% of females from radical cure treatment. This could be reduced to ~4% if 8-aminoquinolines can be prescribed to women breast-feeding infants older than 1 month. At a 30% activity threshold, approximately 8-19% of G6PD heterozygous women are ineligible for primaquine treatment; at a 70% threshold, 50-70% of heterozygous women and approximately 5% of G6PD wild type individuals are ineligible for tafenoquine treatment. Thus, overall in areas where the G6PDd allele frequency is &gt;10% more than 15% of men and more than 25% of women would be unable to receive tafenoquine. In vivax malaria infected patients these proportions will be lowered by any protective effect against P. vivax conferred by G6PD deficiency. CONCLUSION: If tafenoquine is deployed for radical cure, primaquine will still be needed to obtain high population coverage. Better radical cure antimalarial regimens are needed.</style></abstract><notes><style face="normal" font="default" size="100%">1935-2735&#xD;Watson, James&#xD;Orcid: 0000-0001-5524-0325&#xD;Taylor, Walter R J&#xD;Bancone, Germana&#xD;Chu, Cindy S&#xD;Jittamala, Podjanee&#xD;White, Nicholas J&#xD;Journal Article&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;PLoS Negl Trop Dis. 2018 Apr 20;12(4):e0006440. doi: 10.1371/journal.pntd.0006440. eCollection 2018 Apr.</style></notes><urls></urls><custom2><style face="normal" font="default" size="100%">PMC5931686</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1371/journal.pntd.0006440</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>49</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">49</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Campo, B.</style></author><author><style face="normal" font="default" size="100%">Vandal, O.</style></author><author><style face="normal" font="default" size="100%">Wesche, D. L.</style></author><author><style face="normal" font="default" size="100%">Burrows, J. N.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Killing the hypnozoite--drug discovery approaches to prevent relapse in Plasmodium vivax</style></title><secondary-title><style face="normal" font="default" size="100%">Pathog Glob Health</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Pathog Glob Health</style></full-title></periodical><pages><style face="normal" font="default" size="100%">107-22</style></pages><volume><style face="normal" font="default" size="100%">109</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2015/04/22</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Aminoquinolines/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Antimalarials/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Chemical and Drug Induced Liver Injury/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Eradication/*trends</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Discovery/*trends</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Liver/*drug effects/parasitology/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Malaria, Vivax/*drug therapy/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Plasmodium vivax/*drug effects/isolation &amp; purification</style></keyword><keyword><style face="normal" font="default" size="100%">Recurrence</style></keyword><keyword><style face="normal" font="default" size="100%">Sporozoites/*drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Drug discovery assays</style></keyword><keyword><style face="normal" font="default" size="100%">Hypnozoite</style></keyword><keyword><style face="normal" font="default" size="100%">Plasmodium vivax</style></keyword><keyword><style face="normal" font="default" size="100%">Radical cure</style></keyword><keyword><style face="normal" font="default" size="100%">Strategy</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">2047-7724 (Print)&#xD;2047-7724</style></isbn><accession-num><style face="normal" font="default" size="100%">25891812</style></accession-num><abstract><style face="normal" font="default" size="100%">The eradication of malaria will only be possible if effective, well-tolerated medicines kill hypnozoites in vivax and ovale malaria, and thus prevent relapses in patients. Despite progress in the 8-aminoquinoline series, with tafenoquine in Phase III showing clear benefits over primaquine, the drug discovery challenge to identify hypnozoiticidal or hypnozoite-activating compounds has been hampered by the dearth of biological tools and assays, which in turn has been limited by the immense scientific and logistical challenges associated with accessing relevant human tissue and sporozoites. This review summarises the existing drug discovery series and approaches concerning the goal to block relapse.</style></abstract><notes><style face="normal" font="default" size="100%">2047-7732&#xD;Campo, Brice&#xD;Vandal, Omar&#xD;Wesche, David L&#xD;Burrows, Jeremy N&#xD;Journal Article&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Review&#xD;Pathog Glob Health. 2015 May;109(3):107-22. doi: 10.1179/2047773215Y.0000000013. Epub 2015 Apr 18.</style></notes><urls></urls><custom2><style face="normal" font="default" size="100%">PMC4455353</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1179/2047773215y.0000000013</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>93</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">93</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors></contributors><titles><title><style face="normal" font="default" size="100%">Kodatef (Biocelect) 100 mg tablets australian medicines handbook section 5.7, antiprotozoals</style></title><secondary-title><style face="normal" font="default" size="100%">Australian Prescriber</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Australian Prescriber</style></full-title></periodical><pages><style face="normal" font="default" size="100%">110-111</style></pages><volume><style face="normal" font="default" size="100%">42</style></volume><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">mefloquine</style></keyword><keyword><style face="normal" font="default" size="100%">primaquine</style></keyword><keyword><style face="normal" font="default" size="100%">tafenoquine</style></keyword><keyword><style face="normal" font="default" size="100%">abortion</style></keyword><keyword><style face="normal" font="default" size="100%">anemia</style></keyword><keyword><style face="normal" font="default" size="100%">bloodstream infection</style></keyword><keyword><style face="normal" font="default" size="100%">contraception</style></keyword><keyword><style face="normal" font="default" size="100%">delusion</style></keyword><keyword><style face="normal" font="default" size="100%">drug contraindication</style></keyword><keyword><style face="normal" font="default" size="100%">drug withdrawal</style></keyword><keyword><style face="normal" font="default" size="100%">estimated glomerular filtration rate</style></keyword><keyword><style face="normal" font="default" size="100%">eye disease</style></keyword><keyword><style face="normal" font="default" size="100%">gastrointestinal disease</style></keyword><keyword><style face="normal" font="default" size="100%">hemolysis</style></keyword><keyword><style face="normal" font="default" size="100%">hemolytic anemia</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">hypertransaminasemia</style></keyword><keyword><style face="normal" font="default" size="100%">keratopathy</style></keyword><keyword><style face="normal" font="default" size="100%">kidney disease</style></keyword><keyword><style face="normal" font="default" size="100%">malaria</style></keyword><keyword><style face="normal" font="default" size="100%">maximum plasma concentration</style></keyword><keyword><style face="normal" font="default" size="100%">note</style></keyword><keyword><style face="normal" font="default" size="100%">Plasmodium falciparum</style></keyword><keyword><style face="normal" font="default" size="100%">prophylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">psychosis</style></keyword><keyword><style face="normal" font="default" size="100%">randomized controlled trial (topic)</style></keyword><keyword><style face="normal" font="default" size="100%">single drug dose</style></keyword><keyword><style face="normal" font="default" size="100%">kodatef</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2019</style></year></dates><isbn><style face="normal" font="default" size="100%">1839-3942&#xD;0312-8008</style></isbn><notes><style face="normal" font="default" size="100%">L2002019310&#xD;2019-07-03&#xD;2019-07-08</style></notes><work-type><style face="normal" font="default" size="100%">Note</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2002019310&amp;from=export</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.18773/austprescr.2019.034</style></url></related-urls></urls><custom1><style face="normal" font="default" size="100%">kodatef(Biocelect)</style></custom1><custom2><style face="normal" font="default" size="100%">Biocelect</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.18773/austprescr.2019.034</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>77</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">77</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kain, K. C.</style></author><author><style face="normal" font="default" size="100%">Shanks, G. D.</style></author><author><style face="normal" font="default" size="100%">Keystone, J. S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Centre for Travel and Tropical Medicine, Division of Infectious Diseases, Department of Medicine, Toronto General Hospital and University of Toronto, Toronto, Ontario, Canada. kevin.kain@uhn.on.ca</style></auth-address><titles><title><style face="normal" font="default" size="100%">Malaria chemoprophylaxis in the age of drug resistance. I. Currently recommended drug regimens</style></title><secondary-title><style face="normal" font="default" size="100%">Clin Infect Dis</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Clin Infect Dis</style></full-title></periodical><pages><style face="normal" font="default" size="100%">226-34</style></pages><volume><style face="normal" font="default" size="100%">33</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2001/06/22</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Antimalarials/*therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Atovaquone</style></keyword><keyword><style face="normal" font="default" size="100%">Azithromycin/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Chloroquine/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Resistance</style></keyword><keyword><style face="normal" font="default" size="100%">*Health Planning Guidelines</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Malaria, Falciparum/*drug therapy/parasitology</style></keyword><keyword><style face="normal" font="default" size="100%">Mefloquine/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Naphthoquinones/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Plasmodium falciparum/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Primaquine/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Proguanil/therapeutic use</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2001</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul 15</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1058-4838 (Print)&#xD;1058-4838</style></isbn><accession-num><style face="normal" font="default" size="100%">11418883</style></accession-num><abstract><style face="normal" font="default" size="100%">As international travel becomes increasingly common and resistance to antimalarial drugs escalates, a growing number of travelers are at risk for contracting malaria. Parasite resistance to chloroquine and proguanil and real or perceived intolerance among patients to standard prophylactic agents such as mefloquine have highlighted the need for new antimalarial drugs. Promising new regimens include atovaquone and proguanil, in combination; primaquine; and a related 8-aminoquinoline, tafenoquine. These agents are active against the liver stage of the malaria parasite and therefore can be discontinued shortly after the traveler leaves an area where malaria is endemic, which encourages adherence to the treatment regimen. Part 1 of this series reviews currently recommended chemoprophylactic drug regimens, and part 2 will focus on 8-aminoquinoline drugs.</style></abstract><notes><style face="normal" font="default" size="100%">Kain, K C&#xD;Shanks, G D&#xD;Keystone, J S&#xD;Journal Article&#xD;Review&#xD;United States&#xD;Clin Infect Dis. 2001 Jul 15;33(2):226-34. doi: 10.1086/321817. Epub 2001 Jun 14.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1086/321817</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>76</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">76</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Shanks, G. D.</style></author><author><style face="normal" font="default" size="100%">Kain, K. C.</style></author><author><style face="normal" font="default" size="100%">Keystone, J. S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">US Army Medical Component of the Armed Forces Research Institute of Medical Sciences, 315/6 Rajvithi Road, Bangkok 10400, Thailand. shanksdg@thai.amedd.army.mil</style></auth-address><titles><title><style face="normal" font="default" size="100%">Malaria chemoprophylaxis in the age of drug resistance. II. Drugs that may be available in the future</style></title><secondary-title><style face="normal" font="default" size="100%">Clin Infect Dis</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Clin Infect Dis</style></full-title></periodical><pages><style face="normal" font="default" size="100%">381-5</style></pages><volume><style face="normal" font="default" size="100%">33</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2001/07/05</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Aminoquinolines/pharmacology/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Antimalarials/pharmacology/*therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Resistance</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Malaria/*prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Plasmodium/*drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Primaquine/pharmacology/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">*Travel</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2001</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug 1</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1058-4838 (Print)&#xD;1058-4838</style></isbn><accession-num><style face="normal" font="default" size="100%">11438908</style></accession-num><abstract><style face="normal" font="default" size="100%">All current regimens of malaria chemoprophylaxis have serious drawbacks as a result of either suboptimal efficacy, difficulty with medication compliance, or adverse events. Two 8-aminoquinolines may be approaching registration, with primaquine having completed its prophylactic field testing and tafenoquine having begun advanced field testing at the end of 2000. Primaquine has long been used for management of relapses of malaria, but in the past decade, it has been reexamined for use in malaria prevention in order to stop infection in the liver. In field trials performed in Indonesia and Colombia, the efficacy of primaquine for malaria prevention was approximately 90%, compared with that of placebo. Because of its short half-life, primaquine requires daily administration. For adults, the prevention regimen is 30 mg base daily (0.5 mg base/kg/day), and it can probably be discontinued soon after departure from an area where malaria is endemic. To kill parasites that already exist in the liver, terminal prophylaxis is given after exposure to relapses of malaria infection; for adults, such prophylaxis usually consists of 15 mg base (0.3 mg base/kg/day) given daily for 2 weeks. Primaquine-induced gastrointestinal disturbances can be minimized if the drug is taken with food. Neither primaquine nor tafenoquine should be given to persons with glucose-6-phosphate dehydrogenase deficiency, to avoid the development of potentially severe drug-induced hemolysis. Tafenoquine is an analogue of primaquine that is more potent than the parent drug. Field trials in Kenya, Ghana, Gabon, and Southeast Asia have demonstrated an efficacy rate of approximately 90% for tafenoquine. Its long half-life allows for infrequent dosing (currently tested at 200 mg base/week), and its effect on parasites at the liver stage may allow for drug discontinuation at the time of departure from the area of endemicity.</style></abstract><caption><style face="normal" font="default" size="100%">Duplicate</style></caption><notes><style face="normal" font="default" size="100%">Shanks, G D&#xD;Kain, K C&#xD;Keystone, J S&#xD;Journal Article&#xD;Research Support, U.S. Gov&apos;t, Non-P.H.S.&#xD;Review&#xD;United States&#xD;Clin Infect Dis. 2001 Aug 1;33(3):381-5. doi: 10.1086/321866. Epub 2001 Jul 5.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1086/321866</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>139</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">139</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Shanks, G. D.</style></author><author><style face="normal" font="default" size="100%">Kain, K. C.</style></author><author><style face="normal" font="default" size="100%">Keystone, J. S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">G.D. Shanks, USAMC-AFRIMS, 315/6 Rajvithi Rd., Bangkok 10400, Thailand</style></auth-address><titles><title><style face="normal" font="default" size="100%">Malaria chemoprophylaxis in the age of drug resistance. II. Drugs that may be available in the future</style></title><secondary-title><style face="normal" font="default" size="100%">Clinical Infectious Diseases</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Clinical Infectious Diseases</style></full-title></periodical><pages><style face="normal" font="default" size="100%">381-385</style></pages><volume><style face="normal" font="default" size="100%">33</style></volume><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">8 aminoquinoline derivative</style></keyword><keyword><style face="normal" font="default" size="100%">amodiaquine</style></keyword><keyword><style face="normal" font="default" size="100%">antimalarial agent</style></keyword><keyword><style face="normal" font="default" size="100%">artemisinin</style></keyword><keyword><style face="normal" font="default" size="100%">azithromycin</style></keyword><keyword><style face="normal" font="default" size="100%">pyrimethamine plus sulfadoxine</style></keyword><keyword><style face="normal" font="default" size="100%">halofantrine</style></keyword><keyword><style face="normal" font="default" size="100%">dapsone plus pyrimethamine</style></keyword><keyword><style face="normal" font="default" size="100%">primaquine</style></keyword><keyword><style face="normal" font="default" size="100%">quinine</style></keyword><keyword><style face="normal" font="default" size="100%">tafenoquine</style></keyword><keyword><style face="normal" font="default" size="100%">chemoprophylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">Colombia</style></keyword><keyword><style face="normal" font="default" size="100%">dose response</style></keyword><keyword><style face="normal" font="default" size="100%">drug contraindication</style></keyword><keyword><style face="normal" font="default" size="100%">drug efficacy</style></keyword><keyword><style face="normal" font="default" size="100%">drug half life</style></keyword><keyword><style face="normal" font="default" size="100%">drug mechanism</style></keyword><keyword><style face="normal" font="default" size="100%">drug potency</style></keyword><keyword><style face="normal" font="default" size="100%">Gabon</style></keyword><keyword><style face="normal" font="default" size="100%">gastrointestinal symptom</style></keyword><keyword><style face="normal" font="default" size="100%">Ghana</style></keyword><keyword><style face="normal" font="default" size="100%">glucose 6 phosphate dehydrogenase deficiency</style></keyword><keyword><style face="normal" font="default" size="100%">hemolysis</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">Indonesia</style></keyword><keyword><style face="normal" font="default" size="100%">Kenya</style></keyword><keyword><style face="normal" font="default" size="100%">malaria</style></keyword><keyword><style face="normal" font="default" size="100%">malaria control</style></keyword><keyword><style face="normal" font="default" size="100%">multidrug resistance</style></keyword><keyword><style face="normal" font="default" size="100%">patient compliance</style></keyword><keyword><style face="normal" font="default" size="100%">priority journal</style></keyword><keyword><style face="normal" font="default" size="100%">relapse</style></keyword><keyword><style face="normal" font="default" size="100%">review</style></keyword><keyword><style face="normal" font="default" size="100%">Southeast Asia</style></keyword><keyword><style face="normal" font="default" size="100%">fansidar</style></keyword><keyword><style face="normal" font="default" size="100%">halfan</style></keyword><keyword><style face="normal" font="default" size="100%">maloprim</style></keyword><keyword><style face="normal" font="default" size="100%">zithromax</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2001</style></year></dates><isbn><style face="normal" font="default" size="100%">1058-4838</style></isbn><abstract><style face="normal" font="default" size="100%">All current regimens of malaria chemoprophylaxis have serious drawbacks as a result of either suboptimal efficacy, difficulty with medication compliance, or adverse events. Two 8-aminoquinolines may be approaching registration, with primaquine having completed its prophylactic field testing and tafenoquine having begun advanced field testing at the end of 2000. Primaquine has long been used for management of relapses of malaria, but in the past decade, it has been reexamined for use in malaria prevention in order to stop infection in the liver. In field trials performed in Indonesia and Colombia, the efficacy of primaquine for malaria prevention was ∼90%, compared with that of placebo. Because of its short half-life, primaquine requires daily administration. For adults, the prevention regimen is 30 mg base daily (0.5 mg base/kg/day), and it can probably be discontinued soon after departure from an area where malaria is endemic. To kill parasites that already exist in the liver, terminal prophylaxis is given after exposure to relapses of malaria infection; for adults, such prophylaxis usually consists of 15 mg base (0.3 mg base/kg/day) given daily for 2 weeks. Primaquine-induced gastrointestinal disturbances can be minimized if the drug is taken with food. Neither primaquine nor tafenoquine should be given to persons with glucose-6-phosphate dehydrogenase deficiency, to avoid the development of potentially severe drug-induced hemolysis. Tafenoquine is an analogue of primaquine that is more potent than the parent drug. Field trials in Kenya, Ghana, Gabon, and Southeast Asia have demonstrated an efficacy rate of ∼90% for tafenoquine. Its long half-life allows for infrequent dosing (currently tested at 200 mg base/week), and its effect on parasites at the liver stage may allow for drug discontinuation at the time of departure from the area of endemicity.</style></abstract><caption><style face="normal" font="default" size="100%">Duplicate</style></caption><notes><style face="normal" font="default" size="100%">L32664846&#xD;2001-08-08</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L32664846&amp;from=export</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1086/321866</style></url></related-urls></urls><custom1><style face="normal" font="default" size="100%">fansidar(Hoffmann La Roche)&#xD;halfan(SmithKline Beecham)&#xD;maloprim(Glaxo Wellcome)&#xD;zithromax(Pfizer)</style></custom1><custom2><style face="normal" font="default" size="100%">Glaxo Wellcome&#xD;Hoffmann La Roche&#xD;Pfizer&#xD;SmithKline Beecham</style></custom2><custom5><style face="normal" font="default" size="100%">11438908</style></custom5><electronic-resource-num><style face="normal" font="default" size="100%">10.1086/321866</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase&#xD;Medline</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>78</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">78</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lell, B.</style></author><author><style face="normal" font="default" size="100%">Faucher, J. F.</style></author><author><style face="normal" font="default" size="100%">Missinou, M. A.</style></author><author><style face="normal" font="default" size="100%">Borrmann, S.</style></author><author><style face="normal" font="default" size="100%">Dangelmaier, O.</style></author><author><style face="normal" font="default" size="100%">Horton, J.</style></author><author><style face="normal" font="default" size="100%">Kremsner, P. G.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Research Unit, Albert Schweitzer Hospital, Lambaréné, Gabon.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Malaria chemoprophylaxis with tafenoquine: a randomised study</style></title><secondary-title><style face="normal" font="default" size="100%">Lancet</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Lancet</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2041-5</style></pages><volume><style face="normal" font="default" size="100%">355</style></volume><number><style face="normal" font="default" size="100%">9220</style></number><edition><style face="normal" font="default" size="100%">2000/07/08</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Aminoquinolines/administration &amp; dosage/adverse effects/*therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Antimalarials/administration &amp; dosage/adverse effects/*therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Dose-Response Relationship, Drug</style></keyword><keyword><style face="normal" font="default" size="100%">Double-Blind Method</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Administration Schedule</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Gabon</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Malaria, Falciparum/blood/drug therapy/*prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Phenanthrenes/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Africa</style></keyword><keyword><style face="normal" font="default" size="100%">Africa South Of The Sahara</style></keyword><keyword><style face="normal" font="default" size="100%">Clinical Research</style></keyword><keyword><style face="normal" font="default" size="100%">*Clinical Trials</style></keyword><keyword><style face="normal" font="default" size="100%">Developing Countries</style></keyword><keyword><style face="normal" font="default" size="100%">Diseases</style></keyword><keyword><style face="normal" font="default" size="100%">*Double-blind Studies</style></keyword><keyword><style face="normal" font="default" size="100%">*Drugs</style></keyword><keyword><style face="normal" font="default" size="100%">Examinations And Diagnoses</style></keyword><keyword><style face="normal" font="default" size="100%">French Speaking Africa</style></keyword><keyword><style face="normal" font="default" size="100%">Laboratory Examinations And Diagnoses</style></keyword><keyword><style face="normal" font="default" size="100%">*Laboratory Procedures</style></keyword><keyword><style face="normal" font="default" size="100%">*Malaria--prevention and control</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Africa</style></keyword><keyword><style face="normal" font="default" size="100%">Parasitic Diseases</style></keyword><keyword><style face="normal" font="default" size="100%">Research Methodology</style></keyword><keyword><style face="normal" font="default" size="100%">*Research Report</style></keyword><keyword><style face="normal" font="default" size="100%">Studies</style></keyword><keyword><style face="normal" font="default" size="100%">*Treatment</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2000</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun 10</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0140-6736 (Print)&#xD;0140-6736</style></isbn><accession-num><style face="normal" font="default" size="100%">10885356</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Tafenoquine is an analogue of primaquine with an improved therapeutic and safety profile. It has a long half-life and activity against liver-stage malaria parasites, so may be useful for chemoprophylaxis. In this randomised, double-blind study we assessed the efficacy and safety of tafenoquine in different doses. METHODS: 2144 individuals aged 12-20 years living in Lambaréné, Gabon, an endemic area for Plasmodium falciparum malaria, were invited to take part. 535 attended, and 426 eligible participants were randomly assigned tafenoquine (250 mg, 125 mg, 62.5 mg, or 31.25 mg) or placebo daily for 3 days. 417 received initial curative treatment with halofantrine, and 410 completed the assigned prophylaxis regimen. During follow-up of 70 days, adverse events were recorded and thick blood smears were examined weekly. The primary and secondary endpoints were the number of individuals with positive blood smears by day 56 and day 77, respectively. Analyses were per-protocol. FINDINGS: Eight positive blood smears were recorded by day 56 (four/82 participants in the placebo group; four/79 tafenoquine 31.25 mg group). By day 77, 34 positive blood smears had been recorded (14/82 placebo; 16/79 tafenoquine 31.25 mg; three/86 tafenoquine 62.5 mg; one/79 tafenoquine 125 mg; none/84 tafenoquine 250 mg). Numbers of adverse events did not differ significantly between the treatment groups. INTERPRETATION: Tafenoquine is effective and well tolerated. It has the potential to replace currently used drugs for malaria chemoprophylaxis.</style></abstract><caption><style face="normal" font="default" size="100%">Duplicate</style></caption><notes><style face="normal" font="default" size="100%">Lell, B&#xD;Faucher, J F&#xD;Missinou, M A&#xD;Borrmann, S&#xD;Dangelmaier, O&#xD;Horton, J&#xD;Kremsner, P G&#xD;Clinical Trial&#xD;Journal Article&#xD;Randomized Controlled Trial&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;England&#xD;Lancet. 2000 Jun 10;355(9220):2041-5. doi: 10.1016/S0140-6736(00)02352-7.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/s0140-6736(00)02352-7</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>141</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">141</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lell, B.</style></author><author><style face="normal" font="default" size="100%">Faucher, J. F.</style></author><author><style face="normal" font="default" size="100%">Missinou, M. A.</style></author><author><style face="normal" font="default" size="100%">Borrmann, S.</style></author><author><style face="normal" font="default" size="100%">Dangelmaier, O.</style></author><author><style face="normal" font="default" size="100%">Horton, J.</style></author><author><style face="normal" font="default" size="100%">Kremsner, P. G.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">P.G. Kremsner, Sektion Humanparasitologie, Institut fur Tropenmedizin, Wilhelmstrasse 27, D-72074 Tubingen, Germany</style></auth-address><titles><title><style face="normal" font="default" size="100%">Malaria chemoprophylaxis with tafenoquine: A randomised study</style></title><secondary-title><style face="normal" font="default" size="100%">Lancet</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Lancet</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2041-2045</style></pages><volume><style face="normal" font="default" size="100%">355</style></volume><number><style face="normal" font="default" size="100%">9220</style></number><keywords><keyword><style face="normal" font="default" size="100%">tafenoquine</style></keyword><keyword><style face="normal" font="default" size="100%">abdominal pain</style></keyword><keyword><style face="normal" font="default" size="100%">adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">adult</style></keyword><keyword><style face="normal" font="default" size="100%">article</style></keyword><keyword><style face="normal" font="default" size="100%">chemoprophylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">clinical trial</style></keyword><keyword><style face="normal" font="default" size="100%">controlled clinical trial</style></keyword><keyword><style face="normal" font="default" size="100%">controlled study</style></keyword><keyword><style face="normal" font="default" size="100%">diarrhea</style></keyword><keyword><style face="normal" font="default" size="100%">double blind procedure</style></keyword><keyword><style face="normal" font="default" size="100%">drug efficacy</style></keyword><keyword><style face="normal" font="default" size="100%">drug half life</style></keyword><keyword><style face="normal" font="default" size="100%">drug safety</style></keyword><keyword><style face="normal" font="default" size="100%">drug tolerability</style></keyword><keyword><style face="normal" font="default" size="100%">fatigue</style></keyword><keyword><style face="normal" font="default" size="100%">female</style></keyword><keyword><style face="normal" font="default" size="100%">fever</style></keyword><keyword><style face="normal" font="default" size="100%">headache</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">major clinical study</style></keyword><keyword><style face="normal" font="default" size="100%">malaria</style></keyword><keyword><style face="normal" font="default" size="100%">male</style></keyword><keyword><style face="normal" font="default" size="100%">priority journal</style></keyword><keyword><style face="normal" font="default" size="100%">prophylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">randomized controlled trial</style></keyword><keyword><style face="normal" font="default" size="100%">rash</style></keyword><keyword><style face="normal" font="default" size="100%">school child</style></keyword><keyword><style face="normal" font="default" size="100%">vertigo</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2000</style></year></dates><isbn><style face="normal" font="default" size="100%">0140-6736</style></isbn><abstract><style face="normal" font="default" size="100%">Background. Tafenoquine is an analogue of primaquine with an improved therapeutic and safety profile. It has a long half life and activity against liver-stage malaria parasites, so may be useful for chemoprophylaxis. In this randomised, double-blind study we assessed the efficacy and safety of tafenoquine in different doses. Methods. 2144 individuals aged 12-20 years living in Lambarene, Gabon, an endemic area for Plasmodium falciparum malaria. were invited to take part. 535 attended. and 426 eligible participants were randomly assigned tafenoquine (250 mg, 125 mg, 62.5 mg, or 31.25 mg) or placebo daily for 3 days. 417 received initial curative treatment with halofantrine, and 410 completed the assigned prophylaxis regimen. During follow-up of 70 days, adverse events were recorded and thick blood smears were examined weekly. The primary and secondary endpoints were the number of individuals with positive blood smears by day 56 and day 77, respectively. Analyses were per-protocol. Findings. Eight positive blood smears were recorded by day 56 (four/82 participants in the placebo group; four/79 tafenoquine 31.25 mg group). By day 77, 34 positive blood smears had been recorded (14/82 placebo; 16/79 tafenoquine 31.25 mg; three/86 tafenoquine 62.5 mg; one/79 tafenoquine 125 mg; none/84 tafenoquine 250 mg). Numbers of adverse events did not differ significantly between the treatment groups. Interpretation. Tafenoquine is effective and well tolerated. It has the potential to replace currently used drugs for malaria chemoprophylaxis.</style></abstract><caption><style face="normal" font="default" size="100%">Duplicate</style></caption><notes><style face="normal" font="default" size="100%">L30339243&#xD;2000-06-20</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L30339243&amp;from=export</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1016/S0140-6736(00)02352-7</style></url></related-urls></urls><custom1><style face="normal" font="default" size="100%">tafenoquine</style></custom1><custom5><style face="normal" font="default" size="100%">10885356</style></custom5><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/S0140-6736(00)02352-7</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase&#xD;Medline</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>150</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">150</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lell, B.</style></author><author><style face="normal" font="default" size="100%">Faucher, J. F.</style></author><author><style face="normal" font="default" size="100%">Missinou, M. A.</style></author><author><style face="normal" font="default" size="100%">Borrmann, S.</style></author><author><style face="normal" font="default" size="100%">Dangelmaier, O.</style></author><author><style face="normal" font="default" size="100%">Horton, J.</style></author><author><style face="normal" font="default" size="100%">Kremsner, P. G.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Malaria chemoprophylaxis with tafenoquine: a randomised study</style></title><secondary-title><style face="normal" font="default" size="100%">Lancet (london, england)</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Lancet (london, england)</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2041‐2045</style></pages><volume><style face="normal" font="default" size="100%">355</style></volume><number><style face="normal" font="default" size="100%">9220</style></number><keywords><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Aminoquinolines [administration &amp; dosage, adverse effects, *therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Antimalarials [administration &amp; dosage, adverse effects, *therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Dose‐Response Relationship, Drug</style></keyword><keyword><style face="normal" font="default" size="100%">Double‐Blind Method</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Administration Schedule</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Gabon</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Malaria, Falciparum [blood, drug therapy, *prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Phenanthrenes [therapeutic use]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2000</style></year></dates><accession-num><style face="normal" font="default" size="100%">CN-00297995</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Tafenoquine is an analogue of primaquine with an improved therapeutic and safety profile. It has a long half‐life and activity against liver‐stage malaria parasites, so may be useful for chemoprophylaxis. In this randomised, double‐blind study we assessed the efficacy and safety of tafenoquine in different doses. METHODS: 2144 individuals aged 12‐20 years living in Lambaréné, Gabon, an endemic area for Plasmodium falciparum malaria, were invited to take part. 535 attended, and 426 eligible participants were randomly assigned tafenoquine (250 mg, 125 mg, 62.5 mg, or 31.25 mg) or placebo daily for 3 days. 417 received initial curative treatment with halofantrine, and 410 completed the assigned prophylaxis regimen. During follow‐up of 70 days, adverse events were recorded and thick blood smears were examined weekly. The primary and secondary endpoints were the number of individuals with positive blood smears by day 56 and day 77, respectively. Analyses were per‐protocol. FINDINGS: Eight positive blood smears were recorded by day 56 (four/82 participants in the placebo group; four/79 tafenoquine 31.25 mg group). By day 77, 34 positive blood smears had been recorded (14/82 placebo; 16/79 tafenoquine 31.25 mg; three/86 tafenoquine 62.5 mg; one/79 tafenoquine 125 mg; none/84 tafenoquine 250 mg). Numbers of adverse events did not differ significantly between the treatment groups. INTERPRETATION: Tafenoquine is effective and well tolerated. It has the potential to replace currently used drugs for malaria chemoprophylaxis.</style></abstract><caption><style face="normal" font="default" size="100%">Duplicate</style></caption><work-type><style face="normal" font="default" size="100%">Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non‐U.S. Gov&apos;t</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.cochranelibrary.com/central/doi/10.1002/central/CN-00297995/full</style></url></related-urls></urls><custom3><style face="normal" font="default" size="100%">PUBMED 10885356</style></custom3><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/S0140-6736(00)02352-7</style></electronic-resource-num></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>131</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">131</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Petersen, E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">E. Petersen, Department of Infectious Diseases, Aarhus University Hospital Skejby, DK-8200 Aarhus N, Denmark</style></auth-address><titles><title><style face="normal" font="default" size="100%">Malaria chemoprophylaxis: When should we use it and what are the options?</style></title><secondary-title><style face="normal" font="default" size="100%">Expert Review of Anti-Infective Therapy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Expert Review of Anti-Infective Therapy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">119-132</style></pages><volume><style face="normal" font="default" size="100%">2</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">4 aminoquinoline derivative</style></keyword><keyword><style face="normal" font="default" size="100%">8 aminoquinoline derivative</style></keyword><keyword><style face="normal" font="default" size="100%">amodiaquine</style></keyword><keyword><style face="normal" font="default" size="100%">antimalarial agent</style></keyword><keyword><style face="normal" font="default" size="100%">artemisinin</style></keyword><keyword><style face="normal" font="default" size="100%">atovaquone</style></keyword><keyword><style face="normal" font="default" size="100%">atovaquone plus proguanil</style></keyword><keyword><style face="normal" font="default" size="100%">azithromycin</style></keyword><keyword><style face="normal" font="default" size="100%">cycloguanil</style></keyword><keyword><style face="normal" font="default" size="100%">chloroquine</style></keyword><keyword><style face="normal" font="default" size="100%">chloroquine plus proguanil</style></keyword><keyword><style face="normal" font="default" size="100%">chlorproguanil</style></keyword><keyword><style face="normal" font="default" size="100%">chlorproguanil plus dapsone</style></keyword><keyword><style face="normal" font="default" size="100%">dapsone</style></keyword><keyword><style face="normal" font="default" size="100%">deltaprim</style></keyword><keyword><style face="normal" font="default" size="100%">dihydrofolate reductase</style></keyword><keyword><style face="normal" font="default" size="100%">doxycycline</style></keyword><keyword><style face="normal" font="default" size="100%">pyrimethamine plus sulfadoxine</style></keyword><keyword><style face="normal" font="default" size="100%">halofantrine</style></keyword><keyword><style face="normal" font="default" size="100%">dapsone plus pyrimethamine</style></keyword><keyword><style face="normal" font="default" size="100%">mefloquine</style></keyword><keyword><style face="normal" font="default" size="100%">placebo</style></keyword><keyword><style face="normal" font="default" size="100%">primaquine</style></keyword><keyword><style face="normal" font="default" size="100%">primaquine derivative</style></keyword><keyword><style face="normal" font="default" size="100%">proguanil</style></keyword><keyword><style face="normal" font="default" size="100%">pyrimethamine</style></keyword><keyword><style face="normal" font="default" size="100%">quinine</style></keyword><keyword><style face="normal" font="default" size="100%">sulfadoxine</style></keyword><keyword><style face="normal" font="default" size="100%">sulfonamide</style></keyword><keyword><style face="normal" font="default" size="100%">tafenoquine</style></keyword><keyword><style face="normal" font="default" size="100%">tetracycline derivative</style></keyword><keyword><style face="normal" font="default" size="100%">unclassified drug</style></keyword><keyword><style face="normal" font="default" size="100%">Africa</style></keyword><keyword><style face="normal" font="default" size="100%">agranulocytosis</style></keyword><keyword><style face="normal" font="default" size="100%">anorexia</style></keyword><keyword><style face="normal" font="default" size="100%">antimalarial activity</style></keyword><keyword><style face="normal" font="default" size="100%">chemoprophylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">clinical study</style></keyword><keyword><style face="normal" font="default" size="100%">clinical trial</style></keyword><keyword><style face="normal" font="default" size="100%">depression</style></keyword><keyword><style face="normal" font="default" size="100%">disease exacerbation</style></keyword><keyword><style face="normal" font="default" size="100%">drug absorption</style></keyword><keyword><style face="normal" font="default" size="100%">drug efficacy</style></keyword><keyword><style face="normal" font="default" size="100%">drug eruption</style></keyword><keyword><style face="normal" font="default" size="100%">drug fatality</style></keyword><keyword><style face="normal" font="default" size="100%">drug half life</style></keyword><keyword><style face="normal" font="default" size="100%">drug marketing</style></keyword><keyword><style face="normal" font="default" size="100%">drug mechanism</style></keyword><keyword><style face="normal" font="default" size="100%">drug metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">drug potentiation</style></keyword><keyword><style face="normal" font="default" size="100%">drug safety</style></keyword><keyword><style face="normal" font="default" size="100%">drug sensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">drug surveillance program</style></keyword><keyword><style face="normal" font="default" size="100%">drug tolerability</style></keyword><keyword><style face="normal" font="default" size="100%">drug withdrawal</style></keyword><keyword><style face="normal" font="default" size="100%">emergency health service</style></keyword><keyword><style face="normal" font="default" size="100%">epigastric pain</style></keyword><keyword><style face="normal" font="default" size="100%">gastrointestinal symptom</style></keyword><keyword><style face="normal" font="default" size="100%">hallucination</style></keyword><keyword><style face="normal" font="default" size="100%">headache</style></keyword><keyword><style face="normal" font="default" size="100%">heart arrest</style></keyword><keyword><style face="normal" font="default" size="100%">heart arrhythmia</style></keyword><keyword><style face="normal" font="default" size="100%">hematologic disease</style></keyword><keyword><style face="normal" font="default" size="100%">hemolysis</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">IC50</style></keyword><keyword><style face="normal" font="default" size="100%">infection risk</style></keyword><keyword><style face="normal" font="default" size="100%">insect bite</style></keyword><keyword><style face="normal" font="default" size="100%">lactation</style></keyword><keyword><style face="normal" font="default" size="100%">malaria</style></keyword><keyword><style face="normal" font="default" size="100%">malaria falciparum</style></keyword><keyword><style face="normal" font="default" size="100%">mental disease</style></keyword><keyword><style face="normal" font="default" size="100%">methemoglobinemia</style></keyword><keyword><style face="normal" font="default" size="100%">mortality</style></keyword><keyword><style face="normal" font="default" size="100%">mosquito</style></keyword><keyword><style face="normal" font="default" size="100%">nausea</style></keyword><keyword><style face="normal" font="default" size="100%">neurologic disease</style></keyword><keyword><style face="normal" font="default" size="100%">nonhuman</style></keyword><keyword><style face="normal" font="default" size="100%">photoallergy</style></keyword><keyword><style face="normal" font="default" size="100%">Plasmodium falciparum</style></keyword><keyword><style face="normal" font="default" size="100%">Plasmodium vivax</style></keyword><keyword><style face="normal" font="default" size="100%">pregnancy</style></keyword><keyword><style face="normal" font="default" size="100%">prescription</style></keyword><keyword><style face="normal" font="default" size="100%">registration</style></keyword><keyword><style face="normal" font="default" size="100%">retina degeneration</style></keyword><keyword><style face="normal" font="default" size="100%">review</style></keyword><keyword><style face="normal" font="default" size="100%">risk assessment</style></keyword><keyword><style face="normal" font="default" size="100%">Stevens Johnson syndrome</style></keyword><keyword><style face="normal" font="default" size="100%">thrombocytopenia</style></keyword><keyword><style face="normal" font="default" size="100%">travel</style></keyword><keyword><style face="normal" font="default" size="100%">visual impairment</style></keyword><keyword><style face="normal" font="default" size="100%">vomiting</style></keyword><keyword><style face="normal" font="default" size="100%">fansidar</style></keyword><keyword><style face="normal" font="default" size="100%">halfan</style></keyword><keyword><style face="normal" font="default" size="100%">lapdap</style></keyword><keyword><style face="normal" font="default" size="100%">lariam</style></keyword><keyword><style face="normal" font="default" size="100%">malarone</style></keyword><keyword><style face="normal" font="default" size="100%">maloprim</style></keyword><keyword><style face="normal" font="default" size="100%">savarine</style></keyword><keyword><style face="normal" font="default" size="100%">zithromax</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2004</style></year></dates><isbn><style face="normal" font="default" size="100%">1478-7210</style></isbn><abstract><style face="normal" font="default" size="100%">Malaria chemoprophylaxis concerns prescribing healthy individuals medication for an infection they have an unknown chance of getting. Sensible use of malaria chemoprophylaxis is a balance between the risk of infection and death, and the risk of side effects. The risk of infection can be broken down into the risk of being bitten by a malaria-infected mosquito and the risk of the malaria parasites being resistant to the drug used for prophylaxis. Our knowledge of these parameters is patchy. The risk of infection is not uniform at a given location and the standard of living will greatly influence risk. It is suggested that chemoprophylaxis should not be recommended in areas with less than ten reported cases of P. falciparum malaria per 1000 inhabitants per year. The resistance pattern is known to a certain extent but, for instance, diverging opinion of how much resistance to chloroquine there is in West Africa illustrates the lack of data. There is much debate on rare adverse events, which usually escape Phase III studies prior to registration and are only picked up by passive, postmarketing surveillance. The lessons over the past 20 years with the introduction of amodiaquine, pyrimethamine/dapsone (Maloprim®, GlaxoSmithKline) and pyrimethamine/sulfadoxine (Fansidar®, Roche), which were all withdrawn for prophylaxis after a few years, show how sensitive drugs for chemoprophylaxis are to side effects. Three levels of chemoprophylaxis are used: chloroquine in areas with sensitive P. falciparum, chloroquine plus proguanil in areas with low level chloroquine resistance, and atovaquone/proguanil (Malarone®, GlaxoSmithKline), doxycycline or mefloquine (Lariam®, Roche) in areas with extensive resistance against chloroquine and proguanil. Primaquine and the primaquone analog tafenoquine may be future alternatives but otherwise there are few new drugs for chemoprophylaxis on the horizon. © Future Drugs Ltd. All rights reserved.</style></abstract><notes><style face="normal" font="default" size="100%">L38735753&#xD;2004-06-21</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L38735753&amp;from=export</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1586/14787210.2.1.119</style></url></related-urls></urls><custom1><style face="normal" font="default" size="100%">deltaprim&#xD;fansidar(Hoffmann La Roche,Switzerland)&#xD;halfan(Novartis,United States)&#xD;lapdap(Glaxo SmithKline)&#xD;lariam(Hoffmann La Roche)&#xD;malarone(Glaxo SmithKline)&#xD;maloprim(Glaxo SmithKline,United Kingdom)&#xD;savarine(Astra Zeneca,United States)&#xD;zithromax(Pfizer,United States)</style></custom1><custom2><style face="normal" font="default" size="100%">Astra Zeneca(United States)&#xD;Glaxo SmithKline(United Kingdom)&#xD;Hoffmann La Roche(Switzerland)&#xD;Novartis(United States)&#xD;Pfizer(United States)</style></custom2><custom5><style face="normal" font="default" size="100%">15482177</style></custom5><electronic-resource-num><style face="normal" font="default" size="100%">10.1586/14787210.2.1.119</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase&#xD;Medline</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>184</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">184</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Elmes, N. J.</style></author><author><style face="normal" font="default" size="100%">Bennett, S. M.</style></author><author><style face="normal" font="default" size="100%">Nasveld, P. E.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Malaria in the Australian Defence Force: the Bougainville experience</style></title><secondary-title><style face="normal" font="default" size="100%">ADF health</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">ADF health</style></full-title></periodical><pages><style face="normal" font="default" size="100%">69‐72</style></pages><volume><style face="normal" font="default" size="100%">5</style></volume><number><style face="normal" font="default" size="100%">2</style></number><dates><year><style face="normal" font="default" size="100%">2004</style></year></dates><accession-num><style face="normal" font="default" size="100%">CN-00636390</style></accession-num><abstract><style face="normal" font="default" size="100%">During a 5 year period, almost 4000 Australian personnel served in the Papua New Guinean province of Bougainville. The first randomised, double‐blind trial comparing Malarone (a combination of atovaquone and proguanil) with doxycycline was conducted during the deployment. Malarone was as effective as doxycycline and better tolerated. Another trial compared a 3 day course of tafenoquine with the course of primaquine that was standard at that time for post‐exposure prophylaxis. There was no statistical difference in rates of malaria following either regimen. There were 64 episodes of malaria affecting 50 individuals. This gave an attack rate of 41.6 malarious episodes per 1000 man years. Most attacks occurred after the person had returned to Australia. The dosage of primaquine was increased partway through the deployment, from 22.5 mg to 30 mg per day. The attack rate fell from 67.1 to 13.2 per 1000 man years. The attack rate following tafenoquine post‐exposure prophylaxis was 63.5 per 1000 man years. (http://www.defence.gov.au/health/infocentre/journals/ADFHJ_sep04/ADFHealth_5_2_69‐72.pdf). [By permission, Australasian Medical Index, National Library of Australia]</style></abstract><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.cochranelibrary.com/central/doi/10.1002/central/CN-00636390/full</style></url></related-urls></urls></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>122</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">122</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Castelli, F.</style></author><author><style face="normal" font="default" size="100%">Odolini, S.</style></author><author><style face="normal" font="default" size="100%">Autino, B.</style></author><author><style face="normal" font="default" size="100%">Foca, E.</style></author><author><style face="normal" font="default" size="100%">Russo, R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">F. Castelli, Institute for Infectious and Tropical Diseases, University of Brescia, Piazza Spedali Civili, 1 - 25123-Brescia, Italy</style></auth-address><titles><title><style face="normal" font="default" size="100%">Malaria prophylaxis: A comprehensive review</style></title><secondary-title><style face="normal" font="default" size="100%">Pharmaceuticals</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Pharmaceuticals</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3212-3239</style></pages><volume><style face="normal" font="default" size="100%">3</style></volume><number><style face="normal" font="default" size="100%">10</style></number><keywords><keyword><style face="normal" font="default" size="100%">ampicillin</style></keyword><keyword><style face="normal" font="default" size="100%">antacid agent</style></keyword><keyword><style face="normal" font="default" size="100%">artemether plus benflumetol</style></keyword><keyword><style face="normal" font="default" size="100%">atovaquone plus proguanil</style></keyword><keyword><style face="normal" font="default" size="100%">carbamazepine</style></keyword><keyword><style face="normal" font="default" size="100%">chloroquine</style></keyword><keyword><style face="normal" font="default" size="100%">chloroquine plus proguanil</style></keyword><keyword><style face="normal" font="default" size="100%">clindamycin</style></keyword><keyword><style face="normal" font="default" size="100%">cyclosporine</style></keyword><keyword><style face="normal" font="default" size="100%">diethyltoluamide</style></keyword><keyword><style face="normal" font="default" size="100%">doxycycline</style></keyword><keyword><style face="normal" font="default" size="100%">halofantrine</style></keyword><keyword><style face="normal" font="default" size="100%">hydroxychloroquine</style></keyword><keyword><style face="normal" font="default" size="100%">insect repellent</style></keyword><keyword><style face="normal" font="default" size="100%">insecticide</style></keyword><keyword><style face="normal" font="default" size="100%">iron</style></keyword><keyword><style face="normal" font="default" size="100%">mefloquine</style></keyword><keyword><style face="normal" font="default" size="100%">permethrin</style></keyword><keyword><style face="normal" font="default" size="100%">phenobarbital</style></keyword><keyword><style face="normal" font="default" size="100%">phenytoin</style></keyword><keyword><style face="normal" font="default" size="100%">placebo</style></keyword><keyword><style face="normal" font="default" size="100%">praziquantel</style></keyword><keyword><style face="normal" font="default" size="100%">primaquine</style></keyword><keyword><style face="normal" font="default" size="100%">proguanil</style></keyword><keyword><style face="normal" font="default" size="100%">quinine</style></keyword><keyword><style face="normal" font="default" size="100%">rifampicin</style></keyword><keyword><style face="normal" font="default" size="100%">tafenoquine</style></keyword><keyword><style face="normal" font="default" size="100%">thyroxine</style></keyword><keyword><style face="normal" font="default" size="100%">unindexed drug</style></keyword><keyword><style face="normal" font="default" size="100%">valproic acid</style></keyword><keyword><style face="normal" font="default" size="100%">abdominal pain</style></keyword><keyword><style face="normal" font="default" size="100%">Africa</style></keyword><keyword><style face="normal" font="default" size="100%">aminotransferase blood level</style></keyword><keyword><style face="normal" font="default" size="100%">anorexia</style></keyword><keyword><style face="normal" font="default" size="100%">aplastic anemia</style></keyword><keyword><style face="normal" font="default" size="100%">ataxia</style></keyword><keyword><style face="normal" font="default" size="100%">attention disturbance</style></keyword><keyword><style face="normal" font="default" size="100%">bed net</style></keyword><keyword><style face="normal" font="default" size="100%">blurred vision</style></keyword><keyword><style face="normal" font="default" size="100%">bone marrow suppression</style></keyword><keyword><style face="normal" font="default" size="100%">breast feeding</style></keyword><keyword><style face="normal" font="default" size="100%">chemoprophylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">clinical trial</style></keyword><keyword><style face="normal" font="default" size="100%">cognitive defect</style></keyword><keyword><style face="normal" font="default" size="100%">creatinine blood level</style></keyword><keyword><style face="normal" font="default" size="100%">depression</style></keyword><keyword><style face="normal" font="default" size="100%">diarrhea</style></keyword><keyword><style face="normal" font="default" size="100%">disease severity</style></keyword><keyword><style face="normal" font="default" size="100%">dizziness</style></keyword><keyword><style face="normal" font="default" size="100%">drug antagonism</style></keyword><keyword><style face="normal" font="default" size="100%">drug bioavailability</style></keyword><keyword><style face="normal" font="default" size="100%">drug blood level</style></keyword><keyword><style face="normal" font="default" size="100%">drug contraindication</style></keyword><keyword><style face="normal" font="default" size="100%">drug excretion</style></keyword><keyword><style face="normal" font="default" size="100%">drug half life</style></keyword><keyword><style face="normal" font="default" size="100%">drug indication</style></keyword><keyword><style face="normal" font="default" size="100%">drug induced headache</style></keyword><keyword><style face="normal" font="default" size="100%">drug mechanism</style></keyword><keyword><style face="normal" font="default" size="100%">drug metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">drug potentiation</style></keyword><keyword><style face="normal" font="default" size="100%">drug withdrawal</style></keyword><keyword><style face="normal" font="default" size="100%">emergency care</style></keyword><keyword><style face="normal" font="default" size="100%">endemic disease</style></keyword><keyword><style face="normal" font="default" size="100%">epigastric pain</style></keyword><keyword><style face="normal" font="default" size="100%">epileptic state</style></keyword><keyword><style face="normal" font="default" size="100%">esophagitis</style></keyword><keyword><style face="normal" font="default" size="100%">fever</style></keyword><keyword><style face="normal" font="default" size="100%">gastrointestinal symptom</style></keyword><keyword><style face="normal" font="default" size="100%">hair loss</style></keyword><keyword><style face="normal" font="default" size="100%">hearing impairment</style></keyword><keyword><style face="normal" font="default" size="100%">hemolysis</style></keyword><keyword><style face="normal" font="default" size="100%">hemolytic anemia</style></keyword><keyword><style face="normal" font="default" size="100%">high risk population</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">immunocompromised patient</style></keyword><keyword><style face="normal" font="default" size="100%">infection risk</style></keyword><keyword><style face="normal" font="default" size="100%">insomnia</style></keyword><keyword><style face="normal" font="default" size="100%">keratopathy</style></keyword><keyword><style face="normal" font="default" size="100%">liver toxicity</style></keyword><keyword><style face="normal" font="default" size="100%">Loeffler pneumonia</style></keyword><keyword><style face="normal" font="default" size="100%">malaria</style></keyword><keyword><style face="normal" font="default" size="100%">malaria control</style></keyword><keyword><style face="normal" font="default" size="100%">malaria falciparum</style></keyword><keyword><style face="normal" font="default" size="100%">morbidity</style></keyword><keyword><style face="normal" font="default" size="100%">mortality</style></keyword><keyword><style face="normal" font="default" size="100%">mouth ulcer</style></keyword><keyword><style face="normal" font="default" size="100%">myoclonus</style></keyword><keyword><style face="normal" font="default" size="100%">myopathy</style></keyword><keyword><style face="normal" font="default" size="100%">nausea</style></keyword><keyword><style face="normal" font="default" size="100%">neurotoxicity</style></keyword><keyword><style face="normal" font="default" size="100%">nightmare</style></keyword><keyword><style face="normal" font="default" size="100%">patient compliance</style></keyword><keyword><style face="normal" font="default" size="100%">photosensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">phototoxicity</style></keyword><keyword><style face="normal" font="default" size="100%">Plasmodium</style></keyword><keyword><style face="normal" font="default" size="100%">pregnancy</style></keyword><keyword><style face="normal" font="default" size="100%">pruritus</style></keyword><keyword><style face="normal" font="default" size="100%">psoriasis</style></keyword><keyword><style face="normal" font="default" size="100%">psychosis</style></keyword><keyword><style face="normal" font="default" size="100%">retina disease</style></keyword><keyword><style face="normal" font="default" size="100%">review</style></keyword><keyword><style face="normal" font="default" size="100%">risk reduction</style></keyword><keyword><style face="normal" font="default" size="100%">side effect</style></keyword><keyword><style face="normal" font="default" size="100%">skin disease</style></keyword><keyword><style face="normal" font="default" size="100%">skin manifestation</style></keyword><keyword><style face="normal" font="default" size="100%">skin pigmentation</style></keyword><keyword><style face="normal" font="default" size="100%">Stevens Johnson syndrome</style></keyword><keyword><style face="normal" font="default" size="100%">stomatitis</style></keyword><keyword><style face="normal" font="default" size="100%">teratogenicity</style></keyword><keyword><style face="normal" font="default" size="100%">tinnitus</style></keyword><keyword><style face="normal" font="default" size="100%">travel</style></keyword><keyword><style face="normal" font="default" size="100%">vagina candidiasis</style></keyword><keyword><style face="normal" font="default" size="100%">vagina flora</style></keyword><keyword><style face="normal" font="default" size="100%">vector control</style></keyword><keyword><style face="normal" font="default" size="100%">vomiting</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2010</style></year></dates><isbn><style face="normal" font="default" size="100%">1424-8247</style></isbn><abstract><style face="normal" font="default" size="100%">The flow of international travellers to and from malaria-endemic areas, especially Africa, has increased in recent years. Apart from the very high morbidity and mortality burden imposed on malaria-endemic areas, imported malaria is the main cause of fever possibly causing severe disease and death in travellers coming from tropical and subtropical areas, particularly Sub-Saharan Africa. The importance of behavioural preventive measures (bed nets, repellents, etc.), adequate chemoprophylaxis and, in selected circumstances, stand-by emergency treatment may not be overemphasized. However, no prophylactic regimen may offer complete protection. Expert advice is needed to tailor prophylactic advice according to traveller (age, baseline clinical conditions, etc.) and travel (destination, season, etc.) characteristics in order to reduce malaria risk. © 2010 by the authors.</style></abstract><notes><style face="normal" font="default" size="100%">L360158998&#xD;2010-12-22&#xD;2010-12-29</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L360158998&amp;from=export</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.3390/ph3103212</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.3390/ph3103212</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>74</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">74</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Edstein, M. D.</style></author><author><style face="normal" font="default" size="100%">Walsh, D. S.</style></author><author><style face="normal" font="default" size="100%">Eamsila, C.</style></author><author><style face="normal" font="default" size="100%">Sasiprapha, T.</style></author><author><style face="normal" font="default" size="100%">Nasveld, P. E.</style></author><author><style face="normal" font="default" size="100%">Kitchener, S.</style></author><author><style face="normal" font="default" size="100%">Rieckmann, K. H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Australian Army Malaria Institute, Gallipoli Barracks, Enogerra, QLD, 4052 Australia. Mike.Edstein@defence.gov.au</style></auth-address><titles><title><style face="normal" font="default" size="100%">Malaria prophylaxis/radical cure: recent experiences of the Australian Defence Force</style></title><secondary-title><style face="normal" font="default" size="100%">Med Trop (Mars)</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Med Trop (Mars)</style></full-title></periodical><pages><style face="normal" font="default" size="100%">56-8</style></pages><volume><style face="normal" font="default" size="100%">61</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2001/10/05</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Aminoquinolines/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Antimalarials/*therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Australia</style></keyword><keyword><style face="normal" font="default" size="100%">Controlled Clinical Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Endemic Diseases</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Malaria/*drug therapy/epidemiology/*prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Malaria, Falciparum/drug therapy/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Malaria, Vivax/drug therapy/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">*Military Personnel</style></keyword><keyword><style face="normal" font="default" size="100%">Primaquine/therapeutic use</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2001</style></year></dates><isbn><style face="normal" font="default" size="100%">0025-682X (Print)&#xD;0025-682x</style></isbn><accession-num><style face="normal" font="default" size="100%">11584657</style></accession-num><abstract><style face="normal" font="default" size="100%">Since the eighties, the Australian Defence Force has deployed soldiers in malaria-endemic areas: Cambodia, Somalia, Rwanda, Bougainville, and East Timor. Currently, doxycycline is used as first line prophylactic drug and mefloquine is recommended for those who cannot tolerate the antibiotic. In 1998, the Australian Defence Force participated in the evaluation of tafenoquine for prophylaxis of both falciparum and vivax malaria in Thai soldiers. At the completion of this six-month study, 29 of 205 soldiers had come down with malaria including eight with falciparum malaria, 20 with vivax malaria, and one with mixed infection. A total of 28 of the 101 soldiers in the placebo group were infected with malaria as compared with only one of the 104 soldiers in the tafenoquine group. In 1999, another study was started on the island of Bougainville to compare the effectiveness a 3-day course of tafenoquine and a 14-day course of primaquine for radical cure of vivax malaria. At the present time, 411 soldiers have completed the study including 201 in tafenoquine arm and 210 in primaquine arm. Seven soldiers in each arm developed vivax malaria after returning to Australia. These results indicate that tafenoquine is not superior to primaquine in preventing vivax malaria. However study participants preferred the shorter course using tafenoquine and operationally it was found to be more suitable than primaquine.</style></abstract><caption><style face="normal" font="default" size="100%">Duplicate</style></caption><notes><style face="normal" font="default" size="100%">Edstein, M D&#xD;Walsh, D S&#xD;Eamsila, C&#xD;Sasiprapha, T&#xD;Nasveld, P E&#xD;Kitchener, S&#xD;Rieckmann, K H&#xD;Clinical Trial&#xD;Comparative Study&#xD;Journal Article&#xD;Randomized Controlled Trial&#xD;Review&#xD;France&#xD;Med Trop (Mars). 2001;61(1):56-8.</style></notes><urls></urls><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>138</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">138</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Edstein, M. D.</style></author><author><style face="normal" font="default" size="100%">Walsh, D. S.</style></author><author><style face="normal" font="default" size="100%">Eamsila, C.</style></author><author><style face="normal" font="default" size="100%">Sasiprapha, T.</style></author><author><style face="normal" font="default" size="100%">Nasveld, P. E.</style></author><author><style face="normal" font="default" size="100%">Kitchener, S.</style></author><author><style face="normal" font="default" size="100%">Rieckmann, K. H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">M.D. Edstein, Australian Army Malaria Institute, Gallipoli Barracks, Enogerra, QLD, 4052 Australia.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Malaria prophylaxis/radical cure: recent experiences of the Australian Defence Force</style></title><secondary-title><style face="normal" font="default" size="100%">Médecine tropicale : revue du Corps de santé colonial</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Médecine tropicale : revue du Corps de santé colonial</style></full-title></periodical><pages><style face="normal" font="default" size="100%">56-58</style></pages><volume><style face="normal" font="default" size="100%">61</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">aminoquinoline derivative</style></keyword><keyword><style face="normal" font="default" size="100%">antimalarial agent</style></keyword><keyword><style face="normal" font="default" size="100%">primaquine</style></keyword><keyword><style face="normal" font="default" size="100%">tafenoquine</style></keyword><keyword><style face="normal" font="default" size="100%">Australia</style></keyword><keyword><style face="normal" font="default" size="100%">clinical trial</style></keyword><keyword><style face="normal" font="default" size="100%">comparative study</style></keyword><keyword><style face="normal" font="default" size="100%">controlled clinical trial</style></keyword><keyword><style face="normal" font="default" size="100%">controlled study</style></keyword><keyword><style face="normal" font="default" size="100%">endemic disease</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">malaria</style></keyword><keyword><style face="normal" font="default" size="100%">malaria falciparum</style></keyword><keyword><style face="normal" font="default" size="100%">randomized controlled trial</style></keyword><keyword><style face="normal" font="default" size="100%">review</style></keyword><keyword><style face="normal" font="default" size="100%">military personnel</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2001</style></year></dates><isbn><style face="normal" font="default" size="100%">0025-682X</style></isbn><abstract><style face="normal" font="default" size="100%">Since the eighties, the Australian Defence Force has deployed soldiers in malaria-endemic areas: Cambodia, Somalia, Rwanda, Bougainville, and East Timor. Currently, doxycycline is used as first line prophylactic drug and mefloquine is recommended for those who cannot tolerate the antibiotic. In 1998, the Australian Defence Force participated in the evaluation of tafenoquine for prophylaxis of both falciparum and vivax malaria in Thai soldiers. At the completion of this six-month study, 29 of 205 soldiers had come down with malaria including eight with falciparum malaria, 20 with vivax malaria, and one with mixed infection. A total of 28 of the 101 soldiers in the placebo group were infected with malaria as compared with only one of the 104 soldiers in the tafenoquine group. In 1999, another study was started on the island of Bougainville to compare the effectiveness a 3-day course of tafenoquine and a 14-day course of primaquine for radical cure of vivax malaria. At the present time, 411 soldiers have completed the study including 201 in tafenoquine arm and 210 in primaquine arm. Seven soldiers in each arm developed vivax malaria after returning to Australia. These results indicate that tafenoquine is not superior to primaquine in preventing vivax malaria. However study participants preferred the shorter course using tafenoquine and operationally it was found to be more suitable than primaquine.</style></abstract><caption><style face="normal" font="default" size="100%">Duplicate</style></caption><notes><style face="normal" font="default" size="100%">L33534230&#xD;2001-10-03</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L33534230&amp;from=export</style></url></related-urls></urls><custom5><style face="normal" font="default" size="100%">11584657</style></custom5><remote-database-name><style face="normal" font="default" size="100%">Medline</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>171</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">171</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Edstein, M. D.</style></author><author><style face="normal" font="default" size="100%">Walsh, D. S.</style></author><author><style face="normal" font="default" size="100%">Eamsila, C.</style></author><author><style face="normal" font="default" size="100%">Sasiprapha, T.</style></author><author><style face="normal" font="default" size="100%">Nasveld, P. E.</style></author><author><style face="normal" font="default" size="100%">Kitchener, S.</style></author><author><style face="normal" font="default" size="100%">Rieckmann, K. H.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Malaria prophylaxis/radical cure: recent experiences of the Australian Defence Force</style></title><secondary-title><style face="normal" font="default" size="100%">Medecine tropicale</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Medecine tropicale</style></full-title></periodical><pages><style face="normal" font="default" size="100%">56‐58</style></pages><volume><style face="normal" font="default" size="100%">61</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">Aminoquinolines [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Antimalarials [*therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Australia</style></keyword><keyword><style face="normal" font="default" size="100%">Controlled Clinical Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Endemic Diseases</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Malaria [*drug therapy, epidemiology, *prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Malaria, Falciparum [drug therapy, prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Malaria, Vivax [drug therapy, prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Military Personnel</style></keyword><keyword><style face="normal" font="default" size="100%">Primaquine [therapeutic use]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2001</style></year></dates><accession-num><style face="normal" font="default" size="100%">CN-00456319</style></accession-num><abstract><style face="normal" font="default" size="100%">Since the eighties, the Australian Defence Force has deployed soldiers in malaria‐endemic areas: Cambodia, Somalia, Rwanda, Bougainville, and East Timor. Currently, doxycycline is used as first line prophylactic drug and mefloquine is recommended for those who cannot tolerate the antibiotic. In 1998, the Australian Defence Force participated in the evaluation of tafenoquine for prophylaxis of both falciparum and vivax malaria in Thai soldiers. At the completion of this six‐month study, 29 of 205 soldiers had come down with malaria including eight with falciparum malaria, 20 with vivax malaria, and one with mixed infection. A total of 28 of the 101 soldiers in the placebo group were infected with malaria as compared with only one of the 104 soldiers in the tafenoquine group. In 1999, another study was started on the island of Bougainville to compare the effectiveness a 3‐day course of tafenoquine and a 14‐day course of primaquine for radical cure of vivax malaria. At the present time, 411 soldiers have completed the study including 201 in tafenoquine arm and 210 in primaquine arm. Seven soldiers in each arm developed vivax malaria after returning to Australia. These results indicate that tafenoquine is not superior to primaquine in preventing vivax malaria. However study participants preferred the shorter course using tafenoquine and operationally it was found to be more suitable than primaquine.</style></abstract><caption><style face="normal" font="default" size="100%">Duplicate</style></caption><work-type><style face="normal" font="default" size="100%">Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial; Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.cochranelibrary.com/central/doi/10.1002/central/CN-00456319/full</style></url></related-urls></urls><custom3><style face="normal" font="default" size="100%">PUBMED 11584657</style></custom3></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>23</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">23</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Mace, K. E.</style></author><author><style face="normal" font="default" size="100%">Arguin, P. M.</style></author><author><style face="normal" font="default" size="100%">Lucchi, N. W.</style></author><author><style face="normal" font="default" size="100%">Tan, K. R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Malaria Branch, Division of Parasitic Diseases and Malaria, Center for Global Health, CDC.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Malaria Surveillance - United States, 2016</style></title><secondary-title><style face="normal" font="default" size="100%">MMWR Surveill Summ</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">MMWR Surveill Summ</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1-35</style></pages><volume><style face="normal" font="default" size="100%">68</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2019/05/18</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Antimalarials/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Centers for Disease Control and Prevention, U.S.</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Child, Preschool</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Resistance</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Hospitalization/statistics &amp; numerical data</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Infant</style></keyword><keyword><style face="normal" font="default" size="100%">Malaria/*diagnosis/drug therapy/*epidemiology/transmission</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Military Personnel/statistics &amp; numerical data</style></keyword><keyword><style face="normal" font="default" size="100%">Plasmodium/*isolation &amp; purification</style></keyword><keyword><style face="normal" font="default" size="100%">*Population Surveillance</style></keyword><keyword><style face="normal" font="default" size="100%">Pregnancy</style></keyword><keyword><style face="normal" font="default" size="100%">Pregnancy Complications, Infectious/diagnosis/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Seasons</style></keyword><keyword><style face="normal" font="default" size="100%">Severity of Illness Index</style></keyword><keyword><style face="normal" font="default" size="100%">Travel-Related Illness</style></keyword><keyword><style face="normal" font="default" size="100%">United States/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Young Adult</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2019</style></year><pub-dates><date><style face="normal" font="default" size="100%">May 17</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1545-8636</style></isbn><accession-num><style face="normal" font="default" size="100%">31099769</style></accession-num><abstract><style face="normal" font="default" size="100%">PROBLEM/CONDITION: Malaria in humans is caused by intraerythrocytic protozoa of the genus Plasmodium. These parasites are transmitted by the bite of an infective female Anopheles species mosquito. The majority of malaria infections in the United States occur among persons who have traveled to regions with ongoing malaria transmission. However, malaria is occasionally acquired by persons who have not traveled out of the country through exposure to infected blood products, congenital transmission, laboratory exposure, or local mosquitoborne transmission. Malaria surveillance in the United States is conducted to provide information on its occurrence (e.g., temporal, geographic, and demographic), guide prevention and treatment recommendations for travelers and patients, and facilitate transmission control measures if locally acquired cases are identified. PERIOD COVERED: This report summarizes confirmed malaria cases in persons with onset of illness in 2016 and summarizes trends in previous years. DESCRIPTION OF SYSTEM: Malaria cases diagnosed by blood film microscopy, polymerase chain reaction, or rapid diagnostic tests are reported to local and state health departments by health care providers or laboratory staff members. Case investigations are conducted by local and state health departments, and reports are transmitted to CDC through the National Malaria Surveillance System (NMSS), the National Notifiable Diseases Surveillance System (NNDSS), or direct CDC consultations. CDC reference laboratories provide diagnostic assistance and conduct antimalarial drug resistance marker testing on blood samples submitted by health care providers or local or state health departments. This report summarizes data from the integration of all NMSS and NNDSS cases, CDC reference laboratory reports, and CDC clinical consultations. RESULTS: CDC received reports of 2,078 confirmed malaria cases with onset of symptoms in 2016, including two congenital cases, three cryptic cases, and one case acquired through blood transfusion. The number of malaria cases diagnosed in the United States has been increasing since the mid-1970s. However, in 2015 a decrease occurred in the number of cases, specifically from the region of West Africa, likely due to altered travel related to the Ebola virus disease outbreak. The number of confirmed malaria cases in 2016 represents a 36% increase compared with 2015, and the 2016 total is 153 more cases than in 2011, which previously had the highest number of cases (1,925 cases). In 2016, a total of 1,729 cases originated from Africa, and 1,061 (61.4%) of these came from West Africa. P. falciparum accounted for the majority of the infections (1,419 [68.2%]), followed by P. vivax (251 [12.1%]). Fewer than 2% of patients were infected by two species (23 [1.1%]). The infecting species was not reported or was undetermined in 10.8% of cases. CDC provided diagnostic assistance for 12.1% of confirmed cases and tested 10.8% of specimens with P. falciparum infections for antimalarial resistance markers. Of the U.S. resident patients who reported reason for travel, 69.4% were travelers who were visiting friends and relatives. The proportion of U.S. residents with malaria who reported taking any chemoprophylaxis in 2016 (26.3%) was similar to that in 2015 (26.6%), and adherence was poor among those who took chemoprophylaxis. Among the 964 U.S. residents with malaria for whom information on chemoprophylaxis use and travel region were known, 94.0% of patients with malaria did not adhere to or did not take a CDC-recommended chemoprophylaxis regimen. Among 795 women with malaria, 50 were pregnant, and one had adhered to mefloquine chemoprophylaxis. Forty-one (2.0%) malaria cases occurred among U.S. military personnel in 2016, a comparable proportion to that in 2015 (23 cases [1.5%]). Among all reported cases in 2016, a total of 306 (14.7%) were classified as severe illnesses, and seven persons died. In 2016, CDC analyzed 144 P. falciparum-positive and nine P. falciparum mixed species samples for surveillance of antimalarial resistance markers (although certain loci were untestable in some samples); genetic polymorphisms associated with resistance to pyrimethamine were identified in 142 (97.9%), to sulfadoxine in 98 (70.5%), to chloroquine in 67 (44.7%), to mefloquine in six (4.3%), and to atovaquone in one (&lt;1.0%). The completeness of key variables (e.g., species, country of acquisition, and resident status) was 79.4% in 2016 and 75.7% in 2015. INTERPRETATION: The number of reported malaria cases in 2016 continued a decades-long increasing trend and is the highest since 1972. The importation of malaria reflects the overall increase in global travel trends to and from areas where malaria is endemic; a transient decrease in the acquisition of cases, predominantly from West Africa, occurred in 2015. In 2016, more cases (absolute number) originated from regions of the world with widespread malaria transmission. Since the early 2000s, worldwide interventions to reduce malaria have been successful; however, progress has plateaued in recent years, the disease remains endemic in many regions, and the use of appropriate prevention measures by travelers remains inadequate. PUBLIC HEALTH ACTIONS: The best way to prevent malaria is to take chemoprophylaxis medication during travel to a country where malaria is endemic. Malaria infections can be fatal if not diagnosed and treated promptly with antimalarial medications appropriate for the patient&apos;s age and medical history, the likely country of malaria acquisition, and previous use of antimalarial chemoprophylaxis. In 2018, two tafenoquine-based antimalarials were approved by the Food and Drug Administration (FDA) for use in the United States. Arakoda was approved for use by adults for chemoprophylaxis and is available as a weekly dosage that is convenient during travel, which might improve adherence and also can prevent relapses from P. vivax and P. ovale infections. Krintafel was approved for radical cure of P. vivax infections in those &gt;16 years old. In April 2019, intravenous artesunate became the first-line medication for treatment of severe malaria in the United States. Because intravenous artesunate is not FDA approved, it is available from CDC under an investigational new drug protocol. Detailed recommendations for preventing malaria are available to the general public at the CDC website (https://www.cdc.gov/malaria/travelers/drugs.html). Health care providers should consult the CDC Guidelines for Treatment of Malaria in the United States and contact the CDC&apos;s Malaria Hotline for case management advice when needed. Malaria treatment recommendations are available online (https://www.cdc.gov/malaria/diagnosis_treatment) and from the Malaria Hotline (770-488-7788 or toll-free at 855-856-4713). Persons submitting malaria case reports (care providers, laboratories, and state and local public health officials) should provide complete information because incomplete reporting compromises case investigations and efforts to prevent infections and examine trends in malaria cases. Adherence to recommended malaria prevention strategies is low among U.S. travelers; reasons for nonadherence include prematurely stopping after leaving the area where malaria was endemic, forgetting to take the medication, and experiencing a side effect. Molecular surveillance of antimalarial drug resistance markers (https://www.cdc.gov/malaria/features/ars.html) enables CDC to track, guide treatment, and manage drug resistance in malaria parasites both domestically and internationally. More samples are needed to improve the completeness of antimalarial drug resistance analysis; therefore, CDC requests that blood specimens be submitted for all cases of malaria diagnosed in the United States.</style></abstract><notes><style face="normal" font="default" size="100%">1545-8636&#xD;Mace, Kimberly E&#xD;Arguin, Paul M&#xD;Lucchi, Naomi W&#xD;Tan, Kathrine R&#xD;Journal Article&#xD;United States&#xD;MMWR Surveill Summ. 2019 May 17;68(5):1-35. doi: 10.15585/mmwr.ss6805a1.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.15585/mmwr.ss6805a1</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>92</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">92</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Pannu, A. K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">A.K. Pannu, Department of Internal Medicine, Post Graduate Institute of Medical Education and Research, Chandigarh, India</style></auth-address><titles><title><style face="normal" font="default" size="100%">Malaria today: advances in management and control</style></title><secondary-title><style face="normal" font="default" size="100%">Tropical Doctor</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Tropical Doctor</style></full-title></periodical><pages><style face="normal" font="default" size="100%">160-164</style></pages><volume><style face="normal" font="default" size="100%">49</style></volume><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">amodiaquine</style></keyword><keyword><style face="normal" font="default" size="100%">artemether</style></keyword><keyword><style face="normal" font="default" size="100%">artemisinin</style></keyword><keyword><style face="normal" font="default" size="100%">artesunate</style></keyword><keyword><style face="normal" font="default" size="100%">atovaquone plus proguanil</style></keyword><keyword><style face="normal" font="default" size="100%">benflumetol</style></keyword><keyword><style face="normal" font="default" size="100%">chloroquine</style></keyword><keyword><style face="normal" font="default" size="100%">dihydroartemisinin</style></keyword><keyword><style face="normal" font="default" size="100%">doxycycline</style></keyword><keyword><style face="normal" font="default" size="100%">ganaplacide</style></keyword><keyword><style face="normal" font="default" size="100%">malaria vaccine</style></keyword><keyword><style face="normal" font="default" size="100%">mefloquine</style></keyword><keyword><style face="normal" font="default" size="100%">piperaquine</style></keyword><keyword><style face="normal" font="default" size="100%">piperonyl butoxide</style></keyword><keyword><style face="normal" font="default" size="100%">primaquine</style></keyword><keyword><style face="normal" font="default" size="100%">pyrimethamine plus sulfadoxine</style></keyword><keyword><style face="normal" font="default" size="100%">pyronaridine</style></keyword><keyword><style face="normal" font="default" size="100%">quinine</style></keyword><keyword><style face="normal" font="default" size="100%">tafenoquine</style></keyword><keyword><style face="normal" font="default" size="100%">antimalarial drug resistance</style></keyword><keyword><style face="normal" font="default" size="100%">cerebral malaria</style></keyword><keyword><style face="normal" font="default" size="100%">chemoprophylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">clinical assessment</style></keyword><keyword><style face="normal" font="default" size="100%">cost effectiveness analysis</style></keyword><keyword><style face="normal" font="default" size="100%">disease burden</style></keyword><keyword><style face="normal" font="default" size="100%">disseminated intravascular clotting</style></keyword><keyword><style face="normal" font="default" size="100%">drug efficacy</style></keyword><keyword><style face="normal" font="default" size="100%">drug safety</style></keyword><keyword><style face="normal" font="default" size="100%">follow up</style></keyword><keyword><style face="normal" font="default" size="100%">gene mutation</style></keyword><keyword><style face="normal" font="default" size="100%">health program</style></keyword><keyword><style face="normal" font="default" size="100%">hemolysis</style></keyword><keyword><style face="normal" font="default" size="100%">low birth weight</style></keyword><keyword><style face="normal" font="default" size="100%">malaria</style></keyword><keyword><style face="normal" font="default" size="100%">malaria control</style></keyword><keyword><style face="normal" font="default" size="100%">microscopy</style></keyword><keyword><style face="normal" font="default" size="100%">microvasculature</style></keyword><keyword><style face="normal" font="default" size="100%">parasite prevalence</style></keyword><keyword><style face="normal" font="default" size="100%">parasitemia</style></keyword><keyword><style face="normal" font="default" size="100%">phase 2 clinical trial (topic)</style></keyword><keyword><style face="normal" font="default" size="100%">phase 3 clinical trial (topic)</style></keyword><keyword><style face="normal" font="default" size="100%">phase 4 clinical trial (topic)</style></keyword><keyword><style face="normal" font="default" size="100%">Plasmodium falciparum</style></keyword><keyword><style face="normal" font="default" size="100%">Plasmodium vivax</style></keyword><keyword><style face="normal" font="default" size="100%">pregnancy</style></keyword><keyword><style face="normal" font="default" size="100%">premature labor</style></keyword><keyword><style face="normal" font="default" size="100%">pyrimidine synthesis</style></keyword><keyword><style face="normal" font="default" size="100%">randomized controlled trial (topic)</style></keyword><keyword><style face="normal" font="default" size="100%">review</style></keyword><keyword><style face="normal" font="default" size="100%">shock</style></keyword><keyword><style face="normal" font="default" size="100%">vaccination</style></keyword><keyword><style face="normal" font="default" size="100%">vector control</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2019</style></year></dates><isbn><style face="normal" font="default" size="100%">1758-1133&#xD;0049-4755</style></isbn><abstract><style face="normal" font="default" size="100%">Over the past two decades, malaria-related deaths have reduced substantially, especially in African children. However, the global malaria burden still remains high. The recent emergence of resistance to artemisinin, the backbone of malaria management, could threaten malaria control. Importantly, over the past five years, there has been an upsurge in research in the development of novel antimalarial drugs (and combinations), malaria vaccine and new vector-control strategies that can boost the malaria control programme.</style></abstract><notes><style face="normal" font="default" size="100%">L627652920&#xD;2019-05-17&#xD;2019-07-25</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L627652920&amp;from=export</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1177/0049475519846382</style></url></related-urls></urls><custom5><style face="normal" font="default" size="100%">31060446</style></custom5><electronic-resource-num><style face="normal" font="default" size="100%">10.1177/0049475519846382</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase&#xD;Medline</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>140</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">140</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Barlow, G. D.</style></author><author><style face="normal" font="default" size="100%">Nathwani, D.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">D. Nathwani, Kings Cross Hospital, Clepington Road, Dundee DD3 8EA, United Kingdom</style></auth-address><titles><title><style face="normal" font="default" size="100%">Malaria, mefloquine and oil-workers</style></title><secondary-title><style face="normal" font="default" size="100%">Scottish Medical Journal</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Scottish Medical Journal</style></full-title></periodical><pages><style face="normal" font="default" size="100%">167-169</style></pages><volume><style face="normal" font="default" size="100%">45</style></volume><number><style face="normal" font="default" size="100%">6</style></number><keywords><keyword><style face="normal" font="default" size="100%">atovaquone plus proguanil</style></keyword><keyword><style face="normal" font="default" size="100%">chloroquine</style></keyword><keyword><style face="normal" font="default" size="100%">doxycycline</style></keyword><keyword><style face="normal" font="default" size="100%">glucose 6 phosphate dehydrogenase</style></keyword><keyword><style face="normal" font="default" size="100%">malaria vaccine</style></keyword><keyword><style face="normal" font="default" size="100%">mefloquine</style></keyword><keyword><style face="normal" font="default" size="100%">pesticide</style></keyword><keyword><style face="normal" font="default" size="100%">placebo</style></keyword><keyword><style face="normal" font="default" size="100%">primaquine</style></keyword><keyword><style face="normal" font="default" size="100%">proguanil</style></keyword><keyword><style face="normal" font="default" size="100%">tafenoquine</style></keyword><keyword><style face="normal" font="default" size="100%">Africa</style></keyword><keyword><style face="normal" font="default" size="100%">antibiotic prophylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">antimalarial activity</style></keyword><keyword><style face="normal" font="default" size="100%">brain dysfunction</style></keyword><keyword><style face="normal" font="default" size="100%">clinical trial</style></keyword><keyword><style face="normal" font="default" size="100%">controlled clinical trial</style></keyword><keyword><style face="normal" font="default" size="100%">controlled study</style></keyword><keyword><style face="normal" font="default" size="100%">drug choice</style></keyword><keyword><style face="normal" font="default" size="100%">drug contraindication</style></keyword><keyword><style face="normal" font="default" size="100%">drug efficacy</style></keyword><keyword><style face="normal" font="default" size="100%">drug mechanism</style></keyword><keyword><style face="normal" font="default" size="100%">drug safety</style></keyword><keyword><style face="normal" font="default" size="100%">drug tolerability</style></keyword><keyword><style face="normal" font="default" size="100%">erythrocyte</style></keyword><keyword><style face="normal" font="default" size="100%">food</style></keyword><keyword><style face="normal" font="default" size="100%">foreign worker</style></keyword><keyword><style face="normal" font="default" size="100%">glucose 6 phosphate dehydrogenase deficiency</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">industrial worker</style></keyword><keyword><style face="normal" font="default" size="100%">infection control</style></keyword><keyword><style face="normal" font="default" size="100%">job performance</style></keyword><keyword><style face="normal" font="default" size="100%">liver cell</style></keyword><keyword><style face="normal" font="default" size="100%">malaria</style></keyword><keyword><style face="normal" font="default" size="100%">malaria falciparum</style></keyword><keyword><style face="normal" font="default" size="100%">note</style></keyword><keyword><style face="normal" font="default" size="100%">oil industry</style></keyword><keyword><style face="normal" font="default" size="100%">photosensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">Plasmodium falciparum</style></keyword><keyword><style face="normal" font="default" size="100%">Plasmodium vivax</style></keyword><keyword><style face="normal" font="default" size="100%">psychopathy</style></keyword><keyword><style face="normal" font="default" size="100%">travel</style></keyword><keyword><style face="normal" font="default" size="100%">United Kingdom</style></keyword><keyword><style face="normal" font="default" size="100%">lariam</style></keyword><keyword><style face="normal" font="default" size="100%">malarone</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2000</style></year></dates><isbn><style face="normal" font="default" size="100%">0036-9330</style></isbn><notes><style face="normal" font="default" size="100%">L32098166&#xD;2001-02-07</style></notes><work-type><style face="normal" font="default" size="100%">Note</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L32098166&amp;from=export</style></url></related-urls></urls><custom1><style face="normal" font="default" size="100%">lariam&#xD;malarone</style></custom1><custom5><style face="normal" font="default" size="100%">11216305</style></custom5><remote-database-name><style face="normal" font="default" size="100%">Embase&#xD;Medline</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>17</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">17</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kim, S.</style></author><author><style face="normal" font="default" size="100%">Byun, J. H.</style></author><author><style face="normal" font="default" size="100%">Park, A.</style></author><author><style face="normal" font="default" size="100%">Jung, I. H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Mathematics, Pusan National University, Geumjeong-Gu, Busan 46241, Republic of Korea.&#xD;Finance · Fishery · Manufacture Industrial Mathematics Center on Big Data, Pusan National University, Geumjeong-Gu, Busan 46241, Republic of Korea.</style></auth-address><titles><title><style face="normal" font="default" size="100%">A mathematical model for assessing the effectiveness of controlling relapse in Plasmodium vivax malaria endemic in the Republic of Korea</style></title><secondary-title><style face="normal" font="default" size="100%">PLoS One</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">PLoS One</style></full-title></periodical><pages><style face="normal" font="default" size="100%">e0227919</style></pages><volume><style face="normal" font="default" size="100%">15</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2020/01/25</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Antimalarials/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Chronic Disease/*epidemiology/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Culicidae/parasitology</style></keyword><keyword><style face="normal" font="default" size="100%">Endemic Diseases/*prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Malaria, Vivax/drug therapy/*epidemiology/parasitology</style></keyword><keyword><style face="normal" font="default" size="100%">Military Personnel</style></keyword><keyword><style face="normal" font="default" size="100%">*Models, Theoretical</style></keyword><keyword><style face="normal" font="default" size="100%">Plasmodium vivax/pathogenicity</style></keyword><keyword><style face="normal" font="default" size="100%">Republic of Korea/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">United States/epidemiology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2020</style></year></dates><isbn><style face="normal" font="default" size="100%">1932-6203</style></isbn><accession-num><style face="normal" font="default" size="100%">31978085</style></accession-num><abstract><style face="normal" font="default" size="100%">Malaria has persisted as an endemic near the Demilitarized Zone in the Republic of Korea since the re-emergence of Plasmodium vivax malaria in 1993. The number of patients affected by malaria has increased recently despite many controls tools, one of the reasons behind which is the relapse of malaria via liver hypnozoites. Tafenoquine, a new drug approved by the United States Food and Drug Administration in 2018, is expected to reduce the rate of relapse of malaria hypnozoites and thereby decrease the prevalence of malaria among the population. In this work, we have developed a new transmission model for Plasmodium vivax that takes into account a more realistic intrinsic distribution from existing literature to quantify the current values of relapse parameters and to evaluate the effectiveness of the anti-relapse therapy. The model is especially suitable for estimating parameters near the Demilitarized Zone in Korea, in which the disease follows a distinguishable seasonality. Results were shown that radical cure could significantly reduce the prevalence level of malaria. However, eradication would still take a long time (over 10 years) even if the high-level treatment were to persist. In addition, considering that the vector&apos;s behavior is manipulated by the malaria parasite, relapse repression through vector control at the current level may result in a negative effect in containing the disease. We conclude that the use of effective drugs should be considered together with the increased level of the vector control to reduce malaria prevalence.</style></abstract><notes><style face="normal" font="default" size="100%">1932-6203&#xD;Kim, Sungchan&#xD;Orcid: 0000-0002-8384-7746&#xD;Byun, Jong Hyuk&#xD;Park, Anna&#xD;Jung, Il Hyo&#xD;Orcid: 0000-0002-6086-5124&#xD;Journal Article&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;PLoS One. 2020 Jan 24;15(1):e0227919. doi: 10.1371/journal.pone.0227919. eCollection 2020.</style></notes><urls></urls><custom2><style face="normal" font="default" size="100%">PMC6980521</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1371/journal.pone.0227919</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>64</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">64</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Shanks, G. D.</style></author><author><style face="normal" font="default" size="100%">Edstein, M. D.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Australian Army Malaria Institute, Brisbane, Queensland, Australia. george.d.shanks@us.army.mil</style></auth-address><titles><title><style face="normal" font="default" size="100%">Modern malaria chemoprophylaxis</style></title><secondary-title><style face="normal" font="default" size="100%">Drugs</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Drugs</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2091-110</style></pages><volume><style face="normal" font="default" size="100%">65</style></volume><number><style face="normal" font="default" size="100%">15</style></number><edition><style face="normal" font="default" size="100%">2005/10/18</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Antimalarials/adverse effects/*therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">*Chemoprevention</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Resistance/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Malaria/*drug therapy/*prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">*Malaria Vaccines</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Plasmodium falciparum/genetics/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Pregnancy</style></keyword><keyword><style face="normal" font="default" size="100%">Travel</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2005</style></year></dates><isbn><style face="normal" font="default" size="100%">0012-6667 (Print)&#xD;0012-6667</style></isbn><accession-num><style face="normal" font="default" size="100%">16225366</style></accession-num><abstract><style face="normal" font="default" size="100%">Currently available medications for malaria chemoprophylaxis are efficacious but the problems of patient compliance, the advance of parasite drug resistance, and real or perceived serious adverse effects mean that new chemical compounds are needed.Primaquine, which has been widely used to treat relapsing malaria since the 1950s, has been shown to prevent malaria when taken daily. Tafenoquine is a new 8-aminoquinoline with a much longer half-life than primaquine. Field trials to date indicate that tafenoquine is efficacious and can be taken weekly or perhaps even less frequently. Both primaquine and tafenoquine require exact knowledge of a person&apos;s glucose 6-phosphate dehydrogenase status in order to prevent drug-induced haemolysis. Other potential malaria chemoprophylactic drugs such as third-generation antifol compounds and Mannich bases have reached advanced preclinical testing. Mefloquine has been seen to cause serious neuropsychiatric adverse effects on rare occasions. Recent public controversy regarding reputedly common serious adverse effects has made many Western travellers unwilling to take mefloquine. Special risk groups exposed to malaria, such as long-term travellers, children, pregnant women, aircrew and those requiring unimpeded psychomotor reactions, migrants returning to visit malarious countries of origin and febrile persons who have returned from malaria endemic areas, all require a nuanced approach to the use of drugs to prevent malaria. The carrying of therapeutic courses of antimalarial drugs to be taken only if febrile illness develops is indicated in very few travellers despite its appeal to some who fear adverse effects more than they fear potentially lethal malaria infection. Travellers with a significant exposure to malaria require a comprehensive plan for prevention that includes anti-mosquito measures but which is still primarily be based on the regular use of efficacious antimalarial medications.</style></abstract><notes><style face="normal" font="default" size="100%">Shanks, G Dennis&#xD;Edstein, Michael D&#xD;Journal Article&#xD;Review&#xD;New Zealand&#xD;Drugs. 2005;65(15):2091-110. doi: 10.2165/00003495-200565150-00003.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.2165/00003495-200565150-00003</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>13</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">13</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Duparc, S.</style></author><author><style face="normal" font="default" size="100%">Chalon, S.</style></author><author><style face="normal" font="default" size="100%">Miller, S.</style></author><author><style face="normal" font="default" size="100%">Richardson, N.</style></author><author><style face="normal" font="default" size="100%">Toovey, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Medicines for Malaria Venture, Route de Pré-Bois 20, 1215, Geneva 15, Switzerland. duparcs@mmv.org.&#xD;Medicines for Malaria Venture, Route de Pré-Bois 20, 1215, Geneva 15, Switzerland.&#xD;Bill and Melinda Gates Foundation, Seattle, USA.&#xD;Magenta Communications Ltd, Abingdon, UK.&#xD;Pegasus Research, London, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Neurological and psychiatric safety of tafenoquine in Plasmodium vivax relapse prevention: a review</style></title><secondary-title><style face="normal" font="default" size="100%">Malar J</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Malar J</style></full-title></periodical><pages><style face="normal" font="default" size="100%">111</style></pages><volume><style face="normal" font="default" size="100%">19</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2020/03/15</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Aminoquinolines/adverse effects/*therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Antimalarials</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Malaria, Vivax/*drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Nervous System Diseases/*chemically induced</style></keyword><keyword><style face="normal" font="default" size="100%">Plasmodium vivax/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Secondary Prevention/*methods</style></keyword><keyword><style face="normal" font="default" size="100%">Adverse events</style></keyword><keyword><style face="normal" font="default" size="100%">Anti-malarial</style></keyword><keyword><style face="normal" font="default" size="100%">Malaria</style></keyword><keyword><style face="normal" font="default" size="100%">Neuropsychiatric</style></keyword><keyword><style face="normal" font="default" size="100%">Tafenoquine</style></keyword><keyword><style face="normal" font="default" size="100%">Scott Miller is an employee of the Bill and Melinda Gates Foundation. Scott Miller</style></keyword><keyword><style face="normal" font="default" size="100%">is a retired U. S. Army officer, and his views are his own and not those of the U.S.</style></keyword><keyword><style face="normal" font="default" size="100%">Army or the U.S. Department of Defense. Naomi Richardson received funding from</style></keyword><keyword><style face="normal" font="default" size="100%">Medicines for Malaria Venture in regard to this article and has been previously</style></keyword><keyword><style face="normal" font="default" size="100%">employed as an external communications consultant by GlaxoSmithKline and Medicines</style></keyword><keyword><style face="normal" font="default" size="100%">for Malaria Venture. Stephen Toovey has been employed as a consultant to Medicines</style></keyword><keyword><style face="normal" font="default" size="100%">for Malaria Venture in regard to this article and to GlaxoSmithKline and 60P</style></keyword><keyword><style face="normal" font="default" size="100%">Pharmaceuticals.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2020</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar 14</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1475-2875</style></isbn><accession-num><style face="normal" font="default" size="100%">32169086</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Tafenoquine is an 8-aminoquinoline anti-malarial drug recently approved as a single-dose (300 mg) therapy for Plasmodium vivax relapse prevention, when co-administered with 3-days of chloroquine or other blood schizonticide. Tafenoquine 200 mg weekly after a loading dose is also approved as travellers&apos; prophylaxis. The development of tafenoquine has been conducted over many years, using various dosing regimens in diverse populations. METHODS: This review brings together all the preclinical and clinical data concerning tafenoquine central nervous system safety. Data were assembled from published sources. The risk of neuropsychiatric adverse events (NPAEs) with single-dose tafenoquine (300 mg) in combination with chloroquine to achieve P. vivax relapse prevention is particularly examined. RESULTS: There was no evidence of neurotoxicity with tafenoquine in preclinical animal models. In clinical studies in P. vivax relapse prevention, nervous system adverse events, mainly headache and dizziness, occurred in 11.4% (36/317) of patients with tafenoquine (300 mg)/chloroquine versus 10.2% (19/187) with placebo/chloroquine; and in 15.5% (75/483) of patients with tafenoquine/chloroquine versus 13.3% (35/264) with primaquine (15 mg/day for 14 days)/chloroquine. Psychiatric adverse events, mainly insomnia, occurred in 3.8% (12/317) of patients with tafenoquine/chloroquine versus 2.7% (5/187) with placebo/chloroquine; and in 2.9% (14/483) of patients with tafenoquine/chloroquine versus 3.4% (9/264) for primaquine/chloroquine. There were no serious or severe NPAEs observed with tafenoquine (300 mg)/chloroquine in these studies. CONCLUSIONS: The risk:benefit of single-dose tafenoquine/chloroquine in P. vivax relapse prevention is favourable in the presence of malaria, with a low risk of NPAEs, similar to that seen with chloroquine alone or primaquine/chloroquine.</style></abstract><caption><style face="normal" font="default" size="100%">Duplicate</style></caption><notes><style face="normal" font="default" size="100%">1475-2875&#xD;Duparc, Stephan&#xD;Chalon, Stephan&#xD;Miller, Scott&#xD;Richardson, Naomi&#xD;Toovey, Stephen&#xD;Journal Article&#xD;Review&#xD;Malar J. 2020 Mar 14;19(1):111. doi: 10.1186/s12936-020-03184-x.</style></notes><urls></urls><custom2><style face="normal" font="default" size="100%">PMC7071640</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1186/s12936-020-03184-x</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>86</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">86</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Duparc, S.</style></author><author><style face="normal" font="default" size="100%">Chalon, S.</style></author><author><style face="normal" font="default" size="100%">Miller, S.</style></author><author><style face="normal" font="default" size="100%">Richardson, N.</style></author><author><style face="normal" font="default" size="100%">Toovey, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">S. Duparc, Medicines for Malaria Venture, Route de Pré-Bois 20, Geneva 15, Switzerland</style></auth-address><titles><title><style face="normal" font="default" size="100%">Neurological and psychiatric safety of tafenoquine in Plasmodium vivax relapse prevention: A review</style></title><secondary-title><style face="normal" font="default" size="100%">Malaria Journal</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Malaria Journal</style></full-title></periodical><volume><style face="normal" font="default" size="100%">19</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">chloroquine</style></keyword><keyword><style face="normal" font="default" size="100%">placebo</style></keyword><keyword><style face="normal" font="default" size="100%">primaquine</style></keyword><keyword><style face="normal" font="default" size="100%">tafenoquine</style></keyword><keyword><style face="normal" font="default" size="100%">alcohol intolerance</style></keyword><keyword><style face="normal" font="default" size="100%">anxiety</style></keyword><keyword><style face="normal" font="default" size="100%">asthenia</style></keyword><keyword><style face="normal" font="default" size="100%">balance disorder</style></keyword><keyword><style face="normal" font="default" size="100%">burning sensation</style></keyword><keyword><style face="normal" font="default" size="100%">clinical study</style></keyword><keyword><style face="normal" font="default" size="100%">depression</style></keyword><keyword><style face="normal" font="default" size="100%">dizziness</style></keyword><keyword><style face="normal" font="default" size="100%">drug dose regimen</style></keyword><keyword><style face="normal" font="default" size="100%">drug effect</style></keyword><keyword><style face="normal" font="default" size="100%">drug megadose</style></keyword><keyword><style face="normal" font="default" size="100%">drug safety</style></keyword><keyword><style face="normal" font="default" size="100%">dysesthesia</style></keyword><keyword><style face="normal" font="default" size="100%">dysgeusia</style></keyword><keyword><style face="normal" font="default" size="100%">faintness</style></keyword><keyword><style face="normal" font="default" size="100%">fatigue</style></keyword><keyword><style face="normal" font="default" size="100%">headache</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">hypesthesia</style></keyword><keyword><style face="normal" font="default" size="100%">insomnia</style></keyword><keyword><style face="normal" font="default" size="100%">labyrinthitis</style></keyword><keyword><style face="normal" font="default" size="100%">lethargy</style></keyword><keyword><style face="normal" font="default" size="100%">malaria control</style></keyword><keyword><style face="normal" font="default" size="100%">mental disease</style></keyword><keyword><style face="normal" font="default" size="100%">migraine</style></keyword><keyword><style face="normal" font="default" size="100%">monotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">neuralgia</style></keyword><keyword><style face="normal" font="default" size="100%">neurologic disease</style></keyword><keyword><style face="normal" font="default" size="100%">neurotoxicity</style></keyword><keyword><style face="normal" font="default" size="100%">nonhuman</style></keyword><keyword><style face="normal" font="default" size="100%">paresthesia</style></keyword><keyword><style face="normal" font="default" size="100%">patient risk</style></keyword><keyword><style face="normal" font="default" size="100%">Plasmodium vivax malaria</style></keyword><keyword><style face="normal" font="default" size="100%">preclinical study</style></keyword><keyword><style face="normal" font="default" size="100%">prevalence</style></keyword><keyword><style face="normal" font="default" size="100%">relapse</style></keyword><keyword><style face="normal" font="default" size="100%">review</style></keyword><keyword><style face="normal" font="default" size="100%">single drug dose</style></keyword><keyword><style face="normal" font="default" size="100%">somnolence</style></keyword><keyword><style face="normal" font="default" size="100%">toxicity testing</style></keyword><keyword><style face="normal" font="default" size="100%">tremor</style></keyword><keyword><style face="normal" font="default" size="100%">vertigo</style></keyword><keyword><style face="normal" font="default" size="100%">vestibular disorder</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2020</style></year></dates><isbn><style face="normal" font="default" size="100%">1475-2875</style></isbn><abstract><style face="normal" font="default" size="100%">Background: Tafenoquine is an 8-aminoquinoline anti-malarial drug recently approved as a single-dose (300 mg) therapy for Plasmodium vivax relapse prevention, when co-administered with 3-days of chloroquine or other blood schizonticide. Tafenoquine 200 mg weekly after a loading dose is also approved as travellers&apos; prophylaxis. The development of tafenoquine has been conducted over many years, using various dosing regimens in diverse populations. Methods: This review brings together all the preclinical and clinical data concerning tafenoquine central nervous system safety. Data were assembled from published sources. The risk of neuropsychiatric adverse events (NPAEs) with single-dose tafenoquine (300 mg) in combination with chloroquine to achieve P. vivax relapse prevention is particularly examined. Results: There was no evidence of neurotoxicity with tafenoquine in preclinical animal models. In clinical studies in P. vivax relapse prevention, nervous system adverse events, mainly headache and dizziness, occurred in 11.4% (36/317) of patients with tafenoquine (300 mg)/chloroquine versus 10.2% (19/187) with placebo/chloroquine; and in 15.5% (75/483) of patients with tafenoquine/chloroquine versus 13.3% (35/264) with primaquine (15 mg/day for 14 days)/chloroquine. Psychiatric adverse events, mainly insomnia, occurred in 3.8% (12/317) of patients with tafenoquine/chloroquine versus 2.7% (5/187) with placebo/chloroquine; and in 2.9% (14/483) of patients with tafenoquine/chloroquine versus 3.4% (9/264) for primaquine/chloroquine. There were no serious or severe NPAEs observed with tafenoquine (300 mg)/chloroquine in these studies. Conclusions: The risk:benefit of single-dose tafenoquine/chloroquine in P. vivax relapse prevention is favourable in the presence of malaria, with a low risk of NPAEs, similar to that seen with chloroquine alone or primaquine/chloroquine.</style></abstract><caption><style face="normal" font="default" size="100%">Duplicate</style></caption><notes><style face="normal" font="default" size="100%">L631197784&#xD;2020-04-07&#xD;2020-04-10</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L631197784&amp;from=export</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1186/s12936-020-03184-x</style></url></related-urls></urls><custom5><style face="normal" font="default" size="100%">32169086</style></custom5><electronic-resource-num><style face="normal" font="default" size="100%">10.1186/s12936-020-03184-x</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase&#xD;Medline</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>187</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">187</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Duparc, S.</style></author><author><style face="normal" font="default" size="100%">Chalon, S.</style></author><author><style face="normal" font="default" size="100%">Miller, S.</style></author><author><style face="normal" font="default" size="100%">Richardson, N.</style></author><author><style face="normal" font="default" size="100%">Toovey, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">[Duparc, Stephan; Chalon, Stephan; Toovey, Stephen] Med Malaria Venture, Route Pre Bois 20, CH-1215 Geneva 15, Switzerland. [Miller, Scott] Bill &amp; Melinda Gates Fdn, Seattle, WA USA. [Richardson, Naomi] Magenta Commun Ltd, Abingdon, Oxon, England. [Toovey, Stephen] Pegasus Res, London, England.&#xD;Duparc, S (corresponding author), Med Malaria Venture, Route Pre Bois 20, CH-1215 Geneva 15, Switzerland.&#xD;duparcs@mmv.org</style></auth-address><titles><title><style face="normal" font="default" size="100%">Neurological and psychiatric safety of tafenoquine in Plasmodium vivax relapse prevention: a review</style></title><secondary-title><style face="normal" font="default" size="100%">Malaria Journal</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Malar. J.</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Malaria Journal</style></full-title></periodical><pages><style face="normal" font="default" size="100%">18</style></pages><volume><style face="normal" font="default" size="100%">19</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">Malaria</style></keyword><keyword><style face="normal" font="default" size="100%">Tafenoquine</style></keyword><keyword><style face="normal" font="default" size="100%">Neuropsychiatric</style></keyword><keyword><style face="normal" font="default" size="100%">Adverse events</style></keyword><keyword><style face="normal" font="default" size="100%">Anti-malarial</style></keyword><keyword><style face="normal" font="default" size="100%">mental-disorders</style></keyword><keyword><style face="normal" font="default" size="100%">assess risk</style></keyword><keyword><style face="normal" font="default" size="100%">artemisinin derivatives</style></keyword><keyword><style face="normal" font="default" size="100%">cerebral</style></keyword><keyword><style face="normal" font="default" size="100%">malaria</style></keyword><keyword><style face="normal" font="default" size="100%">double-blind</style></keyword><keyword><style face="normal" font="default" size="100%">prophylactic efficacy</style></keyword><keyword><style face="normal" font="default" size="100%">cognitive impairment</style></keyword><keyword><style face="normal" font="default" size="100%">suicide risk</style></keyword><keyword><style face="normal" font="default" size="100%">mefloquine</style></keyword><keyword><style face="normal" font="default" size="100%">neurotoxicity</style></keyword><keyword><style face="normal" font="default" size="100%">Infectious Diseases</style></keyword><keyword><style face="normal" font="default" size="100%">Parasitology</style></keyword><keyword><style face="normal" font="default" size="100%">Tropical Medicine</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2020</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><accession-num><style face="normal" font="default" size="100%">WOS:000520500900002</style></accession-num><abstract><style face="normal" font="default" size="100%">Background Tafenoquine is an 8-aminoquinoline anti-malarial drug recently approved as a single-dose (300 mg) therapy for Plasmodium vivax relapse prevention, when co-administered with 3-days of chloroquine or other blood schizonticide. Tafenoquine 200 mg weekly after a loading dose is also approved as travellers&apos; prophylaxis. The development of tafenoquine has been conducted over many years, using various dosing regimens in diverse populations. Methods This review brings together all the preclinical and clinical data concerning tafenoquine central nervous system safety. Data were assembled from published sources. The risk of neuropsychiatric adverse events (NPAEs) with single-dose tafenoquine (300 mg) in combination with chloroquine to achieve P. vivax relapse prevention is particularly examined. Results There was no evidence of neurotoxicity with tafenoquine in preclinical animal models. In clinical studies in P. vivax relapse prevention, nervous system adverse events, mainly headache and dizziness, occurred in 11.4% (36/317) of patients with tafenoquine (300 mg)/chloroquine versus 10.2% (19/187) with placebo/chloroquine; and in 15.5% (75/483) of patients with tafenoquine/chloroquine versus 13.3% (35/264) with primaquine (15 mg/day for 14 days)/chloroquine. Psychiatric adverse events, mainly insomnia, occurred in 3.8% (12/317) of patients with tafenoquine/chloroquine versus 2.7% (5/187) with placebo/chloroquine; and in 2.9% (14/483) of patients with tafenoquine/chloroquine versus 3.4% (9/264) for primaquine/chloroquine. There were no serious or severe NPAEs observed with tafenoquine (300 mg)/chloroquine in these studies. Conclusions The risk:benefit of single-dose tafenoquine/chloroquine in P. vivax relapse prevention is favourable in the presence of malaria, with a low risk of NPAEs, similar to that seen with chloroquine alone or primaquine/chloroquine.</style></abstract><caption><style face="normal" font="default" size="100%">Duplicate</style></caption><notes><style face="normal" font="default" size="100%">ISI Document Delivery No.: KV5CU&#xD;Times Cited: 0&#xD;Cited Reference Count: 92&#xD;Duparc, Stephan Chalon, Stephan Miller, Scott Richardson, Naomi Toovey, Stephen&#xD;0&#xD;1&#xD;3&#xD;Bmc&#xD;London&#xD;1475-2875</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">&lt;Go to ISI&gt;://WOS:000520500900002</style></url></related-urls></urls><custom7><style face="normal" font="default" size="100%">111</style></custom7><electronic-resource-num><style face="normal" font="default" size="100%">10.1186/s12936-020-03184-x</style></electronic-resource-num><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>70</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">70</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Wiesner, J.</style></author><author><style face="normal" font="default" size="100%">Ortmann, R.</style></author><author><style face="normal" font="default" size="100%">Jomaa, H.</style></author><author><style face="normal" font="default" size="100%">Schlitzer, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Biochemisches Institut der Justus-Liebig-Universität, Friedrichstrasse 24, 35 392 Giessen, Germany. Jochen.Wiesner@biochemie.med.uni-giessen.de</style></auth-address><titles><title><style face="normal" font="default" size="100%">New antimalarial drugs</style></title><secondary-title><style face="normal" font="default" size="100%">Angew Chem Int Ed Engl</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Angew Chem Int Ed Engl</style></full-title></periodical><pages><style face="normal" font="default" size="100%">5274-93</style></pages><volume><style face="normal" font="default" size="100%">42</style></volume><number><style face="normal" font="default" size="100%">43</style></number><edition><style face="normal" font="default" size="100%">2003/11/13</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Aminoquinolines/pharmacology/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Antimalarials/*pharmacology/*therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Artemisinins/pharmacology/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Artesunate</style></keyword><keyword><style face="normal" font="default" size="100%">Atovaquone</style></keyword><keyword><style face="normal" font="default" size="100%">Clinical Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Dapsone/pharmacology/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Combinations</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Design</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Resistance/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Ethanolamines/pharmacology/urine</style></keyword><keyword><style face="normal" font="default" size="100%">Flavonoids/pharmacology/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Fluorenes/pharmacology/urine</style></keyword><keyword><style face="normal" font="default" size="100%">Fosfomycin/*analogs &amp; derivatives/pharmacology/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Global Health</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Lumefantrine</style></keyword><keyword><style face="normal" font="default" size="100%">Malaria/drug therapy/epidemiology/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Naphthoquinones/pharmacology/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Naphthyridines/pharmacology/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Plasmodium falciparum/drug effects/genetics/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Proguanil/*analogs &amp; derivatives/pharmacology/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Sesquiterpenes/pharmacology/therapeutic use</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2003</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov 10</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1433-7851 (Print)&#xD;1433-7851</style></isbn><accession-num><style face="normal" font="default" size="100%">14613157</style></accession-num><abstract><style face="normal" font="default" size="100%">Approximately 40% of the world population live in areas with the risk of malaria. Each year, 300-500 million people suffer from acute malaria, and 0.5-2.5 million die from the disease. Although malaria has been widely eradicated in many parts of the world, the global number of cases continues to rise. The most important reason for this alarming situation is the rapid spread of malaria parasites that are resistant to antimalarial drugs, especially chloroquine, which is by far the most frequently used. The development of new antimalarial drugs has been neglected since the 1970s owing to the end colonialism, changes in the areas of military engagement, and the restricted market potential. Only in recent years, in part supported by public funding programs, has interest in the development of antimalarial drugs been renewed. New data available from the recently sequenced genome of the malaria parasite Plasmodium falciparum and the application of methods of modern drug design promise to bring significant development in the fight against this disease.</style></abstract><notes><style face="normal" font="default" size="100%">Wiesner, Jochen&#xD;Ortmann, Regina&#xD;Jomaa, Hassan&#xD;Schlitzer, Martin&#xD;Journal Article&#xD;Review&#xD;Germany&#xD;Angew Chem Int Ed Engl. 2003 Nov 10;42(43):5274-93. doi: 10.1002/anie.200200569.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/anie.200200569</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>50</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">50</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kumar, S.</style></author><author><style face="normal" font="default" size="100%">Kumari, R.</style></author><author><style face="normal" font="default" size="100%">Pandey, R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">SKA Institution for Research, Education and Development (SKAIRED), 4/11 SarvPriya Vihar, New Delhi, 110016, India, sushil2000_01@yahoo.co.in.</style></auth-address><titles><title><style face="normal" font="default" size="100%">New insight-guided approaches to detect, cure, prevent and eliminate malaria</style></title><secondary-title><style face="normal" font="default" size="100%">Protoplasma</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Protoplasma</style></full-title></periodical><pages><style face="normal" font="default" size="100%">717-53</style></pages><volume><style face="normal" font="default" size="100%">252</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2014/10/18</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Artemisinins/chemistry/pharmacology/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Culicidae/parasitology</style></keyword><keyword><style face="normal" font="default" size="100%">*Diagnostic Techniques and Procedures</style></keyword><keyword><style face="normal" font="default" size="100%">*Disease Eradication</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Resistance/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Malaria/diagnosis/drug therapy/*prevention &amp; control/*therapy</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0033-183x</style></isbn><accession-num><style face="normal" font="default" size="100%">25323622</style></accession-num><abstract><style face="normal" font="default" size="100%">New challenges posed by the development of resistance against artemisinin-based combination therapies (ACTs) as well as previous first-line therapies, and the continuing absence of vaccine, have given impetus to research in all areas of malaria control. This review portrays the ongoing progress in several directions of malaria research. The variants of RTS,S and apical membrane antigen 1 (AMA1) are being developed and test adapted as multicomponent and multistage malaria control vaccines, while many other vaccine candidates and methodologies to produce antigens are under experimentation. To track and prevent the spread of artemisinin resistance from Southeast Asia to other parts of the world, rolling circle-enhanced enzyme activity detection (REEAD), a time- and cost-effective malaria diagnosis in field conditions, and a DNA marker associated with artemisinin resistance have become available. Novel mosquito repellents and mosquito trapping and killing techniques much more effective than the prevalent ones are undergoing field testing. Mosquito lines stably infected with their symbiotic wild-type or genetically engineered bacteria that kill sympatric malaria parasites are being constructed and field tested for stopping malaria transmission. A complementary approach being pursued is the addition of ivermectin-like drug molecules to ACTs to cure malaria and kill mosquitoes. Experiments are in progress to eradicate malaria mosquito by making it genetically male sterile. High-throughput screening procedures are being developed and used to discover molecules that possess long in vivo half life and are active against liver and blood stages for the fast cure of malaria symptoms caused by simple or relapsing and drug-sensitive and drug-resistant types of varied malaria parasites, can stop gametocytogenesis and sporogony and could be given in one dose. Target-based antimalarial drug designing has begun. Some of the putative next-generation antimalarials that possess in their scaffold structure several of the desired properties of malaria cure and control are exemplified by OZ439, NITD609, ELQ300 and tafenoquine that are already undergoing clinical trials, and decoquinate, usnic acid, torin-2, ferroquine, WEHI-916, MMV396749 and benzothiophene-type N-myristoyltransferase (NMT) inhibitors, which are candidates for future clinical usage. Among these, NITD609, ELQ300, decoquinate, usnic acid, torin-2 and NMT inhibitors not only cure simple malaria and are prophylactic against simple malaria, but they also cure relapsing malaria.</style></abstract><notes><style face="normal" font="default" size="100%">1615-6102&#xD;Kumar, Sushil&#xD;Kumari, Renu&#xD;Pandey, Richa&#xD;Journal Article&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Review&#xD;Austria&#xD;Protoplasma. 2015 May;252(3):717-53. doi: 10.1007/s00709-014-0697-x. Epub 2014 Oct 17.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1007/s00709-014-0697-x</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>73</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">73</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Shanks, G. D.</style></author><author><style face="normal" font="default" size="100%">Oloo, A. J.</style></author><author><style face="normal" font="default" size="100%">Aleman, G. M.</style></author><author><style face="normal" font="default" size="100%">Ohrt, C.</style></author><author><style face="normal" font="default" size="100%">Klotz, F. W.</style></author><author><style face="normal" font="default" size="100%">Braitman, D.</style></author><author><style face="normal" font="default" size="100%">Horton, J.</style></author><author><style face="normal" font="default" size="100%">Brueckner, R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">US Army Medical Research Unit, Nairobi, Kenya. shanksdg@thai.amedd.army.mil</style></auth-address><titles><title><style face="normal" font="default" size="100%">A new primaquine analogue, tafenoquine (WR 238605), for prophylaxis against Plasmodium falciparum malaria</style></title><secondary-title><style face="normal" font="default" size="100%">Clin Infect Dis</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Clin Infect Dis</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1968-74</style></pages><volume><style face="normal" font="default" size="100%">33</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2001/11/09</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Aminoquinolines/adverse effects/*therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Antimalarials/adverse effects/*therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Chemoprevention</style></keyword><keyword><style face="normal" font="default" size="100%">Double-Blind Method</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Malaria, Falciparum/*prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Plasmodium falciparum/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2001</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec 15</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1058-4838</style></isbn><accession-num><style face="normal" font="default" size="100%">11700577</style></accession-num><abstract><style face="normal" font="default" size="100%">We tested tafenoquine (WR 238605), a new long-acting 8-aminoquinoline, for its ability to prevent malaria in an area that is holoendemic for Plasmodium falciparum. In a double-blinded, placebo-controlled, randomized clinical trial in western Kenya, adult volunteers received a treatment course of 250 mg halofantrine per day for 3 days, to effect clearance of preexisting parasites. The volunteers were then assigned to 1 of 4 drug regimens: placebo throughout; 3 days of 400 mg (base) of tafenoquine per day, followed by placebo weekly; 3 days of 200 mg of tafenoquine per day, followed by 200 mg per week; and 3 days of 400 mg of tafenoquine per day, followed by 400 mg per week. Prophylaxis was continued for up to 13 weeks. Of the evaluable subjects (223 of 249 randomized subjects), volunteers who received 400 mg tafenoquine for only 3 days had a protective efficacy of 68% (95% confidence interval [CI], 53%-79%), as compared with placebo recipients; those who received 200 mg per day for 3 days followed by 200 mg per week had a protective efficacy of 86% (95% CI, 73%-93%); and those who received 400 mg for 3 days followed by 400 mg per week had a protective efficacy of 89% (95% CI, 77%-95%). A similar number of volunteers in the 4 treatment groups reported adverse events. Prophylactic regimens of 200 mg or 400 mg of tafenoquine, taken weekly for &lt; or =13 weeks, are highly efficacious in preventing falciparum malaria and are well tolerated.</style></abstract><caption><style face="normal" font="default" size="100%">Duplicate</style></caption><notes><style face="normal" font="default" size="100%">1537-6591&#xD;Shanks, G D&#xD;Oloo, A J&#xD;Aleman, G M&#xD;Ohrt, C&#xD;Klotz, F W&#xD;Braitman, D&#xD;Horton, J&#xD;Brueckner, R&#xD;Clinical Trial&#xD;Journal Article&#xD;Randomized Controlled Trial&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Research Support, U.S. Gov&apos;t, Non-P.H.S.&#xD;United States&#xD;Clin Infect Dis. 2001 Dec 15;33(12):1968-74. doi: 10.1086/324081. Epub 2001 Nov 7.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1086/324081</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>136</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">136</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Shanks, G. D.</style></author><author><style face="normal" font="default" size="100%">Oloo, A. J.</style></author><author><style face="normal" font="default" size="100%">Aleman, G. M.</style></author><author><style face="normal" font="default" size="100%">Ohrt, C.</style></author><author><style face="normal" font="default" size="100%">Klotz, F. W.</style></author><author><style face="normal" font="default" size="100%">Braitman, D.</style></author><author><style face="normal" font="default" size="100%">Horton, J.</style></author><author><style face="normal" font="default" size="100%">Brueckner, R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">G.D. Shanks, USAMC, AFFRIMS, APO AP 96546, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">A new primaquine analogue, tafenoquine (WR 238605), for prophylaxis against Plasmodium falciparum malaria</style></title><secondary-title><style face="normal" font="default" size="100%">Clinical Infectious Diseases</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Clinical Infectious Diseases</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1968-1974</style></pages><volume><style face="normal" font="default" size="100%">33</style></volume><number><style face="normal" font="default" size="100%">12</style></number><keywords><keyword><style face="normal" font="default" size="100%">halofantrine</style></keyword><keyword><style face="normal" font="default" size="100%">tafenoquine</style></keyword><keyword><style face="normal" font="default" size="100%">abdominal pain</style></keyword><keyword><style face="normal" font="default" size="100%">adult</style></keyword><keyword><style face="normal" font="default" size="100%">antimalarial activity</style></keyword><keyword><style face="normal" font="default" size="100%">article</style></keyword><keyword><style face="normal" font="default" size="100%">clinical trial</style></keyword><keyword><style face="normal" font="default" size="100%">constipation</style></keyword><keyword><style face="normal" font="default" size="100%">controlled clinical trial</style></keyword><keyword><style face="normal" font="default" size="100%">controlled study</style></keyword><keyword><style face="normal" font="default" size="100%">diarrhea</style></keyword><keyword><style face="normal" font="default" size="100%">double blind procedure</style></keyword><keyword><style face="normal" font="default" size="100%">drug efficacy</style></keyword><keyword><style face="normal" font="default" size="100%">drug tolerability</style></keyword><keyword><style face="normal" font="default" size="100%">female</style></keyword><keyword><style face="normal" font="default" size="100%">gastritis</style></keyword><keyword><style face="normal" font="default" size="100%">gastroenteritis</style></keyword><keyword><style face="normal" font="default" size="100%">headache</style></keyword><keyword><style face="normal" font="default" size="100%">hemolysis</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">Kenya</style></keyword><keyword><style face="normal" font="default" size="100%">major clinical study</style></keyword><keyword><style face="normal" font="default" size="100%">malaria</style></keyword><keyword><style face="normal" font="default" size="100%">male</style></keyword><keyword><style face="normal" font="default" size="100%">musculoskeletal disease</style></keyword><keyword><style face="normal" font="default" size="100%">myalgia</style></keyword><keyword><style face="normal" font="default" size="100%">parasite control</style></keyword><keyword><style face="normal" font="default" size="100%">pharyngitis</style></keyword><keyword><style face="normal" font="default" size="100%">Plasmodium falciparum</style></keyword><keyword><style face="normal" font="default" size="100%">priority journal</style></keyword><keyword><style face="normal" font="default" size="100%">prophylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">randomized controlled trial</style></keyword><keyword><style face="normal" font="default" size="100%">rash</style></keyword><keyword><style face="normal" font="default" size="100%">skin disease</style></keyword><keyword><style face="normal" font="default" size="100%">statistical analysis</style></keyword><keyword><style face="normal" font="default" size="100%">halfan</style></keyword><keyword><style face="normal" font="default" size="100%">wr 238605</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2001</style></year></dates><isbn><style face="normal" font="default" size="100%">1058-4838</style></isbn><abstract><style face="normal" font="default" size="100%">We tested tafenoquine (WR 238605), a new long-acting 8-aminoquinoline, for its ability to prevent malaria in an area that is holoendemic for Plasmodium falciparum. In a double-blinded, placebo-controlled, randomized clinical trial in western Kenya, adult volunteers received a treatment course of 250 mg halofantrine per day for 3 days, to effect clearance of preexisting parasites. The volunteers were then assigned to 1 of 4 drug regimens: placebo throughout; 3 days of 400 mg (base) of tafenoquine per day, followed by placebo weekly; 3 days of 200 mg of tafenoquine per day, followed by 200 mg per week; and 3 days of 400 mg of tafenoquine per day, followed by 400 mg per week. Prophylaxis was continued for up to 13 weeks. Of the evaluable subjects (223 of 249 randomized subjects), volunteers who received 400 mg tafenoquine for only 3 days had a protective efficacy of 68% (95% confidence interval [CI], 53%-79%), as compared with placebo recipients; those who received 200 mg per day for 3 days followed by 200 mg per week had a protective efficacy of 86% (95% CI, 73%-93%); and those who received 400 mg for 3 days followed by 400 mg per week had a protective efficacy of 89% (95% CI, 77%-95%). A similar number of volunteers in the 4 treatment groups reported adverse events. Prophylactic regimens of 200 mg or 400 mg of tafenoquine, taken weekly for ≤13 weeks, are highly efficacious in preventing falciparum malaria and are well tolerated.</style></abstract><caption><style face="normal" font="default" size="100%">Duplicate</style></caption><notes><style face="normal" font="default" size="100%">L33152389&#xD;2002-01-04</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L33152389&amp;from=export</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1086/324081</style></url></related-urls></urls><custom1><style face="normal" font="default" size="100%">halfan(SmithKline Beecham,United States)&#xD;wr 238605</style></custom1><custom2><style face="normal" font="default" size="100%">SmithKline Beecham(United States)</style></custom2><custom5><style face="normal" font="default" size="100%">11700577</style></custom5><electronic-resource-num><style face="normal" font="default" size="100%">10.1086/324081</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase&#xD;Medline</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>145</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">145</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Shanks, G. D.</style></author><author><style face="normal" font="default" size="100%">Oloo, A. J.</style></author><author><style face="normal" font="default" size="100%">Aleman, G. M.</style></author><author><style face="normal" font="default" size="100%">Ohrt, C.</style></author><author><style face="normal" font="default" size="100%">Klotz, F. W.</style></author><author><style face="normal" font="default" size="100%">Braitman, D.</style></author><author><style face="normal" font="default" size="100%">Horton, J.</style></author><author><style face="normal" font="default" size="100%">Brueckner, R.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">A new primaquine analogue, tafenoquine (WR 238605), for prophylaxis against Plasmodium falciparum malaria</style></title><secondary-title><style face="normal" font="default" size="100%">Clinical infectious diseases</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Clinical Infectious Diseases</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1968‐1974</style></pages><volume><style face="normal" font="default" size="100%">33</style></volume><number><style face="normal" font="default" size="100%">12</style></number><keywords><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Aminoquinolines [adverse effects, *therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Antimalarials [adverse effects, *therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Chemoprevention</style></keyword><keyword><style face="normal" font="default" size="100%">Double‐Blind Method</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Malaria, Falciparum [*prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Plasmodium falciparum [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2001</style></year></dates><accession-num><style face="normal" font="default" size="100%">CN-00375485</style></accession-num><abstract><style face="normal" font="default" size="100%">We tested tafenoquine (WR 238605), a new long‐acting 8‐aminoquinoline, for its ability to prevent malaria in an area that is holoendemic for Plasmodium falciparum. In a double‐blinded, placebo‐controlled, randomized clinical trial in western Kenya, adult volunteers received a treatment course of 250 mg halofantrine per day for 3 days, to effect clearance of preexisting parasites. The volunteers were then assigned to 1 of 4 drug regimens: placebo throughout; 3 days of 400 mg (base) of tafenoquine per day, followed by placebo weekly; 3 days of 200 mg of tafenoquine per day, followed by 200 mg per week; and 3 days of 400 mg of tafenoquine per day, followed by 400 mg per week. Prophylaxis was continued for up to 13 weeks. Of the evaluable subjects (223 of 249 randomized subjects), volunteers who received 400 mg tafenoquine for only 3 days had a protective efficacy of 68% (95% confidence interval [CI], 53%‐79%), as compared with placebo recipients; those who received 200 mg per day for 3 days followed by 200 mg per week had a protective efficacy of 86% (95% CI, 73%‐93%); and those who received 400 mg for 3 days followed by 400 mg per week had a protective efficacy of 89% (95% CI, 77%‐95%). A similar number of volunteers in the 4 treatment groups reported adverse events. Prophylactic regimens of 200 mg or 400 mg of tafenoquine, taken weekly for &lt; or =13 weeks, are highly efficacious in preventing falciparum malaria and are well tolerated.</style></abstract><caption><style face="normal" font="default" size="100%">Duplicate</style></caption><work-type><style face="normal" font="default" size="100%">Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non‐U.S. Gov&apos;t; Research Support, U.S. Gov&apos;t, Non‐P.H.S.</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.cochranelibrary.com/central/doi/10.1002/central/CN-00375485/full</style></url></related-urls></urls><custom3><style face="normal" font="default" size="100%">PUBMED 11700577,EMBASE 33152389</style></custom3><electronic-resource-num><style face="normal" font="default" size="100%">10.1086/324081</style></electronic-resource-num></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>25</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">25</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Tse, E. G.</style></author><author><style face="normal" font="default" size="100%">Korsik, M.</style></author><author><style face="normal" font="default" size="100%">Todd, M. H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">School of Chemistry, The University of Sydney, Sydney, NSW, 2006, Australia. etse6978@uni.sydney.edu.au.&#xD;School of Chemistry, The University of Sydney, Sydney, NSW, 2006, Australia.&#xD;School of Chemistry, The University of Sydney, Sydney, NSW, 2006, Australia. matthew.todd@ucl.ac.uk.&#xD;School of Pharmacy, University College London, London, WC1N 1AX, United Kingdom. matthew.todd@ucl.ac.uk.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The past, present and future of anti-malarial medicines</style></title><secondary-title><style face="normal" font="default" size="100%">Malar J</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Malar J</style></full-title></periodical><pages><style face="normal" font="default" size="100%">93</style></pages><volume><style face="normal" font="default" size="100%">18</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2019/03/25</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Antimalarials/*pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Malaria/*drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Drug development</style></keyword><keyword><style face="normal" font="default" size="100%">Drug discovery</style></keyword><keyword><style face="normal" font="default" size="100%">Malaria</style></keyword><keyword><style face="normal" font="default" size="100%">Mechanism of action</style></keyword><keyword><style face="normal" font="default" size="100%">Plasmodium</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2019</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar 22</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1475-2875</style></isbn><accession-num><style face="normal" font="default" size="100%">30902052</style></accession-num><abstract><style face="normal" font="default" size="100%">Great progress has been made in recent years to reduce the high level of suffering caused by malaria worldwide. Notably, the use of insecticide-treated mosquito nets for malaria prevention and the use of artemisinin-based combination therapy (ACT) for malaria treatment have made a significant impact. Nevertheless, the development of resistance to the past and present anti-malarial drugs highlights the need for continued research to stay one step ahead. New drugs are needed, particularly those with new mechanisms of action. Here the range of anti-malarial medicines developed over the years are reviewed, beginning with the discovery of quinine in the early 1800s, through to modern day ACT and the recently-approved tafenoquine. A number of new potential anti-malarial drugs currently in development are outlined, along with a description of the hit to lead campaign from which it originated. Finally, promising novel mechanisms of action for these and future anti-malarial medicines are outlined.</style></abstract><notes><style face="normal" font="default" size="100%">1475-2875&#xD;Tse, Edwin G&#xD;Korsik, Marat&#xD;Todd, Matthew H&#xD;Orcid: 0000-0001-7096-4751&#xD;LP150101226/Australian Research Council/&#xD;Journal Article&#xD;Review&#xD;Malar J. 2019 Mar 22;18(1):93. doi: 10.1186/s12936-019-2724-z.</style></notes><urls></urls><custom2><style face="normal" font="default" size="100%">PMC6431062</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1186/s12936-019-2724-z</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>115</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">115</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Mawson, A. R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">A. R. Mawson, School of Health Sciences, College of Public Service, Jackson State University, 350 West Woodrow Wilson Drive, Jackson, MS 39213, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">The pathogenesis of malaria: A new perspective</style></title><secondary-title><style face="normal" font="default" size="100%">Pathogens and Global Health</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Pathogens and Global Health</style></full-title></periodical><pages><style face="normal" font="default" size="100%">122-129</style></pages><volume><style face="normal" font="default" size="100%">107</style></volume><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">arginine</style></keyword><keyword><style face="normal" font="default" size="100%">CD36 antigen</style></keyword><keyword><style face="normal" font="default" size="100%">primaquine</style></keyword><keyword><style face="normal" font="default" size="100%">retinol</style></keyword><keyword><style face="normal" font="default" size="100%">rosiglitazone</style></keyword><keyword><style face="normal" font="default" size="100%">tafenoquine</style></keyword><keyword><style face="normal" font="default" size="100%">anemia</style></keyword><keyword><style face="normal" font="default" size="100%">antimalarial activity</style></keyword><keyword><style face="normal" font="default" size="100%">article</style></keyword><keyword><style face="normal" font="default" size="100%">disease association</style></keyword><keyword><style face="normal" font="default" size="100%">erythrocyte</style></keyword><keyword><style face="normal" font="default" size="100%">headache</style></keyword><keyword><style face="normal" font="default" size="100%">hemolysis</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">IC50</style></keyword><keyword><style face="normal" font="default" size="100%">infection control</style></keyword><keyword><style face="normal" font="default" size="100%">infection risk</style></keyword><keyword><style face="normal" font="default" size="100%">intracranial hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">malaria</style></keyword><keyword><style face="normal" font="default" size="100%">mixed infection</style></keyword><keyword><style face="normal" font="default" size="100%">morbidity</style></keyword><keyword><style face="normal" font="default" size="100%">nonhuman</style></keyword><keyword><style face="normal" font="default" size="100%">parasite clearance</style></keyword><keyword><style face="normal" font="default" size="100%">randomized controlled trial (topic)</style></keyword><keyword><style face="normal" font="default" size="100%">respiratory distress</style></keyword><keyword><style face="normal" font="default" size="100%">thrombocytopenia</style></keyword><keyword><style face="normal" font="default" size="100%">virus pathogenesis</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><isbn><style face="normal" font="default" size="100%">2047-7724&#xD;2047-7732</style></isbn><abstract><style face="normal" font="default" size="100%">With 3.3 billion people at risk of infection, malaria remains one of the world&apos;s most significant health problems. Increasing resistance of the main causative parasite to currently available drugs has created an urgent need to elucidate the pathogenesis of the disease in order to develop new treatments. A possible clue to such an understanding is that the malaria parasite Plasmodium falciparum selectively absorbs vitamin A from the host and appears to use it for its metabolism; serum vitamin A levels are also reduced in children with malaria. Although vitamin A is essential in low concentration for numerous biological functions, higher concentrations are cytotoxic and pro-oxidant, and potentially toxic quantities of the vitamin are stored in the liver. During their life cycle in the host the parasites remain in the liver for several days before invading the red blood cells (RBCs). The hypothesis proposed is that the parasites emerge from the liver packed with vitamin A and use retinoic acid (RA), the main biologically active metabolite of vitamin A, as a cell membrane destabilizer to invade the RBCs throughout the body. The characteristic hemolysis and anemia of malaria and other symptoms of the disease may thus be manifestations of an endogenous form of vitamin A intoxication associated with high concentrations of RA but low concentrations of retinol (ROL). Retinoic acid released from the parasites may also affect the fetus and cause preterm birth and fetal growth restriction (FGR) as a function of the membranolytic and growth inhibitory effects of these compounds, respectively. Subject to testing, the hypothesis suggests that parasite vitamin A metabolism could become a new target for the treatment and prevention of malaria. © W. S. Maney &amp; Son Ltd 2013.</style></abstract><notes><style face="normal" font="default" size="100%">L368960348&#xD;2013-05-29&#xD;2013-06-12</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L368960348&amp;from=export</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1179/2047773213Y.0000000084</style></url><url><style face="normal" font="default" size="100%">http://docserver.ingentaconnect.com/deliver/connect/maney/20477724/v107n3/s5.pdf</style></url></related-urls></urls><custom5><style face="normal" font="default" size="100%">23683366</style></custom5><electronic-resource-num><style face="normal" font="default" size="100%">10.1179/2047773213Y.0000000084</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase&#xD;Medline</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>155</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">155</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Nct,</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Ph 2B/3 Tafenoquine (TFQ) Study in Prevention of Vivax Relapse</style></title><secondary-title><style face="normal" font="default" size="100%">https://clinicaltrials.gov/show/NCT01376167</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">https://clinicaltrials.gov/show/NCT01376167</style></full-title></periodical><keywords><keyword><style face="normal" font="default" size="100%">Chloroquine</style></keyword><keyword><style face="normal" font="default" size="100%">Chloroquine diphosphate</style></keyword><keyword><style face="normal" font="default" size="100%">Malaria</style></keyword><keyword><style face="normal" font="default" size="100%">Malaria, Vivax</style></keyword><keyword><style face="normal" font="default" size="100%">Primaquine</style></keyword><keyword><style face="normal" font="default" size="100%">Tafenoquine</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2011</style></year></dates><accession-num><style face="normal" font="default" size="100%">CN-02039914</style></accession-num><abstract><style face="normal" font="default" size="100%">Plasmodium vivax represents 50‐80% of all malarial cases in Latin America and South East Asia. It is able to establish a dormant liver stage called the hypnozoite. Hypnozoite activation after initial infection can cause a relapse. Currently the only widely available drug is primaquine which requires administration over 14 days, resulting in poor compliance and treatment failure. Tafenoquine (an 8‐aminoquinoline anti‐malarial drug) has been shown to possess activity against all stages of the plasmodium life cycle, including the dormant stage in the liver. This is a multi‐centre, double dummy, double blind, parallel group, randomized, active control study which is conducted in two parts. For both parts, subjects are treated with Chloroquine on days 1 to 3 (600mg, 600mg, and 300mg) to treat the blood stage vivax malaria. Part 1 will include at least 324 subjects and part 2 at least 600 subjects. Part 1 has 6 treatment arms, arms 1 to 4 contain different doses of Tafenoquine (50mg, 100mg, 300mg, and 600mg) dosed on day 1 or 2, arm 5 contains primaquine (15mg) dosing over 14 days (days 2‐15 (15mg)) and arm 6 contains chloroquine only. The aim of this is to find a dose of Tafenoquine which meets the defined dose criteria. Based on Part 1 efficacy and safety, a single Tafenoquine dose (300 mg) will be studied in the pivotal Part 2. Part 2 contains 3 treatment arms one with the selected Tafenoquine dose (300 mg), the second arm will be 15mg Primaquine which will again be dosed over 14 days and the final arm contains chloroquine only dosed days 1‐3 (600mg, 600mg, 300mg). Therefore as with Part 1, in Part 2 all subjects will receive Chloroquine. The aim of Part 2 is to investigate the safety and efficacy of the selected Tafenoquine/Chloroquine dose in the treatment and radical cure of Plasmodium vivax malaria. In addition to the Primary and Secondary endpoints stated below we will also be collecting; other efficacy endpoints (gametocyte clearance time, Recrudescence defined as any Plasmodium vivax parasitemia occurring on or before Day 29 (blood stage treatment failure), Incidence of Plasmodium falciparum malaria and Incidence of recrudescence and new Plasmodium vivax infection, determined by Polymerase Chain Reaction (PCR), safety endpoints (clinically relevant haemolysis leading to drops in haemoglobin / haematocrit or complications thereof (required transfusions, acute renal failure), changes in methaemoglobin, gastrointestinal (GI) tolerability ‐ incidence of abdominal pain, heartburn, diarrhoea, constipation, nausea and vomiting and ophthalmic safety ‐ incidence of corneal deposits, retinal and visual field abnormalities. Data collected at up to four centres . Additionally, the incidence and severity of adverse events and abnormal laboratory observations will be presented).Pharmacokinetic endpoints (Population pharmacokinetic parameters for tafenoquine including but not limited to oral clearance (CL/F) and volume of distribution (V/F)and Pharmacokinetic/Pharmacodynamic endpoints (e.g. tafenoquine plasma concentrations) and selected Pharmacodynamic endpoints (e.g. relapse efficacy, change in methaemoglobin) if appropriate, will be explored.</style></abstract><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02039914/full</style></url></related-urls></urls></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>185</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">185</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">St Jean, P. L.</style></author><author><style face="normal" font="default" size="100%">Koh, Gckw</style></author><author><style face="normal" font="default" size="100%">Breton, J. J.</style></author><author><style face="normal" font="default" size="100%">Espino, F. E. J.</style></author><author><style face="normal" font="default" size="100%">Hien, T. T.</style></author><author><style face="normal" font="default" size="100%">Krudsood, S.</style></author><author><style face="normal" font="default" size="100%">Lacerda, M. V. G.</style></author><author><style face="normal" font="default" size="100%">Llanos-Cuentas, A.</style></author><author><style face="normal" font="default" size="100%">Lon, C.</style></author><author><style face="normal" font="default" size="100%">Mohammed, R.</style></author><author><style face="normal" font="default" size="100%">Namaik-Larp, C. S.</style></author><author><style face="normal" font="default" size="100%">Pereira, D. B.</style></author><author><style face="normal" font="default" size="100%">Saunders, D. L.</style></author><author><style face="normal" font="default" size="100%">Velez, I. D.</style></author><author><style face="normal" font="default" size="100%">Yilma, D.</style></author><author><style face="normal" font="default" size="100%">Villegas, M. F.</style></author><author><style face="normal" font="default" size="100%">Duparc, S.</style></author><author><style face="normal" font="default" size="100%">Green, J. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">[St Jean, Pamela L.] PAREXEL Int, Genom Med, Durham, NC 27713 USA. [Koh, Gavin C. K. W.; Green, Justin A.] GlaxoSmithKline, Stockley Pk West, Uxbridge, Middx, England. [Breton, John J.] GlaxoSmithKline, Collegeville, PA USA. [Espino, Fe E. J.] Res Inst Trop Med, Manila, Philippines. [Hien, Tran T.] Oxford Univ Clin Res Unit, Ho Chi Minh City, Vietnam. [Krudsood, Srivicha] Mahidol Univ, Bangkok, Thailand. [Lacerda, Marcus V. G.] Fundacao Med Trop Amazonas, Manaus, Amazonas, Brazil. [Llanos-Cuentas, Alejandro] Univ Peruana Cayetano Heredia, Lima, Peru. [Lon, Chanthap; Saunders, David L.] Armed Forces Res Inst Med Sci, Bangkok, Thailand. [Mohammed, Rezika] Univ Gondar, Gondar, Ethiopia. [Namaik-Larp, Chayadol S.] Umphang Hosp, Tak, Thailand. [Pereira, Dhelio B.] Ctr Pesquisa Med Trop Rondonia, Porto Velho, Brazil. [Velez, Ivan D.] Univ Antioquia, PECET, Medellin, Colombia. [Yilma, Daniel] Jimma Univ, Jimma, Ethiopia. [Villegas, Maria F.] Ctr Invest Clin, Cali, Colombia. [Duparc, Stephan] Med Malaria Venture, Geneva, Switzerland.&#xD;St Jean, PL (corresponding author), PAREXEL Int, 2520 Meridian Pkwy,Suite 200, Durham, NC 27713 USA.&#xD;pam.stjean@parexel.com</style></auth-address><titles><title><style face="normal" font="default" size="100%">Pharmacogenetic assessment of tafenoquine efficacy in patients withPlasmodium vivaxmalaria</style></title><secondary-title><style face="normal" font="default" size="100%">Pharmacogenetics and Genomics</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Pharmacogenet. Genomics</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Pharmacogenetics and Genomics</style></full-title><abbr-1><style face="normal" font="default" size="100%">Pharmacogenet. Genomics</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Pharmacogenetics and Genomics</style></full-title><abbr-1><style face="normal" font="default" size="100%">Pharmacogenet. Genomics</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">161-165</style></pages><volume><style face="normal" font="default" size="100%">30</style></volume><number><style face="normal" font="default" size="100%">7</style></number><keywords><keyword><style face="normal" font="default" size="100%">efficacy</style></keyword><keyword><style face="normal" font="default" size="100%">pharmacogenetics</style></keyword><keyword><style face="normal" font="default" size="100%">Plasmodium vivaxmalaria</style></keyword><keyword><style face="normal" font="default" size="100%">tafenoquine</style></keyword><keyword><style face="normal" font="default" size="100%">prevent relapse</style></keyword><keyword><style face="normal" font="default" size="100%">Biotechnology &amp; Applied Microbiology</style></keyword><keyword><style face="normal" font="default" size="100%">Genetics &amp; Heredity</style></keyword><keyword><style face="normal" font="default" size="100%">Pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">&amp; Pharmacy</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2020</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1744-6872</style></isbn><accession-num><style face="normal" font="default" size="100%">WOS:000561869400003</style></accession-num><abstract><style face="normal" font="default" size="100%">Plasmodium vivaxhas the largest geographic range of human malaria species and is challenging to manage and eradicate due to its ability to establish a dormant liver stage, the hypnozoite, which can reactivate leading to relapse. Until recently, the only treatment approved to kill hypnozoites was the 8-aminoquinoline, primaquine, requiring daily treatment for 14 days. Tafenoquine, an 8-aminoquinoline single-dose treatment with activity againstP. vivaxhypnozoites, has recently been approved by the US Food and Drug Administration and Australian Therapeutic Goods Administration for the radical cure ofP. vivaxmalaria in patients 16 years and older. We conducted an exploratory pharmacogenetic analysis (GSK Study 208099) to assess the role of host genome-wide variation on tafenoquine efficacy in patients withP. vivaxmalaria using data from three GSK clinical trials, GATHER and DETECTIVE Part 1 and Part 2. Recurrence-free efficacy at 6 and 4 months and time to recurrence up to 6 months postdosing were analyzed in 438P. vivaxmalaria patients treated with tafenoquine. Among the approximately 10.6 million host genetic variants analyzed, two signals reached genome-wide significance (Pvalue &lt;= 5 x 10(-8)). rs62103056, and variants in a chromosome 12 intergenic region, were associated with recurrence-free efficacy at 6 and 4 months, respectively. Neither of the signals has an obvious biological rationale and would need replication in an independent population. This is the first genome-wide association study to evaluate genetic influence on response to tafenoquine inP. vivaxmalaria.</style></abstract><notes><style face="normal" font="default" size="100%">ISI Document Delivery No.: ND4KA&#xD;Times Cited: 0&#xD;Cited Reference Count: 14&#xD;St Jean, Pamela L. Koh, Gavin C. K. W. Breton, John J. Espino, Fe E. J. Hien, Tran T. Krudsood, Srivicha Lacerda, Marcus V. G. Llanos-Cuentas, Alejandro Lon, Chanthap Mohammed, Rezika Namaik-Larp, Chayadol S. Pereira, Dhelio B. Saunders, David L. Velez, Ivan D. Yilma, Daniel Villegas, Maria F. Duparc, Stephan Green, Justin A.&#xD;Pereira, Dhelio/F-9312-2017&#xD;Pereira, Dhelio/0000-0002-7761-5498&#xD;Medicines for Malaria Venture (MMV); GlaxoSmithKline (GSK)GlaxoSmithKline; GSKGlaxoSmithKline [208099]&#xD;Medicines for Malaria Venture (MMV) and GlaxoSmithKline (GSK) funded the main studies where DNA samples were collected. GSK funded the pharmacogenetic analyses (GSK identifier 208099) described in this article.&#xD;0&#xD;Lippincott williams &amp; wilkins&#xD;Philadelphia&#xD;1744-6880</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">&lt;Go to ISI&gt;://WOS:000561869400003</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1097/fpc.0000000000000407</style></electronic-resource-num><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>176</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">176</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Green, J. A.</style></author><author><style face="normal" font="default" size="100%">Mohamed, K.</style></author><author><style face="normal" font="default" size="100%">Goyal, N.</style></author><author><style face="normal" font="default" size="100%">Bouhired, S.</style></author><author><style face="normal" font="default" size="100%">Hussaini, A.</style></author><author><style face="normal" font="default" size="100%">Jones, S. W.</style></author><author><style face="normal" font="default" size="100%">Koh, Gckw</style></author><author><style face="normal" font="default" size="100%">Kostov, I.</style></author><author><style face="normal" font="default" size="100%">Taylor, M.</style></author><author><style face="normal" font="default" size="100%">Wolstenholm, A.</style></author><author><style face="normal" font="default" size="100%">et al.,</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Pharmacokinetic interactions between tafenoquine and dihydroartemisinin-piperaquine or artemether-lumefantrine in healthy adult subjects</style></title><secondary-title><style face="normal" font="default" size="100%">Antimicrobial agents and chemotherapy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Antimicrobial Agents and Chemotherapy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">7321‐7332</style></pages><volume><style face="normal" font="default" size="100%">60</style></volume><number><style face="normal" font="default" size="100%">12</style></number><keywords><keyword><style face="normal" font="default" size="100%">*artemether plus benflumetol</style></keyword><keyword><style face="normal" font="default" size="100%">*dihydroartemisinin plus piperaquine</style></keyword><keyword><style face="normal" font="default" size="100%">*tafenoquine</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Adverse drug reaction</style></keyword><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Artemether</style></keyword><keyword><style face="normal" font="default" size="100%">Artemisinin</style></keyword><keyword><style face="normal" font="default" size="100%">Benflumetol</style></keyword><keyword><style face="normal" font="default" size="100%">Body weight</style></keyword><keyword><style face="normal" font="default" size="100%">Clinical article</style></keyword><keyword><style face="normal" font="default" size="100%">Clinical trial</style></keyword><keyword><style face="normal" font="default" size="100%">Confidence interval</style></keyword><keyword><style face="normal" font="default" size="100%">Controlled clinical trial</style></keyword><keyword><style face="normal" font="default" size="100%">Controlled study</style></keyword><keyword><style face="normal" font="default" size="100%">Dihydroartemisinin</style></keyword><keyword><style face="normal" font="default" size="100%">Drug combination</style></keyword><keyword><style face="normal" font="default" size="100%">Drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Glucose 6 phosphate dehydrogenase deficiency</style></keyword><keyword><style face="normal" font="default" size="100%">Half life time</style></keyword><keyword><style face="normal" font="default" size="100%">Human</style></keyword><keyword><style face="normal" font="default" size="100%">Human tissue</style></keyword><keyword><style face="normal" font="default" size="100%">Maximum plasma concentration</style></keyword><keyword><style face="normal" font="default" size="100%">Pharmacokinetics</style></keyword><keyword><style face="normal" font="default" size="100%">Piperaquine</style></keyword><keyword><style face="normal" font="default" size="100%">QT prolongation</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized controlled trial</style></keyword><keyword><style face="normal" font="default" size="100%">Registration</style></keyword><keyword><style face="normal" font="default" size="100%">Side effect</style></keyword><keyword><style face="normal" font="default" size="100%">Volunteer</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2016</style></year></dates><accession-num><style face="normal" font="default" size="100%">CN-01244225</style></accession-num><abstract><style face="normal" font="default" size="100%">Tafenoquine is in development as a single‐dose treatment for relapse prevention in individuals with Plasmodium vivax malaria. Tafenoquine must be coadministered with a blood schizonticide, either chloroquine or artemisinin‐based combination therapy (ACT). This open‐label, randomized, parallel‐group study evaluated potential drug interactions between tafenoquine and two ACTs: dihydroartemisinin‐piperaquine and artemether‐lumefantrine. Healthy volunteers of either sex aged 18 to 65 years without glucose‐6‐phosphate dehydrogenase deficiency were randomized into five cohorts (n = 24 per cohort) to receive tafenoquine on day 1 (300 mg) plus once‐daily dihydroartemisinin‐piperaquine on days 1, 2, and 3 (120 mg/960 mg for 36 to &lt;75 kg of body weight and 160 mg/1,280 mg for &gt;75 to 100 kg of body weight), or plus artemether‐lumefantrine (80 mg/480 mg) in two doses 8 h apart on day 1 and then twice daily on days 2 and 3, or each drug alone. The pharmacokinetic parameters of tafenoquine, piperaquine, lumefantrine, artemether, and dihydroartemisinin were determined by using noncompartmental methods. Point estimates and 90% confidence intervals were calculated for area under the concentration‐time curve (AUC) and maximum observed plasma concentration (Cmax) comparisons of tafenoquine plus ACT versus tafenoquine or ACT. All subjects receiving dihydroartemisinin‐piperaquine experienced QTc prolongation (a known risk with this drug), but tafenoquine coadministration had no clinically relevant additional effect. Tafenoquine coadministration had no clinically relevant effects on dihydroartemisinin, piperaquine, artemether, or lumefantrine pharmacokinetics. Dihydroartemisinin‐piperaquine coadministration increased the tafenoquine Cmax by 38% (90% confidence interval, 25 to 52%), the AUC from time zero to infinity (AUC0‐) by 12% (1 to 26%), and the half‐life (t1/2) by 29% (19 to 40%), with no effect on the AUC from time zero to the time of the last nonzero concentration (AUC0‐last). Artemether‐lumefantrine coadministration had no effect on tafenoquine pharmacokinetics. Tafenoquine can be coadministered with dihydroartemisinin‐piperaquine or artemether‐lumefantrine without dose adjustment for any of these compounds. (This study has been registered at ClinicalTrials.gov under registration no. NCT02184637.) Copyright © 2016 Green et al.</style></abstract><caption><style face="normal" font="default" size="100%">Duplicate</style></caption><work-type><style face="normal" font="default" size="100%">Journal: Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01244225/full</style></url></related-urls></urls><custom3><style face="normal" font="default" size="100%">EMBASE 613337567</style></custom3><electronic-resource-num><style face="normal" font="default" size="100%">10.1128/AAC.01588-16</style></electronic-resource-num></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>42</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">42</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Green, J. A.</style></author><author><style face="normal" font="default" size="100%">Mohamed, K.</style></author><author><style face="normal" font="default" size="100%">Goyal, N.</style></author><author><style face="normal" font="default" size="100%">Bouhired, S.</style></author><author><style face="normal" font="default" size="100%">Hussaini, A.</style></author><author><style face="normal" font="default" size="100%">Jones, S. W.</style></author><author><style face="normal" font="default" size="100%">Koh, G. C.</style></author><author><style face="normal" font="default" size="100%">Kostov, I.</style></author><author><style face="normal" font="default" size="100%">Taylor, M.</style></author><author><style face="normal" font="default" size="100%">Wolstenholm, A.</style></author><author><style face="normal" font="default" size="100%">Duparc, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">GlaxoSmithKline Research and Development, Stockley Park West, Uxbridge, Middlesex, United Kingdom justin.a.green@gsk.com.&#xD;GlaxoSmithKline Research and Development, Stockley Park West, Uxbridge, Middlesex, United Kingdom.&#xD;GlaxoSmithKline, Upper Merion, King of Prussia, Pennsylvania, USA.&#xD;Parexel, Harbor Hospital, Baltimore, Baltimore, Maryland, USA.&#xD;GlaxoSmithKline Research and Development, Ware, Hertfordshire, United Kingdom.&#xD;GlaxoSmithKline, Upper Providence, Collegeville, Pennsylvania, USA.&#xD;Medicines for Malaria Venture, Geneva, Switzerland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Pharmacokinetic Interactions between Tafenoquine and Dihydroartemisinin-Piperaquine or Artemether-Lumefantrine in Healthy Adult Subjects</style></title><secondary-title><style face="normal" font="default" size="100%">Antimicrob Agents Chemother</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Antimicrob Agents Chemother</style></full-title></periodical><pages><style face="normal" font="default" size="100%">7321-7332</style></pages><volume><style face="normal" font="default" size="100%">60</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2016/10/05</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Aminoquinolines/adverse effects/*pharmacokinetics</style></keyword><keyword><style face="normal" font="default" size="100%">Antimalarials/adverse effects/*pharmacokinetics</style></keyword><keyword><style face="normal" font="default" size="100%">Artemisinins/adverse effects/*pharmacokinetics</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Interactions</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Therapy, Combination</style></keyword><keyword><style face="normal" font="default" size="100%">Ethanolamines/adverse effects/*pharmacokinetics</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Fluorenes/adverse effects/*pharmacokinetics</style></keyword><keyword><style face="normal" font="default" size="100%">Half-Life</style></keyword><keyword><style face="normal" font="default" size="100%">Healthy Volunteers</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Lumefantrine</style></keyword><keyword><style face="normal" font="default" size="100%">Malaria, Vivax/*drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Plasmodium vivax/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Quinolines/adverse effects/*pharmacokinetics</style></keyword><keyword><style face="normal" font="default" size="100%">Young Adult</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2016</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0066-4804 (Print)&#xD;0066-4804</style></isbn><accession-num><style face="normal" font="default" size="100%">27697758</style></accession-num><abstract><style face="normal" font="default" size="100%">Tafenoquine is in development as a single-dose treatment for relapse prevention in individuals with Plasmodium vivax malaria. Tafenoquine must be coadministered with a blood schizonticide, either chloroquine or artemisinin-based combination therapy (ACT). This open-label, randomized, parallel-group study evaluated potential drug interactions between tafenoquine and two ACTs: dihydroartemisinin-piperaquine and artemether-lumefantrine. Healthy volunteers of either sex aged 18 to 65 years without glucose-6-phosphate dehydrogenase deficiency were randomized into five cohorts (n = 24 per cohort) to receive tafenoquine on day 1 (300 mg) plus once-daily dihydroartemisinin-piperaquine on days 1, 2, and 3 (120 mg/960 mg for 36 to &lt;75 kg of body weight and 160 mg/1,280 mg for ≥75 to 100 kg of body weight), or plus artemether-lumefantrine (80 mg/480 mg) in two doses 8 h apart on day 1 and then twice daily on days 2 and 3, or each drug alone. The pharmacokinetic parameters of tafenoquine, piperaquine, lumefantrine, artemether, and dihydroartemisinin were determined by using noncompartmental methods. Point estimates and 90% confidence intervals were calculated for area under the concentration-time curve (AUC) and maximum observed plasma concentration (C(max)) comparisons of tafenoquine plus ACT versus tafenoquine or ACT. All subjects receiving dihydroartemisinin-piperaquine experienced QTc prolongation (a known risk with this drug), but tafenoquine coadministration had no clinically relevant additional effect. Tafenoquine coadministration had no clinically relevant effects on dihydroartemisinin, piperaquine, artemether, or lumefantrine pharmacokinetics. Dihydroartemisinin-piperaquine coadministration increased the tafenoquine C(max) by 38% (90% confidence interval, 25 to 52%), the AUC from time zero to infinity (AUC(0-∞)) by 12% (1 to 26%), and the half-life (t(1/2)) by 29% (19 to 40%), with no effect on the AUC from time zero to the time of the last nonzero concentration (AUC(0-last)). Artemether-lumefantrine coadministration had no effect on tafenoquine pharmacokinetics. Tafenoquine can be coadministered with dihydroartemisinin-piperaquine or artemether-lumefantrine without dose adjustment for any of these compounds. (This study has been registered at ClinicalTrials.gov under registration no. NCT02184637.).</style></abstract><caption><style face="normal" font="default" size="100%">Duplicate</style></caption><notes><style face="normal" font="default" size="100%">1098-6596&#xD;Green, Justin A&#xD;Mohamed, Khadeeja&#xD;Goyal, Navin&#xD;Bouhired, Samia&#xD;Hussaini, Azra&#xD;Jones, Siôn W&#xD;Koh, Gavin C K W&#xD;Kostov, Ivan&#xD;Taylor, Maxine&#xD;Wolstenholm, Allen&#xD;Duparc, Stephan&#xD;Journal Article&#xD;Randomized Controlled Trial&#xD;Antimicrob Agents Chemother. 2016 Nov 21;60(12):7321-7332. doi: 10.1128/AAC.01588-16. Print 2016 Dec.</style></notes><urls></urls><custom2><style face="normal" font="default" size="100%">PMC5119013</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1128/aac.01588-16</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>170</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">170</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Green, J. A.</style></author><author><style face="normal" font="default" size="100%">Mohamed, K.</style></author><author><style face="normal" font="default" size="100%">Goyal, N.</style></author><author><style face="normal" font="default" size="100%">Bouhired, S.</style></author><author><style face="normal" font="default" size="100%">Hussaini, A.</style></author><author><style face="normal" font="default" size="100%">Jones, S. W.</style></author><author><style face="normal" font="default" size="100%">Koh, G. C.</style></author><author><style face="normal" font="default" size="100%">Kostov, I.</style></author><author><style face="normal" font="default" size="100%">Taylor, M.</style></author><author><style face="normal" font="default" size="100%">Wolstenholm, A.</style></author><author><style face="normal" font="default" size="100%">et al.,</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Pharmacokinetic Interactions between Tafenoquine and Dihydroartemisinin-Piperaquine or Artemether-Lumefantrine in Healthy Adult Subjects</style></title><secondary-title><style face="normal" font="default" size="100%">Antimicrobial agents and chemotherapy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Antimicrobial Agents and Chemotherapy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">7321‐7332</style></pages><volume><style face="normal" font="default" size="100%">60</style></volume><number><style face="normal" font="default" size="100%">12</style></number><keywords><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Aminoquinolines [adverse effects, *pharmacokinetics]</style></keyword><keyword><style face="normal" font="default" size="100%">Antimalarials [adverse effects, *pharmacokinetics]</style></keyword><keyword><style face="normal" font="default" size="100%">Artemisinins [adverse effects, *pharmacokinetics]</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Interactions</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Therapy, Combination</style></keyword><keyword><style face="normal" font="default" size="100%">Ethanolamines [adverse effects, *pharmacokinetics]</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Fluorenes [adverse effects, *pharmacokinetics]</style></keyword><keyword><style face="normal" font="default" size="100%">Half‐Life</style></keyword><keyword><style face="normal" font="default" size="100%">Healthy Volunteers</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Lumefantrine</style></keyword><keyword><style face="normal" font="default" size="100%">Malaria, Vivax [*drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Plasmodium vivax [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Quinolines [adverse effects, *pharmacokinetics]</style></keyword><keyword><style face="normal" font="default" size="100%">Young Adult</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2016</style></year></dates><accession-num><style face="normal" font="default" size="100%">CN-01413825</style></accession-num><abstract><style face="normal" font="default" size="100%">Tafenoquine is in development as a single‐dose treatment for relapse prevention in individuals with Plasmodium vivax malaria. Tafenoquine must be coadministered with a blood schizonticide, either chloroquine or artemisinin‐based combination therapy (ACT). This open‐label, randomized, parallel‐group study evaluated potential drug interactions between tafenoquine and two ACTs: dihydroartemisinin‐piperaquine and artemether‐lumefantrine. Healthy volunteers of either sex aged 18 to 65 years without glucose‐6‐phosphate dehydrogenase deficiency were randomized into five cohorts (n = 24 per cohort) to receive tafenoquine on day 1 (300 mg) plus once‐daily dihydroartemisinin‐piperaquine on days 1, 2, and 3 (120 mg/960 mg for 36 to &lt;75 kg of body weight and 160 mg/1,280 mg for ≥75 to 100 kg of body weight), or plus artemether‐lumefantrine (80 mg/480 mg) in two doses 8 h apart on day 1 and then twice daily on days 2 and 3, or each drug alone. The pharmacokinetic parameters of tafenoquine, piperaquine, lumefantrine, artemether, and dihydroartemisinin were determined by using noncompartmental methods. Point estimates and 90% confidence intervals were calculated for area under the concentration‐time curve (AUC) and maximum observed plasma concentration (Cmax) comparisons of tafenoquine plus ACT versus tafenoquine or ACT. All subjects receiving dihydroartemisinin‐piperaquine experienced QTc prolongation (a known risk with this drug), but tafenoquine coadministration had no clinically relevant additional effect. Tafenoquine coadministration had no clinically relevant effects on dihydroartemisinin, piperaquine, artemether, or lumefantrine pharmacokinetics. Dihydroartemisinin‐piperaquine coadministration increased the tafenoquine Cmax by 38% (90% confidence interval, 25 to 52%), the AUC from time zero to infinity (AUC0‐∞) by 12% (1 to 26%), and the half‐life (t1/2) by 29% (19 to 40%), with no effect on the AUC from time zero to the time of the last nonzero concentration (AUC0‐last). Artemether‐lumefantrine coadministration had no effect on tafenoquine pharmacokinetics. Tafenoquine can be coadministered with dihydroartemisinin‐piperaquine or artemether‐lumefantrine without dose adjustment for any of these compounds. (This study has been registered at ClinicalTrials.gov under registration no. NCT02184637.).</style></abstract><caption><style face="normal" font="default" size="100%">Duplicate</style></caption><work-type><style face="normal" font="default" size="100%">Journal Article; Randomized Controlled Trial</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01413825/full</style></url></related-urls></urls><custom3><style face="normal" font="default" size="100%">PUBMED 27697758</style></custom3><electronic-resource-num><style face="normal" font="default" size="100%">10.1128/AAC.01588-16</style></electronic-resource-num></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>103</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">103</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Green, J. A.</style></author><author><style face="normal" font="default" size="100%">Mohamed, K.</style></author><author><style face="normal" font="default" size="100%">Goyal, N.</style></author><author><style face="normal" font="default" size="100%">Bouhired, S.</style></author><author><style face="normal" font="default" size="100%">Hussaini, A.</style></author><author><style face="normal" font="default" size="100%">Jones, S. W.</style></author><author><style face="normal" font="default" size="100%">Koh, G. C. K. W.</style></author><author><style face="normal" font="default" size="100%">Kostov, I.</style></author><author><style face="normal" font="default" size="100%">Taylor, M.</style></author><author><style face="normal" font="default" size="100%">Wolstenholm, A.</style></author><author><style face="normal" font="default" size="100%">Duparc, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">J.A. Green, GlaxoSmithKline Research and Development, Stockley Park West, Uxbridge, Middlesex, United Kingdom</style></auth-address><titles><title><style face="normal" font="default" size="100%">Pharmacokinetic interactions between tafenoquine and dihydroartemisinin-piperaquine or artemether-lumefantrine in healthy adult subjects</style></title><secondary-title><style face="normal" font="default" size="100%">Antimicrobial Agents and Chemotherapy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Antimicrobial Agents and Chemotherapy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">7321-7332</style></pages><volume><style face="normal" font="default" size="100%">60</style></volume><number><style face="normal" font="default" size="100%">12</style></number><keywords><keyword><style face="normal" font="default" size="100%">NCT02184637</style></keyword><keyword><style face="normal" font="default" size="100%">alanine aminotransferase</style></keyword><keyword><style face="normal" font="default" size="100%">artemether plus benflumetol</style></keyword><keyword><style face="normal" font="default" size="100%">aspartate aminotransferase</style></keyword><keyword><style face="normal" font="default" size="100%">benflumetol</style></keyword><keyword><style face="normal" font="default" size="100%">creatine kinase</style></keyword><keyword><style face="normal" font="default" size="100%">dihydroartemisinin plus piperaquine</style></keyword><keyword><style face="normal" font="default" size="100%">methemoglobin</style></keyword><keyword><style face="normal" font="default" size="100%">piperaquine</style></keyword><keyword><style face="normal" font="default" size="100%">tafenoquine</style></keyword><keyword><style face="normal" font="default" size="100%">abdominal pain</style></keyword><keyword><style face="normal" font="default" size="100%">adult</style></keyword><keyword><style face="normal" font="default" size="100%">aged</style></keyword><keyword><style face="normal" font="default" size="100%">anorexia</style></keyword><keyword><style face="normal" font="default" size="100%">area under the curve</style></keyword><keyword><style face="normal" font="default" size="100%">article</style></keyword><keyword><style face="normal" font="default" size="100%">asthenia</style></keyword><keyword><style face="normal" font="default" size="100%">bradycardia</style></keyword><keyword><style face="normal" font="default" size="100%">contact dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">controlled study</style></keyword><keyword><style face="normal" font="default" size="100%">decreased appetite</style></keyword><keyword><style face="normal" font="default" size="100%">diarrhea</style></keyword><keyword><style face="normal" font="default" size="100%">dizziness</style></keyword><keyword><style face="normal" font="default" size="100%">drug half life</style></keyword><keyword><style face="normal" font="default" size="100%">drug safety</style></keyword><keyword><style face="normal" font="default" size="100%">drug withdrawal</style></keyword><keyword><style face="normal" font="default" size="100%">dysuria</style></keyword><keyword><style face="normal" font="default" size="100%">fatigue</style></keyword><keyword><style face="normal" font="default" size="100%">fever</style></keyword><keyword><style face="normal" font="default" size="100%">flu like syndrome</style></keyword><keyword><style face="normal" font="default" size="100%">headache</style></keyword><keyword><style face="normal" font="default" size="100%">heart ventricle tachycardia</style></keyword><keyword><style face="normal" font="default" size="100%">hot flush</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">major clinical study</style></keyword><keyword><style face="normal" font="default" size="100%">maximum plasma concentration</style></keyword><keyword><style face="normal" font="default" size="100%">nausea</style></keyword><keyword><style face="normal" font="default" size="100%">open study</style></keyword><keyword><style face="normal" font="default" size="100%">pharmacokinetics</style></keyword><keyword><style face="normal" font="default" size="100%">pneumonia</style></keyword><keyword><style face="normal" font="default" size="100%">priority journal</style></keyword><keyword><style face="normal" font="default" size="100%">QT prolongation</style></keyword><keyword><style face="normal" font="default" size="100%">randomized controlled trial</style></keyword><keyword><style face="normal" font="default" size="100%">side effect</style></keyword><keyword><style face="normal" font="default" size="100%">throat irritation</style></keyword><keyword><style face="normal" font="default" size="100%">upper respiratory tract infection</style></keyword><keyword><style face="normal" font="default" size="100%">vomiting</style></keyword><keyword><style face="normal" font="default" size="100%">coartem</style></keyword><keyword><style face="normal" font="default" size="100%">eurartesim</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2016</style></year></dates><isbn><style face="normal" font="default" size="100%">1098-6596&#xD;0066-4804</style></isbn><abstract><style face="normal" font="default" size="100%">Tafenoquine is in development as a single-dose treatment for relapse prevention in individuals with Plasmodium vivax malaria. Tafenoquine must be coadministered with a blood schizonticide, either chloroquine or artemisinin-based combination therapy (ACT). This open-label, randomized, parallel-group study evaluated potential drug interactions between tafenoquine and two ACTs: dihydroartemisinin-piperaquine and artemether-lumefantrine. Healthy volunteers of either sex aged 18 to 65 years without glucose-6-phosphate dehydrogenase deficiency were randomized into five cohorts (n = 24 per cohort) to receive tafenoquine on day 1 (300 mg) plus once-daily dihydroartemisinin-piperaquine on days 1, 2, and 3 (120 mg/960 mg for 36 to &lt;75 kg of body weight and 160 mg/1,280 mg for ≥75 to 100 kg of body weight), or plus artemether-lumefantrine (80 mg/480 mg) in two doses 8 h apart on day 1 and then twice daily on days 2 and 3, or each drug alone. The pharmacokinetic parameters of tafenoquine, piperaquine, lumefantrine, artemether, and dihydroartemisinin were determined by using noncompartmental methods. Point estimates and 90% confidence intervals were calculated for area under the concentration-time curve (AUC) and maximum observed plasma concentration (Cmax) comparisons of tafenoquine plus ACT versus tafenoquine or ACT. All subjects receiving dihydroartemisinin-piperaquine experienced QTc prolongation (a known risk with this drug), but tafenoquine coadministration had no clinically relevant additional effect. Tafenoquine coadministration had no clinically relevant effects on dihydroartemisinin, piperaquine, artemether, or lumefantrine pharmacokinetics. Dihydroartemisinin-piperaquine coadministration increased the tafenoquine Cmax by 38% (90% confidence interval, 25 to 52%), the AUC from time zero to infinity (AUC0-∞) by 12% (1 to 26%), and the half-life (t1/2) by 29% (19 to 40%), with no effect on the AUC from time zero to the time of the last nonzero concentration (AUC0-last). Artemether-lumefantrine coadministration had no effect on tafenoquine pharmacokinetics. Tafenoquine can be coadministered with dihydroartemisinin-piperaquine or artemether-lumefantrine without dose adjustment for any of these compounds. (This study has been registered at ClinicalTrials.gov under registration no. NCT02184637.)</style></abstract><caption><style face="normal" font="default" size="100%">Duplicate</style></caption><notes><style face="normal" font="default" size="100%">L613337567&#xD;2016-11-30&#xD;2017-01-12</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L613337567&amp;from=export</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1128/AAC.01588-16</style></url></related-urls></urls><custom1><style face="normal" font="default" size="100%">coartem(Novartis)&#xD;eurartesim(Sigma Tau,Spain)</style></custom1><custom2><style face="normal" font="default" size="100%">Glaxo SmithKline&#xD;Novartis&#xD;Sigma Tau(Spain)</style></custom2><custom5><style face="normal" font="default" size="100%">27697758</style></custom5><electronic-resource-num><style face="normal" font="default" size="100%">10.1128/AAC.01588-16</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase&#xD;Medline</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>69</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">69</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Edstein, M. D.</style></author><author><style face="normal" font="default" size="100%">Kocisko, D. A.</style></author><author><style face="normal" font="default" size="100%">Walsh, D. S.</style></author><author><style face="normal" font="default" size="100%">Eamsila, C.</style></author><author><style face="normal" font="default" size="100%">Charles, B. G.</style></author><author><style face="normal" font="default" size="100%">Rieckmann, K. H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Australian Army Malaria Institute, Enoggera, QLD, Australia. Mike.Edstein@defence.gov.au</style></auth-address><titles><title><style face="normal" font="default" size="100%">Plasma concentrations of tafenoquine, a new long-acting antimalarial agent, in thai soldiers receiving monthly prophylaxis</style></title><secondary-title><style face="normal" font="default" size="100%">Clin Infect Dis</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Clin Infect Dis</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1654-8</style></pages><volume><style face="normal" font="default" size="100%">37</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2003/12/23</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Aminoquinolines/*blood</style></keyword><keyword><style face="normal" font="default" size="100%">Antimalarials/*blood</style></keyword><keyword><style face="normal" font="default" size="100%">Artemisinins/blood</style></keyword><keyword><style face="normal" font="default" size="100%">Artesunate</style></keyword><keyword><style face="normal" font="default" size="100%">Chemoprevention</style></keyword><keyword><style face="normal" font="default" size="100%">Double-Blind Method</style></keyword><keyword><style face="normal" font="default" size="100%">Doxycycline/blood</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Military Personnel</style></keyword><keyword><style face="normal" font="default" size="100%">Sesquiterpenes/blood</style></keyword><keyword><style face="normal" font="default" size="100%">Thailand</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2003</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec 15</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1058-4838</style></isbn><accession-num><style face="normal" font="default" size="100%">14689348</style></accession-num><abstract><style face="normal" font="default" size="100%">We measured plasma tafenoquine concentrations in Thai soldiers given a monthly regimen of tafenoquine to determine whether these concentrations adequately suppressed malarial infections on the Thai-Cambodian border. After receiving a treatment course of artesunate and doxycycline, 104 male soldiers were administered a loading dose of tafenoquine (400 mg daily for 3 days), followed by tafenoquine monthly (400 mg every 4 weeks) for 5 months. Consecutive monthly mean (+/- standard deviation) trough plasma tafenoquine concentrations were 223+/-41, 127+/-29, 157+/-51, 120+/-24, and 88+/-20 ng/mL. Only 1 soldier developed malaria during the study. At the time of malaria diagnosis, his plasma tafenoquine concentration was 40 ng/mL, which was approximately 3-fold lower than the trough concentrations of the other soldiers. Although low tafenoquine concentrations appear to be uncommon, additional investigations are needed to determine the relationship between plasma tafenoquine concentrations and suppression of malaria.</style></abstract><caption><style face="normal" font="default" size="100%">Duplicate</style></caption><notes><style face="normal" font="default" size="100%">1537-6591&#xD;Edstein, Michael D&#xD;Kocisko, David A&#xD;Walsh, Douglas S&#xD;Eamsila, Chirapa&#xD;Charles, Bruce G&#xD;Rieckmann, Karl H&#xD;Clinical Trial&#xD;Journal Article&#xD;Randomized Controlled Trial&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Research Support, U.S. Gov&apos;t, Non-P.H.S.&#xD;United States&#xD;Clin Infect Dis. 2003 Dec 15;37(12):1654-8. doi: 10.1086/379718. Epub 2003 Nov 20.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1086/379718</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>132</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">132</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Edstein, M. D.</style></author><author><style face="normal" font="default" size="100%">Kocisko, D. A.</style></author><author><style face="normal" font="default" size="100%">Walsh, D. S.</style></author><author><style face="normal" font="default" size="100%">Eamsila, C.</style></author><author><style face="normal" font="default" size="100%">Charles, B. G.</style></author><author><style face="normal" font="default" size="100%">Rieckmann, K. H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">M.D. Edstein, Australian Army Malaria Institute, Enoggera, QLD 4051, Australia</style></auth-address><titles><title><style face="normal" font="default" size="100%">Plasma Concentrations of Tafenoquine, a New Long-Acting Antimalarial Agent, in Thai Soldiers Receiving Monthly Prophylaxis</style></title><secondary-title><style face="normal" font="default" size="100%">Clinical Infectious Diseases</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Clinical Infectious Diseases</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1654-1658</style></pages><volume><style face="normal" font="default" size="100%">37</style></volume><number><style face="normal" font="default" size="100%">12</style></number><keywords><keyword><style face="normal" font="default" size="100%">artesunate</style></keyword><keyword><style face="normal" font="default" size="100%">doxycycline</style></keyword><keyword><style face="normal" font="default" size="100%">placebo</style></keyword><keyword><style face="normal" font="default" size="100%">tafenoquine</style></keyword><keyword><style face="normal" font="default" size="100%">adult</style></keyword><keyword><style face="normal" font="default" size="100%">article</style></keyword><keyword><style face="normal" font="default" size="100%">clinical trial</style></keyword><keyword><style face="normal" font="default" size="100%">controlled clinical trial</style></keyword><keyword><style face="normal" font="default" size="100%">controlled study</style></keyword><keyword><style face="normal" font="default" size="100%">dose time effect relation</style></keyword><keyword><style face="normal" font="default" size="100%">drug blood level</style></keyword><keyword><style face="normal" font="default" size="100%">drug efficacy</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">major clinical study</style></keyword><keyword><style face="normal" font="default" size="100%">malaria</style></keyword><keyword><style face="normal" font="default" size="100%">malaria control</style></keyword><keyword><style face="normal" font="default" size="100%">male</style></keyword><keyword><style face="normal" font="default" size="100%">priority journal</style></keyword><keyword><style face="normal" font="default" size="100%">military personnel</style></keyword><keyword><style face="normal" font="default" size="100%">Thailand</style></keyword><keyword><style face="normal" font="default" size="100%">wr 238605</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2003</style></year></dates><isbn><style face="normal" font="default" size="100%">1058-4838</style></isbn><abstract><style face="normal" font="default" size="100%">We measured plasma tafenoquine concentrations in Thai soldiers given a monthly regimen of tafenoquine to determine whether these concentrations adequately suppressed malarial infections on the Thai-Cambodian border. After receiving a treatment course of artesunate and doxycycline, 104 male soldiers were administered a loading dose of tafenoquine (400 mg daily for 3 days), followed by tafenoquine monthly (400 mg every 4 weeks) for 5 months. Consecutive monthly mean (± standard deviation) trough plasma tafenoquine concentrations were 223 ± 41, 127 ± 29, 157 ± 51, 120 ± 24, and 88 ± 20 ng/mL. Only 1 soldier developed malaria during the study. At the time of malaria diagnosis, his plasma tafenoquine concentration was 40 ng/mL, which was ∼3-fold lower than the trough concentrations of the other soldiers. Although low tafenoquine concentrations appear to be uncommon, additional investigations are needed to determine the relationship between plasma tafenoquine concentrations and suppression of malaria.</style></abstract><caption><style face="normal" font="default" size="100%">Duplicate</style></caption><notes><style face="normal" font="default" size="100%">L37549953&#xD;2004-01-14</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L37549953&amp;from=export</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1086/379718</style></url></related-urls></urls><custom1><style face="normal" font="default" size="100%">wr 238605(SmithKline Beecham)</style></custom1><custom2><style face="normal" font="default" size="100%">SmithKline Beecham</style></custom2><custom5><style face="normal" font="default" size="100%">14689348</style></custom5><electronic-resource-num><style face="normal" font="default" size="100%">10.1086/379718</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase&#xD;Medline</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>162</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">162</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Edstein, M. D.</style></author><author><style face="normal" font="default" size="100%">Kocisko, D. A.</style></author><author><style face="normal" font="default" size="100%">Walsh, D. S.</style></author><author><style face="normal" font="default" size="100%">Eamsila, C.</style></author><author><style face="normal" font="default" size="100%">Charles, B. G.</style></author><author><style face="normal" font="default" size="100%">Rieckmann, K. H.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Plasma concentrations of tafenoquine, a new long-acting antimalarial agent, in thai soldiers receiving monthly prophylaxis</style></title><secondary-title><style face="normal" font="default" size="100%">Clinical infectious diseases</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Clinical Infectious Diseases</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1654‐1658</style></pages><volume><style face="normal" font="default" size="100%">37</style></volume><number><style face="normal" font="default" size="100%">12</style></number><keywords><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Aminoquinolines [*blood]</style></keyword><keyword><style face="normal" font="default" size="100%">Antimalarials [*blood]</style></keyword><keyword><style face="normal" font="default" size="100%">Artemisinins [blood]</style></keyword><keyword><style face="normal" font="default" size="100%">Artesunate</style></keyword><keyword><style face="normal" font="default" size="100%">Chemoprevention</style></keyword><keyword><style face="normal" font="default" size="100%">Double‐Blind Method</style></keyword><keyword><style face="normal" font="default" size="100%">Doxycycline [blood]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Military Personnel</style></keyword><keyword><style face="normal" font="default" size="100%">Sesquiterpenes [blood]</style></keyword><keyword><style face="normal" font="default" size="100%">Thailand</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2003</style></year></dates><accession-num><style face="normal" font="default" size="100%">CN-00459716</style></accession-num><abstract><style face="normal" font="default" size="100%">We measured plasma tafenoquine concentrations in Thai soldiers given a monthly regimen of tafenoquine to determine whether these concentrations adequately suppressed malarial infections on the Thai‐Cambodian border. After receiving a treatment course of artesunate and doxycycline, 104 male soldiers were administered a loading dose of tafenoquine (400 mg daily for 3 days), followed by tafenoquine monthly (400 mg every 4 weeks) for 5 months. Consecutive monthly mean (+/‐ standard deviation) trough plasma tafenoquine concentrations were 223+/‐41, 127+/‐29, 157+/‐51, 120+/‐24, and 88+/‐20 ng/mL. Only 1 soldier developed malaria during the study. At the time of malaria diagnosis, his plasma tafenoquine concentration was 40 ng/mL, which was approximately 3‐fold lower than the trough concentrations of the other soldiers. Although low tafenoquine concentrations appear to be uncommon, additional investigations are needed to determine the relationship between plasma tafenoquine concentrations and suppression of malaria.</style></abstract><caption><style face="normal" font="default" size="100%">Duplicate</style></caption><work-type><style face="normal" font="default" size="100%">Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non‐U.S. Gov&apos;t; Research Support, U.S. Gov&apos;t, Non‐P.H.S.</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.cochranelibrary.com/central/doi/10.1002/central/CN-00459716/full</style></url></related-urls></urls><custom3><style face="normal" font="default" size="100%">PUBMED 14689348</style></custom3><electronic-resource-num><style face="normal" font="default" size="100%">10.1086/379718</style></electronic-resource-num></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>59</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">59</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Charles, B. G.</style></author><author><style face="normal" font="default" size="100%">Miller, A. K.</style></author><author><style face="normal" font="default" size="100%">Nasveld, P. E.</style></author><author><style face="normal" font="default" size="100%">Reid, M. G.</style></author><author><style face="normal" font="default" size="100%">Harris, I. E.</style></author><author><style face="normal" font="default" size="100%">Edstein, M. D.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">The University of Queensland, Brisbane, QLD, Australia. B.Charles@pharmacy.uq.edu.au</style></auth-address><titles><title><style face="normal" font="default" size="100%">Population pharmacokinetics of tafenoquine during malaria prophylaxis in healthy subjects</style></title><secondary-title><style face="normal" font="default" size="100%">Antimicrob Agents Chemother</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Antimicrob Agents Chemother</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2709-15</style></pages><volume><style face="normal" font="default" size="100%">51</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2007/05/23</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Aminoquinolines/administration &amp; dosage/adverse effects/*pharmacokinetics</style></keyword><keyword><style face="normal" font="default" size="100%">Antimalarials/administration &amp; dosage/adverse effects/*pharmacokinetics</style></keyword><keyword><style face="normal" font="default" size="100%">Double-Blind Method</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Malaria/*prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">*Military Personnel</style></keyword><keyword><style face="normal" font="default" size="100%">*Models, Biological</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2007</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0066-4804 (Print)&#xD;0066-4804</style></isbn><accession-num><style face="normal" font="default" size="100%">17517850</style></accession-num><abstract><style face="normal" font="default" size="100%">The population pharmacokinetics of tafenoquine were studied in Australian soldiers taking tafenoquine for malarial prophylaxis. The subjects (476 males and 14 females) received a loading dose of 200 mg tafenoquine base daily for 3 days, followed by a weekly dose of 200 mg tafenoquine for 6 months. Blood samples were collected from each subject after the last loading dose and then at weeks 4, 8, and 16. Plasma tafenoquine concentrations were determined by liquid chromatography-tandem mass spectrometry. Population modeling was performed with NONMEM, using a one-compartment model. Typical values of the first-order absorption rate constant (K(a)), clearance (CL/F), and volume of distribution (V/F) were 0.243 h(-1), 0.056 liters/h/kg, and 23.7 liters/kg, respectively. The intersubject variability (coefficient of variation) in CL/F and V/F was 18% and 22%, respectively. The interoccasion variability in CL/F was 18%, and the mean elimination half-life was 12.7 days. A positive linear association between weight and both CL/F and V/F was found, but this had insufficient impact to warrant dosage adjustments. Model robustness was assessed by a nonparametric bootstrap (200 samples). A degenerate visual predictive check indicated that the raw data mirrored the postdose concentration-time profiles simulated (n = 1,000) from the final model. Individual pharmacokinetic estimates for tafenoquine did not predict the prophylactic outcome with the drug for four subjects who relapsed with Plasmodium vivax malaria, as they had similar pharmacokinetics to those who were free of malaria infection. No obvious pattern existed between the plasma tafenoquine concentration and the pharmacokinetic parameter values for subjects with and without drug-associated moderate or severe adverse events. This validated population pharmacokinetic model satisfactorily describes the disposition and variability of tafenoquine used for long-term malaria prophylaxis in a large cohort of soldiers on military deployment.</style></abstract><caption><style face="normal" font="default" size="100%">Duplicate</style></caption><notes><style face="normal" font="default" size="100%">1098-6596&#xD;Charles, Bruce G&#xD;Miller, Ann K&#xD;Nasveld, Peter E&#xD;Reid, Mark G&#xD;Harris, Ivor E&#xD;Edstein, Michael D&#xD;Journal Article&#xD;Randomized Controlled Trial&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Research Support, U.S. Gov&apos;t, Non-P.H.S.&#xD;Antimicrob Agents Chemother. 2007 Aug;51(8):2709-15. doi: 10.1128/AAC.01183-06. Epub 2007 May 21.</style></notes><urls></urls><custom2><style face="normal" font="default" size="100%">PMC1932489</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1128/aac.01183-06</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>125</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">125</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Charles, B. G.</style></author><author><style face="normal" font="default" size="100%">Miller, A. K.</style></author><author><style face="normal" font="default" size="100%">Nasveld, P. E.</style></author><author><style face="normal" font="default" size="100%">Reid, M. G.</style></author><author><style face="normal" font="default" size="100%">Harris, I. E.</style></author><author><style face="normal" font="default" size="100%">Edstein, M. D.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">B.G. Charles, University of Queensland, Brisbane, QLD, Australia</style></auth-address><titles><title><style face="normal" font="default" size="100%">Population pharmacokinetics of tafenoquine during malaria prophylaxis in healthy subjects</style></title><secondary-title><style face="normal" font="default" size="100%">Antimicrobial Agents and Chemotherapy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Antimicrobial Agents and Chemotherapy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2709-2715</style></pages><volume><style face="normal" font="default" size="100%">51</style></volume><number><style face="normal" font="default" size="100%">8</style></number><keywords><keyword><style face="normal" font="default" size="100%">tafenoquine</style></keyword><keyword><style face="normal" font="default" size="100%">abdominal pain</style></keyword><keyword><style face="normal" font="default" size="100%">adult</style></keyword><keyword><style face="normal" font="default" size="100%">agitation</style></keyword><keyword><style face="normal" font="default" size="100%">amnesia</style></keyword><keyword><style face="normal" font="default" size="100%">anorexia</style></keyword><keyword><style face="normal" font="default" size="100%">article</style></keyword><keyword><style face="normal" font="default" size="100%">Australia</style></keyword><keyword><style face="normal" font="default" size="100%">blood sampling</style></keyword><keyword><style face="normal" font="default" size="100%">bootstrapping</style></keyword><keyword><style face="normal" font="default" size="100%">clinical trial</style></keyword><keyword><style face="normal" font="default" size="100%">controlled clinical trial</style></keyword><keyword><style face="normal" font="default" size="100%">controlled study</style></keyword><keyword><style face="normal" font="default" size="100%">coordination</style></keyword><keyword><style face="normal" font="default" size="100%">depression</style></keyword><keyword><style face="normal" font="default" size="100%">diarrhea</style></keyword><keyword><style face="normal" font="default" size="100%">discomfort</style></keyword><keyword><style face="normal" font="default" size="100%">volume of distribution</style></keyword><keyword><style face="normal" font="default" size="100%">dose response</style></keyword><keyword><style face="normal" font="default" size="100%">double blind procedure</style></keyword><keyword><style face="normal" font="default" size="100%">dreaming</style></keyword><keyword><style face="normal" font="default" size="100%">drug absorption</style></keyword><keyword><style face="normal" font="default" size="100%">drug blood level</style></keyword><keyword><style face="normal" font="default" size="100%">drug clearance</style></keyword><keyword><style face="normal" font="default" size="100%">drug disposition</style></keyword><keyword><style face="normal" font="default" size="100%">drug dose regimen</style></keyword><keyword><style face="normal" font="default" size="100%">drug efficacy</style></keyword><keyword><style face="normal" font="default" size="100%">drug half life</style></keyword><keyword><style face="normal" font="default" size="100%">drug tolerability</style></keyword><keyword><style face="normal" font="default" size="100%">drug withdrawal</style></keyword><keyword><style face="normal" font="default" size="100%">eye malformation</style></keyword><keyword><style face="normal" font="default" size="100%">female</style></keyword><keyword><style face="normal" font="default" size="100%">flatulence</style></keyword><keyword><style face="normal" font="default" size="100%">headache</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">human experiment</style></keyword><keyword><style face="normal" font="default" size="100%">hyperesthesia</style></keyword><keyword><style face="normal" font="default" size="100%">increased appetite</style></keyword><keyword><style face="normal" font="default" size="100%">insomnia</style></keyword><keyword><style face="normal" font="default" size="100%">lipidosis</style></keyword><keyword><style face="normal" font="default" size="100%">liquid chromatography</style></keyword><keyword><style face="normal" font="default" size="100%">loading drug dose</style></keyword><keyword><style face="normal" font="default" size="100%">malaria</style></keyword><keyword><style face="normal" font="default" size="100%">male</style></keyword><keyword><style face="normal" font="default" size="100%">military deployment</style></keyword><keyword><style face="normal" font="default" size="100%">nausea</style></keyword><keyword><style face="normal" font="default" size="100%">normal human</style></keyword><keyword><style face="normal" font="default" size="100%">paranoia</style></keyword><keyword><style face="normal" font="default" size="100%">Plasmodium vivax</style></keyword><keyword><style face="normal" font="default" size="100%">population model</style></keyword><keyword><style face="normal" font="default" size="100%">priority journal</style></keyword><keyword><style face="normal" font="default" size="100%">prophylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">randomized controlled trial</style></keyword><keyword><style face="normal" font="default" size="100%">relapse</style></keyword><keyword><style face="normal" font="default" size="100%">side effect</style></keyword><keyword><style face="normal" font="default" size="100%">military personnel</style></keyword><keyword><style face="normal" font="default" size="100%">somnolence</style></keyword><keyword><style face="normal" font="default" size="100%">statistical analysis</style></keyword><keyword><style face="normal" font="default" size="100%">tandem mass spectrometry</style></keyword><keyword><style face="normal" font="default" size="100%">thirst</style></keyword><keyword><style face="normal" font="default" size="100%">treatment outcome</style></keyword><keyword><style face="normal" font="default" size="100%">tremor</style></keyword><keyword><style face="normal" font="default" size="100%">vertigo</style></keyword><keyword><style face="normal" font="default" size="100%">vomiting</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2007</style></year></dates><isbn><style face="normal" font="default" size="100%">0066-4804</style></isbn><abstract><style face="normal" font="default" size="100%">The population pharmacokinetics of tafenoquine were studied in Australian soldiers taking tafenoquine for malarial prophylaxis. The subjects (476 males and 14 females) received a loading dose of 200 mg tafenoquine base daily for 3 days, followed by a weekly dose of 200 mg tafenoquine for 6 months. Blood samples were collected from each subject after the last loading dose and then at weeks 4, 8, and 16. Plasma tafenoquine concentrations were determined by liquid chromatography-tandem mass spectrometry. Population modeling was performed with NONMEM, using a one-compartment model. Typical values of the first-order absorption rate constant (Ka), clearance (CL/F), and volume of distribution (V/F) were 0.243 h-1, 0.056 liters/h/kg, and 23.7 liters/kg, respectively. The intersubject variability (coefficient of variation) in CL/F and V/F was 18% and 22%, respectively. The interoccasion variability in CL/F was 18%, and the mean elimination half-life was 12.7 days. A positive linear association between weight and both CL/F and V/F was found, but this had insufficient impact to warrant dosage adjustments. Model robustness was assessed by a nonparametric bootstrap (200 samples). A degenerate visual predictive check indicated that the raw data mirrored the postdose concentration-time profiles simulated (n = 1,000) from the final model. Individual pharmacokinetic estimates for tafenoquine did not predict the prophylactic outcome with the drug for four subjects who relapsed with Plasmodium vivax malaria, as they had similar pharmacokinetics to those who were free of malaria infection. No obvious pattern existed between the plasma tafenoquine concentration and the pharmacokinetic parameter values for subjects with and without drug-associated moderate or severe adverse events. This validated population pharmacokinetic model satisfactorily describes the disposition and variability of tafenoquine used for long-term malaria prophylaxis in a large cohort of soldiers on military deployment. Copyright © 2007, American Society for Microbiology. All Rights Reserved.</style></abstract><caption><style face="normal" font="default" size="100%">Duplicate</style></caption><notes><style face="normal" font="default" size="100%">L47206203&#xD;2007-08-01</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L47206203&amp;from=export</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1128/AAC.01183-06</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">Glaxo SmithKline</style></custom2><custom5><style face="normal" font="default" size="100%">17517850</style></custom5><electronic-resource-num><style face="normal" font="default" size="100%">10.1128/AAC.01183-06</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase&#xD;Medline</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>156</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">156</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Charles, B. G.</style></author><author><style face="normal" font="default" size="100%">Miller, A. K.</style></author><author><style face="normal" font="default" size="100%">Nasveld, P. E.</style></author><author><style face="normal" font="default" size="100%">Reid, M. G.</style></author><author><style face="normal" font="default" size="100%">Harris, I. E.</style></author><author><style face="normal" font="default" size="100%">Edstein, M. D.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Population pharmacokinetics of tafenoquine during malaria prophylaxis in healthy subjects</style></title><secondary-title><style face="normal" font="default" size="100%">Antimicrobial agents and chemotherapy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Antimicrobial Agents and Chemotherapy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2709‐2715</style></pages><volume><style face="normal" font="default" size="100%">51</style></volume><number><style face="normal" font="default" size="100%">8</style></number><keywords><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Aminoquinolines [administration &amp; dosage, adverse effects, *pharmacokinetics]</style></keyword><keyword><style face="normal" font="default" size="100%">Antimalarials [administration &amp; dosage, adverse effects, *pharmacokinetics]</style></keyword><keyword><style face="normal" font="default" size="100%">Double‐Blind Method</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Malaria [*prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Military Personnel</style></keyword><keyword><style face="normal" font="default" size="100%">Models, Biological</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2007</style></year></dates><accession-num><style face="normal" font="default" size="100%">CN-00609839</style></accession-num><abstract><style face="normal" font="default" size="100%">The population pharmacokinetics of tafenoquine were studied in Australian soldiers taking tafenoquine for malarial prophylaxis. The subjects (476 males and 14 females) received a loading dose of 200 mg tafenoquine base daily for 3 days, followed by a weekly dose of 200 mg tafenoquine for 6 months. Blood samples were collected from each subject after the last loading dose and then at weeks 4, 8, and 16. Plasma tafenoquine concentrations were determined by liquid chromatography‐tandem mass spectrometry. Population modeling was performed with NONMEM, using a one‐compartment model. Typical values of the first‐order absorption rate constant (K(a)), clearance (CL/F), and volume of distribution (V/F) were 0.243 h(‐1), 0.056 liters/h/kg, and 23.7 liters/kg, respectively. The intersubject variability (coefficient of variation) in CL/F and V/F was 18% and 22%, respectively. The interoccasion variability in CL/F was 18%, and the mean elimination half‐life was 12.7 days. A positive linear association between weight and both CL/F and V/F was found, but this had insufficient impact to warrant dosage adjustments. Model robustness was assessed by a nonparametric bootstrap (200 samples). A degenerate visual predictive check indicated that the raw data mirrored the postdose concentration‐time profiles simulated (n = 1,000) from the final model. Individual pharmacokinetic estimates for tafenoquine did not predict the prophylactic outcome with the drug for four subjects who relapsed with Plasmodium vivax malaria, as they had similar pharmacokinetics to those who were free of malaria infection. No obvious pattern existed between the plasma tafenoquine concentration and the pharmacokinetic parameter values for subjects with and without drug‐associated moderate or severe adverse events. This validated population pharmacokinetic model satisfactorily describes the disposition and variability of tafenoquine used for long‐term malaria prophylaxis in a large cohort of soldiers on military deployment.</style></abstract><caption><style face="normal" font="default" size="100%">Duplicate</style></caption><work-type><style face="normal" font="default" size="100%">Journal Article; Randomized Controlled Trial; Research Support, Non‐U.S. Gov&apos;t; Research Support, U.S. Gov&apos;t, Non‐P.H.S.</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.cochranelibrary.com/central/doi/10.1002/central/CN-00609839/full</style></url></related-urls></urls><custom3><style face="normal" font="default" size="100%">PUBMED 17517850</style></custom3><electronic-resource-num><style face="normal" font="default" size="100%">10.1128/AAC.01183-06</style></electronic-resource-num></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>72</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">72</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Edstein, M. D.</style></author><author><style face="normal" font="default" size="100%">Kocisko, D. A.</style></author><author><style face="normal" font="default" size="100%">Brewer, T. G.</style></author><author><style face="normal" font="default" size="100%">Walsh, D. S.</style></author><author><style face="normal" font="default" size="100%">Eamsila, C.</style></author><author><style face="normal" font="default" size="100%">Charles, B. G.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pharmacology, Australian Army Malaria Institute, Enoggera, QLD, Australia. Mike.Edstein@defence.gov.au</style></auth-address><titles><title><style face="normal" font="default" size="100%">Population pharmacokinetics of the new antimalarial agent tafenoquine in Thai soldiers</style></title><secondary-title><style face="normal" font="default" size="100%">Br J Clin Pharmacol</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">British journal of clinical pharmacology</style></full-title><abbr-1><style face="normal" font="default" size="100%">Br J Clin Pharmacol</style></abbr-1></periodical><pages><style face="normal" font="default" size="100%">663-70</style></pages><volume><style face="normal" font="default" size="100%">52</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2001/12/12</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Administration, Oral</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Aminoquinolines/blood/chemistry/*pharmacokinetics</style></keyword><keyword><style face="normal" font="default" size="100%">Antimalarials/administration &amp; dosage/blood/*pharmacokinetics</style></keyword><keyword><style face="normal" font="default" size="100%">*Artemisinins</style></keyword><keyword><style face="normal" font="default" size="100%">Artesunate</style></keyword><keyword><style face="normal" font="default" size="100%">Computer Simulation</style></keyword><keyword><style face="normal" font="default" size="100%">Doxycycline/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Half-Life</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Malaria, Vivax/drug therapy/*prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Metabolic Clearance Rate</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Military Personnel</style></keyword><keyword><style face="normal" font="default" size="100%">Models, Biological</style></keyword><keyword><style face="normal" font="default" size="100%">Observer Variation</style></keyword><keyword><style face="normal" font="default" size="100%">Sesquiterpenes/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Thailand</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2001</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0306-5251 (Print)&#xD;0306-5251</style></isbn><accession-num><style face="normal" font="default" size="100%">11736877</style></accession-num><abstract><style face="normal" font="default" size="100%">AIMS: To describe the population pharmacokinetics of tafenoquine in healthy volunteers after receiving tafenoquine for malaria prophylaxis. METHODS: The population consisted of 135 male Thai soldiers (mean age 28.9 years; weight 60.3 kg). All soldiers were presumptively treated with artesunate for 3 days plus doxycycline for 7 days to remove any pre-existing malaria infections. After the treatment regime, 104 soldiers (drug group) received a loading dose of 400 mg tafenoquine base daily for 3 days followed by 400 mg tafenoquine monthly for 5 consecutive months. In the placebo group, 31 soldiers were infected with malaria during the study period. They were re-treated with artesunate for 3 days plus doxycycline for 7 days followed by a loading dose of 400 mg tafenoquine daily for 3 days and then 400 mg tafenoquine weekly for prophylaxis. Blood samples were randomly collected from each soldier on monthly and weekly prophylaxis. Plasma tafenoquine concentrations were measured by h.p.l.c. Population pharmacokinetic modelling was performed using NONMEM. RESULTS: A one-compartment model was found best to describe the pharmacokinetics of tafenoquine after oral administration. Age and weight influenced volume of distribution (V/F), and subjects who contracted malaria had higher clearance (CL/F), but none of these factors was considered to have sufficient impact to warrant change in dosing. The population estimates of the first-order absorption rate constant (Ka), CL/F and V/F were 0.694 h(-1), 3.20 l h(-1) and 1820 l, respectively. The intersubject variability in these parameters (coefficient of variation, CV%) was 61.2%, 25.3% and 14.8%, respectively. The absorption and elimination half-lives were 1.0 h and 16.4 days, respectively. The residual (unexplained) variability was 17.9%. CONCLUSIONS: The population pharmacokinetics of orally administered tafenoquine have been determined in Thai soldiers under field conditions. This information, together with its known potent antimalarial activity, portends well for the application of tafenoquine as a useful prophylactic drug or for short-term radical treatment of vivax malaria.</style></abstract><caption><style face="normal" font="default" size="100%">Duplicate</style></caption><notes><style face="normal" font="default" size="100%">1365-2125&#xD;Edstein, M D&#xD;Kocisko, D A&#xD;Brewer, T G&#xD;Walsh, D S&#xD;Eamsila, C&#xD;Charles, B G&#xD;Clinical Trial&#xD;Journal Article&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Br J Clin Pharmacol. 2001 Dec;52(6):663-70. doi: 10.1046/j.0306-5251.2001.01482.x.</style></notes><urls></urls><custom2><style face="normal" font="default" size="100%">PMC2014562</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1046/j.0306-5251.2001.01482.x</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>137</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">137</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Edstein, M. D.</style></author><author><style face="normal" font="default" size="100%">Kocisko, D. A.</style></author><author><style face="normal" font="default" size="100%">Brewer, T. G.</style></author><author><style face="normal" font="default" size="100%">Walsh, D. S.</style></author><author><style face="normal" font="default" size="100%">Eamsila, C.</style></author><author><style face="normal" font="default" size="100%">Charles, B. G.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">M.D. Edstein, Australian Army Malaria Institute, Enoggera, QLD 4052, Australia</style></auth-address><titles><title><style face="normal" font="default" size="100%">Population pharmacokinetics of the new antimalarial agent tafenoquine in Thai soldiers</style></title><secondary-title><style face="normal" font="default" size="100%">British Journal of Clinical Pharmacology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">British journal of clinical pharmacology</style></full-title><abbr-1><style face="normal" font="default" size="100%">Br J Clin Pharmacol</style></abbr-1></periodical><pages><style face="normal" font="default" size="100%">663-670</style></pages><volume><style face="normal" font="default" size="100%">52</style></volume><number><style face="normal" font="default" size="100%">6</style></number><keywords><keyword><style face="normal" font="default" size="100%">antimalarial agent</style></keyword><keyword><style face="normal" font="default" size="100%">artesunate</style></keyword><keyword><style face="normal" font="default" size="100%">doxycycline</style></keyword><keyword><style face="normal" font="default" size="100%">tafenoquine</style></keyword><keyword><style face="normal" font="default" size="100%">adult</style></keyword><keyword><style face="normal" font="default" size="100%">article</style></keyword><keyword><style face="normal" font="default" size="100%">blood sampling</style></keyword><keyword><style face="normal" font="default" size="100%">compartment model</style></keyword><keyword><style face="normal" font="default" size="100%">controlled study</style></keyword><keyword><style face="normal" font="default" size="100%">disease course</style></keyword><keyword><style face="normal" font="default" size="100%">dose response</style></keyword><keyword><style face="normal" font="default" size="100%">drug absorption</style></keyword><keyword><style face="normal" font="default" size="100%">drug blood level</style></keyword><keyword><style face="normal" font="default" size="100%">drug clearance</style></keyword><keyword><style face="normal" font="default" size="100%">drug distribution</style></keyword><keyword><style face="normal" font="default" size="100%">drug elimination</style></keyword><keyword><style face="normal" font="default" size="100%">drug half life</style></keyword><keyword><style face="normal" font="default" size="100%">high performance liquid chromatography</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">infection prevention</style></keyword><keyword><style face="normal" font="default" size="100%">malaria</style></keyword><keyword><style face="normal" font="default" size="100%">male</style></keyword><keyword><style face="normal" font="default" size="100%">normal human</style></keyword><keyword><style face="normal" font="default" size="100%">priority journal</style></keyword><keyword><style face="normal" font="default" size="100%">military personnel</style></keyword><keyword><style face="normal" font="default" size="100%">Thailand</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2001</style></year></dates><isbn><style face="normal" font="default" size="100%">0306-5251</style></isbn><abstract><style face="normal" font="default" size="100%">Aims: To describe the population pharmacokinetics of tafenoquine in healthy volunteers after receiving tafenoquine for malaria prophylaxis. Methods: The population consisted of 135 male Thai soldiers (mean age 28.9 years; weight 60.3 kg). All soldiers were presumptively treated with artesunate for 3 days plus doxycycline for 7 days to remove any pre-existing malaria infections. After the treatment regime, 104 soldiers (drug group) received a loading dose of 400 mg tafenoquine base daily for 3 days followed by 400 mg tafenoquine monthly for 5 consecutive months. In the placebo group, 31 soldiers were infected with malaria during the study period. They were re-treated with artesunate for 3 days plus doxycycline for 7 days followed by a loading dose of 400 mg tafenoquine daily for 3 days and then 400 mg tafenoquine weekly for prophylaxis. Blood samples were randomly collected from each soldier on monthly and weekly prophylaxis. Plasma tafenoquine concentrations were measured by h.p.l.c. Population pharmacokinetic modelling was performed using NONMEM. Results: A one-compartment model was found best to describe the pharmacokinetics of tafenoquine after oral administration. Age and weight influenced volume of distribution (V/F), and subjects who contracted malaria had higher clearance (CL/F), but none of these factors was considered to have sufficient impact to warrant change in dosing. The population estimates of the first-order absorption rate constant (Ka), CL/F and V/F were 0.694 h-1, 3.20 l h-1 and 1820 l, respectively. The intersubject variability in these parameters (coefficient of variation, CV%) was 61.2%, 25.3% and 14.8%, respectively. The absorption and elimination half-lives were 1.0 h and 16.4 days, respectively. The residual (unexplained) variability was 17.9%. Conclusions: The population pharmacokinetics of orally administered tafenoquine have been determined in Thai soldiers under field conditions. This information, together with its known potent antimalarial activity, portends well for the application of tafenoquine as a useful prophylactic drug or for short-term radical treatment of vivax malaria.</style></abstract><caption><style face="normal" font="default" size="100%">Duplicate</style></caption><notes><style face="normal" font="default" size="100%">L34015624&#xD;2002-01-10</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L34015624&amp;from=export</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1046/j.0306-5251.2001.01482.x</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">Glaxo SmithKline(United Kingdom)</style></custom2><custom5><style face="normal" font="default" size="100%">11736877</style></custom5><electronic-resource-num><style face="normal" font="default" size="100%">10.1046/j.0306-5251.2001.01482.x</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase&#xD;Medline</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>177</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">177</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Edstein, M. D.</style></author><author><style face="normal" font="default" size="100%">Kocisko, D. A.</style></author><author><style face="normal" font="default" size="100%">Brewer, T. G.</style></author><author><style face="normal" font="default" size="100%">Walsh, D. S.</style></author><author><style face="normal" font="default" size="100%">Eamsila, C.</style></author><author><style face="normal" font="default" size="100%">Charles, B. G.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Population pharmacokinetics of the new antimalarial agent tafenoquine in Thai soldiers</style></title><secondary-title><style face="normal" font="default" size="100%">British journal of clinical pharmacology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">British journal of clinical pharmacology</style></full-title><abbr-1><style face="normal" font="default" size="100%">Br J Clin Pharmacol</style></abbr-1></periodical><pages><style face="normal" font="default" size="100%">663‐670</style></pages><volume><style face="normal" font="default" size="100%">52</style></volume><number><style face="normal" font="default" size="100%">6</style></number><keywords><keyword><style face="normal" font="default" size="100%">*malaria/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">*malaria/pc [Prevention]</style></keyword><keyword><style face="normal" font="default" size="100%">*tafenoquine/an [Drug Analysis]</style></keyword><keyword><style face="normal" font="default" size="100%">*tafenoquine/cr [Drug Concentration]</style></keyword><keyword><style face="normal" font="default" size="100%">*tafenoquine/do [Drug Dose]</style></keyword><keyword><style face="normal" font="default" size="100%">*tafenoquine/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">*tafenoquine/pd [Pharmacology]</style></keyword><keyword><style face="normal" font="default" size="100%">*tafenoquine/pk [Pharmacokinetics]</style></keyword><keyword><style face="normal" font="default" size="100%">*tafenoquine/po [Oral Drug Administration]</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Antimalarial agent/an [Drug Analysis]</style></keyword><keyword><style face="normal" font="default" size="100%">Antimalarial agent/cr [Drug Concentration]</style></keyword><keyword><style face="normal" font="default" size="100%">Antimalarial agent/do [Drug Dose]</style></keyword><keyword><style face="normal" font="default" size="100%">Antimalarial agent/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Antimalarial agent/pd [Pharmacology]</style></keyword><keyword><style face="normal" font="default" size="100%">Antimalarial agent/pk [Pharmacokinetics]</style></keyword><keyword><style face="normal" font="default" size="100%">Antimalarial agent/po [Oral Drug Administration]</style></keyword><keyword><style face="normal" font="default" size="100%">Artesunate/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Article</style></keyword><keyword><style face="normal" font="default" size="100%">Blood sampling</style></keyword><keyword><style face="normal" font="default" size="100%">Compartment model</style></keyword><keyword><style face="normal" font="default" size="100%">Controlled study</style></keyword><keyword><style face="normal" font="default" size="100%">Disease course</style></keyword><keyword><style face="normal" font="default" size="100%">Dose response</style></keyword><keyword><style face="normal" font="default" size="100%">Doxycycline/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Drug absorption</style></keyword><keyword><style face="normal" font="default" size="100%">Drug blood level</style></keyword><keyword><style face="normal" font="default" size="100%">Drug clearance</style></keyword><keyword><style face="normal" font="default" size="100%">Drug distribution</style></keyword><keyword><style face="normal" font="default" size="100%">Drug elimination</style></keyword><keyword><style face="normal" font="default" size="100%">Drug half life</style></keyword><keyword><style face="normal" font="default" size="100%">High performance liquid chromatography</style></keyword><keyword><style face="normal" font="default" size="100%">Human</style></keyword><keyword><style face="normal" font="default" size="100%">Infection prevention</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Normal human</style></keyword><keyword><style face="normal" font="default" size="100%">Priority journal</style></keyword><keyword><style face="normal" font="default" size="100%">Soldier</style></keyword><keyword><style face="normal" font="default" size="100%">Thailand</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2001</style></year></dates><accession-num><style face="normal" font="default" size="100%">CN-00425425</style></accession-num><abstract><style face="normal" font="default" size="100%">Aims: To describe the population pharmacokinetics of tafenoquine in healthy volunteers after receiving tafenoquine for malaria prophylaxis. Methods: The population consisted of 135 male Thai soldiers (mean age 28.9 years; weight 60.3 kg). All soldiers were presumptively treated with artesunate for 3 days plus doxycycline for 7 days to remove any pre‐existing malaria infections. After the treatment regime, 104 soldiers (drug group) received a loading dose of 400 mg tafenoquine base daily for 3 days followed by 400 mg tafenoquine monthly for 5 consecutive months. In the placebo group, 31 soldiers were infected with malaria during the study period. They were re‐treated with artesunate for 3 days plus doxycycline for 7 days followed by a loading dose of 400 mg tafenoquine daily for 3 days and then 400 mg tafenoquine weekly for prophylaxis. Blood samples were randomly collected from each soldier on monthly and weekly prophylaxis. Plasma tafenoquine concentrations were measured by h.p.l.c. Population pharmacokinetic modelling was performed using NONMEM. Results: A one‐compartment model was found best to describe the pharmacokinetics of tafenoquine after oral administration. Age and weight influenced volume of distribution (V/F), and subjects who contracted malaria had higher clearance (CL/F), but none of these factors was considered to have sufficient impact to warrant change in dosing. The population estimates of the first‐order absorption rate constant (Ka), CL/F and V/F were 0.694 h‐1, 3.20 l h‐1 and 1820 l, respectively. The intersubject variability in these parameters (coefficient of variation, CV%) was 61.2%, 25.3% and 14.8%, respectively. The absorption and elimination half‐lives were 1.0 h and 16.4 days, respectively. The residual (unexplained) variability was 17.9%. Conclusions: The population pharmacokinetics of orally administered tafenoquine have been determined in Thai soldiers under field conditions. This information, together with its known potent antimalarial activity, portends well for the application of tafenoquine as a useful prophylactic drug or for short‐term radical treatment of vivax malaria.</style></abstract><caption><style face="normal" font="default" size="100%">Duplicate</style></caption><work-type><style face="normal" font="default" size="100%">Journal: Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.cochranelibrary.com/central/doi/10.1002/central/CN-00425425/full</style></url></related-urls></urls><custom3><style face="normal" font="default" size="100%">EMBASE 34015624</style></custom3><electronic-resource-num><style face="normal" font="default" size="100%">10.1046/j.0306-5251.2001.01482.x</style></electronic-resource-num></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>54</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">54</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Fernando, D.</style></author><author><style face="normal" font="default" size="100%">Rodrigo, C.</style></author><author><style face="normal" font="default" size="100%">Rajapakse, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Parasitology, Faculty of Medicine, University of Colombo, 25, Kynsey Road, Colombo 8, Sri Lanka. ferndeep@gmail.com</style></auth-address><titles><title><style face="normal" font="default" size="100%">Primaquine in vivax malaria: an update and review on management issues</style></title><secondary-title><style face="normal" font="default" size="100%">Malar J</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Malar J</style></full-title></periodical><pages><style face="normal" font="default" size="100%">351</style></pages><volume><style face="normal" font="default" size="100%">10</style></volume><edition><style face="normal" font="default" size="100%">2011/12/14</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Aminoquinolines/administration &amp; dosage/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Antimalarials/administration &amp; dosage/*therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Artemisinins/administration &amp; dosage/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Chloroquine/administration &amp; dosage/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Clinical Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Resistance</style></keyword><keyword><style face="normal" font="default" size="100%">Glycogen Storage Disease Type I/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Hemolysis</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Malaria, Vivax/*drug therapy/parasitology/*prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Plasmodium vivax/*pathogenicity</style></keyword><keyword><style face="normal" font="default" size="100%">Primaquine/administration &amp; dosage/adverse effects/*therapeutic use</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2011</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec 12</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1475-2875</style></isbn><accession-num><style face="normal" font="default" size="100%">22152065</style></accession-num><abstract><style face="normal" font="default" size="100%">Primaquine was officially licensed as an anti-malarial drug by the FDA in 1952. It has remained the only FDA licensed drug capable of clearing the intra-hepatic schizonts and hypnozoites of Plasmodium vivax. This update and review focuses on five major aspects of primaquine use in treatment of vivax malaria, namely: a) evidence of efficacy of primaquine for its current indications; b) potential hazards of its widespread use, c) critical analysis of reported resistance against primaquine containing regimens; d) evidence for combining primaquine with artemisinins in areas of chloroquine resistance; and e) the potential for replacement of primaquine with newer drugs.</style></abstract><notes><style face="normal" font="default" size="100%">1475-2875&#xD;Fernando, Deepika&#xD;Rodrigo, Chaturaka&#xD;Rajapakse, Senaka&#xD;Journal Article&#xD;Review&#xD;Malar J. 2011 Dec 12;10:351. doi: 10.1186/1475-2875-10-351.</style></notes><urls></urls><custom2><style face="normal" font="default" size="100%">PMC3306765</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1186/1475-2875-10-351</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>105</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">105</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Rodrigo, C.</style></author><author><style face="normal" font="default" size="100%">Rajapakse, S.</style></author><author><style face="normal" font="default" size="100%">Fernando, S. D.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">C. Rodrigo, Faculty of Medicine, University of Colombo, Department of Clinical Medicine, 25. Kynsey Road, Colombo, Sri Lanka</style></auth-address><titles><title><style face="normal" font="default" size="100%">Primaquine or tafenoquine for preventing malaria in people travelling to or living in endemic areas</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><volume><style face="normal" font="default" size="100%">2016</style></volume><number><style face="normal" font="default" size="100%">6</style></number><keywords><keyword><style face="normal" font="default" size="100%">glucose 6 phosphate dehydrogenase</style></keyword><keyword><style face="normal" font="default" size="100%">primaquine</style></keyword><keyword><style face="normal" font="default" size="100%">tafenoquine</style></keyword><keyword><style face="normal" font="default" size="100%">clinical assessment</style></keyword><keyword><style face="normal" font="default" size="100%">comparative effectiveness</style></keyword><keyword><style face="normal" font="default" size="100%">drug dose regimen</style></keyword><keyword><style face="normal" font="default" size="100%">drug effect</style></keyword><keyword><style face="normal" font="default" size="100%">drug efficacy</style></keyword><keyword><style face="normal" font="default" size="100%">drug safety</style></keyword><keyword><style face="normal" font="default" size="100%">endemic disease</style></keyword><keyword><style face="normal" font="default" size="100%">gametocyte</style></keyword><keyword><style face="normal" font="default" size="100%">glucose 6 phosphate dehydrogenase deficiency</style></keyword><keyword><style face="normal" font="default" size="100%">high risk population</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">malaria</style></keyword><keyword><style face="normal" font="default" size="100%">malaria falciparum</style></keyword><keyword><style face="normal" font="default" size="100%">medication compliance</style></keyword><keyword><style face="normal" font="default" size="100%">morbidity</style></keyword><keyword><style face="normal" font="default" size="100%">mortality</style></keyword><keyword><style face="normal" font="default" size="100%">open study</style></keyword><keyword><style face="normal" font="default" size="100%">outcome assessment</style></keyword><keyword><style face="normal" font="default" size="100%">parasitemia</style></keyword><keyword><style face="normal" font="default" size="100%">Plasmodium falciparum</style></keyword><keyword><style face="normal" font="default" size="100%">Plasmodium vivax</style></keyword><keyword><style face="normal" font="default" size="100%">Plasmodium vivax malaria</style></keyword><keyword><style face="normal" font="default" size="100%">priority journal</style></keyword><keyword><style face="normal" font="default" size="100%">prophylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">publishing</style></keyword><keyword><style face="normal" font="default" size="100%">randomized controlled trial (topic)</style></keyword><keyword><style face="normal" font="default" size="100%">review</style></keyword><keyword><style face="normal" font="default" size="100%">risk assessment</style></keyword><keyword><style face="normal" font="default" size="100%">risk factor</style></keyword><keyword><style face="normal" font="default" size="100%">sensitivity analysis</style></keyword><keyword><style face="normal" font="default" size="100%">travel</style></keyword><keyword><style face="normal" font="default" size="100%">treatment outcome</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2016</style></year></dates><isbn><style face="normal" font="default" size="100%">1361-6137&#xD;1469-493X</style></isbn><abstract><style face="normal" font="default" size="100%">This is the protocol for a review and there is no abstract. The objectives are as follows: To assess the effectiveness of primaquine and tafenoquine for primary prophylaxis againstPlasmodium vivax andPlasmodium falciparum infections. To assess the effectiveness of tafenoquine for terminal prophylaxis of vivax malaria. To compare the safety profile and compliance rates of tafenoquine and primaquine when used for primary (P. vivax and P. falciparum infections) and terminal (P. vivax infections) prophylaxis.</style></abstract><notes><style face="normal" font="default" size="100%">L610638104&#xD;2016-06-14&#xD;2016-06-27</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L610638104&amp;from=export</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1002/14651858.CD012242</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD012242</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>80</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">80</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kain, K. C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Tropical Disease Unit, Division of Infectious Diseases, Department of Medicine, The Toronto Hospital, University of Toronto,Toronto, Canada.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Prophylactic drugs for malaria: why do we need another one?</style></title><secondary-title><style face="normal" font="default" size="100%">J Travel Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Travel Med</style></full-title></periodical><pages><style face="normal" font="default" size="100%">S2-7</style></pages><volume><style face="normal" font="default" size="100%">6 Suppl 1</style></volume><edition><style face="normal" font="default" size="100%">1999/05/01</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Antimalarials/*therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Atovaquone/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Chemoprevention/*methods</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Chloroquine/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Developed Countries</style></keyword><keyword><style face="normal" font="default" size="100%">Developing Countries</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Combinations</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Guidelines as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Malaria/*drug therapy/*prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Patient Compliance/statistics &amp; numerical data</style></keyword><keyword><style face="normal" font="default" size="100%">Pregnancy</style></keyword><keyword><style face="normal" font="default" size="100%">Pregnancy Complications, Parasitic/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Proguanil/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Factors</style></keyword><keyword><style face="normal" font="default" size="100%">*Travel</style></keyword><keyword><style face="normal" font="default" size="100%">Travel Medicine/standards</style></keyword><keyword><style face="normal" font="default" size="100%">Young Adult</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">1999</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1195-1982 (Print)&#xD;1195-1982</style></isbn><accession-num><style face="normal" font="default" size="100%">23573545</style></accession-num><abstract><style face="normal" font="default" size="100%">There are currently a limited number of drugs available to prevent malaria in travelers, and new, more efficacious, and better tolerated regimens are urgently needed. Clearly, none of the available regimens are ideal for all travelers, and the travel medicine practitioner should attempt to match the individual&apos;s risk of exposure to malaria with the appropriate regimen based on drug efficacy, tolerance, and safety. To facilitate decision making, we have generated a Clinical Utility Score, in which different attributes of each drug regimen, such as efficacy, tolerance, convenience, cost, etc., are estimated based on our experience with these drugs (see Table 1). Other groups and users may weight each variable somewhat differently depending on the specific needs and risk of drug-resistant malaria. For example, a traveler to rural Irian Jaya may weight efficacy more heavily than cost or convenience. Using this scoring strategy, new agents like atovaquone/proguanil and WR 238605 compare favorably to our current options, indicating their potential to fill important holes in our chemoprophylactic arsenal.</style></abstract><notes><style face="normal" font="default" size="100%">Kain, K C&#xD;Journal Article&#xD;England&#xD;J Travel Med. 1999 May;6 Suppl 1:S2-7.</style></notes><urls></urls><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>102</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">102</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kolifarhood, G.</style></author><author><style face="normal" font="default" size="100%">Raeisi, A.</style></author><author><style face="normal" font="default" size="100%">Ranjbar, M.</style></author><author><style face="normal" font="default" size="100%">Haghdoust, A. A.</style></author><author><style face="normal" font="default" size="100%">Schapira, A.</style></author><author><style face="normal" font="default" size="100%">Hashemi, S.</style></author><author><style face="normal" font="default" size="100%">Masoumi-Asl, H.</style></author><author><style face="normal" font="default" size="100%">Mozafar Saadati, H.</style></author><author><style face="normal" font="default" size="100%">Azimi, S.</style></author><author><style face="normal" font="default" size="100%">Khosravi, N.</style></author><author><style face="normal" font="default" size="100%">Kondrashin, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">A. Raeisi, Department of Medical Parasitology and Mycology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran</style></auth-address><titles><title><style face="normal" font="default" size="100%">Prophylactic efficacy of primaquine for preventing Plasmodium falciparum and Plasmodium vivax parasitaemia in travelers: A meta-analysis and systematic review</style></title><secondary-title><style face="normal" font="default" size="100%">Travel Medicine and Infectious Disease</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Travel Medicine and Infectious Disease</style></full-title></periodical><pages><style face="normal" font="default" size="100%">5-18</style></pages><volume><style face="normal" font="default" size="100%">17</style></volume><keywords><keyword><style face="normal" font="default" size="100%">atovaquone plus proguanil</style></keyword><keyword><style face="normal" font="default" size="100%">chloroquine</style></keyword><keyword><style face="normal" font="default" size="100%">chloroquine plus proguanil</style></keyword><keyword><style face="normal" font="default" size="100%">doxycycline</style></keyword><keyword><style face="normal" font="default" size="100%">mefloquine</style></keyword><keyword><style face="normal" font="default" size="100%">placebo</style></keyword><keyword><style face="normal" font="default" size="100%">primaquine</style></keyword><keyword><style face="normal" font="default" size="100%">proguanil</style></keyword><keyword><style face="normal" font="default" size="100%">tafenoquine</style></keyword><keyword><style face="normal" font="default" size="100%">adverse outcome</style></keyword><keyword><style face="normal" font="default" size="100%">chemoprophylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">confidence interval</style></keyword><keyword><style face="normal" font="default" size="100%">drug efficacy</style></keyword><keyword><style face="normal" font="default" size="100%">gastrointestinal symptom</style></keyword><keyword><style face="normal" font="default" size="100%">glucose 6 phosphate dehydrogenase deficiency</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">incidence</style></keyword><keyword><style face="normal" font="default" size="100%">infection prevention</style></keyword><keyword><style face="normal" font="default" size="100%">malaria falciparum</style></keyword><keyword><style face="normal" font="default" size="100%">mental disease</style></keyword><keyword><style face="normal" font="default" size="100%">meta analysis</style></keyword><keyword><style face="normal" font="default" size="100%">parasitemia</style></keyword><keyword><style face="normal" font="default" size="100%">Plasmodium vivax</style></keyword><keyword><style face="normal" font="default" size="100%">Plasmodium vivax malaria</style></keyword><keyword><style face="normal" font="default" size="100%">priority journal</style></keyword><keyword><style face="normal" font="default" size="100%">randomized controlled trial (topic)</style></keyword><keyword><style face="normal" font="default" size="100%">review</style></keyword><keyword><style face="normal" font="default" size="100%">systematic review</style></keyword><keyword><style face="normal" font="default" size="100%">travel</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2017</style></year></dates><isbn><style face="normal" font="default" size="100%">1873-0442&#xD;1477-8939</style></isbn><abstract><style face="normal" font="default" size="100%">Background With increased international travel over the world the need for safe and effective chemoprophylaxis for malaria is as great as ever. The choice of regimen is difficult, as effectiveness should be weighted against potential adverse effects. Although, some studies have reported high prophylactic efficacy of primaquine, there is no comprehensive evidence comparing its prophylactic effectiveness as well as toxicity. To fill the gap, this systematic review and meta-analysis study was carried out. Methods Using MeSH terms, 756 records were detected through searching “Pubmed”, “Embase”,”Web of Science”and “Cochrane” databases. From these,7 relevant full-text articles with 14 comparisons for final quantitative meta-analysis were included in our review. In order to make a comparison between the studies, Risk Ratios(RRs) and their 95% confidence intervals(CIs) were estimated. Results Overall,74% reduction in the incidence of parasitaemia by primaquine versus other prophylactic regimens was estimated(RRoverall = 0.26, CI 95%:0.16–0.41–RRvivax = 0.16, CI 95%:0.07–0.36–RRfalciparum = 0.31, CI 95%:0.18–0.55). The incidence rate ratios for adverse effects showed no statistically significant difference between primaquine and control groups (p &gt; 0.05). Conclusions For persons without G6PD deficiency, who are not pregnant, primaquine is the most effective presently available prophylactic for P. vivax malaria and comparable to such regimens as doxycycline, mefloquine and atovaquone-proguanil for the prevention of P. falciparum malaria.</style></abstract><notes><style face="normal" font="default" size="100%">L616889348&#xD;2017-06-26&#xD;2017-07-13</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L616889348&amp;from=export</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1016/j.tmaid.2017.04.005</style></url></related-urls></urls><custom5><style face="normal" font="default" size="100%">28450185</style></custom5><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.tmaid.2017.04.005</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase&#xD;Medline</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>82</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">82</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Brueckner, R. P.</style></author><author><style face="normal" font="default" size="100%">Coster, T.</style></author><author><style face="normal" font="default" size="100%">Wesche, D. L.</style></author><author><style face="normal" font="default" size="100%">Shmuklarsky, M.</style></author><author><style face="normal" font="default" size="100%">Schuster, B. G.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Experimental Therapeutics, Walter Reed Army Institute of Research, Washington, DC 20307-5100, USA. LTC_Ralf_Brueckner@WRSMTP-ccMail.Army.Mil</style></auth-address><titles><title><style face="normal" font="default" size="100%">Prophylaxis of Plasmodium falciparum infection in a human challenge model with WR 238605, a new 8-aminoquinoline antimalarial</style></title><secondary-title><style face="normal" font="default" size="100%">Antimicrob Agents Chemother</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Antimicrob Agents Chemother</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1293-4</style></pages><volume><style face="normal" font="default" size="100%">42</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">1998/05/21</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Aminoquinolines/chemistry/*therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Antimalarials/chemistry/*therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Double-Blind Method</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Malaria, Falciparum/*prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Plasmodium falciparum/*drug effects/pathogenicity</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">1998</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0066-4804 (Print)&#xD;0066-4804</style></isbn><accession-num><style face="normal" font="default" size="100%">9593172</style></accession-num><abstract><style face="normal" font="default" size="100%">The prophylactic efficacy of WR 238605, a primaquine analog, was studied with a human Plasmodium falciparum challenge model. A single oral dose of 600 mg, administered 1 day prior to challenge, successfully protected three of four subjects. The fourth subject developed mild, oligosymptomatic malaria on day 31, with drug concentrations one-half of those in the protected individuals. WR 238605 appears to be a promising prophylactic drug for P. falciparum malaria.</style></abstract><caption><style face="normal" font="default" size="100%">Duplicate</style></caption><notes><style face="normal" font="default" size="100%">1098-6596&#xD;Brueckner, R P&#xD;Coster, T&#xD;Wesche, D L&#xD;Shmuklarsky, M&#xD;Schuster, B G&#xD;Clinical Trial&#xD;Journal Article&#xD;Randomized Controlled Trial&#xD;Research Support, U.S. Gov&apos;t, Non-P.H.S.&#xD;Antimicrob Agents Chemother. 1998 May;42(5):1293-4. doi: 10.1128/AAC.42.5.1293.</style></notes><urls></urls><custom2><style face="normal" font="default" size="100%">PMC105811</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1128/aac.42.5.1293</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>144</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">144</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Brueckner, R. P.</style></author><author><style face="normal" font="default" size="100%">Coster, T.</style></author><author><style face="normal" font="default" size="100%">Wesche, D. L.</style></author><author><style face="normal" font="default" size="100%">Shmuklarsky, M.</style></author><author><style face="normal" font="default" size="100%">Schuster, B. G.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">R.P. Brueckner, Department of Pharmacology, Div. of Experimental Therapeutics, Walter Reed Army Inst. of Research, Washington, DC 20307-5100, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Prophylaxis of Plasmodium falciparum infection in a human challenge model with WR 238605, a new 8-aminoquinoline antimalarial</style></title><secondary-title><style face="normal" font="default" size="100%">Antimicrobial Agents and Chemotherapy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Antimicrobial Agents and Chemotherapy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1293-1294</style></pages><volume><style face="normal" font="default" size="100%">42</style></volume><number><style face="normal" font="default" size="100%">5</style></number><keywords><keyword><style face="normal" font="default" size="100%">aralen phosphate tablet</style></keyword><keyword><style face="normal" font="default" size="100%">chloroquine</style></keyword><keyword><style face="normal" font="default" size="100%">doxycycline</style></keyword><keyword><style face="normal" font="default" size="100%">mefloquine</style></keyword><keyword><style face="normal" font="default" size="100%">primaquine</style></keyword><keyword><style face="normal" font="default" size="100%">tafenoquine</style></keyword><keyword><style face="normal" font="default" size="100%">unclassified drug</style></keyword><keyword><style face="normal" font="default" size="100%">adult</style></keyword><keyword><style face="normal" font="default" size="100%">antibiotic prophylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">article</style></keyword><keyword><style face="normal" font="default" size="100%">blood smear</style></keyword><keyword><style face="normal" font="default" size="100%">clinical article</style></keyword><keyword><style face="normal" font="default" size="100%">clinical trial</style></keyword><keyword><style face="normal" font="default" size="100%">controlled clinical trial</style></keyword><keyword><style face="normal" font="default" size="100%">controlled study</style></keyword><keyword><style face="normal" font="default" size="100%">double blind procedure</style></keyword><keyword><style face="normal" font="default" size="100%">drug efficacy</style></keyword><keyword><style face="normal" font="default" size="100%">drug elimination</style></keyword><keyword><style face="normal" font="default" size="100%">drug half life</style></keyword><keyword><style face="normal" font="default" size="100%">drug structure</style></keyword><keyword><style face="normal" font="default" size="100%">female</style></keyword><keyword><style face="normal" font="default" size="100%">gastrointestinal symptom</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">malaria</style></keyword><keyword><style face="normal" font="default" size="100%">male</style></keyword><keyword><style face="normal" font="default" size="100%">oral drug administration</style></keyword><keyword><style face="normal" font="default" size="100%">Plasmodium falciparum</style></keyword><keyword><style face="normal" font="default" size="100%">priority journal</style></keyword><keyword><style face="normal" font="default" size="100%">randomized controlled trial</style></keyword><keyword><style face="normal" font="default" size="100%">treatment indication</style></keyword><keyword><style face="normal" font="default" size="100%">treatment outcome</style></keyword><keyword><style face="normal" font="default" size="100%">wr 238605</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">1998</style></year></dates><isbn><style face="normal" font="default" size="100%">0066-4804</style></isbn><abstract><style face="normal" font="default" size="100%">The prophylactic efficacy of WR 238605, a primaquine analog, was studied with a human Plasmodium falciparum challenge model. A single oral dose of 600 mg, administered 1 day prior to challenge, successfully protected three of four subjects. The fourth subject developed mild, oligosymptomatic malaria on day 31, with drug concentrations one-half of those in the protected individuals. WR 238605 appears to be a promising prophylactic drug for P. falciparum malaria.</style></abstract><caption><style face="normal" font="default" size="100%">Duplicate</style></caption><notes><style face="normal" font="default" size="100%">L28227942&#xD;1998-06-15</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L28227942&amp;from=export</style></url></related-urls></urls><custom1><style face="normal" font="default" size="100%">aralen phosphate tablet(Sanofi Winthrop)&#xD;wr 238605(Walter Reed)</style></custom1><custom2><style face="normal" font="default" size="100%">Sanofi Winthrop&#xD;Walter Reed</style></custom2><custom5><style face="normal" font="default" size="100%">9593172</style></custom5><remote-database-name><style face="normal" font="default" size="100%">Embase&#xD;Medline</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>148</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">148</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Brueckner, R. P.</style></author><author><style face="normal" font="default" size="100%">Coster, T.</style></author><author><style face="normal" font="default" size="100%">Wesche, D. L.</style></author><author><style face="normal" font="default" size="100%">Shmuklarsky, M.</style></author><author><style face="normal" font="default" size="100%">Schuster, B. G.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Prophylaxis of Plasmodium falciparum infection in a human challenge model with WR 238605, a new 8-aminoquinoline antimalarial</style></title><secondary-title><style face="normal" font="default" size="100%">Antimicrobial agents and chemotherapy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Antimicrobial Agents and Chemotherapy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1293‐1294</style></pages><volume><style face="normal" font="default" size="100%">42</style></volume><number><style face="normal" font="default" size="100%">5</style></number><keywords><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Aminoquinolines [chemistry, *therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Antimalarials [chemistry, *therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Double‐Blind Method</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Malaria, Falciparum [*prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Plasmodium falciparum [*drug effects, pathogenicity]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">1998</style></year></dates><accession-num><style face="normal" font="default" size="100%">CN-00683342</style></accession-num><abstract><style face="normal" font="default" size="100%">The prophylactic efficacy of WR 238605, a primaquine analog, was studied with a human Plasmodium falciparum challenge model. A single oral dose of 600 mg, administered 1 day prior to challenge, successfully protected three of four subjects. The fourth subject developed mild, oligosymptomatic malaria on day 31, with drug concentrations one‐half of those in the protected individuals. WR 238605 appears to be a promising prophylactic drug for P. falciparum malaria.</style></abstract><caption><style face="normal" font="default" size="100%">Duplicate</style></caption><work-type><style face="normal" font="default" size="100%">Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, U.S. Gov&apos;t, Non‐P.H.S.</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.cochranelibrary.com/central/doi/10.1002/central/CN-00683342/full</style></url></related-urls></urls><custom3><style face="normal" font="default" size="100%">PUBMED 9593172</style></custom3><electronic-resource-num><style face="normal" font="default" size="100%">10.1128/AAC.42.5.1293</style></electronic-resource-num></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>43</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">43</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Frances, S. P.</style></author><author><style face="normal" font="default" size="100%">Edstein, M. D.</style></author><author><style face="normal" font="default" size="100%">Debboun, M.</style></author><author><style face="normal" font="default" size="100%">Shanks, G. D.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Australian Army Malaria Institute, Enoggera, Queensland, Australia.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Protection of Military Personnel Against Vector-Borne Diseases: A Review of Collaborative Work of the Australian and US Military Over the Last 30 Years</style></title><secondary-title><style face="normal" font="default" size="100%">US Army Med Dep J</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">US Army Med Dep J</style></full-title></periodical><pages><style face="normal" font="default" size="100%">14-21</style></pages><number><style face="normal" font="default" size="100%">3-16</style></number><edition><style face="normal" font="default" size="100%">2016/09/11</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Aminoquinolines/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Australia/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Dengue/drug therapy/epidemiology/prevention &amp; control/transmission</style></keyword><keyword><style face="normal" font="default" size="100%">*Disease Vectors</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Internationality</style></keyword><keyword><style face="normal" font="default" size="100%">Malaria/drug therapy/prevention &amp; control/transmission</style></keyword><keyword><style face="normal" font="default" size="100%">*Military Personnel</style></keyword><keyword><style face="normal" font="default" size="100%">United States/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Australia</style></keyword><keyword><style face="normal" font="default" size="100%">Malaysia</style></keyword><keyword><style face="normal" font="default" size="100%">Thailand</style></keyword><keyword><style face="normal" font="default" size="100%">drug development</style></keyword><keyword><style face="normal" font="default" size="100%">malaria</style></keyword><keyword><style face="normal" font="default" size="100%">personal protection</style></keyword><keyword><style face="normal" font="default" size="100%">scrub typhus</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2016</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct-Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1524-0436</style></isbn><accession-num><style face="normal" font="default" size="100%">27613205</style></accession-num><abstract><style face="normal" font="default" size="100%">Australian and US military medical services have collaborated since World War II to minimize vector-borne diseases such as malaria, dengue, and scrub typhus. In this review, collaboration over the last 30 years is discussed. The collaborative projects and exchange scientist programs have resulted in mutually beneficial outcomes in the fields of drug development and personal protection measures against vector-borne diseases.</style></abstract><notes><style face="normal" font="default" size="100%">1946-1968&#xD;Frances, Stephen P&#xD;Edstein, Michael D&#xD;Debboun, Mustapha&#xD;Shanks, G Dennis&#xD;Journal Article&#xD;United States&#xD;US Army Med Dep J. 2016 Oct-Dec;(3-16):14-21.</style></notes><urls></urls><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>142</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">142</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Walsh, D. S.</style></author><author><style face="normal" font="default" size="100%">Looareesuwan, S.</style></author><author><style face="normal" font="default" size="100%">Wilairatana, P.</style></author><author><style face="normal" font="default" size="100%">Gray Heppner Jr, D.</style></author><author><style face="normal" font="default" size="100%">Tang, D. B.</style></author><author><style face="normal" font="default" size="100%">Brewer, T. G.</style></author><author><style face="normal" font="default" size="100%">Chokejindachai, W.</style></author><author><style face="normal" font="default" size="100%">Viriyavejakul, P.</style></author><author><style face="normal" font="default" size="100%">Kyle, D. E.</style></author><author><style face="normal" font="default" size="100%">Milhous, W. K.</style></author><author><style face="normal" font="default" size="100%">Schuster, B. G.</style></author><author><style face="normal" font="default" size="100%">Horton, J.</style></author><author><style face="normal" font="default" size="100%">Braitman, D. J.</style></author><author><style face="normal" font="default" size="100%">Brueckner, R. P.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">D.S. Walsh, Department of Immunol. and Medicine, US Army Medical Component, AFRIMS, APO, AP 96546-5000, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Randomized dose-ranging study of the safety and efficacy of WR 238605 (Tafenoquine) in the prevention of relapse of Plasmodium vivax malaria in Thailand</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Infectious Diseases</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Infectious Diseases</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1282-1287</style></pages><volume><style face="normal" font="default" size="100%">180</style></volume><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">antimalarial agent</style></keyword><keyword><style face="normal" font="default" size="100%">chloroquine</style></keyword><keyword><style face="normal" font="default" size="100%">tafenoquine</style></keyword><keyword><style face="normal" font="default" size="100%">adult</style></keyword><keyword><style face="normal" font="default" size="100%">article</style></keyword><keyword><style face="normal" font="default" size="100%">clinical article</style></keyword><keyword><style face="normal" font="default" size="100%">clinical trial</style></keyword><keyword><style face="normal" font="default" size="100%">controlled clinical trial</style></keyword><keyword><style face="normal" font="default" size="100%">controlled study</style></keyword><keyword><style face="normal" font="default" size="100%">drug efficacy</style></keyword><keyword><style face="normal" font="default" size="100%">drug induced disease</style></keyword><keyword><style face="normal" font="default" size="100%">drug safety</style></keyword><keyword><style face="normal" font="default" size="100%">female</style></keyword><keyword><style face="normal" font="default" size="100%">gastrointestinal symptom</style></keyword><keyword><style face="normal" font="default" size="100%">headache</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">malaria</style></keyword><keyword><style face="normal" font="default" size="100%">male</style></keyword><keyword><style face="normal" font="default" size="100%">nonhuman</style></keyword><keyword><style face="normal" font="default" size="100%">priority journal</style></keyword><keyword><style face="normal" font="default" size="100%">protozoal infection</style></keyword><keyword><style face="normal" font="default" size="100%">randomized controlled trial</style></keyword><keyword><style face="normal" font="default" size="100%">relapse</style></keyword><keyword><style face="normal" font="default" size="100%">Thailand</style></keyword><keyword><style face="normal" font="default" size="100%">treatment outcome</style></keyword><keyword><style face="normal" font="default" size="100%">tropical disease</style></keyword><keyword><style face="normal" font="default" size="100%">wr 238605</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">1999</style></year></dates><isbn><style face="normal" font="default" size="100%">0022-1899</style></isbn><abstract><style face="normal" font="default" size="100%">WR 238605 is an 8-aminoquinoline developed for the radical cure of Plasmodium vivax. Forty-four P. vivax-infected patients were randomly assigned to 1 of 4 treatment regimens: 3 groups received a blood schizonticidal dose of chloroquine followed by WR 238605: group A (n = 15) received 300 mg daily for 7 days; group B (n = 11), 500 mg daily for 3 days, repeated 1 week after the initial dose; group C (n = 9), 1 dose of 500 mg. A fourth group (D; n = 9) received chloroquine only. Among patients who completed 2-6 months of follow-up (n = 23), there was 1 relapse in group B (day 120) and 1 in group C (day 112). Among patients treated with chloroquine only, there were 4 relapses (days 40, 43, 49, and 84). WR 238605 was safe, well tolerated, and effective in preventing P. vivax relapse.</style></abstract><caption><style face="normal" font="default" size="100%">Duplicate</style></caption><notes><style face="normal" font="default" size="100%">L30070215&#xD;2000-02-10</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L30070215&amp;from=export</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1086/315034</style></url></related-urls></urls><custom1><style face="normal" font="default" size="100%">wr 238605</style></custom1><custom2><style face="normal" font="default" size="100%">Sterling Winthrop(United States)</style></custom2><custom5><style face="normal" font="default" size="100%">10479159</style></custom5><electronic-resource-num><style face="normal" font="default" size="100%">10.1086/315034</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase&#xD;Medline</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>146</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">146</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Walsh, D. S.</style></author><author><style face="normal" font="default" size="100%">Looareesuwan, S.</style></author><author><style face="normal" font="default" size="100%">Wilairatana, P.</style></author><author><style face="normal" font="default" size="100%">Heppner, D. G.</style></author><author><style face="normal" font="default" size="100%">Tang, D. B.</style></author><author><style face="normal" font="default" size="100%">Brewer, T. G.</style></author><author><style face="normal" font="default" size="100%">Chokejindachai, W.</style></author><author><style face="normal" font="default" size="100%">Viriyavejakul, P.</style></author><author><style face="normal" font="default" size="100%">Kyle, D. E.</style></author><author><style face="normal" font="default" size="100%">Milhous, W. K.</style></author><author><style face="normal" font="default" size="100%">et al.,</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Randomized dose-ranging study of the safety and efficacy of WR 238605 (Tafenoquine) in the prevention of relapse of Plasmodium vivax malaria in Thailand</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of infectious diseases</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Infectious Diseases</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1282‐1287</style></pages><volume><style face="normal" font="default" size="100%">180</style></volume><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Aminoquinolines [adverse effects, *therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Antimalarials [adverse effects, *therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Chloroquine [*therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Dose‐Response Relationship, Drug</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Administration Schedule</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Therapy, Combination</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Follow‐Up Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Malaria, Vivax [*drug therapy, *physiopathology]</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Prospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Recurrence</style></keyword><keyword><style face="normal" font="default" size="100%">Thailand</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">1999</style></year></dates><accession-num><style face="normal" font="default" size="100%">CN-00167321</style></accession-num><abstract><style face="normal" font="default" size="100%">WR 238605 is an 8‐aminoquinoline developed for the radical cure of Plasmodium vivax. Forty‐four P. vivax‐infected patients were randomly assigned to 1 of 4 treatment regimens: 3 groups received a blood schizonticidal dose of chloroquine followed by WR 238605: group A (n=15) received 300 mg daily for 7 days; group B (n=11), 500 mg daily for 3 days, repeated 1 week after the initial dose; group C (n=9), 1 dose of 500 mg. A fourth group (D; n=9) received chloroquine only. Among patients who completed 2‐6 months of follow‐up (n=23), there was 1 relapse in group B (day 120) and 1 in group C (day 112). Among patients treated with chloroquine only, there were 4 relapses (days 40, 43, 49, and 84). WR 238605 was safe, well tolerated, and effective in preventing P. vivax relapse.</style></abstract><caption><style face="normal" font="default" size="100%">Duplicate</style></caption><work-type><style face="normal" font="default" size="100%">Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non‐U.S. Gov&apos;t; Research Support, U.S. Gov&apos;t, Non‐P.H.S.</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.cochranelibrary.com/central/doi/10.1002/central/CN-00167321/full</style></url></related-urls></urls><custom3><style face="normal" font="default" size="100%">PUBMED 10479159</style></custom3><electronic-resource-num><style face="normal" font="default" size="100%">10.1086/315034</style></electronic-resource-num></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>79</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">79</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Walsh, D. S.</style></author><author><style face="normal" font="default" size="100%">Looareesuwan, S.</style></author><author><style face="normal" font="default" size="100%">Wilairatana, P.</style></author><author><style face="normal" font="default" size="100%">Heppner, D. G., Jr.</style></author><author><style face="normal" font="default" size="100%">Tang, D. B.</style></author><author><style face="normal" font="default" size="100%">Brewer, T. G.</style></author><author><style face="normal" font="default" size="100%">Chokejindachai, W.</style></author><author><style face="normal" font="default" size="100%">Viriyavejakul, P.</style></author><author><style face="normal" font="default" size="100%">Kyle, D. E.</style></author><author><style face="normal" font="default" size="100%">Milhous, W. K.</style></author><author><style face="normal" font="default" size="100%">Schuster, B. G.</style></author><author><style face="normal" font="default" size="100%">Horton, J.</style></author><author><style face="normal" font="default" size="100%">Braitman, D. J.</style></author><author><style face="normal" font="default" size="100%">Brueckner, R. P.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Immunology, US Army Medical Component, Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand. ltc_douglas_walsh@wrsmtp-ccmail.army.mil</style></auth-address><titles><title><style face="normal" font="default" size="100%">Randomized dose-ranging study of the safety and efficacy of WR 238605 (Tafenoquine) in the prevention of relapse of Plasmodium vivax malaria in Thailand</style></title><secondary-title><style face="normal" font="default" size="100%">J Infect Dis</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Infect Dis</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1282-7</style></pages><volume><style face="normal" font="default" size="100%">180</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">1999/09/09</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Aminoquinolines/adverse effects/*therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Antimalarials/adverse effects/*therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Chloroquine/*therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Dose-Response Relationship, Drug</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Administration Schedule</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Therapy, Combination</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Follow-Up Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Malaria, Vivax/*drug therapy/*physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Prospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Recurrence</style></keyword><keyword><style face="normal" font="default" size="100%">Thailand</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">1999</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0022-1899 (Print)&#xD;0022-1899</style></isbn><accession-num><style face="normal" font="default" size="100%">10479159</style></accession-num><abstract><style face="normal" font="default" size="100%">WR 238605 is an 8-aminoquinoline developed for the radical cure of Plasmodium vivax. Forty-four P. vivax-infected patients were randomly assigned to 1 of 4 treatment regimens: 3 groups received a blood schizonticidal dose of chloroquine followed by WR 238605: group A (n=15) received 300 mg daily for 7 days; group B (n=11), 500 mg daily for 3 days, repeated 1 week after the initial dose; group C (n=9), 1 dose of 500 mg. A fourth group (D; n=9) received chloroquine only. Among patients who completed 2-6 months of follow-up (n=23), there was 1 relapse in group B (day 120) and 1 in group C (day 112). Among patients treated with chloroquine only, there were 4 relapses (days 40, 43, 49, and 84). WR 238605 was safe, well tolerated, and effective in preventing P. vivax relapse.</style></abstract><caption><style face="normal" font="default" size="100%">Duplicate</style></caption><notes><style face="normal" font="default" size="100%">Walsh, D S&#xD;Looareesuwan, S&#xD;Wilairatana, P&#xD;Heppner, D G Jr&#xD;Tang, D B&#xD;Brewer, T G&#xD;Chokejindachai, W&#xD;Viriyavejakul, P&#xD;Kyle, D E&#xD;Milhous, W K&#xD;Schuster, B G&#xD;Horton, J&#xD;Braitman, D J&#xD;Brueckner, R P&#xD;Clinical Trial&#xD;Journal Article&#xD;Randomized Controlled Trial&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Research Support, U.S. Gov&apos;t, Non-P.H.S.&#xD;United States&#xD;J Infect Dis. 1999 Oct;180(4):1282-7. doi: 10.1086/315034.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1086/315034</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>178</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">178</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ackert, J.</style></author><author><style face="normal" font="default" size="100%">Mohamed, K.</style></author><author><style face="normal" font="default" size="100%">Slakter, J. S.</style></author><author><style face="normal" font="default" size="100%">El-Harazi, S.</style></author><author><style face="normal" font="default" size="100%">Berni, A.</style></author><author><style face="normal" font="default" size="100%">Gevorkyan, H.</style></author><author><style face="normal" font="default" size="100%">Hardaker, E.</style></author><author><style face="normal" font="default" size="100%">Hussaini, A.</style></author><author><style face="normal" font="default" size="100%">Jones, S. W.</style></author><author><style face="normal" font="default" size="100%">Koh, Gckw</style></author><author><style face="normal" font="default" size="100%">et al.,</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Randomized Placebo-Controlled Trial Evaluating the Ophthalmic Safety of Single-Dose Tafenoquine in Healthy Volunteers</style></title><secondary-title><style face="normal" font="default" size="100%">Drug safety</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Drug Safety</style></full-title></periodical><dates><year><style face="normal" font="default" size="100%">2019</style></year></dates><accession-num><style face="normal" font="default" size="100%">CN-01953985</style></accession-num><abstract><style face="normal" font="default" size="100%">INTRODUCTION: Tafenoquine has been recently registered for the prevention of relapse in Plasmodium vivax malaria. OBJECTIVE: This study assessed the pharmacodynamic effects of 300‐mg single‐dose tafenoquine on the retina. METHODS: This phase I, prospective, multicenter, randomized, single‐masked, placebo‐controlled, parallel‐group study was conducted between 2 February 2016 and 14 September 2017 at three US study centers. Adult healthy volunteers were randomized (2:1) to receive either a single 300‐mg oral dose of tafenoquine or matched placebo on day 1. Ophthalmic assessments, including spectral domain optical coherence tomography (SD‐OCT) and fundus autofluorescence (FAF), were conducted at baseline and day 90 and evaluated for pre‐determined endpoints by an independent, masked reading center. RESULTS: One subject in each group met the composite primary endpoint for retinal changes identified with SD‐OCT or FAF, i.e., one out of 306 (0.3%) with tafenoquine, one out of 161 (0.6%) with placebo. Both cases had unilateral focal ellipsoid zone disruption at day 90 with no effect on best‐corrected visual acuity. The tafenoquine‐treated subject had this abnormality at baseline, and was enrolled in error. There was no difference in ophthalmic safety between tafenoquine and placebo. CONCLUSION: There was no evidence of any pharmacodynamic effect of 300‐mg single‐dose tafenoquine on the retina or any short‐term clinically relevant effects on ophthalmic safety. This clinical trial is registered with ClinicalTrials.gov (identifier: NCT02658435).</style></abstract><caption><style face="normal" font="default" size="100%">Duplicate</style></caption><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01953985/full</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1007/s40264-019-00839-w</style></electronic-resource-num></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>179</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">179</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ackert, J.</style></author><author><style face="normal" font="default" size="100%">Mohamed, K.</style></author><author><style face="normal" font="default" size="100%">Slakter, J. S.</style></author><author><style face="normal" font="default" size="100%">El-Harazi, S.</style></author><author><style face="normal" font="default" size="100%">Berni, A.</style></author><author><style face="normal" font="default" size="100%">Gevorkyan, H.</style></author><author><style face="normal" font="default" size="100%">Hardaker, E.</style></author><author><style face="normal" font="default" size="100%">Hussaini, A.</style></author><author><style face="normal" font="default" size="100%">Jones, S. W.</style></author><author><style face="normal" font="default" size="100%">Koh, Gckw</style></author><author><style face="normal" font="default" size="100%">et al.,</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Randomized Placebo-Controlled Trial Evaluating the Ophthalmic Safety of Single-Dose Tafenoquine in Healthy Volunteers</style></title><secondary-title><style face="normal" font="default" size="100%">Drug safety</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Drug Safety</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1103‐1114</style></pages><volume><style face="normal" font="default" size="100%">42</style></volume><number><style face="normal" font="default" size="100%">9</style></number><keywords><keyword><style face="normal" font="default" size="100%">*drug safety</style></keyword><keyword><style face="normal" font="default" size="100%">*pharmacodynamics</style></keyword><keyword><style face="normal" font="default" size="100%">*retina</style></keyword><keyword><style face="normal" font="default" size="100%">Administration, Oral</style></keyword><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Aminoquinolines [*administration &amp; dosage, adverse effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Antimalarials [*administration &amp; dosage, adverse effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Article</style></keyword><keyword><style face="normal" font="default" size="100%">Autofluorescence imaging</style></keyword><keyword><style face="normal" font="default" size="100%">Best corrected visual acuity</style></keyword><keyword><style face="normal" font="default" size="100%">Central retinal thickness</style></keyword><keyword><style face="normal" font="default" size="100%">Comparative study</style></keyword><keyword><style face="normal" font="default" size="100%">Controlled study</style></keyword><keyword><style face="normal" font="default" size="100%">Eye examination</style></keyword><keyword><style face="normal" font="default" size="100%">Eye fundus</style></keyword><keyword><style face="normal" font="default" size="100%">Eye photography</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Follow up</style></keyword><keyword><style face="normal" font="default" size="100%">Headache /side effect</style></keyword><keyword><style face="normal" font="default" size="100%">Hematological parameters</style></keyword><keyword><style face="normal" font="default" size="100%">Hemoglobin blood level</style></keyword><keyword><style face="normal" font="default" size="100%">Human</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Intraocular pressure</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Multicenter study</style></keyword><keyword><style face="normal" font="default" size="100%">Nausea and vomiting /side effect</style></keyword><keyword><style face="normal" font="default" size="100%">Normal human</style></keyword><keyword><style face="normal" font="default" size="100%">Optical Imaging</style></keyword><keyword><style face="normal" font="default" size="100%">Perimetry</style></keyword><keyword><style face="normal" font="default" size="100%">Phase 1 clinical trial</style></keyword><keyword><style face="normal" font="default" size="100%">Priority journal</style></keyword><keyword><style face="normal" font="default" size="100%">Prospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized controlled trial</style></keyword><keyword><style face="normal" font="default" size="100%">Retina [*drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Side effect /side effect</style></keyword><keyword><style face="normal" font="default" size="100%">Single blind procedure</style></keyword><keyword><style face="normal" font="default" size="100%">Single drug dose</style></keyword><keyword><style face="normal" font="default" size="100%">Single‐Blind Method</style></keyword><keyword><style face="normal" font="default" size="100%">Slit lamp microscopy</style></keyword><keyword><style face="normal" font="default" size="100%">Spectral domain optical coherence tomography</style></keyword><keyword><style face="normal" font="default" size="100%">Tomography, Optical Coherence</style></keyword><keyword><style face="normal" font="default" size="100%">Tooth abscess /side effect</style></keyword><keyword><style face="normal" font="default" size="100%">Visual Acuity [*drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Young Adult</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2019</style></year></dates><accession-num><style face="normal" font="default" size="100%">CN-01975814</style></accession-num><abstract><style face="normal" font="default" size="100%">Introduction: Tafenoquine has been recently registered for the prevention of relapse in Plasmodium vivax malaria. Objective: This study assessed the pharmacodynamic effects of 300‐mg single‐dose tafenoquine on the retina. Methods: This phase I, prospective, multicenter, randomized, single‐masked, placebo‐controlled, parallel‐group study was conducted between 2 February 2016 and 14 September 2017 at three US study centers. Adult healthy volunteers were randomized (2:1) to receive either a single 300‐mg oral dose of tafenoquine or matched placebo on day 1. Ophthalmic assessments, including spectral domain optical coherence tomography (SD‐OCT) and fundus autofluorescence (FAF), were conducted at baseline and day 90 and evaluated for pre‐determined endpoints by an independent, masked reading center. Results: One subject in each group met the composite primary endpoint for retinal changes identified with SD‐OCT or FAF, i.e., one out of 306 (0.3%) with tafenoquine, one out of 161 (0.6%) with placebo. Both cases had unilateral focal ellipsoid zone disruption at day 90 with no effect on best‐corrected visual acuity. The tafenoquine‐treated subject had this abnormality at baseline, and was enrolled in error. There was no difference in ophthalmic safety between tafenoquine and placebo. Conclusion: There was no evidence of any pharmacodynamic effect of 300‐mg single‐dose tafenoquine on the retina or any short‐term clinically relevant effects on ophthalmic safety. This clinical trial is registered with ClinicalTrials.gov (identifier: NCT02658435).</style></abstract><caption><style face="normal" font="default" size="100%">Duplicate</style></caption><work-type><style face="normal" font="default" size="100%">Clinical Trial, Phase I; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non‐U.S. Gov&apos;t</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01975814/full</style></url></related-urls></urls><custom3><style face="normal" font="default" size="100%">PUBMED 31187437,EMBASE 628178806</style></custom3><electronic-resource-num><style face="normal" font="default" size="100%">10.1007/s40264-019-00839-w</style></electronic-resource-num></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>22</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">22</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ackert, J.</style></author><author><style face="normal" font="default" size="100%">Mohamed, K.</style></author><author><style face="normal" font="default" size="100%">Slakter, J. S.</style></author><author><style face="normal" font="default" size="100%">El-Harazi, S.</style></author><author><style face="normal" font="default" size="100%">Berni, A.</style></author><author><style face="normal" font="default" size="100%">Gevorkyan, H.</style></author><author><style face="normal" font="default" size="100%">Hardaker, E.</style></author><author><style face="normal" font="default" size="100%">Hussaini, A.</style></author><author><style face="normal" font="default" size="100%">Jones, S. W.</style></author><author><style face="normal" font="default" size="100%">Koh, Gckw</style></author><author><style face="normal" font="default" size="100%">Patel, J.</style></author><author><style face="normal" font="default" size="100%">Rasmussen, S.</style></author><author><style face="normal" font="default" size="100%">Kelly, D. S.</style></author><author><style face="normal" font="default" size="100%">Barañano, D. E.</style></author><author><style face="normal" font="default" size="100%">Thompson, J. T.</style></author><author><style face="normal" font="default" size="100%">Warren, K. A.</style></author><author><style face="normal" font="default" size="100%">Sergott, R. C.</style></author><author><style face="normal" font="default" size="100%">Tonkyn, J.</style></author><author><style face="normal" font="default" size="100%">Wolstenholme, A.</style></author><author><style face="normal" font="default" size="100%">Coleman, H.</style></author><author><style face="normal" font="default" size="100%">Yuan, A.</style></author><author><style face="normal" font="default" size="100%">Duparc, S.</style></author><author><style face="normal" font="default" size="100%">Green, J. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Clinical Research and Development, GlaxoSmithKline, Collegeville, PA, USA.&#xD;Quantitative Sciences, GlaxoSmithKline Research and Development, Stockley Park West, Uxbridge, Middlesex, UK.&#xD;Digital Angiography Reading Center (DARC), Great Neck, New York, NY, USA.&#xD;Lugene Eye Institute, Glendale, CA, USA.&#xD;Global Health, GlaxoSmithKline Research and Development Ltd., Stockley Park West, Uxbridge, Middlesex, UB11 1BT, UK.&#xD;California Clinical Trials Medical Group in affiliation with Parexel International, Glendale, CA, USA.&#xD;Safety Evaluation and Risk Management, GlaxoSmithKline Research and Development, Stockley Park West, Uxbridge, Middlesex, UK.&#xD;PAREXEL, Harbor Hospital, Baltimore, Baltimore, MD, USA.&#xD;Clinical Data Management, GlaxoSmithKline Research and Development, Collegeville, PA, USA.&#xD;IQVIA, Overland Park, KS, USA.&#xD;Global Clinical Safety and Pharmacovigilance, GlaxoSmithKline, Collegeville, PA, USA.&#xD;Retina Specialists, Baltimore, MD, USA.&#xD;Neuro-Ophthalmology Service, Wills Eye Hospital, Philadelphia, PA, USA.&#xD;GSK Medicines Research Centre, GlaxoSmithKline, Stevenage, Hertfordshire, UK.&#xD;GlaxoSmithKline, Upper Providence, Collegeville, PA, USA.&#xD;Research and Development, Medicines for Malaria Venture, Geneva, Switzerland.&#xD;Global Health, GlaxoSmithKline Research and Development Ltd., Stockley Park West, Uxbridge, Middlesex, UB11 1BT, UK. justin.a.green@gsk.com.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Randomized Placebo-Controlled Trial Evaluating the Ophthalmic Safety of Single-Dose Tafenoquine in Healthy Volunteers</style></title><secondary-title><style face="normal" font="default" size="100%">Drug Saf</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Drug Saf</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1103-1114</style></pages><volume><style face="normal" font="default" size="100%">42</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2019/06/13</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Administration, Oral</style></keyword><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Aminoquinolines/*administration &amp; dosage/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Antimalarials/*administration &amp; dosage/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Optical Imaging</style></keyword><keyword><style face="normal" font="default" size="100%">Prospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Retina/*drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Single-Blind Method</style></keyword><keyword><style face="normal" font="default" size="100%">Tomography, Optical Coherence</style></keyword><keyword><style face="normal" font="default" size="100%">Visual Acuity/*drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Young Adult</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2019</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0114-5916 (Print)&#xD;0114-5916</style></isbn><accession-num><style face="normal" font="default" size="100%">31187437</style></accession-num><abstract><style face="normal" font="default" size="100%">INTRODUCTION: Tafenoquine has been recently registered for the prevention of relapse in Plasmodium vivax malaria. OBJECTIVE: This study assessed the pharmacodynamic effects of 300-mg single-dose tafenoquine on the retina. METHODS: This phase I, prospective, multicenter, randomized, single-masked, placebo-controlled, parallel-group study was conducted between 2 February 2016 and 14 September 2017 at three US study centers. Adult healthy volunteers were randomized (2:1) to receive either a single 300-mg oral dose of tafenoquine or matched placebo on day 1. Ophthalmic assessments, including spectral domain optical coherence tomography (SD-OCT) and fundus autofluorescence (FAF), were conducted at baseline and day 90 and evaluated for pre-determined endpoints by an independent, masked reading center. RESULTS: One subject in each group met the composite primary endpoint for retinal changes identified with SD-OCT or FAF, i.e., one out of 306 (0.3%) with tafenoquine, one out of 161 (0.6%) with placebo. Both cases had unilateral focal ellipsoid zone disruption at day 90 with no effect on best-corrected visual acuity. The tafenoquine-treated subject had this abnormality at baseline, and was enrolled in error. There was no difference in ophthalmic safety between tafenoquine and placebo. CONCLUSION: There was no evidence of any pharmacodynamic effect of 300-mg single-dose tafenoquine on the retina or any short-term clinically relevant effects on ophthalmic safety. This clinical trial is registered with ClinicalTrials.gov (identifier: NCT02658435).</style></abstract><caption><style face="normal" font="default" size="100%">Duplicate</style></caption><notes><style face="normal" font="default" size="100%">1179-1942&#xD;Ackert, Jessica&#xD;Mohamed, Khadeeja&#xD;Slakter, Jason S&#xD;El-Harazi, Sherif&#xD;Berni, Alessandro&#xD;Gevorkyan, Hakop&#xD;Hardaker, Elizabeth&#xD;Hussaini, Azra&#xD;Jones, Siôn W&#xD;Koh, Gavin C K W&#xD;Patel, Jyoti&#xD;Rasmussen, Scott&#xD;Kelly, Deborah S&#xD;Barañano, David E&#xD;Thompson, John T&#xD;Warren, Keith A&#xD;Sergott, Robert C&#xD;Tonkyn, John&#xD;Wolstenholme, Allen&#xD;Coleman, Hanna&#xD;Yuan, Alex&#xD;Duparc, Stephan&#xD;Green, Justin A&#xD;Clinical Trial, Phase I&#xD;Journal Article&#xD;Multicenter Study&#xD;Randomized Controlled Trial&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Drug Saf. 2019 Sep;42(9):1103-1114. doi: 10.1007/s40264-019-00839-w.</style></notes><urls></urls><custom2><style face="normal" font="default" size="100%">PMC6689320 Jones, Gavin C.K.W Koh, Jyoti Patel, John Tonkyn, Allen Wolstenholme, and Justin A. Green are employees of GlaxoSmithKline and hold shares in the company. Jason S. Slakter, Hakop Gevorkyan, Hanna Coleman, and Alex Yuan are employees of DARC. Hakop Gevorkyan is an employee of California Clinical Trials Medical Group, and Azra Hussaini is an employee of PAREXEL (California Clinical Trials Medical Group in association with PAREXEL International were contracted and reimbursed for conducting this study). Sherif El-Harazi is an employee of the Lugene Eye Institute; Scott Rasmussen and Keith A. Warren are employees of IQVIA; Deborah S. Kelly is a former employee of GSK and a current employee of Spark Therapeutics; David E. Barañano, John T. Thompson, and Robert C. Sergott received research funding for participating in this study, but have no other relevant conflicts. Robert C. Sergott is an employee of the Wills Eye Hospital. Stephan Duparc is an employee of Medicines for Malaria Venture.</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1007/s40264-019-00839-w</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>90</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">90</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ackert, J.</style></author><author><style face="normal" font="default" size="100%">Mohamed, K.</style></author><author><style face="normal" font="default" size="100%">Slakter, J. S.</style></author><author><style face="normal" font="default" size="100%">El-Harazi, S.</style></author><author><style face="normal" font="default" size="100%">Berni, A.</style></author><author><style face="normal" font="default" size="100%">Gevorkyan, H.</style></author><author><style face="normal" font="default" size="100%">Hardaker, E.</style></author><author><style face="normal" font="default" size="100%">Hussaini, A.</style></author><author><style face="normal" font="default" size="100%">Jones, S. W.</style></author><author><style face="normal" font="default" size="100%">Koh, G. C. K. W.</style></author><author><style face="normal" font="default" size="100%">Patel, J.</style></author><author><style face="normal" font="default" size="100%">Rasmussen, S.</style></author><author><style face="normal" font="default" size="100%">Kelly, D. S.</style></author><author><style face="normal" font="default" size="100%">Barañano, D. E.</style></author><author><style face="normal" font="default" size="100%">Thompson, J. T.</style></author><author><style face="normal" font="default" size="100%">Warren, K. A.</style></author><author><style face="normal" font="default" size="100%">Sergott, R. C.</style></author><author><style face="normal" font="default" size="100%">Tonkyn, J.</style></author><author><style face="normal" font="default" size="100%">Wolstenholme, A.</style></author><author><style face="normal" font="default" size="100%">Coleman, H.</style></author><author><style face="normal" font="default" size="100%">Yuan, A.</style></author><author><style face="normal" font="default" size="100%">Duparc, S.</style></author><author><style face="normal" font="default" size="100%">Green, J. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">J.A. Green, Global Health, GlaxoSmithKline Research and Development Ltd., Stockley Park West, Uxbridge, Middlesex, United Kingdom</style></auth-address><titles><title><style face="normal" font="default" size="100%">Randomized Placebo-Controlled Trial Evaluating the Ophthalmic Safety of Single-Dose Tafenoquine in Healthy Volunteers</style></title><secondary-title><style face="normal" font="default" size="100%">Drug Safety</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Drug Safety</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1103-1114</style></pages><volume><style face="normal" font="default" size="100%">42</style></volume><number><style face="normal" font="default" size="100%">9</style></number><keywords><keyword><style face="normal" font="default" size="100%">NCT02658435</style></keyword><keyword><style face="normal" font="default" size="100%">fundus camera</style></keyword><keyword><style face="normal" font="default" size="100%">optical coherence tomography device</style></keyword><keyword><style face="normal" font="default" size="100%">SPECTRALIS system</style></keyword><keyword><style face="normal" font="default" size="100%">Zeiss FF4</style></keyword><keyword><style face="normal" font="default" size="100%">methemoglobin</style></keyword><keyword><style face="normal" font="default" size="100%">tafenoquine</style></keyword><keyword><style face="normal" font="default" size="100%">adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">adult</style></keyword><keyword><style face="normal" font="default" size="100%">article</style></keyword><keyword><style face="normal" font="default" size="100%">autofluorescence imaging</style></keyword><keyword><style face="normal" font="default" size="100%">best corrected visual acuity</style></keyword><keyword><style face="normal" font="default" size="100%">central retinal thickness</style></keyword><keyword><style face="normal" font="default" size="100%">comparative study</style></keyword><keyword><style face="normal" font="default" size="100%">controlled study</style></keyword><keyword><style face="normal" font="default" size="100%">drug safety</style></keyword><keyword><style face="normal" font="default" size="100%">eye examination</style></keyword><keyword><style face="normal" font="default" size="100%">eye fundus</style></keyword><keyword><style face="normal" font="default" size="100%">eye photography</style></keyword><keyword><style face="normal" font="default" size="100%">female</style></keyword><keyword><style face="normal" font="default" size="100%">follow up</style></keyword><keyword><style face="normal" font="default" size="100%">headache</style></keyword><keyword><style face="normal" font="default" size="100%">hematological parameters</style></keyword><keyword><style face="normal" font="default" size="100%">hemoglobin blood level</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">intraocular pressure</style></keyword><keyword><style face="normal" font="default" size="100%">male</style></keyword><keyword><style face="normal" font="default" size="100%">multicenter study</style></keyword><keyword><style face="normal" font="default" size="100%">nausea and vomiting</style></keyword><keyword><style face="normal" font="default" size="100%">normal human</style></keyword><keyword><style face="normal" font="default" size="100%">perimetry</style></keyword><keyword><style face="normal" font="default" size="100%">pharmacodynamics</style></keyword><keyword><style face="normal" font="default" size="100%">phase 1 clinical trial</style></keyword><keyword><style face="normal" font="default" size="100%">priority journal</style></keyword><keyword><style face="normal" font="default" size="100%">randomized controlled trial</style></keyword><keyword><style face="normal" font="default" size="100%">retina</style></keyword><keyword><style face="normal" font="default" size="100%">side effect</style></keyword><keyword><style face="normal" font="default" size="100%">single blind procedure</style></keyword><keyword><style face="normal" font="default" size="100%">single drug dose</style></keyword><keyword><style face="normal" font="default" size="100%">slit lamp microscopy</style></keyword><keyword><style face="normal" font="default" size="100%">spectral domain optical coherence tomography</style></keyword><keyword><style face="normal" font="default" size="100%">tooth abscess</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2019</style></year></dates><isbn><style face="normal" font="default" size="100%">1179-1942&#xD;0114-5916</style></isbn><abstract><style face="normal" font="default" size="100%">Introduction: Tafenoquine has been recently registered for the prevention of relapse in Plasmodium vivax malaria. Objective: This study assessed the pharmacodynamic effects of 300-mg single-dose tafenoquine on the retina. Methods: This phase I, prospective, multicenter, randomized, single-masked, placebo-controlled, parallel-group study was conducted between 2 February 2016 and 14 September 2017 at three US study centers. Adult healthy volunteers were randomized (2:1) to receive either a single 300-mg oral dose of tafenoquine or matched placebo on day 1. Ophthalmic assessments, including spectral domain optical coherence tomography (SD-OCT) and fundus autofluorescence (FAF), were conducted at baseline and day 90 and evaluated for pre-determined endpoints by an independent, masked reading center. Results: One subject in each group met the composite primary endpoint for retinal changes identified with SD-OCT or FAF, i.e., one out of 306 (0.3%) with tafenoquine, one out of 161 (0.6%) with placebo. Both cases had unilateral focal ellipsoid zone disruption at day 90 with no effect on best-corrected visual acuity. The tafenoquine-treated subject had this abnormality at baseline, and was enrolled in error. There was no difference in ophthalmic safety between tafenoquine and placebo. Conclusion: There was no evidence of any pharmacodynamic effect of 300-mg single-dose tafenoquine on the retina or any short-term clinically relevant effects on ophthalmic safety. This clinical trial is registered with ClinicalTrials.gov (identifier: NCT02658435).</style></abstract><caption><style face="normal" font="default" size="100%">Duplicate</style></caption><notes><style face="normal" font="default" size="100%">L628178806&#xD;2019-06-25&#xD;2019-08-21</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L628178806&amp;from=export</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1007/s40264-019-00839-w</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">Glaxo SmithKline(United Kingdom)</style></custom2><custom3><style face="normal" font="default" size="100%">SPECTRALIS system(Heidelberg Engineering,United States)&#xD;Zeiss FF4(Carl Zeiss Meditec,United States)</style></custom3><custom4><style face="normal" font="default" size="100%">Carl Zeiss Meditec(United States)&#xD;Heidelberg Engineering(United States)</style></custom4><custom5><style face="normal" font="default" size="100%">31187437</style></custom5><electronic-resource-num><style face="normal" font="default" size="100%">10.1007/s40264-019-00839-w</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase&#xD;Medline</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>65</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">65</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Walsh, D. S.</style></author><author><style face="normal" font="default" size="100%">Wilairatana, P.</style></author><author><style face="normal" font="default" size="100%">Tang, D. B.</style></author><author><style face="normal" font="default" size="100%">Heppner, D. G., Jr.</style></author><author><style face="normal" font="default" size="100%">Brewer, T. G.</style></author><author><style face="normal" font="default" size="100%">Krudsood, S.</style></author><author><style face="normal" font="default" size="100%">Silachamroon, U.</style></author><author><style face="normal" font="default" size="100%">Phumratanaprapin, W.</style></author><author><style face="normal" font="default" size="100%">Siriyanonda, D.</style></author><author><style face="normal" font="default" size="100%">Looareesuwan, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Immunology and Medicine, US Army Medical Component, Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand. douglas.walsh@se.amedd.army.mil</style></auth-address><titles><title><style face="normal" font="default" size="100%">Randomized trial of 3-dose regimens of tafenoquine (WR238605) versus low-dose primaquine for preventing Plasmodium vivax malaria relapse</style></title><secondary-title><style face="normal" font="default" size="100%">Clin Infect Dis</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Clin Infect Dis</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1095-103</style></pages><volume><style face="normal" font="default" size="100%">39</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2004/10/16</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Aminoquinolines/*administration &amp; dosage/blood/*therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Antimalarials/administration &amp; dosage/*therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Chloroquine/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Dose-Response Relationship, Drug</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Malaria, Vivax/*drug therapy/*prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Methemoglobin/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Primaquine/*administration &amp; dosage/*therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Risk</style></keyword><keyword><style face="normal" font="default" size="100%">Secondary Prevention</style></keyword><keyword><style face="normal" font="default" size="100%">Time Factors</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2004</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct 15</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1058-4838</style></isbn><accession-num><style face="normal" font="default" size="100%">15486831</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Tafenoquine is an 8-aminoquinoline developed as a more effective replacement for primaquine. In a previous dose-ranging study in Thailand, 3 tafenoquine regimens with total doses ranging from 500 mg to 3000 mg prevented relapse of Plasmodium vivax malaria in most patients when administered 2 days after receipt of a blood schizonticidal dose of chloroquine. METHODS: To improve convenience and to begin comparison of tafenoquine with primaquine, 80 patients with P. vivax infection were randomized to receive 1 of the following 5 treatments 1 day after receiving a blood schizonticidal dose of chloroquine: (A) tafenoquine, 300 mg per day for 7 days (n=18); (B) tafenoquine, 600 mg per day for 3 days (n=19); (C) tafenoquine, 600 mg as a single dose (n=18); (D) no further treatment (n=13); or (E) primaquine base, 15 mg per day for 14 days (n=12). The minimum duration of protocol follow-up was 8 weeks, with additional follow-up to 24 weeks. RESULTS: Forty-six of 55 tafenoquine recipients, 10 of 13 recipients of chloroquine only, and 12 of 12 recipients of chloroquine plus primaquine completed at least 8 weeks of follow-up (or had relapse). There was 1 relapse among recipients of chloroquine plus tafenoquine, 8 among recipients of chloroquine only, and 3 among recipients of chloroquine plus primaquine. The rate of protective efficacy (determined on the basis of reduction in incidence density) for all recipients of chloroquine plus tafenoquine, compared with recipients of chloroquine plus primaquine, was 92.6% (95% confidence interval, 7.3%-99.9%; P=.042, by Fisher&apos;s exact test). CONCLUSIONS: Tafenoquine doses as low as a single 600-mg dose may be useful for prevention of relapse of P. vivax malaria in Thailand.</style></abstract><caption><style face="normal" font="default" size="100%">Duplicate</style></caption><notes><style face="normal" font="default" size="100%">1537-6591&#xD;Walsh, Douglas S&#xD;Wilairatana, Polrat&#xD;Tang, Douglas B&#xD;Heppner, D Gray Jr&#xD;Brewer, Thomas G&#xD;Krudsood, Srivicha&#xD;Silachamroon, Udomsak&#xD;Phumratanaprapin, Weerapong&#xD;Siriyanonda, Duangsuda&#xD;Looareesuwan, Sornchai&#xD;Clinical Trial&#xD;Journal Article&#xD;Randomized Controlled Trial&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Research Support, U.S. Gov&apos;t, Non-P.H.S.&#xD;United States&#xD;Clin Infect Dis. 2004 Oct 15;39(8):1095-103. doi: 10.1086/424508. Epub 2004 Sep 24.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1086/424508</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>168</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">168</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Walsh, D. S.</style></author><author><style face="normal" font="default" size="100%">Wilairatana, P.</style></author><author><style face="normal" font="default" size="100%">Tang, D. B.</style></author><author><style face="normal" font="default" size="100%">Heppner, D. G.</style></author><author><style face="normal" font="default" size="100%">Brewer, T. G.</style></author><author><style face="normal" font="default" size="100%">Krudsood, S.</style></author><author><style face="normal" font="default" size="100%">Silachamroon, U.</style></author><author><style face="normal" font="default" size="100%">Phumratanaprapin, W.</style></author><author><style face="normal" font="default" size="100%">Siriyanonda, D.</style></author><author><style face="normal" font="default" size="100%">Looareesuwan, S.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Randomized trial of 3-dose regimens of tafenoquine (WR238605) versus low-dose primaquine for preventing Plasmodium vivax malaria relapse</style></title><secondary-title><style face="normal" font="default" size="100%">Clinical infectious diseases</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Clinical Infectious Diseases</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1095‐1103</style></pages><volume><style face="normal" font="default" size="100%">39</style></volume><number><style face="normal" font="default" size="100%">8</style></number><keywords><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Aminoquinolines [*administration &amp; dosage, blood, *therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Antimalarials [administration &amp; dosage, *therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Chloroquine [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Dose‐Response Relationship, Drug</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Malaria, Vivax [*drug therapy, *prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Methemoglobin [metabolism]</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Primaquine [*administration &amp; dosage, *therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Risk</style></keyword><keyword><style face="normal" font="default" size="100%">Secondary Prevention</style></keyword><keyword><style face="normal" font="default" size="100%">Time Factors</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2004</style></year></dates><accession-num><style face="normal" font="default" size="100%">CN-00560293</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Tafenoquine is an 8‐aminoquinoline developed as a more effective replacement for primaquine. In a previous dose‐ranging study in Thailand, 3 tafenoquine regimens with total doses ranging from 500 mg to 3000 mg prevented relapse of Plasmodium vivax malaria in most patients when administered 2 days after receipt of a blood schizonticidal dose of chloroquine. METHODS: To improve convenience and to begin comparison of tafenoquine with primaquine, 80 patients with P. vivax infection were randomized to receive 1 of the following 5 treatments 1 day after receiving a blood schizonticidal dose of chloroquine: (A) tafenoquine, 300 mg per day for 7 days (n=18); (B) tafenoquine, 600 mg per day for 3 days (n=19); (C) tafenoquine, 600 mg as a single dose (n=18); (D) no further treatment (n=13); or (E) primaquine base, 15 mg per day for 14 days (n=12). The minimum duration of protocol follow‐up was 8 weeks, with additional follow‐up to 24 weeks. RESULTS: Forty‐six of 55 tafenoquine recipients, 10 of 13 recipients of chloroquine only, and 12 of 12 recipients of chloroquine plus primaquine completed at least 8 weeks of follow‐up (or had relapse). There was 1 relapse among recipients of chloroquine plus tafenoquine, 8 among recipients of chloroquine only, and 3 among recipients of chloroquine plus primaquine. The rate of protective efficacy (determined on the basis of reduction in incidence density) for all recipients of chloroquine plus tafenoquine, compared with recipients of chloroquine plus primaquine, was 92.6% (95% confidence interval, 7.3%‐99.9%; P=.042, by Fisher&apos;s exact test). CONCLUSIONS: Tafenoquine doses as low as a single 600‐mg dose may be useful for prevention of relapse of P. vivax malaria in Thailand.</style></abstract><caption><style face="normal" font="default" size="100%">Duplicate</style></caption><work-type><style face="normal" font="default" size="100%">Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non‐U.S. Gov&apos;t; Research Support, U.S. Gov&apos;t, Non‐P.H.S.</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.cochranelibrary.com/central/doi/10.1002/central/CN-00560293/full</style></url></related-urls></urls><custom3><style face="normal" font="default" size="100%">PUBMED 15486831</style></custom3><electronic-resource-num><style face="normal" font="default" size="100%">10.1086/424508</style></electronic-resource-num></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>130</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">130</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Walsh, D. S.</style></author><author><style face="normal" font="default" size="100%">Wilairatana, P.</style></author><author><style face="normal" font="default" size="100%">Tang, D. B.</style></author><author><style face="normal" font="default" size="100%">Heppner Jr, D. G.</style></author><author><style face="normal" font="default" size="100%">Brewer, T. G.</style></author><author><style face="normal" font="default" size="100%">Krudsood, S.</style></author><author><style face="normal" font="default" size="100%">Silachamroon, U.</style></author><author><style face="normal" font="default" size="100%">Phumratanaprapin, W.</style></author><author><style face="normal" font="default" size="100%">Siriyanonda, D.</style></author><author><style face="normal" font="default" size="100%">Looareesuwan, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">D.S. Walsh, Dermatology Service, Eisenhower Army Medical Center, Ft. Gordon, GA 30905, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Randomized trial of 3-dose regimens of tafenoquine (WR238605) versus low-dose primaquine for preventing Plasmodium vivax malaria relapse</style></title><secondary-title><style face="normal" font="default" size="100%">Clinical Infectious Diseases</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Clinical Infectious Diseases</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1095-1103</style></pages><volume><style face="normal" font="default" size="100%">39</style></volume><number><style face="normal" font="default" size="100%">8</style></number><keywords><keyword><style face="normal" font="default" size="100%">chloroquine</style></keyword><keyword><style face="normal" font="default" size="100%">methemoglobin</style></keyword><keyword><style face="normal" font="default" size="100%">primaquine</style></keyword><keyword><style face="normal" font="default" size="100%">tafenoquine</style></keyword><keyword><style face="normal" font="default" size="100%">abdominal discomfort</style></keyword><keyword><style face="normal" font="default" size="100%">abdominal pain</style></keyword><keyword><style face="normal" font="default" size="100%">adult</style></keyword><keyword><style face="normal" font="default" size="100%">anorexia</style></keyword><keyword><style face="normal" font="default" size="100%">article</style></keyword><keyword><style face="normal" font="default" size="100%">chill</style></keyword><keyword><style face="normal" font="default" size="100%">clinical trial</style></keyword><keyword><style face="normal" font="default" size="100%">controlled clinical trial</style></keyword><keyword><style face="normal" font="default" size="100%">controlled study</style></keyword><keyword><style face="normal" font="default" size="100%">diarrhea</style></keyword><keyword><style face="normal" font="default" size="100%">digestive system function disorder</style></keyword><keyword><style face="normal" font="default" size="100%">drug blood level</style></keyword><keyword><style face="normal" font="default" size="100%">drug dose regimen</style></keyword><keyword><style face="normal" font="default" size="100%">drug efficacy</style></keyword><keyword><style face="normal" font="default" size="100%">drug eruption</style></keyword><keyword><style face="normal" font="default" size="100%">drug safety</style></keyword><keyword><style face="normal" font="default" size="100%">drug tolerability</style></keyword><keyword><style face="normal" font="default" size="100%">female</style></keyword><keyword><style face="normal" font="default" size="100%">follow up</style></keyword><keyword><style face="normal" font="default" size="100%">headache</style></keyword><keyword><style face="normal" font="default" size="100%">hemoglobin determination</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">Kaplan Meier method</style></keyword><keyword><style face="normal" font="default" size="100%">major clinical study</style></keyword><keyword><style face="normal" font="default" size="100%">malaria</style></keyword><keyword><style face="normal" font="default" size="100%">male</style></keyword><keyword><style face="normal" font="default" size="100%">muscle weakness</style></keyword><keyword><style face="normal" font="default" size="100%">myalgia</style></keyword><keyword><style face="normal" font="default" size="100%">nausea</style></keyword><keyword><style face="normal" font="default" size="100%">Plasmodium vivax</style></keyword><keyword><style face="normal" font="default" size="100%">priority journal</style></keyword><keyword><style face="normal" font="default" size="100%">randomized controlled trial</style></keyword><keyword><style face="normal" font="default" size="100%">recurrent disease</style></keyword><keyword><style face="normal" font="default" size="100%">vertigo</style></keyword><keyword><style face="normal" font="default" size="100%">wr 238605</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2004</style></year></dates><isbn><style face="normal" font="default" size="100%">1058-4838</style></isbn><abstract><style face="normal" font="default" size="100%">Background. Tafenoquine is an 8-aminoquinoline developed as a more effective replacement for primaquine. In a previous dose-ranging study in Thailand, 3 tafenoquine regimens with total doses ranging from 500 mg to 3000 mg prevented relapse of Plasmodium vivax malaria in most patients when administered 2 days after receipt of a blood schizonticidal dose of chloroquine. Methods. To improve convenience and to begin comparison of tafenoquine with primaquine, 80 patients with P. vivax infection were randomized to receive 1 of the following 5 treatments 1 day after receiving a blood schizonticidal dose of chloroquine: (A) tafenoquine, 300 mg per day for 7 days (n = 18); (B) tafenoquine, 600 mg per day for 3 days (n = 19); (C) tafenoquine, 600 mg as a single dose (n = 18); (D) no further treatment (n = 13); or (E) primaquine base, 15 mg per day for 14 days (n = 12). The minimum duration of protocol follow-up was 8 weeks, with additional follow-up to 24 weeks. Results. Forty-six of 55 tafenoquine recipients, 10 of 13 recipients of chloroquine only, and 12 of 12 recipients of chloroquine plus primaquine completed at least 8 weeks of follow-up (or had relapse). There was 1 relapse among recipients of chloroquine plus tafenoquine, 8 among recipients of chloroquine only, and 3 among recipients of chloroquine plus primaquine. The rate of protective efficacy (determined on the basis of reduction in incidence density) for all recipients of chloroquine plus tafenoquine, compared with recipients of chloroquine plus primaquine, was 92.6% (95% confidence interval, 7.3%-99.9%; P = .042, by Fisher&apos;s exact test). Conclusions. Tafenoquine doses as low as a single 600-mg dose may be useful for prevention of relapse of P. vivax malaria in Thailand.</style></abstract><caption><style face="normal" font="default" size="100%">Duplicate</style></caption><notes><style face="normal" font="default" size="100%">L40169305&#xD;2005-02-11</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L40169305&amp;from=export</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1086/424508</style></url></related-urls></urls><custom1><style face="normal" font="default" size="100%">wr 238605(university of iowa,United States)</style></custom1><custom2><style face="normal" font="default" size="100%">Sterling Winthrop(United States)&#xD;university of iowa(United States)</style></custom2><custom5><style face="normal" font="default" size="100%">15486831</style></custom5><electronic-resource-num><style face="normal" font="default" size="100%">10.1086/424508</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase&#xD;Medline</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>174</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">174</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Nasveld, P. E.</style></author><author><style face="normal" font="default" size="100%">Edstein, M. D.</style></author><author><style face="normal" font="default" size="100%">Reid, M.</style></author><author><style face="normal" font="default" size="100%">Brennan, L.</style></author><author><style face="normal" font="default" size="100%">Harris, I. E.</style></author><author><style face="normal" font="default" size="100%">Kitchener, S. J.</style></author><author><style face="normal" font="default" size="100%">Leggat, P. A.</style></author><author><style face="normal" font="default" size="100%">Pickford, P.</style></author><author><style face="normal" font="default" size="100%">Kerr, C.</style></author><author><style face="normal" font="default" size="100%">Ohrt, C.</style></author><author><style face="normal" font="default" size="100%">et al.,</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Randomized, double-blind study of the safety, tolerability, and efficacy of tafenoquine versus mefloquine for malaria prophylaxis in nonimmune subjects</style></title><secondary-title><style face="normal" font="default" size="100%">Antimicrobial agents and chemotherapy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Antimicrobial Agents and Chemotherapy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">792‐798</style></pages><volume><style face="normal" font="default" size="100%">54</style></volume><number><style face="normal" font="default" size="100%">2</style></number><keywords><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Aminoquinolines [adverse effects, *therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Antimalarials [adverse effects, *therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Australia</style></keyword><keyword><style face="normal" font="default" size="100%">Double‐Blind Method</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Malaria [*drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Mefloquine [adverse effects, *therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Military Personnel</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Young Adult</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2010</style></year></dates><accession-num><style face="normal" font="default" size="100%">CN-00727999</style></accession-num><abstract><style face="normal" font="default" size="100%">This study represents the first phase III trial of the safety, tolerability, and effectiveness of tafenoquine for malaria prophylaxis. In a randomized (3:1), double‐blinded study, Australian soldiers received weekly malaria prophylaxis with 200 mg tafenoquine (492 subjects) or 250 mg mefloquine (162 subjects) for 6 months on a peacekeeping deployment to East Timor. After returning to Australia, tafenoquine‐receiving subjects received a placebo and mefloquine‐receiving subjects received 30 mg primaquine daily for 14 days. There were no clinically significant differences between hematological and biochemical parameters of the treatment groups. Treatment‐related adverse events for the two groups were similar (tafenoquine, 13.4%; mefloquine, 11.7%). Three subjects on tafenoquine (0.6%) and none on mefloquine discontinued prophylaxis because of possible drug‐related adverse events. No diagnoses of malaria occurred for either group during deployment, but 4 cases (0.9%) and 1 case (0.7%) of Plasmodium vivax infection occurred among the tafenoquine and mefloquine groups, respectively, up to 20 weeks after discontinuation of medication. In a subset of subjects recruited for detailed safety assessments, treatment‐related mild vortex keratopathy was detected in 93% (69 of 74) of tafenoquine subjects but none of the 21 mefloquine subjects. The vortex keratopathy was not associated with any effect on visual acuity and was fully resolved in all subjects by 1 year. Tafenoquine appears to be safe and well tolerated as malaria prophylaxis. Although the volunteers&apos; precise exposure to malaria could not be proven in this study, tafenoquine appears to be a highly efficacious drug for malaria prophylaxis.</style></abstract><caption><style face="normal" font="default" size="100%">Duplicate</style></caption><work-type><style face="normal" font="default" size="100%">Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non‐U.S. Gov&apos;t; Research Support, U.S. Gov&apos;t, Non‐P.H.S.</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.cochranelibrary.com/central/doi/10.1002/central/CN-00727999/full</style></url></related-urls></urls><custom3><style face="normal" font="default" size="100%">PUBMED 19995933</style></custom3><electronic-resource-num><style face="normal" font="default" size="100%">10.1128/AAC.00354-09</style></electronic-resource-num></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>57</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">57</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Nasveld, P. E.</style></author><author><style face="normal" font="default" size="100%">Edstein, M. D.</style></author><author><style face="normal" font="default" size="100%">Reid, M.</style></author><author><style face="normal" font="default" size="100%">Brennan, L.</style></author><author><style face="normal" font="default" size="100%">Harris, I. E.</style></author><author><style face="normal" font="default" size="100%">Kitchener, S. J.</style></author><author><style face="normal" font="default" size="100%">Leggat, P. A.</style></author><author><style face="normal" font="default" size="100%">Pickford, P.</style></author><author><style face="normal" font="default" size="100%">Kerr, C.</style></author><author><style face="normal" font="default" size="100%">Ohrt, C.</style></author><author><style face="normal" font="default" size="100%">Prescott, W.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Australian Army Malaria Institute, Brisbane, Queensland, Australia. P.Nasveld@uq.edu.au</style></auth-address><titles><title><style face="normal" font="default" size="100%">Randomized, double-blind study of the safety, tolerability, and efficacy of tafenoquine versus mefloquine for malaria prophylaxis in nonimmune subjects</style></title><secondary-title><style face="normal" font="default" size="100%">Antimicrob Agents Chemother</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Antimicrob Agents Chemother</style></full-title></periodical><pages><style face="normal" font="default" size="100%">792-8</style></pages><volume><style face="normal" font="default" size="100%">54</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2009/12/10</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Aminoquinolines/adverse effects/*therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Antimalarials/adverse effects/*therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Australia</style></keyword><keyword><style face="normal" font="default" size="100%">Double-Blind Method</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Malaria/*drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Mefloquine/adverse effects/*therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Military Personnel</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Young Adult</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2010</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0066-4804 (Print)&#xD;0066-4804</style></isbn><accession-num><style face="normal" font="default" size="100%">19995933</style></accession-num><abstract><style face="normal" font="default" size="100%">This study represents the first phase III trial of the safety, tolerability, and effectiveness of tafenoquine for malaria prophylaxis. In a randomized (3:1), double-blinded study, Australian soldiers received weekly malaria prophylaxis with 200 mg tafenoquine (492 subjects) or 250 mg mefloquine (162 subjects) for 6 months on a peacekeeping deployment to East Timor. After returning to Australia, tafenoquine-receiving subjects received a placebo and mefloquine-receiving subjects received 30 mg primaquine daily for 14 days. There were no clinically significant differences between hematological and biochemical parameters of the treatment groups. Treatment-related adverse events for the two groups were similar (tafenoquine, 13.4%; mefloquine, 11.7%). Three subjects on tafenoquine (0.6%) and none on mefloquine discontinued prophylaxis because of possible drug-related adverse events. No diagnoses of malaria occurred for either group during deployment, but 4 cases (0.9%) and 1 case (0.7%) of Plasmodium vivax infection occurred among the tafenoquine and mefloquine groups, respectively, up to 20 weeks after discontinuation of medication. In a subset of subjects recruited for detailed safety assessments, treatment-related mild vortex keratopathy was detected in 93% (69 of 74) of tafenoquine subjects but none of the 21 mefloquine subjects. The vortex keratopathy was not associated with any effect on visual acuity and was fully resolved in all subjects by 1 year. Tafenoquine appears to be safe and well tolerated as malaria prophylaxis. Although the volunteers&apos; precise exposure to malaria could not be proven in this study, tafenoquine appears to be a highly efficacious drug for malaria prophylaxis.</style></abstract><caption><style face="normal" font="default" size="100%">Duplicate</style></caption><notes><style face="normal" font="default" size="100%">1098-6596&#xD;Nasveld, Peter E&#xD;Edstein, Michael D&#xD;Reid, Mark&#xD;Brennan, Leonard&#xD;Harris, Ivor E&#xD;Kitchener, Scott J&#xD;Leggat, Peter A&#xD;Pickford, Philip&#xD;Kerr, Caron&#xD;Ohrt, Colin&#xD;Prescott, William&#xD;Tafenoquine Study Team&#xD;Clinical Trial, Phase III&#xD;Journal Article&#xD;Randomized Controlled Trial&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Research Support, U.S. Gov&apos;t, Non-P.H.S.&#xD;Antimicrob Agents Chemother. 2010 Feb;54(2):792-8. doi: 10.1128/AAC.00354-09. Epub 2009 Dec 7.</style></notes><urls></urls><custom2><style face="normal" font="default" size="100%">PMC2812156</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1128/aac.00354-09</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>120</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">120</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Nasveld, P. E.</style></author><author><style face="normal" font="default" size="100%">Edstein, M. D.</style></author><author><style face="normal" font="default" size="100%">Reid, M.</style></author><author><style face="normal" font="default" size="100%">Brennan, L.</style></author><author><style face="normal" font="default" size="100%">Harris, I. E.</style></author><author><style face="normal" font="default" size="100%">Kitchener, S. J.</style></author><author><style face="normal" font="default" size="100%">Leggat, P. A.</style></author><author><style face="normal" font="default" size="100%">Pickford, P.</style></author><author><style face="normal" font="default" size="100%">Kerr, C.</style></author><author><style face="normal" font="default" size="100%">Ohrt, C.</style></author><author><style face="normal" font="default" size="100%">Prescott, W.</style></author><author><style face="normal" font="default" size="100%">Rieckmann, K.</style></author><author><style face="normal" font="default" size="100%">Cooper, B.</style></author><author><style face="normal" font="default" size="100%">Frances, S.</style></author><author><style face="normal" font="default" size="100%">Reid, M.</style></author><author><style face="normal" font="default" size="100%">Auliff, A.</style></author><author><style face="normal" font="default" size="100%">Russell, B.</style></author><author><style face="normal" font="default" size="100%">McLeod-Robertson, S.</style></author><author><style face="normal" font="default" size="100%">Staley, J.</style></author><author><style face="normal" font="default" size="100%">Rowcliffe, K.</style></author><author><style face="normal" font="default" size="100%">Ross, J.</style></author><author><style face="normal" font="default" size="100%">Potter, B.</style></author><author><style face="normal" font="default" size="100%">Barker, K.</style></author><author><style face="normal" font="default" size="100%">Galvin, D.</style></author><author><style face="normal" font="default" size="100%">Aultman, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">P. E. Nasveld, Centre for Military and Veterans&apos; Health, Mayne Medical School, University of Queensland, Herston, QLD 4006, Australia</style></auth-address><titles><title><style face="normal" font="default" size="100%">Randomized, double-blind study of the safety, tolerability, and efficacy of tafenoquine versus mefloquine for malaria prophylaxis in nonimmune subjects</style></title><secondary-title><style face="normal" font="default" size="100%">Antimicrobial Agents and Chemotherapy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Antimicrobial Agents and Chemotherapy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">792-798</style></pages><volume><style face="normal" font="default" size="100%">54</style></volume><number><style face="normal" font="default" size="100%">2</style></number><keywords><keyword><style face="normal" font="default" size="100%">mefloquine</style></keyword><keyword><style face="normal" font="default" size="100%">placebo</style></keyword><keyword><style face="normal" font="default" size="100%">primaquine</style></keyword><keyword><style face="normal" font="default" size="100%">tafenoquine</style></keyword><keyword><style face="normal" font="default" size="100%">abdominal pain</style></keyword><keyword><style face="normal" font="default" size="100%">abnormal dreaming</style></keyword><keyword><style face="normal" font="default" size="100%">adult</style></keyword><keyword><style face="normal" font="default" size="100%">agitation</style></keyword><keyword><style face="normal" font="default" size="100%">amnesia</style></keyword><keyword><style face="normal" font="default" size="100%">anxiety</style></keyword><keyword><style face="normal" font="default" size="100%">arthralgia</style></keyword><keyword><style face="normal" font="default" size="100%">article</style></keyword><keyword><style face="normal" font="default" size="100%">Australia</style></keyword><keyword><style face="normal" font="default" size="100%">backache</style></keyword><keyword><style face="normal" font="default" size="100%">clinical trial</style></keyword><keyword><style face="normal" font="default" size="100%">control group</style></keyword><keyword><style face="normal" font="default" size="100%">controlled clinical trial</style></keyword><keyword><style face="normal" font="default" size="100%">controlled study</style></keyword><keyword><style face="normal" font="default" size="100%">coordination disorder</style></keyword><keyword><style face="normal" font="default" size="100%">depression</style></keyword><keyword><style face="normal" font="default" size="100%">dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">diarrhea</style></keyword><keyword><style face="normal" font="default" size="100%">dizziness</style></keyword><keyword><style face="normal" font="default" size="100%">double blind procedure</style></keyword><keyword><style face="normal" font="default" size="100%">drug efficacy</style></keyword><keyword><style face="normal" font="default" size="100%">drug safety</style></keyword><keyword><style face="normal" font="default" size="100%">drug tolerability</style></keyword><keyword><style face="normal" font="default" size="100%">drug withdrawal</style></keyword><keyword><style face="normal" font="default" size="100%">euphoria</style></keyword><keyword><style face="normal" font="default" size="100%">female</style></keyword><keyword><style face="normal" font="default" size="100%">gastroenteritis</style></keyword><keyword><style face="normal" font="default" size="100%">headache</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">hyperesthesia</style></keyword><keyword><style face="normal" font="default" size="100%">insomnia</style></keyword><keyword><style face="normal" font="default" size="100%">keratopathy</style></keyword><keyword><style face="normal" font="default" size="100%">loading drug dose</style></keyword><keyword><style face="normal" font="default" size="100%">maintenance therapy</style></keyword><keyword><style face="normal" font="default" size="100%">malaria falciparum</style></keyword><keyword><style face="normal" font="default" size="100%">male</style></keyword><keyword><style face="normal" font="default" size="100%">musculoskeletal injury</style></keyword><keyword><style face="normal" font="default" size="100%">nausea</style></keyword><keyword><style face="normal" font="default" size="100%">paroniria</style></keyword><keyword><style face="normal" font="default" size="100%">patient compliance</style></keyword><keyword><style face="normal" font="default" size="100%">pharyngitis</style></keyword><keyword><style face="normal" font="default" size="100%">phase 3 clinical trial</style></keyword><keyword><style face="normal" font="default" size="100%">Plasmodium vivax malaria</style></keyword><keyword><style face="normal" font="default" size="100%">priority journal</style></keyword><keyword><style face="normal" font="default" size="100%">prophylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">randomized controlled trial</style></keyword><keyword><style face="normal" font="default" size="100%">rash</style></keyword><keyword><style face="normal" font="default" size="100%">risk assessment</style></keyword><keyword><style face="normal" font="default" size="100%">side effect</style></keyword><keyword><style face="normal" font="default" size="100%">sleep disorder</style></keyword><keyword><style face="normal" font="default" size="100%">military personnel</style></keyword><keyword><style face="normal" font="default" size="100%">somnolence</style></keyword><keyword><style face="normal" font="default" size="100%">Timor-Leste</style></keyword><keyword><style face="normal" font="default" size="100%">treatment duration</style></keyword><keyword><style face="normal" font="default" size="100%">tremor</style></keyword><keyword><style face="normal" font="default" size="100%">upper respiratory tract infection</style></keyword><keyword><style face="normal" font="default" size="100%">vertigo</style></keyword><keyword><style face="normal" font="default" size="100%">virus infection</style></keyword><keyword><style face="normal" font="default" size="100%">visual acuity</style></keyword><keyword><style face="normal" font="default" size="100%">vomiting</style></keyword><keyword><style face="normal" font="default" size="100%">lariam</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2010</style></year></dates><isbn><style face="normal" font="default" size="100%">0066-4804&#xD;1098-6596</style></isbn><abstract><style face="normal" font="default" size="100%">This study represents the first phase III trial of the safety, tolerability, and effectiveness of tafenoquine for malaria prophylaxis. In a randomized (3:1), double-blinded study, Australian soldiers received weekly malaria prophylaxis with 200 mg tafenoquine (492 subjects) or 250 mg mefloquine (162 subjects) for 6 months on a peacekeeping deployment to East Timor. After returning to Australia, tafenoquine-receiving subjects received a placebo and mefloquine-receiving subjects received 30 mg primaquine daily for 14 days. There were no clinically significant differences between hematological and biochemical parameters of the treatment groups. Treatment-related adverse events for the two groups were similar (tafenoquine, 13.4%; mefloquine, 11.7%). Three subjects on tafenoquine (0.6%) and none on mefloquine discontinued prophylaxis because of possible drug-related adverse events. No diagnoses of malaria occurred for either group during deployment, but 4 cases (0.9%) and 1 case (0.7%) of Plasmodium vivax infection occurred among the tafenoquine and mefloquine groups, respectively, up to 20 weeks after discontinuation of medication. In a subset of subjects recruited for detailed safety assessments, treatment-related mild vortex keratopathy was detected in 93% (69 of 74) of tafenoquine subjects but none of the 21 mefloquine subjects. The vortex keratopathy was not associated with any effect on visual acuity and was fully resolved in all subjects by 1 year. Tafenoquine appears to be safe and well tolerated as malaria prophylaxis. Although the volunteers&apos; precise exposure to malaria could not be proven in this study, tafenoquine appears to be a highly efficacious drug for malaria prophylaxis. Copyright © 2010, American Society for Microbiology. All Rights Reserved.</style></abstract><caption><style face="normal" font="default" size="100%">Duplicate</style></caption><notes><style face="normal" font="default" size="100%">L358224558&#xD;2010-02-11&#xD;2010-02-22</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L358224558&amp;from=export</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1128/AAC.00354-09</style></url></related-urls><pdf-urls><url>internal-pdf://4200975394/Antimicrobial Agents and Chemotherapy-2010-Nas.pdf</url></pdf-urls></urls><custom1><style face="normal" font="default" size="100%">lariam(Hoffmann La Roche)</style></custom1><custom2><style face="normal" font="default" size="100%">Glaxo SmithKline&#xD;Hoffmann La Roche</style></custom2><custom5><style face="normal" font="default" size="100%">19995933</style></custom5><electronic-resource-num><style face="normal" font="default" size="100%">10.1128/AAC.00354-09</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase&#xD;Medline</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>182</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">182</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Fukuda, M. M.</style></author><author><style face="normal" font="default" size="100%">Krudsood, S.</style></author><author><style face="normal" font="default" size="100%">Mohamed, K.</style></author><author><style face="normal" font="default" size="100%">Green, J. A.</style></author><author><style face="normal" font="default" size="100%">Warrasak, S.</style></author><author><style face="normal" font="default" size="100%">Noedl, H.</style></author><author><style face="normal" font="default" size="100%">Euswas, A.</style></author><author><style face="normal" font="default" size="100%">Ittiverakul, M.</style></author><author><style face="normal" font="default" size="100%">Buathong, N.</style></author><author><style face="normal" font="default" size="100%">Sriwichai, S.</style></author><author><style face="normal" font="default" size="100%">et al.,</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">A randomized, double-blind, active-control trial to evaluate the efficacy and safety of a three day course of tafenoquine monotherapy for the treatment of Plasmodium vivax malaria</style></title><secondary-title><style face="normal" font="default" size="100%">PloS one</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">PLoS One</style></full-title></periodical><pages><style face="normal" font="default" size="100%">e0187376</style></pages><volume><style face="normal" font="default" size="100%">12</style></volume><number><style face="normal" font="default" size="100%">11</style></number><keywords><keyword><style face="normal" font="default" size="100%">*Plasmodium vivax malaria/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">*tafenoquine/ae [Adverse Drug Reaction]</style></keyword><keyword><style face="normal" font="default" size="100%">*tafenoquine/cm [Drug Comparison]</style></keyword><keyword><style face="normal" font="default" size="100%">*tafenoquine/cr [Drug Concentration]</style></keyword><keyword><style face="normal" font="default" size="100%">*tafenoquine/ct [Clinical Trial]</style></keyword><keyword><style face="normal" font="default" size="100%">*tafenoquine/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Abdominal pain/si [Side Effect]</style></keyword><keyword><style face="normal" font="default" size="100%">Abscess/si [Side Effect]</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Aminoquinolines [blood, pharmacology, *therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Anemia/si [Side Effect]</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Article</style></keyword><keyword><style face="normal" font="default" size="100%">Asthenia/si [Side Effect]</style></keyword><keyword><style face="normal" font="default" size="100%">Chloroquine/ae [Adverse Drug Reaction]</style></keyword><keyword><style face="normal" font="default" size="100%">Chloroquine/cb [Drug Combination]</style></keyword><keyword><style face="normal" font="default" size="100%">Chloroquine/cm [Drug Comparison]</style></keyword><keyword><style face="normal" font="default" size="100%">Chloroquine/ct [Clinical Trial]</style></keyword><keyword><style face="normal" font="default" size="100%">Chloroquine/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Conjunctivitis/si [Side Effect]</style></keyword><keyword><style face="normal" font="default" size="100%">Controlled study</style></keyword><keyword><style face="normal" font="default" size="100%">Creatinine blood level</style></keyword><keyword><style face="normal" font="default" size="100%">Creatinine/ec [Endogenous Compound]</style></keyword><keyword><style face="normal" font="default" size="100%">Diarrhea/si [Side Effect]</style></keyword><keyword><style face="normal" font="default" size="100%">Dizziness/si [Side Effect]</style></keyword><keyword><style face="normal" font="default" size="100%">Dose‐Response Relationship, Drug</style></keyword><keyword><style face="normal" font="default" size="100%">Double blind procedure</style></keyword><keyword><style face="normal" font="default" size="100%">Double‐Blind Method</style></keyword><keyword><style face="normal" font="default" size="100%">Drug blood level</style></keyword><keyword><style face="normal" font="default" size="100%">Drug efficacy</style></keyword><keyword><style face="normal" font="default" size="100%">Drug safety</style></keyword><keyword><style face="normal" font="default" size="100%">Drug treatment failure</style></keyword><keyword><style face="normal" font="default" size="100%">Dyspepsia/si [Side Effect]</style></keyword><keyword><style face="normal" font="default" size="100%">Eczema/si [Side Effect]</style></keyword><keyword><style face="normal" font="default" size="100%">Eosinophil count</style></keyword><keyword><style face="normal" font="default" size="100%">Eosinophilia/si [Side Effect]</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Fever [complications]</style></keyword><keyword><style face="normal" font="default" size="100%">Fever/si [Side Effect]</style></keyword><keyword><style face="normal" font="default" size="100%">Gametocyte</style></keyword><keyword><style face="normal" font="default" size="100%">Headache/si [Side Effect]</style></keyword><keyword><style face="normal" font="default" size="100%">Hepatomegaly/si [Side Effect]</style></keyword><keyword><style face="normal" font="default" size="100%">Human</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Hypokalemia/si [Side Effect]</style></keyword><keyword><style face="normal" font="default" size="100%">Keratopathy/si [Side Effect]</style></keyword><keyword><style face="normal" font="default" size="100%">Limb abscess/si [Side Effect]</style></keyword><keyword><style face="normal" font="default" size="100%">Limb disease/si [Side Effect]</style></keyword><keyword><style face="normal" font="default" size="100%">Liver enzyme/ec [Endogenous Compound]</style></keyword><keyword><style face="normal" font="default" size="100%">Major clinical study</style></keyword><keyword><style face="normal" font="default" size="100%">Malaria falciparum/si [Side Effect]</style></keyword><keyword><style face="normal" font="default" size="100%">Malaria, Vivax [blood, *drug therapy, parasitology]</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Methemoglobin/ec [Endogenous Compound]</style></keyword><keyword><style face="normal" font="default" size="100%">Methemoglobinemia/si [Side Effect]</style></keyword><keyword><style face="normal" font="default" size="100%">Monotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">Myalgia/si [Side Effect]</style></keyword><keyword><style face="normal" font="default" size="100%">Nausea/si [Side Effect]</style></keyword><keyword><style face="normal" font="default" size="100%">Nose obstruction/si [Side Effect]</style></keyword><keyword><style face="normal" font="default" size="100%">Parasite clearance</style></keyword><keyword><style face="normal" font="default" size="100%">Parasitemia</style></keyword><keyword><style face="normal" font="default" size="100%">Parasites [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Parasitosis/si [Side Effect]</style></keyword><keyword><style face="normal" font="default" size="100%">Phase 2 clinical trial</style></keyword><keyword><style face="normal" font="default" size="100%">Placebo</style></keyword><keyword><style face="normal" font="default" size="100%">Plasmodium vivax</style></keyword><keyword><style face="normal" font="default" size="100%">Plasmodium vivax malaria/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Primaquine/ae [Adverse Drug Reaction]</style></keyword><keyword><style face="normal" font="default" size="100%">Primaquine/cb [Drug Combination]</style></keyword><keyword><style face="normal" font="default" size="100%">Primaquine/cm [Drug Comparison]</style></keyword><keyword><style face="normal" font="default" size="100%">Primaquine/ct [Clinical Trial]</style></keyword><keyword><style face="normal" font="default" size="100%">Primaquine/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized controlled trial</style></keyword><keyword><style face="normal" font="default" size="100%">Relapse</style></keyword><keyword><style face="normal" font="default" size="100%">Retina disease/si [Side Effect]</style></keyword><keyword><style face="normal" font="default" size="100%">Retinopathy/si [Side Effect]</style></keyword><keyword><style face="normal" font="default" size="100%">Side effect/si [Side Effect]</style></keyword><keyword><style face="normal" font="default" size="100%">Skin abscess/si [Side Effect]</style></keyword><keyword><style face="normal" font="default" size="100%">Thailand</style></keyword><keyword><style face="normal" font="default" size="100%">Thrombocytopenia/si [Side Effect]</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Upper respiratory tract infection/si [Side Effect]</style></keyword><keyword><style face="normal" font="default" size="100%">Vomiting/si [Side Effect]</style></keyword><keyword><style face="normal" font="default" size="100%">Young Adult</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2017</style></year></dates><accession-num><style face="normal" font="default" size="100%">CN-01425991</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Tafenoquine is an investigational 8‐aminoquinoline for the prevention of Plasmodium vivax relapse. Tafenoquine has a long half‐life and the potential for more convenient dosing, compared with the currently recommended 14‐day primaquine regimen. METHODS: This randomized, active‐control, double‐blind trial was conducted in Bangkok, Thailand. Seventy patients with microscopically confirmed P. vivax were randomized (2:1) to tafenoquine 400 mg once daily for 3 days or 2500 mg total dose chloroquine phosphate (1500 mg chloroquine base) given over 3 days plus primaquine 15 mg daily for 14 days. Patients were followed to day 120. RESULTS: Day 28 adequate clinical response rate in the per‐protocol population was 93% (40/43) (90%CI 83‐98%) with tafenoquine, and 100% (22/22) (90%CI 87‐100%) with chloroquine/primaquine. Day 120 relapse prevention was 100% (35/35) with tafenoquine (90%CI 92‐100%), and 95% (19/20) (90%CI 78‐100%) with chloroquine/primaquine. Mean (SD) parasite, gametocyte and fever clearance times with tafenoquine were 82.5 h (32.3), 49.1 h (33.0), and 41.1 h (31.4) versus 40.0 h (15.7), 22.7 h (16.4), and 24.7 h (17.7) with chloroquine/primaquine, respectively. Peak methemoglobin was 1.4‐25.6% (median 7.4%, mean 9.1%) in the tafenoquine arm, and 0.5‐5.9% (median 1.5%, mean 1.9%) in the chloroquine/primaquine arm. There were no clinical symptoms of methemoglobinemia in any patient. DISCUSSION: Although there was no difference in efficacy in this study, the slow rate of parasite, gametocyte and fever clearance indicates that tafenoquine should not be used as monotherapy for radical cure of P. vivax malaria. Also, monotherapy increases the potential risk of resistance developing to this long‐acting agent. Clinical trials of single‐dose tafenoquine 300 mg combined with standard 3‐day chloroquine or artemisinin‐based combination therapy are ongoing. TRIAL REGISTRATION: Clinicaltrials.gov NCT01290601.</style></abstract><caption><style face="normal" font="default" size="100%">Duplicate</style></caption><work-type><style face="normal" font="default" size="100%">Journal Article; Randomized Controlled Trial</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01425991/full</style></url></related-urls></urls><custom3><style face="normal" font="default" size="100%">PUBMED 29121061,EMBASE 619150463</style></custom3><electronic-resource-num><style face="normal" font="default" size="100%">10.1371/journal.pone.0187376</style></electronic-resource-num></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>37</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">37</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Fukuda, M. M.</style></author><author><style face="normal" font="default" size="100%">Krudsood, S.</style></author><author><style face="normal" font="default" size="100%">Mohamed, K.</style></author><author><style face="normal" font="default" size="100%">Green, J. A.</style></author><author><style face="normal" font="default" size="100%">Warrasak, S.</style></author><author><style face="normal" font="default" size="100%">Noedl, H.</style></author><author><style face="normal" font="default" size="100%">Euswas, A.</style></author><author><style face="normal" font="default" size="100%">Ittiverakul, M.</style></author><author><style face="normal" font="default" size="100%">Buathong, N.</style></author><author><style face="normal" font="default" size="100%">Sriwichai, S.</style></author><author><style face="normal" font="default" size="100%">Miller, R. S.</style></author><author><style face="normal" font="default" size="100%">Ohrt, C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Armed Forces Research Institute of Medical Science, Bangkok, Thailand.&#xD;Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.&#xD;GlaxoSmithKline Research and Development, Uxbridge, Middlesex, United Kingdom.&#xD;Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.&#xD;Walter Reed Army Institute of Research, Silver Spring, Maryland, United States of America.</style></auth-address><titles><title><style face="normal" font="default" size="100%">A randomized, double-blind, active-control trial to evaluate the efficacy and safety of a three day course of tafenoquine monotherapy for the treatment of Plasmodium vivax malaria</style></title><secondary-title><style face="normal" font="default" size="100%">PLoS One</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">PLoS One</style></full-title></periodical><pages><style face="normal" font="default" size="100%">e0187376</style></pages><volume><style face="normal" font="default" size="100%">12</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2017/11/10</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Aminoquinolines/blood/pharmacology/*therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Dose-Response Relationship, Drug</style></keyword><keyword><style face="normal" font="default" size="100%">Double-Blind Method</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Fever/complications</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Malaria, Vivax/blood/*drug therapy/parasitology</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Parasites/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Plasmodium vivax</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Young Adult</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2017</style></year></dates><isbn><style face="normal" font="default" size="100%">1932-6203</style></isbn><accession-num><style face="normal" font="default" size="100%">29121061</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Tafenoquine is an investigational 8-aminoquinoline for the prevention of Plasmodium vivax relapse. Tafenoquine has a long half-life and the potential for more convenient dosing, compared with the currently recommended 14-day primaquine regimen. METHODS: This randomized, active-control, double-blind trial was conducted in Bangkok, Thailand. Seventy patients with microscopically confirmed P. vivax were randomized (2:1) to tafenoquine 400 mg once daily for 3 days or 2500 mg total dose chloroquine phosphate (1500 mg chloroquine base) given over 3 days plus primaquine 15 mg daily for 14 days. Patients were followed to day 120. RESULTS: Day 28 adequate clinical response rate in the per-protocol population was 93% (40/43) (90%CI 83-98%) with tafenoquine, and 100% (22/22) (90%CI 87-100%) with chloroquine/primaquine. Day 120 relapse prevention was 100% (35/35) with tafenoquine (90%CI 92-100%), and 95% (19/20) (90%CI 78-100%) with chloroquine/primaquine. Mean (SD) parasite, gametocyte and fever clearance times with tafenoquine were 82.5 h (32.3), 49.1 h (33.0), and 41.1 h (31.4) versus 40.0 h (15.7), 22.7 h (16.4), and 24.7 h (17.7) with chloroquine/primaquine, respectively. Peak methemoglobin was 1.4-25.6% (median 7.4%, mean 9.1%) in the tafenoquine arm, and 0.5-5.9% (median 1.5%, mean 1.9%) in the chloroquine/primaquine arm. There were no clinical symptoms of methemoglobinemia in any patient. DISCUSSION: Although there was no difference in efficacy in this study, the slow rate of parasite, gametocyte and fever clearance indicates that tafenoquine should not be used as monotherapy for radical cure of P. vivax malaria. Also, monotherapy increases the potential risk of resistance developing to this long-acting agent. Clinical trials of single-dose tafenoquine 300 mg combined with standard 3-day chloroquine or artemisinin-based combination therapy are ongoing. TRIAL REGISTRATION: Clinicaltrials.gov NCT01290601.</style></abstract><caption><style face="normal" font="default" size="100%">Duplicate</style></caption><notes><style face="normal" font="default" size="100%">1932-6203&#xD;Fukuda, Mark M&#xD;Orcid: 0000-0001-5337-8937&#xD;Krudsood, Srivicha&#xD;Mohamed, Khadeeja&#xD;Green, Justin A&#xD;Warrasak, Sukhuma&#xD;Noedl, Harald&#xD;Euswas, Ataya&#xD;Ittiverakul, Mali&#xD;Buathong, Nillawan&#xD;Sriwichai, Sabaithip&#xD;Miller, R Scott&#xD;Ohrt, Colin&#xD;Journal Article&#xD;Randomized Controlled Trial&#xD;PLoS One. 2017 Nov 9;12(11):e0187376. doi: 10.1371/journal.pone.0187376. eCollection 2017.</style></notes><urls></urls><custom2><style face="normal" font="default" size="100%">PMC5679603 the company. HN has received grants and personal fees from GlaxoSmithKline. This does not alter our adherence to PLOS ONE policies on sharing data and materials. For all other authors there is no potential conflict of interest to report, other than writing support for this manuscript as noted in the acknowledgments.</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1371/journal.pone.0187376</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>97</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">97</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Fukuda, M. M.</style></author><author><style face="normal" font="default" size="100%">Krudsood, S.</style></author><author><style face="normal" font="default" size="100%">Mohamed, K.</style></author><author><style face="normal" font="default" size="100%">Green, J. A.</style></author><author><style face="normal" font="default" size="100%">Warrasak, S.</style></author><author><style face="normal" font="default" size="100%">Noedl, H.</style></author><author><style face="normal" font="default" size="100%">Euswas, A.</style></author><author><style face="normal" font="default" size="100%">Ittiverakul, M.</style></author><author><style face="normal" font="default" size="100%">Buathong, N.</style></author><author><style face="normal" font="default" size="100%">Sriwichai, S.</style></author><author><style face="normal" font="default" size="100%">Miller, R. S.</style></author><author><style face="normal" font="default" size="100%">Ohrt, C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">M.M. Fukuda, Armed Forces Research Institute of Medical Science, Bangkok, Thailand</style></auth-address><titles><title><style face="normal" font="default" size="100%">A randomized, double-blind, active-control trial to evaluate the efficacy and safety of a three day course of tafenoquine monotherapy for the treatment of Plasmodium vivax malaria</style></title><secondary-title><style face="normal" font="default" size="100%">PLoS ONE</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">PLoS One</style></full-title></periodical><volume><style face="normal" font="default" size="100%">12</style></volume><number><style face="normal" font="default" size="100%">11</style></number><keywords><keyword><style face="normal" font="default" size="100%">NCT01290601</style></keyword><keyword><style face="normal" font="default" size="100%">chloroquine</style></keyword><keyword><style face="normal" font="default" size="100%">creatinine</style></keyword><keyword><style face="normal" font="default" size="100%">liver enzyme</style></keyword><keyword><style face="normal" font="default" size="100%">methemoglobin</style></keyword><keyword><style face="normal" font="default" size="100%">placebo</style></keyword><keyword><style face="normal" font="default" size="100%">primaquine</style></keyword><keyword><style face="normal" font="default" size="100%">tafenoquine</style></keyword><keyword><style face="normal" font="default" size="100%">abdominal pain</style></keyword><keyword><style face="normal" font="default" size="100%">abscess</style></keyword><keyword><style face="normal" font="default" size="100%">adult</style></keyword><keyword><style face="normal" font="default" size="100%">anemia</style></keyword><keyword><style face="normal" font="default" size="100%">article</style></keyword><keyword><style face="normal" font="default" size="100%">asthenia</style></keyword><keyword><style face="normal" font="default" size="100%">conjunctivitis</style></keyword><keyword><style face="normal" font="default" size="100%">controlled study</style></keyword><keyword><style face="normal" font="default" size="100%">creatinine blood level</style></keyword><keyword><style face="normal" font="default" size="100%">diarrhea</style></keyword><keyword><style face="normal" font="default" size="100%">dizziness</style></keyword><keyword><style face="normal" font="default" size="100%">double blind procedure</style></keyword><keyword><style face="normal" font="default" size="100%">drug blood level</style></keyword><keyword><style face="normal" font="default" size="100%">drug efficacy</style></keyword><keyword><style face="normal" font="default" size="100%">drug safety</style></keyword><keyword><style face="normal" font="default" size="100%">lack of drug effect</style></keyword><keyword><style face="normal" font="default" size="100%">dyspepsia</style></keyword><keyword><style face="normal" font="default" size="100%">eczema</style></keyword><keyword><style face="normal" font="default" size="100%">eosinophil count</style></keyword><keyword><style face="normal" font="default" size="100%">eosinophilia</style></keyword><keyword><style face="normal" font="default" size="100%">female</style></keyword><keyword><style face="normal" font="default" size="100%">fever</style></keyword><keyword><style face="normal" font="default" size="100%">gametocyte</style></keyword><keyword><style face="normal" font="default" size="100%">headache</style></keyword><keyword><style face="normal" font="default" size="100%">hepatomegaly</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">hypokalemia</style></keyword><keyword><style face="normal" font="default" size="100%">keratopathy</style></keyword><keyword><style face="normal" font="default" size="100%">limb abscess</style></keyword><keyword><style face="normal" font="default" size="100%">limb disease</style></keyword><keyword><style face="normal" font="default" size="100%">major clinical study</style></keyword><keyword><style face="normal" font="default" size="100%">malaria falciparum</style></keyword><keyword><style face="normal" font="default" size="100%">male</style></keyword><keyword><style face="normal" font="default" size="100%">methemoglobinemia</style></keyword><keyword><style face="normal" font="default" size="100%">monotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">myalgia</style></keyword><keyword><style face="normal" font="default" size="100%">nausea</style></keyword><keyword><style face="normal" font="default" size="100%">nose obstruction</style></keyword><keyword><style face="normal" font="default" size="100%">parasite clearance</style></keyword><keyword><style face="normal" font="default" size="100%">parasitemia</style></keyword><keyword><style face="normal" font="default" size="100%">parasitosis</style></keyword><keyword><style face="normal" font="default" size="100%">phase 2 clinical trial</style></keyword><keyword><style face="normal" font="default" size="100%">Plasmodium vivax malaria</style></keyword><keyword><style face="normal" font="default" size="100%">randomized controlled trial</style></keyword><keyword><style face="normal" font="default" size="100%">relapse</style></keyword><keyword><style face="normal" font="default" size="100%">retina disease</style></keyword><keyword><style face="normal" font="default" size="100%">retinopathy</style></keyword><keyword><style face="normal" font="default" size="100%">side effect</style></keyword><keyword><style face="normal" font="default" size="100%">skin abscess</style></keyword><keyword><style face="normal" font="default" size="100%">Thailand</style></keyword><keyword><style face="normal" font="default" size="100%">thrombocytopenia</style></keyword><keyword><style face="normal" font="default" size="100%">upper respiratory tract infection</style></keyword><keyword><style face="normal" font="default" size="100%">vomiting</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2017</style></year></dates><isbn><style face="normal" font="default" size="100%">1932-6203</style></isbn><abstract><style face="normal" font="default" size="100%">Background: Tafenoquine is an investigational 8-aminoquinoline for the prevention of Plasmodium vivax relapse. Tafenoquine has a long half-life and the potential for more convenient dosing, compared with the currently recommended 14-day primaquine regimen. Methods: This randomized, active-control, double-blind trial was conducted in Bangkok, Thailand. Seventy patients with microscopically confirmed P. vivax were randomized (2:1) to tafenoquine 400 mg once daily for 3 days or 2500 mg total dose chloroquine phosphate (1500 mg chloroquine base) given over 3 days plus primaquine 15 mg daily for 14 days. Patients were followed to day 120. Results: Day 28 adequate clinical response rate in the per-protocol population was 93% (40/43) (90%CI 83–98%) with tafenoquine, and 100% (22/22) (90%CI 87–100%) with chloroquine/ primaquine. Day 120 relapse prevention was 100% (35/35) with tafenoquine (90%CI 92–100%), and 95% (19/20) (90%CI 78–100%) with chloroquine/primaquine. Mean (SD) parasite, gametocyte and fever clearance times with tafenoquine were 82.5 h (32.3), 49.1 h (33.0), and 41.1 h (31.4) versus 40.0 h (15.7), 22.7 h (16.4), and 24.7 h (17.7) with chloroquine/primaquine, respectively. Peak methemoglobin was 1.4–25.6% (median 7.4%, mean 9.1%) in the tafenoquine arm, and 0.5–5.9% (median 1.5%, mean 1.9%) in the chloroquine/ primaquine arm. There were no clinical symptoms of methemoglobinemia in any patient. Discussion: Although there was no difference in efficacy in this study, the slow rate of parasite, gametocyte and fever clearance indicates that tafenoquine should not be used as monotherapy for radical cure of P. vivax malaria. Also, monotherapy increases the potential risk of resistance developing to this long-acting agent. Clinical trials of single-dose tafenoquine 300 mg combined with standard 3-day chloroquine or artemisinin-based combination therapy are ongoing. Trial registration: Clinicaltrials.gov NCT01290601.</style></abstract><caption><style face="normal" font="default" size="100%">Duplicate</style></caption><notes><style face="normal" font="default" size="100%">L619150463&#xD;2017-11-16&#xD;2017-11-22</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L619150463&amp;from=export</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1371/journal.pone.0187376</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">Astra Zeneca&#xD;Glaxo SmithKline(United Kingdom)&#xD;Muir</style></custom2><custom5><style face="normal" font="default" size="100%">29121061</style></custom5><electronic-resource-num><style face="normal" font="default" size="100%">10.1371/journal.pone.0187376</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase&#xD;Medline</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>183</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">183</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Per,</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">A RANDOMIZED, DOUBLE-BLIND, DOUBLE DUMMY, COMPARATIVE, MULTICENTER STUDY TO ASSESS THE INCIDENCE OF HEMOLYSIS, SAFETY, AND EFFICACY OF TAFENOQUINE (SB-252263, WR238605) VERSUS PRIMAQUINE IN THE TREATMENT OF SUBJECTS WITH PLASMODIUM VIVAX MALARIA</style></title><secondary-title><style face="normal" font="default" size="100%">http://www.who.int/trialsearch/Trial2.aspx?TrialID=PER-048-14</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">http://www.who.int/trialsearch/Trial2.aspx?TrialID=PER-048-14</style></full-title></periodical><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><accession-num><style face="normal" font="default" size="100%">CN-01828838</style></accession-num><abstract><style face="normal" font="default" size="100%">INTERVENTION: Tafenoquine 150 mg, Tablets. Tafenoquine Placebo, Tablets. Chloroquine Tablets, containing 500 mg chloroquine phosphate (equivalent to 300 mg chloroquine free base). Primaquine 15 mg, Capsules. Primaquine Placebo, Capsules. The total duration of treatment is 15 days. Chloroquine will be dosed orally once daily for three days starting on Day 1 of the study. Tafenoquine will be dosed orally as a single dose on Day 1 or Day 2 of the study. Primaquine will be given as a 14‐dose course administered orally once daily for 14 days starting from Day 1 or Day 2 of the study. CONDITION: ‐B51 Plasmodium vivax malaria ; Plasmodium vivax malaria Plasmodium vivax malaria PRIMARY OUTCOME: • Occurrence of clinically relevant hemolysis in all subjects; defined as, a decrease in hemoglobin of &amp;#8805;30% or &gt;3 g/dL from baseline; or, an overall drop in hemoglobin below 6.0 g/dL.; • Occurrence of clinically relevant hemolysis in female subjects with moderate (40‐70%) G6PD deficiency; defined as, a decrease in hemoglobin of &amp;#8805;30% or &gt;3 g/dL from baseline; or, an overall drop in hemoglobin below 6.0 g/dL.; NAME OF THE RESULT: • Occurrence of clinically relevant hemolysis in all subjects; • Occurrence of clinically relevant hemolysis in female subjects with moderate (40‐70%) G6PD deficiency; USED MEASURING METHOD :• a decrease in hemoglobin of &amp;#8805;30% or &gt;3 g/dL from baseline; or, an overall drop in hemoglobin below 6.0 g/dL.; PERIOD OF TIME WHERE THE MEASUREMENT WILL BE CONDUCTED AND WHICH WILL ALLOW OBTAINING THE PRIMARY RESULT: N/A SECONDARY OUTCOME: • Relapse‐free efficacy six months post‐dosing ; • Relapse‐free efficacy four months post‐dosing ; • Time to relapse ; • Parasite clearance time ; • Fever clearance time ; • Gametocyte clearance time ; • Recrudescence, defined as any P. vivax parasitemia occurring on or before Day 29 (i.e., blood stage treatment failure). ; • Incidence of genetically homologous and genetically heterologous P. vivax infections (determined by PCR) ; • Characterization of healthcare resource use and socio‐economic impact of P. vivax relapses and adverse events caused by treatment to prevent P. vivax relapses, especially hemolytic anemia. ; • PK and selected PD endpoints (e.g., relapse‐free efficacy, change in methemoglobin) if appropriate ; • Population PK parameters for tafenoquine including but not limited to oral clearance (CL/F) and volume of distribution (V/F) ; • Safety evaluation of data from clinical laboratory tests, urinalysis, spontaneous/elicited adverse event reporting, ECGs and vital signs in all subjects who received at least one dose of study medication. ; • Incidence of P. falciparum malaria ; NAME OF THE RESULT: N/A ; USED MEASURING METHOD :N/A ; PERIOD OF TIME WHERE THE MEASUREMENT WILL BE CONDUCTED AND WHICH WILL ALLOW OBTAINING THE SECONDARY RESULT: N/A INCLUSION CRITERIA: 1 A female is eligible to enter and participate in the study if she is non‐pregnant, non‐lactating and if she is of: a. Non‐childbearing potential defined as: post‐menopausal (12 months of spontaneous amenorrhea or &lt;6 months of spontaneous amenorrhea with serum FSH &gt;40 mIU/mL), or pre‐menopausal and has had a hysterectomy or a bilateral oophorectomy (removal of the ovaries) or a bilateral tubal ligation, negative pregnancy test or, b. Child‐bearing potential, has a negative pregnancy test at screening, and agrees to comply with one of the following during the treatment stage of the study and for a period of 90 days after stopping study medication 2.The subject has a glucose 6‐phosphate dehydrogenase (G6PD) value (measured by a quantitative spectrophotometric phenotype assay) as follows: • Female subjects must have an enzyme level ≥40% of the site median value for G6PD normal males. • Male subjects must have an enzyme level ≥70% of th</style></abstract><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01828838/full</style></url></related-urls></urls></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>151</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">151</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hale, B. R.</style></author><author><style face="normal" font="default" size="100%">Owusu-Agyei, S.</style></author><author><style face="normal" font="default" size="100%">Fryauff, D. J.</style></author><author><style face="normal" font="default" size="100%">Koram, K. A.</style></author><author><style face="normal" font="default" size="100%">Adjuik, M.</style></author><author><style face="normal" font="default" size="100%">Oduro, A. R.</style></author><author><style face="normal" font="default" size="100%">Prescott, W. R.</style></author><author><style face="normal" font="default" size="100%">Baird, J. K.</style></author><author><style face="normal" font="default" size="100%">Nkrumah, F.</style></author><author><style face="normal" font="default" size="100%">Ritchie, T. L.</style></author><author><style face="normal" font="default" size="100%">et al.,</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">A randomized, double-blind, placebo-controlled, dose-ranging trial of tafenoquine for weekly prophylaxis against Plasmodium falciparum</style></title><secondary-title><style face="normal" font="default" size="100%">Clinical infectious diseases</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Clinical Infectious Diseases</style></full-title></periodical><pages><style face="normal" font="default" size="100%">541‐549</style></pages><volume><style face="normal" font="default" size="100%">36</style></volume><number><style face="normal" font="default" size="100%">5</style></number><keywords><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Aminoquinolines [administration &amp; dosage, adverse effects, *therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Antimalarials [administration &amp; dosage, adverse effects, *therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Chemoprevention</style></keyword><keyword><style face="normal" font="default" size="100%">Double‐Blind Method</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Malaria, Falciparum [*prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Plasmodium falciparum [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2003</style></year></dates><accession-num><style face="normal" font="default" size="100%">CN-00413324</style></accession-num><abstract><style face="normal" font="default" size="100%">Tafenoquine is a promising new 8‐aminoquinoline drug that may be useful for malaria prophylaxis in nonpregnant persons with normal glucose‐6‐phosphate dehydrogenase (G6PD) function. A randomized, double‐blind, placebo‐controlled chemoprophylaxis trial was conducted with adult residents of northern Ghana to determine the minimum effective weekly dose of tafenoquine for the prevention of infection by Plasmodium falciparum. The primary end point was a positive malaria blood smear result during the 13 weeks of study drug coverage. Relative to the placebo, all 4 tafenoquine dosages demonstrated significant protection against P. falciparum infection: for 25 mg/week, protective efficacy was 32% (95% confidence interval [CI], 20%‐43%); for 50 mg/week, 84% (95% CI, 75%‐91%); for 100 mg/week, 87% (95% CI, 78%‐93%); and for 200 mg/week, 86% (95% CI, 76%‐92%). The mefloquine dosage of 250 mg/week also demonstrated significant protection against P. falciparum infection (protective efficacy, 86%; 95% CI, 72%‐93%). There was little difference between study groups in the adverse events reported, and there was no evidence of a relationship between tafenoquine dosage and reports of physical complaints or the occurrence of abnormal laboratory parameters. Tafenoquine dosages of 50, 100, and 200 mg/week were safe, well tolerated, and effective against P. falciparum infection in this study population.</style></abstract><caption><style face="normal" font="default" size="100%">Duplicate</style></caption><work-type><style face="normal" font="default" size="100%">Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, U.S. Gov&apos;t, Non‐P.H.S.</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.cochranelibrary.com/central/doi/10.1002/central/CN-00413324/full</style></url></related-urls></urls><custom3><style face="normal" font="default" size="100%">PUBMED 12594633</style></custom3><electronic-resource-num><style face="normal" font="default" size="100%">10.1086/367542</style></electronic-resource-num></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>71</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">71</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hale, B. R.</style></author><author><style face="normal" font="default" size="100%">Owusu-Agyei, S.</style></author><author><style face="normal" font="default" size="100%">Fryauff, D. J.</style></author><author><style face="normal" font="default" size="100%">Koram, K. A.</style></author><author><style face="normal" font="default" size="100%">Adjuik, M.</style></author><author><style face="normal" font="default" size="100%">Oduro, A. R.</style></author><author><style face="normal" font="default" size="100%">Prescott, W. R.</style></author><author><style face="normal" font="default" size="100%">Baird, J. K.</style></author><author><style face="normal" font="default" size="100%">Nkrumah, F.</style></author><author><style face="normal" font="default" size="100%">Ritchie, T. L.</style></author><author><style face="normal" font="default" size="100%">Franke, E. D.</style></author><author><style face="normal" font="default" size="100%">Binka, F. N.</style></author><author><style face="normal" font="default" size="100%">Horton, J.</style></author><author><style face="normal" font="default" size="100%">Hoffman, S. L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">US Navy Medical Research Unit No. 3, Cairo, Egypt.</style></auth-address><titles><title><style face="normal" font="default" size="100%">A randomized, double-blind, placebo-controlled, dose-ranging trial of tafenoquine for weekly prophylaxis against Plasmodium falciparum</style></title><secondary-title><style face="normal" font="default" size="100%">Clin Infect Dis</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Clin Infect Dis</style></full-title></periodical><pages><style face="normal" font="default" size="100%">541-9</style></pages><volume><style face="normal" font="default" size="100%">36</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2003/02/21</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Aminoquinolines/administration &amp; dosage/adverse effects/*therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Antimalarials/administration &amp; dosage/adverse effects/*therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Chemoprevention</style></keyword><keyword><style face="normal" font="default" size="100%">Double-Blind Method</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Malaria, Falciparum/*prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">*Plasmodium falciparum/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2003</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar 1</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1058-4838</style></isbn><accession-num><style face="normal" font="default" size="100%">12594633</style></accession-num><abstract><style face="normal" font="default" size="100%">Tafenoquine is a promising new 8-aminoquinoline drug that may be useful for malaria prophylaxis in nonpregnant persons with normal glucose-6-phosphate dehydrogenase (G6PD) function. A randomized, double-blind, placebo-controlled chemoprophylaxis trial was conducted with adult residents of northern Ghana to determine the minimum effective weekly dose of tafenoquine for the prevention of infection by Plasmodium falciparum. The primary end point was a positive malaria blood smear result during the 13 weeks of study drug coverage. Relative to the placebo, all 4 tafenoquine dosages demonstrated significant protection against P. falciparum infection: for 25 mg/week, protective efficacy was 32% (95% confidence interval [CI], 20%-43%); for 50 mg/week, 84% (95% CI, 75%-91%); for 100 mg/week, 87% (95% CI, 78%-93%); and for 200 mg/week, 86% (95% CI, 76%-92%). The mefloquine dosage of 250 mg/week also demonstrated significant protection against P. falciparum infection (protective efficacy, 86%; 95% CI, 72%-93%). There was little difference between study groups in the adverse events reported, and there was no evidence of a relationship between tafenoquine dosage and reports of physical complaints or the occurrence of abnormal laboratory parameters. Tafenoquine dosages of 50, 100, and 200 mg/week were safe, well tolerated, and effective against P. falciparum infection in this study population.</style></abstract><caption><style face="normal" font="default" size="100%">Duplicate</style></caption><notes><style face="normal" font="default" size="100%">1537-6591&#xD;Hale, Braden R&#xD;Owusu-Agyei, Seth&#xD;Fryauff, David J&#xD;Koram, Kwadwo A&#xD;Adjuik, Martin&#xD;Oduro, Abraham R&#xD;Prescott, W Roy&#xD;Baird, J Kevin&#xD;Nkrumah, Francis&#xD;Ritchie, Thomas L&#xD;Franke, Eileen D&#xD;Binka, Fred N&#xD;Horton, John&#xD;Hoffman, Stephen L&#xD;Clinical Trial&#xD;Journal Article&#xD;Randomized Controlled Trial&#xD;Research Support, U.S. Gov&apos;t, Non-P.H.S.&#xD;United States&#xD;Clin Infect Dis. 2003 Mar 1;36(5):541-9. doi: 10.1086/367542. Epub 2003 Feb 14.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1086/367542</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>134</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">134</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hale, B. R.</style></author><author><style face="normal" font="default" size="100%">Owusu-Agyei, S.</style></author><author><style face="normal" font="default" size="100%">Fryauff, D. J.</style></author><author><style face="normal" font="default" size="100%">Koram, K. A.</style></author><author><style face="normal" font="default" size="100%">Adjuik, M.</style></author><author><style face="normal" font="default" size="100%">Oduro, A. R.</style></author><author><style face="normal" font="default" size="100%">Prescott, W. R.</style></author><author><style face="normal" font="default" size="100%">Baird, J. K.</style></author><author><style face="normal" font="default" size="100%">Nkrumah, F.</style></author><author><style face="normal" font="default" size="100%">Ritchie, T. L.</style></author><author><style face="normal" font="default" size="100%">Franke, E. D.</style></author><author><style face="normal" font="default" size="100%">Binka, F. N.</style></author><author><style face="normal" font="default" size="100%">Horton, J.</style></author><author><style face="normal" font="default" size="100%">Hoffman, S. L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">D.J. Fryauff, Malaria Program, Naval Medical Research Center, Silver Spring, MD 20910-7500, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">A randomized, double-blind, placebo-controlled, dose-ranging trial of tafenoquine for weekly prophylaxis against Plasmodium falciparum</style></title><secondary-title><style face="normal" font="default" size="100%">Clinical Infectious Diseases</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Clinical Infectious Diseases</style></full-title></periodical><pages><style face="normal" font="default" size="100%">541-549</style></pages><volume><style face="normal" font="default" size="100%">36</style></volume><number><style face="normal" font="default" size="100%">5</style></number><keywords><keyword><style face="normal" font="default" size="100%">mefloquine</style></keyword><keyword><style face="normal" font="default" size="100%">tafenoquine</style></keyword><keyword><style face="normal" font="default" size="100%">abdominal pain</style></keyword><keyword><style face="normal" font="default" size="100%">adult</style></keyword><keyword><style face="normal" font="default" size="100%">aged</style></keyword><keyword><style face="normal" font="default" size="100%">arthralgia</style></keyword><keyword><style face="normal" font="default" size="100%">article</style></keyword><keyword><style face="normal" font="default" size="100%">backache</style></keyword><keyword><style face="normal" font="default" size="100%">blood smear</style></keyword><keyword><style face="normal" font="default" size="100%">chemoprophylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">clinical trial</style></keyword><keyword><style face="normal" font="default" size="100%">confidence interval</style></keyword><keyword><style face="normal" font="default" size="100%">controlled clinical trial</style></keyword><keyword><style face="normal" font="default" size="100%">controlled study</style></keyword><keyword><style face="normal" font="default" size="100%">diarrhea</style></keyword><keyword><style face="normal" font="default" size="100%">dose response</style></keyword><keyword><style face="normal" font="default" size="100%">double blind procedure</style></keyword><keyword><style face="normal" font="default" size="100%">drug efficacy</style></keyword><keyword><style face="normal" font="default" size="100%">drug eruption</style></keyword><keyword><style face="normal" font="default" size="100%">drug safety</style></keyword><keyword><style face="normal" font="default" size="100%">drug tolerability</style></keyword><keyword><style face="normal" font="default" size="100%">dysentery</style></keyword><keyword><style face="normal" font="default" size="100%">female</style></keyword><keyword><style face="normal" font="default" size="100%">gastritis</style></keyword><keyword><style face="normal" font="default" size="100%">gastrointestinal symptom</style></keyword><keyword><style face="normal" font="default" size="100%">Ghana</style></keyword><keyword><style face="normal" font="default" size="100%">headache</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">laboratory test</style></keyword><keyword><style face="normal" font="default" size="100%">major clinical study</style></keyword><keyword><style face="normal" font="default" size="100%">malaria</style></keyword><keyword><style face="normal" font="default" size="100%">malaria control</style></keyword><keyword><style face="normal" font="default" size="100%">male</style></keyword><keyword><style face="normal" font="default" size="100%">musculoskeletal disease</style></keyword><keyword><style face="normal" font="default" size="100%">myalgia</style></keyword><keyword><style face="normal" font="default" size="100%">Plasmodium falciparum</style></keyword><keyword><style face="normal" font="default" size="100%">priority journal</style></keyword><keyword><style face="normal" font="default" size="100%">randomized controlled trial</style></keyword><keyword><style face="normal" font="default" size="100%">respiratory tract infection</style></keyword><keyword><style face="normal" font="default" size="100%">side effect</style></keyword><keyword><style face="normal" font="default" size="100%">sore throat</style></keyword><keyword><style face="normal" font="default" size="100%">thrombocyte aggregation</style></keyword><keyword><style face="normal" font="default" size="100%">thrombocytopenia</style></keyword><keyword><style face="normal" font="default" size="100%">treatment outcome</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2003</style></year></dates><isbn><style face="normal" font="default" size="100%">1058-4838</style></isbn><abstract><style face="normal" font="default" size="100%">Tafenoquine is a promising new 8-aminoquinoline drug that may be useful for malaria prophylaxis in non-pregnant persons with normal glucose-6-phosphate dehydrogenase (G6PD) function. A randomized, double-blind, placebo-controlled chemoprophylaxis trial was conducted with adult residents of northern Ghana to determine the minimum effective weekly dose of tafenoquine for the prevention of infection by Plasmodium falciparum. The primary end point was a positive malaria blood smear result during the 13 weeks of study drug coverage. Relative to the placebo, all 4 tafenoquine dosages demonstrated significant protection against P. falciparum infection: for 25 mg/week, protective efficacy was 32% (95% confidence interval [CI], 20%-43%); for 50 mg/week, 84% (95% CI, 75%-91%); for 100 mg/week, 87% (95% CI, 78%-93%); and for 200 mg/week, 86% (95% CI, 76%-92%). The mefloquine dosage of 250 mg/week also demonstrated significant protection against P. falciparum infection (protective efficacy, 86%; 95% CI, 72%-93%). There was little difference between study groups in the adverse events reported, and there was no evidence of a relationship between tafenoquine dosage and reports of physical complaints or the occurrence of abnormal laboratory parameters. Tafenoquine dosages of 50, 100, and 200 mg/week were safe, well tolerated, and effective against P. falciparum infection in this study population.</style></abstract><caption><style face="normal" font="default" size="100%">Duplicate</style></caption><notes><style face="normal" font="default" size="100%">L36259557&#xD;2003-03-12</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L36259557&amp;from=export</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1086/367542</style></url></related-urls></urls><custom5><style face="normal" font="default" size="100%">12594633</style></custom5><electronic-resource-num><style face="normal" font="default" size="100%">10.1086/367542</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase&#xD;Medline</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>52</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">52</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Dow, G. S.</style></author><author><style face="normal" font="default" size="100%">McCarthy, W. F.</style></author><author><style face="normal" font="default" size="100%">Reid, M.</style></author><author><style face="normal" font="default" size="100%">Smith, B.</style></author><author><style face="normal" font="default" size="100%">Tang, D.</style></author><author><style face="normal" font="default" size="100%">Shanks, G. D.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">United States Army Medical Materiel Development Activity, 1430 Veterans Drive, Fort Detrick, Maryland 21702, USA. geoffdow@hotmail.com.</style></auth-address><titles><title><style face="normal" font="default" size="100%">A retrospective analysis of the protective efficacy of tafenoquine and mefloquine as prophylactic anti-malarials in non-immune individuals during deployment to a malaria-endemic area</style></title><secondary-title><style face="normal" font="default" size="100%">Malar J</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Malar J</style></full-title></periodical><pages><style face="normal" font="default" size="100%">49</style></pages><volume><style face="normal" font="default" size="100%">13</style></volume><edition><style face="normal" font="default" size="100%">2014/02/08</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Aminoquinolines/*administration &amp; dosage/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Antimalarials/*administration &amp; dosage/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Australia</style></keyword><keyword><style face="normal" font="default" size="100%">Chemoprevention/*methods</style></keyword><keyword><style face="normal" font="default" size="100%">Endemic Diseases</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Incidence</style></keyword><keyword><style face="normal" font="default" size="100%">Malaria, Falciparum/epidemiology/*prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Malaria, Vivax/epidemiology/*prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Mefloquine/*administration &amp; dosage/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">*Military Personnel</style></keyword><keyword><style face="normal" font="default" size="100%">Retrospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Timor-Leste</style></keyword><keyword><style face="normal" font="default" size="100%">Travel</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">United States</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb 6</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1475-2875</style></isbn><accession-num><style face="normal" font="default" size="100%">24502679</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: In 2000/2001, the Australian Defense Forces (ADF), in collaboration with SmithKline Beecham and the United States Army, conducted a field trial to evaluate the safety, tolerability and efficacy of tafenoquine and mefloquine/primaquine for the prophylaxis of malaria amongst non-immune Australian soldiers deployed to East Timor (now called Timor Leste) for peacekeeping operations. The lack of a concurrent placebo control arm prevented an internal estimate of the malaria attack rate and so the protective efficacy of the study regimens was not determined at the time. METHODS: In a retrospective analysis of the trial results, the all species malaria attack rate was estimated for the prophylactic phase of the study which was defined as the period between administration of the first prophylactic dose and the first dose of post-deployment medication. First, the Plasmodium vivax attack rate was estimated during the prophylactic phase of the deployment by adjusting the observed P. vivax relapse rate during post-deployment to account for the known anti-relapse efficacies (or effectiveness) of the study medications (determined from prior studies). The all species malaria attack rate (P. vivax and Plasmodium falciparum) was then determined by adjusting the P. vivax attack rate based on the ratio of P. falciparum to P. vivax observed during prior ADF deployments to Timor Leste. This estimated all species malaria attack rate was then used as the &apos;constant estimated attack rate&apos; in the calculation of the protective efficacy of tafenoquine and mefloquine during the prophylactic phase of the deployment. RESULTS: The estimated attack rate during the prophylactic phase of the study was determined to be 7.88%. The protective efficacies of tafenoquine and mefloquine, with corresponding 95% confidence intervals (95% CI), were determined to be 100% (93%-100%) and 100% (79%-100%) respectively. CONCLUSIONS: The protective efficacy of tafenoquine (200 mg per day for three days, followed by weekly 200 mg maintenance doses) is similar to that of the weekly standard of care (mefloquine, 250 mg).</style></abstract><caption><style face="normal" font="default" size="100%">Duplicate</style></caption><notes><style face="normal" font="default" size="100%">1475-2875&#xD;Dow, Geoffrey S&#xD;McCarthy, William F&#xD;Reid, Mark&#xD;Smith, Bryan&#xD;Tang, Douglas&#xD;Shanks, G Dennis&#xD;Journal Article&#xD;Malar J. 2014 Feb 6;13:49. doi: 10.1186/1475-2875-13-49.</style></notes><urls></urls><custom2><style face="normal" font="default" size="100%">PMC3942710</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1186/1475-2875-13-49</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>111</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">111</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Dow, G. S.</style></author><author><style face="normal" font="default" size="100%">McCarthy, W. F.</style></author><author><style face="normal" font="default" size="100%">Reid, M.</style></author><author><style face="normal" font="default" size="100%">Smith, B.</style></author><author><style face="normal" font="default" size="100%">Tang, D.</style></author><author><style face="normal" font="default" size="100%">Shanks, G. D.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">G.S. Dow, United States Army Medical Materiel Development Activity, 1430 Veterans Drive, Fort Detrick, MD 21702, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">A retrospective analysis of the protective efficacy of tafenoquine and mefloquine as prophylactic anti-malarials in non-immune individuals during deployment to a malaria-endemic area</style></title><secondary-title><style face="normal" font="default" size="100%">Malaria Journal</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Malaria Journal</style></full-title></periodical><volume><style face="normal" font="default" size="100%">13</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">mefloquine</style></keyword><keyword><style face="normal" font="default" size="100%">placebo</style></keyword><keyword><style face="normal" font="default" size="100%">primaquine</style></keyword><keyword><style face="normal" font="default" size="100%">tafenoquine</style></keyword><keyword><style face="normal" font="default" size="100%">article</style></keyword><keyword><style face="normal" font="default" size="100%">drug efficacy</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">loading drug dose</style></keyword><keyword><style face="normal" font="default" size="100%">maintenance drug dose</style></keyword><keyword><style face="normal" font="default" size="100%">malaria control</style></keyword><keyword><style face="normal" font="default" size="100%">malaria falciparum</style></keyword><keyword><style face="normal" font="default" size="100%">phase 2 clinical trial (topic)</style></keyword><keyword><style face="normal" font="default" size="100%">Plasmodium falciparum</style></keyword><keyword><style face="normal" font="default" size="100%">Plasmodium vivax</style></keyword><keyword><style face="normal" font="default" size="100%">Plasmodium vivax malaria</style></keyword><keyword><style face="normal" font="default" size="100%">recurrence risk</style></keyword><keyword><style face="normal" font="default" size="100%">retrospective study</style></keyword><keyword><style face="normal" font="default" size="100%">Timor-Leste</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><isbn><style face="normal" font="default" size="100%">1475-2875</style></isbn><abstract><style face="normal" font="default" size="100%">Background: In 2000/2001, the Australian Defense Forces (ADF), in collaboration with SmithKline Beecham and the United States Army, conducted a field trial to evaluate the safety, tolerability and efficacy of tafenoquine and mefloquine/primaquine for the prophylaxis of malaria amongst non-immune Australian soldiers deployed to East Timor (now called Timor Leste) for peacekeeping operations. The lack of a concurrent placebo control arm prevented an internal estimate of the malaria attack rate and so the protective efficacy of the study regimens was not determined at the time. Methods. In a retrospective analysis of the trial results, the all species malaria attack rate was estimated for the prophylactic phase of the study which was defined as the period between administration of the first prophylactic dose and the first dose of post-deployment medication. First, the Plasmodium vivax attack rate was estimated during the prophylactic phase of the deployment by adjusting the observed P. vivax relapse rate during post-deployment to account for the known anti-relapse efficacies (or effectiveness) of the study medications (determined from prior studies). The all species malaria attack rate (P. vivax and Plasmodium falciparum) was then determined by adjusting the P. vivax attack rate based on the ratio of P. falciparum to P. vivax observed during prior ADF deployments to Timor Leste. This estimated all species malaria attack rate was then used as the &apos;constant estimated attack rate&apos; in the calculation of the protective efficacy of tafenoquine and mefloquine during the prophylactic phase of the deployment. Results: The estimated attack rate during the prophylactic phase of the study was determined to be 7.88%. The protective efficacies of tafenoquine and mefloquine, with corresponding 95% confidence intervals (95% CI), were determined to be 100% (93%-100%) and 100% (79%-100%) respectively. Conclusions: The protective efficacy of tafenoquine (200 mg per day for three days, followed by weekly 200 mg maintenance doses) is similar to that of the weekly standard of care (mefloquine, 250 mg). © 2014 Dow et al.; licensee BioMed Central Ltd.</style></abstract><caption><style face="normal" font="default" size="100%">Duplicate</style></caption><notes><style face="normal" font="default" size="100%">L52999377&#xD;2014-02-18&#xD;2014-03-25</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L52999377&amp;from=export</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1186/1475-2875-13-49</style></url></related-urls></urls><custom5><style face="normal" font="default" size="100%">24502679</style></custom5><electronic-resource-num><style face="normal" font="default" size="100%">10.1186/1475-2875-13-49</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase&#xD;Medline</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>127</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">127</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kitchener, S.</style></author><author><style face="normal" font="default" size="100%">Nasveld, P.</style></author><author><style face="normal" font="default" size="100%">Edstein, M. D.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">S. Kitchener, Centre for Military and Veterans Health, University of Queensland, Mayne Medical School Building, Herston Road, Herston, QLD 4006, Australia</style></auth-address><titles><title><style face="normal" font="default" size="100%">Short report: Tafenoquine for the treatment of recurrent Plasmodium vivax malaria</style></title><secondary-title><style face="normal" font="default" size="100%">American Journal of Tropical Medicine and Hygiene</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">American Journal of Tropical Medicine and Hygiene</style></full-title></periodical><pages><style face="normal" font="default" size="100%">494-496</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">chloroquine</style></keyword><keyword><style face="normal" font="default" size="100%">doxycycline</style></keyword><keyword><style face="normal" font="default" size="100%">primaquine</style></keyword><keyword><style face="normal" font="default" size="100%">quinine</style></keyword><keyword><style face="normal" font="default" size="100%">tafenoquine</style></keyword><keyword><style face="normal" font="default" size="100%">adult</style></keyword><keyword><style face="normal" font="default" size="100%">article</style></keyword><keyword><style face="normal" font="default" size="100%">clinical article</style></keyword><keyword><style face="normal" font="default" size="100%">clinical trial</style></keyword><keyword><style face="normal" font="default" size="100%">combination chemotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">controlled clinical trial</style></keyword><keyword><style face="normal" font="default" size="100%">controlled study</style></keyword><keyword><style face="normal" font="default" size="100%">drug dose regimen</style></keyword><keyword><style face="normal" font="default" size="100%">drug efficacy</style></keyword><keyword><style face="normal" font="default" size="100%">female</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">malaria</style></keyword><keyword><style face="normal" font="default" size="100%">male</style></keyword><keyword><style face="normal" font="default" size="100%">parasitemia</style></keyword><keyword><style face="normal" font="default" size="100%">Plasmodium vivax</style></keyword><keyword><style face="normal" font="default" size="100%">randomized controlled trial</style></keyword><keyword><style face="normal" font="default" size="100%">relapse</style></keyword><keyword><style face="normal" font="default" size="100%">treatment failure</style></keyword><keyword><style face="normal" font="default" size="100%">treatment outcome</style></keyword><keyword><style face="normal" font="default" size="100%">unspecified side effect</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2007</style></year></dates><isbn><style face="normal" font="default" size="100%">0002-9637</style></isbn><abstract><style face="normal" font="default" size="100%">Tafenoquine was used to treat Plasmodium vivax malaria cases who had previously failed treatment with chloroquine and primaquine. Chloroquine was followed by a loading dose of tafenoquine (200 mg base/day for 3 days) and 200 mg a week was given for 8 weeks. One of 27 treated patients relapsed after 6 months of observation. A standard course of chloroquine administered with 8 weeks of tafenoquine may be more effective than chloroquine with primaquine (22.5 mg/day for 14 days) in preventing additional P. vivax relapses. Larger studies are required to optimize the combination, but our findings suggest that an extended use of tafenoquine may be required to prevent relapses of primaquine-tolerant strains of P. vivax malaria. Copyright © 2007 by The American Society of Tropical Medicine and Hygiene.</style></abstract><caption><style face="normal" font="default" size="100%">Duplicate</style></caption><notes><style face="normal" font="default" size="100%">L351627742&#xD;2008-06-03</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L351627742&amp;from=export</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.4269/ajtmh.2007.76.494</style></url></related-urls></urls><custom5><style face="normal" font="default" size="100%">17360873</style></custom5><electronic-resource-num><style face="normal" font="default" size="100%">10.4269/ajtmh.2007.76.494</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase&#xD;Medline</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>157</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">157</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kitchener, S.</style></author><author><style face="normal" font="default" size="100%">Nasveld, P.</style></author><author><style face="normal" font="default" size="100%">Edstein, M. D.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Short report: tafenoquine for the treatment of recurrent Plasmodium vivax malaria</style></title><secondary-title><style face="normal" font="default" size="100%">American journal of tropical medicine and hygiene</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">American Journal of Tropical Medicine and Hygiene</style></full-title></periodical><pages><style face="normal" font="default" size="100%">494‐496</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">*malaria /drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Article</style></keyword><keyword><style face="normal" font="default" size="100%">Clinical article</style></keyword><keyword><style face="normal" font="default" size="100%">Clinical trial</style></keyword><keyword><style face="normal" font="default" size="100%">Combination chemotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">Controlled clinical trial</style></keyword><keyword><style face="normal" font="default" size="100%">Controlled study</style></keyword><keyword><style face="normal" font="default" size="100%">Drug dose regimen</style></keyword><keyword><style face="normal" font="default" size="100%">Drug efficacy</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Human</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Parasitemia</style></keyword><keyword><style face="normal" font="default" size="100%">Plasmodium vivax</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized controlled trial</style></keyword><keyword><style face="normal" font="default" size="100%">Relapse</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment failure</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Unspecified side effect /side effect</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2007</style></year></dates><accession-num><style face="normal" font="default" size="100%">CN-01783882</style></accession-num><abstract><style face="normal" font="default" size="100%">Tafenoquine was used to treat Plasmodium vivax malaria cases who had previously failed treatment with chloroquine and primaquine. Chloroquine was followed by a loading dose of tafenoquine (200 mg base/day for 3 days) and 200 mg a week was given for 8 weeks. One of 27 treated patients relapsed after 6 months of observation. A standard course of chloroquine administered with 8 weeks of tafenoquine may be more effective than chloroquine with primaquine (22.5 mg/day for 14 days) in preventing additional P. vivax relapses. Larger studies are required to optimize the combination, but our findings suggest that an extended use of tafenoquine may be required to prevent relapses of primaquine‐tolerant strains of P. vivax malaria. Copyright © 2007 by The American Society of Tropical Medicine and Hygiene.</style></abstract><caption><style face="normal" font="default" size="100%">Duplicate</style></caption><work-type><style face="normal" font="default" size="100%">Journal: Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01783882/full</style></url></related-urls></urls><custom3><style face="normal" font="default" size="100%">PUBMED 17360873,EMBASE 351627742</style></custom3></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>16</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">16</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Anjum, M. U.</style></author><author><style face="normal" font="default" size="100%">Naveed, A. K.</style></author><author><style face="normal" font="default" size="100%">Mahmood, S. N.</style></author><author><style face="normal" font="default" size="100%">Naveed, O. K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Dow Medical College, Dow University of Health Sciences, Karachi, Pakistan. Electronic address: umairanjum1997@gmail.com.&#xD;Dow Medical College, Dow University of Health Sciences, Karachi, Pakistan.&#xD;Department of Nephrology, Dr. Ziauddin Hospital, Karachi, Pakistan.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Single dose tafenoquine for preventing relapse in people with plasmodium vivax malaria-an updated meta-analysis</style></title><secondary-title><style face="normal" font="default" size="100%">Travel Med Infect Dis</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Travel Med Infect Dis</style></full-title></periodical><pages><style face="normal" font="default" size="100%">101576</style></pages><volume><style face="normal" font="default" size="100%">36</style></volume><edition><style face="normal" font="default" size="100%">2020/02/10</style></edition><keywords><keyword><style face="normal" font="default" size="100%">G6pd</style></keyword><keyword><style face="normal" font="default" size="100%">Malaria</style></keyword><keyword><style face="normal" font="default" size="100%">Plasmodium vivax</style></keyword><keyword><style face="normal" font="default" size="100%">Primaquine</style></keyword><keyword><style face="normal" font="default" size="100%">Recurrence</style></keyword><keyword><style face="normal" font="default" size="100%">Tafenoquine</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2020</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul-Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1477-8939</style></isbn><accession-num><style face="normal" font="default" size="100%">32036012</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Plasmodium vivax is a frequent cause of recurring malaria in endemic areas as in its latent stage it resides in liver, and is responsible for relapse. Treatment with 8 aminoquinoline Primaquine is given for 14 days, however studies have shown dismal results with adherence to therapy. A new long acting 8 aminoquinoline, Tafenoquine was introduced that showed efficacy and safety almost similar to Primaquine in a single dose regimen, hence giving hopes for improved compliance and help in eradicating malaria. METHODS: We searched for randomized controlled trials (RCTs) that compared the efficacy of Tafenoquine with Primaquine or placebo. Our primary outcome was the recurrence of Plasmodium vivax parasitemia at 6 months and our safety outcomes included total number of adverse events as well as serious adverse events. We performed pooled data analysis by the random effects model and I2 was used to assess heterogeneity. RESULTS: 4 RCTs were included. Our pooled analysis showed that the number of episodes of recurrence at 6 months between Tafenoquine and Primaquine (RR = 1.08, 95% CI = 0.74-1.59), and between Tafenoquine and placebo (RR = 0.17, 95%CI = 0.03-1.11) was statistically insignificant. Comparison of serious adverse events did not show any significant risk associated with the use of Tafenoquine as compared to Primaquine when analyzed till day 29, which was the time period considered to show most probable drug associated events. CONCLUSION: Tafenoquine as a single dose is an effective alternative to Primaquine for prevention of recurrence of P vivax malaria, with a reasonable safety profile.</style></abstract><caption><style face="normal" font="default" size="100%">Duplicate</style></caption><notes><style face="normal" font="default" size="100%">1873-0442&#xD;Anjum, Muhammad Umair&#xD;Naveed, Ahmed Kunwer&#xD;Mahmood, Sumbal Nasir&#xD;Naveed, Osama Kunwer&#xD;Journal Article&#xD;Netherlands&#xD;Travel Med Infect Dis. 2020 Jul-Aug;36:101576. doi: 10.1016/j.tmaid.2020.101576. Epub 2020 Feb 6.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.tmaid.2020.101576</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>85</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">85</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Anjum, M. U.</style></author><author><style face="normal" font="default" size="100%">Naveed, A. K.</style></author><author><style face="normal" font="default" size="100%">Mahmood, S. N.</style></author><author><style face="normal" font="default" size="100%">Naveed, O. K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">M.U. Anjum, Dow Medical College, Dow University of Health Sciences, Karachi, Pakistan</style></auth-address><titles><title><style face="normal" font="default" size="100%">Single dose tafenoquine for preventing relapse in people with plasmodium vivax malaria-an updated meta-analysis</style></title><secondary-title><style face="normal" font="default" size="100%">Travel Medicine and Infectious Disease</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Travel Medicine and Infectious Disease</style></full-title></periodical><volume><style face="normal" font="default" size="100%">36</style></volume><keywords><keyword><style face="normal" font="default" size="100%">placebo</style></keyword><keyword><style face="normal" font="default" size="100%">primaquine</style></keyword><keyword><style face="normal" font="default" size="100%">tafenoquine</style></keyword><keyword><style face="normal" font="default" size="100%">article</style></keyword><keyword><style face="normal" font="default" size="100%">comparative effectiveness</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">meta analysis</style></keyword><keyword><style face="normal" font="default" size="100%">Plasmodium vivax malaria</style></keyword><keyword><style face="normal" font="default" size="100%">priority journal</style></keyword><keyword><style face="normal" font="default" size="100%">randomized controlled trial (topic)</style></keyword><keyword><style face="normal" font="default" size="100%">relapse</style></keyword><keyword><style face="normal" font="default" size="100%">single drug dose</style></keyword><keyword><style face="normal" font="default" size="100%">systematic review</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2020</style></year></dates><isbn><style face="normal" font="default" size="100%">1873-0442&#xD;1477-8939</style></isbn><abstract><style face="normal" font="default" size="100%">Background: Plasmodium vivax is a frequent cause of recurring malaria in endemic areas as in its latent stage it resides in liver, and is responsible for relapse. Treatment with 8 aminoquinoline Primaquine is given for 14 days, however studies have shown dismal results with adherence to therapy. A new long acting 8 aminoquinoline, Tafenoquine was introduced that showed efficacy and safety almost similar to Primaquine in a single dose regimen, hence giving hopes for improved compliance and help in eradicating malaria. Methods: We searched for randomized controlled trials (RCTs) that compared the efficacy of Tafenoquine with Primaquine or placebo. Our primary outcome was the recurrence of Plasmodium vivax parasitemia at 6 months and our safety outcomes included total number of adverse events as well as serious adverse events. We performed pooled data analysis by the random effects model and I2 was used to assess heterogeneity. Results: 4 RCTs were included. Our pooled analysis showed that the number of episodes of recurrence at 6 months between Tafenoquine and Primaquine (RR = 1.08, 95% CI = 0.74–1.59), and between Tafenoquine and placebo (RR = 0.17, 95%CI = 0.03–1.11) was statistically insignificant. Comparison of serious adverse events did not show any significant risk associated with the use of Tafenoquine as compared to Primaquine when analyzed till day 29, which was the time period considered to show most probable drug associated events. Conclusion: Tafenoquine as a single dose is an effective alternative to Primaquine for prevention of recurrence of P vivax malaria, with a reasonable safety profile.</style></abstract><caption><style face="normal" font="default" size="100%">Duplicate</style></caption><notes><style face="normal" font="default" size="100%">L2004905266&#xD;2020-02-14&#xD;2020-09-17</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2004905266&amp;from=export</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1016/j.tmaid.2020.101576</style></url></related-urls></urls><custom5><style face="normal" font="default" size="100%">32036012</style></custom5><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.tmaid.2020.101576</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase&#xD;Medline</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>186</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">186</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Anjum, M. U.</style></author><author><style face="normal" font="default" size="100%">Naveed, A. K.</style></author><author><style face="normal" font="default" size="100%">Mahmood, S. N.</style></author><author><style face="normal" font="default" size="100%">Naveed, O. K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">[Anjum, Muhammad Umair; Naveed, Ahmed Kunwer; Naveed, Osama Kunwer] Dow Univ Hlth Sci, Dow Med Coll, Karachi, Pakistan. [Mahmood, Sumbal Nasir] Dr Ziauddin Hosp, Dept Nephrol, Karachi, Pakistan.&#xD;Anjum, MU (corresponding author), Dow Univ Hlth Sci, Dow Med Coll, Karachi, Pakistan.&#xD;umairanjum1997@gmail.com</style></auth-address><titles><title><style face="normal" font="default" size="100%">Single dose tafenoquine for preventing relapse in people with plasmodium vivax malaria-an updated meta-analysis</style></title><secondary-title><style face="normal" font="default" size="100%">Travel Medicine and Infectious Disease</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Travel Med. Infect. Dis.</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Travel Medicine and Infectious Disease</style></full-title></periodical><pages><style face="normal" font="default" size="100%">7</style></pages><volume><style face="normal" font="default" size="100%">36</style></volume><keywords><keyword><style face="normal" font="default" size="100%">Malaria</style></keyword><keyword><style face="normal" font="default" size="100%">Plasmodium vivax</style></keyword><keyword><style face="normal" font="default" size="100%">Recurrence</style></keyword><keyword><style face="normal" font="default" size="100%">Primaquine</style></keyword><keyword><style face="normal" font="default" size="100%">Tafenoquine</style></keyword><keyword><style face="normal" font="default" size="100%">G6PD</style></keyword><keyword><style face="normal" font="default" size="100%">double-blind</style></keyword><keyword><style face="normal" font="default" size="100%">primaquine</style></keyword><keyword><style face="normal" font="default" size="100%">trial</style></keyword><keyword><style face="normal" font="default" size="100%">prophylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">efficacy</style></keyword><keyword><style face="normal" font="default" size="100%">therapy</style></keyword><keyword><style face="normal" font="default" size="100%">safety</style></keyword><keyword><style face="normal" font="default" size="100%">Public, Environmental &amp; Occupational Health</style></keyword><keyword><style face="normal" font="default" size="100%">Infectious Diseases</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2020</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul-Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1477-8939</style></isbn><accession-num><style face="normal" font="default" size="100%">WOS:000575401600014</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: Plasmodium vivax is a frequent cause of recurring malaria in endemic areas as in its latent stage it resides in liver, and is responsible for relapse. Treatment with 8 aminoquinoline Primaquine is given for 14 days, however studies have shown dismal results with adherence to therapy. A new long acting 8 aminoquinoline, Tafenoquine was introduced that showed efficacy and safety almost similar to Primaquine in a single dose regimen, hence giving hopes for improved compliance and help in eradicating malaria. Methods: We searched for randomized controlled trials (RCTs) that compared the efficacy of Tafenoquine with Primaquine or placebo. Our primary outcome was the recurrence of Plasmodium vivax parasitemia at 6 months and our safety outcomes included total number of adverse events as well as serious adverse events. We performed pooled data analysis by the random effects model and I2 was used to assess heterogeneity. Results: 4 RCTs were included. Our pooled analysis showed that the number of episodes of recurrence at 6 months between Tafenoquine and Primaquine (RR = 1.08, 95% CI = 0.74-1.59), and between Tafenoquine and placebo (RR = 0.17, 95%CI = 0.03-1.11) was statistically insignificant. Comparison of serious adverse events did not show any significant risk associated with the use of Tafenoquine as compared to Primaquine when analyzed till day 29, which was the time period considered to show most probable drug associated events. Conclusion: Tafenoquine as a single dose is an effective alternative to Primaquine for prevention of recurrence of P vivax malaria, with a reasonable safety profile.</style></abstract><caption><style face="normal" font="default" size="100%">Duplicate</style></caption><notes><style face="normal" font="default" size="100%">ISI Document Delivery No.: NX0IA&#xD;Times Cited: 0&#xD;Cited Reference Count: 26&#xD;Anjum, Muhammad Umair Naveed, Ahmed Kunwer Mahmood, Sumbal Nasir Naveed, Osama Kunwer&#xD;0&#xD;Elsevier sci ltd&#xD;Oxford&#xD;1873-0442</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">&lt;Go to ISI&gt;://WOS:000575401600014</style></url></related-urls></urls><custom7><style face="normal" font="default" size="100%">101576</style></custom7><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.tmaid.2020.101576</style></electronic-resource-num><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>45</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">45</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Mischlinger, J.</style></author><author><style face="normal" font="default" size="100%">Agnandji, S. T.</style></author><author><style face="normal" font="default" size="100%">Ramharter, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">a Centre de Recherches Médicales de Lambaréné , Lambaréné , Gabon.&#xD;b Institut für Tropenmedizin , Universität Tübingen , Tübingen , Germany.&#xD;c Department of Medicine I, Division of Infectious Diseases and Tropical Medicine , Medical University of Vienna , Vienna , Austria.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Single dose treatment of malaria - current status and perspectives</style></title><secondary-title><style face="normal" font="default" size="100%">Expert Rev Anti Infect Ther</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Expert Rev Anti Infect Ther</style></full-title></periodical><pages><style face="normal" font="default" size="100%">669-78</style></pages><volume><style face="normal" font="default" size="100%">14</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2016/06/03</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Antimalarials/*administration &amp; dosage/adverse effects/pharmacokinetics/therapeutic</style></keyword><keyword><style face="normal" font="default" size="100%">use</style></keyword><keyword><style face="normal" font="default" size="100%">Clinical Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Administration Schedule</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Combinations</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Malaria/*drug therapy/*epidemiology/parasitology/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Medication Adherence</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">*aq-13</style></keyword><keyword><style face="normal" font="default" size="100%">*dsm265</style></keyword><keyword><style face="normal" font="default" size="100%">*kae609</style></keyword><keyword><style face="normal" font="default" size="100%">*kaf156</style></keyword><keyword><style face="normal" font="default" size="100%">*oz277</style></keyword><keyword><style face="normal" font="default" size="100%">*oz439</style></keyword><keyword><style face="normal" font="default" size="100%">*Single dose treatment</style></keyword><keyword><style face="normal" font="default" size="100%">*effectiveness</style></keyword><keyword><style face="normal" font="default" size="100%">*falciparum</style></keyword><keyword><style face="normal" font="default" size="100%">*ferroquine</style></keyword><keyword><style face="normal" font="default" size="100%">*malaria</style></keyword><keyword><style face="normal" font="default" size="100%">*naphthoquine</style></keyword><keyword><style face="normal" font="default" size="100%">*piperaquine</style></keyword><keyword><style face="normal" font="default" size="100%">*tafenoquine</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2016</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1478-7210</style></isbn><accession-num><style face="normal" font="default" size="100%">27254098</style></accession-num><abstract><style face="normal" font="default" size="100%">INTRODUCTION: Despite increased international efforts for control and ultimate elimination, malaria remains a major health problem. Currently, artemisinin-based combination therapies are the treatment of choice for uncomplicated malaria exhibiting high efficacy in clinical trial settings in sub-Saharan Africa. However, their administration over a three-day period is associated with important problems of treatment adherence resulting in markedly reduced effectiveness of currently recommended antimalarials under real world settings. AREAS COVERED: Antimalarial drug candidates and antimalarial drug combinations currently under advanced clinical development for the indication as single dose antimalarial therapy. Expert commentary: Several new drug candidates and combinations are currently undergoing pivotal proof-of-concept studies or clinical development programmes. The development of a single dose combination therapy would constitute a breakthrough in the control of malaria. Such an innovative treatment approach would simultaneously close the effectiveness gap of current three-day therapies and revolutionize population based interventions in the context of malaria elimination campaigns.</style></abstract><notes><style face="normal" font="default" size="100%">1744-8336&#xD;Mischlinger, Johannes&#xD;Agnandji, Selidji T&#xD;Ramharter, Michael&#xD;Journal Article&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Review&#xD;England&#xD;Expert Rev Anti Infect Ther. 2016 Jul;14(7):669-78. doi: 10.1080/14787210.2016.1192462. Epub 2016 Jun 7.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1080/14787210.2016.1192462</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>94</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">94</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kain, K. C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">K.C. Kain, Tropical Disease Unit, Division of Infectious Diseases, Department of Medicine, Toronto, Canada</style></auth-address><titles><title><style face="normal" font="default" size="100%">Single-dose radical cure for Plasmodium vivax</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Travel Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Travel Medicine</style></full-title></periodical><volume><style face="normal" font="default" size="100%">26</style></volume><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">chloroquine</style></keyword><keyword><style face="normal" font="default" size="100%">cytochrome P450 2D6</style></keyword><keyword><style face="normal" font="default" size="100%">tafenoquine</style></keyword><keyword><style face="normal" font="default" size="100%">chemoprophylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">drug efficacy</style></keyword><keyword><style face="normal" font="default" size="100%">drug metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">drug safety</style></keyword><keyword><style face="normal" font="default" size="100%">drug tolerability</style></keyword><keyword><style face="normal" font="default" size="100%">editorial</style></keyword><keyword><style face="normal" font="default" size="100%">glucose 6 phosphate dehydrogenase deficiency</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">Indonesia</style></keyword><keyword><style face="normal" font="default" size="100%">intravascular hemolysis</style></keyword><keyword><style face="normal" font="default" size="100%">licensing</style></keyword><keyword><style face="normal" font="default" size="100%">migrant</style></keyword><keyword><style face="normal" font="default" size="100%">multicenter study (topic)</style></keyword><keyword><style face="normal" font="default" size="100%">Papua New Guinea</style></keyword><keyword><style face="normal" font="default" size="100%">Plasmodium ovale malaria</style></keyword><keyword><style face="normal" font="default" size="100%">Plasmodium vivax malaria</style></keyword><keyword><style face="normal" font="default" size="100%">randomized controlled trial (topic)</style></keyword><keyword><style face="normal" font="default" size="100%">single drug dose</style></keyword><keyword><style face="normal" font="default" size="100%">travel</style></keyword><keyword><style face="normal" font="default" size="100%">treatment outcome</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2019</style></year></dates><isbn><style face="normal" font="default" size="100%">1708-8305&#xD;1195-1982</style></isbn><notes><style face="normal" font="default" size="100%">L628421106&#xD;2019-07-11&#xD;2019-07-12</style></notes><work-type><style face="normal" font="default" size="100%">Editorial</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L628421106&amp;from=export</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1093/jtm/tay127</style></url></related-urls></urls><custom5><style face="normal" font="default" size="100%">30541033</style></custom5><electronic-resource-num><style face="normal" font="default" size="100%">10.1093/jtm/tay127</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase&#xD;Medline</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>28</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">28</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lacerda, M. V. G.</style></author><author><style face="normal" font="default" size="100%">Llanos-Cuentas, A.</style></author><author><style face="normal" font="default" size="100%">Krudsood, S.</style></author><author><style face="normal" font="default" size="100%">Lon, C.</style></author><author><style face="normal" font="default" size="100%">Saunders, D. L.</style></author><author><style face="normal" font="default" size="100%">Mohammed, R.</style></author><author><style face="normal" font="default" size="100%">Yilma, D.</style></author><author><style face="normal" font="default" size="100%">Batista Pereira, D.</style></author><author><style face="normal" font="default" size="100%">Espino, F. E. J.</style></author><author><style face="normal" font="default" size="100%">Mia, R. Z.</style></author><author><style face="normal" font="default" size="100%">Chuquiyauri, R.</style></author><author><style face="normal" font="default" size="100%">Val, F.</style></author><author><style face="normal" font="default" size="100%">Casapía, M.</style></author><author><style face="normal" font="default" size="100%">Monteiro, W. M.</style></author><author><style face="normal" font="default" size="100%">Brito, M. A. M.</style></author><author><style face="normal" font="default" size="100%">Costa, M. R. F.</style></author><author><style face="normal" font="default" size="100%">Buathong, N.</style></author><author><style face="normal" font="default" size="100%">Noedl, H.</style></author><author><style face="normal" font="default" size="100%">Diro, E.</style></author><author><style face="normal" font="default" size="100%">Getie, S.</style></author><author><style face="normal" font="default" size="100%">Wubie, K. M.</style></author><author><style face="normal" font="default" size="100%">Abdissa, A.</style></author><author><style face="normal" font="default" size="100%">Zeynudin, A.</style></author><author><style face="normal" font="default" size="100%">Abebe, C.</style></author><author><style face="normal" font="default" size="100%">Tada, M. S.</style></author><author><style face="normal" font="default" size="100%">Brand, F.</style></author><author><style face="normal" font="default" size="100%">Beck, H. P.</style></author><author><style face="normal" font="default" size="100%">Angus, B.</style></author><author><style face="normal" font="default" size="100%">Duparc, S.</style></author><author><style face="normal" font="default" size="100%">Kleim, J. P.</style></author><author><style face="normal" font="default" size="100%">Kellam, L. M.</style></author><author><style face="normal" font="default" size="100%">Rousell, V. M.</style></author><author><style face="normal" font="default" size="100%">Jones, S. W.</style></author><author><style face="normal" font="default" size="100%">Hardaker, E.</style></author><author><style face="normal" font="default" size="100%">Mohamed, K.</style></author><author><style face="normal" font="default" size="100%">Clover, D. D.</style></author><author><style face="normal" font="default" size="100%">Fletcher, K.</style></author><author><style face="normal" font="default" size="100%">Breton, J. J.</style></author><author><style face="normal" font="default" size="100%">Ugwuegbulam, C. O.</style></author><author><style face="normal" font="default" size="100%">Green, J. A.</style></author><author><style face="normal" font="default" size="100%">Koh, Gckw</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">From Fundação de Medicina Tropical Dr Heitor Vieira Dourado, Manaus (M.V.G.L., F.V., W.M.M., M.A.M.B., M.R.F.C.), Fundação Oswaldo Cruz, Manguinhos, Rio de Janeiro (M.V.G.L.), and Centro de Pesquisa em Medicina Tropical Rondônia, Porto Velho (D.B.P., M.S.T.) - all in Brazil; Universidad Peruana Cayetano Heredia, Lima, Peru (A.L.-C., R.C., M.C.); Mahidol University (S.K.) and the Armed Forces Research Institute of Medical Sciences (C.L., D.L.S., N.B.), Bangkok, Thailand; the University of Gondar, Gondar (R.M., E.D., S.G., K.M.W.), and Jimma University, Jimma (D.Y., A.A., A.Z., C.A.) - both in Ethiopia; Research Institute for Tropical Medicine, Manila (F.E.J.E.), and Rio Tuba Nickel Foundation Hospital, Palawan (R.Z.M.) - both in the Philippines; Medical University of Vienna, Vienna (H.N.); Swiss Tropical and Public Health Institute and University of Basel, Basel (F.B., H.-P.B.), and Medicines for Malaria Venture, Geneva (S.D.) - both in Switzerland; Oxford University, Oxford (B.A.), and GlaxoSmithKline, Stockley Park West (J.-P.K., L.M.K., V.M.R., S.W.J., E.H., K.M., D.D.C., K.F., C.O.U., J.A.G., G.C.K.W.K.) - both in the United Kingdom; and GlaxoSmithKline, Collegeville, PA (J.J.B.).</style></auth-address><titles><title><style face="normal" font="default" size="100%">Single-Dose Tafenoquine to Prevent Relapse of Plasmodium vivax Malaria</style></title><secondary-title><style face="normal" font="default" size="100%">N Engl J Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">N Engl J Med</style></full-title></periodical><pages><style face="normal" font="default" size="100%">215-228</style></pages><volume><style face="normal" font="default" size="100%">380</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2019/01/17</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Aminoquinolines/*administration &amp; dosage/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Antimalarials/*administration &amp; dosage/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Chloroquine/administration &amp; dosage</style></keyword><keyword><style face="normal" font="default" size="100%">Cytochrome P-450 CYP2D6/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Disease-Free Survival</style></keyword><keyword><style face="normal" font="default" size="100%">Double-Blind Method</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Therapy, Combination</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Glucosephosphate Dehydrogenase/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Hemoglobins/analysis</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Intention to Treat Analysis</style></keyword><keyword><style face="normal" font="default" size="100%">Kaplan-Meier Estimate</style></keyword><keyword><style face="normal" font="default" size="100%">Logistic Models</style></keyword><keyword><style face="normal" font="default" size="100%">Malaria, Vivax/*drug therapy/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Parasitemia/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">*Plasmodium vivax/isolation &amp; purification</style></keyword><keyword><style face="normal" font="default" size="100%">Primaquine/administration &amp; dosage</style></keyword><keyword><style face="normal" font="default" size="100%">Secondary Prevention/*methods</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2019</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan 17</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0028-4793 (Print)&#xD;0028-4793</style></isbn><accession-num><style face="normal" font="default" size="100%">30650322</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Treatment of Plasmodium vivax malaria requires the clearing of asexual parasites, but relapse can be prevented only if dormant hypnozoites are cleared from the liver (a treatment termed &quot;radical cure&quot;). Tafenoquine is a single-dose 8-aminoquinoline that has recently been registered for the radical cure of P. vivax. METHODS: This multicenter, double-blind, double-dummy, parallel group, randomized, placebo-controlled trial was conducted in Ethiopia, Peru, Brazil, Cambodia, Thailand, and the Philippines. We enrolled 522 patients with microscopically confirmed P. vivax infection (&gt;100 to &lt;100,000 parasites per microliter) and normal glucose-6-phosphate dehydrogenase (G6PD) activity (with normal activity defined as ≥70% of the median value determined at each trial site among 36 healthy male volunteers who were otherwise not involved in the trial). All patients received a 3-day course of chloroquine (total dose of 1500 mg). In addition, patients were assigned to receive a single 300-mg dose of tafenoquine on day 1 or 2 (260 patients), placebo (133 patients), or a 15-mg dose of primaquine once daily for 14 days (129 patients). The primary outcome was the Kaplan-Meier estimated percentage of patients who were free from recurrence at 6 months, defined as P. vivax clearance without recurrent parasitemia. RESULTS: In the intention-to-treat population, the percentage of patients who were free from recurrence at 6 months was 62.4% in the tafenoquine group (95% confidence interval [CI], 54.9 to 69.0), 27.7% in the placebo group (95% CI, 19.6 to 36.6), and 69.6% in the primaquine group (95% CI, 60.2 to 77.1). The hazard ratio for the risk of recurrence was 0.30 (95% CI, 0.22 to 0.40) with tafenoquine as compared with placebo (P&lt;0.001) and 0.26 (95% CI, 0.18 to 0.39) with primaquine as compared with placebo (P&lt;0.001). Tafenoquine was associated with asymptomatic declines in hemoglobin levels, which resolved without intervention. CONCLUSIONS: Single-dose tafenoquine resulted in a significantly lower risk of P. vivax recurrence than placebo in patients with phenotypically normal G6PD activity. (Funded by GlaxoSmithKline and Medicines for Malaria Venture; DETECTIVE ClinicalTrials.gov number, NCT01376167 .).</style></abstract><caption><style face="normal" font="default" size="100%">Duplicate</style></caption><notes><style face="normal" font="default" size="100%">1533-4406&#xD;Lacerda, Marcus V G&#xD;Llanos-Cuentas, Alejandro&#xD;Krudsood, Srivicha&#xD;Lon, Chanthap&#xD;Saunders, David L&#xD;Mohammed, Rezika&#xD;Yilma, Daniel&#xD;Batista Pereira, Dhelio&#xD;Espino, Fe E J&#xD;Mia, Reginaldo Z&#xD;Chuquiyauri, Raul&#xD;Val, Fernando&#xD;Casapía, Martín&#xD;Monteiro, Wuelton M&#xD;Brito, Marcelo A M&#xD;Costa, Mônica R F&#xD;Buathong, Nillawan&#xD;Noedl, Harald&#xD;Diro, Ermias&#xD;Getie, Sisay&#xD;Wubie, Kalehiwot M&#xD;Abdissa, Alemseged&#xD;Zeynudin, Ahmed&#xD;Abebe, Cherinet&#xD;Tada, Mauro S&#xD;Brand, Françoise&#xD;Beck, Hans-Peter&#xD;Angus, Brian&#xD;Duparc, Stephan&#xD;Kleim, Jörg-Peter&#xD;Kellam, Lynda M&#xD;Rousell, Victoria M&#xD;Jones, Siôn W&#xD;Hardaker, Elizabeth&#xD;Mohamed, Khadeeja&#xD;Clover, Donna D&#xD;Fletcher, Kim&#xD;Breton, John J&#xD;Ugwuegbulam, Cletus O&#xD;Green, Justin A&#xD;Koh, Gavin C K W&#xD;Orcid: 0000-0002-7336-1566&#xD;Clinical Trial, Phase II&#xD;Clinical Trial, Phase III&#xD;Journal Article&#xD;Multicenter Study&#xD;Randomized Controlled Trial&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;N Engl J Med. 2019 Jan 17;380(3):215-228. doi: 10.1056/NEJMoa1710775.</style></notes><urls></urls><custom2><style face="normal" font="default" size="100%">PMC6657226</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1056/NEJMoa1710775</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>152</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">152</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lacerda, M. V. G.</style></author><author><style face="normal" font="default" size="100%">Llanos-Cuentas, A.</style></author><author><style face="normal" font="default" size="100%">Krudsood, S.</style></author><author><style face="normal" font="default" size="100%">Lon, C.</style></author><author><style face="normal" font="default" size="100%">Saunders, D. L.</style></author><author><style face="normal" font="default" size="100%">Mohammed, R.</style></author><author><style face="normal" font="default" size="100%">Yilma, D.</style></author><author><style face="normal" font="default" size="100%">Batista Pereira, D.</style></author><author><style face="normal" font="default" size="100%">Espino, F. E. J.</style></author><author><style face="normal" font="default" size="100%">Mia, R. Z.</style></author><author><style face="normal" font="default" size="100%">et al.,</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Single-Dose Tafenoquine to Prevent Relapse of Plasmodium vivax Malaria</style></title><secondary-title><style face="normal" font="default" size="100%">New England journal of medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">New England Journal of Medicine</style></full-title></periodical><pages><style face="normal" font="default" size="100%">215‐228</style></pages><volume><style face="normal" font="default" size="100%">380</style></volume><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Aminoquinolines [*administration &amp; dosage, adverse effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Antimalarials [*administration &amp; dosage, adverse effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Chloroquine [administration &amp; dosage]</style></keyword><keyword><style face="normal" font="default" size="100%">Cytochrome P‐450 CYP2D6 [metabolism]</style></keyword><keyword><style face="normal" font="default" size="100%">Disease‐Free Survival</style></keyword><keyword><style face="normal" font="default" size="100%">Double‐Blind Method</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Therapy, Combination</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Glucosephosphate Dehydrogenase [metabolism]</style></keyword><keyword><style face="normal" font="default" size="100%">Hemoglobins [analysis]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Intention to Treat Analysis</style></keyword><keyword><style face="normal" font="default" size="100%">Kaplan‐Meier Estimate</style></keyword><keyword><style face="normal" font="default" size="100%">Logistic Models</style></keyword><keyword><style face="normal" font="default" size="100%">Malaria, Vivax [*drug therapy, metabolism]</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Parasitemia [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Plasmodium vivax [isolation &amp; purification]</style></keyword><keyword><style face="normal" font="default" size="100%">Primaquine [administration &amp; dosage]</style></keyword><keyword><style face="normal" font="default" size="100%">Secondary Prevention [*methods]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2019</style></year></dates><accession-num><style face="normal" font="default" size="100%">CN-01702702</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Treatment of Plasmodium vivax malaria requires the clearing of asexual parasites, but relapse can be prevented only if dormant hypnozoites are cleared from the liver (a treatment termed &quot;radical cure&quot;). Tafenoquine is a single‐dose 8‐aminoquinoline that has recently been registered for the radical cure of P. vivax. METHODS: This multicenter, double‐blind, double‐dummy, parallel group, randomized, placebo‐controlled trial was conducted in Ethiopia, Peru, Brazil, Cambodia, Thailand, and the Philippines. We enrolled 522 patients with microscopically confirmed P. vivax infection (&gt;100 to &lt;100,000 parasites per microliter) and normal glucose‐6‐phosphate dehydrogenase (G6PD) activity (with normal activity defined as ≥70% of the median value determined at each trial site among 36 healthy male volunteers who were otherwise not involved in the trial). All patients received a 3‐day course of chloroquine (total dose of 1500 mg). In addition, patients were assigned to receive a single 300‐mg dose of tafenoquine on day 1 or 2 (260 patients), placebo (133 patients), or a 15‐mg dose of primaquine once daily for 14 days (129 patients). The primary outcome was the Kaplan‐Meier estimated percentage of patients who were free from recurrence at 6 months, defined as P. vivax clearance without recurrent parasitemia. RESULTS: In the intention‐to‐treat population, the percentage of patients who were free from recurrence at 6 months was 62.4% in the tafenoquine group (95% confidence interval [CI], 54.9 to 69.0), 27.7% in the placebo group (95% CI, 19.6 to 36.6), and 69.6% in the primaquine group (95% CI, 60.2 to 77.1). The hazard ratio for the risk of recurrence was 0.30 (95% CI, 0.22 to 0.40) with tafenoquine as compared with placebo (P&lt;0.001) and 0.26 (95% CI, 0.18 to 0.39) with primaquine as compared with placebo (P&lt;0.001). Tafenoquine was associated with asymptomatic declines in hemoglobin levels, which resolved without intervention. CONCLUSIONS: Single‐dose tafenoquine resulted in a significantly lower risk of P. vivax recurrence than placebo in patients with phenotypically normal G6PD activity. (Funded by GlaxoSmithKline and Medicines for Malaria Venture; DETECTIVE ClinicalTrials.gov number, NCT01376167 .).</style></abstract><caption><style face="normal" font="default" size="100%">Duplicate</style></caption><work-type><style face="normal" font="default" size="100%">Clinical Trial, Phase II; Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non‐U.S. Gov&apos;t</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01702702/full</style></url></related-urls></urls><custom3><style face="normal" font="default" size="100%">PUBMED 30650322</style></custom3><electronic-resource-num><style face="normal" font="default" size="100%">10.1056/NEJMoa1710775</style></electronic-resource-num></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>95</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">95</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lacerda, M. V. G.</style></author><author><style face="normal" font="default" size="100%">Llanos-Cuentas, A.</style></author><author><style face="normal" font="default" size="100%">Krudsood, S.</style></author><author><style face="normal" font="default" size="100%">Lon, C.</style></author><author><style face="normal" font="default" size="100%">Saunders, D. L.</style></author><author><style face="normal" font="default" size="100%">Mohammed, R.</style></author><author><style face="normal" font="default" size="100%">Yilma, D.</style></author><author><style face="normal" font="default" size="100%">Pereira, D. B.</style></author><author><style face="normal" font="default" size="100%">Espino, F. E. J.</style></author><author><style face="normal" font="default" size="100%">Mia, R. Z.</style></author><author><style face="normal" font="default" size="100%">Chuquiyauri, R.</style></author><author><style face="normal" font="default" size="100%">Val, F.</style></author><author><style face="normal" font="default" size="100%">Casapía, M.</style></author><author><style face="normal" font="default" size="100%">Monteiro, W. M.</style></author><author><style face="normal" font="default" size="100%">Brito, M. A. M.</style></author><author><style face="normal" font="default" size="100%">Costa, M. R. F.</style></author><author><style face="normal" font="default" size="100%">Buathong, N.</style></author><author><style face="normal" font="default" size="100%">Noedl, H.</style></author><author><style face="normal" font="default" size="100%">Diro, E.</style></author><author><style face="normal" font="default" size="100%">Getie, S.</style></author><author><style face="normal" font="default" size="100%">Wubie, K. M.</style></author><author><style face="normal" font="default" size="100%">Abdissa, A.</style></author><author><style face="normal" font="default" size="100%">Zeynudin, A.</style></author><author><style face="normal" font="default" size="100%">Abebe, C.</style></author><author><style face="normal" font="default" size="100%">Tada, M. S.</style></author><author><style face="normal" font="default" size="100%">Brand, F.</style></author><author><style face="normal" font="default" size="100%">Beck, H. P.</style></author><author><style face="normal" font="default" size="100%">Angus, B.</style></author><author><style face="normal" font="default" size="100%">Duparc, S.</style></author><author><style face="normal" font="default" size="100%">Kleim, J. P.</style></author><author><style face="normal" font="default" size="100%">Kellam, L. M.</style></author><author><style face="normal" font="default" size="100%">Rousell, V. M.</style></author><author><style face="normal" font="default" size="100%">Jones, S. W.</style></author><author><style face="normal" font="default" size="100%">Hardaker, E.</style></author><author><style face="normal" font="default" size="100%">Mohamed, K.</style></author><author><style face="normal" font="default" size="100%">Clover, D. D.</style></author><author><style face="normal" font="default" size="100%">Fletcher, K.</style></author><author><style face="normal" font="default" size="100%">Breton, J. J.</style></author><author><style face="normal" font="default" size="100%">Ugwuegbulam, C. O.</style></author><author><style face="normal" font="default" size="100%">Green, J. A.</style></author><author><style face="normal" font="default" size="100%">Koh, G. C. K. W.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Single-dose tafenoquine to prevent relapse of plasmodium vivax malaria</style></title><secondary-title><style face="normal" font="default" size="100%">New England Journal of Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">New England Journal of Medicine</style></full-title></periodical><pages><style face="normal" font="default" size="100%">215-228</style></pages><volume><style face="normal" font="default" size="100%">380</style></volume><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">NCT01376167</style></keyword><keyword><style face="normal" font="default" size="100%">chloroquine</style></keyword><keyword><style face="normal" font="default" size="100%">glucose 6 phosphate dehydrogenase</style></keyword><keyword><style face="normal" font="default" size="100%">hemoglobin</style></keyword><keyword><style face="normal" font="default" size="100%">methemoglobin</style></keyword><keyword><style face="normal" font="default" size="100%">placebo</style></keyword><keyword><style face="normal" font="default" size="100%">primaquine</style></keyword><keyword><style face="normal" font="default" size="100%">tafenoquine</style></keyword><keyword><style face="normal" font="default" size="100%">adult</style></keyword><keyword><style face="normal" font="default" size="100%">article</style></keyword><keyword><style face="normal" font="default" size="100%">Brazil</style></keyword><keyword><style face="normal" font="default" size="100%">Cambodia</style></keyword><keyword><style face="normal" font="default" size="100%">controlled study</style></keyword><keyword><style face="normal" font="default" size="100%">disease severity</style></keyword><keyword><style face="normal" font="default" size="100%">dizziness</style></keyword><keyword><style face="normal" font="default" size="100%">double blind procedure</style></keyword><keyword><style face="normal" font="default" size="100%">drug safety</style></keyword><keyword><style face="normal" font="default" size="100%">enzyme activity</style></keyword><keyword><style face="normal" font="default" size="100%">Ethiopia</style></keyword><keyword><style face="normal" font="default" size="100%">female</style></keyword><keyword><style face="normal" font="default" size="100%">hematocrit</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">hypopigmentation</style></keyword><keyword><style face="normal" font="default" size="100%">intention to treat analysis</style></keyword><keyword><style face="normal" font="default" size="100%">keratopathy</style></keyword><keyword><style face="normal" font="default" size="100%">major clinical study</style></keyword><keyword><style face="normal" font="default" size="100%">male</style></keyword><keyword><style face="normal" font="default" size="100%">multicenter study</style></keyword><keyword><style face="normal" font="default" size="100%">parasite clearance</style></keyword><keyword><style face="normal" font="default" size="100%">Peru</style></keyword><keyword><style face="normal" font="default" size="100%">Philippines</style></keyword><keyword><style face="normal" font="default" size="100%">Plasmodium vivax malaria</style></keyword><keyword><style face="normal" font="default" size="100%">priority journal</style></keyword><keyword><style face="normal" font="default" size="100%">randomized controlled trial</style></keyword><keyword><style face="normal" font="default" size="100%">recurrence risk</style></keyword><keyword><style face="normal" font="default" size="100%">relapse</style></keyword><keyword><style face="normal" font="default" size="100%">retina disease</style></keyword><keyword><style face="normal" font="default" size="100%">retinal hypopigmentation</style></keyword><keyword><style face="normal" font="default" size="100%">single drug dose</style></keyword><keyword><style face="normal" font="default" size="100%">Thailand</style></keyword><keyword><style face="normal" font="default" size="100%">treatment duration</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2019</style></year></dates><isbn><style face="normal" font="default" size="100%">1533-4406&#xD;0028-4793</style></isbn><abstract><style face="normal" font="default" size="100%">BACKGROUND Treatment of Plasmodium vivax malaria requires the clearing of asexual parasites, but relapse can be prevented only if dormant hypnozoites are cleared from the liver (a treatment termed “radical cure”). Tafenoquine is a single-dose 8-aminoquinoline that has recently been registered for the radical cure of P. vivax. METHODS This multicenter, double-blind, double-dummy, parallel group, randomized, placebo-controlled trial was conducted in Ethiopia, Peru, Brazil, Cambodia, Thailand, and the Philippines. We enrolled 522 patients with microscopically confirmed P. vivax infection (100 to 100,000 parasites per microliter) and normal glucose-6-phosphate dehydrogenase (G6PD) activity (with normal activity defined as ≥70% of the median value determined at each trial site among 36 healthy male volunteers who were otherwise not involved in the trial). All patients received a 3-day course of chloroquine (total dose of 1500 mg). In addition, patients were assigned to receive a single 300-mg dose of tafenoquine on day 1 or 2 (260 patients), placebo (133 patients), or a 15-mg dose of primaquine once daily for 14 days (129 patients). The primary outcome was the Kaplan-Meier estimated percentage of patients who were free from recurrence at 6 months, defined as P. vivax clearance without recurrent parasitemia. RESULTS In the intention-to-treat population, the percentage of patients who were free from recurrence at 6 months was 62.4% in the tafenoquine group (95% confidence interval [CI], 54.9 to 69.0), 27.7% in the placebo group (95% CI, 19.6 to 36.6), and 69.6% in the primaquine group (95% CI, 60.2 to 77.1). The hazard ratio for the risk of recurrence was 0.30 (95% CI, 0.22 to 0.40) with tafenoquine as compared with placebo (P0.001) and 0.26 (95% CI, 0.18 to 0.39) with primaquine as compared with placebo (P0.001). Tafenoquine was associated with asymptomatic declines in hemoglobin levels, which resolved without intervention. CONCLUSIONS Single-dose tafenoquine resulted in a significantly lower risk of P. vivax recurrence than placebo in patients with phenotypically normal G6PD activity.</style></abstract><caption><style face="normal" font="default" size="100%">Duplicate</style></caption><notes><style face="normal" font="default" size="100%">L625955660&#xD;2019-02-06&#xD;2019-02-08</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L625955660&amp;from=export</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1056/NEJMoa1710775</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">Alliance Pharmaceuticals&#xD;Glaxo SmithKline&#xD;Labaz&#xD;West Ward Pharmaceuticals</style></custom2><custom5><style face="normal" font="default" size="100%">30650322</style></custom5><electronic-resource-num><style face="normal" font="default" size="100%">10.1056/NEJMoa1710775</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase&#xD;Medline</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>119</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">119</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Tomillero, A.</style></author><author><style face="normal" font="default" size="100%">Moral, M. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">A. Tomillero</style></auth-address><titles><title><style face="normal" font="default" size="100%">Summary</style></title><secondary-title><style face="normal" font="default" size="100%">Methods and Findings in Experimental and Clinical Pharmacology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Methods and Findings in Experimental and Clinical Pharmacology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">331-388</style></pages><volume><style face="normal" font="default" size="100%">32</style></volume><number><style face="normal" font="default" size="100%">5</style></number><keywords><keyword><style face="normal" font="default" size="100%">adalimumab</style></keyword><keyword><style face="normal" font="default" size="100%">cannabidiol</style></keyword><keyword><style face="normal" font="default" size="100%">dexamethasone</style></keyword><keyword><style face="normal" font="default" size="100%">dienogest</style></keyword><keyword><style face="normal" font="default" size="100%">folic acid</style></keyword><keyword><style face="normal" font="default" size="100%">hydroxyurea</style></keyword><keyword><style face="normal" font="default" size="100%">icatibant</style></keyword><keyword><style face="normal" font="default" size="100%">imatinib</style></keyword><keyword><style face="normal" font="default" size="100%">infliximab</style></keyword><keyword><style face="normal" font="default" size="100%">lorazepam</style></keyword><keyword><style face="normal" font="default" size="100%">mepolizumab</style></keyword><keyword><style face="normal" font="default" size="100%">metformin</style></keyword><keyword><style face="normal" font="default" size="100%">methotrexate</style></keyword><keyword><style face="normal" font="default" size="100%">omega 3 fatty acid ester</style></keyword><keyword><style face="normal" font="default" size="100%">peginterferon alpha2b</style></keyword><keyword><style face="normal" font="default" size="100%">pegvisomant</style></keyword><keyword><style face="normal" font="default" size="100%">pioglitazone</style></keyword><keyword><style face="normal" font="default" size="100%">posaconazole</style></keyword><keyword><style face="normal" font="default" size="100%">prednisone</style></keyword><keyword><style face="normal" font="default" size="100%">pregabalin</style></keyword><keyword><style face="normal" font="default" size="100%">progesterone</style></keyword><keyword><style face="normal" font="default" size="100%">promethazine</style></keyword><keyword><style face="normal" font="default" size="100%">ribavirin</style></keyword><keyword><style face="normal" font="default" size="100%">rosuvastatin</style></keyword><keyword><style face="normal" font="default" size="100%">sitagliptin</style></keyword><keyword><style face="normal" font="default" size="100%">tetrahydrocannabinol</style></keyword><keyword><style face="normal" font="default" size="100%">tiapride</style></keyword><keyword><style face="normal" font="default" size="100%">tocilizumab</style></keyword><keyword><style face="normal" font="default" size="100%">unindexed drug</style></keyword><keyword><style face="normal" font="default" size="100%">urtoxazumab</style></keyword><keyword><style face="normal" font="default" size="100%">acromegaly</style></keyword><keyword><style face="normal" font="default" size="100%">acute coronary syndrome</style></keyword><keyword><style face="normal" font="default" size="100%">alcoholism</style></keyword><keyword><style face="normal" font="default" size="100%">alopecia areata</style></keyword><keyword><style face="normal" font="default" size="100%">analgesia</style></keyword><keyword><style face="normal" font="default" size="100%">angina pectoris</style></keyword><keyword><style face="normal" font="default" size="100%">angioneurotic edema</style></keyword><keyword><style face="normal" font="default" size="100%">antibiotic therapy</style></keyword><keyword><style face="normal" font="default" size="100%">antiviral therapy</style></keyword><keyword><style face="normal" font="default" size="100%">anxiety</style></keyword><keyword><style face="normal" font="default" size="100%">aortic valve stenosis</style></keyword><keyword><style face="normal" font="default" size="100%">aspergillosis</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">astrocytoma</style></keyword><keyword><style face="normal" font="default" size="100%">bladder cancer</style></keyword><keyword><style face="normal" font="default" size="100%">bone metastasis</style></keyword><keyword><style face="normal" font="default" size="100%">brain artery aneurysm</style></keyword><keyword><style face="normal" font="default" size="100%">breast cancer</style></keyword><keyword><style face="normal" font="default" size="100%">burn</style></keyword><keyword><style face="normal" font="default" size="100%">cancer combination chemotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">candidiasis</style></keyword><keyword><style face="normal" font="default" size="100%">carpal tunnel syndrome</style></keyword><keyword><style face="normal" font="default" size="100%">cervicobrachial neuralgia</style></keyword><keyword><style face="normal" font="default" size="100%">chronic hepatitis</style></keyword><keyword><style face="normal" font="default" size="100%">chronic myeloid leukemia</style></keyword><keyword><style face="normal" font="default" size="100%">chronic obstructive lung disease</style></keyword><keyword><style face="normal" font="default" size="100%">clinical trial (topic)</style></keyword><keyword><style face="normal" font="default" size="100%">cognitive defect</style></keyword><keyword><style face="normal" font="default" size="100%">colorectal cancer</style></keyword><keyword><style face="normal" font="default" size="100%">condyloma acuminatum</style></keyword><keyword><style face="normal" font="default" size="100%">contraception</style></keyword><keyword><style face="normal" font="default" size="100%">coronary artery disease</style></keyword><keyword><style face="normal" font="default" size="100%">Crohn disease</style></keyword><keyword><style face="normal" font="default" size="100%">cytomegalovirus infection</style></keyword><keyword><style face="normal" font="default" size="100%">dengue</style></keyword><keyword><style face="normal" font="default" size="100%">depression</style></keyword><keyword><style face="normal" font="default" size="100%">diabetic neuropathy</style></keyword><keyword><style face="normal" font="default" size="100%">diarrhea</style></keyword><keyword><style face="normal" font="default" size="100%">drug dependence</style></keyword><keyword><style face="normal" font="default" size="100%">drug development</style></keyword><keyword><style face="normal" font="default" size="100%">drug dose titration</style></keyword><keyword><style face="normal" font="default" size="100%">drug efficacy</style></keyword><keyword><style face="normal" font="default" size="100%">drug eruption</style></keyword><keyword><style face="normal" font="default" size="100%">drug megadose</style></keyword><keyword><style face="normal" font="default" size="100%">drug safety</style></keyword><keyword><style face="normal" font="default" size="100%">dyslipidemia</style></keyword><keyword><style face="normal" font="default" size="100%">dyspnea</style></keyword><keyword><style face="normal" font="default" size="100%">endarterectomy</style></keyword><keyword><style face="normal" font="default" size="100%">endometriosis</style></keyword><keyword><style face="normal" font="default" size="100%">endothelial dysfunction</style></keyword><keyword><style face="normal" font="default" size="100%">eosinophilia</style></keyword><keyword><style face="normal" font="default" size="100%">erectile dysfunction</style></keyword><keyword><style face="normal" font="default" size="100%">Escherichia coli infection</style></keyword><keyword><style face="normal" font="default" size="100%">esophagitis</style></keyword><keyword><style face="normal" font="default" size="100%">esophagus cancer</style></keyword><keyword><style face="normal" font="default" size="100%">eye disease</style></keyword><keyword><style face="normal" font="default" size="100%">fallopian tube cancer</style></keyword><keyword><style face="normal" font="default" size="100%">in vitro fertilization</style></keyword><keyword><style face="normal" font="default" size="100%">fibromyalgia</style></keyword><keyword><style face="normal" font="default" size="100%">gastrointestinal stromal tumor</style></keyword><keyword><style face="normal" font="default" size="100%">glioblastoma</style></keyword><keyword><style face="normal" font="default" size="100%">glomerulosclerosis</style></keyword><keyword><style face="normal" font="default" size="100%">glycogen storage disease type 2</style></keyword><keyword><style face="normal" font="default" size="100%">head and neck cancer</style></keyword><keyword><style face="normal" font="default" size="100%">headache</style></keyword><keyword><style face="normal" font="default" size="100%">heart infarction</style></keyword><keyword><style face="normal" font="default" size="100%">heart transplantation</style></keyword><keyword><style face="normal" font="default" size="100%">hemodialysis</style></keyword><keyword><style face="normal" font="default" size="100%">hemolytic uremic syndrome</style></keyword><keyword><style face="normal" font="default" size="100%">hepatitis C</style></keyword><keyword><style face="normal" font="default" size="100%">hospitalization</style></keyword><keyword><style face="normal" font="default" size="100%">hot flush</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">Human immunodeficiency virus infection</style></keyword><keyword><style face="normal" font="default" size="100%">hypercholesterolemia</style></keyword><keyword><style face="normal" font="default" size="100%">hyperinsulinemia</style></keyword><keyword><style face="normal" font="default" size="100%">hyperuricemia</style></keyword><keyword><style face="normal" font="default" size="100%">hypophysis tumor</style></keyword><keyword><style face="normal" font="default" size="100%">influenza</style></keyword><keyword><style face="normal" font="default" size="100%">insomnia</style></keyword><keyword><style face="normal" font="default" size="100%">insulin dependent diabetes mellitus</style></keyword><keyword><style face="normal" font="default" size="100%">insulin resistance</style></keyword><keyword><style face="normal" font="default" size="100%">interstitial cystitis</style></keyword><keyword><style face="normal" font="default" size="100%">intraocular hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">kidney failure</style></keyword><keyword><style face="normal" font="default" size="100%">lipodystrophy</style></keyword><keyword><style face="normal" font="default" size="100%">liver failure</style></keyword><keyword><style face="normal" font="default" size="100%">liver transplantation</style></keyword><keyword><style face="normal" font="default" size="100%">low back pain</style></keyword><keyword><style face="normal" font="default" size="100%">non small cell lung cancer</style></keyword><keyword><style face="normal" font="default" size="100%">lung transplantation</style></keyword><keyword><style face="normal" font="default" size="100%">malaria</style></keyword><keyword><style face="normal" font="default" size="100%">meningitis</style></keyword><keyword><style face="normal" font="default" size="100%">menopause</style></keyword><keyword><style face="normal" font="default" size="100%">metastasis</style></keyword><keyword><style face="normal" font="default" size="100%">microalbuminuria</style></keyword><keyword><style face="normal" font="default" size="100%">multicenter study (topic)</style></keyword><keyword><style face="normal" font="default" size="100%">multiple cycle treatment</style></keyword><keyword><style face="normal" font="default" size="100%">multiple myeloma</style></keyword><keyword><style face="normal" font="default" size="100%">myelodysplastic syndrome</style></keyword><keyword><style face="normal" font="default" size="100%">neurofibromatosis</style></keyword><keyword><style face="normal" font="default" size="100%">neurosis</style></keyword><keyword><style face="normal" font="default" size="100%">neurotoxicity</style></keyword><keyword><style face="normal" font="default" size="100%">non insulin dependent diabetes mellitus</style></keyword><keyword><style face="normal" font="default" size="100%">nonhodgkin lymphoma</style></keyword><keyword><style face="normal" font="default" size="100%">nose obstruction</style></keyword><keyword><style face="normal" font="default" size="100%">note</style></keyword><keyword><style face="normal" font="default" size="100%">obesity</style></keyword><keyword><style face="normal" font="default" size="100%">oligodendroglioma</style></keyword><keyword><style face="normal" font="default" size="100%">open angle glaucoma</style></keyword><keyword><style face="normal" font="default" size="100%">osteoarthritis</style></keyword><keyword><style face="normal" font="default" size="100%">ovary cancer</style></keyword><keyword><style face="normal" font="default" size="100%">overactive bladder</style></keyword><keyword><style face="normal" font="default" size="100%">pancreas cancer</style></keyword><keyword><style face="normal" font="default" size="100%">papillomavirus infection</style></keyword><keyword><style face="normal" font="default" size="100%">peripheral blood stem cell transplantation</style></keyword><keyword><style face="normal" font="default" size="100%">peripheral neuropathy</style></keyword><keyword><style face="normal" font="default" size="100%">peritoneum cancer</style></keyword><keyword><style face="normal" font="default" size="100%">phase 2 clinical trial (topic)</style></keyword><keyword><style face="normal" font="default" size="100%">polyneuropathy</style></keyword><keyword><style face="normal" font="default" size="100%">postoperative pain</style></keyword><keyword><style face="normal" font="default" size="100%">premature labor</style></keyword><keyword><style face="normal" font="default" size="100%">prostatectomy</style></keyword><keyword><style face="normal" font="default" size="100%">proteinuria</style></keyword><keyword><style face="normal" font="default" size="100%">psoriasis</style></keyword><keyword><style face="normal" font="default" size="100%">psoriatic arthritis</style></keyword><keyword><style face="normal" font="default" size="100%">pulmonary hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">randomized controlled trial (topic)</style></keyword><keyword><style face="normal" font="default" size="100%">macular edema</style></keyword><keyword><style face="normal" font="default" size="100%">retina vein occlusion</style></keyword><keyword><style face="normal" font="default" size="100%">rheumatoid arthritis</style></keyword><keyword><style face="normal" font="default" size="100%">rhinitis</style></keyword><keyword><style face="normal" font="default" size="100%">Rotavirus infection</style></keyword><keyword><style face="normal" font="default" size="100%">septic shock</style></keyword><keyword><style face="normal" font="default" size="100%">single drug dose</style></keyword><keyword><style face="normal" font="default" size="100%">sleep disordered breathing</style></keyword><keyword><style face="normal" font="default" size="100%">smoking</style></keyword><keyword><style face="normal" font="default" size="100%">smoking cessation</style></keyword><keyword><style face="normal" font="default" size="100%">stomach cancer</style></keyword><keyword><style face="normal" font="default" size="100%">cerebrovascular accident</style></keyword><keyword><style face="normal" font="default" size="100%">subarachnoid hemorrhage</style></keyword><keyword><style face="normal" font="default" size="100%">systemic sclerosis</style></keyword><keyword><style face="normal" font="default" size="100%">tetanus</style></keyword><keyword><style face="normal" font="default" size="100%">thrombocytopenia</style></keyword><keyword><style face="normal" font="default" size="100%">tonsillitis</style></keyword><keyword><style face="normal" font="default" size="100%">uterine cervix cancer</style></keyword><keyword><style face="normal" font="default" size="100%">vagina bleeding</style></keyword><keyword><style face="normal" font="default" size="100%">vaginitis</style></keyword><keyword><style face="normal" font="default" size="100%">venous thromboembolism</style></keyword><keyword><style face="normal" font="default" size="100%">virus encephalitis</style></keyword><keyword><style face="normal" font="default" size="100%">vitiligo</style></keyword><keyword><style face="normal" font="default" size="100%">withdrawal syndrome</style></keyword><keyword><style face="normal" font="default" size="100%">zygomycosis</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2010</style></year></dates><isbn><style face="normal" font="default" size="100%">0379-0355</style></isbn><abstract><style face="normal" font="default" size="100%">Gateways to Clinical Trials is a guide to the most recent clinical trials in current literature and congresses. The data in the following tables has been retrieved from the Clinical Trials Knowledge Area of Thomson Reuters IntegritySM, the drug discovery and development portal, http://integrity.prous.com. This issue focuses on the following selection of drugs: [11C]RAC; 18F-Fluoromisonidazole; 89-12; 9-[18F]Fluoropropyl-(+)-dihydrotetrabenazine; Adalimumab, Adecatumumab, ADMVA, ADXS-11-001, Aflibercept, Agatolimod sodium, AGS-004, Alglucosidase alfa, Aliskiren fumarate, Alvocidib hydrochloride, AMG-108, AMG-853, Apixaban, Aripiprazole, Armodafinil, Atazanavir sulfate, Atomoxetine hydrochloride; Bevacizumab, BioMatrix Flex drug eluting stent, Biphasic insulin aspart, Bortezomib, Bosentan; Caspofungin acetate, Cediranib, Cetuximab, ChimeriVax-Dengue, Choriogonadotropin alfa, Cinacalcet hydrochloride, Cizolirtine citrate, Clofarabine, Cocaine conjugate vaccine, CX-717; Darbepoetin alfa, Dasatinib, Decitabine, Denosumab, Desvenlafaxine succinate, Dexamethasone sodium phosphate, Dienogest, Diphencyprone, Doripenem, DTaP-HepB-IPV, Dutasteride; E-7010, Ecallantide, Ecstasy, Eicosapentaenoic acid/docosahexaenoic acid, Emtricitabine, Enfuvirtide, Erlotinib hydrochloride, Eszopiclone, Etonogestrel/ethinyl estradiol, Etoricoxib, Everolimus, Everolimus-eluting coronary stent EVT-201, Ezetimibe, Ezetimibe/simvastatin; Ferumoxytol, Fesoterodine fumavate, Figitumumab, Filgrastim, Fingolimod hydrochloride, Fluticasone furoate, Fluval P, Fluzone, Fondaparinux sodium, Fulvestrant, Fungichromin; Gamma-hydroxybutyrate sodium, Gefitinib, GHB-01L1, GLY-230, GSK-1349572; Hib-MenCY-TT, Hib-TT, HPV-6/11/16/18, Hydrocodone bitartrate; IC-51, Icatibant acetate, Imatinib mesylate, Immunoglobulin intravenous (human), Indetanib, Influenza A (H1N1) 2009 Monovalent Vaccine, Inhalable human insulin, Insulin glargine, Insulin glulisine, Interferon-beta, Ispinesib mesylate, Ixabepilone; Laromustine, Latanoprost/timolol maleate, L-Citrulline, Lenalidomide, Lexatumumab, Linezolid, Lopinavir/ritonavir, Lutropin alfa; Mapatumumab, MDX-066, MDX-1388, Mepolizumab, Methoxy polyethylene glycol-epoetin-beta, Metreleptin, Micafungin sodium, Mometasone furoate/oxymetazoline hydrochloride, Mx-dnG1, Mycophenolic acid sodium salt; Nabiximols, Natalizumab, Nemonoxacin, Norelgestromin/ethinyl estradiol; Oblimersen sodium, Ocriplasmin, Olmesartan medoxomil, Omacetaxine mepesuccinate; Paclitaxel-eluting stent, Pagoclone, Paliperidone, Panitumumab, Pazopanib hydrochloride, PCV7, Pegaptanib octasodium, Peginterferon alfa-2a, Peginterferon alfa-2b/ribavirin, Pegvisomant, Pemetrexed disodium, Perifosine, Pimecrolimus, Pitavastatin calcium, Plerixafor hydrochloride, Plitidepsin, Posaconazole, Pregabalin, Progesterone capriate; Raltegravir potassium, Ramucirumab, Ranelic acid distrontium salt, Rasburicase, Recombinant Bet V1, Recombinant human insulin, rhFSH, Rolofylline, Romidepsin, Romiplostim, Rosuvastatin calcium; Sapacitabine, Sevelamer carbonate, Sinecatechins, Sirolimus-eluting stent, Sitagliptin phosphate monohydrate, SN-29244, Sorafenib, Sugammadex sodium, Sunitinib malate; Tadalafil, Tafenoquine, Talnetant, Tanezumab, Tapentadol hydrochloride, Tasocitinib citrate, Technosphere/Insulin, Telcagepant, Tenofovir disoproxil fumarate, Teriparatide, Ticagrelor, Tigecycline, Tiotropium bromide, Tipifarnib, Tocilizumab, TS-041; Ulipristal acetate, Urtoxazumab, Ustekinumab; Vandetanib, Varenicline tartrate, Vicriviroc, Voriconazole, Vorinostat, VRC-HIVADV014-00-VP, VRC-HIVDNA016-00-VP; Zoledronic acid monohydrate. © 2010 Prous Science, S.A.U. or its licensors.</style></abstract><notes><style face="normal" font="default" size="100%">L361608085&#xD;2011-04-22&#xD;2011-05-03</style></notes><work-type><style face="normal" font="default" size="100%">Note</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L361608085&amp;from=export</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1358/mf.2010.32.5.1520420</style></url><url><style face="normal" font="default" size="100%">http://journals.prous.com/journals/servlet/xmlxsl/mf/20103205/pdf/mf320331.pdf?p_JournalId=6&amp;p_refId=1520420&amp;p_IsPs=N</style></url></related-urls></urls><custom5><style face="normal" font="default" size="100%">20664824</style></custom5><electronic-resource-num><style face="normal" font="default" size="100%">10.1358/mf.2010.32.5.1520420</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase&#xD;Medline</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>47</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">47</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Dow, G. S.</style></author><author><style face="normal" font="default" size="100%">Liu, J.</style></author><author><style face="normal" font="default" size="100%">Lin, G.</style></author><author><style face="normal" font="default" size="100%">Hetzell, B.</style></author><author><style face="normal" font="default" size="100%">Thieling, S.</style></author><author><style face="normal" font="default" size="100%">McCarthy, W. F.</style></author><author><style face="normal" font="default" size="100%">Tang, D.</style></author><author><style face="normal" font="default" size="100%">Smith, B.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">60° Pharmaceuticals LLC, Washington, DC, 20036, USA. geoffdow@60degreespharma.com.&#xD;PPD, Inc., Richmond, VA, 23230, USA. Jun.Liu@ppdi.com.&#xD;PPD, Inc., Richmond, VA, 23230, USA. Gina.Lin@ppdi.com.&#xD;PPD, Inc., Richmond, VA, 23230, USA. Brian.Hetzell@ppdi.com.&#xD;PPD, Inc., Richmond, VA, 23230, USA. Sarah.Thieling@ppdi.com.&#xD;USAMMDA, Ft Detrick, MD, 21702, USA. william.f.mccarthy1.civ@mail.mil.&#xD;USAMMDA, Ft Detrick, MD, 21702, USA. dtang38@verizon.net.&#xD;USAMMDA, Ft Detrick, MD, 21702, USA. bryan.l.smith5.mil@mail.mil.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Summary of anti-malarial prophylactic efficacy of tafenoquine from three placebo-controlled studies of residents of malaria-endemic countries</style></title><secondary-title><style face="normal" font="default" size="100%">Malar J</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Malar J</style></full-title></periodical><pages><style face="normal" font="default" size="100%">473</style></pages><volume><style face="normal" font="default" size="100%">14</style></volume><edition><style face="normal" font="default" size="100%">2015/11/28</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Africa</style></keyword><keyword><style face="normal" font="default" size="100%">Aminoquinolines/*administration &amp; dosage</style></keyword><keyword><style face="normal" font="default" size="100%">Antimalarials/*administration &amp; dosage</style></keyword><keyword><style face="normal" font="default" size="100%">Chemoprevention/*methods</style></keyword><keyword><style face="normal" font="default" size="100%">Double-Blind Method</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Malaria, Falciparum/*prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Mefloquine/administration &amp; dosage</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Placebos/administration &amp; dosage</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Young Adult</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov 26</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1475-2875</style></isbn><accession-num><style face="normal" font="default" size="100%">26610844</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Tafenoquine is a long half-life primaquine analog being developed for malaria prophylaxis. The US Army recently performed a unified analysis of efficacy in preparation for a regulatory submission, utilizing legacy data from three placebo-controlled studies conducted in the late 1990s and early 2000s. The subjects were residents of Africa who were naturally exposed to Plasmodium falciparum for 12-26 weeks. METHODS: The prophylactic efficacy of tafenoquine and mefloquine (included in some studies as a comparator) was calculated using incidence density among subjects who had completed the three-day loading doses of study drug, had at least one maintenance dose and had at least one blood smear assessed during the prophylactic period. The three placebo-controlled studies were analysed separately and then in two pooled analyses: one for tafenoquine versus placebo (three studies) and one for tafenoquine and mefloquine versus placebo (two studies). RESULTS: The pooled protective efficacy (PE) of a tafenoquine regimen with three daily loading doses plus weekly maintenance at 200-mg for 10 weeks or longer (referred to as 200-mg weekly hereafter) relative to placebo in three placebo-controlled studies was 93.1 % [95 % confidence interval (CI) 89.1-95.6 %; total N = 492]. The pooled PEs of regimens of tafenoquine 200-mg weekly and mefloquine 250-mg weekly relative to placebo in two placebo-controlled studies (total N = 519) were 93.5 % (95 % CI 88.6-96.2 %) and 94.5 % (95 % CI 88.7-97.3 %), respectively. Three daily loading plus weekly maintenance doses of 50- and 100-mg, but not 25-mg, exhibited similar PEs. The PEs of tafenoquine regimens of a three-day loading dose at 400-mg with and without follow-up weekly maintenance doses at 400-mg were 93.7 % (95 % CI 85.4-97.3 %) and 81.0 % (95 % CI 66.8-89.1 %), respectively. CONCLUSIONS: Tafenoquine provided the same level of prophylactic efficacy as mefloquine in residents of Africa. These data support the prophylactic efficacy of tafenoquine and mefloquine that has already been demonstrated in the intended malaria naive population.</style></abstract><caption><style face="normal" font="default" size="100%">Duplicate</style></caption><notes><style face="normal" font="default" size="100%">1475-2875&#xD;Dow, Geoffrey S&#xD;Liu, Jun&#xD;Lin, Gina&#xD;Hetzell, Brian&#xD;Thieling, Sarah&#xD;McCarthy, William F&#xD;Tang, Douglas&#xD;Smith, Bryan&#xD;Comparative Study&#xD;Journal Article&#xD;Randomized Controlled Trial&#xD;Malar J. 2015 Nov 26;14:473. doi: 10.1186/s12936-015-0991-x.</style></notes><urls></urls><custom2><style face="normal" font="default" size="100%">PMC4661991</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1186/s12936-015-0991-x</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>108</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">108</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Dow, G. S.</style></author><author><style face="normal" font="default" size="100%">Liu, J.</style></author><author><style face="normal" font="default" size="100%">Lin, G.</style></author><author><style face="normal" font="default" size="100%">Hetzell, B.</style></author><author><style face="normal" font="default" size="100%">Thieling, S.</style></author><author><style face="normal" font="default" size="100%">McCarthy, W. F.</style></author><author><style face="normal" font="default" size="100%">Tang, D.</style></author><author><style face="normal" font="default" size="100%">Smith, B.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">G.S. Dow, 60o Pharmaceuticals LLC, Washington, DC, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Summary of anti-malarial prophylactic efficacy of tafenoquine from three placebo-controlled studies of residents of malaria-endemic countries</style></title><secondary-title><style face="normal" font="default" size="100%">Malaria Journal</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Malaria Journal</style></full-title></periodical><volume><style face="normal" font="default" size="100%">14</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">halofantrine</style></keyword><keyword><style face="normal" font="default" size="100%">mefloquine</style></keyword><keyword><style face="normal" font="default" size="100%">placebo</style></keyword><keyword><style face="normal" font="default" size="100%">tafenoquine</style></keyword><keyword><style face="normal" font="default" size="100%">adult</style></keyword><keyword><style face="normal" font="default" size="100%">Africa</style></keyword><keyword><style face="normal" font="default" size="100%">article</style></keyword><keyword><style face="normal" font="default" size="100%">blood smear</style></keyword><keyword><style face="normal" font="default" size="100%">drug efficacy</style></keyword><keyword><style face="normal" font="default" size="100%">lack of drug effect</style></keyword><keyword><style face="normal" font="default" size="100%">drug withdrawal</style></keyword><keyword><style face="normal" font="default" size="100%">endemic disease</style></keyword><keyword><style face="normal" font="default" size="100%">female</style></keyword><keyword><style face="normal" font="default" size="100%">follow up</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">incidence</style></keyword><keyword><style face="normal" font="default" size="100%">loading drug dose</style></keyword><keyword><style face="normal" font="default" size="100%">maintenance therapy</style></keyword><keyword><style face="normal" font="default" size="100%">malaria</style></keyword><keyword><style face="normal" font="default" size="100%">malaria control</style></keyword><keyword><style face="normal" font="default" size="100%">male</style></keyword><keyword><style face="normal" font="default" size="100%">nonhuman</style></keyword><keyword><style face="normal" font="default" size="100%">parasite clearance</style></keyword><keyword><style face="normal" font="default" size="100%">Plasmodium falciparum</style></keyword><keyword><style face="normal" font="default" size="100%">randomized controlled trial (topic)</style></keyword><keyword><style face="normal" font="default" size="100%">treatment duration</style></keyword><keyword><style face="normal" font="default" size="100%">treatment withdrawal</style></keyword><keyword><style face="normal" font="default" size="100%">unspecified side effect</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year></dates><isbn><style face="normal" font="default" size="100%">1475-2875</style></isbn><abstract><style face="normal" font="default" size="100%">Background: Tafenoquine is a long half-life primaquine analog being developed for malaria prophylaxis. The US Army recently performed a unified analysis of efficacy in preparation for a regulatory submission, utilizing legacy data from three placebo-controlled studies conducted in the late 1990s and early 2000s. The subjects were residents of Africa who were naturally exposed to Plasmodium falciparum for 12-26 weeks. Methods: The prophylactic efficacy of tafenoquine and mefloquine (included in some studies as a comparator) was calculated using incidence density among subjects who had completed the three-day loading doses of study drug, had at least one maintenance dose and had at least one blood smear assessed during the prophylactic period. The three placebo-controlled studies were analysed separately and then in two pooled analyses: one for tafenoquine versus placebo (three studies) and one for tafenoquine and mefloquine versus placebo (two studies). Results: The pooled protective efficacy (PE) of a tafenoquine regimen with three daily loading doses plus weekly maintenance at 200-mg for 10 weeks or longer (referred to as 200-mg weekly hereafter) relative to placebo in three placebo-controlled studies was 93.1 % [95 % confidence interval (CI) 89.1-95.6 %; total N = 492]. The pooled PEs of regimens of tafenoquine 200-mg weekly and mefloquine 250-mg weekly relative to placebo in two placebo-controlled studies (total N = 519) were 93.5 % (95 % CI 88.6-96.2 %) and 94.5 % (95 % CI 88.7-97.3 %), respectively. Three daily loading plus weekly maintenance doses of 50- and 100-mg, but not 25-mg, exhibited similar PEs. The PEs of tafenoquine regimens of a three-day loading dose at 400-mg with and without follow-up weekly maintenance doses at 400-mg were 93.7 % (95 % CI 85.4-97.3 %) and 81.0 % (95 % CI 66.8-89.1 %), respectively. Conclusions: Tafenoquine provided the same level of prophylactic efficacy as mefloquine in residents of Africa. These data support the prophylactic efficacy of tafenoquine and mefloquine that has already been demonstrated in the intended malaria naive population.</style></abstract><caption><style face="normal" font="default" size="100%">Duplicate</style></caption><notes><style face="normal" font="default" size="100%">L607174123&#xD;2015-12-15&#xD;2020-07-28</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L607174123&amp;from=export</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1186/s12936-015-0991-x</style></url></related-urls></urls><custom5><style face="normal" font="default" size="100%">26610844</style></custom5><electronic-resource-num><style face="normal" font="default" size="100%">10.1186/s12936-015-0991-x</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase&#xD;Medline</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>180</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">180</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Dow, G. S.</style></author><author><style face="normal" font="default" size="100%">Liu, J.</style></author><author><style face="normal" font="default" size="100%">Lin, G.</style></author><author><style face="normal" font="default" size="100%">Hetzell, B.</style></author><author><style face="normal" font="default" size="100%">Thieling, S.</style></author><author><style face="normal" font="default" size="100%">McCarthy, W. F.</style></author><author><style face="normal" font="default" size="100%">Tang, D.</style></author><author><style face="normal" font="default" size="100%">Smith, B.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Summary of anti-malarial prophylactic efficacy of tafenoquine from three placebo-controlled studies of residents of malaria-endemic countries</style></title><secondary-title><style face="normal" font="default" size="100%">Malaria journal</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Malaria Journal</style></full-title></periodical><pages><style face="normal" font="default" size="100%">473</style></pages><volume><style face="normal" font="default" size="100%">14</style></volume><keywords><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Africa</style></keyword><keyword><style face="normal" font="default" size="100%">Aminoquinolines [*administration &amp; dosage]</style></keyword><keyword><style face="normal" font="default" size="100%">Antimalarials [*administration &amp; dosage]</style></keyword><keyword><style face="normal" font="default" size="100%">Chemoprevention [*methods]</style></keyword><keyword><style face="normal" font="default" size="100%">Double‐Blind Method</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Malaria, Falciparum [*prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Mefloquine [administration &amp; dosage]</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Placebos [administration &amp; dosage]</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Young Adult</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year></dates><accession-num><style face="normal" font="default" size="100%">CN-01168849</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Tafenoquine is a long half‐life primaquine analog being developed for malaria prophylaxis. The US Army recently performed a unified analysis of efficacy in preparation for a regulatory submission, utilizing legacy data from three placebo‐controlled studies conducted in the late 1990s and early 2000s. The subjects were residents of Africa who were naturally exposed to Plasmodium falciparum for 12‐26 weeks. METHODS: The prophylactic efficacy of tafenoquine and mefloquine (included in some studies as a comparator) was calculated using incidence density among subjects who had completed the three‐day loading doses of study drug, had at least one maintenance dose and had at least one blood smear assessed during the prophylactic period. The three placebo‐controlled studies were analysed separately and then in two pooled analyses: one for tafenoquine versus placebo (three studies) and one for tafenoquine and mefloquine versus placebo (two studies). RESULTS: The pooled protective efficacy (PE) of a tafenoquine regimen with three daily loading doses plus weekly maintenance at 200‐mg for 10 weeks or longer (referred to as 200‐mg weekly hereafter) relative to placebo in three placebo‐controlled studies was 93.1 % [95 % confidence interval (CI) 89.1‐95.6 %; total N = 492]. The pooled PEs of regimens of tafenoquine 200‐mg weekly and mefloquine 250‐mg weekly relative to placebo in two placebo‐controlled studies (total N = 519) were 93.5 % (95 % CI 88.6‐96.2 %) and 94.5 % (95 % CI 88.7‐97.3 %), respectively. Three daily loading plus weekly maintenance doses of 50‐ and 100‐mg, but not 25‐mg, exhibited similar PEs. The PEs of tafenoquine regimens of a three‐day loading dose at 400‐mg with and without follow‐up weekly maintenance doses at 400‐mg were 93.7 % (95 % CI 85.4‐97.3 %) and 81.0 % (95 % CI 66.8‐89.1 %), respectively. CONCLUSIONS: Tafenoquine provided the same level of prophylactic efficacy as mefloquine in residents of Africa. These data support the prophylactic efficacy of tafenoquine and mefloquine that has already been demonstrated in the intended malaria naive population.</style></abstract><caption><style face="normal" font="default" size="100%">Duplicate</style></caption><work-type><style face="normal" font="default" size="100%">Comparative Study; Journal Article; Randomized Controlled Trial</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01168849/full</style></url></related-urls></urls><custom3><style face="normal" font="default" size="100%">PUBMED 26610844</style></custom3><electronic-resource-num><style face="normal" font="default" size="100%">10.1186/s12936-015-0991-x</style></electronic-resource-num></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>24</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">24</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Chu, C. S.</style></author><author><style face="normal" font="default" size="100%">Freedman, D. O.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Shoklo Malaria Research Unit, Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Mae Sot, Thailand.&#xD;Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK.&#xD;William C. Gorgas Center for Geographic Medicine, Division of Infectious Diseases, University of Alabama at Birmingham, Birmingham, AL, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Tafenoquine and G6PD: a primer for clinicians</style></title><secondary-title><style face="normal" font="default" size="100%">J Travel Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Travel Med</style></full-title></periodical><volume><style face="normal" font="default" size="100%">26</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2019/04/04</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Aminoquinolines/administration &amp; dosage/*adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Antimalarials/administration &amp; dosage/*adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">*Contraindications, Drug</style></keyword><keyword><style face="normal" font="default" size="100%">Dose-Response Relationship, Drug</style></keyword><keyword><style face="normal" font="default" size="100%">Glucosephosphate Dehydrogenase Deficiency/*complications/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">*Hemolysis</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Malaria/drug therapy/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Recurrence</style></keyword><keyword><style face="normal" font="default" size="100%">8-aminoquinolines</style></keyword><keyword><style face="normal" font="default" size="100%">causal prophylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">glucose-6-phosphate dehydrogenase deficiency</style></keyword><keyword><style face="normal" font="default" size="100%">malaria prophylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">presumptive anti-relapse treatment (PART)</style></keyword><keyword><style face="normal" font="default" size="100%">radical cure</style></keyword><keyword><style face="normal" font="default" size="100%">tafenoquine</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2019</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun 1</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1195-1982 (Print)&#xD;1195-1982</style></isbn><accession-num><style face="normal" font="default" size="100%">30941413</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Tafenoquine, an 8-aminoquinoline, is now indicated for causal prophylaxis against all human malarias and as radical curative (anti-relapse) treatment against Plasmodium vivax and Plasmodium ovale. As with other 8-aminoquinolines, tafenoquine causes hemolysis in individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency (hemizygous males and homozygous females) and is contraindicated in this population. Those with intermediate G6PD activity (heterozygous females) are also at risk for hemolysis. Awareness of how to prescribe tafenoquine in relation to G6PD status is needed so it can be used safely. METHODS: A standard literature search was performed on varying combinations of the terms tafenoquine, Arakoda, Kodatef, Krintafel, Kozenis, primaquine, G6PD deficiency, malaria prophylaxis and radical cure. The data were gathered and interpreted to review how tafenoquine should be prescribed in consideration of the G6PD status of an individual and traveller. RESULTS: Tafenoquine should only be given to those with G6PD activity &gt;70% of the local population median. Qualitative G6PD tests are sufficient for diagnosing G6PD deficiency in males. However, in females quantitative G6PD testing is necessary to differentiate deficient, intermediate and normal G6PD statuses. Testing for G6PD deficiency is mandatory before tafenoquine prescription. Measures can be taken to avoid tafenoquine administration to ineligible individuals (i.e. due to G6PD status, age, pregnancy and lactation). Primaquine is still necessary for some of these cases. This review provides actions that can be taken to diagnose and manage hemolysis when tafenoquine is given inadvertently to ineligible individuals. CONCLUSION: Attention to G6PD status is required for safe prescription of tafenoquine. A high index of suspicion is needed if hemolysis occurs. Clinicians should seek evidence-based information for the management and treatment of iatrogenicy hemolysis caused by 8-aminoquinolines.</style></abstract><notes><style face="normal" font="default" size="100%">1708-8305&#xD;Chu, Cindy S&#xD;Freedman, David O&#xD;Journal Article&#xD;Review&#xD;J Travel Med. 2019 Jun 1;26(4):taz023. doi: 10.1093/jtm/taz023.</style></notes><urls></urls><custom2><style face="normal" font="default" size="100%">PMC6542331</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1093/jtm/taz023</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>44</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">44</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ebstie, Y. A.</style></author><author><style face="normal" font="default" size="100%">Abay, S. M.</style></author><author><style face="normal" font="default" size="100%">Tadesse, W. T.</style></author><author><style face="normal" font="default" size="100%">Ejigu, D. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Microbiology, Immunology and Parasitology.&#xD;Department of Pharmacology.&#xD;Department of Pharmacology and Clinical Pharmacy, School of Medicine, College of Health Sciences, Addis Ababa University.&#xD;Department of Pharmacology, St Paul&apos;s Hospital Millennium Medical College, Addis Ababa, Ethiopia.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Tafenoquine and its potential in the treatment and relapse prevention of Plasmodium vivax malaria: the evidence to date</style></title><secondary-title><style face="normal" font="default" size="100%">Drug Des Devel Ther</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Drug Des Devel Ther</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2387-99</style></pages><volume><style face="normal" font="default" size="100%">10</style></volume><edition><style face="normal" font="default" size="100%">2016/08/17</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Aminoquinolines/administration &amp; dosage/pharmacology/*therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Antimalarials/administration &amp; dosage/pharmacology/*therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Malaria, Vivax/*drug therapy/microbiology/*prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Plasmodium vivax/*drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">hypnozoite</style></keyword><keyword><style face="normal" font="default" size="100%">primaquine</style></keyword><keyword><style face="normal" font="default" size="100%">radical cure</style></keyword><keyword><style face="normal" font="default" size="100%">schizonts</style></keyword><keyword><style face="normal" font="default" size="100%">vivax malaria</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2016</style></year></dates><isbn><style face="normal" font="default" size="100%">1177-8881</style></isbn><accession-num><style face="normal" font="default" size="100%">27528800</style></accession-num><abstract><style face="normal" font="default" size="100%">Despite declining global malaria incidence, the disease continues to be a threat to people living in endemic regions. In 2015, an estimated 214 million new malaria cases and 438,000 deaths due to malaria were recorded. Plasmodium vivax is the second most common cause of malaria next to Plasmodium falciparum. Vivax malaria is prevalent especially in Southeast Asia and the Horn of Africa, with enormous challenges in controlling the disease. Some of the challenges faced by vivax malaria-endemic countries include limited access to effective drugs treating liver stages of the parasite (schizonts and hypnozoites), emergence/spread of drug resistance, and misperception of vivax malaria as nonlethal. Primaquine, the only 8-aminoquinoline derivative approved by the US Food and Drug Administration, is intended to clear intrahepatic hypnozoites of P. vivax (radical cure). However, poor adherence to a prolonged treatment course, drug-induced hemolysis in patients with glucose-6-phosphate dehydrogenase deficiency, and the emergence of resistance make it imperative to look for alternative drugs. Therefore, this review focuses on data accrued to date on tafenoquine and gives insight on the potential role of the drug in preventing relapse and radical cure of patients with vivax malaria.</style></abstract><caption><style face="normal" font="default" size="100%">Duplicate</style></caption><notes><style face="normal" font="default" size="100%">1177-8881&#xD;Ebstie, Yehenew A&#xD;Abay, Solomon M&#xD;Tadesse, Wondmagegn T&#xD;Ejigu, Dawit A&#xD;Journal Article&#xD;Review&#xD;Drug Des Devel Ther. 2016 Jul 26;10:2387-99. doi: 10.2147/DDDT.S61443. eCollection 2016.</style></notes><urls></urls><custom2><style face="normal" font="default" size="100%">PMC4970641</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.2147/dddt.S61443</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>104</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">104</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ebstie, Y. A.</style></author><author><style face="normal" font="default" size="100%">Abay, S. M.</style></author><author><style face="normal" font="default" size="100%">Tadesse, W. T.</style></author><author><style face="normal" font="default" size="100%">Ejigu, D. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Y.A. Ebstie, Department of Microbiology, Immunology and Parasitology, School of Medicine, College of Health Sciences, Addis Ababa University, Zambia Street, PO Box 9086, Addis Ababa, Ethiopia</style></auth-address><titles><title><style face="normal" font="default" size="100%">Tafenoquine and its potential in the treatment and relapse prevention of Plasmodium vivax malaria: The evidence to date</style></title><secondary-title><style face="normal" font="default" size="100%">Drug Design, Development and Therapy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Drug Design, Development and Therapy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2387-2399</style></pages><volume><style face="normal" font="default" size="100%">10</style></volume><keywords><keyword><style face="normal" font="default" size="100%">alanine aminotransferase</style></keyword><keyword><style face="normal" font="default" size="100%">bilirubin</style></keyword><keyword><style face="normal" font="default" size="100%">chloroquine</style></keyword><keyword><style face="normal" font="default" size="100%">glucose 6 phosphate dehydrogenase</style></keyword><keyword><style face="normal" font="default" size="100%">hemoglobin</style></keyword><keyword><style face="normal" font="default" size="100%">methemoglobin</style></keyword><keyword><style face="normal" font="default" size="100%">primaquine</style></keyword><keyword><style face="normal" font="default" size="100%">tafenoquine</style></keyword><keyword><style face="normal" font="default" size="100%">abdominal cramp</style></keyword><keyword><style face="normal" font="default" size="100%">abdominal pain</style></keyword><keyword><style face="normal" font="default" size="100%">abnormal laboratory result</style></keyword><keyword><style face="normal" font="default" size="100%">chemoprophylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">cornea disease</style></keyword><keyword><style face="normal" font="default" size="100%">diarrhea</style></keyword><keyword><style face="normal" font="default" size="100%">drug absorption</style></keyword><keyword><style face="normal" font="default" size="100%">drug bioavailability</style></keyword><keyword><style face="normal" font="default" size="100%">drug distribution</style></keyword><keyword><style face="normal" font="default" size="100%">drug efficacy</style></keyword><keyword><style face="normal" font="default" size="100%">drug excretion</style></keyword><keyword><style face="normal" font="default" size="100%">drug mechanism</style></keyword><keyword><style face="normal" font="default" size="100%">drug metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">drug safety</style></keyword><keyword><style face="normal" font="default" size="100%">drug structure</style></keyword><keyword><style face="normal" font="default" size="100%">dysentery</style></keyword><keyword><style face="normal" font="default" size="100%">gastrointestinal disease</style></keyword><keyword><style face="normal" font="default" size="100%">gastrointestinal symptom</style></keyword><keyword><style face="normal" font="default" size="100%">glucose 6 phosphate dehydrogenase deficiency</style></keyword><keyword><style face="normal" font="default" size="100%">hemolysis</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">keratopathy</style></keyword><keyword><style face="normal" font="default" size="100%">leukocyte count</style></keyword><keyword><style face="normal" font="default" size="100%">malaria control</style></keyword><keyword><style face="normal" font="default" size="100%">meta analysis (topic)</style></keyword><keyword><style face="normal" font="default" size="100%">methemoglobinemia</style></keyword><keyword><style face="normal" font="default" size="100%">multicenter study (topic)</style></keyword><keyword><style face="normal" font="default" size="100%">nausea</style></keyword><keyword><style face="normal" font="default" size="100%">nonhuman</style></keyword><keyword><style face="normal" font="default" size="100%">pharmacodynamics</style></keyword><keyword><style face="normal" font="default" size="100%">phase 1 clinical trial (topic)</style></keyword><keyword><style face="normal" font="default" size="100%">phase 2 clinical trial (topic)</style></keyword><keyword><style face="normal" font="default" size="100%">phase 3 clinical trial (topic)</style></keyword><keyword><style face="normal" font="default" size="100%">Plasmodium vivax malaria</style></keyword><keyword><style face="normal" font="default" size="100%">QT prolongation</style></keyword><keyword><style face="normal" font="default" size="100%">randomized controlled trial (topic)</style></keyword><keyword><style face="normal" font="default" size="100%">relapse</style></keyword><keyword><style face="normal" font="default" size="100%">review</style></keyword><keyword><style face="normal" font="default" size="100%">systematic review (topic)</style></keyword><keyword><style face="normal" font="default" size="100%">platelet count</style></keyword><keyword><style face="normal" font="default" size="100%">treatment outcome</style></keyword><keyword><style face="normal" font="default" size="100%">vector control</style></keyword><keyword><style face="normal" font="default" size="100%">wr 238605</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2016</style></year></dates><isbn><style face="normal" font="default" size="100%">1177-8881</style></isbn><abstract><style face="normal" font="default" size="100%">Despite declining global malaria incidence, the disease continues to be a threat to people living in endemic regions. In 2015, an estimated 214 million new malaria cases and 438, 000 deaths due to malaria were recorded. Plasmodium vivax is the second most common cause of malaria next to Plasmodium falciparum. Vivax malaria is prevalent especially in Southeast Asia and the Horn of Africa, with enormous challenges in controlling the disease. Some of the challenges faced by vivax malaria-endemic countries include limited access to effective drugs treating liver stages of the parasite (schizonts and hypnozoites), emergence/spread of drug resistance, and misperception of vivax malaria as nonlethal. Primaquine, the only 8-aminoquinoline derivative approved by the US Food and Drug Administration, is intended to clear intrahepatic hypnozoites of P. vivax (radical cure). However, poor adherence to a prolonged treatment course, drug-induced hemolysis in patients with glucose-6-phosphate dehydrogenase deficiency, and the emergence of resistance make it imperative to look for alternative drugs. Therefore, this review focuses on data accrued to date on tafenoquine and gives insight on the potential role of the drug in preventing relapse and radical cure of patients with vivax malaria.</style></abstract><caption><style face="normal" font="default" size="100%">Duplicate</style></caption><notes><style face="normal" font="default" size="100%">L611766046&#xD;2016-08-30&#xD;2016-09-02</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L611766046&amp;from=export</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.2147/DDDT.S61443</style></url></related-urls></urls><custom1><style face="normal" font="default" size="100%">wr 238605</style></custom1><custom5><style face="normal" font="default" size="100%">27528800</style></custom5><electronic-resource-num><style face="normal" font="default" size="100%">10.2147/DDDT.S61443</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase&#xD;Medline</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>51</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">51</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Green, J. A.</style></author><author><style face="normal" font="default" size="100%">Patel, A. K.</style></author><author><style face="normal" font="default" size="100%">Patel, B. R.</style></author><author><style face="normal" font="default" size="100%">Hussaini, A.</style></author><author><style face="normal" font="default" size="100%">Harrell, E. J.</style></author><author><style face="normal" font="default" size="100%">McDonald, M. J.</style></author><author><style face="normal" font="default" size="100%">Carter, N.</style></author><author><style face="normal" font="default" size="100%">Mohamed, K.</style></author><author><style face="normal" font="default" size="100%">Duparc, S.</style></author><author><style face="normal" font="default" size="100%">Miller, A. K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Diseases of the Developing World Group, GlaxoSmithKline Research and Development, Stockley Park West, Uxbridge, Middlesex, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Tafenoquine at therapeutic concentrations does not prolong Fridericia-corrected QT interval in healthy subjects</style></title><secondary-title><style face="normal" font="default" size="100%">J Clin Pharmacol</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Clin Pharmacol</style></full-title></periodical><pages><style face="normal" font="default" size="100%">995-1005</style></pages><volume><style face="normal" font="default" size="100%">54</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2014/04/05</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Aminoquinolines/adverse effects/blood/pharmacokinetics/*pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Antimalarials/adverse effects/blood/pharmacokinetics/*pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Electrocardiography/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Healthy Volunteers</style></keyword><keyword><style face="normal" font="default" size="100%">Heart Rate/*drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Models, Biological</style></keyword><keyword><style face="normal" font="default" size="100%">Single-Blind Method</style></keyword><keyword><style face="normal" font="default" size="100%">Young Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Qt</style></keyword><keyword><style face="normal" font="default" size="100%">anti-malarial</style></keyword><keyword><style face="normal" font="default" size="100%">cardiology</style></keyword><keyword><style face="normal" font="default" size="100%">moxifloxacin</style></keyword><keyword><style face="normal" font="default" size="100%">tafenoquine</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0091-2700 (Print)&#xD;0091-2700</style></isbn><accession-num><style face="normal" font="default" size="100%">24700490</style></accession-num><abstract><style face="normal" font="default" size="100%">Tafenoquine is being developed for relapse prevention in Plasmodium vivax malaria. This Phase I, single-blind, randomized, placebo- and active-controlled parallel group study investigated whether tafenoquine at supratherapeutic and therapeutic concentrations prolonged cardiac repolarization in healthy volunteers. Subjects aged 18-65 years were randomized to one of five treatment groups (n = 52 per group) to receive placebo, tafenoquine 300, 600, or 1200 mg, or moxifloxacin 400 mg (positive control). Lack of effect was demonstrated if the upper 90% CI of the change from baseline in QTcF following supratherapeutic tafenoquine 1200 mg versus placebo (ΔΔQTcF) was &lt;10 milliseconds for all pre-defined time points. The maximum ΔΔQTcF with tafenoquine 1200 mg (n = 50) was 6.39 milliseconds (90% CI 2.85, 9.94) at 72 hours post-final dose; that is, lack of effect for prolongation of cardiac depolarization was demonstrated. Tafenoquine 300 mg (n = 48) or 600 mg (n = 52) had no effect on ΔΔQTcF. Pharmacokinetic/pharmacodynamic modeling of the tafenoquine-QTcF concentration-effect relationship demonstrated a shallow slope (0.5 ms/μg mL(-1) ) over a wide concentration range. For moxifloxacin (n = 51), maximum ΔΔQTcF was 8.52 milliseconds (90% CI 5.00, 12.04), demonstrating assay sensitivity. In this thorough QT/QTc study, tafenoquine did not have a clinically meaningful effect on cardiac repolarization.</style></abstract><caption><style face="normal" font="default" size="100%">Duplicate</style></caption><notes><style face="normal" font="default" size="100%">1552-4604&#xD;Green, Justin A&#xD;Patel, Apurva K&#xD;Patel, Bela R&#xD;Hussaini, Azra&#xD;Harrell, Emma J&#xD;McDonald, Mirna J&#xD;Carter, Nick&#xD;Mohamed, Khadeeja&#xD;Duparc, Stephan&#xD;Miller, Ann K&#xD;Clinical Trial, Phase I&#xD;Journal Article&#xD;Randomized Controlled Trial&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;J Clin Pharmacol. 2014 Sep;54(9):995-1005. doi: 10.1002/jcph.302. Epub 2014 Apr 9.</style></notes><urls></urls><custom2><style face="normal" font="default" size="100%">PMC4283056</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/jcph.302</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>113</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">113</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Green, J. A.</style></author><author><style face="normal" font="default" size="100%">Patel, A. K.</style></author><author><style face="normal" font="default" size="100%">Patel, B. R.</style></author><author><style face="normal" font="default" size="100%">Hussaini, A.</style></author><author><style face="normal" font="default" size="100%">Harrell, E. J.</style></author><author><style face="normal" font="default" size="100%">McDonald, M. J.</style></author><author><style face="normal" font="default" size="100%">Carter, N.</style></author><author><style face="normal" font="default" size="100%">Mohamed, K.</style></author><author><style face="normal" font="default" size="100%">Duparc, S.</style></author><author><style face="normal" font="default" size="100%">Miller, A. K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">J.A. Green, GlaxoSmithKline Research and Development, Stockley Park West, Uxbridge, Middlesex UB11 1BT, United Kingdom</style></auth-address><titles><title><style face="normal" font="default" size="100%">Tafenoquine at therapeutic concentrations does not prolong fridericia-corrected QT interval in healthy subjects</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Clinical Pharmacology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Clinical Pharmacology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">995-1005</style></pages><volume><style face="normal" font="default" size="100%">54</style></volume><number><style face="normal" font="default" size="100%">9</style></number><keywords><keyword><style face="normal" font="default" size="100%">alanine aminotransferase</style></keyword><keyword><style face="normal" font="default" size="100%">aspartate aminotransferase</style></keyword><keyword><style face="normal" font="default" size="100%">bilirubin</style></keyword><keyword><style face="normal" font="default" size="100%">bilirubin glucuronide</style></keyword><keyword><style face="normal" font="default" size="100%">creatine kinase</style></keyword><keyword><style face="normal" font="default" size="100%">creatinine</style></keyword><keyword><style face="normal" font="default" size="100%">hemoglobin</style></keyword><keyword><style face="normal" font="default" size="100%">methemoglobin</style></keyword><keyword><style face="normal" font="default" size="100%">moxifloxacin</style></keyword><keyword><style face="normal" font="default" size="100%">tafenoquine</style></keyword><keyword><style face="normal" font="default" size="100%">adult</style></keyword><keyword><style face="normal" font="default" size="100%">aged</style></keyword><keyword><style face="normal" font="default" size="100%">alanine aminotransferase blood level</style></keyword><keyword><style face="normal" font="default" size="100%">area under the curve</style></keyword><keyword><style face="normal" font="default" size="100%">article</style></keyword><keyword><style face="normal" font="default" size="100%">aspartate aminotransferase blood level</style></keyword><keyword><style face="normal" font="default" size="100%">bilirubin blood level</style></keyword><keyword><style face="normal" font="default" size="100%">body mass</style></keyword><keyword><style face="normal" font="default" size="100%">circadian rhythm</style></keyword><keyword><style face="normal" font="default" size="100%">controlled study</style></keyword><keyword><style face="normal" font="default" size="100%">creatinine blood level</style></keyword><keyword><style face="normal" font="default" size="100%">drug blood level</style></keyword><keyword><style face="normal" font="default" size="100%">drug effect</style></keyword><keyword><style face="normal" font="default" size="100%">drug exposure</style></keyword><keyword><style face="normal" font="default" size="100%">drug half life</style></keyword><keyword><style face="normal" font="default" size="100%">drug hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">drug safety</style></keyword><keyword><style face="normal" font="default" size="100%">female</style></keyword><keyword><style face="normal" font="default" size="100%">follow up</style></keyword><keyword><style face="normal" font="default" size="100%">gastrointestinal symptom</style></keyword><keyword><style face="normal" font="default" size="100%">heart depolarization</style></keyword><keyword><style face="normal" font="default" size="100%">heart repolarization</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">human experiment</style></keyword><keyword><style face="normal" font="default" size="100%">limit of quantitation</style></keyword><keyword><style face="normal" font="default" size="100%">male</style></keyword><keyword><style face="normal" font="default" size="100%">maximum plasma concentration</style></keyword><keyword><style face="normal" font="default" size="100%">nausea and vomiting</style></keyword><keyword><style face="normal" font="default" size="100%">normal human</style></keyword><keyword><style face="normal" font="default" size="100%">phase 1 clinical trial</style></keyword><keyword><style face="normal" font="default" size="100%">placebo effect</style></keyword><keyword><style face="normal" font="default" size="100%">Plasmodium vivax malaria</style></keyword><keyword><style face="normal" font="default" size="100%">QT interval</style></keyword><keyword><style face="normal" font="default" size="100%">randomized controlled trial</style></keyword><keyword><style face="normal" font="default" size="100%">side effect</style></keyword><keyword><style face="normal" font="default" size="100%">time to maximum plasma concentration</style></keyword><keyword><style face="normal" font="default" size="100%">treatment duration</style></keyword><keyword><style face="normal" font="default" size="100%">urticaria</style></keyword><keyword><style face="normal" font="default" size="100%">avelox</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><isbn><style face="normal" font="default" size="100%">1552-4604&#xD;0091-2700</style></isbn><abstract><style face="normal" font="default" size="100%">Tafenoquine is being developed for relapse prevention in Plasmodium vivax malaria. This Phase I, single-blind, randomized, placebo- and active-controlled parallel group study investigated whether tafenoquine at supratherapeutic and therapeutic concentrations prolonged cardiac repolarization in healthy volunteers. Subjects aged 18-65 years were randomized to one of five treatment groups (n=52 per group) to receive placebo, tafenoquine 300, 600, or 1200mg, or moxifloxacin 400mg (positive control). Lack of effect was demonstrated if the upper 90% CI of the change from baseline in QTcF following supratherapeutic tafenoquine 1200mg versus placebo (ΔΔQTcF) was &lt;10milliseconds for all pre-defined time points. The maximum ΔΔQTcF with tafenoquine 1200mg (n=50) was 6.39milliseconds (90% CI 2.85, 9.94) at 72hours post-final dose; that is, lack of effect for prolongation of cardiac depolarization was demonstrated. Tafenoquine 300mg (n=48) or 600mg (n=52) had no effect on ΔΔQTcF. Pharmacokinetic/pharmacodynamic modeling of the tafenoquine-QTcF concentration-effect relationship demonstrated a shallow slope (0.5ms/μgmL-1) over a wide concentration range. For moxifloxacin (n=51), maximum ΔΔQTcF was 8.52milliseconds (90% CI 5.00, 12.04), demonstrating assay sensitivity. In this thorough QT/QTc study, tafenoquine did not have a clinically meaningful effect on cardiac repolarization. © 2014, The American College of Clinical Pharmacology.</style></abstract><caption><style face="normal" font="default" size="100%">Duplicate</style></caption><notes><style face="normal" font="default" size="100%">L373699842&#xD;2014-08-14&#xD;2014-08-20</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L373699842&amp;from=export</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1002/jcph.302</style></url></related-urls></urls><custom1><style face="normal" font="default" size="100%">avelox(Bayer)</style></custom1><custom2><style face="normal" font="default" size="100%">Bayer&#xD;Glaxo SmithKline</style></custom2><custom5><style face="normal" font="default" size="100%">24700490</style></custom5><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/jcph.302</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase&#xD;Medline</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>169</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">169</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Green, J. A.</style></author><author><style face="normal" font="default" size="100%">Patel, A. K.</style></author><author><style face="normal" font="default" size="100%">Patel, B. R.</style></author><author><style face="normal" font="default" size="100%">Hussaini, A.</style></author><author><style face="normal" font="default" size="100%">Harrell, E. J.</style></author><author><style face="normal" font="default" size="100%">McDonald, M. J.</style></author><author><style face="normal" font="default" size="100%">Carter, N.</style></author><author><style face="normal" font="default" size="100%">Mohamed, K.</style></author><author><style face="normal" font="default" size="100%">Duparc, S.</style></author><author><style face="normal" font="default" size="100%">Miller, A. K.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Tafenoquine at therapeutic concentrations does not prolong Fridericia-corrected QT interval in healthy subjects</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of clinical pharmacology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Clinical Pharmacology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">995‐1005</style></pages><volume><style face="normal" font="default" size="100%">54</style></volume><number><style face="normal" font="default" size="100%">9</style></number><keywords><keyword><style face="normal" font="default" size="100%">*Plasmodium vivax malaria/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">*Plasmodium vivax malaria/pc [Prevention]</style></keyword><keyword><style face="normal" font="default" size="100%">*QT interval</style></keyword><keyword><style face="normal" font="default" size="100%">*tafenoquine/ae [Adverse Drug Reaction]</style></keyword><keyword><style face="normal" font="default" size="100%">*tafenoquine/cr [Drug Concentration]</style></keyword><keyword><style face="normal" font="default" size="100%">*tafenoquine/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">*tafenoquine/pd [Pharmacology]</style></keyword><keyword><style face="normal" font="default" size="100%">*tafenoquine/pk [Pharmacokinetics]</style></keyword><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Alanine aminotransferase</style></keyword><keyword><style face="normal" font="default" size="100%">Alanine aminotransferase blood level</style></keyword><keyword><style face="normal" font="default" size="100%">Aminoquinolines [adverse effects, blood, pharmacokinetics, *pharmacology]</style></keyword><keyword><style face="normal" font="default" size="100%">Antimalarials [adverse effects, blood, pharmacokinetics, *pharmacology]</style></keyword><keyword><style face="normal" font="default" size="100%">Area under the curve</style></keyword><keyword><style face="normal" font="default" size="100%">Article</style></keyword><keyword><style face="normal" font="default" size="100%">Aspartate aminotransferase</style></keyword><keyword><style face="normal" font="default" size="100%">Aspartate aminotransferase blood level</style></keyword><keyword><style face="normal" font="default" size="100%">Bilirubin</style></keyword><keyword><style face="normal" font="default" size="100%">Bilirubin blood level</style></keyword><keyword><style face="normal" font="default" size="100%">Bilirubin glucuronide</style></keyword><keyword><style face="normal" font="default" size="100%">Body mass</style></keyword><keyword><style face="normal" font="default" size="100%">Circadian rhythm</style></keyword><keyword><style face="normal" font="default" size="100%">Controlled study</style></keyword><keyword><style face="normal" font="default" size="100%">Creatine kinase</style></keyword><keyword><style face="normal" font="default" size="100%">Creatinine</style></keyword><keyword><style face="normal" font="default" size="100%">Creatinine blood level</style></keyword><keyword><style face="normal" font="default" size="100%">Drug blood level</style></keyword><keyword><style face="normal" font="default" size="100%">Drug effect</style></keyword><keyword><style face="normal" font="default" size="100%">Drug exposure</style></keyword><keyword><style face="normal" font="default" size="100%">Drug half life</style></keyword><keyword><style face="normal" font="default" size="100%">Drug hypersensitivity/si [Side Effect]</style></keyword><keyword><style face="normal" font="default" size="100%">Drug safety</style></keyword><keyword><style face="normal" font="default" size="100%">Electrocardiography [drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Follow up</style></keyword><keyword><style face="normal" font="default" size="100%">Gastrointestinal symptom</style></keyword><keyword><style face="normal" font="default" size="100%">Healthy Volunteers</style></keyword><keyword><style face="normal" font="default" size="100%">Heart Rate [*drug effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Heart depolarization</style></keyword><keyword><style face="normal" font="default" size="100%">Heart repolarization</style></keyword><keyword><style face="normal" font="default" size="100%">Hemoglobin</style></keyword><keyword><style face="normal" font="default" size="100%">Human</style></keyword><keyword><style face="normal" font="default" size="100%">Human experiment</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Limit of quantitation</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Maximum plasma concentration</style></keyword><keyword><style face="normal" font="default" size="100%">Methemoglobin</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Models, Biological</style></keyword><keyword><style face="normal" font="default" size="100%">Moxifloxacin/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Moxifloxacin/pd [Pharmacology]</style></keyword><keyword><style face="normal" font="default" size="100%">Moxifloxacin/pk [Pharmacokinetics]</style></keyword><keyword><style face="normal" font="default" size="100%">Nausea and vomiting/si [Side Effect]</style></keyword><keyword><style face="normal" font="default" size="100%">Normal human</style></keyword><keyword><style face="normal" font="default" size="100%">Phase 1 clinical trial</style></keyword><keyword><style face="normal" font="default" size="100%">Placebo effect</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized controlled trial</style></keyword><keyword><style face="normal" font="default" size="100%">Side effect/si [Side Effect]</style></keyword><keyword><style face="normal" font="default" size="100%">Single‐Blind Method</style></keyword><keyword><style face="normal" font="default" size="100%">Time to maximum plasma concentration</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment duration</style></keyword><keyword><style face="normal" font="default" size="100%">Urticaria/si [Side Effect]</style></keyword><keyword><style face="normal" font="default" size="100%">Young Adult</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><accession-num><style face="normal" font="default" size="100%">CN-00998395</style></accession-num><abstract><style face="normal" font="default" size="100%">Tafenoquine is being developed for relapse prevention in Plasmodium vivax malaria. This Phase I, single‐blind, randomized, placebo‐ and active‐controlled parallel group study investigated whether tafenoquine at supratherapeutic and therapeutic concentrations prolonged cardiac repolarization in healthy volunteers. Subjects aged 18‐65 years were randomized to one of five treatment groups (n = 52 per group) to receive placebo, tafenoquine 300, 600, or 1200 mg, or moxifloxacin 400 mg (positive control). Lack of effect was demonstrated if the upper 90% CI of the change from baseline in QTcF following supratherapeutic tafenoquine 1200 mg versus placebo (ΔΔQTcF) was &lt;10 milliseconds for all pre‐defined time points. The maximum ΔΔQTcF with tafenoquine 1200 mg (n = 50) was 6.39 milliseconds (90% CI 2.85, 9.94) at 72 hours post‐final dose; that is, lack of effect for prolongation of cardiac depolarization was demonstrated. Tafenoquine 300 mg (n = 48) or 600 mg (n = 52) had no effect on ΔΔQTcF. Pharmacokinetic/pharmacodynamic modeling of the tafenoquine‐QTcF concentration‐effect relationship demonstrated a shallow slope (0.5 ms/μg mL(‐1) ) over a wide concentration range. For moxifloxacin (n = 51), maximum ΔΔQTcF was 8.52 milliseconds (90% CI 5.00, 12.04), demonstrating assay sensitivity. In this thorough QT/QTc study, tafenoquine did not have a clinically meaningful effect on cardiac repolarization.</style></abstract><caption><style face="normal" font="default" size="100%">Duplicate</style></caption><work-type><style face="normal" font="default" size="100%">Clinical Trial, Phase I; Journal Article; Randomized Controlled Trial; Research Support, Non‐U.S. Gov&apos;t</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.cochranelibrary.com/central/doi/10.1002/central/CN-00998395/full</style></url></related-urls></urls><custom3><style face="normal" font="default" size="100%">PUBMED 24700490,EMBASE 373699842</style></custom3><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/jcph.302</style></electronic-resource-num></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>38</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">38</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Novitt-Moreno, A.</style></author><author><style face="normal" font="default" size="100%">Ransom, J.</style></author><author><style face="normal" font="default" size="100%">Dow, G.</style></author><author><style face="normal" font="default" size="100%">Smith, B.</style></author><author><style face="normal" font="default" size="100%">Read, L. T.</style></author><author><style face="normal" font="default" size="100%">Toovey, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Fast-Track Drugs &amp; Biologics, North Potomac, MD 20878, USA.&#xD;60° Pharmaceuticals LLC, Washington DC 20036, USA. Electronic address: Geoffdow@60degreespharma.com.&#xD;60° Pharmaceuticals LLC, Washington DC 20036, USA.&#xD;United States Army Medical Materiel Development Activity (USAMMDA), Ft Detrick, MD 21702, USA.&#xD;Pegasus Research, 4103 Bottmingen, Switzerland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Tafenoquine for malaria prophylaxis in adults: An integrated safety analysis</style></title><secondary-title><style face="normal" font="default" size="100%">Travel Med Infect Dis</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Travel Med Infect Dis</style></full-title></periodical><pages><style face="normal" font="default" size="100%">19-27</style></pages><volume><style face="normal" font="default" size="100%">17</style></volume><edition><style face="normal" font="default" size="100%">2017/05/13</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Aminoquinolines/*adverse effects/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Antimalarials/*adverse effects/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Drug-Related Side Effects and Adverse Reactions/*epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Incidence</style></keyword><keyword><style face="normal" font="default" size="100%">Malaria/*drug therapy/*prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Military Personnel</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Young Adult</style></keyword><keyword><style face="normal" font="default" size="100%">8-aminoquinoline</style></keyword><keyword><style face="normal" font="default" size="100%">Adverse events</style></keyword><keyword><style face="normal" font="default" size="100%">Malaria</style></keyword><keyword><style face="normal" font="default" size="100%">Safety</style></keyword><keyword><style face="normal" font="default" size="100%">Tafenoquine</style></keyword><keyword><style face="normal" font="default" size="100%">Tolerability</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2017</style></year><pub-dates><date><style face="normal" font="default" size="100%">May-Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1477-8939</style></isbn><accession-num><style face="normal" font="default" size="100%">28495354</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Tafenoquine is a new prophylactic antimalarial drug. The current analysis presents an integrated safety assessment of the Tafenoquine Anticipated Clinical Regimen (Tafenoquine ACR) from 5 clinical trials, including 1 conducted in deployed military personnel and 4 in non-deployed residents, which also incorporated placebo and mefloquine comparator groups. METHODS: Adverse events (AEs) were coded according to the Medical Dictionary for Regulatory Activities (MedDRA(®), Version 15.0) and summarized. Among all subjects who had received the Tafenoquine ACR, safety findings were compared for subjects who were deployed military personnel from the Australian Defence Force (Deployed ADF) versus non-deployed residents (Resident Non-ADF). RESULTS: The incidence of at least one AE was 80.6%, 64.1%, 67.6% and 94.9% in the mefloquine, placebo, tafenoquine Resident Non-ADF and tafenoquine Deployed ADF groups, respectively. The latter group had a higher incidence of AEs related to military deployment. AEs that occurred at ≥ 1% incidence in both tafenoquine sub-groups and at a higher frequency than placebo included diarrhea, nausea, vomiting, gastroenteritis, nasopharyngeal tract infections, and back/neck pain. CONCLUSIONS: Weekly administration of tafenoquine for up to six months increased the incidence of gastrointestinal AEs, certain infections, and back/neck pain, but not the overall incidence of AEs versus placebo. CLINICAL TRIAL REGISTRATION NUMBERS/CLINICALTRIALS. GOV IDENTIFIERS: NCT02491606; NCT02488980; NCT02488902.</style></abstract><caption><style face="normal" font="default" size="100%">Duplicate</style></caption><notes><style face="normal" font="default" size="100%">1873-0442&#xD;Novitt-Moreno, Anne&#xD;Ransom, Janet&#xD;Dow, Geoffrey&#xD;Smith, Bryan&#xD;Read, Lisa Thomas&#xD;Toovey, Stephen&#xD;Journal Article&#xD;Netherlands&#xD;Travel Med Infect Dis. 2017 May-Jun;17:19-27. doi: 10.1016/j.tmaid.2017.05.008. Epub 2017 May 8.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.tmaid.2017.05.008</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>100</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">100</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Novitt-Moreno, A.</style></author><author><style face="normal" font="default" size="100%">Ransom, J.</style></author><author><style face="normal" font="default" size="100%">Dow, G.</style></author><author><style face="normal" font="default" size="100%">Smith, B.</style></author><author><style face="normal" font="default" size="100%">Read, L. T.</style></author><author><style face="normal" font="default" size="100%">Toovey, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">G. Dow, 60° Pharmaceuticals LLC, 1025 Connecticut Ave NW, Suite 1000, Washington DC, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Tafenoquine for malaria prophylaxis in adults: An integrated safety analysis</style></title><secondary-title><style face="normal" font="default" size="100%">Travel Medicine and Infectious Disease</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Travel Medicine and Infectious Disease</style></full-title></periodical><pages><style face="normal" font="default" size="100%">19-27</style></pages><volume><style face="normal" font="default" size="100%">17</style></volume><keywords><keyword><style face="normal" font="default" size="100%">NCT02488902</style></keyword><keyword><style face="normal" font="default" size="100%">alanine aminotransferase</style></keyword><keyword><style face="normal" font="default" size="100%">hemoglobin</style></keyword><keyword><style face="normal" font="default" size="100%">mefloquine</style></keyword><keyword><style face="normal" font="default" size="100%">tafenoquine</style></keyword><keyword><style face="normal" font="default" size="100%">abdominal pain</style></keyword><keyword><style face="normal" font="default" size="100%">abnormal dreaming</style></keyword><keyword><style face="normal" font="default" size="100%">adult</style></keyword><keyword><style face="normal" font="default" size="100%">agitation</style></keyword><keyword><style face="normal" font="default" size="100%">anxiety</style></keyword><keyword><style face="normal" font="default" size="100%">anxiety disorder</style></keyword><keyword><style face="normal" font="default" size="100%">arthralgia</style></keyword><keyword><style face="normal" font="default" size="100%">article</style></keyword><keyword><style face="normal" font="default" size="100%">Australian</style></keyword><keyword><style face="normal" font="default" size="100%">backache</style></keyword><keyword><style face="normal" font="default" size="100%">cellulitis</style></keyword><keyword><style face="normal" font="default" size="100%">cholestasis</style></keyword><keyword><style face="normal" font="default" size="100%">conjunctivitis</style></keyword><keyword><style face="normal" font="default" size="100%">coughing</style></keyword><keyword><style face="normal" font="default" size="100%">depression</style></keyword><keyword><style face="normal" font="default" size="100%">diarrhea</style></keyword><keyword><style face="normal" font="default" size="100%">dizziness</style></keyword><keyword><style face="normal" font="default" size="100%">drug efficacy</style></keyword><keyword><style face="normal" font="default" size="100%">drug safety</style></keyword><keyword><style face="normal" font="default" size="100%">drug withdrawal</style></keyword><keyword><style face="normal" font="default" size="100%">euphoria</style></keyword><keyword><style face="normal" font="default" size="100%">falling</style></keyword><keyword><style face="normal" font="default" size="100%">furunculosis</style></keyword><keyword><style face="normal" font="default" size="100%">gastritis</style></keyword><keyword><style face="normal" font="default" size="100%">gastroenteritis</style></keyword><keyword><style face="normal" font="default" size="100%">glomerulus filtration rate</style></keyword><keyword><style face="normal" font="default" size="100%">headache</style></keyword><keyword><style face="normal" font="default" size="100%">helminthiasis</style></keyword><keyword><style face="normal" font="default" size="100%">hemolytic anemia</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">hyperbilirubinemia</style></keyword><keyword><style face="normal" font="default" size="100%">hyperesthesia</style></keyword><keyword><style face="normal" font="default" size="100%">incidence</style></keyword><keyword><style face="normal" font="default" size="100%">insomnia</style></keyword><keyword><style face="normal" font="default" size="100%">irritable colon</style></keyword><keyword><style face="normal" font="default" size="100%">jaundice</style></keyword><keyword><style face="normal" font="default" size="100%">keratopathy</style></keyword><keyword><style face="normal" font="default" size="100%">laceration</style></keyword><keyword><style face="normal" font="default" size="100%">lactose intolerance</style></keyword><keyword><style face="normal" font="default" size="100%">malaria</style></keyword><keyword><style face="normal" font="default" size="100%">malaria control</style></keyword><keyword><style face="normal" font="default" size="100%">military deployment</style></keyword><keyword><style face="normal" font="default" size="100%">nausea</style></keyword><keyword><style face="normal" font="default" size="100%">neck pain</style></keyword><keyword><style face="normal" font="default" size="100%">neurosis</style></keyword><keyword><style face="normal" font="default" size="100%">night blindness</style></keyword><keyword><style face="normal" font="default" size="100%">nightmare</style></keyword><keyword><style face="normal" font="default" size="100%">oropharynx pain</style></keyword><keyword><style face="normal" font="default" size="100%">otalgia</style></keyword><keyword><style face="normal" font="default" size="100%">panic</style></keyword><keyword><style face="normal" font="default" size="100%">pneumonia</style></keyword><keyword><style face="normal" font="default" size="100%">priority journal</style></keyword><keyword><style face="normal" font="default" size="100%">randomized controlled trial (topic)</style></keyword><keyword><style face="normal" font="default" size="100%">rash</style></keyword><keyword><style face="normal" font="default" size="100%">retina disease</style></keyword><keyword><style face="normal" font="default" size="100%">rhinopharyngitis</style></keyword><keyword><style face="normal" font="default" size="100%">side effect</style></keyword><keyword><style face="normal" font="default" size="100%">sinusitis</style></keyword><keyword><style face="normal" font="default" size="100%">sleep disorder</style></keyword><keyword><style face="normal" font="default" size="100%">sprain</style></keyword><keyword><style face="normal" font="default" size="100%">stress</style></keyword><keyword><style face="normal" font="default" size="100%">suicide attempt</style></keyword><keyword><style face="normal" font="default" size="100%">tinea</style></keyword><keyword><style face="normal" font="default" size="100%">tonsillitis</style></keyword><keyword><style face="normal" font="default" size="100%">treatment duration</style></keyword><keyword><style face="normal" font="default" size="100%">upper abdominal pain</style></keyword><keyword><style face="normal" font="default" size="100%">urinary tract infection</style></keyword><keyword><style face="normal" font="default" size="100%">virus infection</style></keyword><keyword><style face="normal" font="default" size="100%">visual acuity</style></keyword><keyword><style face="normal" font="default" size="100%">visual field defect</style></keyword><keyword><style face="normal" font="default" size="100%">vomiting</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2017</style></year></dates><isbn><style face="normal" font="default" size="100%">1873-0442&#xD;1477-8939</style></isbn><abstract><style face="normal" font="default" size="100%">Background Tafenoquine is a new prophylactic antimalarial drug. The current analysis presents an integrated safety assessment of the Tafenoquine Anticipated Clinical Regimen (Tafenoquine ACR) from 5 clinical trials, including 1 conducted in deployed military personnel and 4 in non-deployed residents, which also incorporated placebo and mefloquine comparator groups. Methods Adverse events (AEs) were coded according to the Medical Dictionary for Regulatory Activities (MedDRA®, Version 15.0) and summarized. Among all subjects who had received the Tafenoquine ACR, safety findings were compared for subjects who were deployed military personnel from the Australian Defence Force (Deployed ADF) versus non-deployed residents (Resident Non-ADF). Results The incidence of at least one AE was 80.6%, 64.1%, 67.6% and 94.9% in the mefloquine, placebo, tafenoquine Resident Non-ADF and tafenoquine Deployed ADF groups, respectively. The latter group had a higher incidence of AEs related to military deployment. AEs that occurred at ≥ 1% incidence in both tafenoquine sub-groups and at a higher frequency than placebo included diarrhea, nausea, vomiting, gastroenteritis, nasopharyngeal tract infections, and back/neck pain. Conclusions Weekly administration of tafenoquine for up to six months increased the incidence of gastrointestinal AEs, certain infections, and back/neck pain, but not the overall incidence of AEs versus placebo. Clinical Trial Registration Numbers/ClinicalTrials.gov Identifiers NCT02491606; NCT02488980; NCT02488902.</style></abstract><caption><style face="normal" font="default" size="100%">Duplicate</style></caption><notes><style face="normal" font="default" size="100%">L616383914&#xD;2017-05-30&#xD;2017-07-13</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L616383914&amp;from=export</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1016/j.tmaid.2017.05.008</style></url></related-urls></urls><custom5><style face="normal" font="default" size="100%">28495354</style></custom5><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.tmaid.2017.05.008</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase&#xD;Medline</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>116</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">116</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Rajapakse, S.</style></author><author><style face="normal" font="default" size="100%">Rodrigo, C.</style></author><author><style face="normal" font="default" size="100%">Fernando, S. D.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">C. Rodrigo, Faculty of Medicine, University of Colombo, Department of Clinical Medicine, 25, Kynsey Road, Colombo, Sri Lanka</style></auth-address><titles><title><style face="normal" font="default" size="100%">Tafenoquine for Plasmodium vivax malaria infection</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><volume><style face="normal" font="default" size="100%">2013</style></volume><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">antimalarial agent</style></keyword><keyword><style face="normal" font="default" size="100%">placebo</style></keyword><keyword><style face="normal" font="default" size="100%">tafenoquine</style></keyword><keyword><style face="normal" font="default" size="100%">article</style></keyword><keyword><style face="normal" font="default" size="100%">drug efficacy</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">Plasmodium vivax malaria</style></keyword><keyword><style face="normal" font="default" size="100%">priority journal</style></keyword><keyword><style face="normal" font="default" size="100%">prophylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">randomized controlled trial (topic)</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><isbn><style face="normal" font="default" size="100%">1469-493X</style></isbn><abstract><style face="normal" font="default" size="100%">This is the protocol for a review and there is no abstract. The objectives are as follows: To assess effects of tafenoquine in relation to cure and prophylaxis of P. vivax malaria To compare the side effects and adverse events of tafenoquine versus placebo or other antimalarial drugs.</style></abstract><notes><style face="normal" font="default" size="100%">L620562271&#xD;2018-02-15&#xD;2018-02-21</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L620562271&amp;from=export</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1002/14651858.CD010458</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD010458</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>11</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">11</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Rodrigo, C.</style></author><author><style face="normal" font="default" size="100%">Rajapakse, S.</style></author><author><style face="normal" font="default" size="100%">Fernando, D.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pathology, School of Medical Sciences, University of New South Wales, Sydney, Australia.&#xD;Department of Clinical Medicine, Faculty of Medicine, University of Colombo, Colombo, Sri Lanka.&#xD;Department of Parasitology, Faculty of Medicine, University of Colombo, Colombo, Sri Lanka.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Tafenoquine for preventing relapse in people with Plasmodium vivax malaria</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database Syst Rev</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database Syst Rev</style></full-title></periodical><pages><style face="normal" font="default" size="100%">Cd010458</style></pages><volume><style face="normal" font="default" size="100%">9</style></volume><edition><style face="normal" font="default" size="100%">2020/09/07</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Aminoquinolines/*administration &amp; dosage/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Antimalarials/*administration &amp; dosage/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Chloroquine/administration &amp; dosage/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Administration Schedule</style></keyword><keyword><style face="normal" font="default" size="100%">Glucosephosphate Dehydrogenase Deficiency/complications</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Malaria, Vivax/*drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Parasitemia/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Placebos</style></keyword><keyword><style face="normal" font="default" size="100%">Primaquine/*administration &amp; dosage/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Recurrence</style></keyword><keyword><style face="normal" font="default" size="100%">*Secondary Prevention</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2020</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep 6</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1361-6137</style></isbn><accession-num><style face="normal" font="default" size="100%">32892362</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Plasmodium vivax malaria has a persistent liver stage that causes relapse of the disease and continued P vivax transmission. Primaquine (PQ) is used to clear the liver stage of the parasite, but treatment is required for 14 days. Primaquine also causes haemolysis in people with glucose-6-phosphate dehydrogenase (G6PD) deficiency. Tafenoquine (TQ) is a new alternative to PQ with a longer half-life and can be used as a single-dose treatment. OBJECTIVES: To assess the effects of tafenoquine 300 mg (single dose) on preventing P vivax relapse. SEARCH METHODS: We searched the following up to 3 June 2020: the Cochrane Infectious Diseases Group Specialized Register; CENTRAL; MEDLINE; Embase; and three other databases. We also searched the WHO International Clinical Trial Registry Platform and the metaRegister of Controlled Trials for ongoing trials using &quot;tafenoquine&quot; and &quot;malaria&quot; as search terms up to 3 June 2020. SELECTION CRITERIA: Randomized controlled trials (RCTs) that gave TQ to prevent relapse in people with P vivax malaria. We planned to include trials irrespective of whether participants had been screened for G6PD enzyme deficiency. DATA COLLECTION AND ANALYSIS: All review authors independently extracted data and assessed risk of bias. As true relapse and reinfection are difficult to differentiate in people living in endemic areas, studies report &quot;recurrences&quot; of infection as a proxy for relapse. We carried out meta-analysis where appropriate, and gave estimates as risk ratios (RR) with 95% confidence intervals (CI). We assessed the certainty of the evidence using the GRADE approach. MAIN RESULTS: Three individually randomized RCTs met our inclusion criteria, all in endemic areas, and thus reporting recurrence. Trials compared TQ with PQ or placebo, and all participants received chloroquine (CQ) to treat the asexual infection). In all trials, pregnant and G6PD-deficient people were excluded. Tafenoquine 300 mg single dose versus no treatment for relapse prevention Two trials assessed this comparison. TQ 300 mg single dose reduces P vivax recurrences compared to no antihypnozoite treatment during a six-month follow-up, but there is moderate uncertainty around effect size (RR 0.32, 95% CI 0.12 to 0.88; 2 trials, 504 participants; moderate-certainty evidence). In people with normal G6PD status, there is probably little or no difference in any type of adverse events (2 trials, 504 participants; moderate-certainty evidence). However, we are uncertain if TQ causes more serious adverse events (2 trials, 504 participants; very low-certainty evidence). Both RCTs reported a total of 23 serious adverse events in TQ groups (One RCT reported 21 events) and a majority (15 events) were a drop in haemoglobin level by &gt; 3g/dl (or &gt;30% reduction from baseline). Tafenoquine 300 mg single dose versus primaquine 15 mg/day for 14 days for relapse prevention Three trials assessed this comparison. There is probably little or no difference between TQ and PQ in preventing recurrences (proxy measure for relapse) up to six months of follow-up (RR 1.04, 95% CI 0.8 to 1.34; 3 trials, 747 participants; moderate-certainty evidence). In people with normal G6PD status, there is probably little or no difference in any type of adverse events (3 trials, 747 participants; moderate-certainty evidence). We are uncertain if TQ can cause more serious adverse events compared to PQ (3 trials, 747 participants; very low-certainty evidence). Two trials had higher point estimates against TQ while the other showed the reverse. Most commonly reported serious adverse event in TQ group was a decline in haemoglobin level (19 out of 29 events). Some other serious adverse events, though observed in the TQ group, are unlikely to be caused by it (Hepatitis E infection, limb abscess, pneumonia, menorrhagia). AUTHORS&apos; CONCLUSIONS: TQ 300 mg single dose prevents relapses after clinically parasitologically confirmed P vivax malaria compared to no antihypnozoite treatment, and with no difference detected in studies comparing it to PQ to date. However, the inability to differentiate a true relapse from a recurrence in the available studies may affect these estimates. The drug is untested in children and in people with G6PD deficiency. Single-dose treatment is an important practical advantage compared to using PQ for the same purpose without an overall increase in adverse events in non-pregnant, non-G6PD-deficient adults.</style></abstract><caption><style face="normal" font="default" size="100%">Duplicate</style></caption><notes><style face="normal" font="default" size="100%">1469-493x&#xD;Rodrigo, Chaturaka&#xD;Rajapakse, Senaka&#xD;Fernando, Deepika&#xD;Journal Article&#xD;Meta-Analysis&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Systematic Review&#xD;England&#xD;Cochrane Database Syst Rev. 2020 Sep 6;9:CD010458. doi: 10.1002/14651858.CD010458.pub3.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD010458.pub3</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>84</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">84</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Rodrigo, C.</style></author><author><style face="normal" font="default" size="100%">Rajapakse, S.</style></author><author><style face="normal" font="default" size="100%">Fernando, D.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">C. Rodrigo, Department of Pathology, School of Medical Sciences, University of New South Wales, Sydney, Australia</style></auth-address><titles><title><style face="normal" font="default" size="100%">Tafenoquine for preventing relapse in people with Plasmodium vivax malaria</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><volume><style face="normal" font="default" size="100%">2020</style></volume><number><style face="normal" font="default" size="100%">9</style></number><keywords><keyword><style face="normal" font="default" size="100%">NCT02802501</style></keyword><keyword><style face="normal" font="default" size="100%">NCT04411836</style></keyword><keyword><style face="normal" font="default" size="100%">alanine aminotransferase</style></keyword><keyword><style face="normal" font="default" size="100%">chloroquine</style></keyword><keyword><style face="normal" font="default" size="100%">creatinine</style></keyword><keyword><style face="normal" font="default" size="100%">glucose 6 phosphate dehydrogenase</style></keyword><keyword><style face="normal" font="default" size="100%">hemoglobin</style></keyword><keyword><style face="normal" font="default" size="100%">primaquine</style></keyword><keyword><style face="normal" font="default" size="100%">tafenoquine</style></keyword><keyword><style face="normal" font="default" size="100%">abdominal pain</style></keyword><keyword><style face="normal" font="default" size="100%">anemia</style></keyword><keyword><style face="normal" font="default" size="100%">arthralgia</style></keyword><keyword><style face="normal" font="default" size="100%">clinical outcome</style></keyword><keyword><style face="normal" font="default" size="100%">coughing</style></keyword><keyword><style face="normal" font="default" size="100%">data analysis</style></keyword><keyword><style face="normal" font="default" size="100%">diarrhea</style></keyword><keyword><style face="normal" font="default" size="100%">dizziness</style></keyword><keyword><style face="normal" font="default" size="100%">drug effect</style></keyword><keyword><style face="normal" font="default" size="100%">factual database</style></keyword><keyword><style face="normal" font="default" size="100%">follow up</style></keyword><keyword><style face="normal" font="default" size="100%">headache</style></keyword><keyword><style face="normal" font="default" size="100%">hemoglobin blood level</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">meta analysis</style></keyword><keyword><style face="normal" font="default" size="100%">myalgia</style></keyword><keyword><style face="normal" font="default" size="100%">nausea</style></keyword><keyword><style face="normal" font="default" size="100%">nonhuman</style></keyword><keyword><style face="normal" font="default" size="100%">Plasmodium vivax malaria</style></keyword><keyword><style face="normal" font="default" size="100%">priority journal</style></keyword><keyword><style face="normal" font="default" size="100%">prophylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">pruritus</style></keyword><keyword><style face="normal" font="default" size="100%">QT prolongation</style></keyword><keyword><style face="normal" font="default" size="100%">randomized controlled trial (topic)</style></keyword><keyword><style face="normal" font="default" size="100%">rash</style></keyword><keyword><style face="normal" font="default" size="100%">reinfection</style></keyword><keyword><style face="normal" font="default" size="100%">relapse</style></keyword><keyword><style face="normal" font="default" size="100%">review</style></keyword><keyword><style face="normal" font="default" size="100%">side effect</style></keyword><keyword><style face="normal" font="default" size="100%">single drug dose</style></keyword><keyword><style face="normal" font="default" size="100%">systematic review</style></keyword><keyword><style face="normal" font="default" size="100%">vertigo</style></keyword><keyword><style face="normal" font="default" size="100%">vomiting</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2020</style></year></dates><isbn><style face="normal" font="default" size="100%">1469-493X</style></isbn><abstract><style face="normal" font="default" size="100%">Background: Plasmodium vivax malaria has a persistent liver stage that causes relapse of the disease and continued P vivax transmission. Primaquine (PQ) is used to clear the liver stage of the parasite, but treatment is required for 14 days. Primaquine also causes haemolysis in people with glucose-6-phosphate dehydrogenase (G6PD) deficiency. Tafenoquine (TQ) is a new alternative to PQ with a longer half-life and can be used as a single-dose treatment. Objectives: To assess the effects of tafenoquine 300 mg (single dose) on preventing P vivax relapse. Search methods: We searched the following up to 3 June 2020: the Cochrane Infectious Diseases Group Specialized Register; CENTRAL; MEDLINE; Embase; and three other databases. We also searched the WHO International Clinical Trial Registry Platform and the metaRegister of Controlled Trials for ongoing trials using &quot;tafenoquine&quot; and &quot;malaria&quot; as search terms up to 3 June 2020. Selection criteria: Randomized controlled trials (RCTs) that gave TQ to prevent relapse in people with P vivax malaria. We planned to include trials irrespective of whether participants had been screened for G6PD enzyme deficiency. Data collection and analysis: All review authors independently extracted data and assessed risk of bias. As true relapse and reinfection are difficult to differentiate in people living in endemic areas, studies report &quot;recurrences&quot; of infection as a proxy for relapse. We carried out meta-analysis where appropriate, and gave estimates as risk ratios (RR) with 95% confidence intervals (CI). We assessed the certainty of the evidence using the GRADE approach. Main results: Three individually randomized RCTs met our inclusion criteria, all in endemic areas, and thus reporting recurrence. Trials compared TQ with PQ or placebo, and all participants received chloroquine (CQ) to treat the asexual infection). In all trials, pregnant and G6PD-deficient people were excluded. Tafenoquine 300 mg single dose versus no treatment for relapse prevention. Two trials assessed this comparison. TQ 300 mg single dose reduces P vivax recurrences compared to no antihypnozoite treatment during a six-month follow-up, but there is moderate uncertainty around effect size (RR 0.32, 95% CI 0.12 to 0.88; 2 trials, 504 participants; moderate-certainty evidence). In people with normal G6PD status, there is probably little or no difference in any type of adverse events (2 trials, 504 participants; moderate-certainty evidence). However, we are uncertain if TQ causes more serious adverse events (2 trials, 504 participants; very low-certainty evidence). Both RCTs reported a total of 23 serious adverse events in TQ groups (One RCT reported 21 events) and a majority (15 events) were a drop in haemoglobin level by &gt; 3g/dl (or &gt;30% reduction from baseline). Tafenoquine 300 mg single dose versus primaquine 15 mg/day for 14 days for relapse prevention. Three trials assessed this comparison. There is probably little or no difference between TQ and PQ in preventing recurrences (proxy measure for relapse) up to six months of follow-up (RR 1.04, 95% CI 0.8 to 1.34; 3 trials, 747 participants; moderate-certainty evidence). In people with normal G6PD status, there is probably little or no difference in any type of adverse events (3 trials, 747 participants; moderate-certainty evidence). We are uncertain if TQ can cause more serious adverse events compared to PQ (3 trials, 747 participants; very low-certainty evidence). Two trials had higher point estimates against TQ while the other showed the reverse. Most commonly reported serious adverse event in TQ group was a decline in haemoglobin level (19 out of 29 events). Some other serious adverse events, though observed in the TQ group, are unlikely to be caused by it (Hepatitis E infection, limb abscess, pneumonia, menorrhagia). Authors&apos; conclusions: TQ 300 mg single dose prevents relapses after clinically parasitologically confirmed P vivax malaria compared to no antihypnozoite treatment, and with no difference detected in studies comparing it to PQ to date. However, the in bility to differentiate a true relapse from a recurrence in the available studies may affect these estimates. The drug is untested in children and in people with G6PD deficiency. Single-dose treatment is an important practical advantage compared to using PQ for the same purpose without an overall increase in adverse events in non-pregnant, non-G6PD-deficient adults.</style></abstract><caption><style face="normal" font="default" size="100%">Duplicate</style></caption><notes><style face="normal" font="default" size="100%">L632751942&#xD;2020-09-14&#xD;2020-09-22</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L632751942&amp;from=export</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1002/14651858.CD010458.pub3</style></url></related-urls></urls><custom5><style face="normal" font="default" size="100%">32892362</style></custom5><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD010458.pub3</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase&#xD;Medline</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>21</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">21</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Rodrigo, C.</style></author><author><style face="normal" font="default" size="100%">Rajapakse, S.</style></author><author><style face="normal" font="default" size="100%">Fernando, S. D.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pathology, School of Medical Sciences, University of New South Wales, Sydney, NSW, Australia.&#xD;Department of Clinical Medicine, Faculty of Medicine, University of Colombo, 25, Kynsey Road, Colombo, Sri Lanka.&#xD;Department of Parasitology, Faculty of Medicine, University of Colombo, 25, Kynsey Road, Colombo, Sri Lanka.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Tafenoquine for primary and terminal prophylaxis of malaria in apparently healthy people: a systematic review</style></title><secondary-title><style face="normal" font="default" size="100%">Trans R Soc Trop Med Hyg</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Trans R Soc Trop Med Hyg</style></full-title></periodical><pages><style face="normal" font="default" size="100%">579-586</style></pages><volume><style face="normal" font="default" size="100%">113</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2019/06/22</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Aminoquinolines/*therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Antimalarials/*therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Malaria/drug therapy/*prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">*malaria</style></keyword><keyword><style face="normal" font="default" size="100%">*primaquine</style></keyword><keyword><style face="normal" font="default" size="100%">*primary prophylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">*tafenoquine</style></keyword><keyword><style face="normal" font="default" size="100%">*terminal prophylaxis</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2019</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct 11</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0035-9203</style></isbn><accession-num><style face="normal" font="default" size="100%">31225623</style></accession-num><abstract><style face="normal" font="default" size="100%">Primaquine was the only licenced antimalarial hypnozoiticidal drug available until recently. Now there is a newly approved alternative: tafenoquine. This review explores the efficacy of tafenoquine as a primary and terminal prophylactic agent in malaria. Multiple databases (Cochrane Central Register of Controlled Trials [CENTRAL], MEDLINE [PubMed], Embase [Ovid], Scopus, CINAHL [EBSCOhost] and LILACS) were searched for clinical randomised controlled trials that had used tafenoquine for prophylaxis without language or time restrictions. The last date of searching was 13 August 2018. For primary prophylaxis, tafenoquine reduced episodes of malaria compared with placebo, at a dose range from 50 mg weekly to 400 mg monthly in three trials conducted in Ghana, Kenya and Thailand. Two trials compared tafenoquine vs mefloquine, but malaria episodes were too few to reach a conclusion. For terminal prophylaxis, evidence from two trials suggest that tafenoquine may have equal or better efficacy compared with primaquine. All trials excluded pregnant participants or those with G6PD deficiency. Tafenoquine is effective for both primary and terminal prophylaxis. If used for primary prophylaxis it may continue to offer protection against vivax relapses after exposure has ended (as terminal prophylaxis).</style></abstract><caption><style face="normal" font="default" size="100%">Duplicate</style></caption><notes><style face="normal" font="default" size="100%">1878-3503&#xD;Rodrigo, Chaturaka&#xD;Rajapakse, Senaka&#xD;Fernando, Sumadhya Deepika&#xD;Journal Article&#xD;Systematic Review&#xD;England&#xD;Trans R Soc Trop Med Hyg. 2019 Oct 11;113(10):579-586. doi: 10.1093/trstmh/trz052.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1093/trstmh/trz052</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>88</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">88</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Rodrigo, C.</style></author><author><style face="normal" font="default" size="100%">Rajapakse, S.</style></author><author><style face="normal" font="default" size="100%">Fernando, S. D.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">C. Rodrigo, Department of Pathology, School of Medical Sciences, University of New South Wales, Sydney, NSW, Australia</style></auth-address><titles><title><style face="normal" font="default" size="100%">Tafenoquine for primary and terminal prophylaxis of malaria in apparently healthy people: A systematic review</style></title><secondary-title><style face="normal" font="default" size="100%">Transactions of the Royal Society of Tropical Medicine and Hygiene</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Transactions of the Royal Society of Tropical Medicine and Hygiene</style></full-title></periodical><pages><style face="normal" font="default" size="100%">579-586</style></pages><volume><style face="normal" font="default" size="100%">113</style></volume><number><style face="normal" font="default" size="100%">10</style></number><keywords><keyword><style face="normal" font="default" size="100%">mefloquine</style></keyword><keyword><style face="normal" font="default" size="100%">placebo</style></keyword><keyword><style face="normal" font="default" size="100%">tafenoquine</style></keyword><keyword><style face="normal" font="default" size="100%">article</style></keyword><keyword><style face="normal" font="default" size="100%">drug efficacy</style></keyword><keyword><style face="normal" font="default" size="100%">evidence based medicine</style></keyword><keyword><style face="normal" font="default" size="100%">Ghana</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">Kenya</style></keyword><keyword><style face="normal" font="default" size="100%">malaria</style></keyword><keyword><style face="normal" font="default" size="100%">malaria control</style></keyword><keyword><style face="normal" font="default" size="100%">malaria falciparum</style></keyword><keyword><style face="normal" font="default" size="100%">meta analysis</style></keyword><keyword><style face="normal" font="default" size="100%">Plasmodium vivax malaria</style></keyword><keyword><style face="normal" font="default" size="100%">primary prevention</style></keyword><keyword><style face="normal" font="default" size="100%">randomized controlled trial (topic)</style></keyword><keyword><style face="normal" font="default" size="100%">systematic review</style></keyword><keyword><style face="normal" font="default" size="100%">Thailand</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2019</style></year></dates><isbn><style face="normal" font="default" size="100%">1878-3503&#xD;0035-9203</style></isbn><abstract><style face="normal" font="default" size="100%">Primaquine was the only licenced antimalarial hypnozoiticidal drug available until recently. Now there is a newly approved alternative: tafenoquine. This review explores the efficacy of tafenoquine as a primary and terminal prophylactic agent in malaria. Multiple databases (Cochrane Central Register of Controlled Trials [CENTRAL], MEDLINE [PubMed], Embase [Ovid], Scopus, CINAHL [EBSCOhost] and LILACS) were searched for clinical randomised controlled trials that had used tafenoquine for prophylaxis without language or time restrictions. The last date of searching was 13 August 2018. For primary prophylaxis, tafenoquine reduced episodes of malaria compared with placebo, at a dose range from 50 mg weekly to 400 mg monthly in three trials conducted in Ghana, Kenya and Thailand. Two trials compared tafenoquine vs mefloquine, but malaria episodes were too few to reach a conclusion. For terminal prophylaxis, evidence from two trials suggest that tafenoquine may have equal or better efficacy compared with primaquine. All trials excluded pregnant participants or those with G6PD deficiency. Tafenoquine is effective for both primary and terminal prophylaxis. If used for primary prophylaxis it may continue to offer protection against vivax relapses after exposure has ended (as terminal prophylaxis).</style></abstract><caption><style face="normal" font="default" size="100%">Duplicate</style></caption><notes><style face="normal" font="default" size="100%">L629745300&#xD;2019-11-08&#xD;2019-12-16</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L629745300&amp;from=export</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1093/trstmh/trz052</style></url></related-urls></urls><custom5><style face="normal" font="default" size="100%">31225623</style></custom5><electronic-resource-num><style face="normal" font="default" size="100%">10.1093/trstmh/trz052</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase&#xD;Medline</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>18</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">18</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Val, F.</style></author><author><style face="normal" font="default" size="100%">Costa, F. T.</style></author><author><style face="normal" font="default" size="100%">King, L.</style></author><author><style face="normal" font="default" size="100%">Brito-Sousa, J. D.</style></author><author><style face="normal" font="default" size="100%">Bassat, Q.</style></author><author><style face="normal" font="default" size="100%">Monteiro, W. M.</style></author><author><style face="normal" font="default" size="100%">Siqueira, A. M.</style></author><author><style face="normal" font="default" size="100%">Luzzatto, L.</style></author><author><style face="normal" font="default" size="100%">Lacerda, M. V.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Fundação de Medicina Tropical Doutor Heitor Vieira Dourado, Manaus, Amazonas, 69040-000, Brazil.&#xD;Universidade Estadual de Campinas (UNICAMP), Campinas, São Paulo, 13083-970, Brazil.&#xD;The Scripps Research Institute, La Jolla, CA 92037, USA.&#xD;Escola Superior de Ciências da Saúde,Universidade do Estado do Amazonas, Manaus, Amazonas, 69065-001, Brazil.&#xD;ISGlobal, Hospital Clínic - Universitat de Barcelona, Barcelona, 08036, Spain.&#xD;Centro de Investigação em Saúde de Manhiça (CISM), Distrito da Manhiça, CP 1929, Maputo, Mozambique.&#xD;ICREA, Pg. Lluís Companys 23, Barcelona, 08010, Spain.&#xD;Pediatric Infectious Diseases Unit, Pediatrics Department, Hospital Sant Joan de Déu (University of Barcelona), Barcelona, 08950, Spain.&#xD;Instituto Nacional de Infectologia Evandro Chagas, Fundação Oswaldo Cruz, Rio de Janeiro, Rio de Janeiro, 21040-360, Brazil.&#xD;Department of Hematology &amp; Blood Transfusion, Muhimbili University of Health &amp; Allied Sciences, Dar-es-Salaam, Tanzania.&#xD;Instituto Leônidas e Maria Deane, FIOCRUZ-AM, Manaus, Amazonas, 69057-070, Brazil.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Tafenoquine for the prophylaxis, treatment and elimination of malaria: eagerness must meet prudence</style></title><secondary-title><style face="normal" font="default" size="100%">Future Microbiol</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Future Microbiol</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1261-1279</style></pages><volume><style face="normal" font="default" size="100%">14</style></volume><edition><style face="normal" font="default" size="100%">2019/10/10</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Aminoquinolines/pharmacokinetics/*therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Antimalarials/pharmacokinetics/*therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Evaluation</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Malaria/*drug therapy/*prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Plasmodium vivax/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">*G6PD deficiency</style></keyword><keyword><style face="normal" font="default" size="100%">*Plasmodium vivax</style></keyword><keyword><style face="normal" font="default" size="100%">*malaria</style></keyword><keyword><style face="normal" font="default" size="100%">*malaria elimination</style></keyword><keyword><style face="normal" font="default" size="100%">*radical cure</style></keyword><keyword><style face="normal" font="default" size="100%">*tafenoquine</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2019</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1746-0913</style></isbn><accession-num><style face="normal" font="default" size="100%">31596137</style></accession-num><abstract><style face="normal" font="default" size="100%">Malaria puts more than 3 billion people at risk of infection and causes high morbidity and mortality. Plasmodium vivax forms hypnozoites, which may initiate recurrences, even in the absence of reinfection or superinfection. Until recently, the only drug available for eliminating hypnozoites was primaquine (PQ), which, given its short half-life, requires a relatively long course of treatment. Tafenoquine (TQ) is a PQ analog with a longer half-life. This enables radical cure of malaria with a single dose and overcomes adherence issues associated with PQ, thereby increasing effectiveness in real-life settings. Clinical studies have provided sound evidence for TQ&apos;s safety and efficacy against malaria, which recently led to its approval by the US FDA. Here, we review aspects of TQ, including how to avoid hemolytic anemia in G6PD deficient patients. We believe that TQ promises to be a major advance toward malaria elimination.</style></abstract><caption><style face="normal" font="default" size="100%">Duplicate</style></caption><notes><style face="normal" font="default" size="100%">1746-0921&#xD;Val, Fernando&#xD;Costa, Fabio Tm&#xD;King, Liam&#xD;Brito-Sousa, Jose D&#xD;Bassat, Quique&#xD;Monteiro, Wuelton M&#xD;Siqueira, André M&#xD;Luzzatto, Lucio&#xD;Lacerda, Marcus Vg&#xD;Journal Article&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;England&#xD;Future Microbiol. 2019 Oct;14:1261-1279. doi: 10.2217/fmb-2019-0202. Epub 2019 Oct 9.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.2217/fmb-2019-0202</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>189</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">189</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Val, F.</style></author><author><style face="normal" font="default" size="100%">Costa, F. T. M.</style></author><author><style face="normal" font="default" size="100%">King, L.</style></author><author><style face="normal" font="default" size="100%">Brito-Sousa, J. D.</style></author><author><style face="normal" font="default" size="100%">Bassat, Q.</style></author><author><style face="normal" font="default" size="100%">Monteiro, W. M.</style></author><author><style face="normal" font="default" size="100%">Siqueira, A. M.</style></author><author><style face="normal" font="default" size="100%">Luzzatto, L.</style></author><author><style face="normal" font="default" size="100%">Lacerda, M. V. G.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">[Val, Fernando; Brito-Sousa, Jose D.; Monteiro, Wuelton M.; Lacerda, Marcus V. G.] Fundacao Med Trop Doutor Heitor Vieira Dourado, BR-69040000 Manaus, Amazonas, Brazil. [Costa, Fabio T. M.] Univ Estadual Campinas UNICAMP, BR-13083970 Campinas, SP, Brazil. [King, Liam] Scripps Res Inst, La Jolla, CA 92037 USA. [Brito-Sousa, Jose D.; Monteiro, Wuelton M.] Univ Estado Amazonas, Escola Super Ciencias Saude, BR-69065001 Manaus, Amazonas, Brazil. [Bassat, Quique] Univ Barcelona, Hosp Clin, ISGlobal, E-08036 Barcelona, Spain. [Bassat, Quique] CISM, Maputo 1929, Mozambique. [Bassat, Quique] ICREA, Pg Lluis Co 23, Barcelona 08010, Spain. [Bassat, Quique] Univ Barcelona, Hosp St Joan de Deu, Pediat Dept, Pediat Infect Dis Unit, Barcelona 08950, Spain. [Siqueira, Andre M.] Fundacao Oswaldo Cruz, Inst Nacl Infectol Evandro Chagas, BR-21040360 Rio De Janeiro, RJ, Brazil. [Luzzatto, Lucio] Muhimbili Univ Hlth &amp; Allied Sci, Dept Hematol &amp; Blood Transfus, Dar Es Salaam, Tanzania. [Lacerda, Marcus V. G.] FIOCRUZ AM, Inst Leonidas &amp; Maria Deane, BR-69057070 Manaus, Amazonas, Brazil.&#xD;Lacerda, MVG (corresponding author), Fundacao Med Trop Doutor Heitor Vieira Dourado, BR-69040000 Manaus, Amazonas, Brazil.; Lacerda, MVG (corresponding author), FIOCRUZ AM, Inst Leonidas &amp; Maria Deane, BR-69057070 Manaus, Amazonas, Brazil.&#xD;marcuslacerda.br@gmail.com</style></auth-address><titles><title><style face="normal" font="default" size="100%">Tafenoquine for the prophylaxis, treatment and elimination of malaria: eagerness must meet prudence</style></title><secondary-title><style face="normal" font="default" size="100%">Future Microbiology</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Future Microbiol.</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Future Microbiology</style></full-title><abbr-1><style face="normal" font="default" size="100%">Future Microbiol.</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Future Microbiology</style></full-title><abbr-1><style face="normal" font="default" size="100%">Future Microbiol.</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">1261-1279</style></pages><volume><style face="normal" font="default" size="100%">14</style></volume><number><style face="normal" font="default" size="100%">15</style></number><keywords><keyword><style face="normal" font="default" size="100%">G6PD deficiency</style></keyword><keyword><style face="normal" font="default" size="100%">malaria</style></keyword><keyword><style face="normal" font="default" size="100%">malaria elimination</style></keyword><keyword><style face="normal" font="default" size="100%">Plasmodium vivax</style></keyword><keyword><style face="normal" font="default" size="100%">radical</style></keyword><keyword><style face="normal" font="default" size="100%">cure</style></keyword><keyword><style face="normal" font="default" size="100%">tafenoquine</style></keyword><keyword><style face="normal" font="default" size="100%">plasmodium-vivax malaria</style></keyword><keyword><style face="normal" font="default" size="100%">in-vitro activity</style></keyword><keyword><style face="normal" font="default" size="100%">double-blind</style></keyword><keyword><style face="normal" font="default" size="100%">pharmacokinetic interactions</style></keyword><keyword><style face="normal" font="default" size="100%">population pharmacokinetics</style></keyword><keyword><style face="normal" font="default" size="100%">plasma-concentrations</style></keyword><keyword><style face="normal" font="default" size="100%">antimalarial agent</style></keyword><keyword><style face="normal" font="default" size="100%">prevent relapse</style></keyword><keyword><style face="normal" font="default" size="100%">rapid test</style></keyword><keyword><style face="normal" font="default" size="100%">wr 238605</style></keyword><keyword><style face="normal" font="default" size="100%">Microbiology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2019</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1746-0913</style></isbn><accession-num><style face="normal" font="default" size="100%">WOS:000508001400002</style></accession-num><abstract><style face="normal" font="default" size="100%">Malaria puts more than 3 billion people at risk of infection and causes high morbidity and mortality. Plasmodium vivax forms hypnozoites, which may initiate recurrences, even in the absence of reinfection or superinfection. Until recently, the only drug available for eliminating hypnozoites was primaquine (PQ), which, given its short half-life, requires a relatively long course of treatment. Tafenoquine (TQ) is a PQ analog with a longer half-life. This enables radical cure of malaria with a single dose and overcomes adherence issues associated with PQ, thereby increasing effectiveness in real-life settings. Clinical studies have provided sound evidence for TQ&apos;s safety and efficacy against malaria, which recently led to its approval by the US FDA. Here, we review aspects of TQ, including how to avoid hemolytic anemia in G6PD deficient patients. We believe that TQ promises to be a major advance toward malaria elimination.</style></abstract><caption><style face="normal" font="default" size="100%">Duplicate</style></caption><notes><style face="normal" font="default" size="100%">ISI Document Delivery No.: KD6UW&#xD;Times Cited: 2&#xD;Cited Reference Count: 105&#xD;Val, Fernando Costa, Fabio T. M. King, Liam Brito-Sousa, Jose D. Bassat, Quique Monteiro, Wuelton M. Siqueira, Andre M. Luzzatto, Lucio Lacerda, Marcus V. G.&#xD;Bassat, Quique/P-2341-2016&#xD;Bassat, Quique/0000-0003-0875-7596; Val, Fernando/0000-0001-9995-0249&#xD;2&#xD;1&#xD;Future medicine ltd&#xD;London&#xD;1746-0921</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">&lt;Go to ISI&gt;://WOS:000508001400002</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.2217/fmb-2019-0202</style></electronic-resource-num><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>15</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">15</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Commons, R. J.</style></author><author><style face="normal" font="default" size="100%">McCarthy, J. S.</style></author><author><style face="normal" font="default" size="100%">Price, R. N.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Menzies School of Health Research, Darwin, NT.&#xD;WorldWide Antimalarial Resistance Network, Darwin, NT.&#xD;Ballarat Health Services, Ballarat, VIC.&#xD;QIMR Berghofer Medical Research Institute, Brisbane, QLD.&#xD;University of Queensland, Brisbane, QLD.&#xD;Centre for Tropical Medicine and Global Health, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK.&#xD;Mahidol University, Bangkok, Thailand.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Tafenoquine for the radical cure and prevention of malaria: the importance of testing for G6PD deficiency</style></title><secondary-title><style face="normal" font="default" size="100%">Med J Aust</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Med J Aust</style></full-title></periodical><pages><style face="normal" font="default" size="100%">152-153.e1</style></pages><volume><style face="normal" font="default" size="100%">212</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2020/02/10</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Aminoquinolines/administration &amp; dosage/*adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Antimalarials/administration &amp; dosage/*adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Glucosephosphate Dehydrogenase Deficiency/*diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Malaria/*drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Practice Guidelines as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Primaquine</style></keyword><keyword><style face="normal" font="default" size="100%">*Anti-infective agents</style></keyword><keyword><style face="normal" font="default" size="100%">*Malaria</style></keyword><keyword><style face="normal" font="default" size="100%">was on the expert panel for the tafenoquine licensing application at the US Federal</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Administration and on the expert committee for the Australian Therapeutic Goods</style></keyword><keyword><style face="normal" font="default" size="100%">Administration. His travel expenses to the US were reimbursed by GlaxoSmithKline.</style></keyword><keyword><style face="normal" font="default" size="100%">James McCarthy received funding from 60 Degrees Pharmaceuticals to conduct a</style></keyword><keyword><style face="normal" font="default" size="100%">randomised controlled trial to test the activity of tafenoquine as a potential drug</style></keyword><keyword><style face="normal" font="default" size="100%">for the chemoprophylaxis of malaria.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2020</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0025-729X (Print)&#xD;0025-729x</style></isbn><accession-num><style face="normal" font="default" size="100%">32036613</style></accession-num><notes><style face="normal" font="default" size="100%">1326-5377&#xD;Commons, Robert J&#xD;Orcid: 0000-0002-3359-5632&#xD;McCarthy, James S&#xD;Price, Ric N&#xD;Journal Article&#xD;Med J Aust. 2020 Mar;212(4):152-153.e1. doi: 10.5694/mja2.50474. Epub 2020 Feb 9.</style></notes><urls></urls><custom2><style face="normal" font="default" size="100%">PMC7064913</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.5694/mja2.50474</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>61</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">61</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kitchener, S.</style></author><author><style face="normal" font="default" size="100%">Nasveld, P.</style></author><author><style face="normal" font="default" size="100%">Edstein, M. D.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Centre for Military and Veterans Health, University of Queensland, Herston, Queensland, Australia. s.kitchener@uq.edu.au</style></auth-address><titles><title><style face="normal" font="default" size="100%">Tafenoquine for the treatment of recurrent Plasmodium vivax malaria</style></title><secondary-title><style face="normal" font="default" size="100%">Am J Trop Med Hyg</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Am J Trop Med Hyg</style></full-title></periodical><pages><style face="normal" font="default" size="100%">494-6</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2007/03/16</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Aminoquinolines/blood/*therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Antimalarials/*therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Chloroquine/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Malaria, Vivax/*drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Recurrence</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2007</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0002-9637 (Print)&#xD;0002-9637</style></isbn><accession-num><style face="normal" font="default" size="100%">17360873</style></accession-num><abstract><style face="normal" font="default" size="100%">Tafenoquine was used to treat Plasmodium vivax malaria cases who had previously failed treatment with chloroquine and primaquine. Chloroquine was followed by a loading dose of tafenoquine (200 mg base/day for 3 days) and 200 mg a week was given for 8 weeks. One of 27 treated patients relapsed after 6 months of observation. A standard course of chloroquine administered with 8 weeks of tafenoquine may be more effective than chloroquine with primaquine (22.5 mg/day for 14 days) in preventing additional P. vivax relapses. Larger studies are required to optimize the combination, but our findings suggest that an extended use of tafenoquine may be required to prevent relapses of primaquine-tolerant strains of P. vivax malaria.</style></abstract><caption><style face="normal" font="default" size="100%">Duplicate</style></caption><notes><style face="normal" font="default" size="100%">Kitchener, Scott&#xD;Nasveld, Peter&#xD;Edstein, Michael D&#xD;Journal Article&#xD;United States&#xD;Am J Trop Med Hyg. 2007 Mar;76(3):494-6.</style></notes><urls></urls><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>31</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">31</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Baird, J. K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Eijkman-Oxford Clinical Research Unit, Eijkman Institute of Molecular Biology, Jakarta 10430, Indonesia; and Nuffield Department of Medicine, the Centre for Tropical Medicine and Global Health, University of Oxford, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Tafenoquine for travelers&apos; malaria: evidence, rationale and recommendations</style></title><secondary-title><style face="normal" font="default" size="100%">J Travel Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Travel Med</style></full-title></periodical><volume><style face="normal" font="default" size="100%">25</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2018/11/01</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Aminoquinolines/*therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Antimalarials/*therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Dose-Response Relationship, Drug</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Infection Control/*methods</style></keyword><keyword><style face="normal" font="default" size="100%">Malaria/drug therapy/*prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Malaria, Vivax/*drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">*Travel</style></keyword><keyword><style face="normal" font="default" size="100%">United States</style></keyword><keyword><style face="normal" font="default" size="100%">United States Food and Drug Administration</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2018</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan 1</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1195-1982 (Print)&#xD;1195-1982</style></isbn><accession-num><style face="normal" font="default" size="100%">30380095</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Endemic malaria occurring across much of the globe threatens millions of exposed travelers. While unknown numbers of them suffer acute attacks while traveling, each year thousands return from travel and become stricken in the weeks and months following exposure. This represents perhaps the most serious, prevalent and complex problem faced by providers of travel medicine services. Since before World War II, travel medicine practice has relied on synthetic suppressive blood schizontocidal drugs to prevent malaria during exposure, and has applied primaquine for presumptive anti-relapse therapy (post-travel or post-diagnosis of Plasmodium vivax) since 1952. In 2018, the US Food and Drug Administration approved the uses of a new hepatic schizontocidal and hypnozoitocidal 8-aminoquinoline called tafenoquine for the respective prevention of all malarias and for the treatment of those that relapse (P. vivax and Plasmodium ovale). METHODS: The evidence and rationale for tafenoquine for the prevention and treatment of malaria was gathered by means of a standard search of the medical literature along with the package inserts for the tafenoquine products Arakoda™ and Krintafel™ for the prevention of all malarias and the treatment of relapsing malarias, respectively. RESULTS: The development of tafenoquine-an endeavor of 40 years-at last brings two powerful advantages to travel medicine practice against the malaria threat: (i) a weekly regimen of causal prophylaxis; and (ii) a single-dose radical cure for patients infected by vivax or ovale malarias. CONCLUSIONS: Although broad clinical experience remains to be gathered, tafenoquine appears to promise more practical and effective prevention and treatment of malaria. Tafenoquine thus applied includes important biological and clinical complexities explained in this review, with particular regard to the problem of hemolytic toxicity in G6PD-deficient patients.</style></abstract><notes><style face="normal" font="default" size="100%">1708-8305&#xD;Baird, J Kevin&#xD;Journal Article&#xD;J Travel Med. 2018 Jan 1;25(1):tay110. doi: 10.1093/jtm/tay110.</style></notes><urls></urls><custom2><style face="normal" font="default" size="100%">PMC6243017</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1093/jtm/tay110</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>163</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">163</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Llanos-Cuentas, A.</style></author><author><style face="normal" font="default" size="100%">Lacerda, M. V.</style></author><author><style face="normal" font="default" size="100%">Rueangweerayut, R.</style></author><author><style face="normal" font="default" size="100%">Krudsood, S.</style></author><author><style face="normal" font="default" size="100%">Gupta, S. K.</style></author><author><style face="normal" font="default" size="100%">Kochar, S. K.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study</style></title><secondary-title><style face="normal" font="default" size="100%">Lancet</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Lancet</style></full-title></periodical><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><accession-num><style face="normal" font="default" size="100%">CN-01051668</style></accession-num><caption><style face="normal" font="default" size="100%">Duplicate</style></caption><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01051668/full</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/s0140-6736(13)62568-4</style></electronic-resource-num></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>158</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">158</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Llanos-Cuentas, A.</style></author><author><style face="normal" font="default" size="100%">Lacerda, M. V.</style></author><author><style face="normal" font="default" size="100%">Rueangweerayut, R.</style></author><author><style face="normal" font="default" size="100%">Krudsood, S.</style></author><author><style face="normal" font="default" size="100%">Gupta, S. K.</style></author><author><style face="normal" font="default" size="100%">Kochar, S. K.</style></author><author><style face="normal" font="default" size="100%">Arthur, P.</style></author><author><style face="normal" font="default" size="100%">Chuenchom, N.</style></author><author><style face="normal" font="default" size="100%">Möhrle, J. J.</style></author><author><style face="normal" font="default" size="100%">Duparc, S.</style></author><author><style face="normal" font="default" size="100%">et al.,</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study</style></title><secondary-title><style face="normal" font="default" size="100%">Lancet (london, england)</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Lancet (london, england)</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1049‐1058</style></pages><volume><style face="normal" font="default" size="100%">383</style></volume><number><style face="normal" font="default" size="100%">9922</style></number><keywords><keyword><style face="normal" font="default" size="100%">*Plasmodium vivax malaria/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">*Plasmodium vivax malaria/pc [Prevention]</style></keyword><keyword><style face="normal" font="default" size="100%">*chloroquine/ae [Adverse Drug Reaction]</style></keyword><keyword><style face="normal" font="default" size="100%">*chloroquine/cb [Drug Combination]</style></keyword><keyword><style face="normal" font="default" size="100%">*chloroquine/ct [Clinical Trial]</style></keyword><keyword><style face="normal" font="default" size="100%">*chloroquine/do [Drug Dose]</style></keyword><keyword><style face="normal" font="default" size="100%">*chloroquine/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">*chloroquine/po [Oral Drug Administration]</style></keyword><keyword><style face="normal" font="default" size="100%">*dose response</style></keyword><keyword><style face="normal" font="default" size="100%">*drug safety</style></keyword><keyword><style face="normal" font="default" size="100%">*drug tolerability</style></keyword><keyword><style face="normal" font="default" size="100%">*tafenoquine/ae [Adverse Drug Reaction]</style></keyword><keyword><style face="normal" font="default" size="100%">*tafenoquine/cb [Drug Combination]</style></keyword><keyword><style face="normal" font="default" size="100%">*tafenoquine/ct [Clinical Trial]</style></keyword><keyword><style face="normal" font="default" size="100%">*tafenoquine/do [Drug Dose]</style></keyword><keyword><style face="normal" font="default" size="100%">*tafenoquine/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">*tafenoquine/po [Oral Drug Administration]</style></keyword><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Alanine aminotransferase blood level</style></keyword><keyword><style face="normal" font="default" size="100%">Alanine aminotransferase/dt [Drug Therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Alanine aminotransferase/ec [Endogenous Compound]</style></keyword><keyword><style face="normal" font="default" size="100%">Aminoquinolines [*administration &amp; dosage]</style></keyword><keyword><style face="normal" font="default" size="100%">Antimalarials [*administration &amp; dosage]</style></keyword><keyword><style face="normal" font="default" size="100%">Arthralgia/si [Side Effect]</style></keyword><keyword><style face="normal" font="default" size="100%">Article</style></keyword><keyword><style face="normal" font="default" size="100%">Asthenia/si [Side Effect]</style></keyword><keyword><style face="normal" font="default" size="100%">Backache/si [Side Effect]</style></keyword><keyword><style face="normal" font="default" size="100%">Brazil</style></keyword><keyword><style face="normal" font="default" size="100%">Chill/si [Side Effect]</style></keyword><keyword><style face="normal" font="default" size="100%">Chloroquine [*therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Chloroquine plus primaquine/ae [Adverse Drug Reaction]</style></keyword><keyword><style face="normal" font="default" size="100%">Chloroquine plus primaquine/ct [Clinical Trial]</style></keyword><keyword><style face="normal" font="default" size="100%">Clinical assessment</style></keyword><keyword><style face="normal" font="default" size="100%">Controlled study</style></keyword><keyword><style face="normal" font="default" size="100%">Coughing/si [Side Effect]</style></keyword><keyword><style face="normal" font="default" size="100%">Diarrhea/si [Side Effect]</style></keyword><keyword><style face="normal" font="default" size="100%">Dizziness/si [Side Effect]</style></keyword><keyword><style face="normal" font="default" size="100%">Dose‐Response Relationship, Drug</style></keyword><keyword><style face="normal" font="default" size="100%">Double blind procedure</style></keyword><keyword><style face="normal" font="default" size="100%">Double‐Blind Method</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Therapy, Combination</style></keyword><keyword><style face="normal" font="default" size="100%">Drug efficacy</style></keyword><keyword><style face="normal" font="default" size="100%">Drug fever/si [Side Effect]</style></keyword><keyword><style face="normal" font="default" size="100%">Drug induced headache/si [Side Effect]</style></keyword><keyword><style face="normal" font="default" size="100%">Drug treatment failure</style></keyword><keyword><style face="normal" font="default" size="100%">Enzyme activity</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Gastroenteritis/si [Side Effect]</style></keyword><keyword><style face="normal" font="default" size="100%">Glucose 6 phosphate dehydrogenase</style></keyword><keyword><style face="normal" font="default" size="100%">Human</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">India</style></keyword><keyword><style face="normal" font="default" size="100%">Insomnia/si [Side Effect]</style></keyword><keyword><style face="normal" font="default" size="100%">Intention to treat analysis</style></keyword><keyword><style face="normal" font="default" size="100%">Major clinical study</style></keyword><keyword><style face="normal" font="default" size="100%">Malaria, Vivax [*drug therapy, prevention &amp; control]</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Multicenter study</style></keyword><keyword><style face="normal" font="default" size="100%">Myalgia/si [Side Effect]</style></keyword><keyword><style face="normal" font="default" size="100%">Nausea/si [Side Effect]</style></keyword><keyword><style face="normal" font="default" size="100%">Parasite clearance</style></keyword><keyword><style face="normal" font="default" size="100%">Peru</style></keyword><keyword><style face="normal" font="default" size="100%">Phase 2 clinical trial</style></keyword><keyword><style face="normal" font="default" size="100%">Primaquine [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Priority journal</style></keyword><keyword><style face="normal" font="default" size="100%">Pruritus/si [Side Effect]</style></keyword><keyword><style face="normal" font="default" size="100%">QT prolongation/si [Side Effect]</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized controlled trial</style></keyword><keyword><style face="normal" font="default" size="100%">Relapse</style></keyword><keyword><style face="normal" font="default" size="100%">Secondary Prevention</style></keyword><keyword><style face="normal" font="default" size="100%">Side effect/si [Side Effect]</style></keyword><keyword><style face="normal" font="default" size="100%">Single drug dose</style></keyword><keyword><style face="normal" font="default" size="100%">Statistical significance</style></keyword><keyword><style face="normal" font="default" size="100%">Thailand</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment duration</style></keyword><keyword><style face="normal" font="default" size="100%">Upper abdominal pain/si [Side Effect]</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary tract infection/si [Side Effect]</style></keyword><keyword><style face="normal" font="default" size="100%">Vomiting/si [Side Effect]</style></keyword><keyword><style face="normal" font="default" size="100%">Young Adult</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><accession-num><style face="normal" font="default" size="100%">CN-00985194</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Clinical effectiveness of previous regimens to treat Plasmodium vivax infection have been hampered by compliance. We aimed to assess the dose‐response, safety, and tolerability of single‐dose tafenoquine plus 3‐day chloroquine for P vivax malaria radical cure. METHODS: In this double‐blind, randomised, dose‐ranging phase 2b study, men and women (aged ≥16 years) with microscopically confirmed P vivax monoinfection (parasite density &gt;100 to &lt;100,000 per μL blood) were enrolled from community health centres and hospitals across seven sites in Brazil, Peru, India, and Thailand. Patients with glucose‐6‐phosphate dehydrogenase enzyme activity of less than 70% were excluded. Eligible patients received chloroquine (days 1‐3) and were randomly assigned (1:1:1:1:1:1) by a computer‐generated randomisation schedule to receive single‐dose tafenoquine 50 mg, 100 mg, 300 mg, or 600 mg, primaquine 15 mg for 14 days, or chloroquine alone. Randomisation was stratified by baseline parasite count (≤7500 and &gt;7500 per μL blood). The primary efficacy endpoint was relapse‐free efficacy at 6 months from initial dose (ie, clearance of initial infection without subsequent microscopically confirmed infection), analysed by intention to treat. This study is registered with ClinicalTrials.gov, number NCT01376167. FINDINGS: Between Sept 19, 2011, and March 25, 2013, 329 patients were randomly assigned to a treatment group (chloroquine plus tafenoquine 50 mg [n=55], 100 mg [n=57], 300 mg [n=57], 600 mg [n=56]; or to chloroquine plus primaquine [n=50]; or chloroquine alone [n=54]). Relapse‐free efficacy at 6 months was 57·7% (95% CI 43‐70) with tafenoquine 50 mg, 54·1% (40‐66) with tafenoquine 100 mg, 89·2% (77‐95) with tafenoquine 300 mg, 91·9% (80‐97) with tafenoquine 600 mg, 77·3% (63‐87) with primaquine, and 37·5% (23‐52) with chloroquine alone. Tafenoquine 300 mg and 600 mg had better efficacy than chloroquine alone (treatment differences 51·7% [95% CI 35‐69], p&lt;0·0001, with tafenoquine 300 mg and 54·5% [38‐71], p&lt;0·0001, with tafenoquine 600 mg), as did primaquine (treatment difference 39·9% [21‐59], p=0·0004). Adverse events were similar between treatments. 29 serious adverse events occurred in 26 (8%) of 329 patients; QT prolongation was the most common serious adverse event (11 [3%] of 329), occurring in five (2%) of 225 patients receiving tafenoquine, four (8%) of 50 patients receiving primaquine, and two (4%) of 54 patients receiving chloroquine alone, with no evidence of an additional effect on QT of chloroquine plus tafenoquine coadministration. INTERPRETATION: Single‐dose tafenoquine 300 mg coadministered with chloroquine for P vivax malaria relapse prevention was more efficacious than chloroquine alone, with a similar safety profile. As a result, it has been selected for further clinical assessment in phase 3. FUNDING: GlaxoSmithKline, Medicines for Malaria Venture.</style></abstract><caption><style face="normal" font="default" size="100%">Duplicate</style></caption><work-type><style face="normal" font="default" size="100%">Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non‐U.S. Gov&apos;t</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.cochranelibrary.com/central/doi/10.1002/central/CN-00985194/full</style></url></related-urls></urls><custom3><style face="normal" font="default" size="100%">PUBMED 24360369,EMBASE 52924831</style></custom3><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/S0140-6736(13)62568-4</style></electronic-resource-num></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>53</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">53</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Llanos-Cuentas, A.</style></author><author><style face="normal" font="default" size="100%">Lacerda, M. V.</style></author><author><style face="normal" font="default" size="100%">Rueangweerayut, R.</style></author><author><style face="normal" font="default" size="100%">Krudsood, S.</style></author><author><style face="normal" font="default" size="100%">Gupta, S. K.</style></author><author><style face="normal" font="default" size="100%">Kochar, S. K.</style></author><author><style face="normal" font="default" size="100%">Arthur, P.</style></author><author><style face="normal" font="default" size="100%">Chuenchom, N.</style></author><author><style face="normal" font="default" size="100%">Möhrle, J. J.</style></author><author><style face="normal" font="default" size="100%">Duparc, S.</style></author><author><style face="normal" font="default" size="100%">Ugwuegbulam, C.</style></author><author><style face="normal" font="default" size="100%">Kleim, J. P.</style></author><author><style face="normal" font="default" size="100%">Carter, N.</style></author><author><style face="normal" font="default" size="100%">Green, J. A.</style></author><author><style face="normal" font="default" size="100%">Kellam, L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Instituto de Medicina Tropical, Alexander von Humboldt, Universidad Peruana Cayetano Heredia, Lima, Peru.&#xD;Fundação de Medicina Tropical Doutor Heitor Vieira Dourado, Manaus, Amazonas, Brazil.&#xD;Mae Sot Hospital, Mae Sot, Tak Province, Thailand.&#xD;Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.&#xD;MV Hospital and Research Centre, Lucknow, Uttar Pradesh, India.&#xD;Sardar Patel Medical College, Bikaner, Rajasthan, India.&#xD;Sri Ramchandra Medical College and Research Institute, Department of Medicine, Porur, Chennai, Tamil Nadu, India.&#xD;Medicines for Malaria Venture, Geneva, Switzerland.&#xD;GlaxoSmithKline, Stockley Park West, Uxbridge, Middlesex, UK.&#xD;GlaxoSmithKline, Stockley Park West, Uxbridge, Middlesex, UK. Electronic address: lynda.m.kellam@gsk.com.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study</style></title><secondary-title><style face="normal" font="default" size="100%">Lancet</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Lancet</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1049-58</style></pages><volume><style face="normal" font="default" size="100%">383</style></volume><number><style face="normal" font="default" size="100%">9922</style></number><edition><style face="normal" font="default" size="100%">2013/12/24</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Aminoquinolines/*administration &amp; dosage</style></keyword><keyword><style face="normal" font="default" size="100%">Antimalarials/*administration &amp; dosage</style></keyword><keyword><style face="normal" font="default" size="100%">Brazil</style></keyword><keyword><style face="normal" font="default" size="100%">Chloroquine/*therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Dose-Response Relationship, Drug</style></keyword><keyword><style face="normal" font="default" size="100%">Double-Blind Method</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Therapy, Combination</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">India</style></keyword><keyword><style face="normal" font="default" size="100%">Malaria, Vivax/*drug therapy/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Peru</style></keyword><keyword><style face="normal" font="default" size="100%">Primaquine/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Secondary Prevention</style></keyword><keyword><style face="normal" font="default" size="100%">Thailand</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Young Adult</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar 22</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0140-6736</style></isbn><accession-num><style face="normal" font="default" size="100%">24360369</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Clinical effectiveness of previous regimens to treat Plasmodium vivax infection have been hampered by compliance. We aimed to assess the dose-response, safety, and tolerability of single-dose tafenoquine plus 3-day chloroquine for P vivax malaria radical cure. METHODS: In this double-blind, randomised, dose-ranging phase 2b study, men and women (aged ≥16 years) with microscopically confirmed P vivax monoinfection (parasite density &gt;100 to &lt;100,000 per μL blood) were enrolled from community health centres and hospitals across seven sites in Brazil, Peru, India, and Thailand. Patients with glucose-6-phosphate dehydrogenase enzyme activity of less than 70% were excluded. Eligible patients received chloroquine (days 1-3) and were randomly assigned (1:1:1:1:1:1) by a computer-generated randomisation schedule to receive single-dose tafenoquine 50 mg, 100 mg, 300 mg, or 600 mg, primaquine 15 mg for 14 days, or chloroquine alone. Randomisation was stratified by baseline parasite count (≤7500 and &gt;7500 per μL blood). The primary efficacy endpoint was relapse-free efficacy at 6 months from initial dose (ie, clearance of initial infection without subsequent microscopically confirmed infection), analysed by intention to treat. This study is registered with ClinicalTrials.gov, number NCT01376167. FINDINGS: Between Sept 19, 2011, and March 25, 2013, 329 patients were randomly assigned to a treatment group (chloroquine plus tafenoquine 50 mg [n=55], 100 mg [n=57], 300 mg [n=57], 600 mg [n=56]; or to chloroquine plus primaquine [n=50]; or chloroquine alone [n=54]). Relapse-free efficacy at 6 months was 57·7% (95% CI 43-70) with tafenoquine 50 mg, 54·1% (40-66) with tafenoquine 100 mg, 89·2% (77-95) with tafenoquine 300 mg, 91·9% (80-97) with tafenoquine 600 mg, 77·3% (63-87) with primaquine, and 37·5% (23-52) with chloroquine alone. Tafenoquine 300 mg and 600 mg had better efficacy than chloroquine alone (treatment differences 51·7% [95% CI 35-69], p&lt;0·0001, with tafenoquine 300 mg and 54·5% [38-71], p&lt;0·0001, with tafenoquine 600 mg), as did primaquine (treatment difference 39·9% [21-59], p=0·0004). Adverse events were similar between treatments. 29 serious adverse events occurred in 26 (8%) of 329 patients; QT prolongation was the most common serious adverse event (11 [3%] of 329), occurring in five (2%) of 225 patients receiving tafenoquine, four (8%) of 50 patients receiving primaquine, and two (4%) of 54 patients receiving chloroquine alone, with no evidence of an additional effect on QT of chloroquine plus tafenoquine coadministration. INTERPRETATION: Single-dose tafenoquine 300 mg coadministered with chloroquine for P vivax malaria relapse prevention was more efficacious than chloroquine alone, with a similar safety profile. As a result, it has been selected for further clinical assessment in phase 3. FUNDING: GlaxoSmithKline, Medicines for Malaria Venture.</style></abstract><caption><style face="normal" font="default" size="100%">Duplicate</style></caption><notes><style face="normal" font="default" size="100%">1474-547x&#xD;Llanos-Cuentas, Alejandro&#xD;Lacerda, Marcus V&#xD;Rueangweerayut, Ronnatrai&#xD;Krudsood, Srivicha&#xD;Gupta, Sandeep K&#xD;Kochar, Sanjay K&#xD;Arthur, Preetam&#xD;Chuenchom, Nuttagarn&#xD;Möhrle, Jörg J&#xD;Duparc, Stephan&#xD;Ugwuegbulam, Cletus&#xD;Kleim, Jörg-Peter&#xD;Carter, Nick&#xD;Green, Justin A&#xD;Kellam, Lynda&#xD;Clinical Trial, Phase II&#xD;Journal Article&#xD;Multicenter Study&#xD;Randomized Controlled Trial&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;England&#xD;Lancet. 2014 Mar 22;383(9922):1049-58. doi: 10.1016/S0140-6736(13)62568-4. Epub 2013 Dec 19.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/s0140-6736(13)62568-4</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>110</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">110</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Llanos-Cuentas, A.</style></author><author><style face="normal" font="default" size="100%">Lacerda, M. V.</style></author><author><style face="normal" font="default" size="100%">Rueangweerayut, R.</style></author><author><style face="normal" font="default" size="100%">Krudsood, S.</style></author><author><style face="normal" font="default" size="100%">Gupta, S. K.</style></author><author><style face="normal" font="default" size="100%">Kochar, S. K.</style></author><author><style face="normal" font="default" size="100%">Arthur, P.</style></author><author><style face="normal" font="default" size="100%">Chuenchom, N.</style></author><author><style face="normal" font="default" size="100%">Möhrle, J. J.</style></author><author><style face="normal" font="default" size="100%">Duparc, S.</style></author><author><style face="normal" font="default" size="100%">Ugwuegbulam, C.</style></author><author><style face="normal" font="default" size="100%">Kleim, J. P.</style></author><author><style face="normal" font="default" size="100%">Carter, N.</style></author><author><style face="normal" font="default" size="100%">Green, J. A.</style></author><author><style face="normal" font="default" size="100%">Kellam, L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">L. Kellam, GlaxoSmithKline, Stockley Park West, Uxbridge, Middlesex UB11 1BT, United Kingdom</style></auth-address><titles><title><style face="normal" font="default" size="100%">Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): A multicentre, double-blind, randomised, phase 2b dose-selection study</style></title><secondary-title><style face="normal" font="default" size="100%">The Lancet</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">The Lancet</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1049-1058</style></pages><volume><style face="normal" font="default" size="100%">383</style></volume><number><style face="normal" font="default" size="100%">9922</style></number><keywords><keyword><style face="normal" font="default" size="100%">NCT01376167</style></keyword><keyword><style face="normal" font="default" size="100%">alanine aminotransferase</style></keyword><keyword><style face="normal" font="default" size="100%">chloroquine</style></keyword><keyword><style face="normal" font="default" size="100%">chloroquine plus primaquine</style></keyword><keyword><style face="normal" font="default" size="100%">glucose 6 phosphate dehydrogenase</style></keyword><keyword><style face="normal" font="default" size="100%">tafenoquine</style></keyword><keyword><style face="normal" font="default" size="100%">adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">adult</style></keyword><keyword><style face="normal" font="default" size="100%">aged</style></keyword><keyword><style face="normal" font="default" size="100%">alanine aminotransferase blood level</style></keyword><keyword><style face="normal" font="default" size="100%">arthralgia</style></keyword><keyword><style face="normal" font="default" size="100%">article</style></keyword><keyword><style face="normal" font="default" size="100%">asthenia</style></keyword><keyword><style face="normal" font="default" size="100%">backache</style></keyword><keyword><style face="normal" font="default" size="100%">Brazil</style></keyword><keyword><style face="normal" font="default" size="100%">chill</style></keyword><keyword><style face="normal" font="default" size="100%">clinical assessment</style></keyword><keyword><style face="normal" font="default" size="100%">controlled study</style></keyword><keyword><style face="normal" font="default" size="100%">coughing</style></keyword><keyword><style face="normal" font="default" size="100%">diarrhea</style></keyword><keyword><style face="normal" font="default" size="100%">dizziness</style></keyword><keyword><style face="normal" font="default" size="100%">dose response</style></keyword><keyword><style face="normal" font="default" size="100%">double blind procedure</style></keyword><keyword><style face="normal" font="default" size="100%">drug efficacy</style></keyword><keyword><style face="normal" font="default" size="100%">drug fever</style></keyword><keyword><style face="normal" font="default" size="100%">drug induced headache</style></keyword><keyword><style face="normal" font="default" size="100%">drug safety</style></keyword><keyword><style face="normal" font="default" size="100%">drug tolerability</style></keyword><keyword><style face="normal" font="default" size="100%">lack of drug effect</style></keyword><keyword><style face="normal" font="default" size="100%">enzyme activity</style></keyword><keyword><style face="normal" font="default" size="100%">female</style></keyword><keyword><style face="normal" font="default" size="100%">gastroenteritis</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">India</style></keyword><keyword><style face="normal" font="default" size="100%">insomnia</style></keyword><keyword><style face="normal" font="default" size="100%">intention to treat analysis</style></keyword><keyword><style face="normal" font="default" size="100%">major clinical study</style></keyword><keyword><style face="normal" font="default" size="100%">male</style></keyword><keyword><style face="normal" font="default" size="100%">middle aged</style></keyword><keyword><style face="normal" font="default" size="100%">multicenter study</style></keyword><keyword><style face="normal" font="default" size="100%">myalgia</style></keyword><keyword><style face="normal" font="default" size="100%">nausea</style></keyword><keyword><style face="normal" font="default" size="100%">parasite clearance</style></keyword><keyword><style face="normal" font="default" size="100%">Peru</style></keyword><keyword><style face="normal" font="default" size="100%">phase 2 clinical trial</style></keyword><keyword><style face="normal" font="default" size="100%">Plasmodium vivax malaria</style></keyword><keyword><style face="normal" font="default" size="100%">priority journal</style></keyword><keyword><style face="normal" font="default" size="100%">pruritus</style></keyword><keyword><style face="normal" font="default" size="100%">QT prolongation</style></keyword><keyword><style face="normal" font="default" size="100%">randomized controlled trial</style></keyword><keyword><style face="normal" font="default" size="100%">relapse</style></keyword><keyword><style face="normal" font="default" size="100%">side effect</style></keyword><keyword><style face="normal" font="default" size="100%">single drug dose</style></keyword><keyword><style face="normal" font="default" size="100%">statistical significance</style></keyword><keyword><style face="normal" font="default" size="100%">Thailand</style></keyword><keyword><style face="normal" font="default" size="100%">treatment duration</style></keyword><keyword><style face="normal" font="default" size="100%">upper abdominal pain</style></keyword><keyword><style face="normal" font="default" size="100%">urinary tract infection</style></keyword><keyword><style face="normal" font="default" size="100%">vomiting</style></keyword><keyword><style face="normal" font="default" size="100%">young adult</style></keyword><keyword><style face="normal" font="default" size="100%">aralen</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><isbn><style face="normal" font="default" size="100%">0140-6736&#xD;1474-547X</style></isbn><abstract><style face="normal" font="default" size="100%">Background Clinical eff ectiveness of previous regimens to treat Plasmodium vivax infection have been hampered by compliance. We aimed to assess the dose-response, safety, and tolerability of single-dose tafenoquine plus 3-day chloroquine for P vivax malaria radical cure. Methods In this double-blind, randomised, dose-ranging phase 2b study, men and women (aged ≥16 years) with microscopically confi rmed P vivax monoinfection (parasite density &gt;100 to &lt;100 000 per μL blood) were enrolled from community health centres and hospitals across seven sites in Brazil, Peru, India, and Thailand. Patients with glucose- 6-phosphate dehydrogenase enzyme activity of less than 70% were excluded. Eligible patients received chloroquine (days 1-3) and were randomly assigned (1:1:1:1:1:1) by a computer-generated randomisation schedule to receive singledose tafenoquine 50 mg, 100 mg, 300 mg, or 600 mg, primaquine 15 mg for 14 days, or chloroquine alone. Randomisation was stratifi ed by baseline parasite count (≤7500 and &gt;7500 per μL blood). The primary effi cacy endpoint was relapse-free effi cacy at 6 months from initial dose (ie, clearance of initial infection without subsequent microscopically confi rmed infection), analysed by intention to treat. This study is registered with ClinicalTrials.gov, number NCT01376167. Findings Between Sept 19, 2011, and March 25, 2013, 329 patients were randomly assigned to a treatment group (chloroquine plus tafenoquine 50 mg [n=55], 100 mg [n=57], 300 mg [n=57], 600 mg [n=56]; or to chloroquine plus primaquine [n=50]; or chloroquine alone [n=54]). Relapse-free effi cacy at 6 months was 57.7% (95% CI 43-70) with tafenoquine 50 mg, 54.1% (40-66) with tafenoquine 100 mg, 89.2% (77-95) with tafenoquine 300 mg, 91.9% (80-97) with tafenoquine 600 mg, 77.3% (63-87) with primaquine, and 37.5% (23-52) with chloroquine alone. Tafenoquine 300 mg and 600 mg had better effi cacy than chloroquine alone (treatment diff erences 51.7% [95% CI 35-69], p&amp;0.0001, with tafenoquine 300 mg and 54.5% [38-71], p &lt;0.0001, with tafenoquine 600 mg), as did primaquine (treatment diff erence 39.9% [21-59], p=0.0004). Adverse events were similar between treatments. 29 serious adverse events occurred in 26 (8%) of 329 patients; QT prolongation was the most common serious adverse event (11 [3%] of 329), occurring in fi ve (2%) of 225 patients receiving tafenoquine, four (8%) of 50 patients receiving primaquine, and two (4%) of 54 patients receiving chloroquine alone, with no evidence of an additional eff ect on QT of chloroquine plus tafenoquine coadministration. Interpretation Single-dose tafenoquine 300 mg coadministered with chloroquine for P vivax malaria relapse prevention was more effi cacious than chloroquine alone, with a similar safety profi le. As a result, it has been selected for further clinical assessment in phase 3. Funding GlaxoSmithKline, Medicines for Malaria Venture.</style></abstract><caption><style face="normal" font="default" size="100%">Duplicate</style></caption><notes><style face="normal" font="default" size="100%">L52924831&#xD;2013-12-24&#xD;2014-04-02</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L52924831&amp;from=export</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1016/S0140-6736(13)62568-4</style></url></related-urls></urls><custom1><style face="normal" font="default" size="100%">aralen(Labaz,United States)</style></custom1><custom2><style face="normal" font="default" size="100%">Glaxo SmithKline(United Kingdom)&#xD;Labaz(United States)</style></custom2><custom5><style face="normal" font="default" size="100%">24360369</style></custom5><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/S0140-6736(13)62568-4</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase&#xD;Medline</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>114</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">114</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Llanos-Cuentas, A.</style></author><author><style face="normal" font="default" size="100%">Lacerda, M. V.</style></author><author><style face="normal" font="default" size="100%">Rueangweerayut, R.</style></author><author><style face="normal" font="default" size="100%">Krudsood, S.</style></author><author><style face="normal" font="default" size="100%">Gupta, S. K.</style></author><author><style face="normal" font="default" size="100%">Kochar, S. K.</style></author><author><style face="normal" font="default" size="100%">Arthur, P.</style></author><author><style face="normal" font="default" size="100%">Chuenchom, N.</style></author><author><style face="normal" font="default" size="100%">Möhrle, J. J.</style></author><author><style face="normal" font="default" size="100%">Duparc, S.</style></author><author><style face="normal" font="default" size="100%">Ugwuegbulam, C.</style></author><author><style face="normal" font="default" size="100%">Kleim, J. P.</style></author><author><style face="normal" font="default" size="100%">Carter, N.</style></author><author><style face="normal" font="default" size="100%">Green, J. A.</style></author><author><style face="normal" font="default" size="100%">Kellam, L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">L. Kellam, GlaxoSmithKline, Stockley Park West, Uxbridge, Middlesex, United Kingdom</style></auth-address><titles><title><style face="normal" font="default" size="100%">Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): A multicentre, double-blind, randomised, phase 2b dose-selection study</style></title><secondary-title><style face="normal" font="default" size="100%">The Lancet</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">The Lancet</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1049-1058</style></pages><volume><style face="normal" font="default" size="100%">383</style></volume><number><style face="normal" font="default" size="100%">9922</style></number><keywords><keyword><style face="normal" font="default" size="100%">NCT01376167</style></keyword><keyword><style face="normal" font="default" size="100%">chloroquine</style></keyword><keyword><style face="normal" font="default" size="100%">chloroquine plus primaquine</style></keyword><keyword><style face="normal" font="default" size="100%">glucose 6 phosphate dehydrogenase</style></keyword><keyword><style face="normal" font="default" size="100%">primaquine</style></keyword><keyword><style face="normal" font="default" size="100%">tafenoquine</style></keyword><keyword><style face="normal" font="default" size="100%">adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">adult</style></keyword><keyword><style face="normal" font="default" size="100%">aged</style></keyword><keyword><style face="normal" font="default" size="100%">article</style></keyword><keyword><style face="normal" font="default" size="100%">Brazil</style></keyword><keyword><style face="normal" font="default" size="100%">controlled study</style></keyword><keyword><style face="normal" font="default" size="100%">double blind procedure</style></keyword><keyword><style face="normal" font="default" size="100%">drug safety</style></keyword><keyword><style face="normal" font="default" size="100%">drug tolerability</style></keyword><keyword><style face="normal" font="default" size="100%">enzyme activity</style></keyword><keyword><style face="normal" font="default" size="100%">female</style></keyword><keyword><style face="normal" font="default" size="100%">hospital</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">India</style></keyword><keyword><style face="normal" font="default" size="100%">intention to treat analysis</style></keyword><keyword><style face="normal" font="default" size="100%">major clinical study</style></keyword><keyword><style face="normal" font="default" size="100%">male</style></keyword><keyword><style face="normal" font="default" size="100%">multicenter study</style></keyword><keyword><style face="normal" font="default" size="100%">Peru</style></keyword><keyword><style face="normal" font="default" size="100%">phase 2 clinical trial (topic)</style></keyword><keyword><style face="normal" font="default" size="100%">Plasmodium vivax malaria</style></keyword><keyword><style face="normal" font="default" size="100%">priority journal</style></keyword><keyword><style face="normal" font="default" size="100%">public health</style></keyword><keyword><style face="normal" font="default" size="100%">QT prolongation</style></keyword><keyword><style face="normal" font="default" size="100%">randomized controlled trial</style></keyword><keyword><style face="normal" font="default" size="100%">relapse</style></keyword><keyword><style face="normal" font="default" size="100%">single drug dose</style></keyword><keyword><style face="normal" font="default" size="100%">Thailand</style></keyword><keyword><style face="normal" font="default" size="100%">treatment duration</style></keyword><keyword><style face="normal" font="default" size="100%">aralen</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><isbn><style face="normal" font="default" size="100%">1474-547X&#xD;0140-6736</style></isbn><abstract><style face="normal" font="default" size="100%">Background Clinical effectiveness of previous regimens to treat Plasmodium vivax infection have been hampered by compliance. We aimed to assess the dose-response, safety, and tolerability of single-dose tafenoquine plus 3-day chloroquine for P vivax malaria radical cure. Methods In this double-blind, randomised, dose-ranging phase 2b study, men and women (aged ≥16 years) with microscopically confirmed P vivax monoinfection (parasite density &gt;100 to &lt;100 000 per μL blood) were enrolled from community health centres and hospitals across seven sites in Brazil, Peru, India, and Thailand. Patients with glucose-6-phosphate dehydrogenase enzyme activity of less than 70% were excluded. Eligible patients received chloroquine (days 1-3) and were randomly assigned (1:1:1:1:1:1) by a computer-generated randomisation schedule to receive single-dose tafenoquine 50 mg, 100 mg, 300 mg, or 600 mg, primaquine 15 mg for 14 days, or chloroquine alone. Randomisation was stratified by baseline parasite count (≤7500 and &gt;7500 per μL blood). The primary efficacy endpoint was relapse-free efficacy at 6 months from initial dose (ie, clearance of initial infection without subsequent microscopically confirmed infection), analysed by intention to treat. This study is registered with ClinicalTrials.gov, number NCT01376167. Findings Between Sept 19, 2011, and March 25, 2013, 329 patients were randomly assigned to a treatment group (chloroquine plus tafenoquine 50 mg [n=55], 100 mg [n=57], 300 mg [n=57], 600 mg [n=56]; or to chloroquine plus primaquine [n=50]; or chloroquine alone [n=54]). Relapse-free efficacy at 6 months was 57·7% (95% CI 43-70) with tafenoquine 50 mg, 54·1% (40-66) with tafenoquine 100 mg, 89·2% (77-95) with tafenoquine 300 mg, 91·9% (80-97) with tafenoquine 600 mg, 77·3% (63-87) with primaquine, and 37·5% (23-52) with chloroquine alone. Tafenoquine 300 mg and 600 mg had better efficacy than chloroquine alone (treatment differences 51·7% [95% CI 35-69], p·0001, with tafenoquine 300 mg and 54·5% [38-71], p·0001, with tafenoquine 600 mg), as did primaquine (treatment difference 39·9% [21-59], p=0·0004). Adverse events were similar between treatments. 29 serious adverse events occurred in 26 (8%) of 329 patients; QT prolongation was the most common serious adverse event (11 [3%] of 329), occurring in five (2%) of 225 patients receiving tafenoquine, four (8%) of 50 patients receiving primaquine, and two (4%) of 54 patients receiving chloroquine alone, with no evidence of an additional effect on QT of chloroquine plus tafenoquine coadministration. Interpretation Single-dose tafenoquine 300 mg coadministered with chloroquine for P vivax malaria relapse prevention was more efficacious than chloroquine alone, with a similar safety profile. As a result, it has been selected for further clinical assessment in phase 3.</style></abstract><caption><style face="normal" font="default" size="100%">Duplicate</style></caption><notes><style face="normal" font="default" size="100%">L601471728&#xD;2015-01-26&#xD;2015-01-29</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L601471728&amp;from=export</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1016/S0140-6736(13)62568-4</style></url></related-urls></urls><custom1><style face="normal" font="default" size="100%">aralen(Labaz,United States)</style></custom1><custom2><style face="normal" font="default" size="100%">Glaxo SmithKline(United Kingdom)&#xD;Labaz</style></custom2><custom5><style face="normal" font="default" size="100%">24360369</style></custom5><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/S0140-6736(13)62568-4</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase&#xD;Medline</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>33</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">33</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Tan, K. R.</style></author><author><style face="normal" font="default" size="100%">Hwang, J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Malaria Branch, Centers for Disease Control and Prevention, Atlanta, GA, USA.&#xD;U.S. President&apos;s Malaria Initiative, Malaria Branch, Centers for Disease Control and Prevention, Atlanta, GA, USA.&#xD;Global Health Group, University of California San Francisco, San Francisco, CA, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Tafenoquine receives regulatory approval in USA for prophylaxis of malaria and radical cure of Plasmodium vivax</style></title><secondary-title><style face="normal" font="default" size="100%">J Travel Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Travel Med</style></full-title></periodical><volume><style face="normal" font="default" size="100%">25</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2018/08/24</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Aminoquinolines/*therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Antimalarials/*therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Approval/*statistics &amp; numerical data</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Malaria, Vivax/drug therapy/*prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Plasmodium vivax</style></keyword><keyword><style face="normal" font="default" size="100%">Secondary Prevention</style></keyword><keyword><style face="normal" font="default" size="100%">United States</style></keyword><keyword><style face="normal" font="default" size="100%">United States Food and Drug Administration</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2018</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan 1</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1195-1982</style></isbn><accession-num><style face="normal" font="default" size="100%">30137454</style></accession-num><notes><style face="normal" font="default" size="100%">1708-8305&#xD;Tan, Kathrine R&#xD;Hwang, Jimee&#xD;Journal Article&#xD;England&#xD;J Travel Med. 2018 Jan 1;25(1). doi: 10.1093/jtm/tay071.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1093/jtm/tay071</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>133</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">133</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">McIntyre, J. A.</style></author><author><style face="normal" font="default" size="100%">Castañer, J.</style></author><author><style face="normal" font="default" size="100%">Bayés, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">J.A. McIntyre, Prous Science, P.O. Box 540, 08080 Barcelona, Spain</style></auth-address><titles><title><style face="normal" font="default" size="100%">Tafenoquine Succinate: Antimalarial</style></title><secondary-title><style face="normal" font="default" size="100%">Drugs of the Future</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Drugs of the Future</style></full-title></periodical><pages><style face="normal" font="default" size="100%">859-869</style></pages><volume><style face="normal" font="default" size="100%">28</style></volume><number><style face="normal" font="default" size="100%">9</style></number><keywords><keyword><style face="normal" font="default" size="100%">2,6 dimethoxy 4 methyl 5 [3 (trifluoromethyl)phenoxy]primaquine succinate</style></keyword><keyword><style face="normal" font="default" size="100%">8 (4 amino 1 methylbutylamino) 2,6 dimethoxy 4 methyl 5 (3 trifluoromethylphenoxy)quinoline succinate</style></keyword><keyword><style face="normal" font="default" size="100%">8 aminoquinoline derivative</style></keyword><keyword><style face="normal" font="default" size="100%">chloroquine</style></keyword><keyword><style face="normal" font="default" size="100%">halofantrine</style></keyword><keyword><style face="normal" font="default" size="100%">mefloquine</style></keyword><keyword><style face="normal" font="default" size="100%">placebo</style></keyword><keyword><style face="normal" font="default" size="100%">primaquine</style></keyword><keyword><style face="normal" font="default" size="100%">tafenoquine</style></keyword><keyword><style face="normal" font="default" size="100%">unclassified drug</style></keyword><keyword><style face="normal" font="default" size="100%">abdominal discomfort</style></keyword><keyword><style face="normal" font="default" size="100%">abdominal pain</style></keyword><keyword><style face="normal" font="default" size="100%">acute disease</style></keyword><keyword><style face="normal" font="default" size="100%">animal cell</style></keyword><keyword><style face="normal" font="default" size="100%">animal experiment</style></keyword><keyword><style face="normal" font="default" size="100%">animal model</style></keyword><keyword><style face="normal" font="default" size="100%">animal tissue</style></keyword><keyword><style face="normal" font="default" size="100%">article</style></keyword><keyword><style face="normal" font="default" size="100%">chemoprophylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">clinical trial</style></keyword><keyword><style face="normal" font="default" size="100%">controlled study</style></keyword><keyword><style face="normal" font="default" size="100%">developing country</style></keyword><keyword><style face="normal" font="default" size="100%">diarrhea</style></keyword><keyword><style face="normal" font="default" size="100%">dose response</style></keyword><keyword><style face="normal" font="default" size="100%">drug efficacy</style></keyword><keyword><style face="normal" font="default" size="100%">drug half life</style></keyword><keyword><style face="normal" font="default" size="100%">drug mechanism</style></keyword><keyword><style face="normal" font="default" size="100%">drug potency</style></keyword><keyword><style face="normal" font="default" size="100%">drug safety</style></keyword><keyword><style face="normal" font="default" size="100%">fever</style></keyword><keyword><style face="normal" font="default" size="100%">gastrointestinal symptom</style></keyword><keyword><style face="normal" font="default" size="100%">headache</style></keyword><keyword><style face="normal" font="default" size="100%">hemolytic anemia</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">human cell</style></keyword><keyword><style face="normal" font="default" size="100%">human tissue</style></keyword><keyword><style face="normal" font="default" size="100%">life cycle</style></keyword><keyword><style face="normal" font="default" size="100%">liver</style></keyword><keyword><style face="normal" font="default" size="100%">major clinical study</style></keyword><keyword><style face="normal" font="default" size="100%">malaria</style></keyword><keyword><style face="normal" font="default" size="100%">meta analysis</style></keyword><keyword><style face="normal" font="default" size="100%">multidrug resistance</style></keyword><keyword><style face="normal" font="default" size="100%">nonhuman</style></keyword><keyword><style face="normal" font="default" size="100%">parasitosis</style></keyword><keyword><style face="normal" font="default" size="100%">Plasmodium falciparum</style></keyword><keyword><style face="normal" font="default" size="100%">Plasmodium vivax</style></keyword><keyword><style face="normal" font="default" size="100%">public health</style></keyword><keyword><style face="normal" font="default" size="100%">relapse</style></keyword><keyword><style face="normal" font="default" size="100%">side effect</style></keyword><keyword><style face="normal" font="default" size="100%">skin disease</style></keyword><keyword><style face="normal" font="default" size="100%">species comparison</style></keyword><keyword><style face="normal" font="default" size="100%">sb 252263</style></keyword><keyword><style face="normal" font="default" size="100%">wr 238605</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2003</style></year></dates><isbn><style face="normal" font="default" size="100%">0377-8282</style></isbn><abstract><style face="normal" font="default" size="100%">Malaria is a significant public health problem in developing and third world countries. Plasmodium falciparum and Plasmodium vivax parasites are responsible for the majority of cases of malaria infection. Treatment focuses on both chemoprevention and treatment of acute infection, but the currently used drugs are threatened by drug-resistant species in many parts of the world. Tafenoquine is a new 8-aminoquinoline with an improved therapeutic index and safety profile as compared to primaquine. In pharmacological studies, tafenoquine has been shown to be at least 10 times more potent than primaquine and has a much longer half-life, allowing less frequent dosing in chemoprophylactic regimens. Its clinical efficacy has been demonstrated in a number of studies, both as a chemoprophylactic agent for the prevention of P. falciparum infection and as an acute treatment against the liver stages of P. vivax. Tafenoquine has the potential to become a widely used drug in the prevention and treatment of malaria infection and could replace some currently used drugs as resistant strains of Plasmodium species increase.</style></abstract><notes><style face="normal" font="default" size="100%">L38009216&#xD;2004-01-20</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L38009216&amp;from=export</style></url></related-urls></urls><custom1><style face="normal" font="default" size="100%">sb 252263&#xD;wr 238605</style></custom1><remote-database-name><style face="normal" font="default" size="100%">Embase</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>27</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">27</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Llanos-Cuentas, A.</style></author><author><style face="normal" font="default" size="100%">Lacerda, M. V. G.</style></author><author><style face="normal" font="default" size="100%">Hien, T. T.</style></author><author><style face="normal" font="default" size="100%">Vélez, I. D.</style></author><author><style face="normal" font="default" size="100%">Namaik-Larp, C.</style></author><author><style face="normal" font="default" size="100%">Chu, C. S.</style></author><author><style face="normal" font="default" size="100%">Villegas, M. F.</style></author><author><style face="normal" font="default" size="100%">Val, F.</style></author><author><style face="normal" font="default" size="100%">Monteiro, W. M.</style></author><author><style face="normal" font="default" size="100%">Brito, M. A. M.</style></author><author><style face="normal" font="default" size="100%">Costa, M. R. F.</style></author><author><style face="normal" font="default" size="100%">Chuquiyauri, R.</style></author><author><style face="normal" font="default" size="100%">Casapía, M.</style></author><author><style face="normal" font="default" size="100%">Nguyen, C. H.</style></author><author><style face="normal" font="default" size="100%">Aruachan, S.</style></author><author><style face="normal" font="default" size="100%">Papwijitsil, R.</style></author><author><style face="normal" font="default" size="100%">Nosten, F. H.</style></author><author><style face="normal" font="default" size="100%">Bancone, G.</style></author><author><style face="normal" font="default" size="100%">Angus, B.</style></author><author><style face="normal" font="default" size="100%">Duparc, S.</style></author><author><style face="normal" font="default" size="100%">Craig, G.</style></author><author><style face="normal" font="default" size="100%">Rousell, V. M.</style></author><author><style face="normal" font="default" size="100%">Jones, S. W.</style></author><author><style face="normal" font="default" size="100%">Hardaker, E.</style></author><author><style face="normal" font="default" size="100%">Clover, D. D.</style></author><author><style face="normal" font="default" size="100%">Kendall, L.</style></author><author><style face="normal" font="default" size="100%">Mohamed, K.</style></author><author><style face="normal" font="default" size="100%">Koh, Gckw</style></author><author><style face="normal" font="default" size="100%">Wilches, V. M.</style></author><author><style face="normal" font="default" size="100%">Breton, J. J.</style></author><author><style face="normal" font="default" size="100%">Green, J. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">From Universidad Peruana Cayetano Heredia, Lima, Peru (A.L.-C., R.C., M.C.); Fundação de Medicina Tropical Dr Heitor Vieira Dourado, Manaus (M.V.G.L., F.V., W.M.M., M.A.M.B., M.R.F.C.), and Fundação Oswaldo Cruz, Manguinhos, Rio de Janeiro (M.V.G.L.) - both in Brazil; Oxford University Clinical Research Unit, Ho Chi Minh City, Vietnam (T.T.H., C.H.N.); Universidad de Antioquia, Medellin (I.D.V.), Centro de Investigaciones Clinicas S.A.S de Cali, Cali (M.F.V.), and IMAT Oncomedica, Monteria (S.A.) - all in Colombia; Umphang Hospital, Tak (C.N.-l., R.P.), and Shoklo Malaria Research Unit, Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Mae Sot (C.S.C., F.H.N., G.B.) - both in Thailand; the Centre for Tropical Medicine and Global Health (C.S.C., F.H.N., G.B.) and the Oxford Centre for Clinical Tropical Medicine (B.A.), Nuffield Department of Medicine, University of Oxford, Oxford, GlaxoSmithKline, Stockley Park West (G.C., V.M.R., S.W.J., E.H., D.D.C., K.M., G.C.K.W.K., J.A.G.), and GlaxoSmithKline, Stevenage (L.K.) - all in the United Kingdom; Medicines for Malaria Venture, Geneva (S.D.); and GlaxoSmithKline, Collegeville, PA (V.M.W., J.J.B.).</style></auth-address><titles><title><style face="normal" font="default" size="100%">Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria</style></title><secondary-title><style face="normal" font="default" size="100%">N Engl J Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">N Engl J Med</style></full-title></periodical><pages><style face="normal" font="default" size="100%">229-241</style></pages><volume><style face="normal" font="default" size="100%">380</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2019/01/17</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Aminoquinolines/*administration &amp; dosage/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Antimalarials/*administration &amp; dosage/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Chloroquine/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Disease-Free Survival</style></keyword><keyword><style face="normal" font="default" size="100%">Double-Blind Method</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Therapy, Combination</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Glucosephosphate Dehydrogenase/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Glucosephosphate Dehydrogenase Deficiency/complications</style></keyword><keyword><style face="normal" font="default" size="100%">Hemoglobins/analysis</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Kaplan-Meier Estimate</style></keyword><keyword><style face="normal" font="default" size="100%">Malaria, Vivax/complications/*drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Parasitemia/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">*Plasmodium vivax/isolation &amp; purification</style></keyword><keyword><style face="normal" font="default" size="100%">Primaquine/*administration &amp; dosage/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Prospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Secondary Prevention/*methods</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2019</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan 17</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0028-4793 (Print)&#xD;0028-4793</style></isbn><accession-num><style face="normal" font="default" size="100%">30650326</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Tafenoquine, a single-dose therapy for Plasmodium vivax malaria, has been associated with relapse prevention through the clearance of P. vivax parasitemia and hypnozoites, termed &quot;radical cure.&quot; METHODS: We performed a phase 3, prospective, double-blind, double-dummy, randomized, controlled trial to compare tafenoquine with primaquine in terms of safety and efficacy. The trial was conducted at seven hospitals or clinics in Peru, Brazil, Colombia, Vietnam, and Thailand and involved patients with normal glucose-6-phosphate dehydrogenase (G6PD) enzyme activity and female patients with moderate G6PD enzyme deficiency; all patients had confirmed P. vivax parasitemia. The patients were randomly assigned, in a 2:1 ratio, to receive a single 300-mg dose of tafenoquine or 15 mg of primaquine once daily for 14 days (administered under supervision); all patients received a 3-day course of chloroquine and were followed for 180 days. The primary safety outcome was a protocol-defined decrease in the hemoglobin level (&gt;3.0 g per deciliter or ≥30% from baseline or to a level of &lt;6.0 g per deciliter). Freedom from recurrence of P. vivax parasitemia at 6 months was the primary efficacy outcome in a planned patient-level meta-analysis of the current trial and another phase 3 trial of tafenoquine and primaquine (per-protocol populations), and an odds ratio for recurrence of 1.45 (tafenoquine vs. primaquine) was used as a noninferiority margin. RESULTS: A protocol-defined decrease in the hemoglobin level occurred in 4 of 166 patients (2.4%; 95% confidence interval [CI], 0.9 to 6.0) in the tafenoquine group and in 1 of 85 patients (1.2%; 95% CI, 0.2 to 6.4) in the primaquine group, for a between-group difference of 1.2 percentage points (95% CI, -4.2 to 5.0). In the patient-level meta-analysis, the percentage of patients who were free from recurrence at 6 months was 67.0% (95% CI, 61.0 to 72.3) among the 426 patients in the tafenoquine group and 72.8% (95% CI, 65.6 to 78.8) among the 214 patients in the primaquine group. The efficacy of tafenoquine was not shown to be noninferior to that of primaquine (odds ratio for recurrence, 1.81; 95% CI, 0.82 to 3.96). CONCLUSIONS: Among patients with normal G6PD enzyme activity, the decline in hemoglobin level with tafenoquine did not differ significantly from that with primaquine. Tafenoquine showed efficacy for the radical cure of P. vivax malaria, although tafenoquine was not shown to be noninferior to primaquine. (Funded by GlaxoSmithKline and Medicines for Malaria Venture; GATHER ClinicalTrials.gov number, NCT02216123 .).</style></abstract><caption><style face="normal" font="default" size="100%">Duplicate</style></caption><notes><style face="normal" font="default" size="100%">1533-4406&#xD;Llanos-Cuentas, Alejandro&#xD;Lacerda, Marcus V G&#xD;Hien, Tran T&#xD;Vélez, Iván D&#xD;Namaik-Larp, Chayadol&#xD;Chu, Cindy S&#xD;Villegas, Maria F&#xD;Val, Fernando&#xD;Monteiro, Wuelton M&#xD;Brito, Marcelo A M&#xD;Costa, Mônica R F&#xD;Chuquiyauri, Raul&#xD;Casapía, Martín&#xD;Nguyen, Chau H&#xD;Aruachan, Sandra&#xD;Papwijitsil, Ratchadaporn&#xD;Nosten, François H&#xD;Bancone, Germana&#xD;Angus, Brian&#xD;Duparc, Stephan&#xD;Craig, Graham&#xD;Rousell, Victoria M&#xD;Jones, Siôn W&#xD;Hardaker, Elizabeth&#xD;Clover, Donna D&#xD;Kendall, Lindsay&#xD;Mohamed, Khadeeja&#xD;Koh, Gavin C K W&#xD;Orcid: 0000-0002-7336-1566&#xD;Wilches, Viviana M&#xD;Breton, John J&#xD;Green, Justin A&#xD;Clinical Trial, Phase III&#xD;Comparative Study&#xD;Equivalence Trial&#xD;Journal Article&#xD;Multicenter Study&#xD;Randomized Controlled Trial&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;N Engl J Med. 2019 Jan 17;380(3):229-241. doi: 10.1056/NEJMoa1802537.</style></notes><urls></urls><custom2><style face="normal" font="default" size="100%">PMC6657225</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1056/NEJMoa1802537</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>96</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">96</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Llanos-Cuentas, A.</style></author><author><style face="normal" font="default" size="100%">Lacerda, M. V. G.</style></author><author><style face="normal" font="default" size="100%">Hien, T. T.</style></author><author><style face="normal" font="default" size="100%">Vélez, I. D.</style></author><author><style face="normal" font="default" size="100%">Namaik-Larp, C.</style></author><author><style face="normal" font="default" size="100%">Chu, C. S.</style></author><author><style face="normal" font="default" size="100%">Villegas, M. F.</style></author><author><style face="normal" font="default" size="100%">Val, F.</style></author><author><style face="normal" font="default" size="100%">Monteiro, W. M.</style></author><author><style face="normal" font="default" size="100%">Brito, M. A. M.</style></author><author><style face="normal" font="default" size="100%">Costa, M. R. F.</style></author><author><style face="normal" font="default" size="100%">Chuquiyauri, R.</style></author><author><style face="normal" font="default" size="100%">Casapía, M.</style></author><author><style face="normal" font="default" size="100%">Nguyen, C. H.</style></author><author><style face="normal" font="default" size="100%">Aruachan, S.</style></author><author><style face="normal" font="default" size="100%">Papwijitsil, R.</style></author><author><style face="normal" font="default" size="100%">Nosten, F. H.</style></author><author><style face="normal" font="default" size="100%">Bancone, G.</style></author><author><style face="normal" font="default" size="100%">Angus, B.</style></author><author><style face="normal" font="default" size="100%">Duparc, S.</style></author><author><style face="normal" font="default" size="100%">Craig, G.</style></author><author><style face="normal" font="default" size="100%">Rousell, V. M.</style></author><author><style face="normal" font="default" size="100%">Jones, S. W.</style></author><author><style face="normal" font="default" size="100%">Hardaker, E.</style></author><author><style face="normal" font="default" size="100%">Clover, D. D.</style></author><author><style face="normal" font="default" size="100%">Kendall, L.</style></author><author><style face="normal" font="default" size="100%">Mohamed, K.</style></author><author><style face="normal" font="default" size="100%">Koh, G. C. K. W.</style></author><author><style face="normal" font="default" size="100%">Wilches, V. M.</style></author><author><style face="normal" font="default" size="100%">Breton, J. J.</style></author><author><style face="normal" font="default" size="100%">Green, J. A.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Tafenoquine versus primaquine to prevent relapse of plasmodium vivax malaria</style></title><secondary-title><style face="normal" font="default" size="100%">New England Journal of Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">New England Journal of Medicine</style></full-title></periodical><pages><style face="normal" font="default" size="100%">229-241</style></pages><volume><style face="normal" font="default" size="100%">380</style></volume><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">NCT02216123</style></keyword><keyword><style face="normal" font="default" size="100%">alanine aminotransferase</style></keyword><keyword><style face="normal" font="default" size="100%">chloroquine</style></keyword><keyword><style face="normal" font="default" size="100%">creatine kinase</style></keyword><keyword><style face="normal" font="default" size="100%">glucose 6 phosphate dehydrogenase</style></keyword><keyword><style face="normal" font="default" size="100%">primaquine</style></keyword><keyword><style face="normal" font="default" size="100%">tafenoquine</style></keyword><keyword><style face="normal" font="default" size="100%">adult</style></keyword><keyword><style face="normal" font="default" size="100%">alanine aminotransferase blood level</style></keyword><keyword><style face="normal" font="default" size="100%">article</style></keyword><keyword><style face="normal" font="default" size="100%">asthenia</style></keyword><keyword><style face="normal" font="default" size="100%">backache</style></keyword><keyword><style face="normal" font="default" size="100%">blurred vision</style></keyword><keyword><style face="normal" font="default" size="100%">controlled study</style></keyword><keyword><style face="normal" font="default" size="100%">coughing</style></keyword><keyword><style face="normal" font="default" size="100%">creatine kinase blood level</style></keyword><keyword><style face="normal" font="default" size="100%">diarrhea</style></keyword><keyword><style face="normal" font="default" size="100%">disease severity</style></keyword><keyword><style face="normal" font="default" size="100%">dizziness</style></keyword><keyword><style face="normal" font="default" size="100%">double blind procedure</style></keyword><keyword><style face="normal" font="default" size="100%">drug efficacy</style></keyword><keyword><style face="normal" font="default" size="100%">drug safety</style></keyword><keyword><style face="normal" font="default" size="100%">enzyme activity</style></keyword><keyword><style face="normal" font="default" size="100%">enzyme deficiency</style></keyword><keyword><style face="normal" font="default" size="100%">female</style></keyword><keyword><style face="normal" font="default" size="100%">fever</style></keyword><keyword><style face="normal" font="default" size="100%">headache</style></keyword><keyword><style face="normal" font="default" size="100%">hemoglobin blood level</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">hypokalemia</style></keyword><keyword><style face="normal" font="default" size="100%">insomnia</style></keyword><keyword><style face="normal" font="default" size="100%">major clinical study</style></keyword><keyword><style face="normal" font="default" size="100%">male</style></keyword><keyword><style face="normal" font="default" size="100%">methemoglobinemia</style></keyword><keyword><style face="normal" font="default" size="100%">nausea</style></keyword><keyword><style face="normal" font="default" size="100%">parasitemia</style></keyword><keyword><style face="normal" font="default" size="100%">pharyngitis</style></keyword><keyword><style face="normal" font="default" size="100%">phase 3 clinical trial</style></keyword><keyword><style face="normal" font="default" size="100%">Plasmodium vivax malaria</style></keyword><keyword><style face="normal" font="default" size="100%">pneumonia</style></keyword><keyword><style face="normal" font="default" size="100%">priority journal</style></keyword><keyword><style face="normal" font="default" size="100%">prospective study</style></keyword><keyword><style face="normal" font="default" size="100%">pruritus</style></keyword><keyword><style face="normal" font="default" size="100%">QT prolongation</style></keyword><keyword><style face="normal" font="default" size="100%">randomized controlled trial</style></keyword><keyword><style face="normal" font="default" size="100%">recurrent disease</style></keyword><keyword><style face="normal" font="default" size="100%">rhinopharyngitis</style></keyword><keyword><style face="normal" font="default" size="100%">side effect</style></keyword><keyword><style face="normal" font="default" size="100%">single drug dose</style></keyword><keyword><style face="normal" font="default" size="100%">treatment duration</style></keyword><keyword><style face="normal" font="default" size="100%">upper abdominal pain</style></keyword><keyword><style face="normal" font="default" size="100%">urinary tract infection</style></keyword><keyword><style face="normal" font="default" size="100%">vomiting</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2019</style></year></dates><isbn><style face="normal" font="default" size="100%">1533-4406&#xD;0028-4793</style></isbn><abstract><style face="normal" font="default" size="100%">BACKGROUND Tafenoquine, a single-dose therapy for Plasmodium vivax malaria, has been associated with relapse prevention through the clearance of P. vivax parasitemia and hypnozoites, termed “radical cure.” METHODS We performed a phase 3, prospective, double-blind, double-dummy, randomized, controlled trial to compare tafenoquine with primaquine in terms of safety and efficacy. The trial was conducted at seven hospitals or clinics in Peru, Brazil, Colombia, Vietnam, and Thailand and involved patients with normal glucose-6-phosphate dehydrogenase (G6PD) enzyme activity and female patients with moderate G6PD enzyme deficiency; all patients had confirmed P. vivax parasitemia. The patients were randomly assigned, in a 2:1 ratio, to receive a single 300-mg dose of tafenoquine or 15 mg of primaquine once daily for 14 days (administered under supervision); all patients received a 3-day course of chloroquine and were followed for 180 days. The primary safety outcome was a protocol-defined decrease in the hemoglobin level (3.0 g per deciliter or ≥30% from baseline or to a level of 6.0 g per deciliter). Freedom from recurrence of P. vivax parasitemia at 6 months was the primary efficacy outcome in a planned patient-level meta-analysis of the current trial and another phase 3 trial of tafenoquine and primaquine (per-protocol populations), and an odds ratio for recurrence of 1.45 (tafenoquine vs. primaquine) was used as a noninferiority margin. RESULTS A protocol-defined decrease in the hemoglobin level occurred in 4 of 166 patients (2.4%; 95% confidence interval [CI], 0.9 to 6.0) in the tafenoquine group and in 1 of 85 patients (1.2%; 95% CI, 0.2 to 6.4) in the primaquine group, for a between-group difference of 1.2 percentage points (95% CI, −4.2 to 5.0). In the patient-level meta-analysis, the percentage of patients who were free from recurrence at 6 months was 67.0% (95% CI, 61.0 to 72.3) among the 426 patients in the tafenoquine group and 72.8% (95% CI, 65.6 to 78.8) among the 214 patients in the primaquine group. The efficacy of tafenoquine was not shown to be noninferior to that of primaquine (odds ratio for recurrence, 1.81; 95% CI, 0.82 to 3.96). CONCLUSIONS Among patients with normal G6PD enzyme activity, the decline in hemoglobin level with tafenoquine did not differ significantly from that with primaquine. Tafenoquine showed efficacy for the radical cure of P. vivax malaria, although tafenoquine was not shown to be noninferior to primaquine.</style></abstract><caption><style face="normal" font="default" size="100%">Duplicate</style></caption><notes><style face="normal" font="default" size="100%">L625955667&#xD;2019-02-06&#xD;2019-02-11</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L625955667&amp;from=export</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1056/NEJMoa1802537</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">Alliance Pharmaceuticals&#xD;Glaxo SmithKline&#xD;Labaz&#xD;West Ward</style></custom2><custom5><style face="normal" font="default" size="100%">30650326</style></custom5><electronic-resource-num><style face="normal" font="default" size="100%">10.1056/NEJMoa1802537</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase&#xD;Medline</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>149</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">149</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Llanos-Cuentas, A.</style></author><author><style face="normal" font="default" size="100%">Lacerda, M. V. G.</style></author><author><style face="normal" font="default" size="100%">Hien, T. T.</style></author><author><style face="normal" font="default" size="100%">Vélez, I. D.</style></author><author><style face="normal" font="default" size="100%">Namaik-Larp, C.</style></author><author><style face="normal" font="default" size="100%">Chu, C. S.</style></author><author><style face="normal" font="default" size="100%">Villegas, M. F.</style></author><author><style face="normal" font="default" size="100%">Val, F.</style></author><author><style face="normal" font="default" size="100%">Monteiro, W. M.</style></author><author><style face="normal" font="default" size="100%">Brito, M. A. M.</style></author><author><style face="normal" font="default" size="100%">et al.,</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria</style></title><secondary-title><style face="normal" font="default" size="100%">New England journal of medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">New England Journal of Medicine</style></full-title></periodical><pages><style face="normal" font="default" size="100%">229‐241</style></pages><volume><style face="normal" font="default" size="100%">380</style></volume><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Aminoquinolines [*administration &amp; dosage, adverse effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Antimalarials [*administration &amp; dosage, adverse effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Chloroquine [therapeutic use]</style></keyword><keyword><style face="normal" font="default" size="100%">Disease‐Free Survival</style></keyword><keyword><style face="normal" font="default" size="100%">Double‐Blind Method</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Therapy, Combination</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Glucosephosphate Dehydrogenase Deficiency [complications]</style></keyword><keyword><style face="normal" font="default" size="100%">Glucosephosphate Dehydrogenase [metabolism]</style></keyword><keyword><style face="normal" font="default" size="100%">Hemoglobins [analysis]</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Kaplan‐Meier Estimate</style></keyword><keyword><style face="normal" font="default" size="100%">Malaria, Vivax [complications, *drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Parasitemia [drug therapy]</style></keyword><keyword><style face="normal" font="default" size="100%">Plasmodium vivax [isolation &amp; purification]</style></keyword><keyword><style face="normal" font="default" size="100%">Primaquine [*administration &amp; dosage, adverse effects]</style></keyword><keyword><style face="normal" font="default" size="100%">Prospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Secondary Prevention [*methods]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2019</style></year></dates><accession-num><style face="normal" font="default" size="100%">CN-01702701</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Tafenoquine, a single‐dose therapy for Plasmodium vivax malaria, has been associated with relapse prevention through the clearance of P. vivax parasitemia and hypnozoites, termed &quot;radical cure.&quot; METHODS: We performed a phase 3, prospective, double‐blind, double‐dummy, randomized, controlled trial to compare tafenoquine with primaquine in terms of safety and efficacy. The trial was conducted at seven hospitals or clinics in Peru, Brazil, Colombia, Vietnam, and Thailand and involved patients with normal glucose‐6‐phosphate dehydrogenase (G6PD) enzyme activity and female patients with moderate G6PD enzyme deficiency; all patients had confirmed P. vivax parasitemia. The patients were randomly assigned, in a 2:1 ratio, to receive a single 300‐mg dose of tafenoquine or 15 mg of primaquine once daily for 14 days (administered under supervision); all patients received a 3‐day course of chloroquine and were followed for 180 days. The primary safety outcome was a protocol‐defined decrease in the hemoglobin level (&gt;3.0 g per deciliter or ≥30% from baseline or to a level of &lt;6.0 g per deciliter). Freedom from recurrence of P. vivax parasitemia at 6 months was the primary efficacy outcome in a planned patient‐level meta‐analysis of the current trial and another phase 3 trial of tafenoquine and primaquine (per‐protocol populations), and an odds ratio for recurrence of 1.45 (tafenoquine vs. primaquine) was used as a noninferiority margin. RESULTS: A protocol‐defined decrease in the hemoglobin level occurred in 4 of 166 patients (2.4%; 95% confidence interval [CI], 0.9 to 6.0) in the tafenoquine group and in 1 of 85 patients (1.2%; 95% CI, 0.2 to 6.4) in the primaquine group, for a between‐group difference of 1.2 percentage points (95% CI, ‐4.2 to 5.0). In the patient‐level meta‐analysis, the percentage of patients who were free from recurrence at 6 months was 67.0% (95% CI, 61.0 to 72.3) among the 426 patients in the tafenoquine group and 72.8% (95% CI, 65.6 to 78.8) among the 214 patients in the primaquine group. The efficacy of tafenoquine was not shown to be noninferior to that of primaquine (odds ratio for recurrence, 1.81; 95% CI, 0.82 to 3.96). CONCLUSIONS: Among patients with normal G6PD enzyme activity, the decline in hemoglobin level with tafenoquine did not differ significantly from that with primaquine. Tafenoquine showed efficacy for the radical cure of P. vivax malaria, although tafenoquine was not shown to be noninferior to primaquine. (Funded by GlaxoSmithKline and Medicines for Malaria Venture; GATHER ClinicalTrials.gov number, NCT02216123 .).</style></abstract><caption><style face="normal" font="default" size="100%">Duplicate</style></caption><work-type><style face="normal" font="default" size="100%">Clinical Trial, Phase III; Comparative Study; Equivalence Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non‐U.S. Gov&apos;t</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01702701/full</style></url></related-urls></urls><custom3><style face="normal" font="default" size="100%">PUBMED 30650326</style></custom3><electronic-resource-num><style face="normal" font="default" size="100%">10.1056/NEJMoa1802537</style></electronic-resource-num></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>56</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">56</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Carvalho, L.</style></author><author><style face="normal" font="default" size="100%">Luque-Ortega, J. R.</style></author><author><style face="normal" font="default" size="100%">Manzano, J. I.</style></author><author><style face="normal" font="default" size="100%">Castanys, S.</style></author><author><style face="normal" font="default" size="100%">Rivas, L.</style></author><author><style face="normal" font="default" size="100%">Gamarro, F.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Instituto de Parasitología y Biomedicina &quot;López-Neyra,&quot; CSIC, Granada, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Tafenoquine, an antiplasmodial 8-aminoquinoline, targets leishmania respiratory complex III and induces apoptosis</style></title><secondary-title><style face="normal" font="default" size="100%">Antimicrob Agents Chemother</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Antimicrob Agents Chemother</style></full-title></periodical><pages><style face="normal" font="default" size="100%">5344-51</style></pages><volume><style face="normal" font="default" size="100%">54</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2010/09/15</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adenosine Triphosphate/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Aminoquinolines/*pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Antimalarials/*pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Apoptosis/*drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Calcium/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Membrane/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">DNA Fragmentation/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Electron Transport Complex III/*drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Leishmania/*drug effects/*metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Oxygen Consumption/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Reactive Oxygen Species/metabolism</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2010</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0066-4804 (Print)&#xD;0066-4804</style></isbn><accession-num><style face="normal" font="default" size="100%">20837758</style></accession-num><abstract><style face="normal" font="default" size="100%">Tafenoquine (TFQ), an 8-aminoquinoline analogue of primaquine, which is currently under clinical trial (phase IIb/III) for the treatment and prevention of malaria, may represent an alternative treatment for leishmaniasis. In this work, we have studied the mechanism of action of TFQ against Leishmania parasites. TFQ impaired the overall bioenergetic metabolism of Leishmania promastigotes, causing a rapid drop in intracellular ATP levels without affecting plasma membrane permeability. TFQ induced mitochondrial dysfunction through the inhibition of cytochrome c reductase (respiratory complex III) with a decrease in the oxygen consumption rate and depolarization of mitochondrial membrane potential. This was accompanied by ROS production, elevation of intracellular Ca(2+) levels and concomitant nuclear DNA fragmentation. We conclude that TFQ targets Leishmania mitochondria, leading to an apoptosis-like death process.</style></abstract><notes><style face="normal" font="default" size="100%">1098-6596&#xD;Carvalho, Luis&#xD;Luque-Ortega, Juan Román&#xD;Manzano, José Ignacio&#xD;Castanys, Santiago&#xD;Rivas, Luis&#xD;Gamarro, Francisco&#xD;Journal Article&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Antimicrob Agents Chemother. 2010 Dec;54(12):5344-51. doi: 10.1128/AAC.00790-10. Epub 2010 Sep 13.</style></notes><urls></urls><custom2><style face="normal" font="default" size="100%">PMC2981264</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1128/aac.00790-10</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>60</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">60</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Crockett, M.</style></author><author><style face="normal" font="default" size="100%">Kain, K. C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">The Hospital for Sick Children, Division of Infectious Diseases, 555 University Avenue, Toronto, M5G 1X8, Canada. maryanne.crockett@utoronto.ca</style></auth-address><titles><title><style face="normal" font="default" size="100%">Tafenoquine: a promising new antimalarial agent</style></title><secondary-title><style face="normal" font="default" size="100%">Expert Opin Investig Drugs</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Expert Opin Investig Drugs</style></full-title></periodical><pages><style face="normal" font="default" size="100%">705-15</style></pages><volume><style face="normal" font="default" size="100%">16</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2007/04/28</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Aminoquinolines/adverse effects/pharmacokinetics/*therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Antimalarials/adverse effects/pharmacokinetics/*therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Malaria, Falciparum/*drug therapy/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Malaria, Vivax/*drug therapy/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Recurrence</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2007</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1354-3784</style></isbn><accession-num><style face="normal" font="default" size="100%">17461742</style></accession-num><abstract><style face="normal" font="default" size="100%">Malaria remains an important cause of global morbidity and mortality. As antimalarial drug resistance escalates, new safe and effective medications are necessary to prevent and treat malarial infection. Tafenoquine is an 8-aminoquinoline antimalarial that is presently under development. It has a long half-life of approximately 14 days and is generally safe and well tolerated, although it cannot be used in pregnant women and individuals who are deficient in the enzyme glucose-6-phosphate dehydrogenase. In well-designed studies, tafenoquine was highly effective in both the radical cure of relapsing malaria and causal prophylaxis of Plasmodium vivax and P. falciparum infections with protective efficacies of &gt; or = 90%. Given its causal activity and safety profile, tafenoquine represents a potentially exciting alternative to standard agents for the prevention and radical cure of malaria.</style></abstract><caption><style face="normal" font="default" size="100%">Duplicate</style></caption><notes><style face="normal" font="default" size="100%">1744-7658&#xD;Crockett, Maryanne&#xD;Kain, Kevin C&#xD;Journal Article&#xD;Review&#xD;England&#xD;Expert Opin Investig Drugs. 2007 May;16(5):705-15. doi: 10.1517/13543784.16.5.705.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1517/13543784.16.5.705</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>126</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">126</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Crockett, M.</style></author><author><style face="normal" font="default" size="100%">Kain, K. C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">K.C. Kain, University of Toronto, Toronto General Hospital-University Health Network, McLaughlin Center for Molecular Medicine, Toronto, ON, Canada</style></auth-address><titles><title><style face="normal" font="default" size="100%">Tafenoquine: A promising new antimalarial agent</style></title><secondary-title><style face="normal" font="default" size="100%">Expert Opinion on Investigational Drugs</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Expert Opinion on Investigational Drugs</style></full-title></periodical><pages><style face="normal" font="default" size="100%">705-715</style></pages><volume><style face="normal" font="default" size="100%">16</style></volume><number><style face="normal" font="default" size="100%">5</style></number><keywords><keyword><style face="normal" font="default" size="100%">alanine aminotransferase</style></keyword><keyword><style face="normal" font="default" size="100%">aminoquinoline derivative</style></keyword><keyword><style face="normal" font="default" size="100%">amodiaquine</style></keyword><keyword><style face="normal" font="default" size="100%">artemisin derivative</style></keyword><keyword><style face="normal" font="default" size="100%">artesunate</style></keyword><keyword><style face="normal" font="default" size="100%">aspartate aminotransferase</style></keyword><keyword><style face="normal" font="default" size="100%">atovaquone plus proguanil</style></keyword><keyword><style face="normal" font="default" size="100%">chloroquine</style></keyword><keyword><style face="normal" font="default" size="100%">chlorproguanil plus dapsone</style></keyword><keyword><style face="normal" font="default" size="100%">clindamycin</style></keyword><keyword><style face="normal" font="default" size="100%">doxycycline</style></keyword><keyword><style face="normal" font="default" size="100%">pyrimethamine plus sulfadoxine</style></keyword><keyword><style face="normal" font="default" size="100%">glucose 6 phosphate dehydrogenase</style></keyword><keyword><style face="normal" font="default" size="100%">halofantrine</style></keyword><keyword><style face="normal" font="default" size="100%">mefloquine</style></keyword><keyword><style face="normal" font="default" size="100%">placebo</style></keyword><keyword><style face="normal" font="default" size="100%">primaquine</style></keyword><keyword><style face="normal" font="default" size="100%">quinidine</style></keyword><keyword><style face="normal" font="default" size="100%">quinine</style></keyword><keyword><style face="normal" font="default" size="100%">tafenoquine</style></keyword><keyword><style face="normal" font="default" size="100%">abdominal pain</style></keyword><keyword><style face="normal" font="default" size="100%">absence of side effects</style></keyword><keyword><style face="normal" font="default" size="100%">alanine aminotransferase blood level</style></keyword><keyword><style face="normal" font="default" size="100%">antiprotozoal activity</style></keyword><keyword><style face="normal" font="default" size="100%">article</style></keyword><keyword><style face="normal" font="default" size="100%">aspartate aminotransferase blood level</style></keyword><keyword><style face="normal" font="default" size="100%">clinical trial</style></keyword><keyword><style face="normal" font="default" size="100%">combination chemotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">concentration response</style></keyword><keyword><style face="normal" font="default" size="100%">creatinine blood level</style></keyword><keyword><style face="normal" font="default" size="100%">diarrhea</style></keyword><keyword><style face="normal" font="default" size="100%">dizziness</style></keyword><keyword><style face="normal" font="default" size="100%">dosage schedule comparison</style></keyword><keyword><style face="normal" font="default" size="100%">drug absorption</style></keyword><keyword><style face="normal" font="default" size="100%">drug bioavailability</style></keyword><keyword><style face="normal" font="default" size="100%">drug blood level</style></keyword><keyword><style face="normal" font="default" size="100%">drug clearance</style></keyword><keyword><style face="normal" font="default" size="100%">drug distribution</style></keyword><keyword><style face="normal" font="default" size="100%">drug dose comparison</style></keyword><keyword><style face="normal" font="default" size="100%">drug eruption</style></keyword><keyword><style face="normal" font="default" size="100%">drug half life</style></keyword><keyword><style face="normal" font="default" size="100%">drug induced headache</style></keyword><keyword><style face="normal" font="default" size="100%">drug marketing</style></keyword><keyword><style face="normal" font="default" size="100%">drug megadose</style></keyword><keyword><style face="normal" font="default" size="100%">drug metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">drug structure</style></keyword><keyword><style face="normal" font="default" size="100%">drug tolerability</style></keyword><keyword><style face="normal" font="default" size="100%">fatigue</style></keyword><keyword><style face="normal" font="default" size="100%">food</style></keyword><keyword><style face="normal" font="default" size="100%">food drug interaction</style></keyword><keyword><style face="normal" font="default" size="100%">gastrointestinal symptom</style></keyword><keyword><style face="normal" font="default" size="100%">glucose 6 phosphate dehydrogenase deficiency</style></keyword><keyword><style face="normal" font="default" size="100%">hemolysis</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">IC50</style></keyword><keyword><style face="normal" font="default" size="100%">laboratory test</style></keyword><keyword><style face="normal" font="default" size="100%">leukocyte</style></keyword><keyword><style face="normal" font="default" size="100%">lipid diet</style></keyword><keyword><style face="normal" font="default" size="100%">loading drug dose</style></keyword><keyword><style face="normal" font="default" size="100%">low drug dose</style></keyword><keyword><style face="normal" font="default" size="100%">malaria</style></keyword><keyword><style face="normal" font="default" size="100%">methemoglobinemia</style></keyword><keyword><style face="normal" font="default" size="100%">monotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">multidrug resistance</style></keyword><keyword><style face="normal" font="default" size="100%">nausea</style></keyword><keyword><style face="normal" font="default" size="100%">nonhuman</style></keyword><keyword><style face="normal" font="default" size="100%">pharmacodynamics</style></keyword><keyword><style face="normal" font="default" size="100%">Plasmodium falciparum</style></keyword><keyword><style face="normal" font="default" size="100%">Plasmodium vivax</style></keyword><keyword><style face="normal" font="default" size="100%">side effect</style></keyword><keyword><style face="normal" font="default" size="100%">single drug dose</style></keyword><keyword><style face="normal" font="default" size="100%">thrombocytopenia</style></keyword><keyword><style face="normal" font="default" size="100%">vertigo</style></keyword><keyword><style face="normal" font="default" size="100%">weakness</style></keyword><keyword><style face="normal" font="default" size="100%">wr 238605</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2007</style></year></dates><isbn><style face="normal" font="default" size="100%">1354-3784</style></isbn><abstract><style face="normal" font="default" size="100%">Malaria remains an important cause of global morbidity and mortality. As antimalarial drug resistance escalates, new safe and effective medications are necessary to prevent and treat malarial infection. Tafenoquine is an 8-amino-quinoline antimalarial that is presently under development. It has a long half-life of ∼ 14 days and is generally safe and well tolerated, although it cannot be used in pregnant women and individuals who are deficient in the enzyme glucose-6-phosphate dehydrogenase. In well-designed studies, tafenoquine was highly effective in both the radical cure of relapsing malaria and causal prophylaxis of Plasmodium vivax and P. falciparum infections with protective efficacies of ≥ 90%. Given its causal activity and safety profile, tafenoquine represents a potentially exciting alternative to standard agents for the prevention and radical cure of malaria. © 2007 Informa UK Ltd.</style></abstract><caption><style face="normal" font="default" size="100%">Duplicate</style></caption><notes><style face="normal" font="default" size="100%">L46723273&#xD;2007-05-01</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L46723273&amp;from=export</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1517/13543784.16.5.705</style></url></related-urls></urls><custom1><style face="normal" font="default" size="100%">wr 238605(Glaxo SmithKline)&#xD;wr 238605(Walter Reed)</style></custom1><custom2><style face="normal" font="default" size="100%">Glaxo SmithKline&#xD;Walter Reed</style></custom2><custom5><style face="normal" font="default" size="100%">17461742</style></custom5><electronic-resource-num><style face="normal" font="default" size="100%">10.1517/13543784.16.5.705</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase&#xD;Medline</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>14</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">14</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lu, K. Y.</style></author><author><style face="normal" font="default" size="100%">Derbyshire, E. R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Molecular Genetics and Microbiology, School of Medicine, Duke University, Durham, North Carolina 27708, United States.&#xD;Department of Chemistry, Duke University, Durham, North Carolina 27708, United States.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Tafenoquine: A Step toward Malaria Elimination</style></title><secondary-title><style face="normal" font="default" size="100%">Biochemistry</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Biochemistry</style></full-title></periodical><pages><style face="normal" font="default" size="100%">911-920</style></pages><volume><style face="normal" font="default" size="100%">59</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2020/02/20</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Aminoquinolines/adverse effects/*therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Anemia, Hemolytic/chemically induced</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Antimalarials/adverse effects/*therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Cytochrome P-450 CYP2D6/genetics/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Gene Knockdown Techniques</style></keyword><keyword><style face="normal" font="default" size="100%">Glucosephosphate Dehydrogenase Deficiency/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Haplorhini</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Malaria, Vivax/*drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Methemoglobinemia/chemically induced</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Plasmodium cynomolgi/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Plasmodium vivax/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Zebrafish</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2020</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar 3</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0006-2960</style></isbn><accession-num><style face="normal" font="default" size="100%">32073254</style></accession-num><abstract><style face="normal" font="default" size="100%">There is a pressing need for compounds with broad-spectrum activity against malaria parasites at various life cycle stages to achieve malaria elimination. However, this goal cannot be accomplished without targeting the tenacious dormant liver-stage hypnozoite that causes multiple relapses after the first episode of illness. In the search for the magic bullet to radically cure Plasmodium vivax malaria, tafenoquine outperformed other candidate drugs and was approved by the U.S. Food and Drug Administration in 2018. Tafenoquine is an 8-aminoquinoline that inhibits multiple life stages of various Plasmodium species. Additionally, its much longer half-life allows for single-dose treatment, which will improve the compliance rate. Despite its approval and the long-time use of other 8-aminoquinolines, the mechanisms behind tafenoquine&apos;s activity and adverse effects are still largely unknown. In this Perspective, we discuss the plausible underlying mechanisms of tafenoquine&apos;s antiparasitic activity and highlight its role as a cellular stressor. We also discuss potential drug combinations and the development of next-generation 8-aminoquinolines to further improve the therapeutic index of tafenoquine for malaria treatment and prevention.</style></abstract><notes><style face="normal" font="default" size="100%">1520-4995&#xD;Lu, Kuan-Yi&#xD;Derbyshire, Emily R&#xD;Orcid: 0000-0001-6664-8844&#xD;DP2 AI138239/AI/NIAID NIH HHS/United States&#xD;Journal Article&#xD;Research Support, N.I.H., Extramural&#xD;United States&#xD;Biochemistry. 2020 Mar 3;59(8):911-920. doi: 10.1021/acs.biochem.9b01105. Epub 2020 Feb 24.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1021/acs.biochem.9b01105</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>32</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">32</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Frampton, J. E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Springer, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. dru@adis.com.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Tafenoquine: First Global Approval</style></title><secondary-title><style face="normal" font="default" size="100%">Drugs</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Drugs</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1517-1523</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">14</style></number><edition><style face="normal" font="default" size="100%">2018/09/20</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Aminoquinolines/adverse effects/pharmacokinetics/*therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Antimalarials/adverse effects/pharmacokinetics/*therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Approval</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Malaria/*drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">United States</style></keyword><keyword><style face="normal" font="default" size="100%">United States Food and Drug Administration</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2018</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0012-6667</style></isbn><accession-num><style face="normal" font="default" size="100%">30229442</style></accession-num><abstract><style face="normal" font="default" size="100%">Tafenoquine (Krintafel™, Arakoda™), an orally-active 8-aminoquinoline anti-malarial drug, is a long-acting analogue of primaquine with activity against pre-erythrocytic (liver) and erythrocytic (asexual) forms as well as gametocytes of Plasmodium species that include Plasmodium vivax (P. vivax) and Plasmodium falciparum. It has been developed by GlaxoSmithKline (formerly SmithKline Beecham) for the radical cure of P. vivax malaria and by 60 Degrees Pharmaceuticals for the prophylaxis of malaria. The exact mechanism(s) of action underlying the anti-Plasmodium activity of tafenoquine are unknown, although it may exert its effect by inhibiting haematin polymerization and, additionally, by inducing mitochondrial dysfunction leading to the apoptotic-like death of the organism. In July 2018, tafenoquine was approved in the USA for the radical cure of P. vivax malaria in patients aged ≥ 16 years who are receiving appropriate antimalarial therapy for acute P. vivax malaria. Subsequently, in August 2018, tafenoquine was approved in the USA for the prophylaxis of malaria in patients aged ≥ 18 years. This article primarily summarizes the milestones in the development of tafenoquine leading to its first global approval for the radical cure of P. vivax malaria.</style></abstract><notes><style face="normal" font="default" size="100%">1179-1950&#xD;Frampton, James E&#xD;Journal Article&#xD;Review&#xD;New Zealand&#xD;Drugs. 2018 Sep;78(14):1517-1523. doi: 10.1007/s40265-018-0979-2.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1007/s40265-018-0979-2</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>20</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">20</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Chen, V.</style></author><author><style face="normal" font="default" size="100%">Daily, J. P.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pharmacy, Montefiore Medical Center.&#xD;Department of Medicine and Microbiology and Immunology, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, New York, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Tafenoquine: the new kid on the block</style></title><secondary-title><style face="normal" font="default" size="100%">Curr Opin Infect Dis</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Curr Opin Infect Dis</style></full-title></periodical><pages><style face="normal" font="default" size="100%">407-412</style></pages><volume><style face="normal" font="default" size="100%">32</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2019/07/16</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Aminoquinolines/*administration &amp; dosage/adverse effects/pharmacokinetics</style></keyword><keyword><style face="normal" font="default" size="100%">Antimalarials/*administration &amp; dosage/adverse effects/pharmacokinetics</style></keyword><keyword><style face="normal" font="default" size="100%">Chemoprevention/*methods</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Therapy/*methods</style></keyword><keyword><style face="normal" font="default" size="100%">Drug-Related Side Effects and Adverse Reactions/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Malaria, Vivax/*drug therapy/*prevention &amp; control</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2019</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0951-7375</style></isbn><accession-num><style face="normal" font="default" size="100%">31305490</style></accession-num><abstract><style face="normal" font="default" size="100%">PURPOSE OF REVIEW: This is a review of tafenoquine, a new antimalarial drug. Here we examine the recent literature supporting the use of tafenoquine and summarize the opportunities and challenges for its well tolerated use worldwide. RECENT FINDINGS: Tafenoquine was recently approved by the US Food and Drug Administration for the treatment of dormant liver stage (hypnozoite) in Plasmodium vivax and for malaria prophylaxis. Single-dose tafenoquine provides equivalent efficacy to 14 days of primaquine for radical cure in P. vivax, and it can be dosed weekly to prevent malaria. However, tafenoquine can only be used in patients with normal G6PD activity and is contraindicated in children and during pregnancy or in lactating mothers with infants of deficient or unknown G6PD status. SUMMARY: Tafenoquine&apos;s long half-life allows a single dose to achieve radical cure, and weekly dosing for chemoprophylaxis to provide an exciting therapeutic option for patient care and as a new weapon for malaria control/eradication programs. Global implementation of tafenoquine will require the development and validation of a robust, low-cost diagnostic to reliably identify G6PD-deficient individuals. In addition, studies on tafenoquine safety in children are needed.</style></abstract><caption><style face="normal" font="default" size="100%">Duplicate</style></caption><notes><style face="normal" font="default" size="100%">1473-6527&#xD;Chen, Victor&#xD;Daily, Johanna P&#xD;Journal Article&#xD;Review&#xD;United States&#xD;Curr Opin Infect Dis. 2019 Oct;32(5):407-412. doi: 10.1097/QCO.0000000000000574.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1097/qco.0000000000000574</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>89</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">89</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Chen, V.</style></author><author><style face="normal" font="default" size="100%">Daily, J. P.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">J.P. Daily, Department of Medicine and Microbiology and Immunology, Albert Einstein College of Medicine, Montefiore Medical Center, 1301 Morris Park Avenue, Bronx, NY, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Tafenoquine: The new kid on the block</style></title><secondary-title><style face="normal" font="default" size="100%">Current Opinion in Infectious Diseases</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Current Opinion in Infectious Diseases</style></full-title></periodical><pages><style face="normal" font="default" size="100%">407-412</style></pages><volume><style face="normal" font="default" size="100%">32</style></volume><number><style face="normal" font="default" size="100%">5</style></number><keywords><keyword><style face="normal" font="default" size="100%">8 aminoquinoline derivative</style></keyword><keyword><style face="normal" font="default" size="100%">antimalarial agent</style></keyword><keyword><style face="normal" font="default" size="100%">atovaquone plus proguanil</style></keyword><keyword><style face="normal" font="default" size="100%">chloroquine</style></keyword><keyword><style face="normal" font="default" size="100%">cytochrome P450 2D6</style></keyword><keyword><style face="normal" font="default" size="100%">doxycycline</style></keyword><keyword><style face="normal" font="default" size="100%">glucose 6 phosphate dehydrogenase</style></keyword><keyword><style face="normal" font="default" size="100%">mefloquine</style></keyword><keyword><style face="normal" font="default" size="100%">methemoglobin</style></keyword><keyword><style face="normal" font="default" size="100%">primaquine</style></keyword><keyword><style face="normal" font="default" size="100%">tafenoquine</style></keyword><keyword><style face="normal" font="default" size="100%">adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">adult</style></keyword><keyword><style face="normal" font="default" size="100%">anemia</style></keyword><keyword><style face="normal" font="default" size="100%">chemoprophylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">child</style></keyword><keyword><style face="normal" font="default" size="100%">dizziness</style></keyword><keyword><style face="normal" font="default" size="100%">drug contraindication</style></keyword><keyword><style face="normal" font="default" size="100%">drug efficacy</style></keyword><keyword><style face="normal" font="default" size="100%">drug formulation</style></keyword><keyword><style face="normal" font="default" size="100%">drug half life</style></keyword><keyword><style face="normal" font="default" size="100%">drug hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">drug indication</style></keyword><keyword><style face="normal" font="default" size="100%">drug safety</style></keyword><keyword><style face="normal" font="default" size="100%">drug withdrawal</style></keyword><keyword><style face="normal" font="default" size="100%">eradication therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Food and Drug Administration</style></keyword><keyword><style face="normal" font="default" size="100%">glucose 6 phosphate dehydrogenase deficiency</style></keyword><keyword><style face="normal" font="default" size="100%">hemolysis</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">infant</style></keyword><keyword><style face="normal" font="default" size="100%">keratopathy</style></keyword><keyword><style face="normal" font="default" size="100%">malaria</style></keyword><keyword><style face="normal" font="default" size="100%">malaria control</style></keyword><keyword><style face="normal" font="default" size="100%">mental disease</style></keyword><keyword><style face="normal" font="default" size="100%">mouth ulcer</style></keyword><keyword><style face="normal" font="default" size="100%">nausea and vomiting</style></keyword><keyword><style face="normal" font="default" size="100%">neurologic disease</style></keyword><keyword><style face="normal" font="default" size="100%">patient care</style></keyword><keyword><style face="normal" font="default" size="100%">Plasmodium vivax</style></keyword><keyword><style face="normal" font="default" size="100%">point of care testing</style></keyword><keyword><style face="normal" font="default" size="100%">review</style></keyword><keyword><style face="normal" font="default" size="100%">single drug dose</style></keyword><keyword><style face="normal" font="default" size="100%">sunburn</style></keyword><keyword><style face="normal" font="default" size="100%">travel</style></keyword><keyword><style face="normal" font="default" size="100%">United States</style></keyword><keyword><style face="normal" font="default" size="100%">arakoda</style></keyword><keyword><style face="normal" font="default" size="100%">krintafel</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2019</style></year></dates><isbn><style face="normal" font="default" size="100%">1473-6527&#xD;0951-7375</style></isbn><abstract><style face="normal" font="default" size="100%">Purpose of review: This is a review of tafenoquine, a new antimalarial drug. Here we examine the recent literature supporting the use of tafenoquine and summarize the opportunities and challenges for its well tolerated use worldwide. Recent findings: Tafenoquine was recently approved by the US Food and Drug Administration for the treatment of dormant liver stage (hypnozoite) in Plasmodium vivax and for malaria prophylaxis. Single-dose tafenoquine provides equivalent efficacy to 14 days of primaquine for radical cure in P. vivax, and it can be dosed weekly to prevent malaria. However, tafenoquine can only be used in patients with normal G6PD activity and is contraindicated in children and during pregnancy or in lactating mothers with infants of deficient or unknown G6PD status. Summary: Tafenoquine&apos;s long half-life allows a single dose to achieve radical cure, and weekly dosing for chemoprophylaxis to provide an exciting therapeutic option for patient care and as a new weapon for malaria control/eradication programs. Global implementation of tafenoquine will require the development and validation of a robust, low-cost diagnostic to reliably identify G6PD-deficient individuals. In addition, studies on tafenoquine safety in children are needed.</style></abstract><caption><style face="normal" font="default" size="100%">Duplicate</style></caption><notes><style face="normal" font="default" size="100%">L629247134&#xD;2019-09-12&#xD;2019-09-20</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L629247134&amp;from=export</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1097/QCO.0000000000000574</style></url></related-urls></urls><custom1><style face="normal" font="default" size="100%">arakoda&#xD;krintafel</style></custom1><custom5><style face="normal" font="default" size="100%">31305490</style></custom5><electronic-resource-num><style face="normal" font="default" size="100%">10.1097/QCO.0000000000000574</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase&#xD;Medline</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>46</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">46</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Thomas, D.</style></author><author><style face="normal" font="default" size="100%">Tazerouni, H.</style></author><author><style face="normal" font="default" size="100%">Sundararaj, K. G.</style></author><author><style face="normal" font="default" size="100%">Cooper, J. C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">College of Pharmacy, Gulf Medical University, Ajman, UAE. Electronic address: dixon.thomas@gmail.com.&#xD;College of Pharmacy, Gulf Medical University, Ajman, UAE.&#xD;Medical University of South Carolina Drug Information Center, Charleston, SC, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Therapeutic failure of primaquine and need for new medicines in radical cure of Plasmodium vivax</style></title><secondary-title><style face="normal" font="default" size="100%">Acta Trop</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Acta Trop</style></full-title></periodical><pages><style face="normal" font="default" size="100%">35-8</style></pages><volume><style face="normal" font="default" size="100%">160</style></volume><edition><style face="normal" font="default" size="100%">2016/04/26</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Antimalarials/*therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Malaria, Vivax/*drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Plasmodium vivax</style></keyword><keyword><style face="normal" font="default" size="100%">Primaquine/*therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Failure</style></keyword><keyword><style face="normal" font="default" size="100%">P. vivax</style></keyword><keyword><style face="normal" font="default" size="100%">Primaquine</style></keyword><keyword><style face="normal" font="default" size="100%">Resistance</style></keyword><keyword><style face="normal" font="default" size="100%">Therapeutic failure</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2016</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0001-706x</style></isbn><accession-num><style face="normal" font="default" size="100%">27109040</style></accession-num><abstract><style face="normal" font="default" size="100%">Primaquine has been the drug of choice for the prevention of Plasmodium vivax relapse for more than 60 years. Primaquine tolerant strain of P. vivax was identified in 1944. Significant mortality and disease burden of P. vivax calls for the need of new drugs. Primaquine resistance is a complex issue, as the mechanism of resistance is not clear. Direct evidence of resistance to primaquine by hypnozoites has not yet been shown. There are some reports detailing risk of primaquine resistance in specific regions, but the overall distribution of primaquine resistance in P. vivax-infected people is largely unknown. Confounding factors contribute to treatment failures; such as inadequate doses, inappropriate dosing intervals, risk of reinfection, combinations with blood schizontocidals, and compliance. Therefore, primaquine resistance needs to be addressed along with additional important confounding factors. Tafenoquine is the most studied drug in replacing primaquine for the radical cure of P. vivax malaria. It has comparable efficacy with primaquine. The potential advantage of tafenoquine is better compliance with a single dose regimen. Rational use of primaquine can secure its effectiveness, but it is essential in the future to have better or similar alternatives to treat P. vivax.</style></abstract><notes><style face="normal" font="default" size="100%">1873-6254&#xD;Thomas, Dixon&#xD;Tazerouni, Hedieh&#xD;Sundararaj, Kishore Gnana Sam&#xD;Cooper, Jason C&#xD;Journal Article&#xD;Review&#xD;Netherlands&#xD;Acta Trop. 2016 Aug;160:35-8. doi: 10.1016/j.actatropica.2016.04.009. Epub 2016 Apr 21.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.actatropica.2016.04.009</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>68</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">68</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ponsa, N.</style></author><author><style face="normal" font="default" size="100%">Sattabongkot, J.</style></author><author><style face="normal" font="default" size="100%">Kittayapong, P.</style></author><author><style face="normal" font="default" size="100%">Eikarat, N.</style></author><author><style face="normal" font="default" size="100%">Coleman, R. E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Entomology, Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Transmission-blocking activity of tafenoquine (WR-238605) and artelinic acid against naturally circulating strains of Plasmodium vivax in Thailand</style></title><secondary-title><style face="normal" font="default" size="100%">Am J Trop Med Hyg</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Am J Trop Med Hyg</style></full-title></periodical><pages><style face="normal" font="default" size="100%">542-7</style></pages><volume><style face="normal" font="default" size="100%">69</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2003/12/26</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Aminoquinolines/administration &amp; dosage/*pharmacology/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Anopheles/*parasitology</style></keyword><keyword><style face="normal" font="default" size="100%">Antimalarials/administration &amp; dosage/*pharmacology/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Artemisinins/administration &amp; dosage/*pharmacology/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Dose-Response Relationship, Drug</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Insect Vectors/parasitology</style></keyword><keyword><style face="normal" font="default" size="100%">Malaria, Vivax/*drug therapy/parasitology</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Parasitic Sensitivity Tests</style></keyword><keyword><style face="normal" font="default" size="100%">Plasmodium vivax/*drug effects/growth &amp; development</style></keyword><keyword><style face="normal" font="default" size="100%">Primaquine/administration &amp; dosage/pharmacology/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Sesquiterpenes/administration &amp; dosage/*pharmacology/therapeutic use</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2003</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0002-9637 (Print)&#xD;0002-9637</style></isbn><accession-num><style face="normal" font="default" size="100%">14695093</style></accession-num><abstract><style face="normal" font="default" size="100%">The sporontocidal activity of tafenoquine (WR-238605) and artelinic acid was determined against naturally circulating isolates of Plasmodium vivax in western Thailand. Primaquine was used as a negative control and a dihydroacridine-dione (WR-250547) was used as a positive control. Laboratory-reared Anopheles dirus mosquitoes were infected with P. vivax by allowing mosquitoes to feed on blood (placed in an artificial-membrane feeding apparatus) collected from gametocytemic volunteers reporting to local malaria clinics in Tak province, Thailand. Four days post-infection, mosquitoes were refed on uninfected mice treated 90 minutes earlier with a given drug. Drug activity was determined by assessing oocyst and sporozoite development. Neither primaquine nor artelinic acid affected oocyst or sporozoite development at a dose of 100 mg of base drug/kg of mouse body weight. In contrast, tafenoquine and WR-250547 affected sporogonic development at doses as low as 25.0 and 0.39 mg/kg, respectively. The potential role of these compounds in the prevention of malaria transmission is discussed, as are alternative strategies for the use of transmission-blocking antimalarial drugs.</style></abstract><notes><style face="normal" font="default" size="100%">Ponsa, Narong&#xD;Sattabongkot, Jetsumon&#xD;Kittayapong, Pattamaporn&#xD;Eikarat, Nantana&#xD;Coleman, Russell E&#xD;Evaluation Study&#xD;Journal Article&#xD;Research Support, U.S. Gov&apos;t, Non-P.H.S.&#xD;United States&#xD;Am J Trop Med Hyg. 2003 Nov;69(5):542-7.</style></notes><urls></urls><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>101</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">101</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Schlagenhauf, P.</style></author><author><style face="normal" font="default" size="100%">Petersen, E.</style></author><author><style face="normal" font="default" size="100%">Grobusch, M. P.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Travellers&apos; Malaria - Horizons 202X</style></title><secondary-title><style face="normal" font="default" size="100%">Travel Medicine and Infectious Disease</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Travel Medicine and Infectious Disease</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1-2</style></pages><volume><style face="normal" font="default" size="100%">17</style></volume><keywords><keyword><style face="normal" font="default" size="100%">8 aminoquinoline derivative</style></keyword><keyword><style face="normal" font="default" size="100%">atovaquone plus proguanil</style></keyword><keyword><style face="normal" font="default" size="100%">doxycycline</style></keyword><keyword><style face="normal" font="default" size="100%">insecticide</style></keyword><keyword><style face="normal" font="default" size="100%">malaria vaccine</style></keyword><keyword><style face="normal" font="default" size="100%">placebo</style></keyword><keyword><style face="normal" font="default" size="100%">primaquine</style></keyword><keyword><style face="normal" font="default" size="100%">tafenoquine</style></keyword><keyword><style face="normal" font="default" size="100%">Africa</style></keyword><keyword><style face="normal" font="default" size="100%">bed net</style></keyword><keyword><style face="normal" font="default" size="100%">Black person</style></keyword><keyword><style face="normal" font="default" size="100%">chemoprophylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">cost</style></keyword><keyword><style face="normal" font="default" size="100%">editorial</style></keyword><keyword><style face="normal" font="default" size="100%">emergency treatment</style></keyword><keyword><style face="normal" font="default" size="100%">emporiatrics</style></keyword><keyword><style face="normal" font="default" size="100%">ethnicity</style></keyword><keyword><style face="normal" font="default" size="100%">Europe</style></keyword><keyword><style face="normal" font="default" size="100%">follow up</style></keyword><keyword><style face="normal" font="default" size="100%">health economics</style></keyword><keyword><style face="normal" font="default" size="100%">high risk population</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">immigration</style></keyword><keyword><style face="normal" font="default" size="100%">infection</style></keyword><keyword><style face="normal" font="default" size="100%">intensive care unit</style></keyword><keyword><style face="normal" font="default" size="100%">malaria</style></keyword><keyword><style face="normal" font="default" size="100%">malaria control</style></keyword><keyword><style face="normal" font="default" size="100%">malaria falciparum</style></keyword><keyword><style face="normal" font="default" size="100%">military research</style></keyword><keyword><style face="normal" font="default" size="100%">mosquito bite</style></keyword><keyword><style face="normal" font="default" size="100%">nonhuman</style></keyword><keyword><style face="normal" font="default" size="100%">peace corps</style></keyword><keyword><style face="normal" font="default" size="100%">priority journal</style></keyword><keyword><style face="normal" font="default" size="100%">travel</style></keyword><keyword><style face="normal" font="default" size="100%">World Health Organization</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2017</style></year></dates><isbn><style face="normal" font="default" size="100%">1873-0442&#xD;1477-8939</style></isbn><notes><style face="normal" font="default" size="100%">L616875486&#xD;2017-06-23&#xD;2017-07-13</style></notes><work-type><style face="normal" font="default" size="100%">Editorial</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L616875486&amp;from=export</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1016/j.tmaid.2017.06.002</style></url></related-urls></urls><custom5><style face="normal" font="default" size="100%">28624509</style></custom5><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.tmaid.2017.06.002</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase&#xD;Medline</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>188</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">188</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Phommasone, K.</style></author><author><style face="normal" font="default" size="100%">van Leth, F.</style></author><author><style face="normal" font="default" size="100%">Imwong, M.</style></author><author><style face="normal" font="default" size="100%">Henriques, G.</style></author><author><style face="normal" font="default" size="100%">Pongvongsa, T.</style></author><author><style face="normal" font="default" size="100%">Adhikari, B.</style></author><author><style face="normal" font="default" size="100%">Peto, T. J.</style></author><author><style face="normal" font="default" size="100%">Promnarate, C.</style></author><author><style face="normal" font="default" size="100%">Dhorda, M.</style></author><author><style face="normal" font="default" size="100%">Sirithiranont, P.</style></author><author><style face="normal" font="default" size="100%">Mukaka, M.</style></author><author><style face="normal" font="default" size="100%">Peerawaranun, P.</style></author><author><style face="normal" font="default" size="100%">Day, N. P. J.</style></author><author><style face="normal" font="default" size="100%">Cobelens, F.</style></author><author><style face="normal" font="default" size="100%">Dondorp, A. M.</style></author><author><style face="normal" font="default" size="100%">Newton, P. N.</style></author><author><style face="normal" font="default" size="100%">White, N. J.</style></author><author><style face="normal" font="default" size="100%">von Seidlein, L.</style></author><author><style face="normal" font="default" size="100%">Mayxay, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">[Phommasone, Koukeo; Newton, Paul N.; Mayxay, Mayfong] Mahosot Hosp, Lao Oxford Mahosot Hosp Wellcome Trust Res Unit L, Microbiol Lab, Viangchan, Laos. [Phommasone, Koukeo; van Leth, Frank; Cobelens, Frank] Univ Amsterdam, Dept Global Hlth, Med Ctr, Locat AMC, Amsterdam, Netherlands. [Phommasone, Koukeo; van Leth, Frank; Cobelens, Frank] Amsterdam Inst Global Hlth &amp; Dev, Amsterdam, Netherlands. [Imwong, Mallika; Henriques, Gisela; Adhikari, Bipin; Peto, Thomas J.; Dhorda, Mehul; Sirithiranont, Pasathorn; Mukaka, Mavuto; Peerawaranun, Pimnara; Day, Nicholas P. J.; Dondorp, Arjen M.; White, Nicholas J.; von Seidlein, Lorenz] Mahidol Univ, Mahidol Oxford Res Unit, Bangkok, Thailand. [Imwong, Mallika] Mahidol Univ, Fac Trop Med, Dept Mol Trop Med &amp; Genet, Bangkok, Thailand. [Pongvongsa, Tiengkham] Savannakhet Prov Hlth Dept, Savannakhet, Savanna Khet Pr, Laos. [Adhikari, Bipin; Peto, Thomas J.; Dhorda, Mehul; Mukaka, Mavuto; Day, Nicholas P. J.; Dondorp, Arjen M.; Newton, Paul N.; White, Nicholas J.; von Seidlein, Lorenz] Univ Oxford, Ctr Trop Med &amp; Global Hlth, Nuffield Dept Med, Oxford, England. [Promnarate, Cholrawee; Dhorda, Mehul] Mahidol Univ, WWARN Asia Reg Ctr, Bangkok, Thailand. [Mayxay, Mayfong] Univ Hlth Sci, Inst Res &amp; Educ Dev, Viangchan, Laos.&#xD;von Seidlein, L (corresponding author), Mahidol Univ, Mahidol Oxford Res Unit, Bangkok, Thailand.; von Seidlein, L (corresponding author), Univ Oxford, Ctr Trop Med &amp; Global Hlth, Nuffield Dept Med, Oxford, England.&#xD;lorenz@tropmedres.ac</style></auth-address><titles><title><style face="normal" font="default" size="100%">The use of ultrasensitive quantitative-PCR to assess the impact of primaquine on asymptomatic relapse of Plasmodium vivax infections: a randomized, controlled trial in Lao PDR</style></title><secondary-title><style face="normal" font="default" size="100%">Malaria Journal</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Malar. J.</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Malaria Journal</style></full-title></periodical><pages><style face="normal" font="default" size="100%">11</style></pages><volume><style face="normal" font="default" size="100%">19</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">Malaria</style></keyword><keyword><style face="normal" font="default" size="100%">P</style></keyword><keyword><style face="normal" font="default" size="100%">vivax</style></keyword><keyword><style face="normal" font="default" size="100%">PCR</style></keyword><keyword><style face="normal" font="default" size="100%">Primaquine</style></keyword><keyword><style face="normal" font="default" size="100%">Relapse</style></keyword><keyword><style face="normal" font="default" size="100%">prevent relapse</style></keyword><keyword><style face="normal" font="default" size="100%">tafenoquine</style></keyword><keyword><style face="normal" font="default" size="100%">malaria</style></keyword><keyword><style face="normal" font="default" size="100%">Infectious Diseases</style></keyword><keyword><style face="normal" font="default" size="100%">Parasitology</style></keyword><keyword><style face="normal" font="default" size="100%">Tropical Medicine</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2020</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><accession-num><style face="normal" font="default" size="100%">WOS:000513249200002</style></accession-num><abstract><style face="normal" font="default" size="100%">Background Trials to assess the efficacy of the radical cure of Plasmodium vivax malaria with 8-aminoquinolines require that most post-treatment relapses are identified, but there is no consensus on the optimal duration of follow-up in either symptomatic or asymptomatic vivax malaria. The efficacy of a 14-day course of primaquine on the cumulative incidence of recurrent asymptomatic P. vivax infections detected by ultrasensitive quantitative PCR (uPCR) as a primary endpoint was assessed. Methods A randomized, placebo-controlled, single-blind trial was conducted in four villages of the Lao PDR during 2016-2018 nested in a larger project evaluating mass drug administrations (MDA) with dihydroartemisinin-piperaquine (DP) and a single low-dose primaquine to clear Plasmodium falciparum infections. In the nested sub-study, eligible participants with mono- or mixed P. vivax infections detected by uPCR were randomized to receive either 14 days of primaquine (0.5 mg/kg/day) or placebo during the last round of MDA (round 3) through directly observed therapy. Participants were checked monthly for 12 months for parasitaemia using uPCR. The primary outcome was cumulative incidence of participants with at least one recurrent episode of P. vivax infection. Results 20 G6PD-normal participants were randomized in each arm. 5 (29%) of 20 participants in the placebo arm experienced asymptomatic, recurrent P. vivax infections, resulting in a cumulative incidence at month 12 of 29%. None of the 20 participants in the intervention arm had recurrent infections (p = 0.047 Fisher&apos;s exact test). Participants with recurrent P. vivax infections were found to be parasitaemic for between one and five sequential monthly tests. The median time to recurrence of P. vivax parasitaemia was 178 days (range 62-243 days). Conclusions A 14-day course of primaquine in addition to a DP-MDA was safe, well-tolerated, and prevented recurrent asymptomatic P. vivax infections. Long follow-up for up to 12 months is required to capture all recurrences following the treatment of asymptomatic vivax infection. To eliminate all malarias in settings where P. vivax is endemic, a full-course of an 8-aminoquinolines should be added to MDA to eliminate all malarias. Trial registration This study was registered with ClinicalTrials.gov under NCT02802813 on 16th June 2016.</style></abstract><notes><style face="normal" font="default" size="100%">ISI Document Delivery No.: KL2HD&#xD;Times Cited: 1&#xD;Cited Reference Count: 26&#xD;Phommasone, Koukeo van Leth, Frank Imwong, Mallika Henriques, Gisela Pongvongsa, Tiengkham Adhikari, Bipin Peto, Thomas J. Promnarate, Cholrawee Dhorda, Mehul Sirithiranont, Pasathorn Mukaka, Mavuto Peerawaranun, Pimnara Day, Nicholas P. J. Cobelens, Frank Dondorp, Arjen M. Newton, Paul N. White, Nicholas J. von Seidlein, Lorenz Mayxay, Mayfong&#xD;White, Nick/AAC-6527-2019&#xD;White, Nick/0000-0002-1897-1978; van Leth, Frank/0000-0002-5490-8968; Peto, Thomas/0000-0003-3197-9891; Newton, Paul/0000-0002-4608-6431&#xD;Wellcome TrustWellcome Trust [101148/Z/13/Z]; Bill and Melinda Gates FoundationBill &amp; Melinda Gates Foundation [OPP10811420]; Wellcome TrustWellcome Trust&#xD;NJW is the recipient of the Wellcome Trust Award Number: 101148/Z/13/Z. AMD is the recipient of the Bill and Melinda Gates Foundation Award Number: OPP10811420. LOMWRU and MORU receive core funding from the Wellcome Trust. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.&#xD;1&#xD;0&#xD;Bmc&#xD;London&#xD;1475-2875</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">&lt;Go to ISI&gt;://WOS:000513249200002</style></url></related-urls></urls><custom7><style face="normal" font="default" size="100%">4</style></custom7><electronic-resource-num><style face="normal" font="default" size="100%">10.1186/s12936-019-3091-5</style></electronic-resource-num><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="Tafenoquine prophylaxis master.enl" path="C:\Users\Conno\Downloads\Tafenoquine prophylaxis master.enl">Tafenoquine prophylaxis master.enl</database><source-app name="EndNote" version="20.0">EndNote</source-app><rec-number>35</rec-number><foreign-keys><key app="EN" db-id="ef0apwsw1t2vtdepadyvvfsg9szdeaazdxax">35</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bancone, G.</style></author><author><style face="normal" font="default" size="100%">Gornsawun, G.</style></author><author><style face="normal" font="default" size="100%">Chu, C. S.</style></author><author><style face="normal" font="default" size="100%">Porn, P.</style></author><author><style face="normal" font="default" size="100%">Pal, S.</style></author><author><style face="normal" font="default" size="100%">Bansil, P.</style></author><author><style face="normal" font="default" size="100%">Domingo, G. J.</style></author><author><style face="normal" font="default" size="100%">Nosten, F.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Shoklo Malaria Research Unit, Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Mae Sot, Thailand.&#xD;Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.&#xD;Diagnostics Program, PATH, Seattle, Washington, United States of America.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Validation of the quantitative point-of-care CareStart biosensor for assessment of G6PD activity in venous blood</style></title><secondary-title><style face="normal" font="default" size="100%">PLoS One</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">PLoS One</style></full-title></periodical><pages><style face="normal" font="default" size="100%">e0196716</style></pages><volume><style face="normal" font="default" size="100%">13</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2018/05/09</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Aminoquinolines/adverse effects/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Antimalarials/adverse effects/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Area Under Curve</style></keyword><keyword><style face="normal" font="default" size="100%">*Biosensing Techniques</style></keyword><keyword><style face="normal" font="default" size="100%">Clinical Enzyme Tests/*instrumentation</style></keyword><keyword><style face="normal" font="default" size="100%">Endemic Diseases</style></keyword><keyword><style face="normal" font="default" size="100%">Ethnic Groups/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Genotype</style></keyword><keyword><style face="normal" font="default" size="100%">Glucosephosphate Dehydrogenase/*blood</style></keyword><keyword><style face="normal" font="default" size="100%">Glucosephosphate Dehydrogenase Deficiency/*diagnosis/epidemiology/ethnology/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Hemoglobinometry</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Malaria, Vivax/drug therapy/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Methemoglobinemia/chemically induced/genetics/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Myanmar/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Point-of-Care Systems</style></keyword><keyword><style face="normal" font="default" size="100%">Pregnancy</style></keyword><keyword><style face="normal" font="default" size="100%">Pregnancy Complications, Hematologic/diagnosis/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Primaquine/adverse effects/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">ROC Curve</style></keyword><keyword><style face="normal" font="default" size="100%">Spectrophotometry, Ultraviolet</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2018</style></year></dates><isbn><style face="normal" font="default" size="100%">1932-6203</style></isbn><accession-num><style face="normal" font="default" size="100%">29738562</style></accession-num><abstract><style face="normal" font="default" size="100%">INTRODUCTION: Glucose-6-phosphate dehydrogenase (G6PD) deficiency is the most common enzymopathy in the human population affecting an estimated 8% of the world population, especially those living in areas of past and present malaria endemicity. Decreased G6PD enzymatic activity is associated with drug-induced hemolysis and increased risk of severe neonatal hyperbilirubinemia leading to brain damage. The G6PD gene is on the X chromosome therefore mutations cause enzymatic deficiency in hemizygote males and homozygote females while the majority of heterozygous females have an intermediate activity (between 30-80% of normal) with a large distribution into the range of deficiency and normality. Current G6PD qualitative tests are unable to diagnose G6PD intermediate activities which could hinder wide use of 8-aminoquinolines for Plasmodium vivax elimination. The aim of the study was to assess the diagnostic performances of the new Carestart G6PD quantitative biosensor. METHODS: A total of 150 samples of venous blood with G6PD deficient, intermediate and normal phenotypes were collected among healthy volunteers living along the north-western Thailand-Myanmar border. Samples were analyzed by complete blood count, by gold standard spectrophotometric assay using Trinity kits and by the latest model of Carestart G6PD biosensor which analyzes both G6PD and hemoglobin. RESULTS: Bland-Altman comparison of the CareStart normalized G6PD values to that of the gold standard assay showed a strong bias in values resulting in poor area under-the-curve values for both 30% and 80% thresholds. Performing a receiver operator curve identified threshold values for the CareStart product equivalent to the 30% and 80% gold standard values with good sensitivity and specificity values, 100% and 92% (for 30% G6PD activity) and 92% and 94% (for 80% activity) respectively. CONCLUSION: The Carestart G6PD biosensor represents a significant improvement for quantitative diagnosis of G6PD deficiency over previous versions. Further improvements and validation studies are required to assess its utility for informing radical cure decisions in malaria endemic settings.</style></abstract><notes><style face="normal" font="default" size="100%">1932-6203&#xD;Bancone, Germana&#xD;Orcid: 0000-0003-4550-0431&#xD;Gornsawun, Gornpan&#xD;Chu, Cindy S&#xD;Porn, Pen&#xD;Pal, Sampa&#xD;Bansil, Pooja&#xD;Domingo, Gonzalo J&#xD;Orcid: 0000-0002-1004-4395&#xD;Nosten, Francois&#xD;Orcid: 0000-0002-7951-0745&#xD;Journal Article&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Validation Study&#xD;PLoS One. 2018 May 8;13(5):e0196716. doi: 10.1371/journal.pone.0196716. eCollection 2018.</style></notes><urls></urls><custom2><style face="normal" font="default" size="100%">PMC5940185 patents, products in development or marketed products to declare. This does not alter our adherence to all the PLOS ONE policies on sharing data and materials.</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1371/journal.pone.0196716</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record></records></xml>